Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

(Mark One)

☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended December 31, 2011

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Commission file number 000-12477

Amgen Inc.

(Exact name of registrant as specified in its charter)

Delaware	**95-3540776**
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
One Amgen Center Drive, Thousand Oaks, California	**91320-1799**
(Address of principal executive offices)	(Zip Code)

(805) 447-1000

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Name of Each Exchange on Which Registered
Common stock, $0.0001 par value	The NASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) Yes ☐ No ☒

The approximate aggregate market value of voting and non-voting stock held by non-affiliates of the registrant was $53,861,879,805 as of June 30, 2011(A)

(A) Excludes 966,638 shares of common stock held by directors and executive officers at June 30, 2011. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant.

791,432,134

(Number of shares of common stock outstanding as of February 10, 2012)

DOCUMENTS INCORPORATED BY REFERENCE

Specified portions of the registrant's Proxy Statement with respect to the 2012 Annual Meeting of stockholders to be held May 23, 2012, are incorporated by reference into Part III of this annual report.

INDEX

PART I

Item 1. BUSINESS

Overview

Amgen Inc. (including its subsidiaries, referred to as "Amgen," "the Company," "we," "our" or "us") is the world's largest independent biotechnology medicines company. We discover, develop, manufacture and market medicines for grievous illnesses. We focus solely on human therapeutics and concentrate on innovating novel medicines based on advances in cellular and molecular biology. Our mission is to serve patients.

We were incorporated in 1980 and organized as a Delaware corporation in 1987. Our public website is www.amgen.com. On our website, investors can find press releases, financial filings and other information about the Company. The U.S. Securities and Exchange Commission (SEC) website, www.sec.gov, also offers access to reports and documents we have electronically filed with or furnished to the SEC. These website addresses are not intended to function as hyperlinks, and the information contained in our website and in the SEC's website is not intended to be a part of this filing.

As of December 31, 2011, we had 17,800 staff members worldwide. Approximately 6,500 of our staff members work in our research and development (R&D) function, approximately 4,900 work in manufacturing, approximately 4,400 work in our commercial operations and the rest are in general and administrative functions.

Currently, we market primarily recombinant protein therapeutics in supportive cancer care, inflammation and nephrology. Our principal products are Neulasta® (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN® (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which selectively stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection); Enbrel® (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body's response to inflammatory diseases; and Aranesp® (darbepoetin alfa) and EPOGEN® (epoetin alfa), erythropoiesis-stimulating agents (ESAs) that stimulate the production of red blood cells. Our principal products represented 87%, 91% and 93% of our sales in 2011, 2010 and 2009, respectively. Our other marketed products include Sensipar®/Mimpara® (cinacalcet), a small molecule calcimimetic that lowers serum calcium levels; Vectibix® (panitumumab), a monoclonal antibody that binds specifically to the epidermal growth factor receptor (EGFr); Nplate® (romiplostim), a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production; and Prolia® (denosumab) and XGEVA® (denosumab), which both contain the same active ingredient but are approved for different indications, patient populations, doses and frequencies of administration. Denosumab is a fully human monoclonal antibody that specifically targets RANKL, an essential regulator of osteoclasts (the cells that break down bone).

We maintain sales and marketing forces primarily in the United States, Europe and Canada. We have also entered into agreements with third parties to assist in the commercialization and marketing of certain of our products in specified geographic areas. (See Business Relationships.) Together with our partners, we market our products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies. Most patients receiving our principal products for approved indications are covered by either government or private payer healthcare programs, which influence demand. The reimbursement environment continues to evolve with greater emphasis on both cost containment and demonstration of the economic value of products.

In addition to our marketed products, we have various product candidates in mid- to late-stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. Our R&D organization has expertise in multiple treatment modalities, including large molecules (such as proteins, antibodies and peptibodies) and small molecules.

Our manufacturing operations consist of bulk manufacturing, formulation, fill and finish and distribution activities for all of our principal products as well as most of our product candidates. We operate a number of commercial and/or clinical manufacturing facilities, and our primary facilities are located in the United States, Puerto Rico and the Netherlands. (See Item 2. Properties.)

Drug development in our industry is complex, challenging and risky, and failure rates are high. Product development cycles are very long — approximately 10 to 15 years from discovery to market. A potential new medicine must undergo many years of preclinical and clinical testing to establish its safety and efficacy for use in humans at appropriate dosing levels and with an acceptable benefit-risk profile. Biological products, which are produced in living systems, are inherently complex due to naturally occurring molecular variations. Highly specialized knowledge and extensive process and product characterization are required to transform laboratory-scale processes into reproducible commercial manufacturing processes. Upon approval, marketed products in our industry generally face substantial competition.

Our industry is highly regulated, and various U.S. and foreign regulatory bodies have substantial authority over how we conduct our business. Government authorities in the United States and other countries regulate the manufacturing and marketing of our products as well as our ongoing R&D activities. In recent years, regulators have placed a greater scrutiny on drug safety. This has led to, and may in the future lead to: fewer products being approved by the U.S. Food and Drug Administration (FDA) or other regulatory bodies; delays in receiving approvals; additional safety-related requirements; restrictions on the use of products, including expanded safety labeling, or required risk management activities.

Significant Developments

Following is a summary of significant developments that occurred in 2011 and early 2012 affecting our business. A more detailed discussion of each development follows in the appropriate section.

ESAs

- The Centers for Medicare & Medicaid Services' (CMS) Final Rule on Bundling in Dialysis became effective on January 1, 2011, and provides a single payment for all dialysis services, including drugs that were previously reimbursed separately.
- On June 24, 2011, we announced that the FDA approved changes to the labels for the use of ESAs, including Aranesp® and EPOGEN®, in patients with chronic kidney disease (CKD) (June 2011 ESA label changes).
- CMS finalized a rule to update various provisions of its bundled payment system for dialysis services and the related end stage renal disease (ESRD) Quality Incentive Program (QIP). The final rule eliminated for payment year 2013 and beyond the QIP's measure that tracks the percent of a provider's Medicare patients with a hemoglobin (Hb) level below 10 grams per deciliter (g/dL).
- We entered into a seven-year supply agreement with DaVita Inc. (DaVita), commencing January 1, 2012, to supply EPOGEN® in amounts necessary to meet no less than 90% of DaVita's and its affiliates' requirements for ESAs used in providing dialysis services in the United States and Puerto Rico.

XGEVA®

- On July 15, 2011, we announced that the European Commission (EC) granted marketing authorization for XGEVA® for the prevention of skeletal-related events (SREs) in adults with bone metastases from solid tumors.

Vectibix®

- On November 10, 2011, the EC approved a variation to the marketing authorization for the use of Vectibix® in first- and second-line treatment of metastatic colorectal cancer (mCRC) in patients whose tumors contain wild-type *KRAS* genes.
- We announced on July 29, 2011, that we received Complete Response Letters from the FDA on the first- and second-line mCRC supplemental Biologics License Applications (sBLA) for Vectibix® that we filed in late 2010. We are currently working to address their requests.

Motesanib

- We along with our partner Takeda Pharmaceutical Company Limited (Takeda) announced that the motesanib pivotal phase 3 trial (MONET1) did not meet its primary objective of demonstrating an improvement in overall survival in patients with advanced non-squamous non small cell lung cancer (NSCLC).

Business combinations

- On March 4, 2011, we acquired BioVex Group, Inc. (BioVex), a privately held biotechnology company developing treatments for cancers and for the prevention of infectious disease, including talimogene laherparepvec (formerly referred to as OncoVEX^{GM-CSF}), a novel oncolytic vaccine in phase 3 clinical development for the treatment of malignant melanoma.
- On April 7, 2011, we acquired Laboratório Químico Farmacêutico Bérgamo Ltda (Bergamo), a privately held Brazilian pharmaceutical company that is a leading supplier of medicines to the hospital sector in Brazil with capabilities in oncology medicines.
- On January 26, 2012, we announced that we entered into an agreement to acquire Micromet, Inc. (Micromet), a publicly held biotechnology company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. The acquisition, which is subject to customary closing conditions, is expected to close in the first quarter of 2012.

Return of capital to shareholders

- In the third quarter of 2011, we began paying quarterly cash dividends of $0.28 per share of common stock, aggregating $500 million paid in 2011. In December 2011, we increased our quarterly declared dividend by 29% to $0.36 per share of common stock, payable in March 2012.
- During 2011, we repurchased approximately 15% of our stock outstanding as of December 31, 2010, for a total cost of $8.3 billion.

Proposed legal settlement

- We recorded a $780 million charge (the legal settlement charge) in connection with an agreement in principle to settle allegations relating to our sales and marketing practices.

Marketed Products

We market our principal products, Neulasta®, NEUPOGEN®, ENBREL, Aranesp® and EPOGEN®, in supportive cancer care, inflammation and nephrology. Certain of our marketed products face, and our product candidates, if approved, are also expected to face, substantial competition, including from products marketed by large pharmaceutical corporations, which may have greater clinical, research, regulatory, manufacturing, marketing, financial and human resources than we do. Our products' competitive position among other biological and pharmaceutical products may be based on, among other things, safety, efficacy, reliability, availability, patient convenience/delivery devices, price, reimbursement and patent position and expirations.

Over the next several years, many of the existing patents on our principal products will expire, and we expect to face increasing competition thereafter, including from biosimilar products. A "biosimilar" product is a follow-on version of another biological product for which marketing approval is sought or has been obtained based on a demonstration that it is "biosimilar" to the original reference product. This demonstration will typically consist of comparative analytical, preclinical and clinical data from the biosimilar product to show that it has similar safety and efficacy as the reference product. The 2010 U.S. healthcare reform legislation authorized the FDA to approve biosimilar products under a new, abbreviated pathway. On February 9, 2012, the FDA released three draft guidance documents that provide insight into the FDA's current thinking on the development of biosimilar products and broad parameters for the scientific assessment of biosimilar applications. The FDA guidance documents leave room for the FDA to consider, on a case-by-case basis, the specifics of what evidence would be required for a biosimilar product to gain approval (see Government Regulation). In the European Union

(EU), there is already an established regulatory pathway for biosimilars and we are facing increasing competition from biosimilars. In the United States after patent expiration, we expect to face greater competition, including from manufacturers with biosimilar products approved in Europe that may seek to quickly obtain U.S. approval. Upon patent expiration for small molecule products, there is typically intense competition from generics manufacturers, which generally leads to significant and rapid declines in sales of the branded product. Given that our principal products are biologics, we do not believe the impact of biosimilar competition will be as significant as with small molecule products in part because successful competitors must have a broad range of specialized skills and capabilities unique to biologics, including significant regulatory, clinical and manufacturing expertise, and since the products are similar, but not identical, the biosimilars will have to compete against a product with an established efficacy and safety record. In some cases we may experience additional competition prior to the expiration of our patents as a result of agreements we have made in connection with the settlement of patent litigation with companies developing potentially competing products. (See, e.g., the discussions of Neulasta®/NEUPOGEN® and Aranesp® later in this section).

Further, the introduction of new products or the development of new processes or technologies by competitors or new information about existing products may result in increased competition for our marketed products, even for those protected by patents, or in a reduction of price that we receive from selling our products. In addition, the development of new treatment options or standards of care may reduce the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates.

In addition to the challenges presented by competition, our existing products and product candidates are also subject to increasing regulatory compliance requirements that could be imposed as conditions of approval or after a product has been approved. This is increasingly true of new therapies with novel mechanisms of action. While such therapies may offer important benefits and/or better treatment alternatives, they may also involve relatively new or higher levels of scientific complexity and may therefore generate increased safety concerns. We design and implement comprehensive proactive pharmacovigilance programs for all of our products to help ensure the detection, assessment and communication of adverse effects. When deemed necessary and appropriate, additional measures for risk communication and mitigation are designed and implemented in consultation with regulatory agencies. As a condition of approval or due to safety concerns after a product has been approved, we may be required to perform additional clinical trials or studies, including postmarketing requirements (PMRs) and postmarketing commitments (PMCs). A PMR is a trial or study that a sponsor company is required by statute or regulation to conduct. A PMC is a trial or study that a sponsor company agrees to in writing, but is not required by law, to conduct. In addition, we may be required to implement risk management plans for our products in the various regions in which they are approved. For example, in 2008 the FDA began requiring risk evaluation and mitigation strategies (REMS) for various approved products to ensure that the benefits of the drugs outweigh the risks. A REMS may also be imposed as a condition of approval or after a product has been on the market. A REMS may include a medication guide or a patient package insert, a healthcare provider communication plan or elements to assure safe use that the FDA deems necessary. While the elements of REMS may vary, all REMS require the sponsor company to submit periodic assessment reports to the FDA to demonstrate that the goals of the REMS are being met. The FDA evaluates such assessments and may require additional modifications to the REMS elements. REMS may also be modified as the FDA and companies gain more experience with REMS and how they are implemented, operated and monitored. We currently have REMS for a number of our marketed products. (See discussion on PMRs, PMCs and REMS in Government Regulation.)

Most patients receiving our principal products for approved indications are covered by either government or private payer healthcare programs, which influence demand. The reimbursement environment continues to evolve with greater emphasis on both cost containment and demonstration of the economic value of products. In addition, the current worldwide economic conditions have also contributed to increasing pressures on cost containment.

Neulasta® (pegfilgrastim)/NEUPOGEN® (Filgrastim)

We were granted an exclusive license to manufacture and market Neulasta® and NEUPOGEN® in the United States, Europe, Canada, Australia and New Zealand under a licensing agreement with Kirin-Amgen, Inc.

(K-A), a joint venture between Kirin Holdings Company, Limited (Kirin) and Amgen (see Business Relationships — Kirin-Amgen, Inc.) (See Business Relationships — Kirin-Amgen, Inc.)

Neulasta® and NEUPOGEN® stimulate production of neutrophils, a type of white blood cell important in the body's fight against infection. Treatments for various diseases and diseases themselves can result in extremely low numbers of neutrophils, a condition called neutropenia. Myelosuppressive chemotherapy, one treatment option for individuals with certain types of cancers, targets cell types that grow rapidly, such as tumor cells. Normal cells that divide rapidly, such as those in the bone marrow that become neutrophils, are also vulnerable to the cytotoxic effects of myelosuppressive chemotherapy, resulting in neutropenia with an increased risk of severe infection. NEUPOGEN® is our registered trademark for Filgrastim, our recombinant-methionyl human G-CSF. Neulasta® is our registered trademark for pegfilgrastim, a pegylated protein based on the Filgrastim molecule. A polyethylene glycol molecule is added to the Filgrastim molecule. Because pegfilgrastim is eliminated through binding to its receptor on neutrophils and neutrophil precursor cells, pegfilgrastim remains in the circulation until neutrophil recovery has occurred. This neutrophil-mediated clearance allows for administration as a single dose per chemotherapy cycle, compared with NEUPOGEN®, which requires more frequent dosing.

We market Neulasta® and NEUPOGEN® primarily in the United States and Europe. Filgrastim is also marketed under the brand name GRANULOKINE® in Italy. Neulasta® was launched in the United States and Europe in 2002 and is indicated to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients with non-myeloid malignancies. Administration of Neulasta® in all cycles of chemotherapy is approved for patients receiving myelosuppressive chemotherapy associated with a clinically significant risk of febrile neutropenia. NEUPOGEN® was launched in the United States and Europe in 1991. NEUPOGEN® is indicated for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy; reducing the duration of neutropenia and neutropenia-related consequences for patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation; reducing the incidence and duration of neutropenia-related consequences in symptomatic patients with congenital neutropenia, cyclic neutropenia or idiopathic neutropenia (collectively, severe chronic neutropenia); mobilizing peripheral blood progenitor cells (PBPC) in cancer patients who have undergone myeloablative chemotherapy for stem cell transplantation; and reducing the recovery time of neutrophils and the duration of fever following induction or consolidation chemotherapy treatment in adult patients with acute myeloid leukemia (AML).

Worldwide Neulasta®/NEUPOGEN® sales for the years ended December 31, 2011, 2010 and 2009, were $5.2 billion, $4.8 billion and $4.6 billion, respectively. U.S. Neulasta®/NEUPOGEN® sales for the years ended December 31, 2011, 2010 and 2009, were $4.0 billion, $3.6 billion and $3.4 billion, respectively. International Neulasta®/NEUPOGEN® sales for each of the three years ended December 31, 2011, 2010 and 2009, were $1.2 billion.

Our outstanding material patents for pegfilgrastim are described in the following table.

Territory	General Subject Matter	Expiration
U.S.	Pegylated G-CSF	10/20/2015
Europe[1]	Pegylated G-CSF	2/8/2015

(1) In some cases, this European patent may also be entitled to supplemental protection in one or more countries in Europe and the length of any such extension will vary by country.

Our outstanding material patents for Filgrastim are described in the following table.

Territory	General Subject Matter	Expiration
U.S.	G-CSF polypeptides	12/3/2013
U.S.	Methods of treatment using G-CSF polypeptides	12/10/2013

Our principal European patent relating to G-CSF expired in August 2006. Upon expiration of that patent, some companies received approval to market products, including biosimilars, that compete with NEUPOGEN® and Neulasta® in Europe, as further discussed below.

Any products or technologies that are directly or indirectly successful in treating neutropenia associated with chemotherapy, for bone marrow and PBPC transplant patients, severe chronic neutropenia and AML could negatively impact Neulasta® and/or NEUPOGEN® sales. Further, NEUPOGEN® competes with Neulasta® in the United States and Europe, and NEUPOGEN® sales have been adversely impacted by conversion to Neulasta®. However, we believe the conversion in the United States is substantially complete and that a significant amount of the conversion in Europe has already occurred.

The following table reflects companies and their currently marketed products that compete with Neulasta® and/or NEUPOGEN® in the United States and Europe in the supportive cancer care setting. The table below and the following discussion of competitor marketed products and products in development may not be exhaustive.

Territory	Competitor Marketed Product	Competitor
U.S.	Leukine®	Bayer HealthCare Pharmaceuticals (Bayer)
Europe	Granocyte®	Chugai Pharmaceuticals Co., Ltd./Sanofi-Aventis (Sanofi)
Europe	Ratiograstim®(1)/Biograstim®(1)	ratiopharm GmbH (ratiopharm)(2)/CT Arzneimittel GmbH (CT Arzneimittel)
Europe	Tevagrastim®(1)	Teva Pharmaceutical Industries Ltd. (Teva Pharmaceutical)
Europe	Zarzio®(1)/Filgrastim Hexal®(1)	Sandoz GmbH (Sandoz)/Hexal Biotech Forschungs GmbH (Hexal)
Europe	Nivestim®(1)	Hospira Inc. (Hospira)

(1) Approved via the EU biosimilar regulatory pathway.

(2) A subsidiary of Teva Pharmaceutical.

Several companies have short-acting filgrastim product candidates in phase 3 clinical development, including:

- Merck & Company, Inc. (Merck) (MK-4214)
- Intas/Apotex Inc. (Neukine)
- Reliance Life Sciences Pvt. Ltd. (Religrast)
- Biocon Ltd./Celgene Corporation (Celgene) (Nufil)

In addition, the following companies have long-acting filgrastim product candidates in phase 3 clinical development:

- Teva Pharmaceutical (Neugranin™ and XM-22)
- Sandoz (Peg G-CSF).

In February 2010, Teva Pharmaceutical announced that the FDA had accepted for review its Biologics License Applications (BLA) seeking U.S. approval to market XM02 (its filgrastim product currently sold under the brand name Tevagrastim® in several European countries) to stimulate the production of neutrophils under the brand name Neutroval™. On September 30, 2010, the FDA issued a Complete Response Letter requesting additional information from Teva Pharmaceutical to complete the review of its applications for approval of

Neutroval™. If approved in the United States, this drug would compete with NEUPOGEN® and Neulasta® subject to the terms of the injunction and settlement agreement discussed below.

On November 30, 2009, Teva Pharmaceutical filed a declaratory judgment action against us alleging that certain of our NEUPOGEN® patents are invalid and not infringed by Neutroval™, and on January 15, 2010, we filed an answer and counterclaims seeking a declaratory judgment that our patents are valid and infringed. On July 15, 2011, we announced that the U.S. District Court in Pennsylvania entered final judgment and a permanent injunction against Teva Pharmaceutical and Teva Pharmaceuticals USA, Inc. (together defined as Teva) prohibiting them from infringing our patents relating to human G-CSF polypeptides and methods of treatment. The Court's injunction extends until November 10, 2013, after which date Teva will no longer be prohibited by the injunction from selling Neutroval™ in the United States, subject to receiving FDA approval for human therapeutic use. Teva also agreed not to sell Neugranin™ in the United States before November 10, 2013, unless it first obtains a final court decision that our patents are not infringed by Neugranin™. Pursuant to the parties' settlement, the launch date for either product could be sooner if certain unexpected events occur: a third party launches a similar G-CSF polypeptide product and we fail to sue that third party, or the patents are held invalid or unenforceable in a final court decision in an action brought by a third party.

Enbrel® (etanercept)

ENBREL is our registered trademark for etanercept, our TNF receptor fusion protein that inhibits the binding of TNF to its receptors, which can result in a significant reduction in inflammatory activity. TNF is one of the chemical messengers that help regulate the inflammatory process. When the body produces too much TNF, it overwhelms the immune system's ability to control inflammation of the joints or of psoriasis-affected skin areas. ENBREL binds certain TNF molecules before they can trigger inflammation.

We acquired the rights to ENBREL in July 2002 with our acquisition of Immunex Corporation (Immunex). ENBREL was launched in the United States in November 1998 and in Canada in March 2001 for the treatment of rheumatoid arthritis (RA). In addition, ENBREL is now indicated for the treatment of adult patients with the following conditions: moderate to severe active RA; chronic moderate to severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy; active psoriatic arthritis; and active ankylosing spondylitis.

We market ENBREL under a collaboration agreement with Pfizer Inc. (Pfizer) in the United States and Canada, which expires in the fourth quarter of 2013. (See Business Relationships — Pfizer Inc.) The rights to market and sell ENBREL outside the United States and Canada are reserved to Pfizer.

ENBREL sales for the years ended December 31, 2011, 2010 and 2009, were $3.7 billion, $3.5 billion and $3.5 billion, respectively.

In November 2011, we announced the issuance of U.S. Patent No. 8,063,182 related to ENBREL, which is owned by F. Hoffmann-La Roche Ltd. (Roche) and exclusively licensed to Amgen. This patent, which has a term of 17 years from issuance, is reflected in the following table along with our other outstanding material patents for etanercept.

Territory	General Subject Matter	Expiration
U.S.	TNFR DNA vectors, cells and processes for making proteins	10/23/2012
U.S.	Aqueous Formulation[(1)]	2/27/2023
U.S.	Fusion protein, and pharmaceutical compositions	11/22/2028

(1) This formulation patent relates to the currently approved liquid formulation of ENBREL, which formulation accounts for the majority of ENBREL sales in the United States. However, ENBREL is also sold as an alternative lyophilized formulation that requires reconstituting before it can be administered to the patient.

Any products or technologies that are directly or indirectly successful in treating rheumatologic conditions, which includes moderate to severe RA; moderate to severe polyarticular juvenile idiopathic arthritis; ankylosing spondylitis and psoriatic arthritis; and dermatologic conditions, which includes moderate to severe plaque

psoriasis, could negatively impact ENBREL sales. Certain of the treatments for these indications include generic methotrexate and other products.

The following table reflects companies and their currently marketed products that compete with ENBREL in the United States and Canada in the inflammatory disease setting. The table below and the following discussion of competitor marketed products and products in development may not be exhaustive.

Territory	Therapeutic Area	Competitor Marketed Product	Competitor
U.S. & Canada	Rheumatology & Dermatology	REMICADE®	Janssen Biotech, Inc. (Janssen)(1)/Merck
U.S. & Canada	Rheumatology & Dermatology	HUMIRA®	Abbott Laboratories (Abbott)
U.S. & Canada	Rheumatology & Dermatology	Simponi®	Janssen (1)
U.S. & Canada	Rheumatology	Cimzia®	UCB/Nektar Therapeutics (Nektar)
U.S. & Canada	Rheumatology	Orencia®	Bristol-Myers Squibb Company (BMS)
U.S. & Canada	Rheumatology	Rituxan®	Roche
U.S.	Rheumatology	Actemra®	Roche
U.S. & Canada	Dermatology	Stelara®	Janssen (1)

(1) A subsidiary of Johnson & Johnson (J&J) formerly known as Centocor Ortho Biotech Products, L.P.

In December 2011, the FDA accepted a new drug application (NDA) from Pfizer for approval of tofacitinib in RA. In addition, several competitors have product candidates in phase 3 clinical development that may compete with ENBREL in the future:

- Celgene (apremilast), in both psoriasis and psoriatic arthritis.
- AstraZeneca PLC and Rigel Pharmaceuticals Inc. (fostamatinib) in RA.
- Eli Lilly and Company (Eli Lilly) (LY 2439821) for moderate to severe plaque psoriasis.
- UCB/Nektar's Cimzia® in psoriatic arthritis,
- Janssen's Simponi® IV in RA and Stelara® in psoriatic arthritis.
- Roche's Actemra® SC in RA.

ESAs

Aranesp® and EPOGEN® are our registered trademarks for darbepoetin alfa and epoetin alfa, respectively, both of which are proteins that stimulate red blood cell production in a process known as erythropoiesis. Red blood cells transport oxygen to all cells of the body. Without adequate amounts of a protein called erythropoietin, the red blood cell count is reduced. A deficient red blood cell count can result in anemia, a condition in which insufficient oxygen is delivered to the body's organs and tissues. Anemia can be associated with CKD in patients either on or not on dialysis. Individuals with CKD may suffer from anemia because they do not produce sufficient amounts of erythropoietin, which is normally produced in healthy kidneys and stimulates erythropoiesis. Anemia can also result from chemotherapy treatments for patients with non-myeloid malignancies.

ESAs, including ours, have faced and continue to face challenges. For example, based on adverse safety results observed beginning in late 2006 in various studies, performed by us and by others, that explored the use of ESAs in settings different from those outlined in the FDA approved label, the product labeling of our ESAs in the United States and the EU has been updated several times to reflect those safety concerns. In addition, due in part to certain of these developments, reimbursement of our ESAs in the United States was also revised resulting in changes in the way ESAs are used in clinical practice, including by decreasing the number of treated patients, average dose and duration of ESA therapy.

Further, the following developments occurred with respect to ESAs in 2011:

- CMS's Final Rule on Bundling in Dialysis became effective on January 1, 2011, and provides a single payment for all dialysis services, including drugs that were previously reimbursed separately (except for oral drugs without intravenous equivalents, such as Sensipar®, which will be included in the bundle beginning in 2014). Substantially all dialysis providers in the United States opted into the bundled payment system in its entirety on January 1, 2011.
- On June 24, 2011, we announced that the FDA had approved the June 2011 ESA label changes. While the previous label language specified a Hb target range of 10-12 g/dL for chronic renal failure (CRF) patients on dialysis as well as those not on dialysis, the modified labeling provides separate treatment guidance for these two populations. For patients on dialysis, who constitute the majority of CKD (or CRF) patients receiving ESA treatment, the new label advises physicians to initiate ESA therapy when the Hb level is less than 10 g/dL and to reduce or interrupt the dose when the Hb approaches or exceeds 11 g/dL. For CKD patients not on dialysis receiving ESA treatment, the new label advises physicians to initiate ESA therapy when the Hb level is less than 10 g/dL and to reduce or interrupt the dose when the Hb exceeds 10 g/dL. (With the June 2011 label changes, the FDA changed the term CRF to CKD in the ESA labels. We use CRF when referring to labels prior to June 2011 for historical accuracy.)
- On November 1, 2011, CMS finalized a rule to update various provisions of its bundled payment system for dialysis services and the related ESRD QIP. The final rule eliminated for payment year 2013 and beyond the QIP's measure that tracks the percent of a provider's Medicare patients with a Hb level below 10 g/dL. CMS indicated that removal of this measure from the QIP was being done in response to the June 2011 ESA label changes.
- On June 16, 2010, CMS opened a National Coverage Analysis (NCA) to examine the use of ESAs to manage anemia in patients with CKD and dialysis-related anemia. Following further analysis, on June 16, 2011, CMS issued a Final Decision Memorandum (FDM) in which it determined that it would not issue a National Coverage Determination (NCD) at that time for ESAs for treatment of anemia in adults with CKD, and that it would instead monitor the use of ESAs through its bundled payment system and its other policy avenues. In the absence of an NCD, Local Coverage Determinations (LCDs) may be made by 11 regional contractors called Medicare Administrative Contractors (MACs), which CMS contracts with to process Medicare claims. LCDs are binding on providers within their respective jurisdictions. Since CMS issued their FDM, one MAC has issued a final LCD relating to anemia in patients with CKD not on dialysis, and two more MACs have issued draft LCDs, all of which would restrict reimbursement to use in accordance with the revised label. Nonetheless, physician behavior may change at any time to be consistent with the label even before formal LCDs are implemented.

Certain of these developments have had a material adverse impact on sales of our ESAs.

In addition, in November 2011, we entered into a seven-year supply agreement with DaVita, commencing January 1, 2012, to supply EPOGEN® in amounts necessary to meet no less than 90% of DaVita's and its affiliates' requirements for ESAs used in providing dialysis services in the United States and Puerto Rico. Effective January 1, 2012, we also entered into a three-year non-exclusive supply agreement to supply EPOGEN® to Fresenius Medical Care North America, a subsidiary of Fresenius Medical Care AG & Co. KGaA (Fresenius Medical Care), following the 2011 expiration of our five-year ESA supply agreement with them.

We have an ongoing oncology pharmacovigilance program in place for Aranesp®. Of the clinical trials included in the program, five explore the use of ESAs in settings different from those outlined in the FDA approved label and are designated by the FDA as PMCs. Of the five studies, one was sponsored by Amgen while the other four were investigator-sponsored. Results of certain of those studies contributed to safety-related product labeling changes for our ESAs and changes in reimbursement, as noted above. Of the five studies, four are complete with final results of the remaining study expected in 2012. In addition, Janssen Research & Development, LLC (JRD), a subsidiary of J&J, and/or its investigators have conducted numerous studies that contribute to the understanding of ESA safety. Results of the JRD studies were submitted to the FDA.

Additionally, based on discussions with the FDA, we and JRD have carefully considered potential new study designs to determine the effects of ESAs on survival and tumor outcomes in anemic patients with metastatic cancer receiving concomitant myelosuppressive chemotherapy. Based on those discussions, we are conducting a randomized, double-blind, placebo-controlled, phase 3 non-inferiority study evaluating overall survival when comparing advanced NSCLC patients on Aranesp® to patients receiving placebo (Study '782) as part of our Aranesp® pharmacovigilance program. In addition, JRD's EPO-ANE-3010 study in breast cancer is ongoing. Both studies are designated by the FDA as PMR clinical trials. For the nephrology setting, we are in ongoing discussions with the FDA regarding additional PMRs to explore alternative ESA dosing strategies in CKD patients on dialysis and not on dialysis.

Adverse events or results of any of these studies could further affect product labeling, healthcare provider prescribing behavior, regulatory or private healthcare organization medical guidelines and/or reimbursement practices related to Aranesp® or EPOGEN®.

Aranesp® (darbepoetin alfa)

We were granted an exclusive license by K-A to manufacture and market Aranesp® in the United States, all European countries, Canada, Australia, New Zealand, Mexico, all Central and South American countries and certain countries in Central Asia, Africa and the Middle East.

We market Aranesp® primarily in the United States and Europe. Aranesp® was launched in 2001 in the United States and Europe for the treatment of anemia associated with CRF (both in patients on dialysis and patients not on dialysis) and is also indicated for the treatment of anemia due to concomitant chemotherapy in patients with non-myeloid malignancies.

Worldwide Aranesp® sales for the years ended December 31, 2011, 2010 and 2009, were $2.3 billion, $2.5 billion and $2.7 billion, respectively. For the years ended December 31, 2011, 2010 and 2009, U.S. Aranesp® sales were $1.0 billion, $1.1 billion and $1.3 billion, respectively, and international Aranesp® sales were $1.3 billion, $1.4 billion and $1.4 billion, respectively.

Our outstanding material patents for darbepoetin alfa are described in the following table.

Territory	General Subject Matter	Expiration
U.S.	Glycosylation analogs of erythropoietin proteins	5/15/2024
Europe[1]	Glycosylation analogs of erythropoietin proteins	8/16/2014

(1) In some cases, this European patent may also be entitled to supplemental protection in one or more countries in Europe and the length of any such extension will vary by country.

Our principal European patent relating to epoetin alfa expired in December 2004. Although we do not market EPOGEN® in Europe, upon expiration of this patent, some companies received approval to market products, including biosimilars, that compete with Aranesp® in Europe, as further discussed below.

Any products or technologies that are directly or indirectly successful in addressing anemia associated with chemotherapy and/or renal failure could negatively impact Aranesp® sales. In the United States, Aranesp® competes with EPOGEN®, primarily in the U.S. hospital dialysis clinic setting.

The following table reflects companies and their currently marketed products that compete with Aranesp® in the United States and Europe in the supportive cancer care and nephrology segments, unless otherwise indicated. The table below and the following discussion of competitor marketed products and products in development may not be exhaustive.

Territory	Competitor Marketed Product	Competitor
U.S.	PROCRIT®(1)	Janssen(2)
Europe	EPREX®/ERYPO®	Janssen-Cilag(2)
Europe	NeoRecormon®	Roche
Europe	Retacrit™(3)/Silapo®(3)	Hospira/Stada Arzneimittel AG
Europe	Binocrit®(3)/epoetin alfa Hexal®(3)/Abseamed®(3)	Sandoz/Hexal/Medice Arzneimittel Pütter GmbH & Co. KG
Europe	MIRCERA®(4)	Roche
Europe	Eporatio®/Biopoin®	ratiopharm (5)/CT Arzneimittel

(1) PROCRIT® competes with Aranesp® in the supportive cancer care and pre-dialysis settings.

(2) A subsidiary of J&J.

(3) Approved via the EU biosimilar regulatory pathway.

(4) Competes with Aranesp® in the nephrology segment only. Pursuant to a December 2009 settlement agreement between Amgen and Roche, Roche is allowed to begin selling MIRCERA® in the United States in mid-2014 under terms of a limited license agreement. MIRCERA® has been approved by the FDA for the treatment of anemia associated with CRF.

(5) A subsidiary of Teva Pharmaceutical.

In addition to competition from these marketed products, Affymax, Inc. (Affymax) and Takeda are co-developing peginesatide, a synthetic, PEGylated peptidic compound that binds to and stimulates the erythropoietin receptor and thus acts as an ESA, for the treatment of anemia in CRF patients on dialysis and have submitted an NDA to the FDA. On December 7, 2011, Affymax and Takeda announced that the Oncology Drug Advisory Committee (ODAC) panel voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable risk-benefit profile for use in the treatment of dialysis patients with anemia due to CKD. The FDA has targeted a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2012.

EPOGEN® (epoetin alfa)

We were granted an exclusive license to manufacture and market EPOGEN® in the United States under a licensing agreement with K-A. We have retained exclusive rights to market EPOGEN® in the United States for dialysis patients. We granted Ortho Pharmaceutical Corporation, a subsidiary of J&J (which has assigned its rights under the Product License Agreement to Janssen), a license to commercialize recombinant human erythropoietin as a human therapeutic in the United States in all indications other than dialysis.

We launched EPOGEN® in the United States in 1989 for the treatment of anemia associated with CRF in patients who are on dialysis. We market EPOGEN® in the United States for the treatment of anemic adult and pediatric patients with CRF who are on dialysis. EPOGEN® is indicated for elevating or maintaining the red blood cell level (as determined by hematocrit or Hb measurements) and decreasing the need for blood transfusions in these patients.

EPOGEN® sales in the United States for the years ended December 31, 2011, 2010 and 2009, were $2.0 billion, $2.5 billion and $2.6 billion, respectively.

Our outstanding material patents for epoetin alfa are described in the following table.

Territory	General Subject Matter	Expiration
U.S.	Process of making erythropoietin	8/15/2012
U.S.	Product claims to erythropoietin	8/20/2013
U.S.	Pharmaceutical compositions of erythropoietin	8/20/2013
U.S.	Cells that make certain levels of erythropoietin	5/26/2015

Any products or technologies that are directly or indirectly successful in addressing anemia associated with renal failure could negatively impact EPOGEN® sales. In the United States, as noted above, EPOGEN® and Aranesp® compete with each other, primarily in the U.S. hospital dialysis clinic setting. In addition, EPOGEN® could face additional competition from those products noted in the Aranesp® section above that may be used in dialysis in the United States.

Other Marketed Products

Our other marketed products include Sensipar®/Mimpara® (cinacalcet), Vectibix® (panitumumab), Nplate® (romiplostim), Prolia® (denosumab) and XGEVA® (denosumab).

Sensipar®/Mimpara® (cinacalcet)

Sensipar® is our registered trademark in the United States and Mimpara® is our registered trademark in Europe for cinacalcet, our small molecule medicine used in treating CKD patients on dialysis who produce too much parathyroid hormone (PTH), a condition known as secondary hyperparathyroidism. In 2004, Sensipar®/Mimpara® was approved in the United States and Europe for the treatment of secondary hyperparathyroidism in CKD patients on dialysis and for the treatment of hypercalcemia in patients with parathyroid carcinoma. In 2008, Mimpara® was approved in Europe for the reduction of hypercalcemia in patients with primary hyperparathyroidism (PHPT) where a parathyroidectomy is not clinically appropriate or is contraindicated. In 2011, Sensipar® was approved in the United States for the treatment of severe hypercalcemia in patients with PHPT who are unable to undergo parathyroidectomy. We market Sensipar® primarily in the United States and Mimpara® primarily in Europe.

As previously discussed, CMS's Final Rule on Bundling in Dialysis became effective on January 1, 2011 and provides a single payment for all dialysis services. Oral drugs without intravenous equivalents, such as Sensipar® and phosphate binders, will continue to be reimbursed separately under the Medicare Part D benefit until 2014 when they will be reimbursed under the bundled payment system. Inclusion in the bundled payment system may reduce utilization of these oral drugs and have a material adverse impact on Sensipar® sales. (See Reimbursement.)

The phase 3 EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (E.V.O.L.V.E™) trial, initiated in 2006, is a large (3,800 patient), multi-center, international, randomized, double-blind study to assess the effects of Sensipar®/Mimpara® on mortality and cardiovascular morbidity in patients with CKD undergoing maintenance dialysis. The E.V.O.L.V.E™ study completed enrollment in January 2008 and we anticipate data from the study in 2012.

Worldwide Sensipar®/Mimpara® sales for the years ended December 31, 2011, 2010 and 2009, were $808 million, $714 million and $651 million, respectively.

Our outstanding material patents for cinacalcet are described in the following table.

Territory	General Subject Matter	Expiration
U.S.	Calcium receptor-active molecules including species	10/23/2015
U.S.	Calcium receptor-active molecules	3/8/2018
U.S.	Methods of treatment	12/14/2016
Europe[1]	Calcium receptor-active molecules	10/23/2015

(1) In some cases, this European patent may also be entitled to supplemental protection in one or more countries in Europe and the length of any such extension will vary by country.

Any products or technologies that are directly or indirectly successful in treating secondary hyperparathyroidism in patients with CKD on dialysis and/or hypercalcemia in patients with parathyroid carcinoma could negatively impact Sensipar®/Mimpara® sales.

The following table reflects companies and their currently marketed products that compete with Sensipar® in the United States and with Mimpara® in Europe in the nephrology segment for patients with CKD on dialysis. The table below and the following discussion of competitor marketed products and products in development may not be exhaustive.

Territory	Competitor Marketed Product	Competitor
U.S.	Hectorol®	Genzyme Corporation (Genzyme)
U.S.	Rocaltrol®	Roche
U.S.	Calcijex®	Abbott
U.S.	Calcium Acetate®	Roxane Laboratories/Sandoz
U.S. & Europe	Zemplar®	Abbott
U.S. & Europe	Renagel®	Genzyme
U.S. & Europe	Renvela®	Genzyme
U.S. & Europe	PhosLo®/Rephoren®	Fresenius Medical Care
U.S. & Europe	OsvaRen®	Fresenius Medical Care
U.S. & Europe	Fosrenol®	Shire Pharmaceuticals Group Plc

On July 25, 2008, we filed a lawsuit against Teva and Barr Pharmaceuticals Inc. (Barr) for infringement of four Sensipar® patents. The lawsuit was based on Abbreviated New Drug Applications filed by Teva and Barr that sought approval to market generic versions of Sensipar®. Following trial, on January 7, 2011, the U.S. District Court for the District of Delaware granted an injunction prohibiting Teva and Barr from commercializing generic versions of Sensipar® in the United States until expiration of three of those patents. These generic versions could compete with Sensipar® in the future.

Vectibix® (panitumumab)

Vectibix® is our registered trademark for panitumumab, our monoclonal antibody for the treatment of patients with EGFr expressing mCRC after disease progression on, or following fluoropyrimidine-, oxaliplatin- and irinotecan- containing chemotherapy regimens. EGFr is a protein that plays an important role in cancer cell signaling and is over-expressed in many human cancers. Vectibix® binds with high affinity to EGFrs and interferes with signals that might otherwise stimulate growth and survival of the cancer cell. We acquired full ownership of Vectibix® with our acquisition of Abgenix, Inc. (Abgenix) in April 2006. In September 2006, Vectibix® received FDA accelerated approval in the United States, based upon clinical trial data from a study demonstrating a statistically significant improvement in progression-free survival and with the condition that Amgen conduct a confirmatory trial to verify the clinical benefit of panitumumab through demonstration of an improvement in overall survival. (See discussion of the ‘181 trial below.) In the EU, the conditional approval of Vectibix® as monotherapy, for the treatment of patients with EGFr expressing metastatic colorectal carcinoma with non-mutated (wild-type) *KRAS* genes after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens, was received in December 2007 and is reviewed annually by the Committee for Medicinal Products for Human Use (CHMP). Each year thereafter, the EU conditional marketing authorization was renewed with an additional specific obligation to conduct a clinical trial in the approved monotherapy indication. In 2010, we began enrollment for this additional clinical trial which compares the effect of Vectibix® versus Erbitux® (cetuximab) on overall survival for chemorefractory mCRC patients with wild-type *KRAS* genes. *KRAS* is a protein found in all human cells. Some colorectal cancers have mutations in the *KRAS* gene. Vectibix® has been shown to be ineffective in people whose tumors had *KRAS* mutations in codon 12 or 13.

In 2009, we announced results from the ‘203 and ‘181 pivotal phase 3 trials evaluating Vectibix® in combination with chemotherapy (FOLFOX or FOLFIRI) as a first- and second-line treatment for mCRC, respectively. Both studies demonstrated that Vectibix® administered with chemotherapy significantly improved progression-free survival in patients with wild-type *KRAS* mCRC. Additionally, both studies showed numeric improvements in median overall survival in the same patient population. The numeric improvements in median overall survival failed to achieve statistical significance. It was previously agreed with the FDA that the ‘181 study would serve as the confirmatory trial for establishing full approval for the mCRC indication.

On February 8, 2011, we and four other sponsor companies met with the FDA and the ODAC to discuss the status of our respective PMCs for product indications that had been granted accelerated approval by the FDA prior to 2009, including Vectibix®. At that meeting, we updated the Committee on the completion and submission of the main PMC for Vectibix® and on the confirmatory ’181 study; and we participated in an open discussion with the ODAC on the accelerated approval process.

On July 29, 2011, we announced that we received Complete Response Letters from the FDA on the first- and second-line mCRC sBLAs that we filed in late 2010. The FDA did not ask for new clinical studies but did request an updated safety analysis and additional analyses of the overall survival data in the ’181 and ’203 studies using more mature data sets. The FDA has also informed us that approval for the first- and second-line mCRC indications will be contingent upon approval of the companion diagnostic device being developed in collaboration with QIAGEN N.V., which identifies a patient’s *KRAS* gene status. We are currently working on addressing the FDA’s requests in the Complete Response Letters.

On November 10, 2011, the EC approved a variation to the marketing authorization for Vectibix® to include indications for the treatment of patients with wild-type *KRAS* mCRC in first- and second-line in combination with chemotherapy.

Worldwide Vectibix® sales for the years ended December 31, 2011, 2010 and 2009, were $322 million, $288 million and $233 million, respectively.

Our outstanding material patents for panitumumab are described in the following table.

Territory	General Subject Matter	Expiration
U.S.	Human monoclonal antibodies to EGFr	4/8/2020
U.S.	Human monoclonal antibodies to EGFr	5/5/2017
Europe	Fully human antibodies that bind EGFr	12/3/2017
Europe[(1)]	Human monoclonal antibodies to EGFr	5/5/2018

(1) In some cases, this European patent may also be entitled to supplemental protection in one or more countries in Europe and the length of any such extension will vary by country.

Any products or technologies that are directly or indirectly successful in treating mCRC after disease progression on, or following fluoropyrimidine-, oxaliplatin- and irinotecan- containing chemotherapy regimens could negatively impact Vectibix® sales. The following table reflects the companies that currently market Erbitux®, which competes with Vectibix® in the United States and Europe. The table below and the following discussion of products in development may not be exhaustive.

Territory	Competitor Marketed Product	Competitor
U.S.	Erbitux®	Eli Lilly/BMS
Europe	Erbitux®	Merck KGaA

In addition to competition from Erbitux®, the following products in development could compete with Vectibix® in the future:

- Sanofi filed a BLA with the FDA for approval of ZALTRAP™ for second-line mCRC in early 2012.
- Bayer announced results from its phase 3 trial for regorafenib in patients with mCRC. Bayer is in discussions with health authorities worldwide regarding next steps in filing for approval.

Nplate® (romiplostim)

In August 2008, the FDA approved Nplate® for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune thrombocytopenic purpura (ITP). Nplate® works by raising and sustaining platelet counts. We were granted an exclusive license by K-A to manufacture and market Nplate® in the United States, all European countries, Canada, Australia, New Zealand, Mexico, all Central and South American countries and certain countries in Central Asia, Africa and the Middle East. In

February 2009, we announced that the EC had granted marketing authorization for Nplate® for the treatment of splenectomized adult chronic ITP patients who are refractory to other treatments (e.g., corticosteroids, immunoglobulins). In the EU, Nplate® may also be considered as second-line treatment for adult non-splenectomized ITP patients where surgery is contraindicated.

Worldwide Nplate® sales for the years ended December 31, 2011, 2010 and 2009, were $297 million, $229 million and $110 million, respectively.

Our outstanding material patents for romiplostim are described in the following table.

Territory	General Subject Matter	Expiration
U.S.	Thrombopoietic compounds	1/19/2022
U.S.	Thrombopoietic compounds	10/22/2019
Europe[1]	Thrombopoietic compounds	10/22/2019

(1) In some cases, this European patent may also be entitled to supplemental protection in one or more countries in Europe and the length of any such extension will vary by country.

Any products or technologies that are directly or indirectly successful in treating thrombocytopenia in splenectomized and non-splenectomized adults with chronic ITP could negatively impact Nplate® sales. The following table reflects companies and their currently marketed products that compete with Nplate® in the United States and Europe and may not be exhaustive.

Territory	Competitor Marketed Product	Competitor
U.S.	Promacta®	GlaxoSmithKline plc (GSK)
Europe	Revolade®	GSK

Prolia®/XGEVA® (denosumab)

In 2010, we launched Prolia® and XGEVA®, both of which contain the same active ingredient but which are approved for different indications, patient populations, doses and frequencies of administration. We have a collaboration agreement with Glaxo Group Limited (Glaxo), a wholly owned subsidiary of GSK, for the commercialization of denosumab in certain countries. (See Business Relationships — Glaxo Group Limited.)

Prolia®

On June 1, 2010, the FDA approved Prolia® for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. On September 19, 2011, we announced that the FDA approved two additional indications for Prolia® as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.

We estimate that the large majority of Prolia® usage to date in the United States has been under Medicare Part B. Additionally, most potential U.S. Prolia® patients now also have coverage for Prolia® under Medicare Part D. Future U.S. product sales for Prolia® will depend primarily on postmenopausal osteoporosis disease state awareness, the willingness of primary care physicians to prescribe the product and the availability of reimbursement for and patient acceptance of the product.

On May 25, 2010, the EC granted marketing authorization for Prolia® for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Since the first reimbursement authority was received in Germany in July 2010, reimbursement authority approval has been granted in most EU countries.

Worldwide Prolia® sales for the years ended December 31, 2011 and 2010, were $203 million and $33 million, respectively.

Any products or technologies that are directly or indirectly successful in treating postmenopausal osteoporosis (PMO) in women at high risk for fracture could negatively impact Prolia® sales.

The following table and discussion reflect other companies and their currently marketed products that compete with Prolia®. The table below and the following discussion of competitor marketed products and products in development may not be exhaustive.

Territory	Competitor Marketed Product	Competitor
U.S. & Europe	FOSAMAX®(1)	Merck
U.S. & Europe	Actonel®Atelvia™	Warner Chilcott PLC
U.S. & Europe	Boniva®/Bonviva®	Roche
U.S. & Europe	Evista®	Eli Lilly
U.S. & Europe	Forteo®/Forsteo™	Eli Lilly
U.S. & Europe	Miacalcin®	Novartis AG (Novartis)
U.S. & Europe	Aclasta®/Reclast®	Novartis
Europe	Conbriza®	Pfizer
Europe	Fablyn®	Pfizer

(1) Merck's patent covering the use of FOSAMAX® to treat bone loss expired in the United States in February 2008. Following the patent expiry, generic alendronate, which competes with FOSAMAX® and Prolia®, became available.

We expect several additional marketed products noted above to lose patent protection over the next several years, including Boniva® in 2012, at which time we expect generic versions of these products would become commercially available and compete with Prolia®.

The following companies have product candidates in phase 3 clinical development that may compete with Prolia® in the future:

- Merck (odanacatib), for PMO.
- Radius Health, Inc. (BA058) for PMO.

XGEVA®

On November 18, 2010, the FDA approved XGEVA® for the prevention of SREs in patients with bone metastases from solid tumors. XGEVA® is not indicated for the prevention of SREs in patients with multiple myeloma.

On May 17, 2011, we announced results of a pivotal phase 3 trial (Study '147) in 1,432 men with castration-resistant prostate cancer that has not yet spread to bone. The trial demonstrated that XGEVA® significantly improved median bone metastasis-free survival by 4.2 months compared to placebo (primary endpoint) and significantly improved time to first occurrence of bone metastases (secondary endpoint). Overall survival was similar between the XGEVA® and placebo arms (secondary endpoint), and adverse events and serious adverse events were relatively similar. Hypocalcemia and osteonecrosis of the jaw (ONJ) were reported with increased frequencies in the XGEVA® treated patients compared to placebo. The yearly rate of ONJ in the XGEVA® arm was similar to prior XGEVA® trial results. Back pain was the most common adverse event reported in the XGEVA® arm of the trial. On June 27, 2011, we announced the submission of an sBLA to the FDA to expand the indication to treat men with castration-resistant prostate cancer to reduce the risk of developing bone metastases. On February 8, 2012, the FDA convened the ODAC to discuss the sBLA filing. The ODAC panel voted 12 to 1 that the overall magnitude of benefit demonstrated with early treatment with XGEVA® to delay bone metastases was not sufficient to conclude a positive risk-benefit ratio in the absence of additional measures impacting quality of life or other disease outcomes. The FDA often seeks the advice of an advisory committee such as ODAC when evaluating a potential new treatment. The FDA has targeted a PDUFA action date of April 26, 2012.

On July 15, 2011, we announced that the EC granted marketing authorization for XGEVA® for the prevention of SREs (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. The timing of reimbursement authority approval of pricing in individual EU countries will vary by country, which could follow the EC approval by many months. For example, in August 2011, XGEVA® received reimbursement authority in Germany. The EC also granted XGEVA® an additional year of data and market exclusivity in the EU since the indication was considered new for denosumab and based on the significant clinical benefit of XGEVA® in comparison with existing therapies.

U.S. XGEVA® sales for the years ended December 31, 2011 and 2010, were $351 million and $8 million, respectively.

Any products or technologies that are directly or indirectly successful in treating for the prevention of SREs in patients with bone metastases from solid tumors could negatively impact XGEVA® sales.

The following table reflects currently marketed products that compete with XGEVA®. The table below and the following discussion of competitor marketed products may not be exhaustive.

Territory	Competitor Marketed Product	Competitor
U.S. & Europe	Zometa®(1)	Novartis
U.S. & Europe	Aredia®(2)	Novartis

(1) Novartis has indicated that patent protection on the active ingredient for Zometa® will expire in 2013 in the United States and 2012 in other major markets. At such time, we expect that generic forms of zoledronic acid may become commercially available and compete with Zometa® and XGEVA®.

(2) Novartis's patent covering the use of Aredia® to treat tumor-induced hypercalcemia, osteolysis from multiple myeloma and bone metastases from breast cancer expired in the United States in 2001. Following the patent expiry, generic pamidronate, which competes with Aredia® and XGEVA®, became available from other companies.

In addition, Bayer has a product candidate, alpharadin, in phase 3 clinical development for SREs in patients with prostate cancer, that may compete with XGEVA® in the future.

Our outstanding material patents for denosumab are described in the following table.

Territory	General Subject Matter	Expiration(1)
U.S.	RANKL antibodies; methods of interfering with RANK signaling	12/22/2017
U.S.	Methods of treatment	11/11/2018
U.S.	RANKL antibodies including sequences	2/19/2025
U.S.	Nucleic acids encoding RANKL antibodies, and methods of producing the same	11/11/2023
Europe	RANKL antibodies	12/22/2017
Europe	Medical use of RANKL antibodies	4/15/2018
Europe	RANKL antibodies including epitope binding	2/23/2021
Europe	RANKL antibodies including sequences	6/25/2022

(1) In some cases, these patents may be entitled to patent term extension in the United States or supplemental protection in one or more countries in Europe and the length of any such extension will vary by country.

Marketing and Distribution

We maintain sales and marketing forces primarily in the United States, Europe and Canada to support our currently marketed products. We have also entered into agreements with third parties to assist in the commercialization and marketing of certain of our products in specified geographic areas. (See Business Relationships.) Together with our partners, we market our products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies. We also market certain products directly to consumers

through direct-to-consumer print and television advertising, and also through the Internet. In addition, for certain of our products, we promote programs to increase public awareness of the health risks associated with the diseases these products treat, as well as provide support to various patient education and support programs in the related therapeutic areas. (See Government Regulation — FDA Regulation of Product Marketing and Promotion for a discussion of the government regulation over product marketing and promotion.)

In the United States, we sell primarily to pharmaceutical wholesale distributors. We utilize those wholesale distributors as the principal means of distributing our products to healthcare providers. In Europe, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers, and we limit our credit exposure by setting credit limits and, for certain customers, by requiring letters of credit.

We had product sales to three customers each accounting for more than 10% of total revenues for the years ended December 31, 2011, 2010 and 2009. For 2011, on a combined basis, these customers accounted for 72% and 90% of worldwide gross revenues and U.S. gross product sales, respectively, as noted in the following table. Certain information with respect to these customers for the years ended December 31, 2011, 2010 and 2009, was as follows (dollar amounts in millions):

	2011	2010	2009
AmerisourceBergen Corporation:			
Gross product sales	$7,574	$7,678	$7,179
% of total gross revenues	36%	38%	37%
% of U.S. gross product sales	45%	47%	46%
McKesson Corporation:			
Gross product sales	$4,591	$3,913	$3,694
% of total gross revenues.	22%	19%	19%
% of U.S. gross product sales	27%	24%	24%
Cardinal Health, Inc:			
Gross product sales	$3,021	$2,813	$2,841
% of total gross revenues.	14%	14%	15%
% of U.S. gross product sales	18%	17%	18%

Reimbursement

Sales of all of our principal products are dependent in large part on the availability and extent of coverage and reimbursement from third-party payers, including government and private insurance plans. Most patients receiving our products are covered by government healthcare programs or private insurers. Governments may regulate coverage, reimbursement and/or pricing of our products to control costs or to affect levels of use of our products, and private insurers may adopt or be influenced by government coverage and reimbursement methodologies. Worldwide use of our products may be affected by cost containment pressures and cost shifting from governments and private insurers to healthcare providers or patients in response to ongoing initiatives to reduce or reallocate healthcare expenditures. An increasing worldwide focus on patient access controls and cost containment by public and private insurers has resulted, and may continue to result, in reduced reimbursement rates for our products. In addition, recent healthcare reform efforts enacted in the United States have made substantial long-term changes to the reimbursement of our products, and those changes have had, and are expected to continue to have, a significant impact on our business.

U.S. Reimbursement System

Our principal products are sold primarily in the United States and healthcare providers, including doctors, hospitals and other healthcare professionals and providers, are reimbursed for covered services and products they use by the government through Medicare, Medicaid and other government healthcare programs as well as through private payers. Government healthcare programs are funded primarily through the payment of taxes by individuals and businesses. The public and private components of this multi-payer system are described below.

Medicare and Other Forms of Public Health Insurance

Medicare is a federal program administered by the federal government that covers individuals age 65 and over as well as those with certain disabilities or ESRD, regardless of their age. The primary Medicare programs that affect reimbursement for our products are Medicare Part B, which covers physician services and outpatient care, and Medicare Part D, which provides a voluntary outpatient prescription drug benefit. CMS is the federal agency responsible for administering Medicare (as well as Medicaid, described below) and, among its responsibilities, has authority to promulgate regulations and policies, as well as issue reimbursement codes for drugs, all of which can determine how medical items and services are covered and reimbursed by Medicare. CMS can also issue Medicare NCDs which are national policy statements granting, limiting or excluding Medicare coverage for specific medical items or services applicable throughout the United States. In the absence of a relevant NCD, Medicare coverage determinations for a particular medical item or service are left to MACs, whose LCD's are binding on providers within their respective jurisdictions. CMS sometimes uses advisory committees of external experts in order to obtain independent expert advice on scientific, technical and policy matters. For example, the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) was established to provide independent guidance and expert advice to CMS on specific clinical topics. The MEDCAC reviews and evaluates medical literature, technology assessments, and examines data and information on the effectiveness and appropriateness of medical items and services that are covered under Medicare, or that may be eligible for coverage under Medicare.

Medicare Part B Coverage of Drugs and ESRD. Medicare Part B provides limited coverage of outpatient drugs and biologicals that are reasonable and necessary for a medically accepted diagnosis or treatment of an illness or injury and that fall into a statutory benefit category. One such category relevant to our products is for drugs and biologicals furnished "incident to" a physician's services. Generally, "incident to" drugs and biologicals are covered if they satisfy certain criteria, including that they are of the type that are not usually self-administered by the patient. Medicare Part B also covers certain drugs pursuant to specific statutory benefit categories, such as blood-clotting factors and certain immunosuppressive drugs, erythropoietin and certain oral cancer drugs. Many of our principal products are currently covered under Medicare Part B (as well as other government healthcare programs). In addition, most patients with ESRD, regardless of age, are eligible for coverage of dialysis treatment through the ESRD Program under Medicare Part B. Because Medicare Part B is the primary payer for dialysis treatment, reimbursement for products, such as EPOGEN®, that are typically administered in dialysis centers and other settings is particularly sensitive to changes in Medicare coverage and reimbursement policy. Since January 1, 2011, dialysis treatment has been reimbursed by Medicare under a bundled payment system described in more detail below. (See Dialysis Reimbursement.)

Medicare Part D. Medicare Part D provides a voluntary prescription drug benefit for Medicare eligible beneficiaries. The coverage is available through various private plans that provide insurance coverage for prescription drugs for a monthly premium and with patient cost sharing. The list of prescription drugs covered by Medicare Part D plans varies by plan, but drug lists maintained by individual plans must cover certain classes of drugs and biologicals; specifically the statute stipulates that Medicare Part D plans have at least two drugs in each unique therapeutic category or class, subject to certain exceptions.

Medicaid. Medicaid is a joint federal and state program administered by individual states for low-income and disabled eligible beneficiaries. CMS also has responsibility for federal administration of the Medicaid program. Under federal law, states must cover low-income adults and children, pregnant women, disabled individuals and seniors, and states have the option of expanding eligibility beyond those groups of beneficiaries. Medicaid is financed jointly by the states and federal government through taxes. Medicaid offers a broad set of benefits, including prescription drugs. Medicaid includes the Drug Rebate Program which requires manufacturers to provide rebates to the states for products covered and reimbursed by state Medicaid programs.

See Item 1A. Risk Factors — Our sales depend on coverage and reimbursement from third-party payers.

Private Health Insurance

Employer-sponsored insurance. Employer-sponsored insurance currently represents the main pathway by which Americans receive private health insurance. Many employers provide health insurance as part of

employees' benefit packages. Insurance plans are administered by private companies, both for-profit and not-for-profit, and some companies are "self-insured" (i.e., they pay for all healthcare costs incurred by employees directly through a plan administered by a third party). Generally, employer-sponsored insurance premiums are paid primarily by employers and secondarily by employees.

Individual market. The individual market covers part of the population that is self-employed or retired. In addition, it covers some people who are unable to obtain insurance through their employers. The plans are administered by private insurance companies. Individuals pay out-of-pocket insurance premiums for coverage, and the benefits vary widely according to plan specifications.

Reimbursement of Our Principal Products

Neulasta®, NEUPOGEN® and Aranesp®. Medicare and Medicaid payment policies for drugs and biologicals are subject to various laws and regulations. The Medicare program covers our principal products Neulasta®, NEUPOGEN® and Aranesp® (as well as certain of our other products including Vectibix®, Nplate®, Prolia® and XGEVA®) under Part B, when administered in the physician clinic setting and the hospital outpatient settings. Healthcare providers are reimbursed for these products under a "buy and bill" process where providers purchase the product in advance of treatment and then submit a reimbursement claim to Medicare following administration of the product. Medicare reimburses providers using a payment methodology based on a fixed percentage of each product's average sales price (ASP). ASP is calculated by the manufacturer based on a statutorily defined formula and submitted to CMS. A product's ASP is calculated and reported to CMS on a quarterly basis and therefore may change each quarter. The ASP in effect for a given quarter (the Current Period) is based upon certain historical sales and sales incentive data covering a defined period of time preceding the Current Period. CMS publishes the ASPs for products in advance of the quarter in which they go into effect so healthcare providers will know the applicable reimbursement rates. In the calculation of ASP, CMS currently allows manufacturers to make reasonable assumptions consistent with the general requirements and the intent of the Medicare statute and regulations and their customary business practices and in the future CMS may provide more specific guidance. Any changes to the ASP calculations directly affect the Medicare reimbursement for our products administered in the physician clinic setting, hospital outpatient setting and, to a lesser extent, the dialysis facility setting. (See EPOGEN® and Dialysis Reimbursement.) Our ASP calculations are reviewed quarterly for completeness and based on such review, we have on occasion restated our reported ASPs to reflect calculation changes both prospectively and retroactively. (See Items 1A. Risk Factors — Our sales depend on coverage and reimbursement from third-party payers.)

Since 2005, products provided in the physician office setting under Medicare Part B have been reimbursed at 106% of their ASP (sometimes referred to as "ASP+6%"), and in 2012 will continue to be reimbursed at this rate pursuant to the 2012 Medicare Physician Fee Schedule Final Rule. In the hospital outpatient setting, from 2006 to 2010 Medicare reimbursement rates fell incrementally from ASP+6% to ASP+4%, then rose in 2011 to ASP+5%. Pursuant to the 2012 Hospital Outpatient Prospective Payment Final Rule, the rate will fall again to ASP+4% in 2012. CMS has the regulatory authority to further adjust formulas in future years. The extent to which commercial payers adopt the use of ASP as a payment methodology is often based on the contractual relationship between the provider and the insurer.

Dialysis Reimbursement. Currently, dialysis providers in the United States are reimbursed for EPOGEN® primarily by Medicare through the ESRD Program, which is established by federal law and implemented by CMS. Historically, the ESRD Program reimbursed Medicare providers for 80% of allowed dialysis costs; the remainder was paid by other sources, including patients, state Medicaid programs, private insurance, and to a lesser extent, state kidney patient programs. Until January 1, 2011, Medicare reimbursed for separately billable dialysis drugs (including Aranesp® and EPOGEN®) administered in both freestanding and hospital-based dialysis centers, at ASP+6%, using the same payment amount methodology used in the physician clinic setting under Part B. On January 1, 2011, CMS's bundled payment system went into effect for dialysis providers which provides a single payment for all dialysis services including drugs, supplies and non-routine laboratory tests that were previously reimbursed separately. ESRD providers receive a designated payment for each dialysis treatment and can be paid for up to three treatments per week, unless medical necessity justifies more frequent treatments. Oral

drugs without intravenous equivalents, including Sensipar® and phosphate binders, will remain under the Medicare Part D benefit until 2014 when they will be reimbursed under the bundled payment system.

To encourage dialysis providers to continue to provide quality dialysis treatment under the new bundled payment system, CMS also implemented the ESRD QIP. Under the QIP, beginning in 2012, ESRD facilities will be subject to a payment penalty of up to 2% of amounts reimbursed for failure to meet or exceed CMS' quality performance standards, including performance standards related to anemia management and dialysis adequacy. Under the QIP as originally implemented, a provider's penalty in 2012 will be based on the provider's composite score for the following performance measures achieved during 2010:

- the percent of Medicare patients with Hb levels below 10 g/dL constitutes 50% of the weighting;
- the percent of Medicare patients with Hb levels above 12 g/dL represents 25% of the weighting; and
- the percent of Medicare patients with an average Urea Reduction Ratio of greater than or equal to 65% constitutes 25% of the weighting.

On November 1, 2011, CMS finalized a rule to update the QIP, eliminating for payment year 2013 and beyond the QIP's measure that tracks the percent of a provider's Medicare patients with a Hb level below 10 g/dL. Beginning in payment year 2013, the remaining two metrics will each constitute 50% of the weighting. CMS indicated that removal of this measure from the QIP was being done in response to the June 2011 ESA label changes.

ENBREL Reimbursement. The majority of prescription claims for ENBREL are paid through private insurance companies. Under Medicare, ENBREL is reimbursed through the Part D program, although less than 10% of all ENBREL U.S. prescriptions are reimbursed by Medicare.

Medicaid Reimbursement

Since 1991, we have participated in the Medicaid drug rebate program established in Section 1927 of the Social Security Act by the Omnibus Budget Reconciliation Act of 1990 and subsequent amendments of that law. Under the Medicaid drug rebate program, we pay a rebate to the states for each unit of our product reimbursed by state Medicaid programs. As more fully described below, the healthcare reform law enacted in the United States in March 2010 made certain changes in how those rebates are calculated and to whom they must be extended. (See U.S. Healthcare Reform.) The amount of the rebate for each of our products is currently set by law as a minimum of 23.1% of the Average Manufacturer Price (AMP) of that product, or if it is greater, the difference between AMP and the best price available from us to any non-government customer. The rebate amount is determined for each quarter based on our reports to CMS of the quarter's AMP and best price for each of our products. The rebate amount also includes an inflation adjustment if AMP increases faster than inflation. As described below, the statutory definition of AMP changed in 2010 as a result of the U.S. healthcare reform law, and in January 2012, CMS issued a proposed rule further defining the new AMP definition. Until that rule is finalized, we are required to make reasonable assumptions when calculating AMP. Once CMS's proposed rule is finalized, we will have to determine whether our calculations should be amended and whether we will need to restate our prior AMPs.The terms of our participation in the Medicaid drug rebate program impose an obligation to correct the prices reported in previous quarters, as may be necessary. Any such corrections could result in an overage or underage in our rebate liability for past quarters, depending on the direction of the correction. In addition to retroactive rebates, if we were found to have knowingly submitted false information to the government, in addition to other penalties available to the government, the statute provides for civil monetary penalties in the amount of $100,000 per item of false information.

Related to our participation in the Medicaid drug rebate program is a requirement that we extend comparable discounts under the Public Health Service (PHS) drug pricing program to a variety of community health clinics and other entities that receive health services grants from the PHS, as well as hospitals that serve a disproportionate share of Medicare and Medicaid beneficiaries. As more fully described below, the list of entities to which we are required to extend these discounts also expanded as a result of the U.S. healthcare reform law.

We also make our products available to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration. Since 1993, as a result of the Veterans Health Care Act of 1992 (the VHC Act), federal law has required that we offer deeply discounted FSS contract pricing for purchases by the Department of Veterans Affairs, the Department of Defense, the Coast Guard and the PHS (including the Indian Health Service) in order for federal funding to be available for reimbursement of our products under the Medicaid program or purchase of our products by those four federal agencies and certain federal grantees. FSS pricing to those four federal agencies must be equal to or less than the Federal Ceiling Price (FCP), which is 24% below the Non-Federal Average Manufacturer Price (Non-FAMP) for the prior fiscal year. The accuracy of our reported Non-FAMPs, FCPs and our FSS contract prices may be audited by the government under applicable federal procurement laws and the terms of our FSS contract. Among the remedies available to the government for inaccuracies in calculation of Non-FAMPs and FCPs is recoupment of any overcharges to the four specified Federal agencies based on those inaccuracies. Also, if we were found to have knowingly reported a false Non-FAMP, in addition to other penalties available to the government, the VHC Act provides for civil monetary penalties of $100,000 per item that is incorrect. Finally, we are required to disclose in our FSS contract proposal all commercial pricing that is equal to or less than our proposed FSS pricing, and subsequent to award of an FSS contract, we are required to monitor certain commercial price reductions and extend commensurate price reductions to the government, under the terms of the FSS contract Price Reductions Clause. Among the remedies available to the government for any failure to properly disclose commercial pricing and/or to extend FSS contract price reductions is recoupment of any FSS overcharges that may result from such omissions.

U.S. Healthcare Reform. In March 2010, the Patient Protection and Affordable Care Act (the PPACA) and the companion Health Care and Education Reconciliation Act, which made certain changes and adjustments to the PPACA, primarily with respect to the PPACA's financial and budgetary impacts, were signed into law. We refer to those two laws collectively as the "U.S. healthcare reform law." The U.S. healthcare reform law imposes additional costs on and reduces the revenue of companies in the biotechnology and pharmaceutical industries. The following paragraphs describe certain provisions of the new healthcare reform law that are affecting and will affect the reimbursement of our products.

The U.S. healthcare reform law increased the rebates we pay to the states for our products that are covered and reimbursed by state Medicaid programs. The healthcare reform law increased the minimum base Medicaid rebate rate payable on our products reimbursed by Medicaid from 15.1% to 23.1% of the AMP of the product, or if it is greater, the difference between the AMP and the best price available from us to any non-government customer. The change in the minimum rebate percentage was effective on January 1, 2010. The healthcare reform law also extended the Medicaid drug rebate program to patients in Medicaid managed care insurance plans for whom rebates were not previously required. The extension of rebates to patients in Medicaid managed care plans was effective on March 23, 2010.

As mentioned above, the U.S. healthcare reform law also expanded the list of provider institutions to which we must extend discounts under the PHS 340B drug pricing program. The U.S. healthcare reform law added certain cancer centers, children's hospitals, critical access hospitals and rural referral centers to the list of entities to which these discounts must be extended. This change to the list of eligible entities was effective on January 1, 2010. The U.S. healthcare reform law also imposed a new fee (the U.S. healthcare reform federal excise fee) on manufacturers and importers of "branded prescription drugs," which includes drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act or biologicals licensed under section 351(a) of the Public Health Service Act. Beginning in 2011, the U.S. healthcare reform law sets an aggregate annual fee, to be paid by these manufacturers and importers, totaling $28 billion over 10 years, of which $2.5 billion was payable in 2011. This annual fee is apportioned among the participating companies, including us, based on each company's sales of qualifying products to, and utilization by, certain U.S. government programs during the preceding calendar year. The additional fee became effective January 1, 2011, and is not deductible for U.S. federal income tax purposes. Manufacturers and importers of generic or biosimilar drugs are not subject to the fee.

Since the Medicare Part D drug benefit took effect in 2006, beneficiaries enrolled in Part D plans have been required to pay 100% of their prescription drug costs after their total drug spending exceeds an initial coverage limit until they qualify for catastrophic coverage. This coverage gap is sometimes referred to as the Part D

"doughnut hole." The U.S. healthcare reform law reduces the "doughnut hole" by requiring manufacturers like us to provide a 50% discount to Medicare Part D patients whose prescription expenses exceed the Part D prescription drug coverage limit but have not yet reached the catastrophic coverage threshold. This provision became effective January 1, 2011.

The U.S. healthcare reform law also expands the Medicaid eligibility to include those with incomes up to 133% of the federal poverty level (FPL), from 100% of the FPL. This provision becomes effective January 1, 2014.

Impact of Budget Control Act on U.S. Reimbursement

The Budget Control Act of 2011, signed into law in the United States in August 2011, mandated a two percent reduction in government payments for all Medicare services (including the administration of separately-billable drugs and payment for drugs in all Medicare programs) for federal fiscal years 2013 through 2021, unless a subsequent deficit reduction law was passed before January 2012. As no additional deficit reduction law was enacted by January 2012, the payment reduction (or "sequestration") will likely start in January 2013 and continue until December 2021, subject to administrative implementation of the Budget Control Act or future statutory revision. A reduction in the availability or extent of reimbursement from U.S. government programs as a result of the sequestration or from other changes designed to achieve similar federal budget savings could have a material adverse effect on the sales of our products, our business and results of operations.

Reimbursement Outside the United States

Generally, in Europe and other countries outside the United States, government-sponsored healthcare systems have traditionally been the primary payers of all healthcare costs, including payment for drugs and biologicals. Over the past several years, the reimbursement environment in Europe has become very challenging, including as a result of the proliferation of Health Technology Assessment (HTA) organizations (e.g., National Institute for Health and Clinical Excellence (NICE) in the UK) that make recommendations and/or determinations of coverage and reimbursement based on both the clinical as well as the economic value of a product. Although the methods employed by different HTA agencies vary from country to country, the use of formal economic metrics has been increasing across Europe as well as in several emerging markets throughout the world. In addition to determining whether or not a new product will be reimbursed, these agencies are becoming increasingly involved in setting the maximum price at which the product will be reimbursed — the "value-based" price for a product.

With increased budgetary constraints, payers in many countries employ a variety of measures to exert downward price pressure. In some countries, international price referencing is the primary mechanism for price control whereby the ceiling price of a pharmaceutical or biological product is set based on the prices in particular benchmark countries. These price referencing rules are increasing in complexity as payers seek lower-price benchmarks against which to compare themselves. Trends across Europe are also leading toward increased price transparency, with the development of databases to include prices across Europe and requests from specific national payers to provide commercially confidential net price information. Additional cost-containment measures can include therapeutic reference pricing (e.g., setting the reimbursement rate for a given class of agents at the lowest price within the class), increasing mandates or incentives for generic substitution and government-mandated price cuts. In addition, healthcare reform in France, Germany and Spain, as well as austerity plans in a number of countries, including Greece, Italy and Portugal, have targeted the pharmaceutical sector with multiple mechanisms to reduce government healthcare expenditures. Other countries may follow and/or take similar or more extensive actions to reduce expenditures on drugs and biologics, including implementing mandatory price reductions, initiating clawbacks of payments made to companies when national hospital drug spending thresholds are exceeded, establishing preferences for biosimilar products, or reducing the amount of reimbursement. Similarly, fiscal constraints may also impact the extent to which countries are willing to reward new innovative therapies and/or allow access to new technologies.

In many countries, the influence of regional and hospital payers also contributes to whether patients have access to certain products. For example, a product may be successfully listed on a national formulary, but may also be subject to further evaluations or competitive bidding by payers at a regional or hospital level. The impact of multiple layers of assessment can result in delay or failure to secure access and/or net price pressure.

Payers in some countries are using and others are beginning to experiment with alternative payment mechanisms (e.g., payment caps, risk sharing) as a means to maintain access to innovative therapies while increasing their budget certainty. Requirements for such payment mechanisms can impact Amgen's business through increased net price concessions and added administrative burden.

Fraud and Abuse Regulations Related to Reimbursement

As participants in government reimbursement programs, we are subject to various U.S. federal and state laws, as well as foreign laws, pertaining to healthcare "fraud and abuse," including anti-kickback laws and false claims laws. (See Government Regulation — Other.) Violations of fraud and abuse laws can result in stringent enforcement penalties up to and including complete exclusion from federal healthcare programs (including Medicare and Medicaid).

Manufacturing, Distribution and Raw Materials

Manufacturing

Biological products, which are produced in living systems, are inherently complex due to naturally-occurring molecular variations. Highly specialized knowledge and extensive process and product characterization are required to transform laboratory scale processes into reproducible commercial manufacturing processes. Our manufacturing operations consist of bulk manufacturing, formulation, fill and finish and distribution activities. Bulk manufacturing includes fermentation and/or cell culture, processes by which our proteins are produced, and also includes purification of the proteins to a high quality. The proteins are then formulated into a stable form. The fill process dispenses the formulated bulk protein into vials or syringes. Finally, in the finish process, our products are packaged for distribution.

We operate a number of commercial and/or clinical manufacturing facilities, and our primary facilities are located in the United States, Puerto Rico and the Netherlands. (See Item 2. Properties.) We also use and expect to continue to use third-party contract manufacturers to produce or assist in the production of certain of our large molecule marketed products as well as a number of our clinical product candidates. Manufacturing of Sensipar®/Mimpara®, our small molecule product, is currently performed by third-party contract manufacturers, except for certain finish activities performed by us in Puerto Rico.

The global supply of our products depends on actively managing the inventory produced at our facilities and by third-party contract manufacturers and the uninterrupted and efficient operation of these facilities. During the manufacturing scale-up process, and even after achieving sustainable commercial manufacturing, we may encounter difficulties or disruptions due to defects in raw materials or equipment, contamination or other factors that could impact product availability. (See Item 1A. Risk Factors — Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales and — We rely on third-party suppliers for certain of our raw materials, medical devices and components.)

Commercial Bulk Manufacturing

We operate commercial bulk manufacturing facilities in Puerto Rico and in several locations throughout the United States. (See Item 2. Properties.) We perform commercial bulk manufacturing for our proteins except Vectibix®, which is performed by a third-party contract manufacturer. We also supplement commercial bulk manufacturing for ENBREL, Prolia® and XGEVA® with a third-party contract manufacturer.

Commercial Formulation, Fill and Finish Manufacturing

We perform most of our commercial protein formulation, fill and finish manufacturing in our Puerto Rico facility. Formulation, fill and finish manufacturing for Nplate® and Vectibix® is performed by third-party

contract manufacturers. In addition to the formulation, fill and finish of ENBREL performed by us in Puerto Rico, fill and finish of a certain portion of ENBREL is also performed by third-party contract manufacturers. We also conduct certain finish activities in the Netherlands. (See Item 2. Properties.)

Clinical Manufacturing

Clinical bulk, formulation, fill and finish manufacturing facilities are operated primarily in our Thousand Oaks, California location. (See Item 2. Properties.) Clinical bulk and fill manufacturing activities for our clinical product candidate, talimogene laherparepvec, are performed at our Woburn, Massachusetts facility. Certain finish activities for our clinical products are also performed in the Netherlands. In addition, we also utilize third-party contract manufacturers for certain of our clinical products.

See Item 1A. Risk Factors — We perform a substantial amount of our commercial manufacturing activities at our Puerto Rico manufacturing facility and a substantial amount of our clinical manufacturing activities at our Thousand Oaks, California manufacturing facility; if significant natural disasters or production failures occur at the Puerto Rico facility, we may not be able to supply these products or, at the Thousand Oaks facility, we may not be able to continue our clinical trials.

Distribution

We operate distribution centers in the United States, principally in Kentucky and California, and in the Netherlands for worldwide distribution of the majority of our commercial and clinical products. In addition, we also use third-party distributors to supplement distribution of our commercial and clinical products in certain areas of the world.

Other

In addition to the manufacturing and distribution activities noted above, our operations in the United States, Puerto Rico and the Netherlands perform key manufacturing support functions, including quality control, process development, procurement, distribution and production scheduling. Certain of those manufacturing and distribution activities are highly regulated by the FDA as well as other international regulatory agencies. (See Government Regulation — FDA Regulation of Manufacturing Standards.)

Manufacturing Initiatives

We have multiple ongoing initiatives that are designed to optimize our manufacturing network and/or mitigate risks while continuing to ensure adequate supply of our commercial products. The facilities impacted by each of these initiatives will require qualification and licensure by various regulatory authorities. These initiatives include:

- Construction of a new formulation and fill facility at our Puerto Rico site;
- Expansion of our bulk protein facilities at our Puerto Rico site;
- Modification and expansion of our recently acquired formulation, fill and finish site in Ireland; and
- Expansion of our Colorado and Rhode Island facilities to enable manufacturing of certain clinical products as well as to provide alternative bulk manufacturing sources for certain marketed products.

In addition to these initiatives, we have projects designed to operate our facilities at appropriate production capacity over the next few years, further optimize manufacturing asset utilization, continue our use of third-party contract manufacturers and maintain a state of regulatory compliance. (See Item 1A. Risk Factors — Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.)

Raw Materials and Medical Devices

Certain raw materials necessary for the commercial and clinical bulk manufacturing of our products are provided by unaffiliated third-party suppliers, certain of which may be our only source for such materials. Also,

certain medical devices and components necessary for the formulation, fill and finish of our products are provided by unaffiliated third-party suppliers, certain of which may be the sole source. Certain of the raw materials, medical devices and components are the proprietary products of those unaffiliated third-party suppliers and are specifically cited in our drug application with regulatory agencies so that they must be obtained from the specific sole source or sources and could not be obtained from another supplier unless and until the regulatory agency approved such supplier. We currently attempt to manage the risk associated with such suppliers by inventory management, relationship management and evaluation of alternative sources when feasible. We also monitor the financial condition of certain suppliers and their ability to supply our needs.

Certain of the raw materials required in the commercial and clinical manufacturing of our products are sourced from other countries and/or derived from biological sources, including mammalian tissues. In addition, one of our marketed products also uses bovine serum and human serum albumin. Some countries in which we market our products may restrict the use of certain biologically derived substances in the manufacture of drugs. We continue to investigate alternatives to certain biological sources and alternative manufacturing processes that do not require the use of certain biologically derived substances because such raw materials may be subject to contamination and/or recall. A material shortage, contamination, recall and/or restriction of the use of certain biologically derived substances or other raw materials, which may be sourced from other countries and that are used in the manufacture of our products could adversely impact or disrupt the commercial manufacturing of our products or could result in a mandated withdrawal of our products from the market. (See Item 1A. Risk Factors — We rely on third-party suppliers for certain of our raw materials, medical devices and components.)

We perform various procedures to assist in authenticating the source of raw materials, including intermediary materials used in the manufacture of our products, which include verification of the country of origin. These procedures are incorporated into the manufacturing processes we and our third-party contract manufacturers perform.

Government Regulation

Regulation by government authorities in the United States and other countries is a significant factor in the production and marketing of our products and our ongoing R&D activities.

In order to clinically test, manufacture and market products for therapeutic use, we must satisfy mandatory procedures and safety and effectiveness standards established by various regulatory bodies. In the United States, the Public Health Service Act, the Federal Food, Drug and Cosmetic Act (FDCA) and the regulations promulgated thereunder, as well as other federal and state statutes and regulations govern, among other things, the raw materials and components used in the production, research, development, testing, manufacture, quality control, labeling, storage, record keeping, approval, advertising and promotion, and distribution of our products. Failure to comply with the applicable regulatory requirements may subject us to a variety of administrative and/or judicially imposed sanctions. The sanctions could include the FDA's refusal to approve pending applications, withdrawals of approvals, delay or suspension of clinical trials, warning letters, product recalls, product seizures, total or partial suspension of our operations, injunctions, fines, civil penalties and/or criminal prosecution.

Clinical Development. We must conduct extensive clinical trials designed to establish the safety and efficacy of product candidates in order to file for regulatory approval to market a product. Product development and approval within that regulatory framework takes a number of years and involves our expenditure of substantial resources, and any approval we obtain remains costly for us to maintain. After laboratory analysis and preclinical testing in animals, we file an investigational new drug application (IND) with the FDA to begin human testing. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions. In such a case, we and the FDA must resolve any outstanding concerns before the clinical trial can begin.

Typically, we undertake a three-phase human clinical testing program. In phase 1, we conduct small clinical trials to investigate the safety and proper dose ranges of our product candidates in a small number of human subjects. In phase 2, we conduct clinical trials to investigate side effect profiles and the efficacy of our product candidates in a larger number of patients who have the disease or condition under study. In phase 3, we conduct

clinical trials to investigate the safety and efficacy of our product candidates in a large number of patients who have the disease or condition under study. The time and expense required for us to perform this clinical testing is substantial and may vary by product. For example, the clinical trials for the BLA for Prolia®/XGEVA® were large and required substantial time and resources to recruit patients and significant expense to execute. Historically, our products have required smaller, shorter trials. Foreign studies performed under an IND must meet the same requirements that apply to U.S. studies. The FDA will accept a foreign clinical study not conducted under an IND only if the study is well-designed, well-conducted, performed by qualified investigators, and conforms to good clinical practice. Phase 1, 2 and 3 testing may not be completed successfully within any specified time period, if at all. (See Item 1A. Risk Factors — We may not be able to develop commercial products.) The FDA monitors the progress of each trial conducted under an IND and may, at its discretion, re-evaluate, alter, suspend, or terminate the testing based on the data accumulated to that point and the FDA's risk/benefit assessment with regard to the patients enrolled in the trial. (See Item 1A. Risk Factors — We must conduct clinical trials in humans before we can commercialize and sell any of our product candidates or existing products for new indications.)

Applications. The results of preclinical and clinical trials are submitted to the FDA in the form of a BLA for biologic products subject to the Public Health Service Act or an NDA for drugs subject to the approval provisions of the FDCA. The submission of the application is no guarantee that the FDA will find it complete and accept it for filing. If an application is accepted for filing, following the FDA's review, the FDA may grant marketing approval, request additional information, or deny the application if it determines that the application does not provide an adequate basis for approval. We cannot take any action to market any new drug or biologic product in the United States until our appropriate marketing application has been approved by the FDA.

Post-approval Phase. After we have obtained approval to market our products, we monitor adverse events from the use of our products and report such events to regulatory agencies, along with information from post marketing surveillance or studies. We may utilize other research approaches to learn or confirm information about our marketed products, including observational studies and patient registries, and may engage in risk management activities such as physician education initiatives and patient advocacy group initiatives. We may also conduct, or be required by regulatory agencies to conduct, further clinical trials to provide additional information on our marketed products' safety and efficacy. Those additional trials may include studying different doses or schedules of administration that were used in previous studies, use in other patient populations or other stages of the disease or use over a longer period of time. Additional trials of this nature are sometimes required by regulatory agencies as a condition of their approval to market our products and they might also request or require that we conduct specific studies, including observational epidemiological studies, in order to identify or assess possible safety risks of our marketed products that are observed or suggested by available scientific data and such trials are sometimes referred to as PMCs or PMRs. In the United States, under the Food and Drug Administration Amendments Act of 2007 (the FDAAA), if the FDA becomes aware of new safety information after approval of a product, it may require us to conduct further clinical trials to assess a known or potential serious risk. If we are required to conduct such a post-approval study, periodic status reports must be submitted to the FDA. Failure to conduct such post-approval studies in a timely manner may result in substantial civil or criminal penalties. Data resulting from these clinical trials may result in expansions or restrictions to the labeled indications for which our products have already been approved and to the reimbursement provided by government and commercial payers for our products.

The FDAAA also gave the FDA authority to require companies to implement a REMS for a product to ensure that the benefits of the drugs outweigh the risks. While risk management activities and programs are not new, with FDAAA the FDA gained new authority to implement specific risk management requirements and new enforcement power to ensure that the goals of the REMS are being met. The FDA began to implement REMS in 2008. The FDA may require the submission of a REMS before a product is approved or after approval based on new safety information, including new analyses of existing safety information. In determining whether a product will require a REMS before the product is approved, the FDA may consider a number of factors including:

- estimated size of the population likely to use the product;
- seriousness of the condition treated and expected benefits of the product;

- duration of treatment with the product;
- seriousness of known or potential adverse events associated with the product; and
- whether the product is a new molecular entity.

All REMS are required to have a timetable for assessment and may have one or more of the following:

- distribution of a medication guide or a patient package insert to patients;
- communication plan for the healthcare provider or institution, such as a Dear Healthcare Professional Letter;
- elements to assure safe use including, but not limited to:
    - specific training, experience or certification for prescribers;
    - certification of medication dispensing sites and dispensing in limited settings;
    - monitoring of specific patients; and
    - enrollment of patients in a registry.

Each REMS is unique and varies depending on the specific factors required. While the elements of REMS may vary, all REMS require the sponsor to submit periodic assessment reports to the FDA to demonstrate that the goals of the REMS are being met. Failure to comply with a REMS, including submission of a required assessment or any modification to a REMS, may result in substantial civil or criminal penalties and can result in additional limitations being placed on a product's use and, potentially, withdrawal of the product from the market. We currently have approved REMS for our ESAs, Prolia® and Nplate®. As REMS are relatively new, the FDA and sponsor companies continue to learn how best to implement, operate and monitor the effectiveness of REMS, and the requirements of our REMS and those of other companies may change over time.

Adverse events that are reported after marketing approval also can result in additional limitations being placed on a product's use and, potentially, withdrawal of the product from the market. The FDA has authority to mandate labeling changes to products at any point in a product's lifecycle based on new safety information or as part of an evolving label change to a particular class of products.

The FDA also uses various advisory committees of external experts to assist in its mission to protect and promote the public health, to obtain independent expert advice on scientific, technical and policy matters. The committees are generally advisory only and FDA officials are not bound to or limited by their recommendations. We have participated in meetings of the ODAC, the Cardiovascular and Renal Drug Advisory Committee and the Advisory Committee for Reproductive Health Drugs, among others, to address certain issues related to our products, including Aranesp®, EPOGEN®, Prolia® and XGEVA®.

FDA Approval of Biosimilar Products. The U.S. healthcare reform law authorizes the FDA to approve biosimilar products under a separate, abbreviated pathway. The new law establishes a period of 12 years of data exclusivity for reference products in order to preserve incentives for future innovation and outlines statutory criteria for science-based biosimilar approval standards that take into account patient safety considerations. Under this framework, data exclusivity protects the data in the innovator's regulatory application by prohibiting others, for a period of 12 years, from gaining FDA approval based in part on reliance or reference to the innovator's data in their application to the FDA. The new law does not change the duration of patents granted on biologic products. On February 9, 2012, the FDA released three draft guidance documents as part of the implementation of the abbreviated approval pathway for biosimilar products. While FDA guidance documents are not legally binding on the public or on the FDA, they indicate the FDA's views on a subject. The draft guidance documents provide insight to the FDA's current thinking on the development of biosimilar products and address a range of technical, scientific and regulatory issues. The guidance documents generally provide that, for approval, a sponsor must demonstrate that the proposed product is "biosimilar" to a single reference product already licensed by the FDA. In assessing biosimilarity, the FDA indicated that it intends to use a risk-based "totality of the evidence" approach to evaluate all available data submitted by the applicant. Generally, a

biosimilar application must include a clinical study or studies sufficient to demonstrate safety, purity and potency in one or more indications for which the reference product is licensed and the biosimilar applicant seeks approval. The scope and magnitude of clinical data needed will depend on the extent of uncertainty about the biosimilarity of the product as well as the frequency and severity of safety risks associated with the reference product. The FDA indicated that it is still evaluating a number of relevant issues, including criteria for interchangeability (which FDA indicated would be "higher standard" than biosimilarity). The FDA will accept public comments on the guidance documents for 60 days, following which it may issue final guidance. The FDA has also stated publicly that it intends to hold a follow-up public meeting in the near future to obtain feedback on what additional clarification on the biosimilars approval process is needed.

FDA Regulation of Product Marketing and Promotion. The FDA closely reviews and regulates the marketing and promotion of products. We are required to obtain FDA approval before marketing or promoting a product as a treatment for a particular indication. Our product promotion for approved product indications must comply with the statutory standards of the FDCA, and the FDA's implementing regulations and standards. The FDA's review of marketing and promotional activities encompasses, but is not limited to, direct-to-consumer advertising, healthcare provider-directed advertising and promotion, sales representative communications to healthcare professionals, promotional programming and promotional activities involving the Internet. The FDA may also review industry-sponsored scientific and educational activities. The FDA may take enforcement action against a company for promoting unapproved uses of a product or for other violations of its advertising and labeling laws and regulations. Enforcement action may include product seizures, injunctions, civil or criminal penalties or regulatory letters, which may require corrective advertising or other corrective communications to healthcare professionals. Failure to comply with the FDA's regulations also can result in adverse publicity or increased scrutiny of company activities by the U.S. Congress or other legislators.

FDA Regulation of Manufacturing Standards. The FDA regulates and inspects equipment, facilities, laboratories and processes used in the manufacturing and testing of products prior to providing approval to market a product. If after receiving approval from the FDA, we make a material change in manufacturing equipment, location or process, additional regulatory review may be required. We also must adhere to current Good Manufacturing Practice regulations and product-specific regulations enforced by the FDA through its facilities inspection program. The FDA also conducts regular, periodic visits to re-inspect our equipment, facilities, laboratories and processes following an initial approval. If, as a result of those inspections, the FDA determines that our equipment, facilities, laboratories or processes do not comply with applicable FDA regulations and conditions of product approval, the FDA may seek civil, criminal or administrative sanctions and/or remedies against us, including suspension of our manufacturing operations. Such issues may also delay the approval of new products undergoing FDA review.

Approval and Post-Approval Regulation Outside the United States. In the EU countries, Switzerland, Canada and Australia, regulatory requirements and approval processes are similar in principle to those in the United States. Additionally, depending on the type of drug for which approval is sought, there are currently two potential tracks for marketing approval in the EU, including a centralized procedure. In the centralized procedure, which is required of all products derived from biotechnology, a company submits a single marketing authorization application to the European Medicines Agency (EMA) who conducts a thorough evaluation, drawing from its scientific resources across Europe. If the drug product is proven to fulfill the requirements for quality, safety and efficacy, the CHMP adopts a positive opinion, which is transmitted to the EC for final approval of the marketing authorization. While the EC generally follows the CHMP's opinion, it is not bound to do so. In the EU, biosimilar products have been approved under a sub-pathway of the centralized procedure since 2006. The pathway allows sponsors of a biosimilar product to seek and obtain regulatory approval based in part on the clinical trial data of an originator product to which the biosimilar product has been demonstrated to be "similar." In many cases, this allows biosimilar products to be brought to market without conducting the full suite of clinical trials typically required of originators. After evaluation and marketing authorization, various parties, including the national competent authorities, the EMA, the EC and the marketing authorization holders share responsibilities for the detection, assessment and prevention of adverse effects and other medicine-related problems in a process known as pharmacovigilance. Healthcare professionals and patients are also encouraged to

report adverse effects and other medicine-related problems. This process includes the collection of adverse drug reaction reports as part of the follow-up on any side effects of a product, and upon assessment, the authorities can decide to demand that product labels be updated with safety data or warnings, that safety data or warnings be provided to healthcare professionals, or recommend the temporary suspension or complete withdrawal of a product from the market.

Other. We are also subject to various federal and state laws, as well as foreign laws, pertaining to healthcare "fraud and abuse," including anti-kickback laws and false claims laws. Anti-kickback laws make it illegal to solicit, offer, receive or pay any remuneration in exchange for, or to induce, the referral of business, including the purchase or prescription of a particular drug that is reimbursed by a state or federal program. The federal government and the states have published regulations that identify "safe harbors" or exemptions for certain arrangements that do not violate the anti-kickback statute. We seek to comply with the safe harbors wherever possible. Due to the breadth of the statutory provisions and the absence of guidance in the form of regulations or court decisions addressing some of our practices, it is possible that our practices might be challenged under anti-kickback or similar laws. False claims laws prohibit knowingly and willingly presenting, or causing to be presented for payment to third-party payers (including Medicare and Medicaid), claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services. Our activities related to the sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid). If the government were to allege against or convict us of violating those laws or if we entered into a settlement with the government, there could be a material adverse effect on our business, including our stock price. Our activities could be subject to challenge for the reasons discussed above and due to the broad scope of those laws and the increasing attention being given to them by law enforcement authorities.

We are also subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other current and potential future federal, state or local laws, rules and/or regulations. Our R&D activities involve the controlled use of hazardous materials, chemicals, biological materials and various radioactive compounds. We believe our procedures comply with the standards prescribed by federal, state or local laws, rules and/or regulations; however, the risk of injury or accidental contamination cannot be completely eliminated. While we are not required to do so, we strive to conduct our research and manufacturing activities in a manner that meets the intents and purposes of the National Institutes of Health Guidelines for Recombinant DNA Research.

Additionally, the U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.

Our present and future business has been and will continue to be subject to various other U.S. and foreign laws, rules and/or regulations.

Research and Development and Selected Product Candidates

Our vision is to deliver therapeutics that can make a meaningful difference in patients' lives. Therefore, we focus our R&D on novel human therapeutics for the treatment of grievous illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. We take a modality-independent approach to R&D — that is, we identify targets, and then choose the modality best suited to address a specific target. As such, our discovery research programs may yield targets that lead to the development of human therapeutics delivered as large molecules (such as proteins, antibodies and peptibodies) or small molecules.

We have major R&D centers in several locations throughout the United States and in the United Kingdom, as well as smaller research centers and development facilities globally. (See Item 2. Properties.)

We conduct clinical trial activities using both our internal staff and third-party contract clinical trial service providers. In order to increase the number of patients available for enrollment for our clinical trials, we have and will continue to open clinical sites and enroll patients in a number of geographic locations. (See Item 1A. Risk Factors — We must conduct clinical trials in humans before we can commercialize and sell any of our product candidates or existing products for new indications.)

Some of our competitors are actively engaged in R&D in areas where we have products or where we are developing product candidates or new indications for existing products. For example, we compete with other clinical trials for eligible patients, which may limit the number of available patients who meet the criteria for certain clinical trials. The competitive marketplace for our product candidates is significantly dependent upon the timing of entry into the market. Early entry may have important advantages in gaining product acceptance, contributing to the product's eventual success and profitability. Accordingly, we expect that in some cases, the relative speed with which we can develop products, complete clinical testing, receive regulatory approval and supply commercial quantities of the product to the market is expected to be important to our competitive position.

In addition to product candidates and marketed products generated from our internal R&D efforts, we acquire companies, acquire and license certain product and R&D technology rights and establish R&D arrangements with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&D capabilities, product pipeline and marketed product base. These licenses and arrangements generally provide for non-refundable upfront license fees, R&D and commercial performance milestone payments, cost sharing, royalty payments and/or profit sharing.

Various public and privately owned companies, research organizations, academic institutions and governmental agencies conduct a significant amount of R&D in the biotechnology industry. We face competition in pursuing R&D arrangements and licensing or acquisition activities from other pharmaceutical and biotechnology companies that also seek to license or acquire technologies, product candidates or marketed products from these entities. Accordingly, we may have difficulty entering into R&D arrangements and licensing or acquiring technologies, product candidates and marketed products on acceptable terms.

See Government Regulation — Clinical Development for a discussion of the government regulation over clinical development.

The following table is a selection of certain of our product candidates by phase of development in our therapeutic areas of focus as of February 10, 2012, unless otherwise indicated. Each target indication for product candidates in phase 3 is listed separately. Additional product candidate (pipeline) information can be found on our website at http://www.amgen.com. (This website address is not intended to function as a hyperlink, and the information contained on our website is not intended to be a part of this filing.)

Molecule	Disease/Condition	Therapeutic Area
Phase 3 Programs		
AMG 386	Ovarian cancer	Hematology/Oncology
Aranesp® (darbepoetin alfa)	Myelodysplastic syndromes	Hematology/Oncology
Aranesp® (darbepoetin alfa)	Anemia in heart failure	Nephrology
Ganitumab	Pancreatic cancer	Hematology/Oncology
Motesanib	First-line non-small cell lung cancer	Hematology/Oncology
Prolia® (denosumab)	Male osteoporosis	Bone Health
Sensipar®/Mimpara® (cinacalcet)	Cardiovascular disease in patients with secondary hyperparathyroidism and chronic kidney disease undergoing maintenance dialysis	Nephrology
Sensipar®/Mimpara® (cinacalcet)	Post renal transplant	Nephrology
Talimogene laherparepvec	Malignant melanoma	Hematology/ Oncology
Vectibix® (panitumumab) — US Only	First- and second-line colorectal cancer	Hematology/Oncology
XGEVA® (denosumab)	Delay or prevention of bone metastases in prostate cancer	Hematology/Oncology
XGEVA® (denosumab)	Delay or prevention of bone metastases in breast cancer	Hematology/Oncology
Phase 2 Programs		
AMG 145	Hypercholesterolemia	Cardiovascular
AMG 151	Type 2 diabetes	General Medicine
AMG 386	Various cancer types	Hematology/Oncology
AMG 785	Bone-related conditions, including postmenopausal osteoporosis and fracture healing	Bone Health
AMG 827	Inflammatory diseases	Inflammation
AMG 888	Various cancer types	Hematology/Oncology
Prolia® (denosumab)	Rheumatoid arthritis	Inflammation
Ganitumab	Various cancer types	Hematology/Oncology
Nplate® (romiplostim)	Chemotherapy-induced thrombocytopenia	Hematology/Oncology
Omecamtiv mecarbil	Heart failure	Cardiovascular
Rilotumumab	Various cancer types	Hematology/Oncology
Vectibix® (panitumumab)	Locally advanced head and neck cancer	Hematology/Oncology
XGEVA® (denosumab)	Giant cell tumor of the bone	Hematology/Oncology
Phase 1 Programs		
AMG 139	Inflammatory diseases	Inflammation
AMG 157	Asthma	Inflammation
AMG 167	Bone-related conditions	Bone Health
AMG 181	Inflammatory diseases	Inflammation
AMG 208	Various cancer types	Hematology/Oncology
AMG 319	Hematologic malignancies	Hematology/Oncology
AMG 337	Various cancer types	Hematology/Oncology
AMG 557	Systemic lupus erythematosus	Inflammation
AMG 579	Neuroscience	General Medicine
AMG 729	Autoimmune diseases	Inflammation
AMG 745	Muscle-wasting disorders	General Medicine
AMG 747	Neuroscience	General Medicine
AMG 761	Asthma	Inflammation
AMG 780	Various cancer types	Hematology/Oncology
AMG 811	Systemic lupus erythematosus	Inflammation
AMG 820	Various cancer types	Hematology/Oncology
AMG 876	Type 2 diabetes	General Medicine
AMG 900	Various cancer types	Hematology/Oncology

Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.

Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

The following text provides additional information about selected product candidates that have advanced into human clinical trials.

AMG 386

AMG 386 is a peptibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1and Ang2. It is being investigated as a cancer treatment.

In 2011, we announced that enrollment was suspended in the phase 3 study in recurrent ovarian cancer due to DOXIL® (doxorubicin HCl liposome injection) supply issues. We initiated a second phase 3 study in recurrent ovarian cancer in 2011. We initiated a phase 3 study for the treatment of first-line ovarian cancer and plan to initiate other phase 2 studies for the treatment of NSCLC and breast cancer in 2012. Phase 2 studies of AMG 386 for treatment of renal cell carcicoma and hepatocellular carcinoma are ongoing.

Aranesp® (darbepoetin alfa)

Aranesp® is a recombinant human protein agonist of the erythropoietin receptor.

The RED-HF® trial phase 3 study, initiated in 2006, is a large (2,600 subjects planned), global, randomized, double-blind, placebo-controlled study to evaluate the effect of treatment of anemia with darbepoetin alfa on morbidity and mortality in patients with symptomatic left ventricular heart failure. The RED-HF® trial continues to enroll subjects and we anticipate data from the study in 2013. In 2011, we initiated a phase 3 study of Aranesp® for the treatment of low risk myelodysplastic syndromes.

Ganitumab (AMG 479)

Ganitumab is a fully human monoclonal antibody antagonist of IGF-1 receptor. It is being investigated as a cancer treatment.

In 2011, we initiated a phase 3 study for the treatment of first-line metastatic pancreatic cancer.

A phase 2 study for the treatment of small cell lung cancer is ongoing.

Motesanib

Motesanib is an orally-administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2 and 3, platelet-derived growth factor receptors and stem cell factor receptor. It is being investigated as a cancer treatment. We are developing this product in collaboration with Takeda and Millennium Pharmaceuticals: The Takeda Oncology Company (Millennium).

In March 2011, we along with Takeda and Millennium announced top-line results from the MONET1 pivotal phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous NSCLC. The trial did not meet its primary objective of demonstrating an improvement in overall survival (hazard ratio 0.90, 95% confidence interval 0.78 — 1.04, p=0.14). Detailed results were also presented at a medical meeting in May 2011. The parties continue to further analyze the data to explore potential opportunities for additional development in first-line NSCLC.

Denosumab

Denosumab is a fully human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. Denosumab is being studied across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases.

Prolia® (denosumab)

The phase 3 study evaluating Prolia® patients with male osteoporosis was completed and based on the results we announced on November 21, 2011, an sBLA was filed with the FDA for the indication to increase

bone mass in men with osteoporosis at high risk for fracture. We also plan to initiate a phase 3 study of Prolia® for the treatment of Glucocorticoid-Induced Osteoporosis in 2012.

XGEVA® (denosumab)

In April 2011, we announced that we plan to file for the treatment of giant cell tumor of the bone. On June 27, 2011, we announced the submission of an sBLA to the FDA to expand the indication for XGEVA® to treat men with castration-resistant prostate cancer to reduce the risk of developing bone metastases. On February 8, 2012, the FDA convened the ODAC to discuss the sBLA filing. The ODAC panel voted 12 to 1 that the overall magnitude of benefit demonstrated with early treatment with XGEVA® to delay bone metastases was not sufficient to conclude a positive risk-benefit ratio in the absence of additional measures impacting quality of life or other disease outcomes. The FDA has targeted a PDUFA action date of April 26, 2012. A phase 3 study for the delay or prevention of bone metastases in patients with adjuvant breast cancer is ongoing. We are planning an additional phase 3 SRE study in patients with multiple myeloma.

Sensipar®/Mimpara® (cinacalcet)

Sensipar®/Mimpara® is an orally-administered small molecule that lowers PTH levels in blood by signaling through the calcium-sensing receptor in parathyroid tissue to inhibit PTH secretion. It also lowers blood calcium and phosphorous levels.

The phase 3 E.V.O.L.V.E™ trial, initiated in 2006, is a large (3,800 patient), multi-center, international, randomized, double-blind study to assess the effects of Sensipar®/Mimpara® on mortality and cardiovascular morbidity in patients with CKD undergoing maintenance dialysis. The E.V.O.L.V.E™ study completed enrollment in January 2008 and we anticipate data from the study in 2012.

Sensipar®/Mimpara ® is also being evaluated in post renal transplant patients.

Talimogene laherparepvec (formerly known as OncoVEX$^{GM\text{-}CSF}$)

Talimogene laherparepvec is an oncolytic immunotherapy derived from HSV-1. It is being investigated as a cancer treatment.

On March 4, 2011, we acquired BioVex, a privately held biotechnology company developing treatments for cancer and the prevention of infectious disease, including talimogene laherparepvec, then in phase 3 clinical development for the treatment of malignant melanoma and head and neck cancer. On July 29, 2011, we announced our decision to terminate the phase 3 trial in patients with head and neck cancer. The phase 3 study for the treatment of malignant melanoma is ongoing.

Vectibix® (panitumumab)

Vectibix® is a monoclonal antibody antagonist of the EGFr pathway. It is being investigated as a cancer treatment.

In July 2011, we announced that we received Complete Response Letters from the FDA on the first- and second-line line mCRC sBLAs requesting additional information from the ‘181 and ‘203 studies. A phase 2 study for the treatment of locally advanced head and neck cancer is ongoing.

AMG 145

AMG 145 is a fully human monoclonal antibody to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a negative regulator of low-density lipoprotein receptor. AMG 145 is being investigated for the treatment of hypercholesterolemia.

Phase 1 single and multiple ascending dose studies have been completed. Results of the phase 1 single dose study were presented at a medical conference in November 2011. In 2011, phase 2 studies of AMG 145 for the treatment of hypercholesterolemia were initiated.

AMG 151

AMG 151 is an orally-administered small molecule glucokinase activator. It reduces glucose levels via a dual mechanism of action — working in both the pancreas and the liver. It is being investigated as a treatment of type 2 diabetes.

In 2011 we initiated a phase 2 study of AMG 151 for the treatment of type 2 diabetes.

AMG 785

AMG 785 is a humanized monoclonal antibody that targets sclerostin, a protein secreted by bone cells that inhibits bone formation. AMG 785 (also known as CDP7851) is being developed in collaboration with UCB for bone-related conditions, including postmenopausal osteoporosis and fracture healing.

In April 2011, we announced top-line results from the phase 2 clinical study comparing sclerostin-antibody AMG 785 to placebo in postmenopausal women with low bone mineral density BMD for the treatment of PMO. We plan to initiate phase 3 studies for the treatment of PMO in 2012. Phase 2 studies of AMG 785 for the treatment of fracture healing are ongoing.

AMG 827

AMG 827 is a human monoclonal antibody that binds to and blocks signaling via the interleukin-17 receptor. It is being investigated as a treatment for a variety of inflammatory diseases.

We reported the results from the phase 2 psoriasis study at a medical meeting in May 2011. Based on the study results, we plan to initiate phase 3 studies for the treatment of psoriasis in 2012. In 2011, we announced that following the review of the results, we have elected to discontinue our phase 2 studies for the treatment of RA and Crohn's disease. In October 2011, we initiated a phase 2 study for the treatment for psoriatic arthritis. A phase 2 study of AMG 827 for the treatment of asthma is ongoing.

AMG 888

AMG 888 is a fully human monoclonal antibody that inhibits human epidermal growth factor receptor 3 (HER3) oncogenic signaling. AMG 888 is being investigated as a cancer treatment. Amgen is developing this product in collaboration with Daiichi Sankyo.

Daiichi Sankyo initiated a phase 1b/2 study of AMG 888 (U3-1287) in advanced NSCLC in 2010, a phase 1b study in Japan in 2nd line NSCLC in 2011, and a phase 1b/2 study in metastatic breast cancer in 2012.

Nplate® (romiplostim)

Nplate® is a peptibody agonist of the TPO receptor.

Nplate® is being evaluated in chemotherapy-induced thrombocytopenia.

Omecamtiv mecarbil

Omecamtiv mecarbil is a small molecule activator of cardiac myosin. Omecamtiv mecarbil is being investigated to improve cardiac contractility in subjects with heart failure. We are developing this product in collaboration with Cytokinetics, Inc.

In 2011, we initiated a phase 2 study for the treatment of heart failure in patients with left ventricular systolic dysfunction who are hospitalized for acute heart failure.

Rilotumumab (AMG 102)

Rilotumumab is a fully human monoclonal antibody that blocks the action of hepatocyte growth factor/scatter factor. It is being investigated as a cancer treatment.

Results from a phase 2 study in gastric cancer in combination with chemotherapy were reported at a meeting in September 2011. Phase 2 combination studies in the prostate and small cell lung cancer settings continue.

As of February 9, 2011, we had nine phase 3 programs. As of February 10, 2012, we had twelve phase 3 programs, as one was added as the result of our BioVex acquisition and two programs had advanced into phase 3 trials. These changes are set forth in the following table:

Molecule	Disease / Condition	Program Change
Talimogene laherparepvec	Malignant melanoma	Added through acquisition of BioVex
Sensipar®/ Mimpara® (cinacalcet)	Post Renal Transplant	Advanced to Phase 3
Aranesp® (darbepoetin alfa)	Myelodysplastic syndromes	Advanced to Phase 3

Phase 3 Product Candidate Patent Information

Our outstanding patents for each of our product candidates in phase 3 development that have yet to be approved for any indication are described in the following table. Patents for products already approved for one or more indications but currently undergoing phase 3 clinical trials for additional indications are previously described. (See Marketed Products.)

Molecule	Territory	General Subject Matter	Estimated Expiration*
AMG 386	U.S.	DNA, polypeptides and compositions	2025
	Europe	DNA, polypeptides, compositions and method of treatment	2019-2022
Ganitumab	U.S.	Antibodies and compositions	2029
Motesanib	U.S.	Motesanib and compositions	2022
	Europe	Motesanib, compositions and use for treatment of cancer	2022
Talimogene laherparepvec	U.S.	Modified HSV1 compounds and strains and methods of treatment using modified HSV1 strains	2021
	Europe	Modified HSV1 compounds and strains and methods of treatment using modified HSV1 strains	2021

* Patent expiration ranges for each region are based on one or more issued patents, some of which may be or become eligible for term adjustments, extensions or supplemental protection certificates not captured in this estimate. In addition, new patents may be issued in the future, and existing patents may be challenged, invalidated or circumvented by third parties.

Business Relationships

From time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&D, manufacture and/or commercialization of products and/or product candidates. In addition, we also acquire product and R&D technology rights and establish R&D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&D capabilities, product pipeline and marketed product base. These arrangements generally provide for non-refundable upfront license fees, regulatory and commercial performance milestone payments, cost sharing, royalty payments and/or profit sharing. The activities under our collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.

Trade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we generally require counterparties to execute confidentiality agreements upon the commencement of the business relationship with us. However, others could either develop independently the same or similar information or obtain access to our information.

Kirin-Amgen, Inc.

K-A is a 50-50 joint venture with Kirin. K-A develops and then out licenses to third parties certain product rights which have been transferred to this joint venture from Kirin and Amgen.

K-A has given us exclusive licenses to manufacture and market: (i) G-CSF and pegfilgrastim in the United States, Europe, Canada, Australia and New Zealand, (ii) darbepoetin alfa, romiplostim and AMG 827 in the United States, Europe, Canada, Australia, New Zealand, Mexico, all Central and South American countries and certain countries in Central Asia, Africa and the Middle East, and (iii) recombinant human erythropoietin in the United States. We currently market pegfilgrastim, G-CSF, darbepoetin alfa, recombinant human erythropoietin and romiplostim under the brand names Neulasta®, NEUPOGEN®/GRANULOKINE®, Aranesp®, EPOGEN® and Nplate®, respectively. AMG 827 is currently in phase 2 development. Under these agreements, we pay K-A royalties based on product sales. In addition, we also receive payments from K-A for milestones earned and for conducting certain R&D activities on its behalf. (See Note 7, Related party transactions, to the Consolidated Financial Statements.)

K-A has also given Kirin exclusive licenses to manufacture and market: (i) G-CSF and pegfilgrastim in Japan, Taiwan and South Korea, (ii) darbepoetin alfa, romiplostim and AMG 827 in Japan, China, Taiwan, South Korea and in certain other countries in Asia, and (iii) recombinant human erythropoietin in Japan. K-A also gave Kirin and Amgen co-exclusive licenses to manufacture and market G-CSF, pegfilgrastim and recombinant human erythropoietin in China, which Amgen subsequently assigned to Kirin, and as a result, Kirin now exclusively manufactures and markets G-CSF and recombinant human erythropoietin in China. Kirin markets G-CSF, darbepoetin alfa, romiplostim and recombinant human erythropoietin under the brand names GRAN®/Grasin®/Filgrastim®, NESP®, ROMIPLATE® and ESPO®, respectively. Kirin received approval for pegfilgrastim in Taiwan in September 2011 under the brand name Neulasta®. Kirin is currently in the process of seeking marketing approval for pegfilgrastim in South Korea. Under these agreements, Kirin pays K-A royalties based on product sales. In addition, Kirin also receives payments from K-A for conducting certain R&D activities on its behalf.

K-A has also given J&J exclusive licenses to manufacture and market recombinant human erythropoietin for all geographic areas of the world outside the United States, China and Japan. K-A has also given Roche exclusive licenses to market pegfilgrastim and G-CSF in all territories not licensed to Amgen and Kirin. Under these agreements, J&J and Roche pay royalties to K-A based on product sales.

Pfizer Inc.

We are in a collaboration with Pfizer to co-promote ENBREL in the United States and Canada. The rights to market ENBREL outside of the United States and Canada are reserved to Pfizer. Under the agreement, a management committee comprised of equal representation from Amgen and Pfizer is responsible for overseeing the marketing and sales of ENBREL, including strategic planning, the approval of an annual marketing plan, product pricing and the establishment of a brand team. Amgen and Pfizer share in the agreed-upon selling and marketing expenses approved by the joint management committee. We currently pay Pfizer a percentage of annual gross profits on our ENBREL sales in the United States and Canada attributable to all approved indications on a scale that increases as gross profits increase; however, we maintain a majority share of ENBREL profits. After expiration of the agreement in the fourth quarter of 2013, we will be required to pay Pfizer a declining percentage of annual net ENBREL sales in the United States and Canada for three years, ranging from 12% to 10%. The amounts of such payments are anticipated to be significantly less than what would be owed based on the terms of the current ENBREL profit share.

Glaxo Group Limited

We are in a collaboration with Glaxo for the commercialization of denosumab for osteoporosis indications in Europe, Australia, New Zealand and Mexico (the Primary Territories). We have retained the rights to commercialize denosumab for all indications in the United States and Canada and for oncology indications in the Primary Territories. Under a related agreement, Glaxo will commercialize denosumab for all indications in countries, excluding Japan, where we did not have a commercial presence at the commencement of the agreement, including China, Brazil, India, Taiwan and South Korea (the Expansion Territories). In the Expansion Territories, Glaxo is responsible for all development and commercialization costs and will purchase denosumab from us to meet demand. In the future, we have the option of expanding our role in the commercialization of denosumab in the Primary Territories and certain of the Expansion Territories. In the Primary Territories, we share equally in the commercialization profits and losses related to the collaboration after accounting for expenses, including an amount payable to us in recognition of our discovery and development of denosumab. Glaxo is also responsible for bearing a portion of the cost of certain specified development activities in the Primary Territories.

Takeda Pharmaceutical Company Limited

We are in a collaboration with Takeda, which provides Takeda the exclusive rights to develop and commercialize for the Japanese market up to 12 molecules from our portfolio across a range of therapeutic areas, including oncology and inflammation (collectively the "Japanese market products") and for the worldwide development and commercialization of our product candidate, motesanib, in the oncology area. The Japanese market products include: (i) Vectibix®, which received regulatory approval in Japan, in 2010, for unresectable, advanced or recurrent colorectal cancer with wild-type *KRAS*, (ii) AMG 386, which is in a phase 3 trial for recurrent ovarian cancer, and (iii) ganitumab (AMG 479), which is in a phase 3 trial for first-line metastatic pancreatic cancer. Through collaboration committees, the parties jointly coordinate and oversee Takeda's development and commercialization of the Japanese market products in Japan. The parties share responsibility for the development of motesanib outside Japan and Takeda is responsible for development in Japan. Additionally, Amgen shall be responsible for commercialization of motesanib in North America and Takeda shall be responsible for commercialization outside of North America. Each party has the right to participate in the commercialization of motesanib in the other party's territory. In addition, under the collaboration Amgen will manufacture and supply Takeda motesanib and the Japanese market products for both clinical and commercial purposes. In 2011, we announced that the motesanib pivotal phase 3 trial (MONET1) did not meet its primary objective of demonstrating an improvement in overall survival.

Daiichi Sankyo Company, Limited

We are in a collaboration with Daiichi Sankyo, which provides Daiichi Sankyo the exclusive rights to develop and commercialize denosumab in Japan for osteoporosis, oncology and certain other indications. As part of the agreement, Amgen received exclusive worldwide rights to certain Daiichi Sankyo intellectual property to the extent applicable to denosumab. Through collaboration committees, the parties jointly coordinate and oversee Daiichi Sankyo's development and commercialization of denosumab in Japan.

DaVita Inc.

In November 2011, we entered into a seven-year supply agreement with DaVita, commencing January 1, 2012. Pursuant to this agreement, we will supply EPOGEN in amounts necessary to meet no less than 90% of DaVita's and its affiliates' requirements for ESAs used in providing dialysis services in the United States and Puerto Rico. The agreement may be terminated by either party before expiration of its term in the event of certain breaches of the agreement by the other party.

Fresenius Medical Care North America

In October 2011, the five-year supply agreement for ESAs with Fresenius Medical Care North America expired. Effective January 1, 2012, we entered into a three-year non-exclusive supply agreement with them to supply EPOGEN®.

Human Resources

As of December 31, 2011, Amgen had approximately 17,800 staff members, which includes approximately 300 part-time staff members. There can be no assurance that we will be able to continue attracting and retaining qualified personnel in sufficient numbers to meet our needs. None of our staff members are covered by a collective bargaining agreement, and we have experienced no work stoppages. We consider our staff relations to be good.

Trade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we generally require our staff members, material consultants and scientific advisors to execute confidentiality agreements upon commencement of employment or a consulting relationship with us. However, others could either develop independently the same or similar information or obtain access to our information.

Executive Officers of the Registrant

The executive officers of the Company as of February 13, 2012, are as follows:

Mr. Kevin W. Sharer, age 63, has served as a director of the Company since November 1992. Mr. Sharer has been the Company's Chief Executive Officer since May 2000 and has also been Chairman of the Board of Directors since January 2001. Effective as of May 23, 2012, Mr. Sharer will step down as CEO of the Company. Mr. Sharer will remain as Chairman of the Board of Directors until December 31, 2012, at which time he will retire from the Board and the Company. From May 2000 to May 2010, Mr. Sharer served as the Company's President and Chief Operating Officer. From October 1992 to May 2000, Mr. Sharer served as President and Chief Operating Officer of the Company. From April 1989 to October 1992, Mr. Sharer was President of the Business Markets Division of MCI Communications Corporation. From February 1984 to March 1989, Mr. Sharer held numerous executive capacities at General Electric Company (GE). Mr. Sharer is a director of Chevron Corporation and Northrop Grumman Corporation. He is Chairman of the Board of the Los Angeles County Museum of Natural History.

Mr. David W. Beier, age 63, became Senior Vice President, Global Government and Corporate Affairs in March 2008. He joined the Company in 2003 as Senior Vice President, Global Government Affairs. Previously, Mr. Beier was a partner with the law firm of Hogan and Hartson in Washington, D.C. From 1998 to early 2001, Mr. Beier served as Chief Domestic Policy Advisor to the Vice President of the United States. He also held positions as Vice President of Government Affairs and Public Policy for Genentech and staff counsel in the U.S. House of Representatives.

Dr. Fabrizio Bonanni, age 65, became Executive Vice President, Operations in August 2007. He served as Senior Vice President, Manufacturing of the Company from 2004 to August 2007. Dr. Bonanni joined the Company in 1999 as Senior Vice President, Quality and Compliance, and in June 2001, he also became the Corporate Compliance Officer. Previously, Dr. Bonanni held various management positions at Baxter International, Inc. from 1974 to 1999, including positions as Corporate Vice President, Regulatory and Clinical Affairs and Corporate Vice President, Quality System.

Mr. Robert A. Bradway, age 49, has served as a director of the Company since October 2011. Mr. Bradway has been the Company's President and Chief Operating Officer since May 2010 and will succeed to the role of Chief Executive Officer in May 2012. Mr. Bradway joined the Company in 2006 as Vice President, Operations Strategy and served as Executive Vice President and Chief Financial Officer from April 2007 to May 2010. Prior to joining the Company, he was a Managing Director at Morgan Stanley in London where he had responsibility for the firm's banking department and corporate finance activities in Europe and focused on healthcare.

Dr. Sean E. Harper, age 49, became Executive Vice President, Research and Development in February 2012. Dr. Harper joined the Company in 2002, and has held leadership roles in early development, medical sciences and global regulatory and safety. Dr. Harper served as Senior Vice President, Global Development and

Corporate Chief Medical Officer from March 2007 to February 2012. Prior to joining the Company, Dr. Harper worked for five years at Merck Research Laboratories.

Mr. Anthony C. Hooper, age 57, became Executive Vice President, Global Commercial Operations in October 2011. From March 2010 to October 2011, Mr. Hooper was Senior Vice President, Commercial Operations and President, U.S., Japan and Intercontinental of BMS, a pharmaceutical company. From January 2009 to March 2010, Mr. Hooper was President, Americas of BMS. From January 2004 to January 2009, Mr. Hooper was President, U.S. Pharmaceuticals, Worldwide Pharmaceuticals Group, a division of BMS. Prior to this, Mr. Hooper held various senior leadership positions at BMS. In his roles at BMS, Mr. Hooper led commercial operations in mature and emerging markets. Prior to joining BMS, Mr. Hooper was Assistant Vice President of Global Marketing for Wyeth Laboratories.

Mr. Brian McNamee, age 55, became Senior Vice President, Human Resources in June 2001. From November 1999 to June 2001, Mr. McNamee served as Vice President of Human Resources at Dell Computer Corp. From 1998 to 1999, Mr. McNamee served as Senior Vice President, Human Resources for the National Broadcasting Corporation, a division of GE. From July 1988 to November 1999, Mr. McNamee held human resources positions at GE.

Mr. Jonathan M. Peacock, age 53, became Executive Vice President and Chief Financial Officer in September 2010. Prior to joining Amgen, Mr. Peacock served as Chief Financial and Administration Officer of Novartis Pharmaceuticals AG, a healthcare company based in Switzerland, beginning in 2005. From 1998 to 2005, Mr. Peacock was a partner at McKinsey and Co., where he co-led the European Corporate Finance Practice. Mr. Peacock was also a partner at Price Waterhouse in London and New York from 1993 to 1998.

Ms. Anna S. Richo, age 51, became Senior Vice President and Chief Compliance Officer in June 2008. From December 2003 to June 2008, Ms. Richo served as Vice President, Law. Prior to Amgen, she spent 12 years at Baxter Healthcare Corporation in roles of increasing responsibility in law, including Vice President, Law, for Baxter's BioScience Division. Also, for more than five years, Ms. Richo served on the Board of Directors of Cytyc Corporation and was a member of the Audit and Finance Committees.

Mr. David J. Scott, age 59, became Senior Vice President, General Counsel and Secretary in March 2004. From May 1999 to February 2004, Mr. Scott served as Senior Vice President and General Counsel of Medtronic, Inc. and also as Secretary from January 2000. From December 1997 to April 1999, Mr. Scott served as General Counsel of London-based United Distillers & Vintners. Mr. Scott also served in executive roles at Grand Metropolitan plc and RJR Nabisco, Inc., and was an attorney in private practice.

Geographic Area Financial Information

For financial information concerning the geographic areas in which we operate, see Note 19, Segment information — Geographic information, to the Consolidated Financial Statements.

Investor Information

Financial and other information about us is available on our website (http://www.amgen.com) (This website address is not intended to function as a hyperlink, and the information contained in our website is not intended to be a part of this filing). We make available on our website, free of charge, copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after filing or submitting such material electronically or otherwise furnishing it to the SEC. In addition, we have previously filed registration statements and other documents with the SEC. Any document we file may be inspected, without charge, at the SEC's public reference room at 100 F Street NE, Washington, D.C. 20549 or at the SEC's internet address at http://www.sec.gov (This website address is not intended to function as a hyperlink, and the information contained in the SEC's website is not intended to be a part of this filing). Information related to the operation of the SEC's public reference room may be obtained by calling the SEC at 1-800-SEC-0330.

Item 1A. RISK FACTORS

This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business or others on our behalf, our beliefs and our management's assumptions. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties facing our business. The risks described below are not the only ones facing us. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions, geopolitical events and international operations. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price.

Our sales depend on coverage and reimbursement from third-party payers.

Sales of all of our principal products are dependent on the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans. Governments and private payers may regulate prices, reimbursement levels and/or access to our products to control costs or to affect levels of use of our products. We rely in large part on the reimbursement of our principal products through government programs such as Medicare and Medicaid in the United States and similar programs in foreign countries and a reduction in the coverage and/or reimbursement for our products could have a material adverse effect on our product sales, business and results of operations.

In the United States, there is an increased focus by the federal government and others on analyzing the impact of various regulatory programs on the federal deficit, which could result in increased pressure on federal programs to reduce costs. For example, the Budget Control Act of 2011, signed into law in the United States in August 2011, mandated a two percent reduction in government payments for all Medicare services (including the administration of separately-billable drugs and payment for drugs in all Medicare programs) for federal fiscal years 2013 through 2021, unless a subsequent deficit reduction law was passed before January 2012. As no additional deficit reduction law was enacted by January 2012, the payment "sequestration" will likely start in January 2013 and continue until December 2021. The sequestration remains subject to administrative implementation of the Budget Control Act or future statutory revision by Congress, who could block, limit or otherwise modify the automatic spending cuts. Several alternative deficit reduction proposals have been put forth by President Obama and/or Congressional committees, including proposals designed to further limit federal healthcare expenditures. While we cannot predict whether any deficit reduction actions will be approved by Congress and/or whether a budget sequestration will ultimately occur for Medicare services, a reduction in the availability or extent of reimbursement from U.S. government programs as a result of changes such as those that have been proposed or from other changes designed to achieve similar federal budget savings could have a material adverse effect on the sales of our products, our business and results of operations.

In March 2010 the United States adopted significant healthcare reform through the enactment of the PPACA and the Healthcare and Education Reconciliation Act (See Item 1. Business — Reimbursement — U.S. Healthcare Reform.) A major goal of the healthcare reform law is to provide greater access to healthcare coverage for more Americans. Accordingly, the healthcare reform law requires individual U.S. citizens and legal residents to maintain qualifying health coverage, imposes certain requirements on employers with respect to offering health coverage to employees, amends insurance regulations regarding when coverage can be provided and denied to individuals, and expands existing government healthcare coverage programs to more individuals in more situations, with most of these changes going into effect by January 2014. We do not expect a significant increase in sales of our products as a result of the 2014 expansions in healthcare coverage. While we cannot fully predict the ultimate impact the healthcare reform law will have on us, or how the law may change due to statutory revision or judicial review, we expect that the new law will continue to have a material adverse effect on our business and results of operations.

Public and private insurers have pursued, and continue to pursue, aggressive cost containment initiatives, including increased focus on comparing the effectiveness, benefits and costs of similar treatments, which could result in lower reimbursement rates for our products. A substantial portion of our U.S. business relies on

reimbursement under Medicare Part B coverage. Any deterioration in the timeliness or certainty of payment by Medicare to physicians, including as a result of changes in policy or regulations, or as a result of operational difficulties, could negatively impact the willingness of physicians to prescribe our products for patients relying on Medicare for their medical coverage. Most of our products furnished to Medicare beneficiaries in both a physician office setting and hospital outpatient setting are reimbursed under the Medicare Part B ASP payment methodology. (See Item1. Business — Reimbursement — Reimbursement of Our Principal Products.) ASP-based reimbursements of products under Medicare may be below or could fall below the cost that some medical providers pay for such products, which could materially and adversely affect sales of our products. We also face certain risks relating to the calculation of ASP. ASP is calculated by the manufacturer based on a statutorily defined formula and submitted to CMS. However, the statute, regulations and CMS guidance do not define specific methodologies for all aspects of the calculation of ASP. For example, in the Medicare Physician Fee Schedule Final Rule for 2012, CMS did not address a proposed methodology for treatment of bundled price concessions. Consequently, the current CMS guidance is that manufacturers may make "reasonable assumptions" in their calculation of ASP consistent with the general requirements and the intent of the Medicare statute, federal regulations and their customary business practices. As a result, we are required to apply our judgment in certain aspects of calculating ASP which are disclosed to CMS and also are subject to further CMS review. If our calculation of ASP is incorrect, we could be subject to substantial fines and penalties which could have a material adverse impact on our business and results of operations. Additionally, we are required to pay rebates to the federal government on products reimbursed by Medicaid at a rate of 23.1% of the AMP of a product, or if it is greater, the difference between the AMP and the best price available to any non-government customer. The PPACA changed the definition of AMP, and in January 2012 CMS issued a proposed rule further defining the new AMP definition. Until that rule is final, we will be required to apply our reasonable judgment in certain aspects of the AMP calculation. Once this CMS rule has been finalized, we will have to determine whether our interpretation of AMP follows the rule or if our calculations will need to be amended and this could have a material adverse impact on our business and results of operations.

Other initiatives reviewing the coverage or reimbursement of our products could result in less extensive coverage or lower reimbursement rates. For example, in July 2007, CMS issued an NCD where it determined that ESA treatment was not reasonable and necessary for certain clinical conditions and established Medicare coverage parameters for FDA-approved ESA use in oncology. Generally, an NCD is a national policy statement granting, limiting or excluding Medicare coverage or reimbursement for a specific medical item or service. We believe the restrictions in the 2007 NCD changed the way ESAs are used in clinical practice, for example, by decreasing the number of treated patients, the average ESA dose and the duration of ESA therapy in the oncology setting. As a result, we believe these restrictions have had a material adverse effect on the use, reimbursement and sales of Aranesp®, which in turn had a material adverse effect on our business and results of operations. The reimbursement of ESAs in the nephrology setting has also been reviewed by CMS. On June 16, 2010, CMS opened an NCA to examine the use of ESAs to manage anemia in patients with CKD and dialysis-related anemia. Following further analysis, on June 16, 2011, CMS issued a FDM in which it determined that it would not issue an NCD at that time for ESAs for treatment of anemia in adults with CKD, and that it would instead monitor the use of ESAs through the ESRD bundled payment system and its other policy avenues. In the absence of an NCD, Medicare determinations are made by the eleven regional MACs, one of which has already issued a final LCD relating to anemia in patients with CKD not on dialysis, and two more MACs have issued draft LCDs in this setting. All three final or draft LCDs would restrict reimbursement of ESAs to use in accordance with the revised FDA label. Other MACs could also issue LCDs that similarly or further restrict reimbursement for ESAs in this setting, and physician behavior may change to be consistent with the revised label even before formal LCDs are implemented, all of which could have a further material adverse effect on the reimbursement, use and sales of Aranesp®. Additionally, CMS could still propose an NCD and/or further review or change the reimbursement of ESAs in the nephrology setting at some point in the future. CMS has also previously identified a list of potential future NCDs that includes the category of thrombopoiesis stimulating agents (platelet growth factors), the category of drugs that includes Nplate®, and a discussion on bisphosphonates used to treat osteoporosis. CMS has not announced whether it will proceed with an NCA related to thrombopoiesis stimulating agents and, while

Prolia® and XGEVA® are not bisphosphonates, there is the possibility that CMS might evaluate other agents, including RANK Ligand inhibitors such as Prolia® and XGEVA®.

In the dialysis setting, the reimbursement rates for our products are also subject to downward pressure. In the United States, dialysis providers are reimbursed for EPOGEN® primarily by the federal government through Medicare's ESRD Program. (See Item 1. Business — Reimbursement — Reimbursement of Our Principal Products — Dialysis Reimbursement.) Until January 1, 2011, Medicare reimbursed for separately billable dialysis drugs (including Aranesp® and EPOGEN®) administered in both freestanding and hospital-based dialysis centers at ASP+6%, using the same ASP payment amount methodology used in the physician clinic setting under Part B. On January 1, 2011, CMS's bundled payment system went into effect for dialysis providers which provides a single payment for all dialysis services including drugs, supplies, and non-routine laboratory tests that were previously reimbursed separately. On November 1, 2011, following our June 2011 announcement of changes to the labels for the use of ESAs in patients with CKD (See Item 1. Business — Marketed Products — ESAs), CMS finalized a rule to update various provisions of its bundled payment system for dialysis services and the related ESRD QIP. The final rule eliminated for payment year 2013 and beyond one of the QIP's measures which tracks the percent of a provider's Medicare patients with a Hb level below 10 g/dL. (See Item 1. Business — Reimbursement — Reimbursement of Our Principal Products — Dialysis Reimbursement.) CMS indicated that removal of this quality measure from the QIP was being done in response to the June 2011 ESA label changes. We believe that the implementation of these various changes in the dialysis setting has resulted and may continue to result in a material adverse impact on the reimbursement, use and sales of EPOGEN® and on our business and results of operations.

The government-sponsored healthcare systems in Europe and many other foreign countries are the primary payers for healthcare expenditures, including payment for drugs and biologics, in those regions. Mandatory price reductions continue to be a significant aspect of business for the pharmaceutical and biotechnology industries outside of the United States. Healthcare reform in France, Germany and Spain, as well as austerity plans in a number of countries, including Italy, Greece and Portugal, have targeted the pharmaceutical sector with multiple mechanisms to reduce government expenditures. We expect that countries will continue to take aggressive actions to reduce expenditures on drugs and biologics, including mandatory price reductions, clawbacks of payments made to companies when national hospital drug spending thresholds are exceeded, preferences for biosimilar products, changes in international price referencing and transparency to achieve prices similar to that in lower-priced countries, and reductions in the amount of reimbursement. Similarly, fiscal constraints may also impact the extent to which countries are willing to reward new innovative therapies and/or allow access to new technologies. The proliferation of HTA organizations (e.g., NICE in the UK) has led to determinations of coverage and reimbursement based on both the clinical as well as the economic value of a product; these agencies are also increasingly setting the maximum price at which products will be reimbursed. While we cannot fully predict the extent of further price reductions and/or reimbursement restrictions taken by governmental payers outside of the United States or the impact such actions will have on our business, such reductions in price and/or the coverage and reimbursement for our products could have a material adverse effect on the sales of our products, our business and results of operation.

Additional initiatives addressing the coverage or reimbursement of our products could result in less extensive coverage or lower reimbursement, which could negatively affect sales of our products. If, for any of these or other reasons, reimbursement rates are reduced, or if healthcare providers anticipate reimbursement being reduced, providers may narrow the circumstances in which they prescribe or administer our products, which could reduce the use and/or sales of our products. A reduction in the use and sales of our products could have a material adverse effect on our business and results of operations.

Our current products and products in development cannot be sold if we do not maintain or gain regulatory approval.

Our business is subject to extensive regulation by numerous state and federal governmental authorities in the United States, including the FDA, and by foreign regulatory authorities, including the EMA. We are required in the United States and in foreign countries to obtain approval from regulatory authorities before we can

manufacture, market and sell our products. Once approved, the FDA and other U.S. and foreign regulatory agencies have substantial authority to require additional testing, change product labeling or mandate withdrawals of our products. Also, legislative bodies or regulatory agencies could enact new laws or regulations or change existing laws or regulations at any time, which could affect our ability to obtain or maintain approval of our products. For example, the 2007 creation of the FDAAA significantly added to the FDA's authority, allowing the FDA to (i) require sponsors of marketed products to conduct post-approval clinical studies; (ii) mandate labeling changes to products and (iii) require sponsors to implement a REMS for a product. Failure to comply with FDAAA requirements could result in significant civil monetary penalties, reputational harm and increased product liability risk. Current policy discussions underway in the United States include debates about the implementation of the new, abbreviated pathway for biosimilars established under the healthcare reform law; renegotiation of the PDUFA, which governs the user fees pharmaceutical and biological companies pay to the FDA that provide a substantial portion of the FDA's operating budget, in anticipation of re-authorization before September 30, 2012; and reforms to the regulations that govern diagnostics and medical devices which are sometimes used in conjunction with our products. We are unable to predict when and whether any changes to laws or regulatory policies affecting our business could occur, and such changes could have a material adverse effect on our business and results of operations.

Obtaining and maintaining regulatory approval has been and will continue to be increasingly difficult, time-consuming and costly. For example, in October 2009 we received Complete Response Letters from the FDA for the BLA for Prolia® in the treatment and prevention of PMO and in the treatment and prevention of bone loss due to hormone ablation therapy (HALT) in breast and prostate cancer patients. The Complete Response Letter related to the PMO indication requested several items, including further information on the design and background adverse event rates to inform the methodology of our previously submitted post-marketing surveillance program. The FDA also requested a new clinical program to support the approval of Prolia® for the prevention of PMO, updated safety data and stated that a REMS is necessary for Prolia®. The Complete Response Letter related to the HALT indication requested additional information regarding the safety of Prolia® in patients with breast cancer receiving aromatase inhibitor therapy and patients with prostate cancer receiving Androgen Deprivation Therapy. The FDA specifically requested results from additional adequate and well-controlled clinical trials demonstrating that Prolia® has no detrimental effects on either time to disease progression or overall survival. Following the submission of further information, including clinical trial data from a number of trials evaluating denosumab in various oncology indications, in September 2011 the FDA approved Prolia® as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer. In addition, there may be situations in which demonstrating the efficacy and safety of a product candidate may not be sufficient to gain regulatory approval unless superiority to comparative products can be shown.

Some of our products are approved by U.S. and foreign regulatory authorities on a conditional basis with full approval conditioned upon fulfilling the requirements of regulators. Regulatory authorities are placing greater focus on monitoring products originally approved on an accelerated or conditional basis and on whether the sponsors of such products have met the conditions of the accelerated or conditional approvals. Vectibix®, for example, received accelerated approval in the United States and conditional approval in the EU, with full approval conditioned on conducting additional clinical trials of the use of Vectibix® as a therapy in treating mCRC. (See Item 1. Business — Marketed Products — Other Marketed Products — Vectibix® (panitumumab).) If we are unable to fulfill the requirements of regulators that were conditions of our products' accelerated or conditional approval, we may not receive full approval for these products or may be required to change the products' labeled indications or even withdraw the products from the market.

Following recent FDA and FDA advisory committee discussions and actions with respect to other therapeutic oncology products previously granted accelerated approval by the FDA, questions remain about regulatory authorities' views regarding the adequacy for approval of therapeutic oncology products that have demonstrated a statistically significant improvement in progression-free survival but have not shown a statistically significant improvement in overall survival. A number of our products and product candidates have

used endpoints other than overall survival, such as progression-free survival and bone-metastasis-free survival (BMFS), in the clinical trial data submitted for agency review or in clinical trials now being conducted. The use of endpoints such as progression-free survival or BMFS, in the absence of other measures of clinical benefit, may not be sufficient for approval even when such results are statistically significant. For example, our pivotal phase 3 Study ’147 evaluated XGEVA® for its ability to improve BMFS in men with castration-resistant prostate cancer that has not yet spread to bone. On February 8, 2012, the FDA convened the ODAC to discuss our sBLA filing for XGEVA® to delay bone metastases in prostate cancer and the data from Study ’147 submitted to support the filing. During its presentation to the ODAC, the FDA questioned the magnitude of the improvement in BMFS demonstrated in Study ’147, and indicated that a further clinical trial might help address some of the remaining unresolved questions regarding the clinical significance of the benefit achieved by XGEVA® in this setting. The ODAC panel concluded that the magnitude of benefit demonstrated with early treatment with XGEVA® to delay bone metastases was not sufficient to conclude a positive risk-benefit ratio for XGEVA® in the absence of additional measures impacting quality of life or other disease outcomes. Further, some of our products or product candidates may be used with a companion diagnostic product, such as a test kit, or companion device, such as an injector or other delivery system. These product candidates or expanded indications of our products may not be approved if the companion diagnostic product or companion device does not gain or maintain regulatory approval. These companion diagnostics and devices may be provided by single-source unaffiliated third-party companies. We are dependent on the sustained cooperation and effort of those third-party companies in conducting the studies required for such approval by the applicable regulatory agencies. Delays in the studies or failure of the third-party company to obtain regulatory approval of the companion diagnostic or device could negatively impact the approval of our product candidate or the expanded indication of our product and we may incur increased development costs, delays in regulatory approval and/or associated delays in a product candidate reaching the market or the expansion of existing product labels for new indications.

In addition to the clinical trials that we choose to or are required to conduct, other organizations may also conduct clinical trials that use our products. Such clinical trials may evaluate our products in areas in which we do not have and are not seeking an approved indication. However, negative results or safety signals arising in other organizations’ clinical trials may nonetheless prompt regulatory agencies to take regulatory actions that affect our approved indications, including requiring the addition of relevant safety data to the approved labeling or even withdrawing approval for our products.

The occurrence of a number of high profile safety events has caused an increased public and governmental concern about potential safety issues relating to pharmaceutical and biological products and certain of our products and product candidates. (See Our ESAs continue to be under review and receive scrutiny by regulatory authorities.) As a result of this increased concern in recent years, the U.S. regulatory environment has evolved and safety signals and safety concerns resulting from pre-clinical data, clinical trials (including sub-analyses and meta-analyses), market use or other sources are receiving greater scrutiny. For example, a number of regulatory agencies around the world, including the FDA and the EMA, have initiated programs to directly monitor for safety issues rather than wait for patients, providers or manufacturers to report safety problems with products or medical devices. And at least one private, for-profit company has begun aggregating and analyzing FDA adverse event data on its website using its own independent methodology, which could highlight new perceived risks of our products and product candidates. Actual or perceived safety problems or signals could lead to revised or restrictive labeling of our approved products or a class of products, potentially including limitations on the use of approved products in certain patients because of:

- the identification of actual or theoretical safety or efficacy concerns with respect to any of our products by regulatory agencies;
- an increased rate or number of previously-identified safety-related events;
- the discovery of significant problems or safety signals or trends with a similar product that implicates an entire class of products;

- subsequent concerns about the sufficiency of the data or studies underlying the label or changes to the underlying safety/efficacy analysis related to results from clinical trials, including sub-analyses, or meta-analysis (a meta-analysis is the review of studies using various statistical methods to combine results from previous separate but related studies) of clinical trials or clinical data performed by us or others; and
- new legislation or rules by regulatory agencies.

For example, in December 2009, based on the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) results, we updated the boxed warning in the labeling information for ESAs, to reflect an increased risk of stroke when ESAs are administered to CRF patients to target Hb levels of 13 g/dL and above. In October 2010, we submitted additional proposed labeling changes regarding the use of ESAs in CRF patients not on dialysis that would limit treatment to patients who are most likely to benefit, specifically those with significant anemia (<10 g/dL), and who are at high risk for transfusion and for whom transfusion avoidance is considered clinically important, including those in whom it is important to preserve kidney transplant eligibility. In June 2011, we announced that the FDA had approved further changes to the labels for the use of ESAs, including Aranesp® and EPOGEN®, in patients with CKD. (See Our ESAs continue to be under review and receive scrutiny by regulatory authorities.)

In addition to revised labeling for our products, discovery of new safety information or previously unknown safety concerns and/or safety signals with our products or similar products could also lead to:

- requirement of risk management activities (including a REMS) or other FDA compliance actions related to the promotion and sale of our products;
- mandated PMCs/PMRs or pharmacovigilance programs for our approved products;
- product recalls of our approved products;
- revocation of approval for our products from the market completely, or within particular therapeutic areas, and/or;
- increased timelines or delays in being approved by the FDA or other regulatory bodies; and
- fewer treatments or product candidates being approved by regulatory bodies.

Product safety concerns could cause regulatory agencies to impose risk management activities upon us (including a REMS), which may require substantial costs and resources to negotiate, develop, implement and administer. The results of these risk management activities could:

- impact the ability of healthcare providers to prescribe, dispense or use our products;
- limit patient access to our products;
- reduce patient willingness to use our products;
- place administrative burdens on healthcare providers in prescribing our products; and
- affect our ability to compete against products that do not have a REMS or similar risk management activities.

We currently have approved REMS for our ESAs, Prolia® and Nplate®, and we use third-party service providers to assist in the administration of our REMS that include elements to assure safe use. For example, our ESA REMS requires applicable healthcare providers and institutions to enroll in the program, receive education about the product and the REMS and document and report certain information to us over time. We are responsible for tracking and documenting certain elements of healthcare provider and institution compliance with the ESA REMS and providing the FDA with periodic assessment reports to demonstrate that the goals of the REMS are being met. If we or third-party service providers acting on our behalf fail to effectively implement and/or administer the REMS for our products, we may be required to modify such REMS, and we may be subject to FDA enforcement actions or to civil penalties.

Further, if new medical data or product quality issues suggest an unacceptable safety risk or previously unidentified side-effects, we may withdraw some or all affected product — either voluntarily or by regulatory mandate — in certain therapeutic areas, or completely recall a product presentation from the market for some period or permanently. For example, in September 2009, we initiated a voluntary recall of a limited number of ENBREL SureClick® lots due to a defect in the glass syringe barrel which resulted in a small number of broken syringes following assembly of the autoinjector device. In October 2010, we initiated a voluntary recall of certain lots of ENBREL due to identification of cracks in a small number of the glass syringes which may have resulted in product leakage and syringe breakage. Further, beginning in September 2010, we initiated a voluntary recall of certain lots of EPOGEN® and J&J voluntarily recalled certain lots of PROCRIT®, manufactured by us, because a small number of vials in each lot were found to contain glass lamellae (extremely thin, barely visible glass flakes) which we believed was a result of the interaction of the product formulation with glass vials during the shelf life of the product. The recalls were executed in close cooperation with the FDA. We may experience the same or other problems in the future, resulting in broader product recalls, adverse event trends, delayed shipments, supply constraints, contract disputes and/or stock-outs of our products, which may materially and adversely affect the sales of our products, our business and results of operations. Additionally, if other parties (including our independent clinical trial investigators or our licensees, such as J&J, Pfizer, Glaxo, Takeda and Daiichi Sankyo) report or fail to effectively report to regulatory agencies side effects or other safety concerns that occur from their use of our products in clinical trials or studies or from marketed use, resulting regulatory action could materially and adversely affect the sales of our products, our business and results of operations.

Current global economic conditions may negatively affect us and may magnify certain risks that affect our business.

Our operations and performance have been, and may continue to be, affected by economic conditions in the United States and throughout the world. Sales of our principal products are dependent, in part, on the availability and extent of reimbursement from third-party payers, including government programs such as Medicare and Medicaid and private payer healthcare and insurance programs. (See Our sales depend on coverage and reimbursement from third-party payers.) As more fully explained below, financial pressures may cause government or other third-party payers to more aggressively seek cost containment through mandatory discounts on our products, policies requiring the automatic substitution of generic or biosimilar products, higher hurdles for initial reimbursement approval for new products or other similar measures. (See We expect to face increasing competition from biosimilar products which could impact our profitability.) Additionally, as a result of the current global economic downturn, our third-party payers may delay or be unable to satisfy their reimbursement obligations. A reduction in the availability or extent of reimbursement from government and/or private payer healthcare programs or increased competition from lower cost biosimilar products could have a material adverse effect on the sales of our products, our business and results of operations. In addition, as a result of the economic downturn, some employers may seek to reduce costs by reducing or eliminating employer group healthcare plans or transferring a greater portion of healthcare costs to their employees. Job losses or other economic hardships may also result in reduced levels of coverage for some individuals, potentially resulting in lower levels of healthcare coverage for themselves or their families. These economic conditions may affect patients' ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. We believe such conditions have led and could continue to lead to changes in patient behavior and spending patterns that negatively affect usage of certain of our products, including delaying treatment, rationing prescription medications, leaving prescriptions unfilled, reducing the frequency of visits to healthcare facilities, utilizing alternative therapies and/or foregoing healthcare insurance coverage. In addition to its effects on consumers, the economic downturn may have also increased cost sensitivities among medical providers in the United States, such as oncology clinics, particularly in circumstances where providers may experience challenges in the collection of patient co-pays or be forced to absorb treatment costs as a result of coverage decisions or reimbursement terms. Collectively, we believe these changes have resulted and may continue to result in reduced demand for our products, which could materially and adversely affect the sales of our products, our business and

results of operations. Any resulting decrease in demand for our products could also cause us to experience excess inventory write-offs and/or excess capacity or impairment charges at certain of our manufacturing facilities.

In Europe, economic conditions across the region could potentially be impacted by countries of key concern like Greece, which is facing possible default of its sovereign debt obligations, and Spain, France and Italy, whose sovereign debt obligations were recently downgraded. Economic conditions continue to affect our operations and performance outside the United States as well, particularly in countries where government-sponsored healthcare systems are the primary payers for healthcare expenditures, including drugs and biologics. (See Our sales depend on coverage and reimbursement from third-party payers.)

We also rely upon third parties for certain parts of our business, including licensees and partners, wholesale distributors of our products, contract clinical trial providers, contract manufacturers and single third-party suppliers. Because of the recent volatility in the financial markets, there may be a disruption or delay in the performance or satisfaction of commitments to us by these third parties which could have a material adverse effect on the sales of our products, our business and results of operations. Current economic conditions may adversely affect the ability of our distributors, customers and suppliers to obtain liquidity required to buy inventory or raw materials and to perform their obligations under agreements with us, which could disrupt our operations. Further, economic conditions appear to have affected, and may continue to affect, the business practices of our wholesale distributors in a manner that contributes to lower sales of our products. Although we monitor our distributors', customers' and suppliers' financial condition and their liquidity in order to mitigate our business risks, some of our distributors, customers and suppliers may become insolvent, which could have a material adverse effect on the sales of our products, our business and results of operations. These risks may be elevated with respect to our interactions with third parties with substantial operations in countries where current economic conditions are the most severe, particularly where such third parties are themselves exposed to sovereign risk from business interactions directly with fiscally-challenged government payers.

We maintain a significant portfolio of investments disclosed as cash equivalents and marketable securities on our Consolidated Balance Sheet. The value of our investments may be adversely affected by interest rate fluctuations, downgrades in credit ratings, illiquidity in the capital markets and other factors that may result in other than temporary declines in the value of our investments. Any of those events could cause us to record impairment charges with respect to our investment portfolio or to realize losses on the sale of investments.

Our ESAs continue to be under review and receive scrutiny by regulatory authorities.

Beginning in 2006, adverse safety results involving ESAs were observed and since that time our ESAs have been the subject of ongoing review and scrutiny by regulatory authorities and other agencies. In the United States, the FDA has reviewed and continues to review the benefit-risk profile of ESAs, which has resulted in and could result in future changes to ESA labeling and usage. For example, in August 2008, we revised the labeling for our ESAs as the FDA directed. In addition, in July 2007 CMS issued an NCD for non-renal ESAs that determined that ESA treatment was not reasonable and necessary for certain clinical conditions, and established Medicare coverage parameters for FDA-approved ESA use in oncology. Since these labeling and reimbursement changes, we experienced a substantial reduction in our ESA sales, in particular Aranesp sales in the U.S. supportive cancer care setting. U.S. regulators have also reviewed the use of ESAs in the nephrology setting. In October 2009, the results from TREAT, a phase 3 pivotal study of patients with CKD not on dialysis were published in the New England Journal of Medicine. The study failed to meet its primary objectives of demonstrating a reduction in all-cause mortality, cardiovascular morbidity, including heart failure, heart attack, stroke or hospitalization for myocardial ischemia, or time to ESRD. On December 16, 2009, based on the TREAT results, we updated the boxed warning in the labeling information for ESAs, to reflect an increased risk of stroke when ESAs are administered to CRF patients to target Hb levels of 13 g/dL and above. And in June 2011, we announced that the FDA approved further changes to the labels for the use of ESAs, including Aranesp® and EPOGEN®, in patients with CKD. Over the past several years, CMS has also reviewed the use of ESAs and has considered and incorporated significant changes in the ways ESAs are reimbursed in the nephrology setting, including the implementation of the ESRD bundled payment system, subsequent changes to

the QIP and consideration of a possible NCD to manage anemia in patients with CKD and dialysis-related anemia. Further restrictions are possible as the regional MACs implement LCDs to address Medicare coverage for ESAs in CKD not on dialysis within their respective geographic areas, and such restrictions could have a material adverse effect on the reimbursement, use and sales of Aranesp®. (See Our sales depend on coverage and reimbursement from third-party payers.) Together, these labeling and reimbursement changes, along with the approved REMS for ESAs, have had and may continue to have a material adverse effect on sales of our ESAs, our business and results of operations. We do not know what effect, if any, the June 2011 ESA label changes will have on the final version of the Kidney Disease: Improving Global Outcomes group (KDIGO) global anemia clinical practice guidelines which KDIGO has indicated could be available by early 2012. (See Guidelines and recommendations published by various organizations can reduce the use of our products.)

We have also agreed with the FDA to conduct a number of PMCs for our ESAs. In 2004, we agreed with the FDA to a robust pharmacovigilance program to continue to study the safety surrounding the use of darbepoetin alfa in the oncology setting. Of the five studies originally part of that pharmacovigilance program, four are complete, and the results of certain of those studies contributed to safety-related product labeling changes for our ESAs and changes in reimbursement, as noted above. The remaining study, the LNH03-6B Study, is being conducted by the Groupe d'Etudes des Lymphomes de l'Adulte, which presented second interim analysis results at the annual meeting of the American Society of Clinical Oncology in June 2011, and is currently estimated to be completed in 2012. Other trials have subsequently been initiated to inform on the safety of ESAs. In 2009 we initiated Study '782, a phase 3 non-inferiority study evaluating overall survival when comparing NSCLC patients on Aranesp® to patients receiving placebo, as part of our Aranesp® pharmacovigilance program. In addition, JRD's EPO-ANE-3010 study, which evaluates the use of epoetin alfa in patients with breast cancer, is ongoing. Both of these studies are designated by the FDA as PMRs and must be conducted to maintain regulatory approval and marketing authorization. For the nephrology setting, we are in ongoing discussions with the FDA regarding additional PMRs to explore alternative ESA dosing strategies in CKD patients on dialysis and not on dialysis. Although we cannot predict the results or the outcomes of ongoing clinical trials, or the extent to which regulatory authorities may require additional labeling changes as a result of these or other trials, we cannot exclude the possibility that unfavorable results from clinical trials, including PMCs, could have a material adverse effect on the reimbursement, use and sales of our ESAs and on our business and results of operations.

Regulatory authorities outside the United States have also reviewed and scrutinized the use of ESAs. In June 2008, the EMA recommended updating the product information for ESAs with a new warning for their use in cancer patients, which was approved by the EC in October 2008. The product information for all ESAs was updated to advise that, in some clinical situations, blood transfusions should be the preferred treatment for the management of anemia in patients with cancer and that the decision to administer ESAs should be based on a benefit-risk assessment with the participation of the individual patient. Following the October 2008 revision, we experienced a reduction of Aranesp® sales in the supportive cancer care setting in the EU. In addition, following the June 2011 ESA label changes in the United States, regulatory agencies outside the United States have sought additional information from us about the use and safety of ESAs in the CKD setting. Additional labeling or reimbursement changes by these regulatory authorities could materially and adversely affect the reimbursement, use and sales of our ESAs, our business and results of operations.

We continue to receive results from meta-analyses or previously initiated clinical trials using ESAs, including PMCs. For example, in May 2009, the Cochrane Collaboration published its independent meta-analysis of patient-level data from previously conducted, randomized, controlled, clinical studies evaluating ESAs in cancer patients which we submitted to the FDA and the EMA. This Cochrane meta-analysis of patient-level data from previous studies corroborates prior analyses indicating that the use of ESAs may increase the risk of death in cancer patients. The studies in the analysis all predate the current label, which advises using the least amount of ESA necessary to avoid transfusion, but they do not exclude the potential for adverse outcomes when ESAs are prescribed according to the current label. In addition, data from the RED-HF® trial evaluating the effect of treatment of anemia with darbepoetin alfa on morbidity and mortality in patients with symptomatic left ventricular heart failure is anticipated in 2012. Unfavorable results from these or similar trials or meta-analyses

of previous clinical trials could materially and adversely affect the use and sales of our ESAs, our business and results of operations.

We must conduct clinical trials in humans before we can commercialize and sell any of our product candidates or existing products for new indications.

Before we can sell any products, we must conduct clinical trials to demonstrate that our product candidates are safe and effective for use in humans. The results of those clinical trials are used as the basis to obtain approval from regulatory authorities such as the FDA and EMA. (See Our current products and products in development cannot be sold if we do not maintain or gain regulatory approval.) We are required to conduct clinical trials using an appropriate number of trial sites and patients to support the product label claims. The length of time, number of trial sites and patients required for clinical trials vary substantially and therefore, we may spend several years and incur substantial expense in completing certain clinical trials. Delays in planned clinical trials can result in increased development costs, delays in regulatory approvals, associated delays in product candidates reaching the market and revisions to existing product labels.

In addition, in order to increase the number of patients available for enrollment for our clinical trials, we have and will continue to open clinical sites and enroll patients in a number of new geographic locations where our experience conducting clinical trials is more limited, including Russia, India, China, South Korea, the Philippines, Singapore and some Central and South American countries either through utilization of third-party contract clinical trial providers entirely or in combination with local staff. Conducting clinical trials in locations where we have limited experience requires substantial time and resources to identify and understand the unique regulatory environments of individual countries. Further, we must ensure the timely production, distribution and delivery of the clinical supply of our product candidates to the numerous and varied clinical trial sites. If we fail to adequately manage the design, execution and regulatory aspects of our large, complex and regulatorily diverse clinical trials or manage the production or distribution of our clinical supply, corresponding regulatory approvals may be delayed or we may fail to gain approval for our product candidates or could lose our ability to market existing products in certain therapeutic areas or altogether. If we are unable to market and sell our product candidates or are unable to obtain approvals in the timeframe needed to execute our product strategies, our business and results of operations could be materially and adversely affected. Additional information on our clinical trials can be found on our website at www.amgen.com. (This website address is not intended to function as a hyperlink, and the information contained on our website is not intended to be a part of this filing.)

We rely on independent third-party clinical investigators to recruit subjects and conduct clinical trials in accordance with the applicable study protocols and laws and regulations. We also may acquire companies that have ongoing clinical trials. These trials may not be conducted to the same standards as ours; however, once an acquisition has been completed we assume responsibility for the conduct of the trial, including any potential risks and liabilities associated with the past and prospective conduct of those trials. If regulatory authorities determine that we or others, including our licensees or the independent investigators selected by us or by a company we have acquired, have not complied with regulations in the research and development of a product candidate, a new indication for an existing product or information to support a current indication, they may refuse to accept trial data from the site, not approve the product candidate or new indication or maintain approval of the current indication in its current form or at all, and we would not be able to market and sell it. If we were unable to market and sell our products or product candidates, our business and results of operations could be materially and adversely affected.

Further, we rely on unaffiliated third-party vendors to perform certain aspects of our clinical trial operations. In addition, some of our clinical trials involve drugs manufactured and marketed by other pharmaceutical companies. These drugs may be administered in a clinical trial in combination with one of our product candidates or in a head-to-head study comparing the products' relative efficacy and safety. In the event that any of these vendors or pharmaceutical companies have unforeseen issues that negatively impact the quality of their work or creates a shortage of supply, our ability to complete our applicable clinical trials and/or evaluate clinical results may also be negatively impacted. As a result, this could adversely affect our ability to file for, gain or maintain regulatory approvals worldwide on a timely basis, if at all.

Patients may also suffer adverse medical events or side effects in the course of our, our licensees, partners or independent investigators' clinical trials which could:

- delay the clinical trial program;
- require additional or longer trials to gain approval;
- prohibit regulatory approval of our product candidates or new indications for existing products; and
- render the product candidate commercially unfeasible or limit our ability to market existing products completely or in certain therapeutic areas.

Safety signals, trends, adverse events or results from clinical trials or studies performed by us or by others (including our licensees or independent investigators) or from the marketed use of our drugs or similar products that result in revised safety-related labeling or restrictions on the use of our approved products could negatively impact healthcare provider prescribing behavior, use and sales of our products, regulatory or private health organization medical guidelines and reimbursement for our products, all of which could have a material adverse effect on our business and results of operations.

Clinical trials must be designed based on the current standard of medical care. However in certain diseases, such as cancer, the standard of care is evolving rapidly. In these diseases, the duration of time needed to complete certain clinical trials may result in the design of such clinical trials being based on an out of date standard of medical care, limiting the utility and application of such trials. We may not obtain favorable clinical trial results and may not be able to obtain regulatory approval for new product candidates, new indications for existing products or maintenance of our current labels on this basis. Further, clinical trials conducted by others, including our licensees, partners or independent investigators, may result in unfavorable clinical trials results that may call into question the safety of our products in off-label or on label uses that may result in label restrictions and/or additional trials.

Even after a product is on the market, safety concerns may require additional or more extensive clinical trials as part of a pharmacovigilance program of our product or for approval of a new indication. For example, we have initiated Study '782 as part of our Aranesp® oncology pharmacovigilance program. (See Our ESAs continue to be under review and receive scrutiny by regulatory authorities.) In connection with the June 2011 ESA label changes, we also agreed to conduct additional clinical trials examining the use of ESAs in CKD. Additional clinical trials we initiate, including those required by the FDA, could result in substantial additional expense and the outcomes could result in additional label restrictions or the loss of regulatory approval for an approved indication, each of which could have a material adverse effect on the sales of our products, our business and results of operations. Additionally, any negative results from such trials could materially affect the extent of approvals, the use, reimbursement and sales of our products.

We expect to face increasing competition from biosimilar products.

We currently face competition in Europe from biosimilar products, and we expect to face increasing competition from biosimilars in the future. In 2010, lawmakers in the United States enacted healthcare reform legislation which included an abbreviated regulatory pathway for the approval of biosimilars. The EU has already created such a regulatory pathway. To the extent that governments adopt more permissive approval frameworks and competitors are able to obtain broader marketing approval for biosimilars, our products will become subject to increased competition. Expiration or successful challenge of applicable patent rights could trigger such competition, and we could face more litigation regarding the validity and/or scope of our patents.

In the EU, the EC has granted marketing authorizations for several biosimilars pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In 2006, the EMA developed and issued final regulatory guidelines related to the development and approval of biosimilar products. The final guidelines included clinical trial guidance for certain biosimilar products, including erythropoietins and G-CSFs, recommending that applicants seeking approval of such biosimilar products conduct pharmacodynamic, toxicological and clinical safety studies as well as a pharmacovigilance program. In late 2011, the EMA

announced plans to issue in the first half of 2012 final guidelines on the approval process for biosimilar monoclonal antibodies and draft guidelines on the approval process for other biosimilar drugs. Some companies have received and other companies are seeking approval to market erythropoietin and G-CSF biosimilars in the EU, presenting additional competition for our products. (See Our marketed products face substantial competition.) For example, following the expiration of the principal European patent relating to recombinant G-CSF in August 2006, the EC issued marketing authorizations for the first G-CSF biosimilar products and the products were launched in certain EU countries in 2008 and 2009. There are now several G-CSF biosimilars available in the EU marketed by different companies and these G-CSF biosimilar products compete with NEUPOGEN® and Neulasta®. Further, as in an effort to reduce costs, countries in the EU may in the future permit the automatic substitution by pharmacists of biosimilars for the corresponding innovator products or adopt other biosimilar uptake measures. We cannot predict to what extent the entry of biosimilar products or other competing products will impact future sales of our products in the EU. Our inability to compete effectively could reduce sales, which could have a material adverse effect on our business and results of operations.

On March 23, 2010, President Obama signed into law the PPACA which authorized the FDA to approve biosimilar products under a separate, abbreviated pathway. The law established a period of 12 years of data exclusivity for reference products in order to preserve incentives for future innovation and outlined statutory criteria for science-based biosimilar approval standards that take into account patient safety considerations. Under this framework, data exclusivity protects the data in the innovator's regulatory application by prohibiting, for a period of 12 years, others from gaining FDA approval based in part on reliance or reference to the innovator's data in their application to the FDA. The law does not change the duration of patents granted on biologic products. On February 9, 2012, the FDA released three draft guidance documents that provide insight into the FDA's current thinking on the development of biosimilar products and broad parameters for the scientific assessment of biosimilar applications. The documents provide guidance in the development of biosimilar versions of currently approved biological products and indicate that the clinical trials and other steps required for approval of each biosimilar product will depend on a variety of factors, including the complexity of the protein, the sophistication of the manufacturing required and the potential risks of the product. A growing number of companies have announced their intentions to develop biosimilar versions of existing biotechnology products, including a number of our products. Further, biosimilar manufacturers with approved products in Europe may seek to quickly obtain U.S. approval now that the regulatory pathway for biosimilars has been enacted. In addition, critics of the 12-year exclusivity period in the biosimilar pathway law will likely seek to shorten the data exclusivity period. President Obama's proposed 2013 budget includes a proposal to lower the data exclusivity period to seven years, but this would require new legislation be passed by Congress. Critics may also encourage the FDA to interpret narrowly the law's provisions regarding which new products receive data exclusivity. While we are unable to predict the precise impact of the pending introduction of biosimilars on our products, or the degree to which the FDA's recent guidelines will contribute to that impact, we expect in the future to face greater competition in the United States as a result of biosimilar products and downward pressure on our product prices and sales, subject to our ability to enforce our patents. (See Item 7A. Management's Discussion and Analysis of Financial Condition and Results of Operations — Financial Condition, Liquidity and Capital Resources.) This additional competition could have a material adverse effect on our business and results of operations.

We may not be able to develop commercial products.

Successful product development in the biotechnology industry is highly uncertain, and very few R&D projects produce a commercial product. We intend to continue to make significant R&D investments. Product candidates or new indications for existing products (collectively, "product candidates") that appear promising in the early phases of development may fail to reach the market for a number of reasons, such as:

- the product candidate did not demonstrate acceptable clinical trial results even though it demonstrated positive preclinical trial results, for reasons that could include changes in the standard of care of medicine;
- the product candidate was not effective or more effective than currently available therapies in treating a specified condition or illness;

- the product candidate is not cost effective in light of existing therapeutics;
- the product candidate had harmful side effects in humans or animals;
- the necessary regulatory bodies, such as the FDA or EMA, did not approve our product candidate for an intended use;
- the product candidate was not economical for us to manufacture and commercialize;
- other parties have or may have proprietary rights relating to our product candidate, such as patent rights, and will not let us sell it on reasonable terms, or at all;
- we and certain of our licensees, partners or independent investigators may fail to effectively conduct clinical development or clinical manufacturing activities; and
- the regulatory pathway to approval for product candidates is uncertain or not well-defined.

Several of our product candidates have failed or been discontinued at various stages in the product development process. For example, in June 2004, we announced that the phase 2 study of Glial Cell Lined-Derived Neurotrophic Factor (GDNF) for the treatment of advanced Parkinson's disease did not meet the primary study endpoint upon completion of nine months of the double-blind treatment phase of the study. The conclusion was reached even though a small phase 1 pilot investigator-initiated open-label study over a three-year period appeared to result in improvements for advanced Parkinson's disease patients. Subsequently, we discontinued clinical development of GDNF in patients with advanced Parkinson's disease.

Our marketed products face substantial competition.

We operate in a highly competitive environment. Our products compete with other products or treatments for diseases for which our products may be indicated. Our competitors market products or are actively engaged in R&D in areas where we have products, where we are developing product candidates or new indications for existing products. In the future, we expect that our products will compete with new drugs currently in development, drugs currently approved for other indications that may later be approved for the same indications as those of our products and drugs approved for other indications that are used off-label. Large pharmaceutical companies and generics manufacturers of pharmaceutical products are expanding into the biotechnology field with increasing frequency, and some pharmaceutical companies and generics manufacturers have formed partnerships to pursue biosimilar products. These companies may have greater resources than we do. In addition, some of our competitors may have technical or competitive advantages over us for the development of technologies and processes. These resources may make it difficult for us to compete with them to successfully discover, develop and market new products and for our current products to compete with new products or new product indications that these competitors may bring to market. As a result, our products may compete against products that have lower prices, equivalent or superior performance, better safety profile, are easier to administer or that are otherwise competitive with our products.

Concentration of sales at certain of our wholesaler distributors and consolidation of free-standing dialysis clinic businesses may negatively impact our bargaining power and profit margins.

The substantial majority of our U.S. product sales are made to three pharmaceutical product wholesaler distributors, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. These distributors, in turn, sell our products to their customers, which include physicians or their clinics, dialysis centers, hospitals and pharmacies. In addition, one of our products, EPOGEN®, is sold primarily to free-standing dialysis clinics, which have experienced significant consolidation. Two organizations, DaVita and Fresenius Medical Care North America, own or manage a large number of the outpatient dialysis facilities located in the United States and account for a substantial majority of all EPOGEN® sales in the free-standing dialysis clinic setting. Due to this concentration, these entities have substantial purchasing leverage, which may put pressure on

our pricing by their potential ability to extract price discounts on our products or fees for other services, correspondingly negatively impacting our bargaining position and profit margins.

Our business may be affected by litigation and government investigations.

We and certain of our subsidiaries are involved in legal proceedings. (See Note 18, Contingencies and commitments, in the notes to our consolidated financial statements in our annual report.) Civil and criminal litigation is inherently unpredictable, and the outcome can result in excessive verdicts, fines, penalties, exclusion from the federal healthcare programs and/or injunctive relief that affect how we operate our business. Defense of litigation claims can be expensive, time-consuming and distracting and it is possible that we could incur judgments or enter into settlements of claims for monetary damages or change the way we operate our business, which could have a material adverse effect on our business and results of operations. In addition, product liability is a major risk in testing and marketing biotechnology and pharmaceutical products. We may face substantial product liability exposure in human clinical trials and for products that we sell after regulatory approval. Product liability claims, regardless of their merits, could be costly and divert management's attention and adversely affect our reputation and the demand for our products. Amgen and Immunex have previously been named as defendants in product liability actions for certain of our products.

We are also involved in government investigations that arise in the ordinary course of our business. Beginning in 2007, we received a number of subpoenas from various government entities, including the U.S. Attorney's Offices for the Eastern District of New York and the Western District of Washington, as well as the Attorneys General of New York and New Jersey. The federal subpoenas were issued pursuant to the Health Insurance Portability and Accountability Act of 1996 (18 U.S.C. 3486), and by a federal grand jury, while the Attorneys General subpoenas were issued pursuant to state specific statutes relating to consumer fraud laws and state false claims acts. In general, the subpoenas requested documents relating to the sales and marketing of our products, and our collection and dissemination of information reflecting clinical research as to the safety and efficacy of our ESAs. Based on representations in a U.S. government filing that became public in May 2009 relating to the Massachusetts Qui Tam Action (as defined in Note 18, Contingencies and commitments in the notes to our consolidated financial statements) and subsequent conversations with government prosecutors, we learned that the subpoenas we received from the U.S. Attorney's Offices for the Eastern District of New York and the Western District of Washington relate to the Massachusetts Qui Tam Action and nine additional Qui Tam Actions (as defined in Note 18, Contingencies and commitments in the notes to our consolidated financial statements) pending against us in various federal jurisdictions. In October 2011 we announced that we had reached an agreement in principle to settle the allegations regarding our sales and marketing practices arising out of the ongoing civil and criminal investigations conducted by the U.S. Attorney's Offices for the Eastern District of New York and the Western District of Washington. The proposed settlement involves numerous state and federal agencies and remains subject to continuing discussions regarding the components of the agreement, and the completion and execution of all required documentation. Until the proposed settlement becomes final, there can be no guarantee that these matters will be resolved by the agreement in principle. If the proposed settlement is not finalized as proposed, we would have to continue to explain and defend our actions to government entities involved, which would be burdensome, expensive and time-consuming for us and could result in criminal charges, civil penalties or other enforcement actions. In addition, while the agreement in principle includes the dismissal of the claims of the government in the Qui Tam Actions, the individual relators in the Qui Tam Actions have the opportunity to join in the proposed settlement or, if they object, to have the settlement evaluated in a federal court fairness hearing to determine whether it is fair, adequate and reasonable under all the circumstances. If the court determines that the settlement is not fair, adequate and reasonable, then we would have the option to continue to defend our actions in court, or to seek to negotiate a new settlement. We have been made aware that we are also a defendant in several other civil qui tam actions that remain under seal in the U.S. federal courts where they were filed. Included with these actions are allegations that our promotional, contracting, sales and marketing activities relating to ENBREL and Aranesp® caused the submission of various false claims under the Federal Civil False Claims Act and various State False Claims Acts. Certain of the allegations in these other actions are not encompassed in the proposed settlement discussed above. In addition, as described in Note 18, Contingencies and commitments in the notes to our consolidated financial statements, this proposed settlement does not cover a number of other litigation matters that will continue to be pending against us.

Throughout these investigations, the government entities are asserting that we violated various state and federal laws. These investigations are very burdensome, expensive and time-consuming for us to explain and defend to these entities. Although we cannot predict whether additional proceedings may be initiated against us, or predict when these matters may be resolved, it is not unusual for investigations such as these to continue for a considerable period of time and to require management's attention and significant legal expense. A determination that we are in violation of the various federal and state laws that govern the sales and marketing of our products could result in federal criminal liability and/or federal or state civil or administrative liability, and thus could result in substantial financial damages or criminal penalties and possible exclusion from future participation in the Medicare and Medicaid programs. In addition, we may see new governmental investigations of or actions against us citing novel theories of recovery. Any of these results could have a material adverse effect on our business and results of operations.

We rely on third-party suppliers for certain of our raw materials, medical devices and components.

We rely on unaffiliated third-party suppliers for certain raw materials, medical devices and components necessary for the manufacturing of our commercial and clinical products. Certain of those raw materials, medical devices and components are the proprietary products of those unaffiliated third-party suppliers and are specifically cited in our drug application with regulatory agencies so that they must be obtained from that specific sole source or sources and could not be obtained from another supplier unless and until the regulatory agency approved such supplier.

Among the reasons we may be unable to obtain these raw materials, medical devices and components include:

- regulatory requirements or action by regulatory agencies or others;
- adverse financial or other strategic developments at or affecting the supplier;
- unexpected demand for or shortage of raw materials, medical devices or components;
- labor disputes or shortages, including the effects of a pandemic flu outbreak, natural disaster, or otherwise;
- failure to comply with our quality standards which results in quality and product failures, product contamination and/or recall; and
- discovery of previously unknown or undetected imperfections in raw materials, medical devices or components.

These events could negatively impact our ability to satisfy demand for our products, which could materially and adversely affect our product use and sales and our business and operating results. For example, in prior years we have experienced shortages in certain components necessary for the formulation, fill and finish of certain of our products in our Puerto Rico facility. Further quality issues which result in unexpected additional demand for certain components may lead to shortages of required raw materials or components (such as we have experienced with EPOGEN® glass vials). We may experience or continue to experience these or other shortages in the future resulting in delayed shipments, supply constraints, contract disputes and/or stock-outs of our products. Also, certain of the raw materials required in the commercial and clinical manufacturing of our products are sourced from other countries and/or derived from biological sources, including mammalian tissues. In addition, one of our marketed products also uses bovine serum and human serum albumin. Some countries in which we market our products may restrict the use of certain biologically derived substances in the manufacture of drugs. We continue to investigate alternatives to certain biological sources and alternative manufacturing processes that do not require the use of certain biologically derived substances because such raw materials may be subject to contamination and/or recall.

A material shortage, contamination, recall and/or restriction of the use of certain biologically derived substances or other raw materials, which may be sourced from other countries and that are used in the manufacture of our products could adversely impact or disrupt the commercial manufacturing of our products or

could result in a mandated withdrawal of our products from the market. This could negatively impact our ability to satisfy demand for our products, which could materially and adversely affect our product sales, business and operating results. Further, any disruptions or delays by us or by third-party suppliers or partners in converting to alternatives to certain biologically derived substances and alternative manufacturing processes or our ability to gain regulatory approval for the alternative materials and manufacturing processes could increase our associated costs or result in the recognition of an impairment in the carrying value of certain related assets, which could have a material and adverse effect on our business and results of operations.

Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.

Manufacturing biologic human therapeutic products is difficult, complex and highly regulated. We currently manufacture all of our principal products and plan to manufacture many of our product candidates. In addition, we currently use third-party contract manufacturers to produce or assist in the production of ENBREL, Prolia®, Sensipar®/Mimpara®, Nplate®, XGEVA® and Vectibix® and plan to use contract manufacturers to produce or assist in the production of a number of our late-stage product candidates. Our ability to adequately and timely manufacture and supply our products is dependent on the uninterrupted and efficient operation of our facilities and those of our third-party contract manufacturers, which may be impacted by:

- availability or contamination of raw materials, components and equipment used in the manufacturing process, particularly those for which we have no other source or supplier;
- capacity of our facilities and those of our contract manufacturers;
- contamination by microorganisms or viruses;
- natural or other disasters, including hurricanes, earthquakes, volcanoes or fires;
- labor disputes or shortages, including the effects of a pandemic flu outbreak, natural disaster, or otherwise;
- degree of compliance with regulatory requirements;
- changes in forecasts of future demand;
- timing and actual number of production runs;
- updating of manufacturing specifications;
- production success rates and yields; and
- timing and outcome of product quality testing.

If the efficient manufacture and supply of our products is interrupted, we may experience delayed shipments, supply constraints, stock-outs and/or recalls of our products. For example, over the past several years we have initiated a number of voluntary recalls of certain lots of our products. (See Our current products and products in development cannot be sold if we do not maintain or gain regulatory approval.) If we are at any time unable to provide an uninterrupted supply of our products to patients, we may lose patients and physicians may elect to prescribe competing therapeutics instead of our products, which could materially and adversely affect our product sales, business and results of operations.

Our manufacturing processes and those of our third-party contract manufacturers must undergo a potentially lengthy FDA or other regulatory approval process and are subject to continued review by the FDA and other regulatory authorities. It can take longer than five years to build, validate and license a new manufacturing plant and it can take longer than three years to qualify and license a new contract manufacturer. For example, in order to maintain supply and to satisfy anticipated future demand for denosumab, we are qualifying the expansion of our existing bulk protein facilities at our Puerto Rico site. In addition, in order mitigate the risk associated with the majority of our formulation and fill operations being performed in a single facility, we are completing the construction and qualification of a new formulation and filling facility at our Puerto Rico site, and are modifying

and expanding our recently acquired formulation, fill and finish manufacturing site in Ireland. Upon completion, these facilities will require licensure by the various regulatory authorities.

If regulatory authorities determine that we or our third-party contract manufacturers or certain of our third-party service providers have violated regulations or if they restrict, suspend or revoke our prior approvals, they could prohibit us from manufacturing our products or conducting clinical trials or selling our marketed products until we or the affected third-party contract manufacturers or third-party service providers comply, or indefinitely. Because our third-party contract manufacturers and certain of our third-party service providers are subject to the FDA and foreign regulatory authorities, alternative qualified third-party contract manufacturers and third-party service providers may not be available on a timely basis or at all. If we or our third-party contract manufacturers or third-party service providers cease or interrupt production or if our third-party contract manufacturers and third-party service providers fail to supply materials, products or services to us, we may experience delayed shipments, supply constraints, stock-outs and/or recalls of our products. Additionally, we distribute a substantial volume of our commercial products through our primary distribution centers in Louisville, Kentucky for the United States and in Breda, the Netherlands for Europe and much of the rest of the world. We also conduct all the labeling and packaging of our products distributed in Europe and much of the rest of the world in Breda, the Netherlands. Our ability to timely supply products is dependent on the uninterrupted and efficient operations of our distribution and logistics centers, our third-party logistics providers and our labeling and packaging facility in Breda. Further, we rely on commercial transportation for the distribution of our products to our customers which may be negatively impacted by natural disasters or security threats.

We perform a substantial amount of our commercial manufacturing activities at our Puerto Rico manufacturing facility and a substantial amount of our clinical manufacturing activities at our Thousand Oaks, California manufacturing facility; if significant natural disasters or production failures occur at the Puerto Rico facility, we may not be able to supply these products or, at the Thousand Oaks facility, we may not be able to continue our clinical trials.

We currently perform all of the formulation, fill and finish for Neulasta®, NEUPOGEN®, Aranesp®, EPOGEN®, Prolia® and XGEVA® and substantially all of the formulation, fill and finish operations for ENBREL at our manufacturing facility in Juncos, Puerto Rico. We also currently perform all of the bulk manufacturing for Neulasta®, NEUPOGEN® and Aranesp® and the purification of bulk EPOGEN® material at this facility, and plan to perform substantially all of the bulk manufacturing for Prolia® and XGEVA® at the Puerto Rico facility once the facility has been approved by the FDA for that purpose. We perform substantially all of the bulk manufacturing and formulation, fill and finish, and packaging for product candidates to be used in clinical trials at our manufacturing facility in Thousand Oaks, California. The global supply of our products and product candidates is significantly dependent on the uninterrupted and efficient operation of these facilities. A number of factors could materially and adversely affect our operations, including:

- power failures and/or other utility failures;
- breakdown, failure or substandard performance of equipment;
- improper installation or operation of equipment;
- labor disputes or shortages, including the effects of a pandemic flu outbreak;
- inability or unwillingness of third-party suppliers to provide raw materials and components;
- natural or other disasters, including hurricanes, earthquakes or fires; and
- failures to comply with regulatory requirements, including those of the FDA.

In the past, the Puerto Rico facility has experienced manufacturing component shortages and there was evidence of adverse trends in the microbial bioburden of the production environment that reduced the production output. The same or other problems may result in our being unable to supply these products, which could materially and adversely affect our product sales, business and operating results. Although we have obtained limited insurance to protect against certain business interruption losses, there can be no assurance that such

coverage will be adequate or that such coverage will continue to remain available on acceptable terms, if at all. The extent of the coverage of our insurance could limit our ability to mitigate for lost sales and such losses could materially and adversely affect our product sales, business and operating results. Our Puerto Rico facility is also subject to the same difficulties, disruptions or delays in manufacturing experienced in our other manufacturing facilities. For example, the limited number of lots of ENBREL and EPOGEN® voluntarily recalled in 2009 and 2010 were manufactured at our Puerto Rico facility. In future inspections, our failure to adequately address the FDA's expectations could lead to further inspections of the facility or regulatory actions. (See Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.)

Our intellectual property positions may be challenged, invalidated, circumvented or expire, or we may fail to prevail in present and future intellectual property litigation.

Our success depends in part on our ability to obtain and defend patent rights and other intellectual property rights that are important to the commercialization of our products and product candidates. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and often involve complex legal, scientific and factual questions. Third parties may challenge, invalidate or circumvent our patents and patent applications relating to our products, product candidates and technologies. In addition, our patent positions might not protect us against competitors with similar products or technologies because competing products or technologies may not infringe our patents. For certain of our product candidates, there are third parties who have patents or pending patent applications that they may claim necessitate payment of a royalty or prevent us from commercializing these product candidates in certain territories. Patent disputes are frequent, costly and can preclude, delay or increase the cost of commercialization of products. We have been in the past, and may be in the future, involved in patent litigation. A determination made by a court, agency or tribunal concerning infringement, validity, enforceability, injunctive or economic remedy, or the right to patent protection, for example, are typically subject to appellate or administrative review. Upon review, such initial determinations may be afforded little or no deference by the reviewing tribunal and may be affirmed, reversed, or made the subject of reconsideration through further proceedings. A patent dispute or litigation may not discourage a potential violator from bringing the product that is alleged to infringe to market prior to a final resolution of the dispute or litigation. For example, until the Pennsylvania District Court entered final judgment and a permanent injunction against Teva on July 15, 2011 pursuant to a joint stipulation and settlement agreement between the parties, Teva had announced that it intended to sell its filgrastim product, upon approval from the FDA, in the United States without a license from us and prior to the expiration of our G-CSF patents. The period of time from inception until resolution of a patent dispute or litigation is subject to the availability and schedule of the court, agency or tribunal before which the dispute or litigation is pending. We may be subject to competition during this period and may not be able to fully recover for the losses, damages, and harms we incur from infringement by the competitor product even if we prevail. Moreover, if we lose or settle current or future litigations at certain stages or entirely, we could be subject to competition and/or significant liabilities, be required to enter into third-party licenses for the infringed product or technology or be required to cease using the technology or product in dispute. In addition, we cannot guarantee that such licenses will be available on terms acceptable to us, or at all.

Further, under the Hatch-Waxman Act, our products approved by the FDA under the Food, Drug and Cosmetic Act may be the subject of patent litigation with generic competitors before expiry of the five year period of data exclusivity provided for under the Hatch-Waxman Act and prior to the expiration of the patents listed for the product. Likewise, our biologic products may be the subject of patent litigation prior to the expiration of our patents and, with respect to competitors seeking approval as a biosimilar or interchangeable version of our products, prior to the twelve year exclusivity period provided under the Biologics Price Competition and Innovation Act of 2009.

Over the next several years, many of the existing patents on our principal products will expire. (See Item 1. Business — Marketed Products.) As our patents expire, competitors may be able to legally produce and market similar products or technologies, including biosimilars, which may have a material adverse effect on our product sales, business and results of operations. (See Item 7A. Management's Discussion and Analysis of Financial Condition and Results of Operations — Financial Condition, Liquidity and Capital Resources.) We have received,

and we continue to seek, additional patent protection relating to our products, including patents on our products, specific processes for making our products, formulations and particular uses of our products. However, competitors may be able to invalidate, design around or otherwise circumvent our patents and sell competing products. For example, while we do not expect biosimilars competition on ENBREL in the United States for the foreseeable future, there are a number of competing therapies currently on the market and more in clinical development that are different from ENBREL but are used to treat the same inflammatory diseases treated by ENBREL. Although we continue to develop new products, and obtain patent protection for these new product candidates, we may not be able to replace the revenue lost upon the expiration of the patents on our current products.

From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011, after years of Congressional debate regarding patent reform legislation, President Obama signed into law the America Invents Act (the Act) considered by many to be the most substantial revision of U.S. patent law since 1952. The Act's various provisions will go into effect over an 18-month period. The Act changes the current "first-to-invent" system to a system that awards a patent to the "first-inventor-to-file" for an application for a patentable invention. This change alters the pool of available materials that can be used to challenge patents and eliminates the ability to rely on prior research work in order to lay claim to patent rights. Disputes as to whether the first filer is in fact the true inventor will be resolved through newly implemented derivation proceedings. The Act also creates mechanisms to allow challenges to newly issued patents in the patent office in post-grant proceedings and new inter partes reexamination proceedings. Although many of the changes bring U.S. law into closer harmony with European and other national patent laws, the new bases and procedures may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention.

Our stock price is volatile.

Our stock price, like that of our peers in the biotechnology and pharmaceutical industries, is volatile. Our revenues and operating results may fluctuate from period to period for a number of reasons. Events such as a delay in product development or even a relatively small revenue shortfall may cause financial results for a period to be below our expectations or projections. As a result, our revenues and operating results and, in turn, our stock price may be subject to significant fluctuations.

We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

The capital and credit markets may experience extreme volatility and disruption which may lead to uncertainty and liquidity issues for both borrowers and investors. We may access the capital markets to supplement our existing funds and cash generated from operations in satisfying our needs for working capital; capital expenditure and debt service requirements; our plans to pay dividends and repurchase stock; and other business initiatives we plan to strategically pursue, including acquisitions and licensing activities. In the event of adverse capital and credit market conditions, we may not be able to obtain capital market financing on similar favorable terms, or at all, which could have a material adverse effect on our business and results of operations. Changes in credit ratings issued by nationally recognized credit rating agencies could adversely affect our cost of financing and have an adverse effect on the market price of our securities.

Guidelines and recommendations published by various organizations can reduce the use of our products.

Government agencies promulgate regulations and guidelines directly applicable to us and to our products. However, professional societies, HTA organizations, practice management groups, insurance carriers, physicians, private health/science foundations and organizations involved in various diseases from time to time may also publish guidelines or recommendations to healthcare providers, administrators and payers, and patient communities. Recommendations by government agencies or those other groups/organizations may relate to such matters as usage, dosage, route of administration and use of related therapies as well as reimbursement of our products by government and private payers. Recommendations or guidelines that are followed by patients,

healthcare providers and payers could result in decreased use and/or dosage of our products. Some examples of agency and organizational guidelines include:

- In August 2007, the National Kidney Foundation (NKF) distributed to the nephrology community final updated Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guidelines and clinical practice recommendations for anemia in CKD. The NKF-KDOQI™ Anemia Work Group recommended in its 2007 Update to the NKF-KDOQI™ Anemia Management Guidelines that physicians target Hb in the range of 11 g/dL to 12 g/dL, and also stipulated that the target not be above 13 g/dL.
- In December 2008, the KDIGO, a not-for-profit foundation managed by NKF, announced that it was developing a new global anemia guideline. The announcement stated that an updated anemia guideline is necessary in light of new study results, particularly the data from the TREAT trial, which had become available since the NKF-KDOQI™'s clinical practice guidelines and clinical practice recommendations for anemia in CKD were released. On September 30, 2011, the KDIGO released its draft global anemia clinical practice guidelines for public review and comment. KDIGO has indicated that final guidelines could be available by early 2012.
- In February 2007, following the reported results from our Anemia of Cancer 103 Study, the U.S. Pharmacopoeia Dispensing Information Drug Reference Guides removed Aranesp® in the treatment of anemia of cancer.

In addition, HTA organizations, such as NICE in the UK and the Canadian Agency for Drugs and Technologies in Health, make reimbursement recommendations to payers in their jurisdictions based on the clinical effectiveness, cost-effectiveness and service impact of new, emerging and existing medicines and treatments.

Any recommendations or guidelines that result in decreased use, dosage or reimbursement of our products could materially and adversely affect our product sales, business and operating results. In addition, the perception by the investment community or stockholders that such recommendations or guidelines will result in decreased use and dosage of our products could adversely affect the market price for our common stock.

The commercialization of certain of our product candidates and the marketing of certain of our products is dependent in part on our partners.

We have entered into agreements with third parties to assist in the commercialization of certain of our product candidates and the marketing of certain of our products in specified geographic areas. (See Item 1. Business — Business Relationships.) Many of these agreements involve the sharing of certain decisions and a division of responsibilities, costs and benefits. If our partners fail to effectively deliver on their marketing and commercialization commitments to us or if we and our partners fail to coordinate our efforts effectively, sales of our products may be materially and adversely affected.

Our corporate compliance and risk mitigation programs cannot guarantee that we are in compliance with all potentially applicable U.S. federal and state regulations and all potentially applicable foreign regulations and/or that we effectively manage all operational risks.

The development, manufacturing, distribution, pricing, sales, marketing and reimbursement of our products, together with our general operations, are subject to extensive federal and state regulation in the United States and to extensive regulation in foreign countries. (See Our current products and products in development cannot be sold if we do not maintain or gain regulatory approval and manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.) While we have developed and instituted a corporate compliance program, we cannot guarantee that we, our employees, our consultants or our contractors are or will be in compliance with all potentially applicable U.S. federal and state regulations and/or laws or all potentially applicable foreign regulations and/or laws. If we or our agents fail to comply with any of those regulations and/or laws, a range of actions could result, including, but not limited to, the termination of clinical trials, the failure to approve a product candidate, restrictions on our products or manufacturing processes, withdrawal of our products from the market, significant fines, exclusion from government healthcare programs or other sanctions or litigation. Additionally, while we have implemented numerous risk mitigation measures, we cannot guarantee

that we will be able to effectively mitigate all operational risks. If we fail to effectively mitigate all operational risks, our product supply may be negatively impacted, which could have a material and adverse effect on our product sales, business and results of operations.

Cost savings initiatives may result in the carrying value of certain existing manufacturing facilities or other assets becoming impaired or other related charges being incurred.

Our business continues to face many challenges. In response to these challenges, we have worked and continue to work to improve cost efficiencies and to reduce discretionary expenditures. As part of those efforts, we undertake cost savings initiatives to evaluate our processes and procedures in order to identify opportunities for achieving greater efficiencies in how we conduct our business. In particular, we evaluate our manufacturing operations to identify opportunities to increase production yields and/or success rates as well as capacity utilization. Depending on the timing and outcomes of these cost savings initiatives, the carrying value of certain manufacturing or other assets may not be fully recoverable and could result in the recognition of impairment and/or other related charges. The recognition of such charges, if any, could have a material adverse effect on our results of operations.

The adoption of new tax legislation or exposure to additional tax liabilities could affect our profitability.

We are subject to income and other taxes in the United States and other jurisdictions in which we do business. Our provision for income taxes and results of operations in the future could be adversely affected by changes to our operating structure, changes in the mix of earnings in countries with differing tax rates, changes in the valuation of deferred tax assets and liabilities, and changes in applicable tax laws, regulations or administrative interpretations thereof. For example, there are several proposals under consideration in the United States to reform tax law, including proposals that may reduce or eliminate the deferral of U.S. income tax on our unrepatriated foreign earnings. While it is uncertain how the U.S. Congress may address U.S. tax policy matters in the future, reform of U.S. taxation, including taxation of international income, continues to be a topic of discussion for the U.S. Congress and the Administration. A significant change to the U.S. tax system, such as a change to the taxation of international income, could have a material and adverse effect on our business and results of operations.

There can be no assurance that we will continue to declare cash dividends or repurchase stock.

On April 20, 2011, our Board of Directors adopted a dividend policy pursuant to which the Company would pay quarterly dividends on our common stock, and increased the total authorization for repurchases of our common stock to approximately $7.2 billion. On October 13, 2011, our Board of Directors increased the total authorization for repurchases of our common stock by approximately $6.1 billion to $10 billion, and in December 2011 we repurchased approximately $5 billion of our common stock in a modified Dutch auction tender offer, leaving approximately $5 billion remaining for future repurchases under our Board authorization. Whether we continue and the amount and timing of such dividends and/or stock repurchases are subject to capital availability and periodic determinations by our Board of Directors that cash dividends and/or stock repurchases are in the best interest of our stockholders and are in compliance with all respective laws and agreements of the Company applicable to the declaration and payment of cash dividends and the repurchase of stock. Future dividends and stock repurchases, including their timing and amount, may be affected by, among other factors: our views on potential future capital requirements for strategic transactions, including acquisitions; debt service requirements; our credit rating; changes to applicable tax laws or corporate laws; and changes to our business model. In addition, the amount we spend and the number of shares we are able to repurchase under our stock repurchase program may further be affected by a number of other factors, including the stock price and blackout periods in which we are restricted from repurchasing shares. Our dividend payments and/or stock repurchases may change from time to time, and we cannot provide assurance that we will continue to declare dividends and/or repurchase stock in any particular amounts or at all. A reduction in or elimination of our dividend payments and/or stock repurchases could have a negative effect on our stock price.

Item 1B. UNRESOLVED STAFF COMMENTS

None.

Item 2. PROPERTIES

The following table summarizes our significant properties and their primary functions as of December 31, 2011. For additional information regarding manufacturing initiatives, see Item 1. Business — Manufacturing, Distribution and Raw Materials.

Location	Number of spaces or buildings		Manufacturing							Other functions				
			Commercial											
	Owned	Leased	Neulasta®	NEUPOGEN®	Enbrel®	Aranesp®	epoetin alfa	Other products	Clinical	Administrative	Research and/or development	Sales and marketing	Warehouse	Distribution center
United States:														
Thousand Oaks, California	35	6							B F	✔	✔	✔	✔	✔
San Francisco, California	-	5								✔	✔			
Boulder, Colorado	2	2						B	B	✔			✔	
Longmont, Colorado	6	1					B		B	✔			✔	
Washington, D.C.	-	1								✔		✔		
Louisville, Kentucky	1	-											✔	✔
Cambridge, Massachusetts	1	-									✔			
Woburn, Massachusetts	-	2							B F	✔			✔	
West Greenwich, Rhode Island	6	-			B				B	✔			✔	
Bothell, Washington	3	1									✔		✔	
Seattle, Washington	6	-								✔	✔			
Other U.S. cities	-	5								✔		✔		
Outside United States:														
Australia	-	2								✔		✔		
Brazil	1	5						F		✔		✔	✔	✔
Canada	-	3								✔	✔	✔		
Ireland	8	2						F		✔		✔	✔	
Japan	-	1								✔	✔			
Netherlands	8	-	F1	F1		F1		F1	F1	✔		✔	✔	✔
Puerto Rico	21	-	B F	B F	F	B F	B1 F	F	B F	✔			✔	
Switzerland	-	2								✔		✔		
United Kingdom	1	4								✔	✔	✔		
Other countries	-	30									✔	✔		

B—Bulk manufacturing
B1—Bulk manufacturing (purification only)
F—Formulation, fill and finish
F1—Finish only

Our corporate headquarters are located in Thousand Oaks, California. In addition to the properties listed above, we have undeveloped land at certain U.S. locations, principally in Thousand Oaks, California; Longmont, Colorado; Louisville, Kentucky; Allentown, Pennsylvania; West Greenwich, Rhode Island; Seattle and Bothell, Washington; and in Juncos, Puerto Rico, to accommodate future expansion, as required. Excluded from the table above are leased properties that have been abandoned and certain buildings that we still own but are no longer used in our business. There are no material encumbrances on our properties.

We believe our facilities are suitable for their intended use and, in conjunction with our third-party contracting manufacturing agreements, provide adequate capacity. We also believe that our existing facilities, third-party contract manufacturing agreements and our anticipated additions are sufficient to meet our expected needs. (See Item 1A. Risk Factors — We perform a substantial amount of our commercial manufacturing activities at our Puerto Rico manufacturing facility and a substantial amount of our clinical manufacturing activities at our Thousand Oaks, California manufacturing facility; if significant natural disasters or production failures occur at the Puerto Rico facility, we may not be able to supply these products or, at the Thousand Oaks facility, we may not be able to continue our clinical trials, — We rely on third-party suppliers for certain of our raw materials, medical devices and components and — Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.)

Item 3. LEGAL PROCEEDINGS

Certain of the legal proceedings in which we are involved are discussed in Note 18, Contingencies and commitments, to our Consolidated Financial Statements in this Annual Report on Form 10-K, and are hereby incorporated by reference.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Common stock

Our common stock trades on The NASDAQ Global Select Market under the symbol AMGN. As of February 10, 2012, there were approximately 9,153 holders of record of our common stock.

The following table sets forth, for the periods indicated, the range of high and low quarterly closing sales prices of the common stock as quoted on The NASDAQ Global Select Market:

Year ended December 31, 2011	High	Low
Fourth quarter	$ 64.74	$ 53.90
Third quarter	58.28	48.27
Second quarter	61.17	53.08
First quarter	57.31	50.95
Year ended December 31, 2010		
Fourth quarter	$ 57.96	$ 52.69
Third quarter	56.32	50.93
Second quarter	61.14	50.36
First quarter	60.09	55.71

Performance graph

The following graph shows the value of an investment of $100 on December 31, 2006, in each of Amgen common stock, the Amex Biotech Index, the Amex Pharmaceutical Index and Standard & Poor's 500 Index (S&P 500). All values assume reinvestment of the pretax value of dividends paid by companies included in these indices and are calculated as of December 31 of each year. The historical stock price performance of the Company's common stock shown in the performance graph is not necessarily indicative of future stock price performance.

Amgen vs. Amex Biotech, Amex Pharmaceutical and S&P 500 Indices
Comparison of Five-Year Cumulative Total Return
Value of Investment of $100 on December 31, 2006



	12/31/2006	12/31/2007	12/31/2008	12/31/2009	12/31/2010	12/31/2011
Amgen (AMGN)	$ 100.00	$ 67.98	$ 84.54	$ 82.81	$ 80.37	$ 94.98
Amex Biotech (BTK)	100.00	104.28	85.80	124.91	172.04	144.79
Amex Pharmaceutical (DRG)	100.00	101.01	84.76	99.15	101.64	114.77
S&P 500 (SPX)	100.00	105.48	66.93	84.28	96.78	98.81

The material in this performance graph is not soliciting material, is not deemed filed with the SEC, and is not incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made on, before or after the date of this filing and irrespective of any general incorporation language in such filing.

Stock repurchase program

The Company intends to continue to return capital to stockholders through share repurchases, reflecting our confidence in the long-term value of the Company. The amount we spend, the number of shares repurchased and the timing of such repurchases will vary based on a number of factors, including the stock price, the availability of financing on acceptable terms, the amount and timing of dividend payments and blackout periods in which we are restricted from repurchasing shares; and the manner of purchases may include private block purchases, tender offers, as well as market transactions.

During the three months and year ended December 31, 2011, we had one outstanding stock repurchase program. Our repurchase activity for the three months and year ended December 31, 2011, was as follows:

	Total number of shares purchased	Average price paid per share[1]	Total number of shares purchased as part of publicly announced program	Maximum $ value that may yet be purchased under the program[2]
October 1 - October 31	2,728,703	$ 53.99	2,728,703	$ 10,000,000,000
November 1 - November 30	—	—	—	10,000,000,000
December 1 - December 31	83,333,333	60.08	83,333,333	4,993,072,585
	86,062,036	59.89	86,062,036	
January 1 - December 31	144,331,565	$ 57.55	144,331,565	

(1) Average price paid per share includes related expenses.

(2) Following the repurchase of $147 million in additional shares in early October 2011, on October 13, 2011, our Board of Directors increased the authorization for repurchase of our common stock by $6.1 billion to an aggregate of $10 billion.

Dividends

We began paying quarterly cash dividends in 2011. On July 28 and October 13, 2011, the Board of Directors declared quarterly cash dividends of $0.28 per share of common stock, which were paid on September 8 and December 8, 2011, respectively. Additionally, on December 15, 2011, the Board of Directors declared a quarterly cash dividend of $0.36 per share of common stock, which will be paid on March 7, 2012, to all stockholders of record as of the close of business on February 15, 2012. We expect to continue to pay quarterly dividends, although the amount and timing of any future dividends are subject to approval by our Board of Directors.

Item 6. SELECTED FINANCIAL DATA

Consolidated Statement of Income Data:	Years ended December 31,				
	2011	2010	2009	2008	2007
	(In millions, except per share data)				
Revenues:					
Product sales	$15,295	$14,660	$14,351	$14,687	$14,311
Other revenues	287	393	291	316	460
Total revenues	15,582	15,053	14,642	15,003	14,771
Operating expenses[1]:					
Cost of sales (excludes amortization of certain acquired intangible assets presented separately)	2,427	2,220	2,091	2,296	2,548
Research and development	3,167	2,894	2,864	3,030	3,266
Selling, general and administrative	4,486	3,983	3,820	3,789	3,361
Amortization of certain acquired intangible assets	294	294	294	294	298
Write-off of acquired in-process research and development[2]	—	—	—	—	590
Other[3]	896	117	67	380	728
Net income[4]	3,683	4,627	4,605	4,052	3,078
Diluted earnings per share[4]	4.04	4.79	4.51	3.77	2.74
Dividends paid per share	0.56	—	—	—	—

Consolidated Balance Sheet Data:	As of December 31,				
	2011	2010	2009	2008	2007
			(In millions)		
Total assets	$48,871	$43,486	$39,629	$36,427	$34,618
Total debt[4][5][6]	21,428	13,362	10,601	9,352	10,114
Total stockholders' equity[4][6]	19,029	23,944	22,667	20,885	18,512

In addition to the following notes, see Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and accompanying notes and previously filed Annual Reports on Form 10-K for further information regarding our consolidated results of operations and financial position for periods reported therein and for known factors that will impact comparability of future results. Also, see Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities for information regarding cash dividends declared per common share.

(1) On August 15, 2007, we announced a plan to restructure our worldwide operations in order to improve our cost structure. Under this plan in 2009, 2008 and 2007, we incurred restructuring charges of $70 million ($44 million, net of tax), $148 million ($111 million, net of tax) and $739 million ($576 million, net of tax), respectively, related primarily to staff separation costs, asset impairment charges, accelerated depreciation (primarily in 2007) and loss accruals for leases on certain facilities that will not be used in our business.

(2) As part of the accounting for the business combinations of Alantos Pharmaceutical Holding, Inc. and Ilypsa, Inc. in 2007, under the then existing accounting rules we recorded charges to write-off acquired in-process R&D (IPR&D) of $270 million and $320 million, respectively. The charges represent the estimated fair values of the IPR&D that, as of the respective acquisition dates, had not reached technological feasibility and had no alternative future use.

(3) In 2011, we recorded a $780 million legal settlement charge ($705 million, net of tax) in connection with an agreement in principle to settle allegations relating to our sales and marketing practices. In 2008, we recorded loss accruals for settlements of certain commercial legal proceedings aggregating $288 million, related principally to the settlement of the Ortho Biotech Products L.P. (Ortho Biotech) antitrust suit.

(4) Effective January 1, 2009, we adopted a new accounting standard that changed the method of accounting for convertible debt that may be partially or wholly settled in cash. As required by this standard, we retrospectively applied this change in accounting to all prior periods for which we had applicable outstanding convertible debt. Under this method of accounting, the debt and equity components of our convertible notes are bifurcated and accounted for separately. The equity components of our convertible notes are included in Common stock and additional paid-in capital in the Consolidated Balance Sheets, with a corresponding reduction in the carrying values of these convertible notes as of the date of issuance or modification, as applicable. The reduced carrying values of our convertible notes are being accreted back to their principal amounts through the recognition of non-cash interest expense. This results in recognizing interest expense on these borrowings at effective rates approximating what we would have incurred had we issued nonconvertible debt with otherwise similar terms. Included in net income for 2011, 2010, 2009, 2008 and 2007 is the incremental non-cash interest expense of $143 million ($91 million, net of tax), $266 million ($168 million, net of tax), $250 million ($155 million, net of tax), $235 million ($144 million, net of tax) and $168 million ($88 million, net of tax), respectively, related to the adoption of the new accounting standard.

(5) See Note 14, Financing arrangements, to the Consolidated Financial Statements for discussion of our financing arrangements. In addition, in 2008 and 2007 we issued $1.0 billion and $4.0 billion, respectively, aggregate principal amount of notes. In 2008, we repaid our $2.0 billion of floating rate notes. In 2007, as a result of holders of substantially all of our outstanding zero-coupon 2032 Modified Convertible Notes exercising their put option, we repurchased the majority of the then outstanding convertible notes, at their then-accreted value of $1.7 billion.

(6) Throughout the five years ended December 31, 2011, we had a share repurchase program authorized by the Board of Directors through which we repurchased $8.3 billion, $3.8 billion, $3.2 billion, $2.3 billion and $5.1 billion, respectively, of Amgen common stock.

Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-looking statements

This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business or others on our behalf, our beliefs and our management's assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases or written statements, or in our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. Such words as "expect," "anticipate," "outlook," "could," "target," "project," "intend," "plan," "believe," "seek," "estimate," "should," "may," "assume" and "continue," as well as variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. We describe our respective risks, uncertainties and assumptions that could affect the outcome or results of operations in Item 1A. Risk Factors. We have based our forward-looking statements on our management's beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecast by our forward-looking statements. Reference is made in particular to forward-looking statements regarding product sales, regulatory activities, clinical trial results, reimbursement, expenses, earnings per share (EPS), liquidity and capital resources, trends and planned dividends and stock repurchases. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.

Overview

The following management's discussion and analysis (MD&A) is intended to assist the reader in understanding Amgen's business. MD&A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and accompanying notes. Our results of operations discussed in MD&A are presented in conformity with accounting principles generally accepted in the United States (GAAP).

We are the world's largest independent biotechnology medicines company. We discover, develop, manufacture and market medicines for grievous illnesses. We concentrate on innovative novel medicines based on advances in cellular and molecular biology. Our mission is to serve patients. We operate in one business segment — human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.

We earn revenues and income and generate cash primarily from sales of human therapeutic products in the areas of supportive cancer care, inflammation and nephrology. Our principal products include Neulasta®, NEUPOGEN®, ENBREL, Aranesp® and EPOGEN®. For additional information about our products, their approved indications and where they are marketed, see Item 1. Business — Marketed Products.

In 2011, we had several notable accomplishments, including achieving record U.S. and international product sales of $11.7 billion and $3.6 billion, respectively. We also paid our first ever dividends, aggregating $500 million paid in 2011. In December 2011, we declared a quarterly dividend of $0.36 per share of common stock payable in March 2012, representing a 29% increase over prior quarters. Additionally, in 2011, we repurchased approximately 15% of our stock outstanding as of December 31, 2010, for a total cost of $8.3 billion. Of this amount, $5 billion was purchased in a modified Dutch auction tender offer following an increase in our authorized stock repurchase program to $10 billion and our announcement that we intended to accelerate our repurchases, reflecting our confidence in the long-term value of the Company and the attractive interest rate environment. We issued $7.5 billion of debt, in part to fund the purchase of stock related to the tender offer. We expect to repurchase the remaining $5 billion of stock under our authorized stock repurchase program through open-market purchases.

We enter 2012 with various opportunities to continue growing our business. We believe the currently approved indications for XGEVA® and Prolia® represent significant commercial opportunities. In addition, receiving regulatory and/or reimbursement approvals in new geographic territories or for additional indications

for these products may provide further opportunities for growth. Longer-term growth may also be achieved by expansion into emerging markets and Japan, by the successful development of our later stage pipeline and through strategic business development opportunities, such as our acquisitions of BioVex, Bergamo and our recently announced agreement to acquire Micromet. Our continued focus on increasing cost efficiencies, along with the significant savings that we will realize upon the expiration of our ENBREL co-promotion agreement with Pfizer in the fourth quarter of 2013, may assist in providing the necessary resources to fund many of these future opportunities.

Our business will, however, continue to face various challenges. Certain of our products will continue to face increasing competitive pressure, including in Europe as a result of biosimilars. In the United States, ENBREL will also continue to face increasing competition and our ESAs may begin facing competition in the near term. Additionally, over the next several years, many of the existing patents on our principal products will expire and, as a result, we expect to face increasing competition from biosimilars. We also believe our products and product candidates will continue to face regulatory and reimbursement challenges. In addition, the current global economic conditions continue to pose challenges to our business, including increased pressure to reduce healthcare expenditures.

Certain of the above challenges may have a material adverse impact on our sales, results of operations and liquidity. However, these effects may be offset by certain of the opportunities we have to grow our business, as discussed above.

Selected financial information

The following provides an overview of our results of operations as well as our financial condition (amounts in millions, except percentages and per-share data):

	2011	Change	2010
Product sales:			
U.S.	$11,725	4 %	$11,254
International	3,570	5 %	3,406
Total product sales	15,295	4 %	14,660
Other revenues	287	(27)%	393
Total revenues	$15,582	4 %	$15,053
Operating expenses	$11,270	19 %	$ 9,508
Operating income	$ 4,312	(22)%	$ 5,545
Net income	$ 3,683	(20)%	$ 4,627
Diluted EPS	$ 4.04	(16)%	$ 4.79
Diluted shares	912	(5)%	965

When discussing changes in product sales below, any reference to unit growth or decline refers to changes in the purchases of our products by healthcare providers, such as physicians or their clinics, dialysis centers, hospitals and pharmacies.

The increase in U.S. product sales for 2011 reflects overall growth for all marketed products except ESAs, which declined 17%. Excluding sales of ESAs, U.S. product sales increased 14%, driven primarily by unit growth and, to a lesser extent, increases in average net sales prices. International product sales for 2011 were negatively impacted by a decline in sales of Aranesp® of 5%. Excluding Aranesp® sales, international product sales grew 11%.

The decrease in other revenues for 2011 was due principally to certain milestone payments earned in 2010.

The increase in operating expenses for 2011 was driven primarily by a legal settlement charge and higher SG&A expenses.

The decrease in diluted EPS for 2011 was due to the reduction in net income, attributable primarily to lower operating income. This decrease in diluted EPS was offset partially by the favorable impact of our stock repurchase program, which reduced the number of shares used to compute diluted EPS.

Although changes in foreign currency exchange rates result in increases or decreases in our reported international product sales, the benefit or detriment that such movements have on our international product sales is offset partially by corresponding increases or decreases in our international operating expenses and our related foreign currency hedging activities. Our hedging activities seek to offset the impacts, both positive and negative, that foreign currency exchange rate changes may have on our net income by hedging our net foreign currency exposure, primarily with respect to product sales denominated in the euro.

Our results of operations for 2011 were impacted by the Puerto Rico excise tax. Commencing January 1, 2011, Puerto Rico imposes a temporary excise tax on the acquisition of goods and services from a related manufacturer in Puerto Rico. This tax is currently scheduled to expire in 2016. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes in the year in which the excise tax is incurred. This excise tax has had and will continue to have a significant adverse impact on our cost of sales and a significant favorable impact on our provision for income taxes. In addition, the overall impact of the excise tax will vary from period to period as a result of the timing difference between recognizing the expense and the applicable foreign tax credit. As a result of the excise tax, for 2011 cost of sales increased by $211 million, the provision for income taxes was reduced by $321 million and EPS was favorably impacted by $0.12.

As of December 31, 2011, our cash, cash equivalents and marketable securities totaled $20.6 billion, and total debt outstanding was $21.4 billion. Of our total cash, cash equivalents and marketable securities balance as of December 31, 2011, approximately $16.9 billion was generated from operations in foreign tax jurisdictions and is intended to be invested indefinitely outside of the United States. Under current tax laws, if these funds were repatriated for use in our U.S. operations, we would be required to pay additional income taxes at the tax rates then in effect.

Results of Operations

Product sales

Worldwide product sales were as follows (dollar amounts in millions):

	2011	Change	2010	Change	2009
Neulasta®/NEUPOGEN ®	$ 5,212	8 %	$ 4,844	4 %	$ 4,643
ENBREL	3,701	5 %	3,534	1 %	3,493
Aranesp®	2,303	(7)%	2,486	(6)%	2,652
EPOGEN®	2,040	(19)%	2,524	(2)%	2,569
Other products	2,039	60 %	1,272	28 %	994
Total product sales	$15,295	4 %	$14,660	2 %	$14,351
Total U.S.	$11,725	4 %	$11,254	1 %	$11,135
Total International	3,570	5 %	3,406	6 %	3,216
Total product sales	$15,295	4 %	$14,660	2 %	$14,351

Product sales are influenced by a number of factors, some of which may impact the sales of certain of our existing products more significantly than others, including, but not necessarily limited to:

- our contracting and pricing strategies;
- recent and future reimbursement changes resulting from:
  - governmental or private organization regulations or guidelines relating to the use of our products;
  - legislative reform in federal, state and foreign jurisdictions;

- cost containment pressures; and
- the mix of reimbursement from governmental and private payers;

- clinical trial outcomes, including adverse events or results from clinical trials, including sub-analyses, studies or meta-analyses performed by us or by others (including our licensees or independent investigators), which could impact product safety labeling and may negatively impact healthcare provider prescribing behavior, use of our products, regulatory or private healthcare organization medical guidelines and reimbursement practices;
- competitive products, including biosimilars;
- physician and patient compliance with product dosing regimens;
- changes in clinical practice, including those resulting from the development of new protocols, tests and/or treatments;
- adoption of and adherence to risk management activities, such as a REMS, undertaken by us or required by the FDA or other regulatory authorities;
- product label changes;
- patient population growth;
- segment growth and penetration;
- new product launches and indications;
- expansion into new international markets;
- patent expirations and our ability to obtain and defend our patent and other intellectual property rights;
- fluctuations in foreign currency exchange rates;
- adequacy of product supply and distribution;
- effectiveness of our marketing efforts, including those conducted under collaboration agreements;
- concentration of customer purchasing power; and
- acquisitions and divestures.

Our U.S. product sales are also subject to certain other influences throughout the year, including wholesaler and end-user buying patterns (e.g., holiday-driven wholesaler and end-user stocking, contract-driven buying and patients purchasing products later in the year after satisfying their annual insurance deductibles). Such factors can result in higher demand for our products and/or higher wholesaler inventory levels and, therefore, higher product sales for a given three-month period, generally followed by a reduction in demand and/or a drawdown in wholesaler inventories and a corresponding decline in product sales in the subsequent three-month period. For example, sales of certain of our products in the United States for the three months ended March 31 have been slightly lower relative to the immediately preceding three-month period, which we believe to be due, in part, to certain of these factors. While this can result in variability in quarterly product sales on a sequential basis, these effects have generally not been significant when comparing product sales in the three months ended March 31 with product sales in the corresponding period of the prior year.

In addition, general economic conditions may affect, or in some cases amplify, certain of these factors with a corresponding impact on our product sales.

See Item 1. Business — Marketed Products for a discussion of our principal products and their approved indications.

Neulasta®/NEUPOGEN®

Total Neulasta®/NEUPOGEN® sales by geographic region were as follows (dollar amounts in millions):

	2011	Change	2010	Change	2009
Neulasta® — U.S.	$3,006	13 %	$2,654	5 %	$2,527
NEUPOGEN® — U.S.	959	3 %	932	3 %	901
Total U.S. Neulasta®/NEUPOGEN®	3,965	11 %	3,586	5 %	3,428
Neulasta® — International	946	5 %	904	9 %	828
NEUPOGEN® — International	301	(15)%	354	(9)%	387
Total International Neulasta®/NEUPOGEN®	1,247	(1)%	1,258	4 %	1,215
Total Neulasta®/NEUPOGEN®	$5,212	8 %	$4,844	4 %	$4,643

The increase in U.S. sales of Neulasta®/NEUPOGEN® for 2011 was driven principally by an increase in the average net sales price and Neulasta® unit growth. The decrease in Neulasta®/NEUPOGEN® international sales was driven by a decline in NEUPOGEN® sales due, in part, to biosimilar competition, offset partially by an increase in Neulasta® sales due, in part, to continued conversion from NEUPOGEN®.

The increase in U.S. sales of Neulasta®/NEUPOGEN® for 2010 was driven principally by an increase in the average net sales price and, to a lesser extent, favorable changes in wholesaler inventories. The increase in international Neulasta®/NEUPOGEN® sales for 2010 reflects primarily growth in Neulasta®, principally from the continued conversion from NEUPOGEN®, offset partially by a decline in NEUPOGEN® sales due, in part, to biosimilar competition.

In addition to other factors mentioned in the Product sales section above, future Neulasta®/NEUPOGEN® sales will depend, in part, on the development of new protocols, tests and/or treatments for cancer and/or new chemotherapy treatments or alternatives to chemotherapy that may have reduced and may continue to reduce the use of chemotherapy in some patients.

See Item 1. Business — Marketed Products and Item 1A. Risk Factors for further discussion of certain of the above factors that could impact our future product sales.

ENBREL

Total ENBREL sales by geographic region were as follows (dollar amounts in millions):

	2011	Change	2010	Change	2009
ENBREL — U.S.	$3,458	5 %	$3,304	1 %	$3,283
ENBREL — Canada	243	6 %	230	10 %	210
Total ENBREL	$3,701	5 %	$3,534	1 %	$3,493

The increase in ENBREL sales for 2011 reflects primarily an increase in the average net sales price.

The increase in ENBREL sales for 2010 reflects an increase in the average net sales price, offset partially by a low single-digit percentage point unit decline, resulting primarily from share declines in dermatology.

ENBREL continues to maintain a leading position in both the rheumatology and dermatology segments.

See Item 1. Business — Marketed Products and Item 1A. Risk Factors for further discussion of certain of the above factors that could impact our future product sales.

Aranesp®

Total Aranesp® sales by geographic region were as follows (dollar amounts in millions):

	2011	Change	2010	Change	2009
Aranesp® — U.S.	$ 986	(11)%	$1,103	(12)%	$1,251
Aranesp® — International	1,317	(5)%	1,383	(1)%	1,401
Total Aranesp®	$2,303	(7)%	$2,486	(6)%	$2,652

The decrease in U.S. Aranesp® sales for 2011 was due principally to a high-teens percentage point unit decline, offset partially by an increase in the average net sales price. The unit decline reflects segment contraction resulting from changes to reimbursement in 2011 and the June 2011 ESA label changes. The decrease in international Aranesp® sales for 2011 was due to a decrease in the average net sales price and a unit decline, reflecting segment contraction.

The decrease in U.S. Aranesp® sales for 2010 was due primarily to a unit decline, reflecting segment contraction. The decrease in international Aranesp® sales for 2010 was due primarily to a unit decline.

In addition to other factors mentioned in the Product sales section above, future Aranesp® sales will depend, in part, on such factors as:

- regulatory developments, including the June 2011 ESA label changes and any other product label changes;
- reimbursement developments, including LCDs;
- changes in dose utilization as healthcare providers continue to refine their treatment practices in accordance with approved labeling; and
- development of new protocols, tests and/or treatments for cancer and/or new chemotherapy treatments or alternatives to chemotherapy that may have reduced and may continue to reduce the use of chemotherapy in some patients.

Certain of the above factors may have a material adverse impact on future sales of Aranesp®.

See Item 1. Business — Significant Developments, Item 1. Business — Marketed Products and Item 1A. Risk Factors for further discussion of certain of the above factors that could impact our future product sales.

EPOGEN®

Total EPOGEN® sales were as follows (dollar amounts in millions):

	2011	Change	2010	Change	2009
EPOGEN® — U.S.	$2,040	(19)%	$2,524	(2)%	$2,569

The decrease in EPOGEN® sales for 2011 was due primarily to a decrease in dose utilization related to changes to reimbursement in 2011 and the June 2011 ESA label changes, offset partially by an increase in the average net sales price and patient population growth.

The decrease in EPOGEN® sales for 2010 was due primarily to a unit decline and certain changes in accounting estimates. The unit decline reflects a decrease in dose utilization, offset partially by patient population growth.

In addition to other factors mentioned in the Product sales section above, future EPOGEN® sales will depend, in part, on such factors as:

- potential peginesatide launch;

- reimbursement developments, including those resulting from:
  - CMS's 2011 Final Rule on Bundling in Dialysis; and
  - other CMS activities, including recent changes related to the QIP;
- regulatory developments, including the June 2011 ESA label changes and any other product label changes;
- changes in dose utilization as healthcare providers continue to refine their treatment practices in accordance with approved labeling;
- new contracts with dialysis centers; and
- adoption of alternative therapies or development of new modalities to treat anemia associated with CRF.

Certain of the above factors may have a material adverse impact on future sales of EPOGEN®.

See Item 1. Business — Significant Developments, Item 1. Business — Marketed Products and Item 1A. Risk Factors for further discussion of certain of the above factors that could impact our future product sales.

Other products

Other product sales by geographic region were as follows (dollar amounts in millions):

	2011	Change	2010	Change	2009
Sensipar®/Mimpara ® — U.S.	$ 518	13 %	$ 459	7 %	$429
Sensipar®/Mimpara ® — International	290	14 %	255	15 %	222
Vectibix® — U.S.	122	6 %	115	19 %	97
Vectibix® — International	200	16 %	173	27 %	136
Nplate® — U.S.	163	26 %	129	65 %	78
Nplate® — International	134	34 %	100	—	32
Prolia® — U.S.	130	—	26	—	—
Prolia® — International	73	—	7	—	—
XGEVA® — U.S.	343	—	8	—	—
XGEVA® — International	8	—	—	—	—
Other — International	58	—	—	—	—
Total other product sales	$2,039	60 %	$1,272	28 %	$994
Total U.S. — other products	$1,276	73 %	$ 737	22 %	$604
Total International — other products	763	43 %	535	37 %	390
Total other product sales	$2,039	60 %	$1,272	28 %	$994

See Item 1. Business — Significant Developments, Item 1. Business — Marketed Products and Item 1A. Risk Factors for further discussion of certain of the above factors that could impact our future product sales.

Operating expenses

Operating expenses were as follows (dollar amounts in millions):

	2011	Change	2010	Change	2009
Operating expenses:					
Cost of sales (excludes amortization of certain acquired intangible assets presented separately)	$ 2,427	9%	$ 2,220	6%	$ 2,091
% of product sales	15.9%		15.1%		14.6%
Research and development	$ 3,167	9%	$ 2,894	1%	$ 2,864
% of product sales	20.7%		19.7%		20.0%
Selling, general and administrative	$ 4,486	13%	$ 3,983	4%	$ 3,820
% of product sales	29.3%		27.2%		26.6%
Amortization of certain acquired intangible assets	$ 294	—	$ 294	—	$ 294
Other	$ 896	—	$ 117	—	$ 67

Cost of sales

Cost of sales, which excludes the amortization of certain acquired intangible assets, increased to 15.9% of product sales for 2011. Excluding the impact of the Puerto Rico excise tax, cost of sales would have been 14.5% of product sales compared with 15.1% for 2010. This decrease was driven by improved productivity, offset partially by certain expenses related to actions to improve cost efficiencies.

Cost of sales increased to 15.1% of product sales for 2010, driven primarily by higher bulk material costs and higher inventory write-offs due to voluntary EPOGEN®, PROCRIT® (epoetin alfa) and ENBREL recalls. These increases were offset partially by lower excess capacity charges and lower royalties, primarily for ENBREL.

Research and development

R&D costs are expensed as incurred and include primarily salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems' costs and amortization of acquired technology used in R&D with alternative future uses. R&D expenses also include costs and cost recoveries associated with K-A and third-party R&D arrangements, including upfront fees and milestones paid to third parties in connection with technologies which had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery.

The Company groups all of its R&D activities and related expenditures into three categories: (1) Discovery Research and Translational Sciences, (2) later stage clinical programs and (3) marketed products. These categories include the Company's R&D activities as set forth in the following table:

Category	Description
Discovery Research and Translational Sciences	R&D expenses incurred in activities substantially in support of early research through the completion of phase 1 clinical trials. These activities encompass our discovery research and translational sciences functions, including drug discovery, toxicology, pharmacokinetics and drug metabolism, and process development.
Later stage clinical programs	R&D expenses incurred in or related to phase 2 and phase 3 clinical programs intended to result in registration of a new product or a new indication for an existing product in the United States or the EU.
Marketed products	R&D expenses incurred in support of the Company's marketed products that are authorized to be sold in the United States or the EU. Includes clinical trials designed to gather information on product safety (certain of which may be required by regulatory authorities) and their product characteristics after regulatory approval has been obtained, as well as the costs of obtaining regulatory approval of a product in a new market after approval in either the United States or the EU has been obtained.

R&D expense by category was as follows (in millions):

	2011	2010	2009
Discovery Research and Translational Sciences	$1,125	$1,154	$1,157
Later stage clinical programs	983	832	1,000
Marketed products	1,059	908	707
Total R&D expense.	$3,167	$2,894	$2,864

The increase in R&D expense for 2011 was driven primarily by an increase of $151 million in our marketed product support largely driven by our continued support for Prolia® and XGEVA® which, subsequent to their approvals during 2010, were categorized as marketed products rather than later stage clinical programs; and an increase of $151 million in our later stage clinical program support, including AMG 386, ganitumab (AMG 479), talimogene laherparepvec and AMG 145, offset partially by decreased support for Prolia® and XGEVA® as a result of their aforementioned approvals. These increases were offset partially by a decrease of $29 million in our Discovery Research and Translational Sciences activities, due primarily to reduced amortization expense related to R&D technology intangible assets acquired in business combinations in prior years.

The increase in R&D expense for 2010 was driven primarily by an increase of $201 million in our marketed product support largely driven by our support for Prolia® and XGEVA® which, subsequent to their approvals during 2010, were categorized as marketed products rather than later stage clinical programs and, to a lesser extent, lower cost recoveries from ongoing collaborations. This increase was offset by a reduction of $168 million in our later stage clinical programs as a result of the aforementioned approvals of Prolia® and XGEVA®, as well as licensing fees paid in 2009, and lower expenses associated with our Discovery Research and Translational Sciences activities of $3 million.

Certain amounts for 2010 have been reclassified to better conform to the above descriptions of R&D activities.

Selling, general and administrative

SG&A expenses are comprised primarily of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; and other general and administrative costs. Advertising costs are expensed as incurred. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaboration arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. Beginning January 1, 2011, SG&A expenses also include the annual U.S. healthcare reform federal excise fee.

The increase in SG&A expense for 2011 was driven primarily by the U.S. healthcare reform federal excise fee of $151 million; higher ENBREL profit share expense of $104 million; increased expenses related to the launches of Prolia® and XGEVA® and expansion of our international operations of $89 million; and the unfavorable impact of foreign exchange of $67 million.

The increase in SG&A expense for 2010 was due primarily to higher promotional costs for Prolia® and other marketed products of $148 million, higher staff-related costs of $46 million and higher litigation expenses of $45 million, offset partially by charges of $29 million in 2009 for certain cost savings initiatives related to our 2007 restructuring plan.

For the years ended December 31, 2011, 2010 and 2009, the expenses associated with the ENBREL profit share were $1,288 million, $1,184 million and $1,163 million, respectively.

Other

In 2011, we recorded a $780 million legal settlement charge in connection with an agreement in principle to settle allegations relating to our sales and marketing practices. In addition in 2011, as part of our continuing efforts to improve cost efficiencies in our operations, we recorded certain charges, primarily severance related, of $109 million. In 2010, we recorded a $118 million asset impairment charge for our manufacturing operations located in Fremont, California, associated with our continuing efforts to optimize our network of manufacturing facilities and improve cost efficiencies. In 2009, we recorded loss accruals for settlements of certain legal proceedings aggregating $33 million.

See Note 18, Contingencies and commitments, to the Consolidated Financial Statements for further discussion of our 2011 legal settlement.

Non-operating expenses/income and provision for income taxes

Non-operating expenses/income and provisions for income taxes were as follows (dollar amounts in millions):

	2011	2010	2009
Interest expense, net	$ 610	$ 604	$ 578
Interest and other income, net	$ 448	$ 376	$ 276
Provisions for income taxes	$ 467	$ 690	$ 599
Effective tax rate	11.3%	13.0%	11.5%

Interest expense, net

Included in interest expense, net, for the years ended December 31, 2011, 2010 and 2009, is the impact of non-cash interest expense of $143 million, $266 million and $250 million, respectively, resulting from the change in the accounting for our convertible debt effective January 1, 2009. The reduction of non-cash interest expense in 2011 was offset by increased interest expense associated with recent borrowings.

Interest and other income, net

The increase in interest and other income, net, for 2011 was due primarily to higher net realized gains on sales of investments of $67 million.

The increase in interest and other income, net, for 2010 was due primarily to higher net realized gains on sales of investments of $48 million and higher interest income of $51 million, due principally to higher average cash, cash equivalents and marketable securities balances.

Income taxes

The decrease in our effective tax rate for 2011 was due primarily to the foreign tax credits associated with the Puerto Rico excise tax described below offset partially by the effect of the non-deductible U.S. healthcare reform federal excise fee in 2011, the non-deductible portion of the legal settlement reached in principle in 2011 and the favorable resolution in 2010 of certain prior years' non-routine transfer pricing matters with tax authorities.

Commencing January 1, 2011, Puerto Rico imposes a temporary excise tax on the acquisition of goods and services from a related manufacturer in Puerto Rico. The excise tax is imposed over a six year period beginning in 2011 with the excise tax rate declining in each year (4% in 2011, 3.75% in 2012, 2.75% in 2013, 2.5% in 2014, 2.25% in 2015, and 1% in 2016). We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes in the year in which the excise tax is incurred. The effective tax rate for 2011 would have been approximately 18% without the impact of the tax credits associated with the Puerto Rico excise tax.

The increase in our effective tax rate for 2010 was due primarily to the incremental favorable impact resulting from the resolution of certain prior years' matters with tax authorities in 2009 compared to 2010; the unfavorable tax impact of changes in revenue and expense mix in 2010; and the tax impact from adjustments to deferred taxes arising from changes in California tax law enacted in 2009 and effective for subsequent periods. The resolution of prior years' tax matters recognized in 2010 and 2009 reduced the effective tax rate by 3.1% and 4.2%, respectively.

As permitted under U.S. GAAP, we do not provide for U.S. income taxes on undistributed earnings of our foreign operations that are intended to be invested indefinitely outside of the United States.

See Summary of Critical Accounting Policies — Income taxes and Note 4, Income taxes, to the Consolidated Financial Statements for further discussion.

Recent accounting pronouncements

In June 2011, a new accounting standard was issued that changed the disclosure requirements for the presentation of other comprehensive income (OCI) in the financial statements, including the elimination of the option to present OCI in the statement of stockholders' equity. OCI and its components will be required to be presented for both interim and annual periods either in a single financial statement, the statement of comprehensive income, or in two separate but consecutive financial statements, consisting of a statement of income followed by a separate statement presenting OCI. This standard is required to be applied retrospectively beginning January 1, 2012, except for certain provisions for which adoption was delayed.

Financial Condition, Liquidity and Capital Resources

Selected financial data was as follows as of December 31, 2011 and 2010 (in millions):

	2011	2010
Cash, cash equivalents and marketable securities	$20,641	$17,422
Total assets	48,871	43,486
Current portion of long-term debt	84	2,488
Long-term debt	21,344	10,874
Stockholders' equity	19,029	23,944

The Company intends to continue to return capital to stockholders through share repurchases and the payment of cash dividends, reflecting our confidence in the future cash flows of our business. The amount we spend, the number of shares repurchased and the timing of such repurchases will vary based on a number of factors, including the stock price, the availability of financing on acceptable terms, the amount and timing of dividend payments and blackout periods in which we are restricted from repurchasing shares; and the manner of purchases may include private block purchases, tender offers, as well as market transactions. Whether and when we declare dividends or repurchase stock, the size of any dividend and the amount of stock we repurchase could be affected by a number of additional factors. (See Item 1A. Risk Factors — There can be no assurance that we will continue to declare cash dividends or repurchase stock). In April 2011, the Board of Directors authorized us to repurchase up to an additional $5 billion of our common stock. Subsequently in October 2011, the Board of Directors increased the total authorization for stock repurchases by $6.1 billion to $10 billion. At that time, we announced our intent to accelerate our stock repurchase program, reflecting our confidence in the long-term value of the Company and the attractive interest rate environment. During 2011, we repurchased 144 million shares of our common stock at an aggregate cost of $8.3 billion, including $5 billion purchased in a modified Dutch auction tender offer. We expect to repurchase the remaining $5 billion of stock under our authorized stock repurchase program through open-market purchases. In April 2011, the Board of Directors also approved a dividend policy related to our common stock and subsequently declared quarterly cash dividends of $0.28 per share of common stock in July and October 2011, resulting in dividend payments aggregating $500 million in 2011. Additionally in December 2011, the Board of Directors declared a 29% increase in our quarterly cash dividend to $0.36 per share of common stock, payable in March 2012.

We believe existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital; capital expenditure and debt service requirements; our plans to pay dividends and repurchase stock; and other business initiatives we plan to strategically pursue, including acquisitions and licensing activities, in each case for the foreseeable future. We anticipate that our liquidity needs can be met through a variety of sources, including cash provided by operating activities, sales of marketable securities, borrowings through commercial paper and/or our syndicated credit facility and access to other domestic and foreign debt markets and equity markets. With respect to our U.S. operations, we believe that existing funds intended for use in the United States; cash generated from our U.S. operations, including intercompany payments and receipts; and existing sources of and access to financing (collectively referred to as "U.S. funds") are adequate to continue to meet our U.S. obligations (including our plans to repurchase stock and pay dividends with U.S. funds) for the foreseeable future. See Item 1A. Risk Factors — Current economic conditions may magnify certain risks that affect our business.

A significant portion of our operating cash flows is dependent upon the timing of payments from our customers located in the United States and, to a lesser extent, customers outside the United States, which include government owned or supported healthcare providers (government healthcare providers). Payments from these government healthcare providers are dependent, in part, upon the economic stability and creditworthiness of their applicable country. Deteriorating credit and economic conditions in parts of Southern Europe, particularly in Spain, Italy, Greece and Portugal, may continue to increase the average length of time it takes to collect payments, particularly in certain regions within these countries. However, the timing of payments from government healthcare providers has not nor is it expected to have a material adverse impact on our operating cash flows. To date we have not incurred any significant losses on collections of trade receivables from these government healthcare providers.

Over the next several years, many of the existing patents on our principal products will expire. As a result, we expect to face increasing competition from biosimilars that may have a material adverse impact on our product sales, results of operations and liquidity. Upon patent expiration for small molecule products, there is typically intense competition from generics manufacturers, which generally leads to significant and rapid declines in sales of the branded product. Given that our principal products are biologics, we do not believe the impact of biosimilar competition will be as significant as with small molecule products, in part because successful competitors must have a broad range of specialized skills and capabilities unique to biologics, including significant regulatory, clinical and manufacturing expertise, and since the products are similar, but not identical, the biosimilars will have to compete against a product with an established efficacy and safety record. As discussed above, we have many opportunities to grow our business, including the continued commercialization of XGEVA® and Prolia® and expansion into emerging markets and Japan, which we believe may offset the adverse financial impact of our principal products' patent expiries.

Cash, cash equivalents and marketable securities

Of our total cash, cash equivalents and marketable securities balances as of December 31, 2011, approximately $16.9 billion was generated from operations in foreign tax jurisdictions and is intended to be invested indefinitely outside of the United States. Under current tax laws, if these funds were repatriated for use in our U.S. operations, we would be required to pay additional income taxes at the tax rates then in effect.

The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits debt security investments to certain types of debt and money market instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer.

Financing arrangements

The current and noncurrent portions of our long-term borrowings at December 31, 2011, were $84 million and $21.3 billion, respectively. The current and noncurrent portions of our long-term borrowings at December 31, 2010, were $2.5 billion and $10.9 billion, respectively.

We issued debt securities in various offerings during the three years ended December 31, 2011, including:

- In 2011, we issued $10.5 billion aggregate principal amount of notes, comprised of the 1.875% 2014 Notes, the 2.30% 2016 Notes, the 2.50% 2016 Notes, the 4.375% 2018 euro Notes (€550 million aggregate principal amount), the 4.10% 2021 Notes, the 3.875% 2021 Notes, the 5.50% 2026 pound sterling Notes (£475 million aggregate principal amount), the 5.15% 2041 Notes and the 5.65% 2042 Notes.
- In 2010, we issued $2.5 billion aggregate principal amount of notes, comprised of the 4.50% 2020 Notes, the 3.45% 2020 Notes, the 5.75% 2040 Notes and the 4.95% 2041 Notes.
- In 2009, we issued $2.0 billion aggregate principal amount of notes, comprised of the 5.70% 2019 Notes and the 6.40% 2039 Notes.

In February 2011, our 0.125% 2011 Convertible Notes became due, and we repaid the $2.5 billion aggregate principal amount. No debt was due or repaid in 2010, and we repaid $1.0 billion aggregate principal amount of notes with a fixed interest rate of 4.00% in 2009.

To achieve a desired mix of fixed and floating interest rate debt, we enter into interest rate swap contracts that effectively convert a fixed rate interest coupon for certain of our debt issuances to a floating London Interbank Offered Rates (LIBOR) based coupon over the life of the respective note. These interest rate swap contracts qualify and are designated as fair value hedges. As of December 31, 2011 and 2010, we had interest rate swap contracts with an aggregate face value of $3.6 billion. See Note 14, Financing arrangements, and Note 17, Derivative instruments, to the Consolidated Financial Statements for further discussion of our interest rate swap contracts.

In order to hedge our exposure to foreign currency exchange rate risk associated with our pound sterling denominated long-term notes issued in 2011, we entered into cross currency swap contracts. These cross currency swap contracts qualify and are designated as cash flow hedges. Under the terms of these contracts, we receive interest payments in pounds sterling at a fixed rate of 5.5% on £475 million and pay interest in U.S. dollars at a fixed rate of 5.8% on $748 million, the aggregate notional amounts paid to/received from the counterparties upon exchange of currencies at the inception of these contracts. We will pay U.S. dollars to and receive pounds sterling from the counterparties at the maturity of the contracts for the same notional amounts. The terms of these contracts correspond to the related hedged notes, effectively converting the interest payments and principal repayment on these notes from pounds sterling to U.S. dollars.

As of December 31, 2011, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working capital needs. At December 31, 2011 and 2010, we had no amounts outstanding under our commercial paper program.

In December 2011, we entered into a $2.5 billion syndicated, unsecured, revolving credit agreement which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $500 million with the agreement of the banks. Each bank which is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.1% based on our current credit rating. We would be charged interest at LIBOR plus 0.9% for any amounts borrowed under this facility. As of December 31, 2011, no amounts were outstanding under this facility. In connection with the new revolving credit agreement we terminated our prior $2.3 billion revolving credit agreement that was scheduled to expire in November 2012.

In March 2011, we filed a shelf registration statement with the SEC to replace an existing shelf registration statement that was scheduled to expire in April 2011. This shelf registration statement allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depository shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in March 2014.

In 1997, we established a $400 million medium-term note program under which medium-term debt securities may be offered from time to time with terms to be determined at the time of issuance. As of December 31, 2011 and 2010, no securities were outstanding under this medium-term note program.

Certain of our financing arrangements contain non-financial covenants. In addition, our revolving credit agreement includes a financial covenant with respect to the level of our borrowings in relation to our equity, as defined. We were in compliance with all applicable covenants under these arrangements as of December 31, 2011.

See Note 14, Financing arrangements, to the Consolidated Financial Statements for further discussion of our financing arrangements.

Cash flows

Our cash flow activity was as follows (in millions):

	2011	2010	2009
Net cash provided by operating activities	$5,119	$ 5,787	$ 6,336
Net cash used in investing activities	(786)	(4,152)	(3,202)
Net cash used in financing activities	(674)	(1,232)	(2,024)

Operating

Cash provided by operating activities has been and is expected to continue to be our primary recurring source of funds. Cash provided by operating activities decreased during the 2011 due primarily to: increased interest payments; working capital increases related to the launch of Prolia® and XGEVA®; and the prepayment of certain royalties. The reduction in net income during 2011 was driven primarily by the accrual of the legal settlement charge of $780 million, which will be paid in a subsequent period. Cash provided by operating activities during 2010 decreased due primarily to the timing and amount of payments to taxing authorities.

Investing

Capital expenditures totaled $567 million, $580 million and $530 million in 2011, 2010 and 2009, respectively. Capital expenditures in 2011, 2010 and 2009 were associated primarily with manufacturing capacity expansions in Puerto Rico and other site developments. We currently estimate 2012 spending on capital projects and equipment to be approximately $700 million.

Cash used in investing activities during the year ended December 31, 2011, also included the cost of acquiring certain businesses totaling $701 million.

Net proceeds from marketable securities were $437 million for 2011, compared to net purchases of marketable securities of $3.5 billion for 2010 and $2.7 billion for 2009.

Financing

Cash used in financing activities during 2011 was due to the repurchases of our common stock of $8.3 billion, including $5 billion purchased in a modified Dutch auction tender offer in December 2011; repayment of long-term debt of $2.5 billion; and payment of dividends of $500 million, offset partially by the net proceeds from issuance of long-term debt of $10.4 billion, including $7.5 billion issued in November and December 2011, in part, to finance the repurchase of our common stock in the modified Dutch auction tender offer. Cash used in financing activities during 2010 was due to the repurchases of our common stock of $3.8 billion, offset partially by the net proceeds from issuance of long-term debt of $2.5 billion. Cash used in financing activities during 2009 was due to repurchases of our common stock of $3.2 billion and repayment of long-term debt of $1.0 billion, offset partially by the net proceeds from issuance of long-term debt of $2.0 billion.

See Note 14, Financing arrangements, and Note 15, Stockholders' equity, to the Consolidated Financial Statements for further discussion.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that are material or reasonably likely to become material to our consolidated financial position or consolidated results of operations.

Contractual Obligations

Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which we cannot reasonably predict future payment. Additionally, the expected timing of payment of the obligations presented below is estimated based on current information. Timing of payments and actual amounts paid may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations.

The following table represents our contractual obligations as of December 31, 2011, aggregated by type (in millions):

	Payments due by period				
Contractual obligations	Total	Year 1	Years 2 and 3	Years 4 and 5	Years 6 and beyond
Long-term debt obligations [1] [2] [3]	$37,521	$ 888	$6,131	$3,396	$ 27,106
Operating lease obligations	774	116	189	141	328
Purchase obligations [4]	2,992	865	420	243	1,464
Unrecognized tax benefits [5]	—	—	—	—	—
Total contractual obligations	$41,287	$1,869	$6,740	$3,780	$ 28,898

(1) The long-term debt obligation amounts also include future interest payments. Future interest payments are included on our financing arrangements at the fixed contractual coupon rates. To achieve a desired mix of fixed and floating interest rate debt, we enter into interest rate swap contracts that effectively convert a fixed rate interest coupon for certain of our debt issuances to a floating LIBOR-based coupon over the life of the respective note. We used an interest rate forward curve at December 31, 2011, in computing net amounts to be paid or received under our interest rate swap contracts which resulted in an aggregate net reduction in future interest payments of $366 million. See Note 14, Financing arrangements, to the Consolidated Financial Statements for further discussion of our interest swap contracts.

(2) In order to hedge our exposure to foreign currency exchange rate risk associated with our pound sterling denominated long-term debt issued in December 2011, we entered into cross currency swap contracts that effectively convert interest payments and principal repayment on this debt from pounds sterling to U.S. dollars. For purposes of this table, we used the contracted exchange rates in the cross currency swap contracts to compute the net amounts of future interest and principal payments and on this debt. See Note 14, Financing arrangements, to the Consolidated Financial Statements for further discussion of our cross currency swap contracts.

(3) The long-term debt obligations amounts include the repayment of principal on our euro denominated foreign currency debt at the foreign currency exchange rates in effect at December 31, 2011. See Note 14, Financing arrangements, to the Consolidated Financial Statements for further discussion of our long-term debt obligations.

(4) Purchase obligations relate primarily to (i) our long-term supply agreements with third-party manufacturers, which are based on firm commitments for the purchase of production capacity; (ii) R&D commitments (including those related to clinical trials) for new and existing products; (iii) capital expenditures; and (iv) open purchase orders for the acquisition of goods and services in the ordinary course of business. Our obligation to pay certain of these amounts may be reduced based on certain future events.

(5) Liabilities for unrecognized tax benefits (UTBs) (net of foreign tax credits and federal tax benefit of state taxes) and related accrued interest and penalties totaling approximately $912 million at December 31, 2011, are not included in the table above because, due to their nature, there is a high degree of uncertainty regarding the timing of future cash outflows and other events that extinguish these liabilities.

In addition to amounts in the table above, we are contractually obligated to pay additional amounts, which in the aggregate are significant, upon the achievement of various development, regulatory and commercial milestones for agreements we have entered into with third parties, including contingent consideration incurred with the acquisition of BioVex. These payments are contingent upon the occurrence of various future events, substantially all of which have a high degree of uncertainty of occurring. These contingent payments have not been included in the table above, and, except with respect to the fair value of the BioVex contingent consideration, are not recorded on our Consolidated Balance Sheets. As of December 31, 2011, the maximum amount that may be payable in the future for agreements we have entered into with third parties is approximately $3.6 billion, including $575 million in connection with the acquisition of BioVex (see Note 2, Business combinations, to the Consolidated Financial Statements).

Summary of Critical Accounting Policies

The preparation of our consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions.

Product sales, sales deductions and returns

Revenues from sales of our products are recognized when the products are shipped and title and risk of loss have passed. Product sales are recorded net of accruals for estimated rebates, wholesaler chargebacks, cash discounts and other deductions (collectively, “sales deductions”) and returns, which are established at the time of sale.

We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that adjustment is appropriate. Accruals are also adjusted to reflect actual results. Amounts recorded in Accrued liabilities in the Consolidated Balance Sheets for sales deductions were as follows (in millions):

	Rebates	Chargebacks	Other deductions	Total
Balance as of January 1, 2009	$ 653	$ 84	$ 139	$ 876
Amounts charged against product sales	1,663	2,424	552	4,639
Payments	(1,609)	(2,380)	(556)	(4,545)
Balance as of December 31, 2009	707	128	135	970
Amounts charged against product sales	1,861	2,593	580	5,034
Payments	(1,724)	(2,548)	(588)	(4,860)
Balance as of December 31, 2010	844	173	127	1,144
Amounts charged against product sales	1,795	2,626	670	5,091
Payments	(1,592)	(2,600)	(717)	(4,909)
Balance as of December 31, 2011	$ 1,047	$ 199	$ 80	$ 1,326

For the years ended December 31, 2011, 2010 and 2009, total sales deductions were 25%, 25% and 24% of gross product sales, respectively. Included in these amounts are immaterial adjustments related to prior-year sales due to changes in estimates. Such amounts represent 2% or less of the aggregate sales deductions charged against product sales for the three year ended December 31, 2011.

In the United States, we utilize wholesalers as the principal means of distributing our products to healthcare providers, such as physicians or their clinics, dialysis centers, hospitals and pharmacies. Products we sell in the EU are distributed principally to hospitals and/or wholesalers depending on the distribution practice in each country where the product is sold. We monitor the inventory levels of our products at our wholesalers by using data from our wholesalers and other third parties, and we believe wholesaler inventories have been maintained at appropriate levels (generally two to three weeks) given end-user demand. Accordingly, historical fluctuations in wholesaler inventory levels have not significantly impacted our method of estimating sales deductions and returns.

Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product-specific and, therefore, for any given year, can be impacted by the mix of products sold.

Rebates include primarily amounts paid to payers and providers in the United States, including those paid to state Medicaid programs, and are based on contractual arrangements which vary by product, by payer and individual payer plans. We estimate the amount of rebate that will be paid based on the product sold, contractual terms, historical experience and wholesaler inventory levels and accrue these rebates in the period the related sale is recorded. We adjust the accrual as more information becomes available and to reflect actual experience. Estimating such rebates is complicated, in part, due to the time delay between the date of sale and the actual settlement of the liability, which for certain rebates can take up to one year and greater than one year for certain recent government programs. Rebates totaled $1.8 billion, $1.9 billion and $1.7 billion for the years ended December 31, 2011, 2010 and 2009, respectively. We believe the methodology we use to accrue for rebates is reasonable and appropriate given current facts and circumstances. However, actual results may differ. Changes in annual estimates related to prior annual periods have been less than 5% of the estimated rebate amounts charged against product sales for each of the three years ended December 31, 2011. A 5% change in our rebate estimate attributable to rebates recognized in 2011 would have had an impact of approximately $90 million, or approximately one-half of 1% of our 2011 product sales and a corresponding impact on our financial condition and liquidity.

Wholesaler chargebacks relate to our contractual agreements to sell products to healthcare providers in the United States at fixed prices that are lower than the prices we charge wholesalers. When the healthcare providers purchase our products through wholesalers at these reduced prices, the wholesaler charges us for the difference between their purchase price and the contractual price between Amgen and the healthcare providers. The provision for chargebacks is based on the expected sales by our wholesaler customers to healthcare providers. Those chargebacks from wholesalers totaled $2.6 billion, $2.6 billion and $2.4 billion for the years ended December 31, 2011, 2010 and 2009, respectively. Accruals for wholesaler chargebacks are less difficult to estimate than rebates and closely approximate actual results since chargeback amounts are fixed at the date of purchase by the healthcare providers, and we generally settle the liability for these deductions within a few weeks.

Product returns

Returns are estimated through comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have been insignificant, amounting to less than 1.5% of gross product sales. Furthermore, changes in estimates for prior year sales return provisions have historically also been insignificant.

Income taxes

The Company provides for income taxes based on pretax income, applicable tax rates and tax planning opportunities available in the various jurisdictions in which it operates.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that is more likely than not to be realized upon settlement. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We believe our estimates for uncertain tax positions are appropriate and sufficient for any assessments that may result from examinations of our tax returns. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense.

Certain items are included in the Company's tax return at different times than they are reflected in the financial statements. Such timing differences create deferred tax assets and liabilities. Deferred tax assets are generally items that can be used as a tax deduction or credit in the tax return in future years but for which the Company has already recorded the tax benefit in the financial statements. The Company establishes valuation allowances against its deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities are either: (i) a tax expense recognized in the financial statements for which payment has been deferred; or (ii) an expense for which the Company has already taken a deduction on the tax return, but has not yet recognized the expense in the financial statements.

The Company is a vertically integrated enterprise with operations in the U.S. and various foreign jurisdictions. The Company is subject to income tax in the foreign jurisdictions where it conducts activities based on the tax laws and principles of such jurisdictions and the functions, risks and activities performed therein. The Company's pre-tax income is therefore attributed to domestic or foreign sources based on the operations performed in each location and the tax laws and principles of the respective taxing jurisdictions. For example, the Company conducts significant operations outside the United States in Puerto Rico pertaining to manufacturing, distribution and other related functions to meet its worldwide product demand. Income from the Company's operations in Puerto Rico is subject to a tax incentive grant that expires in 2020.

Our effective tax rate reflects the impact of undistributed foreign earnings for which no U.S. taxes have been provided because such earnings are intended to be invested indefinitely outside the United States. Substantially all of this benefit is attributable to the Company's foreign income associated with the Company's operations conducted in Puerto Rico.

If future events, including material changes in cash, working capital and long-term investment requirements necessitate that certain assets associated with these earnings be repatriated to the United States, under current tax laws an additional tax provision and related liability would be required at the applicable income tax rates which could have a material adverse effect on both our future effective tax rate and our financial results.

Our operations are subject to the tax laws, regulations and administrative practices of the United States, U.S. state jurisdictions and other countries in which we do business. Significant changes in these rules could have a material adverse effect on the results of operations. (See Item 1A. Risk Factors — The adoption of new tax legislation or exposure to additional tax liabilities could affect our profitability.)

Contingencies

In the ordinary course of business, we are involved in various legal proceedings and other matters such as intellectual property disputes, contractual disputes, governmental investigations and class action suits which are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 18, Contingencies and commitments, to the Consolidated Financial Statements. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We consider all relevant factors when making assessments regarding these contingencies.

While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

Valuation of assets and liabilities in connection with business combinations

We have acquired and continue to acquire intangible assets in connection with business combinations. These intangible assets consist primarily of technology associated with currently marketed human therapeutic products and IPR&D product candidates. Discounted cash flow models are typically used to determine the fair values of these intangible assets for purposes of allocating consideration paid to the net assets acquired in a business combination. These models require the use of significant estimates and assumptions, including, but not limited to:

- determining the timing and expected costs to complete in-process projects taking into account the stage of completion at the acquisition date;
- projecting the probability and timing of obtaining marketing approval from the FDA and other regulatory agencies for product candidates;
- estimating the timing of and future net cash flows from product sales resulting from completed products and in-process projects; and
- developing appropriate discount rates to calculate the present values of the cash flows.

Significant estimates and assumptions are also required to determine the acquisition date fair values of any contingent consideration obligations incurred in connection with business combinations. In addition, we must revalue these obligations each subsequent reporting period until the related contingencies are resolved and record changes in their fair values in earnings. The acquisition date fair values of the various contingent consideration obligations incurred in the acquisition of BioVex (see Note 2, Business combinations, to the Consolidated Financial Statements) were determined using a combination of valuation techniques. Significant estimates and assumptions required for these valuations included, but were not limited to, the probability of achieving regulatory milestones, product sales projections under various scenarios and discount rates used to calculate the present value of the required payments. These estimates and assumptions are required to be updated in order to revalue these contingent consideration obligations each reporting period. Accordingly, subsequent changes in underlying facts and circumstances could result in changes in these estimates and assumptions, which could have a material impact on the estimated future fair values of these obligations.

We believe the fair values used to record intangible assets acquired and contingent consideration obligations incurred in connection with business combinations are based upon reasonable estimates and assumptions given the facts and circumstances as of the related valuation dates.

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risks that may result from changes in interest rates, foreign currency exchange rates and prices of equity instruments as well as changes in the general economic conditions in the countries where we conduct business. To reduce certain of these risks, we enter into various types of foreign currency and interest rate derivative hedging transactions as part of our risk management program. We do not use derivatives for speculative trading purposes.

In the capital and credit markets, strong demand for fixed income instruments led to historically low interest rates on corporate debt issuances during 2011. Short-term interest rates on U.S. Treasury instruments continued to decline due to a combination of the Federal Reserve’s monetary policies and the challenging macroeconomic environment. As a result, in the discussion that follows, we have assumed a hypothetical change in interest rates of 100 basis points from those at December 31, 2011 and 2010. Continued uncertainty surrounding European sovereign debt resulted in ongoing volatility in the foreign exchange markets, and we have consequently assumed a hypothetical 20% change in foreign currency exchange rates against the U.S. dollar based on its position relative to other currencies as of December 31, 2011 and 2010.

Interest rate sensitive financial instruments

Our portfolio of available-for-sale debt security investments at December 31, 2011 and 2010, was comprised of: U.S. Treasury securities and other government-related debt securities; corporate debt securities; mortgage- and

asset-backed securities; money market mutual funds; and additionally at December 31, 2010, other short-term interest bearing securities, composed principally of commercial paper. The fair value of our investment portfolio of debt securities was $20.0 billion and $17.3 billion at December 31, 2011 and 2010, respectively. Duration is a sensitivity measure that can be used to approximate the change in the value of a security that will result from a 100 basis point change in interest rates. Applying a duration model, a hypothetical 100 basis point increase in interest rates at December 31, 2011 and 2010, would not have resulted in a material effect on the fair values of these securities on these dates. In addition, a hypothetical 100 basis point decrease in interest rates at December 31, 2011 and 2010, would not result in a material effect on the related income or cash flows in the respective ensuing year.

As of December 31, 2011, we had outstanding debt with a carrying value of $21.4 billion and a fair value of $23.0 billion. As of December 31, 2010, we had outstanding debt with a carrying value of $13.4 billion and a fair value of $14.5 billion. Our outstanding debt at December 31, 2011 and 2010, was comprised entirely of debt with fixed interest rates. Changes in interest rates do not affect interest expense or cash flows on fixed rate debt. Changes in interest rates would, however, affect the fair values of fixed rate debt. A hypothetical 100 basis point decrease in interest rates relative to interest rates at December 31, 2011, would have resulted in an increase of approximately $2.1 billion in the aggregate fair value of our outstanding debt on this date. A hypothetical 100 basis point decrease in interest rates relative to the interest rates at December 31, 2010, would have resulted in an increase of approximately $1.0 billion in the aggregate fair value of our outstanding debt on this date. The analysis for the debt does not consider the impact that hypothetical changes in interest rates would have on the related interest rate swap and cross currency swap contracts.

To achieve a desired mix of fixed and floating interest rate debt, we have entered into interest rate swap contracts, which qualify and have been designated for accounting purposes as fair value hedges, for certain of our fixed rate debt with notional amounts totaling $3.6 billion at December 31, 2011 and 2010. These derivative contracts effectively convert a fixed rate interest coupon to a floating rate LIBOR-based coupon over the life of the respective note. A hypothetical 100 basis point increase in interest rates relative to interest rates at December 31, 2011 and 2010, would have resulted in a reduction fair value of approximately $200 million on our interest rate swap contracts on these dates and would not result in a material effect on the related income or cash flows in the respective ensuing year. The analysis for the interest rate swap contracts does not consider the impact that hypothetical changes in interest rates would have on the related fair values of debt that these interest rate sensitive instruments were designed to offset.

As of December 31, 2011, we had open cross currency swap contracts with an aggregate notional amount of $748 million that hedge the entire principal amount of our pound sterling denominated debt and related interest payments. These contracts effectively convert payments on this debt to U.S. dollars and are designated for accounting purposes as cash flow hedges. A hypothetical 100 basis point adverse movement in interest rates relative to interest rates at December 31, 2011, would have resulted in approximately a $130 million reduction in the fair value of our cross currency swap contracts on this date but would not have a material effect on cash flows or income in the ensuing year.

Foreign currency sensitive financial instruments

Our international operations are affected by fluctuations in the value of the U.S. dollar as compared to foreign currencies, predominately the euro. Increases and decreases in our international product sales from movements in foreign currency exchange rates are offset partially by the corresponding increases or decreases in our international operating expenses. Increases and decreases in our foreign currency denominated assets from movements in foreign currency exchange rates are offset partially by the corresponding increases or decreases in our foreign currency denominated liabilities. To further reduce our net exposure to foreign currency exchange rate fluctuations on our results of operations, we enter into foreign currency forward, option and cross currency swap contracts.

As of December 31, 2011, we had outstanding debt with a carrying value and fair value of $1.5 billion that was denominated in pounds sterling and euros. A hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates at December 31, 2011, would have

resulted in an increase in fair value of this debt of approximately $290 million on this date with a corresponding reduction in income in the ensuing year and would not result in a material effect on the related cash flows in the ensuing year. The analysis for this debt does not consider the impact that hypothetical changes in foreign exchange would have on the related cross currency swap contracts.

With regard to our cross currency swap contracts that are designated as cash flow hedges of our pound sterling denominated debt, a hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates at December 31, 2011, would have resulted in a reduction in the fair value of these contracts of approximately $210 million on this date and would not result in a material effect on the related cash flows in the ensuing year. The impact on income in the ensuing year of this hypothetical adverse movement in foreign currency exchange rates, which would equal the entire change in the carrying amount of the hedged debt, would be approximately $150 million.

We enter into foreign currency forward and options contracts that are designated for accounting purposes as cash flow hedges of certain anticipated foreign currency transactions. As of December 31, 2011, we had open foreign currency forward and options contracts, primarily euro-based, with notional amounts of $3.5 billion and $292 million, respectively. As of December 31, 2010, we had open foreign currency forward and options contracts, primarily euro-based, with notional amounts of $3.2 billion and $398 million, respectively. As of December 31, 2011 and 2010, the net unrealized gains on these contracts were not material. With regard to foreign currency forward and option contracts that were open at December 31, 2011, a hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates at December 31, 2011, would have resulted in a reduction in fair value of these contracts of approximately $700 million on this date and, in the ensuing year, a reduction in income and cash flows of approximately $330 million. With regard to contracts that were open at December 31, 2010, a hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates at December 31, 2010, would have resulted in a reduction in fair value of these contracts of approximately $670 million on this date and, in the ensuing year, a reduction in income and cash flows of approximately $330 million. The analysis does not consider the impact that hypothetical changes in foreign currency exchange rates would have on anticipated transactions that these foreign currency sensitive instruments were designed to offset.

As of December 31, 2011 and 2010, we had open foreign currency forward contracts with notional amounts totaling $389 million and $670 million, respectively, that hedged fluctuations of certain assets and liabilities denominated in foreign currencies but were not designated as hedges for accounting purposes. These contracts had no material net unrealized gains or losses at December 31, 2011 and 2010. With regard to these foreign currency forward contracts that were open at December 31, 2011, a hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates at December 31, 2011, would not have resulted in a material reduction in the fair value of these contracts on this date and would not result in a material effect on the related income or cash flows in the respective ensuing year. With regard to these foreign currency forward contracts that were open at December 31, 2010, a hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates at December 31, 2010, would have resulted in a reduction in fair value of these contracts on these dates of approximately $130 million and would not result in a material effect on the related income or cash flows in the ensuing year. The analysis does not consider the impact that hypothetical changes in foreign currency exchange rates would have on assets and liabilities that these foreign currency sensitive instruments were designed to offset.

Market price sensitive financial instruments

As of December 31, 2011 and 2010, we were also exposed to price risk on equity securities included in our portfolio of investments, which were acquired primarily for the promotion of business and strategic objectives. These investments are generally in small capitalization stocks in the biotechnology industry sector. Price risk relative to our equity investment portfolio as of December 31, 2011 and 2010, was not material.

Counterparty credit risks

Our financial instruments, including derivatives, are subject to counterparty credit risk which we consider as part of the overall fair value measurement. Our financial risk management policy limits derivative transactions by

requiring transactions to be with institutions with investment grade credit ratings and requires placing exposure limits on the amount with any individual counterparty. In addition, we have an investment policy that limits investments to certain types of debt and money market instruments issued by institutions primarily with investment grade credit ratings and places restriction on maturities and concentrations by asset class and issuer.

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The information required by this item is incorporated herein by reference to the financial statements and schedule listed in Item 15(a)1 and (a)2 of Part IV and included in this Annual Report on Form 10-K.

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES

None.

Item 9A. CONTROLS AND PROCEDURES

We maintain “disclosure controls and procedures,” as such term is defined under Exchange Act Rule 13a-15(e), that are designed to ensure that information required to be disclosed in Amgen’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to Amgen’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, Amgen’s management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and in reaching a reasonable level of assurance Amgen’s management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. We have carried out an evaluation under the supervision and with the participation of our management, including Amgen’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Amgen’s disclosure controls and procedures. Based upon their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2011.

Management determined that, as of December 31, 2011, there were no changes in our internal control over financial reporting that occurred during the fiscal quarter then ended that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Management’s Report on Internal Control over Financial Reporting

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States. However, all internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and reporting.

Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2011. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework. Based on our assessment, management believes that the Company maintained effective internal control over financial reporting as of December 31, 2011, based on the COSO criteria.

The effectiveness of the Company’s internal control over financial reporting has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their attestation report appearing below, which expresses an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting as of December 31, 2011.

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders of Amgen Inc.

We have audited Amgen Inc.'s (the "Company") internal control over financial reporting as of December 31, 2011, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Amgen Inc.'s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, Amgen Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2011, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Consolidated Balance Sheets as of December 31, 2011 and 2010, and the related Consolidated Statements of Income, Stockholders' Equity, and Cash Flows for each of the three years in the period ended December 31, 2011 of Amgen Inc. and our report dated February 29, 2012 expressed an unqualified opinion thereon.

/s/ Ernst & Young LLP

Los Angeles, California
February 29, 2012

Item 9B. OTHER INFORMATION

Not applicable.

PART III

Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE OF THE REGISTRANT

Information about our Directors is incorporated by reference from the section entitled ITEM 1 — ELECTION OF DIRECTORS in our Proxy Statement for the 2012 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2011 (the Proxy Statement). Information about compliance with Section 16(a) of the Securities Exchange Act of 1934 is incorporated by reference from the section entitled OTHER MATTERS — Section 16(a) Beneficial Ownership Reporting Compliance in our Proxy Statement. Information about the procedures by which stockholders may recommend nominees for the Board of Directors is incorporated by reference from Appendix A — AMGEN INC. BOARD OF DIRECTORS GUIDELINES FOR DIRECTOR QUALIFICATIONS AND EVALUATIONS in our Proxy Statement. Information about our Audit Committee, members of the committee and our Audit Committee financial experts is incorporated by reference from the section entitled CORPORATE GOVERNANCE — Board Committees and Charters — Audit Committee in our Proxy Statement. Information about our executive officers is contained in the discussion entitled Item 1. Business — Executive Officers of the Registrant.

Code of Ethics

We maintain a code of ethics applicable to our principal executive officer, principal financial officer, principal accounting officer or controller, and other persons performing similar functions. To view this code of ethics free of charge, please visit our website at www.amgen.com (This website address is not intended to function as a hyperlink, and the information contained in our website is not intended to be a part of this filing). We intend to satisfy the disclosure requirements under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this code of ethics, if any, by posting such information on our website as set forth above.

Item 11. EXECUTIVE COMPENSATION

Information about director and executive compensation is incorporated by reference from the section entitled EXECUTIVE COMPENSATION in our Proxy Statement. Information about compensation committee matters is incorporated by reference from the sections entitled CORPORATE GOVERNANCE — Board Committees and Charters — Compensation and Management Development Committee and CORPORATE GOVERNANCE — Compensation Committee Report in our Proxy Statement.

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Securities Authorized for Issuance Under Existing Equity Compensation Plans

The following table sets forth certain information as of December 31, 2011, concerning our common stock that may be issued under any form of award granted under all of our equity compensation plans approved by stockholders and equity compensation plans not approved by stockholders in effect as of December 31, 2011 (including upon the exercise of options, pursuant to purchases of stock or upon vesting of awards of restricted stock units (RSUs) or performance units).

Plan Category	(a) Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights	(b) Weighted Average Exercise Price Outstanding Options and Rights	(c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))
Equity compensation plans approved by Amgen security holders:			
2009 Equity Incentive Plan[1]	25,145,740	$ 54.78	58,012,064
Amended and Restated 1991 Equity Incentive Plan [2]	10,937,360	$ 58.16	—
Amended and Restated Employee Stock Purchase Plan[3]	—	$ —	5,961,514
Total Approved Plans	36,083,100	$ 56.25	63,973,578
Equity compensation plans not approved by Amgen security holders:			
Amended and Restated 1993 Equity Incentive Plan[4]	6,077	$ 52.60	—
Amended and Restated 1999 Equity Incentive Plan[4]	5,752,222	$ 65.37	—
Amended and Restated 1997 Equity Incentive Plan[5]	772,456	$ 51.71	—
Amended and Restated 1997 Special Non-Officer Equity Incentive Plan[6]	3,136,770	$ 66.46	—
Amended and Restated 1996 Incentive Stock Plan[7]	290,500	$ 68.86	—
Amended and Restated 1999 Incentive Stock Plan[7]	1,271,686	$ 68.40	—
Amended and Restated Assumed Avidia Equity Plan[8]	11,415	$ 1.96	—
Amgen Profit Sharing Plan for Employees in Ireland[9]	—	$ —	192,180
Total Unapproved Plans	11,241,126	$ 65.06	192,180
Total All Plans	47,324,226	$ 59.11	64,165,758

(1) The number under column (a) with respect to this plan includes approximately 13.06 million shares issuable upon the exercise of outstanding options with a weighted-average exercise price of approximately $54.78, approximately 8.03 million shares issuable upon the vesting of outstanding RSUs and approximately 4.05 million shares issuable upon the vesting of outstanding performance units. The performance units awarded in 2010 and 2011 continue to be subject to performance goals and the maximum number of units that could be earned is 200% of the units awarded in 2010 and 150% of the units awarded in 2011. The number under column (c) with respect to this plan represents the maximum number of shares that remain available for future issuance under this plan. This number may fluctuate depending on the nature of the award granted. Shares that are subject to awards of options or stock appreciation rights granted under the 2009 Plan will be counted against the pool of available shares under the 2009 Plan as one (1) share for every one (1) share granted. Shares that are subject to awards granted under the 2009 Plan other than options or

stock appreciation rights will be counted against the pool of available shares under the 2009 Plan as 1.9 shares for every one (1) share granted. Furthermore, if any shares subject to an award under the 2009 Plan are forfeited or expire or an award under the 2009 Plan is settled for cash, then any shares subject to such award may, to the extent of such forfeiture, expiration or cash settlement, be used again for new grants under the 2009 Plan and the shares subject to such awards will be added back to the pool of available shares under the 2009 Plan as (i) one (1) share if such shares were subject to an option or stock appreciation right granted under the 2009 Plan and (ii) as 1.9 shares if such shares were subject to awards other than options or stock appreciation rights granted under the 2009 Plan.

(2) This plan has terminated as to future grants. The number under column (a) with respect to this plan includes approximately 10.04 million shares issuable upon the exercise of outstanding options with a weighted-average exercise price of approximately $58.16 and approximately 0.89 million shares issuable upon the vesting of outstanding RSUs.

(3) The purchases occurred on June 15, 2011, and December 15, 2011 (the Purchase Dates), with a purchase of 204,758 shares of Common Stock at a purchase price of $55.00 per shares on June 15, 2011, and 149,728 shares of Common Stock at a purchase price of $55.69 per share on December 15, 2011. Such purchases reflect 95% of the closing price of the Common Stock on the applicable Purchase Date.

(4) These plans have terminated as to future grants. These Plans were originally assumed pursuant to the terms of the merger agreement between Amgen and Immunex which was approved by our stockholders in May 2002. Both plans were previously approved by Immunex's shareholders. The number under column (a) with respect to the Amended and Restated 1999 Equity Incentive Plan includes approximately 5.74 million shares issuable upon the exercise of outstanding options with a weighted-average exercise price of approximately $65.37 and approximately 12,000 shares issuable upon the vesting of outstanding RSUs.

(5) This plan has terminated as to future grants. This plan was originally assumed by Amgen in connection with the merger of Tularik with and into Amgen SF, LLC, a wholly owned subsidiary of Amgen, on August 13, 2004. This plan was previously approved by Tularik's shareholders.

(6) This plan has terminated as to future grants.

(7) These plans have terminated as to future grants. These plans were originally assumed by Amgen in connection with the merger of Abgenix with and into Amgen Fremont Inc., a wholly owned subsidiary of Amgen, on April 1, 2006. The Amended and Restated 1996 Incentive Stock Plan (1996 Plan) was previously approved by Abgenix's shareholders. The number under column (a) with respect to the 1996 Plan includes approximately 291,000 shares issuable upon the exercise of outstanding options with a weighted-average exercise price of approximately $68.86. The number under column (a) with respect to the Amended and Restated 1999 Incentive Stock Plan includes approximately 1.15 million shares issuable upon the exercise of outstanding options with a weighted-average exercise price of approximately $68.40 and approximately 119,000 shares issuable upon the vesting of outstanding RSUs.

(8) This plan has terminated as to future grants. This plan was originally assumed by Amgen in connection with the merger of Avidia, Inc. with and into Amgen Mountain View Inc., a wholly owned subsidiary of Amgen, on October 24, 2006.

(9) The Amgen Profit Sharing Plan for Employees in Ireland (the Profit Sharing Plan) was approved by the Board of Directors on July 28, 2011. The Profit Sharing Plan permits eligible employees of the Company's subsidiaries located in Ireland, which participate in the Profit Sharing Plan, to apply a portion of their qualifying bonus and salary to the purchase the Company's Common Stock on the open market at the market price by a third-party trustee as described in the Profit Sharing Plan. 7,820 shares were purchased on December 16, 2011.

Security Ownership of Directors and Executive Officers and Certain Beneficial Owners

Information about security ownership of certain beneficial owners and management is incorporated by reference from the sections entitled SECURITY OWNERSHIP OF DIRECTORS AND EXECUTIVE OFFICERS and SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS in our Proxy Statement.

Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

Information about certain relationships and related transactions and directors independence is incorporated by reference from the sections entitled CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS and CORPORATE GOVERNANCE — Board Independence in our Proxy Statement.

Item 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

Information about the fees for professional services rendered by our independent registered public accountants is incorporated by reference from the section entitled AUDIT MATTERS — Independent Registered Public Accountants in our Proxy Statement.

PART IV

Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a)1. Index to Financial Statements

The following Consolidated Financial Statements are included herein:

(a)2. Index to Financial Statement Schedules

The following Schedule is filed as part of this Annual Report on Form 10-K:

All other schedules are omitted because they are not applicable, not required or because the required information is included in the consolidated financial statements or notes thereto.

(a)3. Exhibits

Exhibit No.	Description
2.1	Agreement and Plan of Merger, dated as of January 25, 2012, among Micromet, Inc., Amgen Inc., and Armstrong Acquisition Corp. (Filed as an exhibit to Form 8-K filed on January 26, 2012 and incorporated herein by reference.)
3.1	Restated Certificate of Incorporation (As Restated December 7, 2005). (Filed as an exhibit to Form 10-K for the year ended December 31, 2005 on March 10, 2006 and incorporated herein by reference.)
3.2	Certificate of Amendment of the Restated Certificate of Incorporation (As Amended May 24, 2007). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2007 on August 9, 2007 and incorporated herein by reference.)
3.3	Certificate of Correction of the Restated Certificate of Incorporation (As Corrected May 24, 2007). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2007 on August 9, 2007 and incorporated herein by reference.)
3.4	Certificate of Elimination of the Certificate of Designations of the Series A Junior Participating Preferred Stock (As Eliminated December 9, 2008). (Filed as an exhibit to Form 10-K for the year ended December 31, 2008 on February 27, 2009 and incorporated herein by reference.)
3.5	Certificate of Amendment of the Restated Certificate of Incorporation (As Amended May 11, 2009). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2009 on August 10, 2009 and incorporated herein by reference.)
3.6	Certificate of Correction of the Restated Certificate of Incorporation (As Corrected May 11, 2009). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2009 on August 10, 2009 and incorporated herein by reference.)
3.7	Certificate of Correction of the Restated Certificate of Incorporation (As Corrected May 13, 2010). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2010 on August 9, 2010.)
3.8	Amended and Restated Bylaws of Amgen Inc. (As Amended and Restated October 6, 2009). (Filed as an exhibit to Form 8-K filed on October 7, 2009 and incorporated herein by reference.)
4.1	Form of stock certificate for the common stock, par value $.0001 of the Company. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 1997 on May 13, 1997 and incorporated herein by reference.)
4.2	Form of Indenture, dated January 1, 1992. (Filed as an exhibit to Form S-3 Registration Statement filed on December 19, 1991 and incorporated herein by reference.)
4.3	Agreement of Resignation, Appointment and Acceptance dated February 15, 2008. (Filed as an exhibit to Form 10-K for the year ended December 31, 2007 on February 28, 2008 and incorporated herein by reference.)
4.4	Two Agreements of Resignation, Appointment and Acceptance in the same form as the previously filed Exhibit 4.3 hereto are omitted pursuant to instruction 2 to Item 601 of Regulation S-K. Each of these agreements, which are dated December 15, 2008, replaces the current trustee under the agreements listed as Exhibits 4.9 and 4.15, respectively, with Bank of New York Mellon. Amgen Inc. hereby agrees to furnish copies of these agreements to the Securities and Exchange Commission upon request.
4.5	First Supplemental Indenture, dated February 26, 1997. (Filed as an exhibit to Form 8-K on March 14, 1997 and incorporated herein by reference.)
4.6	8-1/8% Debentures due April 1, 2097. (Filed as an exhibit to Form 8-K filed on April 8, 1997 and incorporated herein by reference.)

Exhibit No.	Description
4.7	Officer's Certificate, dated as of January 1, 1992, as supplemented by the First Supplemental Indenture, dated as of February 26, 1997, establishing a series of securities entitled "8 1/8% Debentures due April 1, 2097." (Filed as an exhibit to Form 8-K filed on April 8, 1997 and incorporated herein by reference.)
4.8	Form of Liquid Yield Option™ Note due 2032. (Filed as an exhibit to Form 8-K on March 1, 2002 and incorporated herein by reference.)
4.9	Indenture, dated as of March 1, 2002. (Filed as an exhibit to Form 8-K on March 1, 2002 and incorporated herein by reference.)
4.10	First Supplemental Indenture, dated March 2, 2005. (Filed as an exhibit to Form 8-K filed on March 4, 2005 and incorporated herein by reference.)
4.11	Indenture, dated as of August 4, 2003. (Filed as an exhibit to Form S-3 Registration Statement on August 4, 2003 and incorporated herein by reference.)
4.12	Form of 4.85% Senior Notes due 2014. (Filed as an exhibit to Form 8-K on November 19, 2004 and incorporated herein by reference.)
4.13	Officers' Certificate, dated November 18, 2004, including forms of the 4.00% Senior Notes due 2009 and 4.85% Senior Notes due 2014. (Filed as an exhibit to Form 8-K on November 19, 2004 and incorporated herein by reference.)
4.14	Form of Zero Coupon Convertible Note due 2032. (Filed as an exhibit to Form 8-K on May 6, 2005 and incorporated herein by reference.)
4.15	Indenture, dated as of May 6, 2005. (Filed as an exhibit to Form 8-K on May 6, 2005 and incorporated herein by reference.)
4.16	Indenture, dated as of February 17, 2006 and First Supplemental Indenture, dated as of June 8, 2006 (including form of 0.375% Convertible Senior Note due 2013). (Filed as exhibit to Form 10-Q for the quarter ended June 30, 2006 on August 9, 2006 and incorporated herein by reference.)
4.17	Corporate Commercial Paper - Master Note between and among Amgen Inc., as Issuer, Cede & Co., as Nominee of The Depository Trust Company, and Citibank, N.A., as Paying Agent. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 1998 on May 13, 1998 and incorporated herein by reference.)
4.18	Officers' Certificate of Amgen Inc. dated as of May 30, 2007, including forms of the Company's Senior Floating Rate Notes due 2008, 5.85% Senior Notes due 2017 and 6.375% Senior Notes due 2037. (Filed as an exhibit to Form 8-K on May 30, 2007 and incorporated herein by reference.)
4.19	Officers' Certificate of Amgen Inc. dated as of May 23, 2008, including forms of the Company's 6.15% Senior Notes due 2018 and 6.90% Senior Notes due 2038. (Filed as exhibit to Form 8-K on May 23, 2009 and incorporated herein by reference.)
4.20	Officers' Certificate of Amgen Inc. dated as of January 16, 2009, including forms of the Company's 5.70% Senior Notes due 2019 and 6.40% Senior Notes due 2039. (Filed as exhibit to Form 8-K on January 16, 2009 and incorporated herein by reference.)
4.21	Officers' Certificate of Amgen Inc. dated as of March 12, 2010, including forms of the Company's 4.50% Senior Notes due 2020 and 5.75% Senior Notes due 2040. (Filed as exhibit to Form 8-K on March 15, 2010 and incorporated herein by reference.)
4.22	Officers' Certificate of Amgen Inc., dated as of September 16, 2010, including forms of the Company's 3.45% Senior Notes due 2020 and 4.95% Senior Notes due 2041. (Filed as an exhibit to Form 8-K on September 17, 2010 and incorporated herein by reference.)

Exhibit No.	Description
4.23	Officers' Certificate of Amgen Inc., dated as of June 30, 2011, including forms of the Company's 2.30% Senior Notes due 2016, 4.10% Senior Notes due 2021 and 5.65% Senior Notes due 2042. (Filed as an exhibit to Form 8-K on June 30, 2011 and incorporated herein by reference.)
4.24	Officers' Certificate of Amgen Inc., dated as of November 10, 2011, including forms of the Company's 1.875% Senior Notes due 2014, 2.50% Senior Notes due 2016, 3.875% Senior Notes due 2021 and 5.15% Senior Notes due 2041. (Filed as an exhibit to Form 8-K on November 10, 2011 and incorporated herein by reference.)
4.25	Officers' Certificate of Amgen Inc., dated as of December 5, 2011, including forms of the Company's 4.375% Senior Notes due 2018 and 5.50% Senior Notes due 2026. (Filed as an exhibit to Form 8-K on December 5, 2011 and incorporated herein by reference.)
10.1+	Amgen Inc. 2009 Equity Incentive Plan. (Filed as Appendix A to Amgen Inc.'s Proxy Statement on March 26, 2009 and incorporated herein by reference.)
10.2+	Form of Stock Option Agreement for the Amgen Inc. 2009 Equity Incentive Plan. (As Amended on March 2, 2011.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 on May 10, 2011 and incorporated herein by reference.)
10.3+	Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Equity Incentive Plan. (As Amended on March 2, 2011.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 on May 10, 2011 and incorporated herein by reference.)
10.4+	Amgen Inc. 2009 Performance Award Program. (As Amended and Restated on December 4, 2009.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2009 on March 1, 2010 and incorporated herein by reference.)
10.5+	Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on March 2, 2011.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 on May 10, 2011 and incorporated herein by reference.)
10.6+	Amgen Inc. 2009 Director Equity Incentive Program. (Filed as an exhibit to Form 8-K on May 8, 2009 and incorporated herein by reference.)
10.7+	Form of Grant of Non-Qualified Stock Option Agreement and Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (Filed as an exhibit to Form 8-K on May 8, 2009 and incorporated herein by reference.)
10.8+	Amgen Supplemental Retirement Plan. (As Amended and Restated effective January 1, 2009.) (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2008 on November 7, 2008 and incorporated herein by reference.)
10.9+	First Amendment to the Amgen Supplemental Retirement Plan, effective April 11, 2011. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2011 on August 8, 2011 and incorporated herein by reference.)
10.10+*	Second Amendment to the Amgen Supplemental Retirement Plan, effective October 12, 2011.
10.11+*	Third Amendment to the Amgen Supplemental Retirement Plan, executed December 16, 2011.
10.12+	Amended and Restated Amgen Change of Control Severance Plan. (As Amended and Restated effective December 9, 2010 and subsequently amended effective March 2, 2011.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 on May 10, 2011 and incorporated herein by reference.)
10.13+	Amgen Inc. Executive Incentive Plan. (As Amended and Restated effective January 1, 2009.) (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2008 on November 7, 2008 and incorporated herein by reference.)
10.14+	Amgen Inc. Executive Nonqualified Retirement Plan. (As Amended and Restated effective January 1, 2009.) (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2008 on November 7, 2008 and incorporated herein by reference.)

Exhibit No.	Description
10.15+	First Amendment to the Amgen Inc. Executive Nonqualified Retirement Plan. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2010 on August 9, 2010 and incorporated herein by reference.)
10.16+	Amgen Nonqualified Deferred Compensation Plan. (As Amended and Restated effective January 1, 2009.) (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2008 on November 7, 2008 and incorporated herein by reference.)
10.17+	First Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective April 11, 2011. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2011 on August 8, 2011 and incorporated herein by reference.)
10.18+*	Second Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective October 12, 2011.
10.19+	2002 Special Severance Pay Plan for Amgen Employees. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2002 on August 13, 2002 and incorporated herein by reference.)
10.20+	Agreement between Amgen Inc. and Mr. Jonathan M. Peacock, dated July 5, 2010. (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2010 on November 8, 2010 and incorporated herein by reference.)
10.21+*	Agreement between Amgen Inc. and Mr. Anthony C. Hooper, dated October 12, 2011.
10.22+	Consulting Agreement, effective February 1, 2011, between Amgen Inc. and Mr. George Morrow. (Filed as an exhibit to Form 8-K on October 22, 2010 and incorporated herein by reference).
10.23	Product License Agreement, dated September 30, 1985, and Technology License Agreement, dated, September 30, 1985 between Amgen and Ortho Pharmaceutical Corporation. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2000 on August 1, 2000 and incorporated herein by reference.)
10.24	Shareholders' Agreement, dated May 11, 1984, among Amgen, Kirin Brewery Company, Limited and Kirin-Amgen, Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2000 on March 7, 2001 and incorporated herein by reference.)
10.25	Amendment No. 1 dated March 19, 1985, Amendment No. 2 dated July 29, 1985 (effective July 1, 1985), and Amendment No. 3, dated December 19, 1985, to the Shareholders' Agreement dated May 11, 1984. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2000 on August 1, 2000 and incorporated herein by reference.)
10.26	Amendment No. 4 dated October 16, 1986 (effective July 1, 1986), Amendment No. 5 dated December 6, 1986 (effective July 1, 1986), Amendment No. 6 dated June 1, 1987, Amendment No. 7 dated July 17, 1987 (effective April 1, 1987), Amendment No. 8 dated May 28, 1993 (effective November 13, 1990), Amendment No. 9 dated December 9, 1994 (effective June 14, 1994), Amendment No. 10 effective March 1, 1996, and Amendment No. 11 effective March 20, 2000 to the Shareholders' Agreement, dated May 11, 1984. (Filed as exhibits to Form 10-K for the year ended December 31, 2000 on March 7, 2001 and incorporated herein by reference.)
10.27	Amendment No. 12 to the Shareholders' Agreement, dated January 31, 2001. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2005 on August 8, 2005 and incorporated herein by reference.)
10.28	Amendment No. 13 to the Shareholders' Agreement, dated June 28, 2007 (with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2007 on August 9, 2007 and incorporated herein by reference.)

Exhibit No.	Description
10.29	Product License Agreement, dated September 30, 1985, and Technology License Agreement, dated September 30, 1985, between Kirin-Amgen, Inc. and Ortho Pharmaceutical Corporation. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2000 on August 1, 2000 and incorporated herein by reference.)
10.30	Research, Development Technology Disclosure and License Agreement: PPO, dated January 20, 1986, by and between Kirin Brewery Co., Ltd. and Amgen Inc. (Filed as an exhibit to Amendment No. 1 to Form S-1 Registration Statement on March 11, 1986 and incorporated herein by reference.)
10.31	Assignment and License Agreement, dated October 16, 1986 (effective July 1, 1986, between Amgen and Kirin-Amgen, Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2000 on March 7, 2001 and incorporated herein by reference.)
10.32	G-CSF United States License Agreement, dated June 1, 1987 (effective July 1, 1986), Amendment No. 1, dated October 20, 1988, and Amendment No. 2, dated October 17, 1991 (effective November 13, 1990), between Kirin-Amgen, Inc. and Amgen Inc. (Filed as exhibits to Form 10-K for the year ended December 31, 2000 on March 7, 2001 and incorporated herein by reference.)
10.33	G-CSF European License Agreement, dated December 30, 1986, between Kirin-Amgen and Amgen, Amendment No. 1 to Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement, dated June 1, 1987, Amendment No. 2 to Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement, dated March 15, 1998, Amendment No. 3 to Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement, dated October 20, 1988, and Amendment No. 4 to Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement, dated December 29, 1989, between Kirin-Amgen, Inc. and Amgen Inc. (Filed as exhibits to Form 10-K for the year ended December 31, 2000 on March 7, 2001 and incorporated herein by reference.)
10.34	Agreement Regarding Governance and Commercial Matters, dated December 16, 2001, by and among American Home Products Corporation, American Cyanamid Company and Amgen Inc. (with certain confidential information deleted therefrom). (Filed as an exhibit to Amendment No. 1 to Form S-4 Registration Statement on March 22, 2002 and incorporated herein by reference.)
10.35	Amended and Restated Promotion Agreement, dated as of December 16, 2001, by and among Immunex Corporation, American Home Products Corporation and Amgen Inc. (with certain confidential information deleted therefrom). (Filed as an exhibit to Amendment No. 1 to Form S-4 Registration Statement on March 22, 2002 and incorporated herein by reference.)
10.36	Description of Amendment No. 1 to Amended and Restated Promotion Agreement, effective as of July 8, 2003, among Wyeth, Amgen Inc. and Immunex Corporation (with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-K for the year ended December 31, 2003 on March 11, 2004 and incorporated herein by reference.)
10.37	Description of Amendment No. 2 to Amended and Restated Promotion Agreement, effective as of April 20, 2004, by and among Wyeth, Amgen Inc. and Immunex Corporation. (Filed as an exhibit to Form S-4/A on June 29, 2004 and incorporated herein by reference.)
10.38	Amendment No. 3 to Amended and Restated Promotion Agreement, effective as of January 1, 2005, by and among Wyeth, Amgen Inc. and Immunex Corporation (with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2005 on May 4, 2005 and incorporated herein by reference.)
10.39	Confirmation of OTC Convertible Note Hedge related to 2013 Notes, dated February 14, 2006, to Amgen Inc. from Merrill Lynch International related to 0.375% Convertible Senior Notes Due 2013. (Filed as an exhibit to Form 10-K for the year ended December 31, 2005 on March 10, 2006 and incorporated herein by reference.)
10.40	Confirmation of OTC Warrant Transaction, dated February 14, 2006, to Amgen Inc. from Merrill Lynch International for warrants expiring in 2013. (Filed as an exhibit to Form 10-K for the year ended December 31, 2005 on March 10, 2006 and incorporated herein by reference.)

Exhibit No.	Description
10.41	Collaboration Agreement, dated July 11, 2007, between Amgen Inc. and Daiichi Sankyo Company (with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2007 on November 9, 2007 and incorporated herein by reference.)
10.42	Credit Agreement, dated as of December 2, 2011, among Amgen Inc., with Citibank, N.A., as administrative agent, JPMorgan Chase Bank, N.A., as syndication agent, Citigroup Global Markets Inc. and J.P. Morgan Securities LLC as joint lead arrangers and joint book runners, and the other banks party thereto. (Filed as an exhibit to Form 8-K filed on December 2, 2011 and incorporated herein by reference.)
10.43	Multi-product License Agreement with Respect to Japan between Amgen Inc. and Takeda Pharmaceutical Company Limited dated February 1, 2008 (with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2008 on May 12, 2008 and incorporated herein by reference.)
10.44	License Agreement for motesanib diphosphate between Amgen Inc. and Takeda Pharmaceutical Company Limited dated February 1, 2008 (with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2008 on May 12, 2008 and incorporated herein by reference.)
10.45	Supply Agreement between Amgen Inc. and Takeda Pharmaceutical Company Limited dated February 1, 2008 (with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2008 on May 12, 2008 and incorporated herein by reference.)
10.46	Sale and Purchase Agreement between Amgen Inc. and Takeda Pharmaceutical Company Limited dated February 1, 2008 (with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2008 on May 12, 2008 and incorporated herein by reference.)
10.47	Integrated Facilities Management Services Agreement, dated February 4, 2009, between Amgen Inc. and Jones Lang LaSalle Americas, Inc. (with certain confidential information deleted therefrom) (Previously filed as an exhibit to Form 10-K for the year ended December 31, 2008 on February 27, 2009.), as amended by Amendment Number 1 dated March 31, 2010 (with certain confidential information deleted therefrom), Amendment Number 2 dated May 12, 2011 (as corrected by the Letter Agreement) (with certain confidential information deleted therefrom), and Letter Agreement dated July 19, 2011. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2011 on August 8, 2011 and incorporated herein by reference.)
10.48	Amendment Number 3, dated July 1, 2011, to the Integrated Facilities Management Services Agreement, dated February 4, 2009, between Amgen Inc. and Jones Lang LaSalle Americas, Inc. (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2011 on November 4, 2011 and incorporated herein by reference.)
10.49	Collaboration Agreement dated July 27, 2009 between Amgen Inc. and Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc (with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2009 on November 6, 2009 and incorporated herein by reference.)
10.50	Expansion Agreement dated July 27, 2009 between Amgen Inc. and Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc (with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2009 on November 6, 2009 and incorporated herein by reference.)
10.51	Amendment Number 1, dated September 20, 2010, to Expansion Agreement dated July 27, 2009 between Amgen Inc. and Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc (with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2010 on November 8, 2010 and incorporated herein by reference.)

Exhibit No.	Description
10.52 *	Sourcing and Supply Agreement, dated November 15, 2011, by and between Amgen USA Inc., a wholly owned subsidiary of Amgen Inc., and DaVita Inc. (with certain confidential information deleted therefrom).
21*	Subsidiaries of the Company
23	Consent of the Independent Registered Public Accounting Firm. The consent is set forth on pages 105 and 106 of this Annual Report on Form 10-K.
24	Power of Attorney. The Power of Attorney is set forth on pages 107 and 108 of this Annual Report on Form 10-K.
31*	Rule 13a-14(a) Certifications.
32**	Section 1350 Certifications.
101.INS*	XBRL Instance Document.
101.SCH*	XBRL Taxonomy Extension Schema Document.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase.

(* = filed herewith)

(** = furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended)

(+ = management contract or compensatory plan or arrangement)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMGEN INC.
(Registrant)

Date: 02/29/2012

By: /S/ JONATHAN M. PEACOCK

Jonathan M. Peacock
Executive Vice President
and Chief Financial Officer

EXHIBIT 23

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

- Registration Statement (Form S-8 No. 333-159377) pertaining to the Amgen Inc. 2009 Equity Incentive Plan;
- Registration Statement (Form S-8 No. 33-39183) pertaining to the Amended and Restated Employee Stock Purchase Plan;
- Registration Statements (Form S-8 No. 33-39104, as amended by Form S-8 No. 333-144581) pertaining to the Amended and Restated Amgen Retirement and Savings Plan (formerly known as the Amgen Retirement and Savings Plan);
- Registration Statements (Form S-8 Nos. 33-42072 and 333-144579) pertaining to the Amgen Inc. Amended and Restated 1991 Equity Incentive Plan;
- Registration Statements (Form S-8 Nos. 33-47605 and 333-144580) pertaining to the Retirement and Savings Plan for Amgen Manufacturing, Limited (formerly known as the Retirement and Savings Plan for Amgen Manufacturing, Inc.);
- Registration Statements (Form S-8 Nos. 333-44727, 333-62735, 333-56672 and 333-83824) pertaining to the Amgen Inc. Amended and Restated 1997 Special Non-Officer Equity Incentive Plan (formerly known as the Amgen Inc. 1997 Special Non-Officer Equity Incentive Plan);
- Registration Statement (Form S-3 No. 333-19931) pertaining to debt securities of Amgen Inc.;
- Registration Statement (Form S-3 No. 333-40405) pertaining to debt securities of Amgen Inc.;
- Registration Statement (Form S-3 No. 333-53929) pertaining to the Amgen Inc. 1997 Special Non-Officer Equity Incentive Plan, the Amgen Inc. Amended and Restated 1991 Equity Incentive Plan, the Amended and Restated 1988 Stock Option Plan of Amgen Inc. and the Amended and Restated 1987 Directors' Stock Option Plan;
- Registration Statements (Form S-8 Nos. 333-81284 and 333-177868) pertaining to the Amgen Nonqualified Deferred Compensation Plan;
- Registration Statements (Form S-3 No. 333-56664 and Amendment No. 1 thereto) pertaining to the Amgen Inc. 1997 Special Non-Officer Equity Incentive Plan, the Amgen Inc. Amended and Restated 1991 Equity Incentive Plan;
- Registration Statement (Form S-3 No. 333-88834) pertaining to Amgen Inc.'s Liquid Yield Option™ Notes due 2032;
- Registration Statements (Form S-3 No. 333-92450 and Amendment No. 1 thereto) pertaining to Amgen Inc.'s Common Stock;
- Registration Statements (Form S-8 No. 333-92424 and Amendment No. 1 thereto) pertaining to the Amgen Inc. Amended and Restated 1993 Equity Incentive Plan (formerly known as the Immunex Corporation 1993 Stock Option Plan), the Amgen Inc. Amended and Restated 1999 Equity Incentive Plan (formerly known as the Immunex Corporation 1999 Stock Option Plan);
- Registration Statements (Form S-3 No. 333-107639 and Amendment 1 thereto) relating to debt securities, common stock and associated preferred share repurchase rights, preferred stock, warrants to purchase debt securities, common stock or preferred stock, securities purchase contracts, securities purchase units and depositary shares of Amgen Inc. and in the related Prospectuses;

- Registration Statement (Form S-8 No. 333-118254) pertaining to the Amgen Inc. Amended and Restated 1997 Equity Incentive Plan (formerly known as the Tularik Inc. 1997 Equity Incentive Plan, as amended);
- Registration Statement (Form S-3 No. 333-132286) relating to the potential resale of securities acquired from Amgen Inc. by selling security holders in unregistered private offerings;
- Registration Statement (Form S-8 No. 333-132932) pertaining to the Amgen Inc. Amended and Restated 1996 Incentive Stock Plan (formerly known as Abgenix, Inc. 1996 Incentive Stock Plan, as amended and restated), the Amgen Inc. Amended and Restated 1999 Incentive Stock Plan (formerly known as Abgenix, Inc. 1999 Nonstatutory Stock Option Plan, as amended and restated);
- Registration Statement (Form S-8 No. 333-133002) pertaining to the Amgen Inc. Amended and Restated 1999 Incentive Stock Plan (formerly known as Abgenix, Inc. 1999 Nonstatutory Stock Option Plan, as amended and restated);
- Registration Statement (Form S-8 No. 333-138325) pertaining to the Amgen Inc. Amended and Restated Assumed Avidia Equity Incentive Plan (formerly known as the Avidia, Inc. Amended and Restated 2003 Equity Incentive Plan);
- Registration Statement (Form S-4 No. 333-147482) relating to the possible exchange of unregistered Senior Floating Notes for registered Senior Floating Notes relating to the Prospectus of Amgen Inc. for the registration of Senior Floating Rate Notes due 2008, 5.85% Senior Notes due 2017, 6.375% Senior Notes Due 2037; and
- Registration Statements (Form S-3 Nos. 333-150290 and 333-172617) relating to debt securities, common stock, preferred stock, warrants to purchase debt securities, common stock, preferred stock or depositary shares, rights to purchase common stock or preferred stock, securities purchase contracts, securities purchase units and depositary shares of Amgen Inc. and in the related Prospectuses.
- Registration Statement (Form S-8 No. 333-176240) pertaining to the Amgen Profit Sharing Plan for Employees in Ireland;

of our reports dated February 29, 2012, with respect to the consolidated financial statements and schedule of Amgen Inc. and the effectiveness of internal control over financial reporting of Amgen Inc. included in this Annual Report (Form 10-K) of Amgen Inc. for the year ended December 31, 2011.

/s/ Ernst & Young LLP

Los Angeles, California
February 29, 2012

EXHIBIT 24

POWER OF ATTORNEY

KNOW ALL MEN AND WOMEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jonathan M. Peacock and Thomas J.W. Dittrich, or either of them, his or her attorney-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Report, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

Signature	Title	Date
/S/ KEVIN W. SHARER **Kevin W. Sharer**	Chairman of the Board, Chief Executive Officer and Director (Principal Executive Officer)	02/29/2012
/S/ JONATHAN M. PEACOCK **Jonathan M. Peacock**	Executive Vice President and Chief Financial Officer (Principal Financial Officer)	02/29/2012
/S/ THOMAS J.W. DITTRICH **Thomas J.W. Dittrich**	Vice President Finance and Chief Accounting Officer (Principal Accounting Officer)	02/27/2012
/S/ ROBERT A. BRADWAY **Robert A. Bradway**	President, Chief Operating Officer and Director	02/29/2012
/S/ DAVID BALTIMORE **David Baltimore**	Director	02/29/2012
/S/ FRANK J. BIONDI, JR. **Frank J. Biondi, Jr.**	Director	02/29/2012
/S/ VANCE D. COFFMAN **Vance D. Coffman**	Director	02/29/2012
/S/ FRANÇOIS DE CARBONNEL **François de Carbonnel**	Director	02/29/2012
/S/ REBECCA M. HENDERSON **Rebecca M. Henderson**	Director	02/29/2012
/S/ FRANK C. HERRINGER **Frank C. Herringer**	Director	02/23/2012
/S/ GILBERT S. OMENN **Gilbert S. Omenn**	Director	02/29/2012

Signature	Title	Date
/S/ JUDITH C. PELHAM **Judith C. Pelham**	Director	02/29/2012
/S/ J. PAUL REASON **J. Paul Reason**	Director	02/29/2012
/S/ LEONARD D. SCHAEFFER **Leonard D. Schaeffer**	Director	02/29/2012
/S/ RONALD D. SUGAR **Ronald D. Sugar**	Director	02/29/2012

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders of Amgen Inc.

We have audited the accompanying Consolidated Balance Sheets of Amgen Inc. (the "Company") as of December 31, 2011 and 20010, and the related Consolidated Statements of Income, Stockholders' Equity, and Cash Flows for each of the three years in the period ended December 31, 2011. Our audits also included the financial statement schedule listed in the Index at Item 15(a) 2. These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Amgen Inc. at December 31, 2011 and 2010, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2011, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Amgen Inc.'s internal control over financial reporting as of December 31, 2011, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 29, 2012 expressed an unqualified opinion thereon.

/s/ Ernst & Young LLP

Los Angeles, California
February 29, 2012

AMGEN INC.

CONSOLIDATED STATEMENTS OF INCOME

Years ended December 31, 2011, 2010 and 2009

(In millions, except per share data)

	2011	2010	2009
Revenues:			
Product sales	$15,295	$14,660	$14,351
Other revenues	287	393	291
Total revenues	15,582	15,053	14,642
Operating expenses:			
Cost of sales (excludes amortization of certain acquired intangible assets presented separately)	2,427	2,220	2,091
Research and development	3,167	2,894	2,864
Selling, general and administrative	4,486	3,983	3,820
Amortization of certain acquired intangible assets	294	294	294
Other	896	117	67
Total operating expenses	11,270	9,508	9,136
Operating income	4,312	5,545	5,506
Interest expense, net	610	604	578
Interest and other income, net	448	376	276
Income before income taxes	4,150	5,317	5,204
Provision for income taxes	467	690	599
Net income	$ 3,683	$ 4,627	$ 4,605
Earnings per share:			
Basic	$ 4.07	$ 4.82	$ 4.53
Diluted	$ 4.04	$ 4.79	$ 4.51
Shares used in the calculation of earnings per share:			
Basic	905	960	1,016
Diluted	912	965	1,021

See accompanying notes.

AMGEN INC.

CONSOLIDATED BALANCE SHEETS

December 31, 2011 and 2010

(In millions, except per share data)

	2011	2010
ASSETS		
Current assets:		
Cash and cash equivalents	$ 6,946	$ 3,287
Marketable securities	13,695	14,135
Trade receivables, net	2,896	2,335
Inventories	2,484	2,022
Other current assets	1,572	1,350
Total current assets	27,593	23,129
Property, plant and equipment, net	5,420	5,522
Intangible assets, net	2,584	2,230
Goodwill	11,750	11,334
Other assets	1,524	1,271
Total assets	$48,871	$43,486
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	$ 642	$ 716
Accrued liabilities	5,028	3,366
Current portion of long-term debt	84	2,488
Total current liabilities	5,754	6,570
Long-term debt	21,344	10,874
Other noncurrent liabilities	2,744	2,098
Contingencies and commitments		
Stockholders' equity:		
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding — 795.6 shares in 2011 and 932.1 shares in 2010	27,777	27,299
Accumulated deficit	(8,919)	(3,508)
Accumulated other comprehensive income	171	153
Total stockholders' equity	19,029	23,944
Total liabilities and stockholders' equity	$48,871	$43,486

See accompanying notes.

AMGEN INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

Years ended December 31, 2011, 2010 and 2009

(In millions)

	Number of shares of common stock	Common stock and additional paid-in capital	Accumulated deficit	Accumulated other comprehensive income	Total
Balance at December 31, 2008	1,047.5	$ 26,441	$ (5,673)	$ 117	$ 20,885
Comprehensive income:					
Net income	—	—	4,605	—	4,605
Other comprehensive loss, net of tax	—	—	—	(72)	(72)
Comprehensive income					4,533
Issuance of common stock in connection with the Company's equity award programs	6.3	190	—	—	190
Stock-based compensation	—	324	—	—	324
Tax impact related to employee stock options	—	(11)	—	—	(11)
Repurchases of common stock	(59.2)	—	(3,254)	—	(3,254)
Balance at December 31, 2009	994.6	26,944	(4,322)	45	22,667
Comprehensive income:					
Net income	—	—	4,627	—	4,627
Other comprehensive income, net of tax	—	—	—	108	108
Comprehensive income					4,735
Issuance of common stock in connection with the Company's equity award programs	4.0	69	—	—	69
Stock-based compensation	—	357	—	—	357
Tax impact related to employee stock options	—	(71)	—	—	(71)
Repurchases of common stock	(66.5)	—	(3,800)	—	(3,800)
Other	—	—	(13)	—	(13)
Balance at December 31, 2010	932.1	27,299	(3,508)	153	23,944
Comprehensive income:					
Net income	—	—	3,683	—	3,683
Other comprehensive income, net of tax	—	—	—	18	18
Comprehensive income					3,701
Dividends	—	—	(787)	—	(787)
Issuance of common stock in connection with the Company's equity award programs	7.8	230	—	—	230
Stock-based compensation	—	337	—	—	337
Tax impact related to employee stock options	—	(89)	—	—	(89)
Repurchases of common stock	(144.3)	—	(8,307)	—	(8,307)
Balance at December 31, 2011	795.6	$ 27,777	$ (8,919)	$ 171	$ 19,029

See accompanying notes.

AMGEN INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Years ended December 31, 2011, 2010 and 2009

(In millions)

	2011	2010	2009
Cash flows from operating activities:			
Net income	$ 3,683	$ 4,627	$ 4,605
Depreciation and amortization	1,060	1,017	1,049
Stock-based compensation expense	341	353	284
Deferred income taxes	(399)	(167)	47
Property, plant and equipment impairments	6	118	21
Dividend received from equity investee	—	—	110
Other items, net	63	140	111
Changes in operating assets and liabilities, net of acquisitions:			
Trade receivables, net	(557)	(210)	(36)
Inventories	(383)	153	(134)
Other assets	(133)	36	(3)
Accounts payable	(95)	142	71
Accrued income taxes	(20)	(656)	(142)
Legal reserve	780	—	—
Other liabilities	773	234	353
Net cash provided by operating activities	5,119	5,787	6,336
Cash flows from investing activities:			
Purchases of property, plant and equipment	(567)	(580)	(530)
Cash paid for acquisitions, net of cash acquired	(701)	—	—
Purchases of marketable securities	(21,183)	(14,602)	(12,418)
Proceeds from sales of marketable securities	20,871	10,485	8,252
Proceeds from maturities of marketable securities	749	642	1,443
Other	45	(97)	51
Net cash used in investing activities	(786)	(4,152)	(3,202)
Cash flows from financing activities:			
Repurchases of common stock	(8,315)	(3,786)	(3,208)
Repayment of debt	(2,500)	—	(1,000)
Repayments of commercial paper	(762)	—	—
Dividends paid	(500)	—	—
Net proceeds from issuance of debt	10,387	2,471	1,980
Net proceeds from issuance of commercial paper	762	—	—
Other	254	83	204
Net cash used in financing activities	(674)	(1,232)	(2,024)
Increase in cash and cash equivalents	3,659	403	1,110
Cash and cash equivalents at beginning of period	3,287	2,884	1,774
Cash and cash equivalents at end of period	$ 6,946	$ 3,287	$ 2,884

See accompanying notes.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2011

1. Summary of significant accounting policies

Business

Amgen Inc. (including its subsidiaries, referred to as "Amgen," "the Company," "we," "our" or "us") is a global biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. We concentrate on innovating novel medicines based on advances in cellular and molecular biology, and we operate in one business segment: human therapeutics.

Principles of consolidation

The consolidated financial statements include the accounts of Amgen as well as its wholly owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.

Use of estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.

Product sales

Product sales consist primarily of sales of Neulasta® (pegfilgrastim), NEUPOGEN® (Filgrastim), Enbrel® (etanercept), Aranesp® (darbepoetin alfa) and EPOGEN® (epoetin alfa). Sales of our products are recognized when shipped and title and risk of loss have passed. Product sales are recorded net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively "sales deductions") and returns. Taxes collected from customers and remitted to government authorities related to the sales of the Company's products, primarily in Europe, are excluded from revenues.

We have the exclusive right to sell epoetin alfa for dialysis, certain diagnostics and all non-human, non-research uses in the United States. We sell epoetin alfa under the brand name EPOGEN®. We granted to Ortho Pharmaceutical Corporation (which has assigned its rights under the product license agreement to Janssen Biotech, Inc., formerly known as Centocor Ortho Biotech Products, L.P.), a subsidiary of Johnson & Johnson (J&J), a license relating to epoetin alfa for sales in the United States for all human uses except dialysis and diagnostics. This license agreement, which is perpetual, may be terminated for various reasons, including upon mutual agreement of the parties, or default. The parties are required to compensate each other for epoetin alfa sales that either party makes into the other party's exclusive market, sometimes referred to as "spillover." Accordingly, we do not recognize product sales we make into the exclusive market of J&J and do recognize the product sales made by J&J into our exclusive market. Sales in our exclusive market are derived from our sales to our customers, as adjusted for spillover. We are employing an arbitrated audit methodology to measure each party's spillover based on estimates of and subsequent adjustments thereto of third-party data on shipments to and usage by end users.

Other revenues

Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded in accordance with contract terms when

third-party results are reliably measurable and collectability is reasonably assured. Royalty estimates are made in advance of amounts collected using historical and forecasted trends. Corporate partner revenues are comprised of amounts earned from Kirin-Amgen, Inc. (K-A) for certain research and development (R&D) activities, which are earned as the R&D activities are performed. Corporate partner revenues also include license fees and milestone payments earned from K-A and from third parties. See Multiple-deliverable revenue arrangements, discussed below, Note 6, Collaborative arrangements, and Note 7, Related party transactions.

Muliple-deliverable revenue arrangements

Effective January 1, 2011, we adopted a new accounting standard that amends the guidance on the accounting for arrangements involving the delivery of more than one element. Pursuant to the new standard, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. For Amgen this determination is generally based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. The Company adopted this new accounting standard on a prospective basis for all multiple-deliverable revenue arrangements (MDRAs) entered into on or after January 1, 2011, and for any MDRAs that were entered into prior to January 1, 2011, but materially modified on or after that date.

For MDRAs entered into prior to January 1, 2011, (pre-2011 arrangements) and not materially modified thereafter, we continue to apply our prior accounting policy with respect to such arrangements. Under this policy, in general, revenue from non-refundable, up-front fees related to intellectual property rights/licenses, where we have continuing involvement and where standalone value could not be determined under the previous guidance, is recognized ratably over the estimated period of ongoing involvement. In general, the consideration with respect to the other deliverables is recognized when the goods or services are delivered.

Under all of our MDRAs, consideration associated with at-risk substantive performance milestones is recognized as revenue upon the achievement of the related milestone, as defined in the respective contracts.

The primary impact of adopting the new accounting standard is expected to be the earlier recognition of revenue associated with delivering rights to the underlying intellectual property. The adoption of this accounting standard did not have a material impact on our consolidated results of operations for the year ended December 31, 2011, or on our financial position as of December 31, 2011. Our consolidated results of operations for the year ended December 31, 2010, or our financial position as of December 31, 2010, also would not have been materially impacted if the accounting standard had been adopted on January 1, 2010. The impact of adopting this new accounting standard is dependent on the terms and conditions of any future arrangements that we may enter into that include multiple-deliverables and pre-2011 arrangements that are materially modified. Depending on the terms of any such arrangements, the adoption of this accounting standard may have a material impact on our consolidated results of operations or financial position.

Research and development costs

R&D costs are expensed as incurred and include primarily salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems’ costs and amortization of acquired technology used in R&D with alternative future uses. R&D expenses also include costs and cost recoveries associated with K-A and third-party R&D arrangements, including upfront fees and milestones paid to third parties in connection with technologies which

had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 6, Collaborative arrangements, and Note 7, Related party transactions.

Selling, general and administrative costs

Selling, general and administrative (SG&A) expenses are comprised primarily of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; and other general and administrative costs. Advertising costs are expensed as incurred. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaboration arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 6, Collaborative arrangements.

Beginning January 1, 2011, SG&A expenses also include the amortization of the annual fee mandated by the Patient Protection and Affordable Care Act and the companion Health Care and Education Reconciliation Act (the U.S. healthcare reform federal excise fee). The liability for the annual U.S. healthcare reform federal excise fee is estimated and recorded in full upon the first qualifying sale of our covered products with a corresponding deferred cost established that is amortized on a straight-line basis over the calendar year that it is payable.

Stock-based compensation

We have stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units (RSU) and performance units. The estimated fair values of stock option and RSU awards which are subject only to service conditions with graded vesting are generally recognized as compensation expense on a straight-line basis over the service period. The estimated fair values of performance unit awards are generally recognized as compensation expense on a straight-line basis from the grant date to the end of the performance period. See Note 3, Stock-based compensation.

Income taxes

We provide for income taxes based on pretax income, applicable tax rates and tax planning opportunities available in the various jurisdictions in which we operate.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. The amount of unrecognized tax benefits (UTBs) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense. See Note 4, Income taxes.

Business combinations

Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&D) projects and liabilities assumed, are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired

is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. See Note 2, Business combinations, and Note 16, Fair value measurement.

Cash equivalents

We consider cash equivalents to be only those investments which are highly liquid, readily convertible to cash and which mature within three months from the date of purchase.

Available-for-sale investments

We consider our investment portfolio available-for-sale and, accordingly, these investments are recorded at fair value with unrealized gains and losses generally recorded in other comprehensive income. See Note 9, Available-for-sale investments, and Note 16, Fair value measurement.

Inventories

Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Cost also includes the Puerto Rico excise tax enacted in 2011 related to our manufacturing operations in Puerto Rico. See Note 10, Inventories.

Derivatives

We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether it has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter, whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 16, Fair value measurement, and Note 17, Derivative instruments.

Property, plant and equipment, net

Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is provided over the assets' useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.

Intangible assets and goodwill

Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Intangible assets.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The estimated fair values of IPR&D projects acquired in a business combination which have not reached technological feasibility are capitalized and accounted for as indefinite-lived intangible assets subject to impairment testing until completion or abandonment of the project. Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written-off immediately.

Goodwill relates principally to our 2002 acquisition of Immunex Corporation (Immunex). We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Convertible debt

The debt and equity components of convertible debt instruments that may be partially or wholly cash settled (cash settleable convertible notes), including our 0.125% 2011 Convertible Notes and 0.375% 2013 Convertible Notes, are bifurcated and accounted for separately. The debt component of cash settleable convertible notes, which excludes the associated equity conversion option, is recorded at fair value as of the issuance date. The difference between the amount allocated to the debt component and the proceeds received upon issuance of the debt is allocated to the equity component and recorded in Common stock and additional paid-in capital in the Consolidated Balance Sheets. The reduced or discounted carrying value of cash settleable convertible notes resulting from bifurcation is subsequently accreted back to its principal amount through the recognition of non-cash interest expense. This results in recognizing interest expense on the borrowing at an effective rate approximating what would have been incurred had nonconvertible debt with otherwise similar terms been issued. See Note 14, Financing arrangements.

Recent accounting pronouncements

In June 2011, a new accounting standard was issued that changed the disclosure requirements for the presentation of other comprehensive income (OCI) in the financial statements, including the elimination of the option to present OCI in the statement of stockholders' equity. OCI and its components will be required to be presented for both interim and annual periods either in a single financial statement, the statement of comprehensive income, or in two separate but consecutive financial statements, consisting of a statement of income followed by a separate statement presenting OCI. This standard is required to be applied retrospectively beginning January 1, 2012, except for certain provisions for which adoption was delayed.

2. Business combinations

BioVex Group, Inc.

On March 4, 2011, we acquired all of the outstanding stock of BioVex Group, Inc. (BioVex), a privately held biotechnology company developing treatments for cancer and for the prevention of infectious disease, including talimogene laherparepvec (formerly referred to as OncoVEX$^{GM\text{-}CSF}$), a novel oncolytic vaccine in phase 3 clinical development for the treatment of malignant melanoma. This transaction, which was accounted for as a business combination, provides us with an opportunity to expand our efforts to bring novel therapeutics to market. Upon its acquisition, BioVex became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The aggregate acquisition date consideration to acquire BioVex consisted of (in millions):

Cash paid to former shareholders of BioVex	$407
Fair value of contingent consideration obligations	190
Total consideration	$597

In connection with this acquisition, we are obligated to make additional payments to the former shareholders of BioVex of up to $575 million contingent upon the achievement of various regulatory and sales milestones with regard to talimogene laherparepvec, including the filing of a Biologics License Application with the U.S. Food and Drug Administration (FDA); the first commercial sale in each of the United States and the European Union (EU) following receipt of marketing approval, which includes use of the product in specified patient populations; and upon achieving specified levels of sales. The estimated fair values of the contingent consideration obligations aggregated $190 million as of the acquisition date and were determined using a combination of valuation techniques. The contingent consideration obligations to make regulatory milestone payments were valued based on assumptions regarding the probability of achieving the milestones and making the related payments, with such amounts discounted to present value based on our credit risk. The contingent consideration obligations to make sales milestone payments were valued based on assumptions regarding the probability of achieving specified product sales thresholds to determine the required payments, with such amounts discounted to present value based on our credit risk.

We allocated the total consideration to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):

Intangible assets — IPR&D	$ 675
Goodwill	170
Deferred tax liabilities	(246)
Other assets (liabilities) acquired, net	(2)
Total consideration	$ 597

Intangible assets are composed of the estimated fair value of acquired IPR&D related to talimogene laherparepvec. The estimated fair value was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The estimated net cash flows were discounted to present value using a discount rate of 11%, which is based on the estimated weighted-average cost of capital for companies with characteristics similar to those of BioVex. This is comparable to the estimated internal rate of return on BioVex operations and represents the rate that market participants would use to value the intangible assets. The projected cash flows from talimogene laherparepvec were based on certain key assumptions, including estimates of future revenue and expenses and taking into account the stage of development of talimogene laherparepvec at the acquisition date, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies. IPR&D intangible assets acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts.

The estimated incremental R&D costs to be incurred to obtain necessary regulatory approvals for talimogene laherparepvec are not material. The major risks and uncertainties associated with the timely and successful completion of development and commercialization of this product candidate include our ability to confirm its safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not able to market a

human therapeutic without obtaining regulatory approvals, and such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D may vary from its estimated fair value at the date of acquisition.

The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $170 million was recorded as goodwill, which is not deductible for tax purposes. Goodwill is attributable primarily to the deferred tax consequences of acquired IPR&D recorded for financial statement purposes.

Other acquisitions

During the year ended December 31, 2011, we also acquired the businesses described below, which were accounted for as business combinations, and accordingly, their operations have been included in our consolidated financial statements commencing on their respective acquisition dates.

On April 7, 2011, we acquired all of the outstanding stock of Laboratório Químico Farmacêutico Bérgamo Ltda (Bergamo), a privately held Brazilian pharmaceutical company. Upon its acquisition, Bergamo became a wholly owned subsidiary of Amgen.

On May 16, 2011, we acquired a manufacturing facility in Dun Laoghaire, Ireland, from Pfizer Inc. (Pfizer) (Dun Laoghaire). Under the terms of the agreement, most staff at the facility became Amgen employees, and we agreed to manufacture certain products for Pfizer at the facility for an interim period.

On June 15, 2011, we reacquired rights to distribute certain of our products in the Brazilian pharmaceutical market from our local distributor in Brazil and its parent company, Hypermarcas, and in connection therewith acquired all business operations relating to these products in Brazil.

The aggregate acquisition date consideration for these businesses was approximately $453 million, composed primarily of cash paid to the former owners of the businesses. The aggregate acquisition date consideration was allocated to (i) goodwill of $265 million, of which $130 million related to Bergamo was tax deductible: (ii) property, plant and equipment of $99 million; (iii) amortizable intangible assets composed primarily of licenses to distribute products and customer contracts of $58 million; and (iv) other assets, net of $31 million. The purchase price allocation for the Bergamo transaction is preliminary and will be finalized upon collection of information regarding certain tax-related items. Goodwill resulting from these acquisitions is attributable primarily to the benefits of immediate, direct access to the Brazilian market for expediting our international expansion efforts and geographic diversification to assist in risk mitigation efforts related to our manufacturing operations.

Pro forma supplemental consolidated results of operations for the years ended December 31, 2011 and 2010, that assumes the acquisitions of BioVex, Bergamo, Dun Laoghaire and Hypermarcas all occurred on January 1, 2010, are not provided because the impact would not be material to our consolidated results of operations either individually or in the aggregate.

In addition to the increase in goodwill for the acquisitions of the businesses discussed above, goodwill decreased by $19 million for the year ended December 31, 2011, due to changes in foreign currency exchange rates.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

3. Stock-based compensation

Our 2009 Equity Incentive Plan (the 2009 Plan) provides for the grant of equity-based awards, including stock options, RSUs and performance units, to employees and consultants of Amgen, its subsidiaries and non-employee members of our Board of Directors. The 2009 Plan, which was approved by our stockholders on May 6, 2009, replaced our prior equity plans (the Prior Plans) and no further awards may be made under these Prior Plans. The 2009 Plan authorizes the issuance of 100 million shares of our common stock. Under the terms of the 2009 Plan, the pool of available shares that may be used for all types of awards, including those issued under our Prior Plans after December 31, 2008, and before May 6, 2009 (the stub period), is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including RSUs and performance units. If any shares subject to an award granted under our Prior Plans during the stub period or any awards granted under the 2009 Plan expire, or are forfeited, terminated or cancelled without the issuance of shares, the shares subject to such awards are added back to the pool of available shares under the 2009 Plan on the same basis that they were removed. As of December 31, 2011, the 2009 Plan provides for future grants and/or issuances of up to approximately 58 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.

The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income for the years ended December 31, 2011, 2010 and 2009 (in millions):

	2011	2010	2009
Stock options	$ 85	$ 124	$115
Restricted stock units	188	182	134
Performance units	68	47	35
Total stock-based compensation expense, pre-tax	341	353	284
Tax benefit from stock-based compensation expense	(124)	(120)	(97)
Total stock-based compensation expense, net of tax	$ 217	$ 233	$187

Employee stock options and restricted stock units

Eligible employees generally receive a grant of stock options and/or RSUs annually with the size and type of award generally determined by the employee's salary grade and performance level. In addition, certain management and professional level employees typically receive RSU grants upon commencement of employment. Our stock option and RSU grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, a change in control, termination in connection with a change in control and retirement of employees who meet certain service and/or age requirements. Stock options and RSUs granted prior to April 25, 2011, generally vest in equal amounts on each of the first four anniversaries of the grant date. Stock options and RSUs granted on and after April 25, 2011, generally vest in approximately equal amounts on the second, third and fourth anniversaries of the grant date.

Stock options

The exercise price for stock options is set at the closing price of our common stock on the date of grant and the related number of shares granted is fixed at that point in time. Awards granted to employees on and after April 26, 2010, expire 10 years from the date of grant; options granted to employees prior to that date expire seven years from the date of grant.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

We use an option valuation model to estimate the grant date fair value of our employee stock options. The weighted-average assumptions used in the option valuation model and the resulting weighted-average estimated grant date fair values of our employee stock options were as follows for the years ended December 31, 2011, 2010 and 2009:

	2011	2010	2009
Closing price of our common stock on grant date	$ 54.66	$ 58.32	$ 50.65
Expected volatility	23.5%	28.0%	39.6%
Expected life (in years)	5.9	6.6	4.6
Risk-free interest rate	2.5%	3.2%	2.1%
Expected dividend yield	2.0%	0%	0%
Fair value of stock options granted	$ 11.39	$ 20.97	$ 18.35

The expected volatility reflects the consideration of the implied volatility in publicly traded instruments associated with Amgen's common stock during the period the options were granted. We believe implied volatility in these instruments is more indicative of expected future volatility than the historical volatility in the price of our common stock. We use historical data to estimate the expected life of the options. The risk-free interest rates for periods within the expected life of the option are based on the U.S. Treasury yield curve in effect during the period the options were granted. The expected dividend yield for options granted on and after April 25, 2011, was based on expectations regarding our policy of paying dividends announced in April 2011.

The following summarizes select information regarding our stock options during the year ended December 31, 2011:

	Options (in millions)	Weighted-average exercise price	Weighted-average remaining contractual life (years)	Aggregate intrinsic value (in millions)
Balance unexercised at December 31, 2010	46.8	$ 58.66		
Granted	2.3	$ 54.66		
Exercised	(5.0)	$ 50.22		
Expired/forfeited	(9.9)	$ 60.43		
Balance unexercised at December 31, 2011	34.2	$ 59.11	3.8	$ 245
Vested or expected to vest at December 31, 2011	33.8	$ 59.15	3.7	$ 242
Exercisable at December 31, 2011	23.6	$ 61.49	2.3	$ 135

The total intrinsic value of options exercised during the three years ended December 31, 2011, 2010 and 2009, was $47 million, $15 million and $57 million, respectively.

Restricted stock units

The fair value of an RSU granted prior to April 25, 2011, is equal to the closing price of our common stock on the grant date. The fair values of RSUs granted on and after April 25, 2011, are based on the closing price of our common stock on the grant date reduced by the weighted average expected dividend yield of 1.9% over the weighted-average vesting period, discounted at a weighted-average risk-free interest rate of 1.0%. The weighted-

average grant date fair values of RSUs granted in 2011, 2010 and 2009 were $51.83, $58.19 and $51.24, respectively. The following summarizes select information regarding our RSUs during the year ended December 31, 2011:

	Units (in millions)	Weighted-average grant date fair value
Balance nonvested at December 31, 2010	9.3	$ 52.67
Granted	4.0	$ 51.83
Vested	(3.4)	$ 52.06
Forfeited	(0.9)	$ 52.77
Balance nonvested at December 31, 2011	9.0	$ 52.64

The total fair values of shares associated with RSUs that vested during the year ended December 31, 2011, 2010 and 2009, were $176 million, $184 million and $139 million, respectively.

As of December 31, 2011, there was approximately $407 million of unrecognized compensation costs related to nonvested stock option and RSU awards, which is expected to be recognized over a weighted-average period of 1.7 years.

Performance units

Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified pre-established performance goals over the performance period, which is generally three years. The performance goals for the units granted in 2011, 2010 and 2009, which are accounted for as equity awards, are based upon Amgen's annual stockholder return compared with a comparator group of companies, which are considered market conditions and are reflected in the grant date fair value of the units, and for units granted in 2010 and 2009, Amgen's standalone financial performance, which are considered performance conditions. The expense recognized for the awards granted in 2011 is based on the grant date fair value of a unit multiplied by the number of units granted, net of estimated forfeitures. The expense recognized for the awards granted in 2010 and 2009 was based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a one-for-one basis for each performance unit earned. In general, participants vest in their performance unit awards at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements.

We used payout simulation models to estimate the grant date fair value of performance units granted in 2011, 2010 and 2009. The weighted average assumptions used in these models and the resulting weighted average grant date fair values of our performance units were as follows for the years ended December 31, 2011, 2010 and 2009:

	2011	2010	2009
Closing price of our common stock on grant date	$ 51.67	$ 56.90	$ 47.63
Volatility	32.8%	34.7%	34.3%
Risk-free interest rate	1.2%	1.3%	1.2%
Expected dividend yield	0.1%	0%	0%
Fair value of unit	$ 49.50	$ 62.06	$ 48.22

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The payout simulation models also assumed correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies.

As of December 31, 2011 and 2010, a total of 4.1 million and 2.7 million performance units were outstanding with weighted-average grant date fair values of $51.92 and $49.49 per unit, respectively. During the year ended December 31, 2011, 2.5 million performance units with a weighted average grant date fair value of $49.50 were granted, 0.4 million performance units with a grant date fair value of $48.22 vested and 0.2 million performance units with a weighted-average grant date fair value of $52.70 were forfeited.

The total fair values of performance units that vested during 2011, 2010 and 2009 were $25 million, $34 million and $29 million, respectively, based upon the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period. Performance unit awards granted for performance periods that ended prior to 2009 were accounted for as liability awards and were paid in the year after the performance period ended. Performance unit liability awards paid in 2009 aggregated $30 million.

As of December 31, 2011, there was approximately $90 million of unrecognized compensation cost related to the 2011 and 2010 performance unit grants that is expected to be recognized over a weighted-average period of approximately 1.1 years.

4. Income taxes

The provision for income taxes includes the following for the years ended December 31, 2011, 2010 and 2009 (in millions):

	2011	2010	2009
Current provision:			
Federal	$ 618	$ 636	$325
State	58	52	85
Foreign	148	153	155
Total current provision	824	841	565
Deferred (benefit) provision:			
Federal	(340)	(196)	92
State	(16)	43	(59)
Foreign	(1)	2	1
Total deferred (benefit) provision	(357)	(151)	34
Total provision	$ 467	$ 690	$599

Deferred income taxes reflect the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of net operating loss carryforwards.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Significant components of our deferred tax assets and liabilities are as follows as of December 31, 2011 and 2010 (in millions):

	2011	2010
Deferred income tax assets:		
Intercompany inventory related items	$ 387	$ 306
Expense accruals	751	626
Acquired net operating loss and credit carryforwards	192	147
Expenses capitalized for tax	167	188
Stock-based compensation	241	269
Deferred revenue	133	117
Other	72	72
Total deferred income tax assets	1,943	1,725
Valuation allowance	(126)	(80)
Net deferred income tax assets	1,817	1,645
Deferred income tax liabilities:		
Acquired intangibles	(832)	(739)
Fixed assets	(219)	(181)
Unremitted foreign earnings	(61)	(118)
Other	(110)	(142)
Total deferred income tax liabilities	(1,222)	(1,180)
Total deferred income taxes, net	$ 595	$ 465

The valuation allowance for deferred tax assets increased by $46 million in 2011, due primarily to valuation allowances established as part of the BioVex and Dun Laoghaire acquisitions and the Company's expectation that some state R&D credits will not be utilized, offset partially by the release of valuation allowance related to the expiration of state investment credits. The valuation allowance for deferred tax assets decreased by $12 million in 2010, due primarily to the utilization and expiration of certain acquired net operating loss carryforwards. Valuation allowances are provided when we believe our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax planning strategies.

At December 31, 2011, we had $44 million of tax credit carryforwards available to reduce future federal income taxes for which a full valuation allowance has been provided. In addition, we had $176 million of tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $67 million of those state tax credit carryforwards. The majority of the state tax credit carryforwards have no expiry; the remainder expires between 2012 and 2025.

The reconciliation of the total gross amounts of UTBs (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to UTBs) for the years ended December 31, 2011, 2010 and 2009, is as follows (in millions):

	2011	2010	2009
Balance at beginning of year	$ 920	$1,140	$1,113
Additions based on tax positions related to the current year	283	305	302
Reductions for tax positions of prior years	(7)	(110)	(215)
Settlements	(221)	(415)	(60)
Balance at end of year	$ 975	$ 920	$1,140

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Substantially all of the UTBs as of December 31, 2011, if recognized, would affect our effective tax rate.

During the year ended December 31, 2011, we settled our examination with the Internal Revenue Service (IRS) related to certain transfer pricing tax positions for the years ended December 31, 2007, 2008 and 2009. As a result of these developments, we remeasured our UTBs accordingly.

During the year ended December 31, 2010, we settled our examination with the IRS related to certain transfer pricing tax positions for the years ended December 31, 2007 and 2008. In addition, we also settled issues under appeal with the IRS for the years ended December 31, 2005 and 2006, primarily related to the impact of transfer pricing adjustments on the repatriation of funds. During the year ended December 31, 2010, the IRS also agreed to Competent Authority relief for certain transfer pricing tax positions for the years ended December 31, 2002, through December 31, 2006. As a result of these developments, we remeasured our UTBs accordingly.

During the year ended December 31, 2009, we settled the examination of our U.S. income tax returns with the IRS for certain matters, primarily related to transfer pricing tax positions, for the years ended December 31, 2005 and 2006. Also during the year ended December 31, 2009, we settled the examination of our California state income tax returns for certain matters for the years ended December 31, 2004 and 2005. As a result of these developments, we remeasured our UTBs accordingly.

As of December 31, 2011, we believe it is reasonably possible that our gross liabilities for UTBs may decrease by approximately $270 million within the succeeding twelve months due to the resolution of federal and state audits.

Interest and penalties related to UTBs are included in our provision for income taxes. During 2011, 2010 and 2009, we accrued approximately $23 million, $41 million and $57 million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. At December 31, 2011 and 2010, accrued interest and penalties associated with UTBs totaled approximately $105 million and $90 million, respectively.

The reconciliation between the federal statutory tax rate applied to income before income taxes and our effective tax rate for the years ended December 31, 2011, 2010 and 2009, is as follows:

	2011	2010	2009
Federal statutory tax rate	35.0 %	35.0 %	35.0 %
Foreign earnings, including earnings invested indefinitely	(19.4)%	(19.1)%	(19.6)%
State taxes	0.7 %	1.6 %	1.1 %
Credits, Puerto Rico Excise Tax	(6.5)%	0.0 %	0.0 %
Credits, primarily research and experimentation	(1.5)%	(0.9)%	(0.8)%
Legal settlements	2.2 %	0.0 %	0.0 %
Audit settlements	0.0 %	(3.1)%	(4.2)%
Other, net	0.8 %	(0.5)%	0.0 %
Effective tax rate	11.3 %	13.0 %	11.5 %

We do not provide for U.S. income taxes on undistributed earnings of our foreign operations that are intended to be invested indefinitely outside of the United States. Substantially all of the benefit from foreign earnings on our effective tax rate results from foreign income associated with the Company’s operation conducted in Puerto Rico that is subject to a tax incentive grant that expires in 2020. At December 31, 2011, the

cumulative amount of these earnings was approximately $19.5 billion. If these earnings were repatriated to the United States, we would be required to accrue and pay approximately $6.9 billion of additional income taxes based on the current tax rates in effect.

Our total foreign income before income taxes was approximately $2.6 billion, $3.1 billion and $3.1 billion for the years ended December 31, 2011, 2010 and 2009, respectively.

Commencing January 1, 2011, Puerto Rico imposes a temporary excise tax on the acquisition of goods and services from a related manufacturer in Puerto Rico. The excise tax is imposed over a six year period beginning in 2011 with the excise tax rate declining in each year (4% in 2011, 3.75% in 2012, 2.75% in 2013, 2.5% in 2014, 2.25% in 2015, and 1% in 2016). We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes in the year in which the excise tax is incurred.

One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely audited by the tax authorities in those jurisdictions. Significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions, the use of tax credits and allocations of income among various tax jurisdictions because of differing interpretations of tax laws and regulations. We are no longer subject to U.S. federal income tax examinations for tax years ending on or before December 31, 2006, or to California state income tax examinations for tax years ending on or before December 31, 2003.

Income taxes paid during the years ended December 31, 2011, 2010 and 2009, totaled $595 million, $1,344 million and $497 million, respectively.

5. Earnings per share

The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which principally include: shares that may be issued under our stock option, RSU and performance unit awards, determined using the treasury stock method; our outstanding convertible notes, as discussed below; and our outstanding warrants (collectively “dilutive securities”). The convertible note hedges purchased in connection with the issuance of our convertible notes are excluded from the calculation of diluted EPS because their impact is always anti-dilutive. For further information regarding our convertible notes and warrants, see Note 14, Financing arrangements.

Upon conversion of our convertible notes, the principal amount would be settled in cash, and the excess of the conversion value, as defined, over the principal amount may be settled in cash and/or shares of our common stock. Therefore, only the shares of our common stock potentially issuable with respect to the excess of the notes’ conversion value over their principal amount, if any, are considered as dilutive potential common shares for purposes of calculating diluted EPS. For the years ended December 31, 2011, 2010 and 2009, the conversion values for our convertible notes were less than the related principal amounts and, accordingly, no shares were assumed to be issued for purposes of computing diluted EPS.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The computation for basic and diluted EPS was as follows (in millions, except per share data):

	2011	2010	2009
Income (Numerator):			
Net income for basic and diluted EPS	$3,683	$4,627	$4,605
Shares (Denominator):			
Weighted-average shares for basic EPS	905	960	1,016
Effect of dilutive securities	7	5	5
Weighted-average shares for diluted EPS	912	965	1,021
Basic EPS	$ 4.07	$ 4.82	$ 4.53
Diluted EPS	$ 4.04	$ 4.79	$ 4.51

For the years ended December 31, 2011, 2010 and 2009, there were employee stock-based awards, calculated on a weighted-average basis, to purchase 33 million, 43 million and 42 million shares of our common stock, respectively, that are not included in the computation of diluted EPS because their impact would have been anti-dilutive. In addition, shares of our common stock that may be issued upon exercise of our warrants are not included in the computation of diluted EPS for any of the periods presented above because their impact would have been anti-dilutive.

6. Collaborative arrangements

A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are both: (i) active participants in the activity; and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity.

From time to time, we enter into collaborative arrangements for the R&D, manufacture and/or commercialization of products and product candidates. These collaborations generally provide for non-refundable upfront license fees, regulatory and commercial performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration agreements are performed on a “best efforts” basis with no guarantee of either technological or commercial success and each is unique in nature. Our significant arrangements are discussed below.

Pfizer Inc.

We are in a collaboration with Pfizer to co-promote ENBREL in the United States and Canada. The rights to market ENBREL outside of the United States and Canada are reserved to Pfizer. Under the agreement, a management committee comprised of equal representation from Amgen and Pfizer is responsible for overseeing the marketing and sales of ENBREL, including strategic planning, the approval of an annual marketing plan, product pricing and the establishment of a brand team. Amgen and Pfizer share in the agreed-upon selling and marketing expenses approved by the joint management committee. We currently pay Pfizer a percentage of annual gross profits on our ENBREL sales in the United States and Canada attributable to all approved indications on a scale that increases as gross profits increase; however, we maintain a majority share of ENBREL profits. After expiration of the agreement in the fourth quarter of 2013, we will be required to pay Pfizer a declining percentage of annual net ENBREL sales in the United States and Canada for three years, ranging from 12% to 10%. The amounts of such payments are anticipated to be significantly less than what would be owed based on the terms of the current ENBREL profit share.

We have determined that we are the principal participant in the collaboration with Pfizer to market ENBREL in the United States and Canada. Accordingly, we record our product sales of ENBREL to third parties net of estimated returns, rebates and other deductions. For the years ended December 31, 2011, 2010 and 2009, ENBREL sales aggregated $3.7 billion, $3.5 billion and $3.5 billion, respectively.

During the years ended December 31, 2011, 2010 and 2009, the ENBREL profit share expense was $1,288 million, $1,184 million and $1,163 million, respectively, and is included in Selling, general and administrative expense in the Consolidated Statements of Income. In addition, cost recoveries from Pfizer for their share of the selling and marketing expense were $84 million, $87 million and $75 million for the years ended December 31, 2011, 2010 and 2009, respectively, and are included in Selling, general and administrative expense in the Consolidated Statements of Income.

Glaxo Group Limited

We are in a collaboration with Glaxo Group Limited (Glaxo), a wholly owned subsidiary of GlaxoSmithKline plc, for the commercialization of denosumab for osteoporosis indications in Europe, Australia, New Zealand and Mexico (the Primary Territories). We have retained the rights to commercialize denosumab for all indications in the United States and Canada and for oncology indications in the Primary Territories. Under a related agreement, Glaxo will commercialize denosumab for all indications in countries, excluding Japan, where we did not have a commercial presence at the commencement of the agreement, including China, Brazil, India, Taiwan and South Korea (the Expansion Territories). In the Expansion Territories, Glaxo is responsible for all development and commercialization costs and will purchase denosumab from us to meet demand. In the future, we have the option of expanding our role in the commercialization of denosumab in the Primary Territories and certain of the Expansion Territories.

In the Primary Territories, we share equally in the commercialization profits and losses related to the collaboration after accounting for expenses, including an amount payable to us in recognition of our discovery and development of denosumab. Glaxo is also responsible for bearing a portion of the cost of certain specified development activities in the Primary Territories.

The collaboration agreement with Glaxo for the Primary Territories will expire in 2022 and the related agreement for the Expansion Territories will expire in 2024, unless either agreement is terminated earlier in accordance with its terms.

As the principal participant in the Primary Territories, Amgen records related product sales to third parties net of estimated returns, rebates and other deductions. During the years ended December 31, 2011 and 2010, product sales in the Primary Territories for osteoporosis indications were $62 million and $5 million, respectively. In the Expansion Territories, we record product sales to Glaxo. During the years ended December 31, 2011 and 2010, product sales of denosumab to Glaxo for the Expansion Territories were not material.

During the years ended December 31, 2011, 2010 and 2009, the net recoveries from Glaxo were $30 million, $46 million and $29 million, respectively, and are included in Selling, general and administrative expense in the Consolidated Statements of Income. In addition, during 2010, we received payments aggregating $75 million for the achievement of certain commercial milestones, which were recognized upon the achievement of the related milestone events as Other revenue in our Consolidated Statement of Income. Under these agreements, we also received an initial payment of $45 million during the year ended December 31, 2009, which was deferred and is being recognized as Other revenue in our Consolidated Statements of Income, over our estimated period of continuing involvement of approximately 13 years.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Takeda Pharmaceutical Company Limited

We are in a collaboration with Takeda Pharmaceutical Company Limited (Takeda), which provides Takeda the exclusive rights to develop and commercialize for the Japanese market up to 12 molecules from our portfolio across a range of therapeutic areas, including oncology and inflammation (collectively the "Japanese market products") and for the worldwide development and commercialization of our product candidate, motesanib, in the oncology area. The Japanese market products include: (i) Vectibix®, which received regulatory approval in Japan, in 2010, for unresectable, advanced or recurrent colorectal cancer with wild-type *KRAS*, (ii) AMG 386, which is in a phase 3 trial for recurrent ovarian cancer, and (iii) ganitumab (AMG 479), which is in a phase 3 trial for first-line metastatic pancreatic cancer. Through collaboration committees, the parties jointly coordinate and oversee Takeda's development and commercialization of the Japanese market products in Japan. The parties share responsibility for the development of motesanib outside Japan and Takeda is responsible for development in Japan. Additionally, Amgen shall be responsible for commercialization of motesanib in North America and Takeda shall be responsible for commercialization outside of North America. Each party has the right to participate in the commercialization of motesanib in the other party's territory. In addition, under the collaboration Amgen will manufacture and supply Takeda motesanib and the Japanese market products for both clinical and commercial purposes. In 2011, we announced that the motesanib pivotal phase 3 trial (MONET1) did not meet its primary objective of demonstrating an improvement in overall survival.

For the Japanese market products Takeda is obligated to pay Amgen up to an additional $60 million of future worldwide development costs for these products in 2012 and a reduced amount of such costs, thereafter. Takeda will be solely responsible for all development and commercialization costs of these products in Japan and will pay Amgen royalties on future sales in Japan. Amgen has the right to participate in the promotion of these products in Japan. With respect to motesanib, Takeda is obligated to pay 60% of future worldwide development costs (excluding Japan, for which Takeda shall bear all such costs), and the parties will share equally all other costs and profits resulting from the commercialization of motesanib outside Japan. If approved for sale, Amgen will receive royalties on future sales of motesanib in Japan.

The collaboration agreements will continue in effect unless terminated earlier in accordance with their terms.

In connection with the collaboration, Amgen received upfront payments of $300 million in 2008 which were deferred and are being recognized as Other revenue in our Consolidated Statements of Income, over our estimated period of continuing involvement of approximately 20 years. Additionally, during 2010, we received payments aggregating $55 million for the achievement of certain regulatory milestones which were recognized as Other revenue in our Consolidated Statement of Income upon the achievement of the related milestone events. We may also receive numerous individually immaterial milestones aggregating $472 million upon the achievement of various substantive success-based development and regulatory approval milestones. The receipt of these amounts, however, is contingent upon the occurrence of various future events which have a high degree of uncertainty of occurring.

During the years ended December 31, 2011, 2010 and 2009, cost recoveries from Takeda were $83 million, $91 million and $112 million, respectively, and are included in Research and development expense in the Consolidated Statements of Income. In addition, for the years December 31, 2011 and 2010, we recognized royalties on sales of Vectibix® in Japan of $20 million and $7 million, respectively.

Daiichi Sankyo Company, Limited

We are in a collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo), which provides Daiichi Sankyo the exclusive rights to develop and commercialize denosumab in Japan for osteoporosis, oncology and

certain other indications. As part of the agreement, Amgen received exclusive worldwide rights to certain Daiichi Sankyo intellectual property to the extent applicable to denosumab. Through collaboration committees, the parties jointly coordinate and oversee Daiichi Sankyo's development and commercialization of denosumab in Japan.

Under the terms of the agreement, Daiichi Sankyo assumed all related development and commercialization costs in Japan and agreed to reimburse Amgen for certain worldwide development costs related to denosumab. As of December 31, 2009, Daiichi Sankyo had substantially satisfied its obligations to reimburse Amgen for these costs. If approved for sale, Amgen will receive royalties on future sales of denosumab recorded by Daiichi Sankyo in Japan.

Pursuant to the terms of the agreement, we paid Daiichi Sankyo milestone payments aggregating $60 million, in 2010, as a result of various regulatory approvals of denosumab. The milestone payments were capitalized within Intangible assets, net in the Consolidated Balance Sheets and are being amortized over 11 years and the amortization expense is included in Cost of sales (excludes amortization of certain acquired intangible assets) in the Consolidated Statements of Income.

The collaboration agreement will expire in 2027 unless terminated earlier in accordance with its terms.

During the years ended December 31, 2011, 2010 and 2009, cost recoveries from Daiichi Sankyo were $4 million, $3 million and $64 million, respectively. The cost recoveries are included in Research and development expense in the Consolidated Statements of Income.

Other

We have various other collaborations, in addition to those discussed above, that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay or we may receive additional amounts upon the achievement of various development, regulatory and commercial milestones which in the aggregate could be significant. We may also incur or have reimbursed to us significant R&D costs if the related product candidate were to advance to late stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay or we may receive significant royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurring.

7. Related party transactions

We own a 50% interest in K-A, a corporation formed in 1984 with Kirin Holdings Company, Limited (Kirin) for the development and commercialization of certain products based on advanced biotechnology. All of our rights to manufacture and market certain products including pegfilgrastim, granulocyte colony-stimulating factor, darbepoetin alfa, recombinant human erythropoietin and romiplostim are pursuant to exclusive licenses from K-A, which we currently market under the brand names Neulasta®, NEUPOGEN®, Aranesp®, EPOGEN®, and Nplate®, respectively.

We account for our interest in K-A using the equity method and include our share of K-A's profits or losses in Selling, general and administrative expense in the Consolidated Statements of Income. For the years ended December 31, 2011, 2010 and 2009, our share of K-A's profits was $47 million, $71 million and $72 million, respectively. During 2009, we received $110 million in dividends from K-A. At both December 31, 2011 and 2010, the carrying value of our equity method investment in K-A, net of dividends received, was approximately $0.4 billion and is included in noncurrent Other assets in the Consolidated Balance Sheets.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

K-A's revenues consist of royalty income related to its licensed technology rights. K-A receives royalty income from us, as well as from Kirin, J&J and F. Hoffmann-La Roche Ltd. (Roche) under separate product license contracts for certain geographic areas outside of the United States. During the years ended December 31, 2011, 2010 and 2009, K-A earned royalties from us of $298 million, $322 million and $327 million, respectively. These amounts are included in Cost of sales (excludes amortization of certain acquired intangible assets) in the Consolidated Statements of Income.

K-A's expenses consist primarily of costs related to R&D activities conducted on its behalf by Amgen and Kirin. K-A pays Amgen and Kirin for such services at negotiated rates. During the years ended December 31, 2011, 2010 and 2009, we earned revenues from K-A of $130 million, $96 million and $102 million, respectively, for certain R&D activities performed on K-A's behalf. These amounts are recognized as Other revenues in the Consolidated Statements of Income. We may also receive numerous individually immaterial milestones aggregating $125 million upon the achievement of various substantive success-based development and regulatory approval milestones contingent upon the occurrence of various future events, most of which have a high degree of uncertainty of occurring. During the years ended December 31, 2011, 2010 and 2009, we recorded cost recoveries from K-A of $85 million, $88 million and $96 million, respectively, related to certain third-party costs. These amounts are included in Research and development expense in the Consolidated Statements of Income.

As of December 31, 2011 and 2010, we owed K-A $75 million and $62 million, respectively, which are included in Accrued liabilities in the Consolidated Balance Sheets.

8. Cost savings initiatives and restructuring

Manufacturing operations optimization

As part of our continuing efforts to optimize our network of manufacturing facilities and improve cost efficiencies, on January 18, 2011, we entered into an agreement whereby Boehringer Ingelheim (BI) agreed to acquire our rights in and substantially all assets at our manufacturing facility located in Fremont, California. The transaction was approved by Amgen's Board of Directors in December 2010 and closed in March 2011. In connection with the closing of this transaction, BI has assumed our obligations under certain of the facility's operating lease contracts and has entered into an agreement to manufacture certain quantities of our marketed product Vectibix® for us at this facility through December 31, 2012 (the supply period).

We considered the transaction with BI to be a potential indicator of impairment, and accordingly, we performed an impairment analysis of the carrying values of the related fixed assets as of December 31, 2010. Based on this analysis, we determined that no future economic benefit would be received from a manufacturing line at the facility that had not yet been completed. As a result, we wrote off its entire carrying value, which aggregated $118 million during the year ended December 31, 2010. This amount is included in Other operating expenses in the Consolidated Statement of Income. The carrying values of the remaining fixed assets, aggregating approximately $133 million at December 31, 2010, were determined to be fully recoverable.

Due to the lack of sufficient initial investment by BI in the acquisition of this facility and our ongoing involvement with these operations, the transaction did not meet the accounting requirements to be treated as a sale involving real estate. As a result, the related assets continue to be carried on our Consolidated Balance Sheets.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

As a result of this transaction, we reduced the estimated useful lives of the remaining fixed assets to coincide with the supply period. During the year ended December 31, 2011, we recorded incremental depreciation of approximately $42 million in excess of what otherwise would have been recorded. In addition, due to the assignment to BI of the obligations under certain of the facility's operating leases, we recorded charges of approximately $23 million during the year ended December 31, 2011, with respect to the lease period beyond the end of the supply period. These amounts are recorded in Cost of sales (excludes amortization of certain acquired intangible assets presented separately) in the Consolidated Statement of Income.

Other cost savings initiatives

As part of our continuing efforts to improve cost efficiencies in our operations, we recorded certain charges, primarily severance-related, aggregating approximately $109 million during the year ended December 31, 2011, which are included in Other operating expenses in the Consolidated Statement of Income.

Restructuring

On August 15, 2007, we announced a plan to restructure our worldwide operations in order to improve our cost structure. This restructuring plan was primarily the result of regulatory and reimbursement developments that began in 2007 involving erythropoiesis-stimulating agents (ESAs), including our marketed ESAs, Aranesp® and EPOGEN®, and the resulting impact on our operations. As of December 31, 2009, we completed all of the actions included in our restructuring plan and subsequently identified initiatives. During the year ended December 31, 2009, we recorded charges associated with these actions aggregating $70 million, comprised primarily of staff separation costs of $25 million, included principally in Other operating expenses in the Consolidated Statement of Income, and integration-related costs of $32 million, which were included principally in Selling, general and administrative expenses in the Consolidated Statement of Income.

9. Available-for-sale investments

The amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security were as follows (in millions):

Type of security as of December 31, 2011	Amortized cost	Gross unrealized gains	Gross unrealized losses	Estimated fair value
U.S. Treasury securities	$ 3,878	$ 68	$ —	$ 3,946
Other government-related debt securities:				
Obligations of U.S. government agencies and FDIC-guaranteed bank debt	1,548	23	—	1,571
Foreign and other	441	9	—	450
Corporate debt securities:				
Financial	2,493	30	(15)	2,508
Industrial	3,077	79	(10)	3,146
Other	280	9	-	289
Mortgage- and asset-backed securities	1,789	6	(10)	1,785
Money market mutual funds	6,266	—	—	6,266
Total debt security investments	19,772	224	(35)	19,961
Equity securities	42	—	—	42
Total available-for-sale investments	$ 19,814	$ 224	$ (35)	$ 20,003

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Type of security as of December 31, 2010	Amortized cost	Gross unrealized gains	Gross unrealized losses	Estimated fair value
U.S. Treasury securities	$ 5,044	$ 50	$ (14)	$ 5,080
Other government-related debt securities:				
Obligations of U.S. government agencies and FDIC-guaranteed bank debt	2,158	51	(1)	2,208
Foreign and other	837	16	(1)	852
Corporate debt securities:				
Financial	2,252	53	(9)	2,296
Industrial	2,441	71	(5)	2,507
Other	307	10	(1)	316
Mortgage- and asset-backed securities	841	5	(5)	841
Money market mutual funds	3,030	—	—	3,030
Other short-term interest-bearing securities	147	—	—	147
Total debt security investments	17,057	256	(36)	17,277
Equity securities	50	—	(2)	48
Total available-for-sale investments	$ 17,107	$ 256	$ (38)	$ 17,325

The fair values of available-for-sale investments by classification in the Consolidated Balance Sheets were as follows as of December 31, 2011 and 2010 (in millions):

Classification in the Consolidated Balance Sheets	2011	2010
Cash and cash equivalents	$ 6,266	$ 3,142
Marketable securities	13,695	14,135
Other assets — noncurrent	42	48
Total available-for-sale investments	$20,003	$17,325

Cash and cash equivalents in the table above excludes cash of $680 million and $145 million as of December 31, 2011 and 2010, respectively.

The fair values of available-for-sale debt security investments by contractual maturity were as follows as of December 31, 2011 and 2010 (in millions):

Contractual maturity	2011	2010
Maturing in one year or less	$ 6,811	$ 4,118
Maturing after one year through three years	6,346	6,736
Maturing after three years through five years	5,710	5,812
Maturing after five years	1,094	611
Total debt securities	$19,961	$17,277

For the years ended December 31, 2011, 2010 and 2009, realized gains totaled $191 million, $115 million and $104 million, respectively, and realized losses totaled $37 million, $25 million and $62 million, respectively. The cost of securities sold is based on the specific identification method.

The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy

limits debt security investments to certain types of debt and money market instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer.

We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a number of factors including, the length of time and the extent to which the fair value has been below our cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security. As of December 31, 2011 and 2010, we believe the cost bases for our available-for-sale investments were recoverable in all material respects.

10. Inventories

Inventories consisted of the following as of December 31, 2011 and 2010 (in millions):

	2011	2010
Raw materials	$ 158	$ 128
Work in process	1,802	1,382
Finished goods	524	512
Total inventories	$2,484	$2,022

11. Property, plant and equipment

Property, plant and equipment consisted of the following as of December 31, 2011 and 2010 (dollar amounts in millions):

	Useful life (in years)	2011	2010
Land	—	$ 366	$ 361
Buildings and improvements	10-40	3,463	3,392
Manufacturing equipment	8-12	1,897	1,802
Laboratory equipment	8-12	1,016	955
Other	3-15	3,745	3,547
Construction in progress	—	744	631
Property, plant and equipment, gross		11,231	10,688
Less accumulated depreciation and amortization		(5,811)	(5,166)
Property, plant and equipment, net		$ 5,420	$ 5,522

During the years ended December 31, 2011, 2010 and 2009, we recognized depreciation and amortization charges associated with our property, plant and equipment of $679 million, $594 million and $624 million, respectively.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

12. Intangible assets

Finite-lived and indefinite-lived identifiable intangible assets consisted of the following as of December 31, 2011 and 2010 (in millions):

	2011			2010		
	Gross carrying amount	Accumulated amortization	Intangible assets, net	Gross carrying amount	Accumulated amortization	Intangible assets, net
Finite-lived intangible assets:						
Acquired product technology rights:						
Developed product technology	$2,872	$ (1,811)	$ 1,061	$2,872	$ (1,619)	$ 1,253
Core technology	1,348	(850)	498	1,348	(760)	588
Trade name	190	(120)	70	190	(107)	83
Acquired R&D technology rights	350	(350)	—	350	(329)	21
Other acquired intangible assets	686	(406)	280	627	(342)	285
Total finite-lived intangible assets	5,446	(3,537)	1,909	5,387	(3,157)	2,230
Indefinite-lived intangible assets — IPR&D	675	—	675	—	—	—
Total identifiable intangible assets	$6,121	$ (3,537)	$ 2,584	$5,387	$ (3,157)	$ 2,230

Amortization of finite-lived intangible assets is provided over their estimated useful lives ranging from 5 to 15 years on a straight-line basis.

Acquired product technology rights relate to the identifiable intangible assets acquired in connection with the 2002 Immunex acquisition and the related amortization expense is included in Amortization of certain acquired intangible assets in the Consolidated Statements of Income. Acquired R&D technology rights consist of technology used in R&D with alternative future uses and the related amortization expense is included in Research and development expense in the Consolidated Statements of Income. The amortization expense related to other acquired intangible assets is included principally in Cost of sales (excludes amortization of certain acquired intangible assets) and Selling, general and administrative expense in the Consolidated Statements of Income. During the years ended December 31, 2011, 2010 and 2009, we recognized amortization charges associated with our finite-lived intangible assets of $380 million, $423 million and $425 million, respectively. The total estimated amortization for each of the next five years for our intangible assets is $354 million, $359 million, $340 million, $327 million and $317 million in 2012, 2013, 2014, 2015 and 2016, respectively.

IPR&D relates to identifiable intangible assets acquired in connection with the acquisition of BioVex. (See Note 2, Business combinations — BioVex Group, Inc.)

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

13. Accrued liabilities

Accrued liabilities consisted of the following as of December 31, 2011 and 2010 (in millions):

	2011	2010
Sales deductions	$1,326	$1,144
Employee compensation and benefits	916	764
Sales returns reserve	339	339
Legal reserve	780	—
Other	1,667	1,119
Total accrued liabilities	$5,028	$3,366

See Note 18, Contingencies and commitments, for further discussion of the legal reserve.

14. Financing arrangements

The carrying values and the fixed contractual coupon rates of our long-term borrowings were as follows as of December 31, 2011 and 2010 (in millions):

	2011	2010
0.125% convertible notes due 2011 (0.125% 2011 Convertible Notes)	$ —	$ 2,488
0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes)	2,346	2,213
1.875% notes due 2014 (1.875% 2014 Notes)	1,000	—
4.85% notes due 2014 (4.85% 2014 Notes)	1,000	1,000
2.30% notes due 2016 (2.30% 2016 Notes)	748	—
2.50% notes due 2016 (2.50% 2016 Notes)	999	—
5.85% notes due 2017 (5.85% 2017 Notes)	1,099	1,099
6.15% notes due 2018 (6.15% 2018 Notes)	499	499
4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes)	714	—
5.70% notes due 2019 (5.70% 2019 Notes)	998	998
4.50% notes due 2020 (4.50% 2020 Notes)	300	300
3.45% notes due 2020 (3.45% 2020 Notes)	897	897
4.10% notes due 2021 (4.10% 2021 Notes)	998	—
3.875% notes due 2021 (3.875% 2021 Notes)	1,745	—
5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes)	739	—
6.375% notes due 2037 (6.375% 2037 Notes)	899	899
6.90% notes due 2038 (6.90% 2038 Notes)	499	499
6.40% notes due 2039 (6.40% 2039 Notes)	996	996
5.75% notes due 2040 (5.75% 2040 Notes)	697	696
4.95% notes due 2041 (4.95% 2041 Notes)	595	595
5.15% notes due 2041 (5.15% 2041 Notes)	2,232	—
5.65% notes due 2042 (5.65% 2042 Notes)	1,244	—
Other notes, including our zero-coupon convertible notes	184	183
Total debt	21,428	13,362
Less current portion	(84)	(2,488)
Total noncurrent debt	$21,344	$ 10,874

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Debt repayments

In February 2011, our 0.125% 2011 Convertible Notes became due, and we repaid the $2.5 billion aggregate principal amount. As these convertible notes were cash settleable, their debt and equity components were bifurcated and accounted for separately. The discounted carrying value of the debt component resulting from the bifurcation was accreted back to the principal amount over the period the notes were outstanding. The total aggregate amount repaid, including the amount related to the debt discount of $643 million resulting from the bifurcation, is included in Cash flows from financing activities in the Consolidated Statement of Cash Flows. No debt was due or repaid in 2010, and we repaid $1.0 billion aggregate principal amount of notes with a fixed interest rate of 4.00% in 2009.

Debt issuances

We issued debt securities in various offerings during the three years ended December 31, 2011, including:

- In 2011, we issued $10.5 billion aggregate principal amount of notes, comprised of the 1.875% 2014 Notes, the 2.30% 2016 Notes, the 2.50% 2016 Notes, the 4.375% 2018 euro Notes (€550 million aggregate principal amount), the 4.10% 2021 Notes, the 3.875% 2021 Notes, the 5.50% 2026 pound sterling Notes (£475 million aggregate principal amount), the 5.15% 2041 Notes and the 5.65% 2042 Notes.
- In 2010, we issued $2.5 billion aggregate principal amount of notes, comprised of the 4.50% 2020 Notes, the 3.45% 2020 Notes, the 5.75% 2040 Notes and the 4.95% 2041 Notes.
- In 2009, we issued $2.0 billion aggregate principal amount of notes, comprised of the 5.70% 2019 Notes and the 6.40% 2039 Notes.

Debt issuance costs incurred in connection with these debt offerings in 2011, 2010 and 2009 totaled $55 million, $17 million and $13 million, respectively. These debt issuance costs are being amortized over the respective lives of the notes, and the related charge is included in Interest expense, net, in the Consolidated Statements of Income.

All of our debt issuances other than our 0.375% 2013 Convertible Notes and Other notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued interest and a make-whole amount, as defined. In addition, except with respect to our 0.375% 2013 Convertible Notes, the 4.85% 2014 Notes and Other notes, in the event of a change in control triggering event, as defined, we may be required to purchase for cash all or a portion of these debt issuances at a price equal to 101% of the principal amount of the notes plus accrued interest.

Convertible Notes

In 2006, we issued $5.0 billion principal amount of convertible notes at par. While outstanding, the notes are convertible into shares of our common stock upon the occurrence of specified events. In February 2011, $2.5 billion principal amount of the convertible notes (the 0.125% 2011 Convertible Notes) became due and were repaid in full. While outstanding, the conversion rate on the 0.125% 2011 Convertible Notes was 12.5247 shares per $1,000 principal amount of notes, which represented a conversion price of approximately $79.84 per share. The conversion rate on the $2.5 billion principal amount of convertible notes, which mature in February 2013 (the 0.375% 2013 Convertible Notes), was 12.7473 shares per $1,000 principal amount of notes at December 31, 2011, which represents a conversion price of approximately $78.45 per share. This conversion rate is adjusted as we make specified types of distributions, including paying cash dividends on our common stock, or enter into

certain other transactions with respect to our common stock. The 0.375% 2013 Convertible Notes may only be converted: (i) during any calendar quarter if the closing price of our common stock exceeds 130% of the then conversion price per share during a defined period at the end of the previous quarter, (ii) if we make specified distributions to holders of our common stock or specified corporate transactions occur or (iii) within one month prior to the maturity date. Upon conversion, a holder would receive the conversion value equal to the conversion rate multiplied by the volume weighted-average price of our common stock during a specified period following the conversion date. The conversion value will be paid in: (i) cash equal to the lesser of the principal amount of the note or the conversion value, as defined, and (ii) cash, shares of our common stock, or a combination of cash and shares of our common stock, at our option, to the extent the conversion value exceeds the principal amount of the note (the excess conversion value). In addition, upon a change in control, as defined, the holders may require us to purchase for cash all or a portion of their notes for the principal amount of the notes plus accrued interest. As of December 31, 2011, the 0.375% 2013 Convertible Notes were not convertible. While outstanding, the 0.125% 2011 Convertible Notes had terms similar to the 0.375% 2013 Convertible Notes.

Concurrent with the issuance of the 0.375% 2013 Convertible Notes, we purchased a convertible note hedge. The convertible note hedge allows us to receive shares of our common stock and/or cash from the counterparty to the transaction equal to the amounts of common stock and/or cash related to the excess conversion value that we would issue and/or pay to the holders of the 0.375% 2013 Convertible Notes upon conversion. This convertible note hedge will terminate at the earlier of the maturity of the 0.375% 2013 Convertible Notes or the first day none of these notes remain outstanding due to conversion or otherwise. We also purchased a convertible note hedge with similar terms in connection with the issuance of the 0.125% 2011 Convertible Notes, which terminated unexercised when these notes were repaid.

Also concurrent with the issuance of the 0.375% 2013 Convertible Notes, we sold warrants to acquire 31.5 million shares of our common stock in May 2013 (the settlement date) at an exercise price of $107.90 per share. If the average price of our common stock during a defined period ending on or about the settlement date exceeds the exercise price of the warrants, the warrants will be net settled, at our option, in cash or shares of our common stock. In connection with the issuance of the 0.125% 2011 Convertible Notes, we sold warrants to purchase 31.3 million shares of our stock on similar terms, which expired unexercised in May 2011.

Because the convertible note hedges and warrants can be settled at our option in cash or shares of our common stock, and these contracts meet all of the applicable criteria for equity classification under the applicable accounting standards, the cost of the convertible note hedges and net proceeds from the sale of the warrants are classified in Stockholders' equity in the Consolidated Balance Sheets. In addition, because both of these contracts are classified in Stockholders' equity and are indexed to our common stock, they are not accounted for as derivatives.

As required for cash settleable convertible notes, the debt and equity components of the 0.375% 2013 Convertible Notes were bifurcated and accounted for separately. The resulting discounted carrying value of the debt is being accreted back to the principal amount through the scheduled maturity date, resulting in the recognition of non-cash interest expense. After giving effect to this bifurcation, the effective interest rate on this borrowing is 6.35%. For the years ended December 31, 2011, 2010 and 2009, total interest expense for the 0.375% 2013 Convertibles Notes was $143 million, $134 million, and $127 million, respectively, including non-cash interest expense of $133 million, $125 million, and $118 million, respectively. While outstanding, the 0.125% 2011 Convertible Notes were accounted for in the same manner, resulting in an effective interest rate of 6.24%. For the years ended December 31, 2011, 2010 and 2009, total interest expense for the 0.125% 2011 Convertible Notes was $13 million, $149 million, and $140 million, respectively, including non-cash interest expense of $12 million, $146 million, and $136 million, respectively.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The principal balance, unamortized discount and net carrying amount of the liability and equity components of our 0.375% 2013 Convertible Notes were as follows as of December 31, 2011 and 2010 (in millions):

	Liability component			Equity component
0.375% 2013 Convertible Notes	Principal balance	Unamortized discount	Net carrying amount	Net carrying amount
December 31, 2011	$ 2,500	$ 154	$ 2,346	$ 829
December 31, 2010	$ 2,500	$ 287	$ 2,213	$ 829

Other

Other notes include zero-coupon convertible notes due in 2032 with a carrying value of $84 million and $83 million at December 31, 2011 and 2010, respectively, and notes due in 2097 with a carrying value of $100 million.

Interest rate swaps

To achieve a desired mix of fixed and floating interest rate debt, we enter into interest rate swap contracts that effectively convert a fixed rate interest coupon for certain of our debt issuances to a floating London Interbank Offered Rate (LIBOR)-based coupon over the life of the respective note. These interest rate swap contracts qualify and are designated as fair value hedges. The effective interest rates on these notes after giving effect to the related interest rate swap contracts and the notional amounts of these interest rate swap contracts were as follows as of December 31, 2011 and 2010 (dollar amounts in millions):

		Notional amount	
	Effective interest rate	2011	2010
4.85% 2014 Notes	LIBOR + 0.3%	$1,000	$1,000
5.85% 2017 Notes	LIBOR + 2.5%	1,100	1,100
6.15% 2018 Notes	LIBOR + 1.8%	500	500
5.70% 2019 Notes	LIBOR + 2.6%	1,000	1,000
		$3,600	$3,600

Cross currency swaps

In order to hedge our exposure to foreign currency exchange rate risk associated with our pound sterling denominated long-term notes issued in 2011, we entered into cross currency swap contracts. These cross currency swap contracts qualify and are designated as cash flow hedges. Under the terms of these contracts, we receive interest payments in pounds sterling at a fixed rate of 5.5% on £475 million and pay interest in U.S. dollars at a fixed rate of 5.8% on $748 million, the aggregate notional amounts paid to/received from the counterparties upon exchange of currencies at the inception of these contracts. We will pay U.S. dollars to and receive pounds sterling from the counterparties at the maturity of the contracts for the same notional amounts. The terms of these contracts correspond to the related hedged notes, effectively converting the interest payments and principal repayment on these notes from pounds sterling to U.S. dollars.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Shelf registration statements and other facilities

As of December 31, 2011, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working capital needs. At December 31, 2011 and 2010, we had no amounts outstanding under our commercial paper program.

In December 2011, we entered into a $2.5 billion syndicated, unsecured, revolving credit agreement which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $500 million with the agreement of the banks. Each bank which is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.1% based on our current credit rating. We would be charged interest at LIBOR plus 0.9% for any amounts borrowed under this facility. As of December 31, 2011, no amounts were outstanding under this facility. In connection with the new revolving credit agreement we terminated our prior $2.3 billion revolving credit agreement that was scheduled to expire in November 2012.

In March 2011, we filed a shelf registration statement with the U.S. Securities and Exchange Commission to replace an existing shelf registration statement that was scheduled to expire in April 2011. This shelf registration statement allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depository shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in March 2014.

In 1997, we established a $400 million medium-term note program under which medium-term debt securities may be offered from time to time with terms to be determined at the time of issuance. As of December 31, 2011 and 2010, no securities were outstanding under this medium-term note program.

Certain of our financing arrangements contain non-financial covenants. In addition, our revolving credit agreement includes a financial covenant with respect to the level of our borrowings in relation to our equity, as defined. We were in compliance with all applicable covenants under these arrangements as of December 31, 2011.

Contractual maturities of long-term debt obligations

The aggregate contractual maturities of all long-term debt obligations due subsequent to December 31, 2011, are as follows (in millions):

Maturity date	Amount
2012[(1)]	$ 84
2013[(2)]	2,500
2014	2,000
2015	—
2016	1,750
Thereafter	15,312
Total	$21,646

(1) This amount represents the accreted value of our zero-coupon convertible notes due in 2032 which will be redeemed on March 1, 2012.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(2) This amount represents the principal amount for our 0.375% 2013 Convertible Notes after full accretion of the debt discount.

Interest costs

Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest expense, net, for the years ended December 31, 2011, 2010 and 2009, was $610 million, $604 million and $578 million, respectively. Interest costs capitalized for the years ended December 31, 2011, 2010 and 2009, were $22 million, $33 million and $32 million, respectively. Interest paid, net of interest rate swaps, during the years ended December 31, 2011, 2010 and 2009, totaled $446 million, $323 million and $293 million, respectively.

15. Stockholders' equity

Stock repurchase program

Activity under our stock repurchase program was as follows for the years ended December 31, 2011, 2010 and 2009 (in millions):

	2011		2010		2009	
	Shares	Dollars	Shares	Dollars	Shares	Dollars
First quarter	—	$ —	29.1	$1,684	37.5	$1,997
Second quarter	12.9	732	10.3	616	—	—
Third quarter	45.4	2,421	6.6	364	—	—
Fourth quarter	86.0	5,154(1)	20.5	1,136	21.7	1,211
Total stock repurchases	144.3	$8,307	66.5	$3,800	59.2	$3,208

(1) Includes the repurchase of 83.3 million shares of our common stock at an average price paid per share of $60.08 including related expenses, for an aggregate cost of $5.0 billion, under a modified Dutch auction tender offer.

In April 2011, the Board of Directors authorized us to repurchase up to an additional $5.0 billion of our common stock under our stock repurchase program, and in October 2011, the Board of Directors further increased the total authorization for stock repurchases by $6.1 billion to $10.0 billion. As of December 31, 2011, $5.0 billion remained available under the program.

In July and October 2011, the Board of Directors declared quarterly cash dividends of $0.28 per share of common stock, which were paid in September and December 2011, respectively. Additionally, on December 15, 2011, the Board of Directors declared a quarterly cash dividend of $0.36 per share of common stock, which will be paid on March 7, 2012, to all stockholders of record as of the close of business on February 15, 2012.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Accumulated other comprehensive income

The components of Accumulated Other Comprehensive Income (AOCI) are as follows for the years ended December 31, 2011, 2010 and 2009 (in millions):

	Foreign currency translation	Cash flow hedges	Available-for-sale securities	Other	AOCI
Balance as of December 31, 2008	$ 25	$ 50	$ 49	$ (7)	$ 117
Foreign currency translation adjustments	25	—	—	—	25
Unrealized (losses) gains	—	(213)	116	(12)	(109)
Reclassification adjustments to income	—	8	(42)	—	(34)
Other	—	—	—	5	5
Income taxes	(10)	73	(28)	6	41
Balance as of December 31, 2009	40	(82)	95	(8)	45
Foreign currency translation adjustments	(29)	—	—	—	(29)
Unrealized gains	—	186	155	1	342
Reclassification adjustments to income	—	(46)	(90)	—	(136)
Income taxes	11	(55)	(25)	—	(69)
Balance as of December 31, 2010	22	3	135	(7)	153
Foreign currency translation adjustments	(6)	—	—	—	(6)
Unrealized (losses) gains	—	(51)	125	2	76
Reclassification adjustments to income	—	112	(154)	—	(42)
Other	—	—	—	(8)	(8)
Income taxes	5	(21)	14	—	(2)
Balance as of December 31, 2011	$ 21	$ 43	$ 120	$ (13)	$ 171

Income tax expense or benefit for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges was a $20 million benefit and $41 million expense in 2011, a $71 million expense and $16 million benefit in 2010 and a $76 million benefit and $3 million expense in 2009, respectively. Income tax expense/benefit for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities was a $45 million expense and $59 million benefit for 2011, a $60 million expense and $35 million benefit in 2010 and a $44 million expense and $16 million benefit in 2009, respectively.

Other

In addition to common stock, our authorized capital includes 5 million shares of preferred stock, $0.0001 par value. As of December 31, 2011 and 2010, no shares of preferred stock were issued or outstanding.

16. Fair value measurement

To determine the fair value of our financial assets and liabilities we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants

would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:

Level 1	—	Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access
Level 2	—	Valuations for which all significant inputs are observable, either directly or indirectly, other than level 1 inputs
Level 3	—	Valuations based on inputs that are unobservable and significant to the overall fair value measurement

The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.

The fair value of each major class of the Company's financial assets and liabilities measured at fair value on a recurring basis was as follows (in millions):

Fair value measurement as of December 31, 2011, using:	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
Assets:				
Available-for-sale investments:				
U.S. Treasury securities	$ 3,946	$ —	$ —	$ 3,946
Other government-related debt securities:				
Obligations of U.S. government agencies and FDIC-guaranteed bank debt	—	1,571	—	1,571
Foreign and other	—	450	—	450
Corporate debt securities:				
Financial	—	2,508	—	2,508
Industrial	—	3,146	—	3,146
Other	—	289	—	289
Mortgage- and asset-backed securities	—	1,785	—	1,785
Money market mutual funds	6,266	—	—	6,266
Equity securities	42	—	—	42
Derivatives:				
Foreign currency contracts	—	172	—	172
Interest rate swap contracts	—	377	—	377
Total assets	$ 10,254	$ 10,298	$ —	$20,552
Liabilities:				
Derivatives:				
Foreign currency contracts	$ —	$ 48	$ —	$ 48
Cross currency swap contracts	—	26	—	26
Contingent consideration obligations in connection with a business combination	—	—	190	190
Total liabilities	$ —	$ 74	$ 190	$ 264

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Fair value measurement as of December 31, 2010, using:	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
Assets:				
Available-for-sale investments:				
U.S. Treasury securities	$ 5,080	$ —	$ —	$ 5,080
Other government-related debt securities:				
Obligations of U.S. government agencies and FDIC-guaranteed bank debt	—	2,208	—	2,208
Foreign and other	—	852	—	852
Corporate debt securities:				
Financial	—	2,296	—	2,296
Industrial	—	2,507	—	2,507
Other	—	316	—	316
Mortgage- and asset-backed securities	—	841	—	841
Money market mutual funds	3,030	—	—	3,030
Other short-term interest-bearing securities	—	147	—	147
Equity securities	48	—	—	48
Derivatives:				
Foreign currency contracts	—	154	—	154
Interest rate swap contracts	—	195	—	195
Total assets	$ 8,158	$ 9,516	$ —	$ 17,674
Liabilities:				
Derivatives:				
Foreign currency contracts	$ —	$ 103	$ —	$ 103
Total liabilities	$ —	$ 103	$ —	$ 103

The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets with no valuation adjustment.

Substantially all of our other government related and corporate debt securities are investment grade with maturity dates of five years or less from the balance sheet date. Our other government related debt securities portfolio is composed of securities with weighted-average credit ratings of AA+ by Standard & Poor's (S&P) and AAA or equivalent by Moody's Investors Service, Inc. (Moody's) or Fitch, Inc. (Fitch); and our corporate debt securities portfolio has a weighted-average credit rating of A- by S&P and A or equivalent by Moody's or Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.

Our mortgage and asset backed securities portfolio is composed entirely of senior tranches, with credit ratings of AAA or equivalent by S&P, Moody's or Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and

broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.

We value our other short-term interest bearing securities at amortized cost, which approximates fair value given their near-term maturity dates.

Substantially all of our foreign currency forward and option derivatives contracts have maturities of three years or less and all are with counterparties that have a minimum credit rating of A- or equivalent by S&P, Moody's or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts also include implied volatility measures. These inputs, where applicable, are at commonly quoted intervals. As of December 31, 2011 and 2010, we had open foreign currency forward contracts with notional amounts of $3.5 billion and $3.2 billion, respectively, and open foreign currency option contracts with notional amounts of $292 million and $398 million, respectively, that were primarily euro-based and were designated as cash flow hedges. In addition, as of December 31, 2011 and 2010, we had $389 million and $670 million, respectively, of open foreign currency forward contracts to reduce exposure to fluctuations in value of certain assets and liabilities denominated in foreign currencies that were primarily euro-based and that were not designated as hedges. (See Note 17, Derivative instruments.)

Our interest rate and cross currency swap contracts are with counterparties that have a minimum credit rating of A- or equivalent by S&P, Moody's or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency rates, LIBOR, swap rates, obligor credit default swap rates and cross currency basis swap spreads. We had interest rate swap contracts with an aggregate notional amount of $3.6 billion as of December 31, 2011 and 2010, that were designated as fair value hedges. We had cross currency swap contracts on all of our 5.50% 2026 pound sterling Notes as of December 31, 2011, that were designated as cash flow hedges. (See Note 17, Derivative instruments.)

Contingent consideration obligations in connection with a business combination result from our acquisition of BioVex in March 2011. The fair value measurements of these obligations are based on significant unobservable inputs, and accordingly, such amounts are considered Level 3 measurements. There were no changes in assumptions that had a material impact on the estimated fair values of these obligations during the period from the acquisition date to December 31, 2011, and accordingly, there was no significant impact on net income for this period. For a description of the valuation methodology and related assumptions used for estimating the fair values of these obligations, see Note 2, Business combinations.

There have been no transfers of assets or liabilities between the fair value measurement levels, and there were no material remeasurements to fair value during the years ended December 31, 2011 and 2010, of assets and liabilities that are not measured at fair value on a recurring basis, except as discussed in Note 8, Cost savings initiatives and restructuring, regarding an impairment of fixed assets that we recognized in 2010.

Summary of the fair value of other financial instruments

Cash equivalents

The estimated fair values of cash equivalents approximate their carrying values due to the short-term nature of these financial instruments.

Borrowings

We estimate the fair values of our convertible notes by using an income-based industry standard valuation model for which all significant inputs are observable either directly or indirectly, including benchmark yields adjusted for our credit risk (Level 2). The fair value of our convertible notes represent only the liability components of these instruments, as their equity components are included in Common stock and additional paid-in capital in the Consolidated Balance Sheets. We estimate the fair values of our other long-term notes by taking into consideration indicative prices obtained from a third-party financial institution that utilizes industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; credit spreads; benchmark yields; and other observable inputs (Level 2). As of December 31, 2011 and 2010, the aggregate fair values of our long-term debt were $23.0 billion and $14.5 billion, respectively, and the carrying values were $21.4 billion and $13.4 billion, respectively.

17. Derivative instruments

The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to these exposures, we utilize certain derivative instruments, including foreign currency forward, foreign currency option, cross currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.

Cash flow hedges

We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates, associated primarily with our euro-denominated international product sales. Increases or decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by the corresponding increases and decreases in our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations on our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods. As of December 31, 2011, 2010 and 2009, we had open foreign currency forward contracts with notional amounts of $3.5 billion, $3.2 billion and $3.4 billion and open foreign currency option contracts with notional amounts of $292 million, $398 million and $376 million, respectively. These foreign currency forward and option contracts, primarily euro-based, have been designated as cash flow hedges, and accordingly, the effective portion of the unrealized gains and losses on these contracts are reported in AOCI and reclassified to earnings in the same periods during which the hedged transactions affect earnings.

In order to hedge our exposure to foreign currency exchange rate risk associated with our pound sterling denominated long-term notes issued in 2011, we entered into cross currency swap contracts. Under the terms of these contracts, we receive interest payments in pounds sterling at a fixed rate of 5.5% on £475 million and pay interest in U.S. dollars at a fixed rate of 5.8% on $748 million, the aggregate notional amounts paid to/received from the counterparties upon exchange of currencies at the inception of these contracts. We will pay U.S. dollars to and receive pounds sterling from the counterparties at the maturity of the contracts for the same notional amounts. The terms of these contracts correspond to the related hedged notes, effectively converting the interest payments and principal repayment on these notes from pounds sterling to U.S. dollars. These cross currency

swap contracts have been designated as cash flow hedges, and accordingly, the effective portion of the unrealized gains and losses on these contracts are reported in AOCI and reclassified to earnings in the same periods during which the hedged debt affects earnings.

In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on such contracts, which are designated as cash flow hedges, are reported in AOCI and amortized into earnings over the lives of the associated debt issuances.

The effective portion of the unrealized gain/(loss) recognized in OCI for our derivative instruments designated as cash flow hedges was as follows (in millions):

	Years ended December 31,		
Derivatives in cash flow hedging relationships	**2011**	**2010**	**2009**
Foreign currency contracts	$ (25)	$191	$ (202)
Cross currency swap contracts	(26)	—	—
Forward interest rate contracts	—	(5)	(11)
Total	$ (51)	$186	$ (213)

The location in the Consolidated Statements of Income and the effective portion of the gain/(loss) reclassified from AOCI into earnings for our derivative instruments designated as cash flow hedges was as follows (in millions):

		Years ended December 31,		
Derivatives in cash flow hedging relationships	**Statements of Income location**	**2011**	**2010**	**2009**
Foreign currency contracts	Product sales	$ (108)	$47	$ (7)
Cross currency swap contracts	Interest and other income, net	(3)	—	—
Forward interest rate contracts	Interest expense, net	(1)	(1)	(1)
Total		$ (112)	$46	$ (8)

No portions of our cash flow hedge contracts are excluded from the assessment of hedge effectiveness, and the ineffective portions of these hedging instruments were approximately $1 million of gain for the year ended December 31, 2011, and approximately $1 million of loss for both the years ended December 31, 2010 and 2009. As of December 31, 2011, the amounts expected to be reclassified from AOCI into earnings over the next 12 months are approximately $75 million of net gains on foreign currency and cross currency swap contracts and approximately $1 million of losses on forward interest rate contracts.

Fair value hedges

To achieve a desired mix of fixed and floating interest rates on our long-term debt, we have entered into interest rate swap contracts, which qualify and have been designated as fair value hedges. The terms of these interest rate swap contracts correspond to the related hedged debt instruments and effectively convert a fixed interest rate coupon to a floating LIBOR-based coupon over the lives of the respective notes. The rates on these swaps range from LIBOR plus 0.3% to LIBOR plus 2.6%. As of December 31, 2011, 2010 and 2009, we had interest rate swap contracts with aggregate notional amounts of $3.6 billion, $3.6 billion and $1.5 billion,

respectively. The interest rate swap contracts as of December 31, 2011 and 2010, were for our 4.85% 2014 Notes, 5.85% 2017 Notes, 6.15% 2018 Notes and 5.70% 2019 Notes, and, as of December 31, 2009, for our 4.85% 2014 Notes and 6.15% 2018 Notes. For derivative instruments that are designated and qualify as fair value hedges, the unrealized gain or loss on the derivative resulting from the change in fair value during the period as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk is recognized in current earnings. For the years ended December 31, 2011 and 2010, we included unrealized losses on the hedged debt of $182 million and $105 million, respectively, in the same line item, Interest expense, net, in the Consolidated Statements of Income, as the offsetting unrealized gains of $182 million and $105 million, respectively, on the related interest rate swap contracts. For the year ended December 31, 2009, we included the unrealized gain on the hedged debt of $116 million in the same line item, Interest expense, net, in the Consolidated Statement of Income, as the offsetting unrealized loss of $116 million on the related interest rate swap contracts.

Derivatives not designated as hedges

We enter into foreign currency forward contracts that are not designated as hedging transactions to reduce our exposure to foreign currency fluctuations of certain assets and liabilities denominated in foreign currencies. These exposures are hedged on a month-to-month basis. As of December 31, 2011, 2010 and 2009, the total notional amounts of these foreign currency forward contracts, primarily euro-based, were $389 million, $670 million and $414 million, respectively.

The location in the Consolidated Statements of Income and the amount of gain/(loss) recognized in earnings for the derivative instruments not designated as hedging instruments was as follows (in millions):

		Years ended December 31,		
Derivatives not designated as hedging instruments	**Statements of Income location**	**2011**	**2010**	**2009**
Foreign currency contracts	Interest and other income, net	$ (1)	$ 32	$ (24)

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The fair values of both derivatives designated as hedging instruments and derivatives not designated as hedging instruments included in the Consolidated Balance Sheets were as follows (in millions):

	Derivative assets		Derivative liabilities	
December 31, 2011	**Balance Sheet location**	**Fair value**	**Balance Sheet location**	**Fair value**
Derivatives designated as hedging instruments:				
Interest rate swap contracts	Other current assets/ Other noncurrent assets	$ 377	Accrued liabilities/ Other noncurrent liabilities	$ —
Cross currency swap contracts	Other current assets/ Other noncurrent assets	—	Accrued liabilities/ Other noncurrent liabilities	26
Foreign currency contracts	Other current assets/ Other noncurrent assets	172	Accrued liabilities/ Other noncurrent liabilities	48
Total derivatives designated as hedging instruments		549		74
Derivatives not designated as hedging instruments:				
Foreign currency contracts	Other current assets	—	Accrued liabilities	—
Total derivatives not designated as hedging instruments		—		—
Total derivatives		$ 549		$ 74

	Derivative assets		Derivative liabilities	
December 31, 2010	**Balance Sheet location**	**Fair value**	**Balance Sheet location**	**Fair value**
Derivatives designated as hedging instruments:				
Interest rate swap contracts	Other current assets/ Other noncurrent assets	$ 195	Accrued liabilities/ Other noncurrent liabilities	$ —
Foreign currency contracts	Other current assets/ Other noncurrent assets	154	Accrued liabilities/ Other noncurrent liabilities	103
Total derivatives designated as hedging instruments		349		103
Derivatives not designated as hedging instruments:				
Foreign currency contracts	Other current assets	—	Accrued liabilities	—
Total derivatives not designated as hedging instruments		—		—
Total derivatives		$ 349		$ 103

Our derivative contracts that were in liability positions as of December 31, 2011, contain certain credit risk related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity's creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts.

The cash flow effects of our derivatives contracts for the three years ended December 31, 2011, are included within Net cash provided by operating activities in the Consolidated Statements of Cash Flows.

18. Contingencies and commitments

Contingencies

In the ordinary course of business, we are involved in various legal proceedings and other matters, including those discussed in this Note, that are complex in nature and have outcomes that are difficult to predict.

We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. As more fully described below, in the three months ended September 30, 2011, excluding fees paid to our external counsel, the Company recorded a $780 million legal settlement charge associated with the proposed settlement of the allegations arising out of the previously disclosed federal civil and criminal investigations pending in the U.S. Attorney's Offices for the Eastern District of New York and the Western District of Washington. The charge is included in Other operating expenses in the Consolidated Statements of Income.

Our legal proceedings range from cases brought by a single plaintiff to a class action with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims (including but not limited to patent infringement, marketing, pricing and trade practices and securities law), some of which present novel factual allegations and/or unique legal theories. Except for the proposed settlement of the litigation referenced above, in each of the matters described in this filing, plaintiffs seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process (which in complex proceedings of the sort faced by us often extend for several years). As a result, some pending matters have not yet progressed sufficiently through discovery and/or development of important factual information and legal issues to enable us to estimate a range of possible loss, if any. While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending, including further adverse determinations associated with the pending investigations described above, could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

Certain of our legal proceedings and other matters are discussed below:

Roche U.S. International Trade Commission Complaint

On April 11, 2006, Amgen filed a complaint with the U.S. International Trade Commission (ITC) in Washington D.C. requesting that the ITC institute an investigation of the importation of pegylated erythropoietin

(alternatively referred to as peg-EPO or MIRCERA®) into the United States as Amgen believes that importation of peg-EPO is unlawful because peg-EPO, and the method of its manufacture, are covered by Amgen's EPO patents. Amgen asked the ITC to issue a permanent exclusion order that would prohibit importation of peg-EPO into the United States. The ITC instituted an investigation naming Roche Holding Ltd., F. Hoffmann-La Roche Ltd., Roche Diagnostics GmbH, and Hoffmann-La Roche Inc. (collectively, Roche) as respondents in the investigation. On July 7, 2006, the Administrative Law Judge (ALJ) at the ITC issued a summary determination that Roche's importation and use of peg-EPO in the United States had been subject to a clinical trial exemption to patent infringement under 35 U.S.C. 271(e)(1). On August 31, 2006, the ITC adopted the ALJ's summary determination terminating the investigation.

On October 11, 2006, Amgen filed a petition for review of the ITC's decision with the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). On March 19, 2008, the Federal Circuit Court reversed the ITC's dismissal of the investigation on jurisdictional grounds. In response to Roche's request for rehearing, on April 30, 2009, the Federal Circuit Court vacated the ITC's dismissal of the ITC investigation for non-infringement. The Federal Circuit Court remanded the case back to the ITC for further proceedings to determine if patent infringement had occurred and to provide a remedy, if appropriate.

Amgen had previously filed a separate lawsuit in November 2006 in the U.S. District Court for the District of Massachusetts (the Massachusetts District Court) against F. Hoffmann-La Roche Ltd., Roche Diagnostics GmbH and Hoffmann-La Roche Inc. (collectively, Roche Defendants) seeking a declaration by the Massachusetts District Court that the importation, use, sale or offer to sell peg-EPO infringes Amgen's EPO patents, specifically U.S. Patent Nos. 5,547,933; 5,621,080; 5,955,422; 5,756,349; 5,618,698 and 5,441,868. After a jury trial and an appeal, on December 22, 2009, the Massachusetts District Court entered final judgment and a permanent injunction against the Roche Defendants prohibiting the Roche Defendants from infringing the five Amgen patents-in-suit. The judgment was accompanied by the Roche Defendants' admission that the patents involved in the lawsuit are valid, enforceable and infringed by the Roche Defendant's peg-EPO product, and by Amgen allowing Roche to begin selling peg-EPO in the United States in mid-2014 under terms of a limited license agreement. The settlement terms did not include any financial payments between the parties. Thereafter, in the ITC matter Amgen filed a motion for summary determination of violation with a request for entry of a limited exclusion order. The Roche respondents notified the ITC that they were not opposing Amgen's motion. On March 11, 2011, the ITC issued an order to show cause why the investigation should not be terminated without a determination of violation or by way of consent order in view of the resolution of the Massachusetts District Court proceedings. In response, on April 21, 2011, the parties filed a joint response requesting termination of the investigation on the basis of a proposed Consent Order and Stipulation. On October 17, 2011, the ITC terminated the investigation without entry of a consent order on the basis of the December 2009 settlement between the parties and resolution of the parallel litigation in the Massachusetts District Court.

Average Wholesale Price (AWP) Litigation

Amgen and its wholly owned subsidiary Immunex Inc. are named as defendants, either separately or together, in numerous civil actions broadly alleging that they, together with many other pharmaceutical manufacturers, reported prices for certain products in a manner that allegedly inflated reimbursement under Medicare and/or Medicaid programs and commercial insurance plans, including co-payments paid to providers who prescribe and administer the products. The complaints generally assert varying claims under the Medicare and Medicaid statutes, as well as state law claims for deceptive trade practices, common law fraud and various related state law claims. The complaints seek an undetermined amount of damages, as well as other relief, including declaratory and injunctive relief.

The AWP litigation was commenced against Amgen and Immunex on December 19, 2001 with the filing of Citizens for Consumer Justice, et al. v. Abbott Laboratories, Inc., et al. Additional cases have been filed since

that time. Most of these actions, as discussed below, have been consolidated, or are in the process of being consolidated, in a federal Multi-District Litigation proceeding (the MDL Proceeding), captioned In Re: Pharmaceutical Industry Average Wholesale Price Litigation MDL No. 1456 and pending in the Massachusetts District Court.

The following cases have been consolidated into the MDL Proceeding, and include cases brought by consumer classes and certain state and local governmental entities:

Citizens for Consumer Justice, et al., v. Abbott Laboratories, Inc., et al.; Teamsters Health & Welfare Fund of Philadelphia, et al., v. Abbott Laboratories, Inc., et al.; Action Alliance of Senior Citizens of Greater Philadelphia v. Immunex Corporation; Constance Thompson, et al., v. Abbott Laboratories, Inc., et al.; Ronald Turner, et al., v. Abbott Laboratories, Inc., et al.; Congress of California Seniors v. Abbott Laboratories, Inc., et al.

In the MDL Proceeding, the Massachusetts District Court has set various deadlines relating to motions to dismiss the complaints, discovery, class certification, summary judgment and other pre-trial issues. For the private class action cases, the Massachusetts District Court has divided the defendant companies into a Track I group and a Track II group. Both Amgen and Immunex are in the Track II group. On March 2, 2006, plaintiffs filed a fourth amended master consolidated complaint, which did not include their motion for class certification as to the Track II group. On September 12, 2006, a hearing before the Massachusetts District Court was held on plaintiffs' motion for class certification as to the Track II group defendants, which include Amgen and Immunex. On March 7, 2008, the Track II defendants reached a tentative class settlement of the MDL Proceeding, which was subsequently amended on April 3, 2008. The tentative Track II settlement relates to claims against numerous defendants, including Abbott Laboratories, Inc., Amgen Inc., Aventis Pharmaceuticals Inc., Hoechst Marion Roussel, Inc., Baxter Healthcare Corporation, Baxter International Inc., Bayer Corporation, Dey, Inc., Fujisawa Healthcare, Inc., Fujisawa USA, Inc., Immunex Corporation, Pharmacia Corporation, Pharmacia & Upjohn LLC (f/k/a Pharmacia & Upjohn, Inc.), Sicor, Inc., Gensia, Inc., Gensia Sicor Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and ZLB Behring, L.L.C. Following repeated hearings on the sufficiency of the notice given by the plaintiffs, the Massachusetts District Court approved the Track II settlement on December 8, 2011, and dismissed with prejudice the fourth amended master consolidated complaint effective January 31, 2012.

The following AWP litigation case is not part of the MDL Proceeding:

State of Louisiana v. Abbott Laboratories, Inc., et al. The State of Louisiana filed a complaint against Amgen and several other pharmaceutical manufacturers, on November 3, 2010, in the Parish of East Baton Rouge, 19th Judicial District (the Louisiana Court). Amgen was served the complaint on November 9, 2010. The complaint alleges that the manufacturers misrepresented product pricing information reported to the state by falsely inflating those prices. On May 12, 2011, Amgen and the other defendants filed joint exceptions seeking to dismiss the complaint. On October 27, 2011 the Louisiana Court denied the defendants' joint exceptions.

Federal Securities Litigation — In re Amgen Inc. Securities Litigation

The six federal class action stockholder complaints filed against Amgen Inc., Kevin W. Sharer, Richard D. Nanula, Dennis M. Fenton, Roger M. Perlmutter, Brian M. McNamee, George J. Morrow, Edward V. Fritzky, Gilbert S. Omenn and Franklin P. Johnson, Jr., (the Federal Defendants) in the U.S. District Court for the Central District of California (the California Central District Court) on April 17, 2007 (Kairalla v. Amgen Inc., et al.), May 1, 2007 (Mendall v. Amgen Inc., et al., & Jaffe v. Amgen Inc., et al.), May 11, 2007 (Eldon v. Amgen Inc.,

et al.), May 21, 2007 (Rosenfield v. Amgen Inc., et al.) and June 18, 2007 (Public Employees' Retirement Association of Colorado v. Amgen Inc., et al.) were consolidated by the California Central District Court into one action captioned *In re Amgen Inc. Securities Litigation*. The consolidated complaint was filed with the California Central District Court on October 2, 2007. The consolidated complaint alleges that Amgen and these officers and directors made false statements that resulted in: (i) deceiving the investing public regarding Amgen's prospects and business; (ii) artificially inflating the prices of Amgen's publicly traded securities and (iii) causing plaintiff and other members of the class to purchase Amgen publicly traded securities at inflated prices. The complaint also makes off-label marketing allegations that, throughout the class period, the Federal Defendants improperly marketed Aranesp® and EPOGEN® for off-label uses while aware that there were alleged safety signals with these products. The plaintiffs seek class certification, compensatory damages, legal fees and other relief deemed proper. The Federal Defendants filed a motion to dismiss on November 8, 2007. On February 4, 2008, the California Central District Court granted in part, and denied in part, the Federal Defendants' motion to dismiss the consolidated amended complaint. Specifically, the California Central District Court granted the Federal Defendants' motion to dismiss as to individual defendants Fritzky, Omenn, Johnson, Fenton and McNamee, but denied the Federal Defendants' motion to dismiss as to individual defendants Sharer, Nanula, Perlmutter and Morrow.

A class certification hearing before the California Central District Court, was held on July 17, 2009 and on August 12, 2009, the California Central District Court granted plaintiffs' motion for class certification. On August 28, 2009, Amgen filed a petition for permission to appeal with the U.S. Court of Appeals for the Ninth Circuit (the Ninth Circuit Court) under Rule 23(f), regarding the Order on Class Certification and the Ninth Circuit Court granted Amgen's permission to appeal on December 11, 2009. On February 2, 2010, the California Central District Court granted Amgen's motion to stay the underlying action pending the outcome of the Ninth Circuit Court 23(f) appeal. On October 14, 2011, the appeal under Rule 23(f) was argued before the Ninth Circuit Court and on December 28, 2011, the Ninth Circuit Court denied the appeal. On January 3, 2012, Amgen filed a motion to stay the mandate and the Ninth Circuit Court granted the motion and stayed the mandate on January 12, 2012. The staying of the mandate effectively stays the underlying action in the California Central District Court for ninety days pending the filing of a writ of certiorari with the U.S. Supreme Court. Amgen has until March 27, 2012 to file a petition for certiorari with the U.S. Supreme Court.

State Derivative Litigation

Larson v. Sharer, et al.

The three state stockholder derivative complaints filed against Amgen Inc., Kevin W. Sharer, George J. Morrow, Dennis M. Fenton, Brian M. McNamee, Roger M. Perlmutter, David Baltimore, Gilbert S. Omenn, Judith C. Pelham, Frederick W. Gluck, Jerry D. Choate, J. Paul Reason, Frank J. Biondi, Jr., Leonard D. Schaeffer, Frank C. Herringer, Richard D. Nanula, Willard H. Dere, Edward V. Fritzky, Franklin P. Johnson, Jr. and Donald B. Rice as defendants (the State Defendants) on May 1, 2007 (*Larson v. Sharer, et al.*, & *Anderson v. Sharer, et al.*), and August 13, 2007 (*Weil v. Sharer, et al.*) in the Superior Court of the State of California, Ventura County (the Superior Court) were consolidated by the Superior Court under one action captioned *Larson v. Sharer, et al*. The consolidated complaint was filed on July 5, 2007. The complaint alleges that the State Defendants breached their fiduciary duties, wasted corporate assets, were unjustly enriched and violated the California Corporations Code. Plaintiffs allege that the State Defendants failed to disclose and/or misrepresented results of Aranesp® clinical studies, marketed both Aranesp® and EPOGEN® for off-label uses and that these actions or inactions caused stockholders to suffer damages. The complaints also allege insider trading by the State Defendants. The plaintiffs seek treble damages based on various causes of action, reformed corporate governance, equitable and/or injunctive relief, restitution, disgorgement of profits, benefits and other compensation, and legal costs.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

An amended consolidated complaint was filed on March 13, 2008, adding Anthony Gringeri as a State Defendant and removing the causes of action for insider selling and misappropriation of information, violation of California Corporations Code Section 25402 and violation of California Corporations Code Section 25403. On July 14, 2008, the Superior Court dismissed without prejudice the consolidated state derivative class action. The judge also ordered a stay of any re-filing of an amended complaint until the federal court has determined whether any securities fraud occurred.

Birch v. Sharer, et al.

On January 23, 2009, a stockholder derivative lawsuit titled *Birch v. Sharer, et al*. was filed in the Superior Court of the State of California, Los Angeles County (the Los Angeles Superior Court) naming Amgen Inc., Kevin W. Sharer, David Baltimore, Frank J. Biondi, Jr., Jerry D. Choate, Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer, Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, Leonard D. Schaeffer and Tom Zindrick as defendants. The complaint alleges derivative claims for breach of fiduciary duty based on a purported failure to implement adequate internal controls and to oversee the Company's operations, which plaintiff claims resulted in numerous lawsuits and investigations over a number of years. Plaintiff seeks damages on behalf of Amgen, including costs and expenses, allegedly incurred, among other things, in connection with wrongful termination lawsuits and potential violations of the Health Insurance Portability and Accountability Act. On February 25, 2009, the case was reassigned to a judge in the Complex Department of the Los Angeles Superior Court. Amgen and the individual defendants filed motions to dismiss on June 23, 2009.

Oral argument on Amgen and the individual defendants' motions to dismiss were heard on September 25, 2009 before the Los Angeles Superior Court and the court granted the motions to dismiss but allowed the plaintiff an opportunity to amend her complaint by October 21, 2009. Plaintiff filed a request for dismissal without prejudice with the court on October 23, 2009. On October 29, 2009, Amgen received from plaintiff a stockholder demand on the Board of Directors to take action to remedy breaches of fiduciary duties by the directors and certain executive officers of the Company. Ms. Birch alleged that the directors and certain executive officers violated their core fiduciary principles, causing Amgen to suffer damages. She demanded that the Board of Directors take action against each of the officers and directors to recover damages and to correct deficiencies in the Company's internal controls that allowed the misconduct to occur. The Board of Directors completed its investigation and determined in its business judgment that it was not in the best interests of the Company to pursue the claims made in the demand against any of the individuals mentioned in the demand. Therefore, the Board voted to reject the demand and communicated this to Ms. Birch on May 19, 2010.

On February 8, 2010, plaintiff filed another stockholder demand lawsuit in the Los Angeles Superior Court against the same defendants in the original lawsuit but also added Board of Director members François de Carbonnel and Rebecca Henderson. The allegations in the new complaint are nearly identical to those in the previously filed complaint. The case filed on February 8, 2010 by plaintiff Birch was assigned to the Complex Division of the Los Angeles Superior Court. On June 30, 2010, Amgen filed its demurrer to plaintiff's complaint with the Complex Division of the Los Angeles Superior Court. On September 29, 2010, the Complex Division of the Los Angeles Superior Court denied Amgen's and the individual defendants' demurrers finding that the plaintiff had adequately pled wrongful refusal. Amgen and the individual defendants filed answers on October 29, 2010. On December 9, 2010, the Complex Division of the Los Angeles Superior Court stayed the underlying action and Amgen and the individual defendants filed a motion for judgment on the pleadings/motion for summary judgment. The motion for the judgment on the pleadings was heard on January 31, 2011 and the Complex Division of the Los Angeles Superior Court dismissed the entire lawsuit with prejudice against both Amgen and the individual defendants without leave to amend. On February 24, 2011, plaintiff filed a notice of appeal with the California State Appellate Court. The briefing schedule for the appeal was issued by the California State Appellate Court and plaintiff's opening brief was filed September 7, 2011. The opposition brief from Amgen and the individual defendants was filed on November 21, 2011. No date has been set for oral argument.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Federal Derivative Litigation

On May 7, 2007, the stockholder derivative lawsuit of *Durgin v. Sharer, et al.*, was filed in the California Central District Court and named Amgen Inc., Kevin W. Sharer, George J. Morrow, Dennis M. Fenton, Brian M. McNamee, Roger M. Perlmutter, David Baltimore, Gilbert S. Omenn, Judith C. Pelham, Frederick W. Gluck, Jerry D. Choate, J. Paul Reason, Frank J. Biondi, Jr., Leonard D. Schaeffer, Frank C. Herringer, Richard D. Nanula, Edward V. Fritzky and Franklin P. Johnson, Jr. as defendants. The complaint alleges the same claims and requests the same relief as in the three state stockholder derivative complaints now consolidated as *Larson v. Sharer, et al*. The case has been stayed for all purposes until thirty days after a final ruling on the motion to dismiss by the California Central District Court in the *In re Amgen Inc. Securities Litigation* action.

On September 21, 2007, the stockholder derivative lawsuit of *Rosenblum v. Sharer, et al.*, was filed in the California Central District Court. This lawsuit was brought by the stockholder who previously made a demand on the Amgen Board on May 14, 2007. The complaint alleges that the defendants breached their fiduciary duties, wasted corporate assets and were unjustly enriched. Plaintiffs allege that the defendants failed to disclose and/or misrepresented results of Aranesp® clinical studies, marketed both Aranesp® and EPOGEN® for off-label uses and that these actions or inactions as well as the Amgen market strategy caused damage to the Company resulting in several inquiries, investigations and lawsuits that are costly to defend. The complaint also alleges insider trading by the defendants. The plaintiffs seek treble damages based on various causes of action, reformed corporate governance, equitable and/or injunctive relief, restitution, disgorgement of profits, benefits and other compensation, and legal costs. The case was stayed for all purposes until thirty days after a final ruling on the motion to dismiss by the California Central District Court in the *In re Amgen Inc. Securities Litigation* action.

Thereafter, on May 1, 2008, plaintiff in *Rosenblum v. Sharer, et al.*, filed an amended complaint which removed Dennis Fenton as a defendant and also eliminated the claims for insider selling by defendants. On July 28, 2008, the California Central District Court heard Amgen and the defendants' motion to dismiss and motion to stay. On July 30, 2008, the California Central District Court granted Amgen and the defendants' motion to dismiss without prejudice and also granted a stay of the case pending resolution of the *In re Amgen Inc. Securities Litigation* action.

ERISA Litigation

On August 20, 2007, the ERISA class action lawsuit of *Harris v. Amgen Inc., et al.*, was filed in the California Central District Court and named Amgen Inc., Kevin W. Sharer, Frank J. Biondi, Jr., Jerry Choate, Frank C. Herringer, Gilbert S. Omenn, David Baltimore, Judith C. Pelham, Frederick W. Gluck, Leonard D. Schaeffer, Jacqueline Allred, Raul Cermeno, Jackie Crouse, Lori Johnston, Michael Kelly and Charles Bell as defendants. Plaintiffs claim that Amgen and the individual defendants breached their fiduciary duties by failing to inform current and former employees who participated in the Amgen Retirement and Savings Plan and the Retirement and Savings Plan for Amgen Manufacturing Limited of the alleged off-label promotion of both Aranesp® and EPOGEN® while a number of studies allegedly demonstrated safety concerns in patients using ESAs. On February 4, 2008, the California Central District Court dismissed the complaint with prejudice as to plaintiff Harris, who had filed claims against Amgen Inc. The claims alleged by the second plaintiff, Ramos, were also dismissed but the court granted the plaintiff leave to amend his complaint. On February 1, 2008, the plaintiffs appealed the decision by the California Central District Court to dismiss the claims of both plaintiffs Harris and Ramos to the Ninth Circuit Court, which remains pending before the Ninth Circuit Court. On May 19, 2008, plaintiff Ramos in the *Harris v. Amgen Inc., et al.*, action filed another lawsuit captioned *Ramos v. Amgen Inc., et al.*, in the California Central District Court. The lawsuit is another ERISA class action. The *Ramos v. Amgen Inc., et al*., matter names the same defendants in the *Harris v. Amgen Inc., et al.*, matter plus four new defendants: Amgen Manufacturing Limited, Richard Nanula, Dennis Fenton and the Fiduciary Committee.

Pursuant to the parties' stipulation, the Ramos matter has been stayed pending the outcome of the Harris matter appeal. Oral argument before the Ninth Circuit Court on the plaintiffs' appeal of the California Central District Court's dismissal of the plaintiffs' claims occurred on May 8, 2009. On July 14, 2009, the Ninth Circuit Court reversed the California Central District Court's decision and remanded the case back to the district court. In the meantime, a third ERISA class action was filed by Don Hanks on June 2, 2009 in the California Central District Court alleging the same ERISA violations as in the Harris and Ramos lawsuits.

On October 13, 2009, the California Central District Court granted plaintiffs Harris' and Ramos' motion to be appointed interim co-lead counsel. Plaintiffs filed an amended complaint on November 11, 2009 and added two additional plaintiffs, Jorge Torres and Albert Cappa. Amgen filed a motion to dismiss the amended/consolidated complaint, and on March 2, 2010, the California Central District Court dismissed the entire lawsuit without prejudice. Plaintiffs filed an amended complaint on March 23, 2010. Amgen then filed another motion to dismiss on April 20, 2010. On June 16, 2010, the California Central District Court entered an order dismissing the entire lawsuit with prejudice. On June 24, 2010, the plaintiffs filed a notice of appeal with the Ninth Circuit Court. Petitioner's opening brief was served on December 20, 2010 and Amgen's answering brief was filed on February 2, 2011. Oral argument occurred on February 17, 2012.

Government Investigations and Qui Tam Actions

On May 10, 2007, Amgen received a subpoena from the Attorney General of the State of New York seeking documents related to Amgen's promotional activities, sales and marketing activities, medical education, clinical studies, pricing and contracting, license and distribution agreements and corporate communications. Amgen fully cooperated in responding to the subpoena.

Beginning in late 2007, Amgen received a number of subpoenas from the U.S. Attorney's Offices for the Eastern District of New York and the Western District of Washington, pursuant to the Health Insurance Portability and Accountability Act (18 U.S.C. 3486), for broad production of documents relating to its products and clinical trials. Amgen fully cooperated with the government's document requests. Over the next several years, numerous current and former Amgen employees received civil and grand jury subpoenas to provide testimony on a wide variety of subjects. We refer herein to these investigations being conducted by the U.S. Attorney's Offices for the Eastern District of New York and the Western District of Washington as the Federal Investigations.

On January 14, 2008, Amgen received a subpoena from the New Jersey Attorney General's Office for production of documents relating to one of its products. Amgen completed its response per the terms of the subpoena.

A U.S. government filing in the Massachusetts District Court concerning the partially unsealed complaint filed pursuant to the Qui Tam provisions of the Federal Civil False Claims Act and on behalf of 17 named states and the District of Columbia under their respective State False Claims Acts (the Massachusetts Qui Tam Action) became public on or about May 7, 2009. The filing stated that the relator in the Massachusetts Qui Tam Action is a former Amgen employee. Further, the filing represented that, in addition to the Massachusetts Qui Tam Action, there were nine other actions under the False Claim Act pending under seal against Amgen, including eight pending in the U.S. District Court for the Eastern District of New York and one pending in the U.S. District Court for the Western District of Washington (together, the Qui Tam Actions). In the filing made public on May 7, 2009, the U.S. government represented that these ten Qui Tam Actions alleged that Amgen engaged in a wide variety of illegal marketing practices with respect to various Amgen products and that these were joint civil and criminal investigations being conducted by a wide variety and large number of federal and state agencies.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

On September 1, 2009, the U.S. government filed a notice of non-intervention and 14 states and the District of Columbia filed notices of intervention in the Massachusetts Qui Tam Action. On October 30, 2009, 14 states and the District of Columbia filed an amended complaint in the Massachusetts District Court entitled *The United States of America, States of California, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana, Michigan, Nevada, New Hampshire, New Mexico, New York, Tennessee and Texas and the Commonwealths of Massachusetts and Virginia and the District of Columbia, ex rel Kassie Westmoreland v. Amgen Inc., Integrated Nephrology Network, AmerisourceBergen Specialty Group, ASD Healthcare and AmerisourceBergen Corporation.* The relator, Kassie Westmoreland, also filed a second amended complaint with the Massachusetts District Court on the same day. The complaints alleged violations of the federal Anti-Kickback Statute and violations of state false claims act statutes with regard to Amgen's marketing of overfill in vials of Aranesp® and with regard to Amgen's relationship with the Integrated Nephrology Network (INN), a group purchasing organization. The relator's seconded amended complaint also alleged that Amgen retaliated against and wrongfully terminated Ms. Westmoreland.

On January 20, 2010, the states of Florida and Texas voluntarily dismissed their complaints against Amgen. On February 12, 2010, February 16, 2010 and February 18, 2010, respectively, the states of New Hampshire, Louisiana and Nevada voluntarily dismissed their complaints against Amgen. On February 23, 2010, the state of Delaware voluntarily dismissed its complaint against Amgen. Also, on February 23, 2010, the Massachusetts District Court granted Amgen's motion to stay and sever the relator's employment claims.

On April 23, 2010, the Massachusetts District Court dismissed all of the claims of the relator, on behalf of the federal government and the states of New Mexico and Georgia, and all of the claims of the remaining states, for failure to state valid legal grounds upon which relief could be granted. On May 26, 2010, the Massachusetts District Court granted leave for the relator to file a fourth amended complaint. On May 24, 2010, the states of New York, Massachusetts, Michigan, California, Illinois, and Indiana (the States) filed notices of intent to appeal the Massachusetts District Court's judgment to the U.S. Court of Appeals for the First Circuit (the First Circuit Court).

On September 20, 2010, the Massachusetts District Court entered a written ruling denying Amgen's motions to dismiss the relator's fourth amended complaint. On April 11, 2011, the Massachusetts District Court heard summary judgment arguments on the fourth amended complaint from Amgen, INN and the relator. On July 22, 2011, the First Circuit Court issued a written decision reversing the Massachusetts District Court's dismissal of the claims of the states of California, Illinois, Indiana, Massachusetts, New Mexico, and New York and affirming the dismissal of the claims of Georgia.

In March 2011, the U.S. Attorney's Office of the Western District of Washington informed Amgen that the subject matter of its investigation would be transferred to the U.S. Attorney's Office of the Eastern District of New York.

On October 24, 2011, Amgen announced it had reached an agreement in principle to settle allegations relating to its sales and marketing practices arising out of the Federal Investigations. In connection with the agreement in principle, Amgen recorded a $780 million charge in the three months ended September 30, 2011. This amount represents Amgen's currently estimable loss with respect to these matters. If the ongoing discussions are successfully concluded, Amgen expects that the proposed settlement will resolve the Federal Investigations, the related state Medicaid claims and the claims in *U.S. ex rel. Westmoreland v. Amgen, et al.* and the other nine Qui Tam Actions in a manner that will not result in exclusion from U.S. federally-funded health care programs. In connection with the settlement discussions, the Massachusetts District Court vacated the previously scheduled trial date and administratively closed that case. The relators in the Qui Tam Actions have

the opportunity to join in the proposed settlement or, if they object, to have the settlement evaluated in a federal court fairness hearing to determine whether it is fair, adequate and reasonable under all the circumstances. The proposed settlement remains subject to continuing discussions regarding the components of the agreement and the completion and execution of all required documentation, and until the proposed settlement becomes final, there can be no guarantee that these matters will be resolved by the agreement in principle.

In addition, on September 19, 2011, Amgen filed a petition for certiorari with the U.S. Supreme Court in the *U.S. ex rel. Westmoreland v. Amgen, et al.* matter. The petition sought leave to appeal the First Circuit Court's reinstatement of the claims of the states of California, Illinois, Indiana, Massachusetts, New Mexico and New York, which had been dismissed by the Massachusetts District Court. However, as described above, Amgen expects that these state claims will be resolved if the ongoing settlement discussions are successfully concluded. Accordingly, on December 12, 2011, Amgen withdrew its petition for certiorari and the U.S. Supreme Court subsequently dismissed the petition on December 29, 2011.

As part of the settlement discussions described above, Amgen was made aware that it is a defendant in several other civil qui tam actions. These other qui tam actions are in addition to the Qui Tam Actions described above. One of these other qui tam actions, *U.S. ex rel. May v. Amgen, et al.* was filed by Samuel May on June 6, 2010, in the U.S. District Court for the Northern District of California, and was unsealed in connection with it being dismissed by the Court on January 5, 2012 for failure to prosecute the matter. The remaining other qui tam actions remain under seal in the U.S. federal courts in which they were filed. Included with these other actions (including the *May* action) are allegations that Amgen's promotional, contracting, sales and marketing activities relating to Enbrel® and Aranesp® caused the submission of various false claims under the Federal Civil False Claims Act and various State False Claims Acts. Certain of the allegations in these remaining other actions are not encompassed in the proposed settlement described above, and Amgen intends to cooperate fully with the government in its investigation of these new allegations. Amgen continues to explore with the government whether these remaining matters will be resolved in connection with the proposed settlement discussed above.

U.S. ex rel. Streck v. Allergan, et al.

A complaint filed in the U.S. District Court for the Eastern District of Pennsylvania against Amgen and numerous other pharmaceutical manufacturers, pursuant to the Qui Tam provisions of the Federal Civil False Claims Act and on behalf of 24 named states and the District of Columbia under their respective State False Claims Acts, was unsealed and became public on or about June 6, 2011. The plaintiff, Ronald Streck, alleges that from 2004 to the present, defendants failed to report accurate pricing data to Medicare and Medicaid, including data used to calculate average sales price and average manufacturer's price, thereby causing the federal and state governments to reimburse defendants at inflated rates and causing the manufacturers to underpay Medicaid rebates. This matter, in which the federal government has declined to intervene, is not affected by the proposed settlement described above. On September 7, 2011, plaintiff filed a fourth amended complaint and on December 9, 2011, defendants filed a joint motion to dismiss the plaintiff's complaint.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Commitments

We lease certain facilities and equipment related primarily to administrative, R&D, sales and marketing activities under non-cancelable operating leases that expire through 2032. The following table summarizes the minimum future rental commitments under non-cancelable operating leases as of December 31, 2011 (in millions):

2012	$116
2013	104
2014	85
2015	76
2016	65
Thereafter	328
Total minimum operating lease commitments	$774

Included in the table above are future rental commitments for abandoned leases in the amount of $254 million. Rental expense on operating leases for the years ended December 31, 2011, 2010 and 2009, was $131 million, $115 million and $114 million, respectively.

In addition, we have minimum contractual purchase commitments with third-party manufacturers through 2014 that total $157 million as of December 31, 2011. Amounts purchased under these contractual purchase commitments for the years ended December 31, 2011, 2010 and 2009, were $87 million, $68 million and $207 million, respectively.

19. Segment information

We operate in one business segment — human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Enterprise-wide disclosures about product sales, revenues and long-lived assets by geographic area, and revenues from major customers are presented below.

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Revenues

Revenues were as follows for the years ended December 31, 2011, 2010 and 2009 (in millions):

	2011	2010	2009
Product sales:			
Neulasta® — U.S.	$ 3,006	$ 2,654	$ 2,527
NEUPOGEN® — U.S.	959	932	901
Neulasta® — International	946	904	828
NEUPOGEN® — International	301	354	387
ENBREL — U.S.	3,458	3,304	3,283
ENBREL — Canada	243	230	210
Aranesp® — U.S.	986	1,103	1,251
Aranesp® — International	1,317	1,383	1,401
EPOGEN® — U.S.	2,040	2,524	2,569
Sensipar® — U.S.	518	459	429
Sensipar® (Mimpara®) — International	290	255	222
Vectibix® — U.S.	122	115	97
Vectibix® — International	200	173	136
Nplate® — U.S.	163	129	78
Nplate® — International	134	100	32
Prolia® — U.S.	130	26	—
Prolia® — International	73	7	—
XGEVA® — U.S.	343	8	—
XGEVA® — International	8	—	—
Other — International	58	—	—
Total product sales	15,295	14,660	14,351
Other revenues	287	393	291
Total revenues	$15,582	$15,053	$14,642

Geographic information

Outside the United States, we sell products principally in Europe and Canada. The geographic classification of product sales was based upon the location of the customer. The geographic classification of all other revenues was based upon the domicile of the entity from which the revenues were earned.

Certain geographical information with respect to revenues and long-lived assets (consisting of property, plant and equipment) was as follows (in millions):

	Years ended December 31,		
	2011	2010	2009
Revenues:			
United States	$11,985	$11,636	$11,421
International countries	3,597	3,417	3,221
Total revenues	$15,582	$15,053	$14,642

	December 31, 2011	2010
Long-lived assets:		
United States	$3,144	$3,248
Puerto Rico	1,993	2,079
International countries	283	195
Total long-lived assets	$5,420	$5,522

Major customers

In the United States, we sell primarily to pharmaceutical wholesale distributors. We utilize those wholesale distributors as the principal means of distributing our products to healthcare providers. In Europe, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers, and we limit our credit exposure by setting credit limits and, for certain customers, by requiring letters of credit.

We had product sales to three customers each accounting for more than 10% of total revenues for the years ended December 31, 2011, 2010 and 2009. For 2011, on a combined basis, these customers accounted for 72% and 90% of worldwide gross revenues and U.S. gross product sales, respectively, as noted in the following table. Certain information with respect to these customers for the years ended December 31, 2011, 2010 and 2009, was as follows (dollar amounts in millions):

	2011	2010	2009
AmerisourceBergen Corporation:			
Gross product sales	$7,574	$7,678	$7,179
% of total gross revenues	36%	38%	37%
% of U.S. gross product sales	45%	47%	46%
McKesson Corporation:			
Gross product sales	$4,591	$3,913	$3,694
% of total gross revenues	22%	19%	19%
% of U.S. gross product sales	27%	24%	24%
Cardinal Health, Inc:			
Gross product sales	$3,021	$2,813	$2,841
% of total gross revenues	14%	14%	15%
% of U.S. gross product sales	18%	17%	18%

At December 31, 2011 and 2010, amounts due from these three customers each exceeded 10% of gross trade receivables, and accounted for 60% and 54%, respectively, of net trade receivables on a combined basis. At December 31, 2011 and 2010, 39% and 44%, respectively, of trade receivables, net were due from customers located outside the United States, primarily in Europe. Our total allowance for doubtful accounts as of December 31, 2011 and 2010, was not material.

20. Subsequent event

On January 26, 2012, we announced that we had entered into an agreement to acquire Micromet, Inc. (Micromet), a publicly held biotechnology company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in phase 2 clinical development for acute lymphoblastic leukemia and BiTE antibody technology, which is proprietary to Micromet, which provides an

AMGEN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

innovative platform for future clinical research. Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma and could have applications in other hematologic malignancies. In connection with this acquisition, which will be accounted for as a business combination, we have commenced a tender offer to acquire all of the outstanding shares of Micromet's common stock at a price of $11 per share in cash, which values Micromet at approximately $1.16 billion. Upon its acquisition, Micromet will become a wholly owned subsidiary of Amgen. This acquisition will provide us with an opportunity to further expand our oncology pipeline. Micromet will be included in our consolidated financial statements commencing on the acquisition date. The acquisition, which is subject to customary closing conditions, is expected to close during the three months ended March 31, 2012.

21. Quarterly financial data (unaudited)

	2011 Quarters ended			
(In millions, except per share data)	December 31	September 30[1]	June 30	March 31
Product sales	$ 3,907	$ 3,877	$3,893	$ 3,618
Gross profit from product sales	3,251	3,272	3,291	3,054
Net income	934	454	1,170	1,125
Earnings per share:				
Basic	$ 1.09	$ 0.50	$ 1.26	$ 1.21
Diluted	$ 1.08	$ 0.50	$ 1.25	$ 1.20

	2010 Quarters ended			
(In millions, except per share data)	December 31[2]	September 30[3]	June 30	March 31
Product sales	$ 3,760	$ 3,759	$3,613	$ 3,528
Gross profit from product sales	3,188	3,172	3,060	3,020
Net income	1,022	1,236	1,202	1,167
Earnings per share:				
Basic	$ 1.09	$ 1.29	$ 1.25	$ 1.19
Diluted	$ 1.08	$ 1.28	$ 1.25	$ 1.18

(1) We recorded a $780 million legal settlement charge ($705 million, net of tax) in connection with an agreement in principle to settle allegations relating to our sales and marketing practices.

(2) We recorded $113 million of income tax benefit as the result of resolving certain transfer pricing issues with tax authorities for prior periods and a $118 million ($74 million, net of tax) asset impairment charge associated with a strategic decision to optimize our network of manufacturing facilities and improve cost efficiencies.

(3) We recorded $38 million of income tax benefit as the result of resolving certain transfer pricing issues with tax authorities for prior periods.

See Note 4, Income taxes, and Note 18, Contingencies and commitments, for further discussion of the items described above.

SCHEDULE II

AMGEN INC.

VALUATION ACCOUNTS

Years ended December 31, 2011, 2010 and 2009

(In millions)

Allowance for doubtful accounts	Balance at beginning of period	Additions charged to costs and expenses	Other additions	Deductions	Balance at end of period
Year ended December 31, 2011	$ 42	$ 17	$ —	$ 5	$ 54
Year ended December 31, 2010	$ 32	$ 10	$ —	$ —	$ 42
Year ended December 31, 2009	$ 38	$ (6)	$ —	$ —	$ 32

Exhibit 10.10

SECOND AMENDMENT TO THE
AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN
AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009

The Amgen Inc. Supplemental Retirement Plan (As Amended and Restated Effective January 1, 2009) (the "Plan") is hereby amended, effective October 12, 2011, as follows:

1. Article II is amended to add the following two definitions alphabetically and to renumber the definitions accordingly:

   2.6 Change of Control Plan shall mean the Amgen Inc. Change of Control Severance Plan, as amended and restated, effective as of December 9, 2010 (and any subsequent amendments thereto).

   2.19 Qualifying Termination shall mean your termination of employment within two (2) years following a Change of Control (as defined in the Change of Control Plan) (i) by the Company other than for Cause (as defined in the Change of Control Plan), Disability (as defined in the Change of Control Plan) or as a result of your death, or (ii) by you for Good Reason (as defined in the Change of Control Plan). No termination can qualify as a Qualifying Termination if there is no Change of Control Plan in effect at the time of the termination.

2. Section 4.2 is amended and restated as follows:

   4.2 Credits. For each year you are eligible, the Company will credit your Account with your share of Plan Credits in an amount equal to (i) ten percent (10%), multiplied by (ii) your Compensation for the year that is not recognized under the Retirement Plan either because it is in excess of the Salary Cap, or deferred under the NQDC, or both. In addition, if your employment terminates as a result of a Qualifying Termination, the Company may determine, in its sole discretion, to credit an amount determined under the Change in Control Plan to any Participant's Account. Notwithstanding anything herein (including Article 5) or in the Change of Control Plan to the contrary, any Plan Credits resulting from a Qualifying Termination (and any Earnings thereon) will be paid to you in a lump sum as soon as administratively practicable during the Plan Year immediately following the Plan Year in which your Separation from Service occurs, but in no event more than two and one-half months after the end of the calendar year in which your Separation from Service occurs.

3. Section 4.4 is amended and restated as follows:

4.4 Vesting of Your Account. Your Account will become fully vested upon termination of your employment with the Company (1) on or after (a) your Normal Retirement Date, (b) the date of your Disability, or (c) your death or (2) that is a Qualifying Termination. If your employment with the Company is terminated for any other reason, your Account will be vested in accordance with the following schedule:

Years of Service	Vested Percentage
Less than 3	0%
3 or more	100%

Notwithstanding the foregoing vesting schedule, if a portion of your Compensation for a year consists of amounts that were deferred under the NQDC, then a portion of that year's Plan Credits in an amount equal to (i) 10%, multiplied by (ii) the amount of Compensation deferred under the NQDC that would have been taken into account under the Retirement Plan if it had not been deferred, shall be immediately vested.

Any portion of your Account that is not vested on your termination of employment will be permanently forfeited. All Accounts will be subject to the creditors of the Company in the event of the insolvency of the Company.

4. Section 5.1 is amended to add the following sentence to the end thereof to read as follows:

Notwithstanding anything in this Section 5.1 or the balance of Article 5 to the contrary, the time and form of payment of any Plan Credits resulting from a Qualifying Termination (and any Earnings thereon), which will be treated as a right to receive a separate and distinct payment, shall be paid to you pursuant to and be governed by Section 4.2.

5. The list of Participating and Subsidiaries and Affiliates of Amgen Inc. in Appendix A is amended and restated to read as follows:

1. Amgen USA Inc. – January 1, 2002
2. BioVex, Inc. – April 11, 2011
3. Immunex Corporation – January 1, 2003
4. Immunex Manufacturing Corporation – January 1, 2003
5. Immunex Rhode Island Corporation – January 1, 2003
6. Amgen Worldwide Services, Inc. – January 1, 2004
7. Amgen SF, LLC – January 1, 2005

To record this Second Amendment to the Plan as set forth herein, the Company has caused its authorized officer to execute this document this 13th day of October, 2011.

AMGEN INC.

By: /s/ Brian McNamee
Brian McNamee
Senior Vice President, Human Resources

Exhibit 10.11

THIRD AMENDMENT TO THE
AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN
AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009

The Amgen Inc. Supplemental Retirement Plan (As Amended and Restated Effective January 1, 2009) (the "Plan") is hereby amended, effective January 1, 2012, as follows:

1. Section 1.1 "Purpose" will be amended and restated as follows:

   The purpose of this Plan is to provide benefits to employees of the Company and certain of its affiliates and subsidiaries whose Matching Contributions and Nonelective Contributions are limited under the Retirement Plan or the AML Plan (each as defined below), whether because of statutory limitations or because of employee deferrals to the Amgen Nonqualified Deferred Compensation Plan (the "NQDC"), or both. The Company intends that the Plan will provide benefits to a select group of management or highly compensated employees. The Plan is intended to be an unfunded "top hat" plan meeting the requirements of Sections 201(2), 301(a)(3), 401(a)(1) and 4021(b)(6) of ERISA. The Plan is not intended to be a plan described in Section 401(a) of the Code and/or Section 1081.01(a) or the Puerto Rico Code.

2. The first two sentences of "Article II DEFINITIONS" will be amended and restated as follows:

   For the purposes of this Plan, the following terms, when capitalized, have the following meanings. Any capitalized term in this Plan that is not defined in this Article II has the meaning given such term in the Retirement Plan (or the AML Plan with respect to Puerto Rico Participants).

3. A new Section 2.2A that reads as follows is added:

   AML Plan means the Savings Plan for Amgen Manufacturing, Limited.

4. Section 2.7 is amended and restated as follows:

   Code means the Internal Revenue Code of 1986, as amended from time to time, and any applicable IRS Regulations promulgated thereunder and any successor thereto. References to any section of the Code include reference to any comparable or succeeding provisions or regulations that amends, supplements or replaces the section.

5. Section 2.10 is amended and restated as follows:

   Compensation has the same meaning as the term "Deferral Compensation" has under the Retirement Plan (or with respect to Puerto Rico Participants, as the term "Compensation" has under the AML Plan), except that, for purposes of this Plan, Compensation is not limited by the Salary Cap and includes amounts that are deferred into the NQDC.

6. A new Section 2.11 that read as follows is added:

ERISA means the Employee Retirement Income Security Act of 1974, as amended from time to time.

7. Section 2.15 is amended and restated as follows:

Section 2.15 Reserved

8. A new Section 2.17A that reads as follows is added:

Puerto Rico Code means The Internal Revenue Code for a New Puerto Rico, as amended from time to time, and any applicable regulation thereunder and any successor thereto. Reference to any section or subsection of the Internal Revenue Code for a New Puerto Rico includes reference to any comparable or succeeding provisions that amends, supplements or replaces that section.

9. A new Section 2.17B that reads as follows is added:

Puerto Rico Participant means each eligible employee who effective on or after January 1, 2012, is an active participant in the AML Plan.

10. Section 2.19 is amended and restated as follows:

Qualifying Termination shall mean your termination of employment within two (2) years following a Change of Control (as defined in the Change of Control Plan) (i) by the Company other than for Cause (as defined in the Change of Control Plan), Disability (as defined in the Change of Control Plan) or as a result of your death, or (ii) by you for Good Reason (as defined in the Change of Control Plan). Your termination of employment will not qualify as a Qualifying Termination if you are not covered by the Change of Control Plan at the time of your termination or if there is no Change of Control Plan in effect at the time of your termination.

11. Section 2.21 is amended and restated as follows:

Salary Cap means the highest level of compensation that can be considered for the purpose of calculating benefits under Section 401(a)(17) of the Code (or Puerto Rico Code Section 1081.01(a)(12) in the case of Puerto Rico Participants).

12. Section 4.2 is amended and restated as follows:

Credits. For each year you are eligible, the Company will credit your Account with your share of Plan Credits in an amount equal to (i) ten percent (10%) (nine percent (9%) for Puerto Rico Participants), multiplied by (ii) your Compensation for the year that is not recognized under the Retirement Plan (or the AML Plan with respect to Puerto Rico Participants) either because it is in excess of the Salary Cap, or deferred under the

NQDC, or both. In addition, if your employment terminates as a result of a Qualifying Termination, the Company may determine, in its sole discretion, to credit an amount determined under the Change in Control Plan to any Plan participant's Account. Notwithstanding anything herein (including Article 5) or in the Change of Control Plan to the contrary, any Plan Credits resulting from a Qualifying Termination (and any Earnings thereon) will be paid to you in a lump sum as soon as administratively practicable during the Plan Year immediately following the Plan Year in which your Separation from Service occurs, but in no event more than two and one-half months after the end of the calendar year in which your Separation from Service occurs.

13. Section 3.1 is amended to add the following sentence at the end thereof:

Effective January 1, 2012, Puerto Rico Participants are eligible to participate (and only on a prospective basis) to the extent they satisfy on or after such date the eligibility requirements under this Section.

14. Section 5.6 is amended to add the following subsection (d) to the end thereof to read as follows:

(d) If there is an inclusion in income under Section Code 457A with respect to any portion of your Account, such inclusion is treated as a payment for purposes of the short-term deferral rule under §1.409A-1(b)(4). If the short-term deferral rule under §1.409A-1(b)(4) is satisfied, the amount included in income will be distributed to you during the taxable year in which such income inclusion occurs. If the short-term deferral rule under §1.409A-1(b)(4) is not satisfied, the amount included in income will be accelerated to the extent permitted under applicable IRS guidance.

15. Section 7.1 is amended and restated as follows:

7.1 Committee; Duties. This Plan is administered by the Committee, or its duly appointed delegate or delegates, who may or may not be employees of the Company. The Committee (or its delegates) shall have all rights, powers and authority with respect to the administration and operation of the Plan, including, without limitation (i) the sole discretion and authority to make such rules, interpretations and computations and shall take such other actions to administer the Plan as it may deem appropriate, (ii) the sole discretion and authority to interpret the Plan and conclusively to determine all questions arising under the Plan, including questions relating to eligibility and benefits, (iii) the power to maintain and keep adequate records concerning the Plan and its proceedings and acts in such form and detail as the Committee may decide; provided, however, nothing in this Section 7.1 shall be construed to impose any fiduciary duty on the Committee or its delegates under ERISA. The decisions or actions of the Committee with respect to any question arising out of or in connection with the administration, interpretation or application of the Plan and the rules or regulations promulgated hereunder will be final, conclusive and binding upon all persons having any interest in the Plan.

16. Section 7.3 is amended and restated as follows:

Section 7.3 CLAIMS AND REVIEW PROCEDURES

(a) **Applications for Benefits.** Any application for benefits under the Plan shall be submitted to the Company at its principal office. Such application shall be in writing on the prescribed form and shall be signed by the applicant. All claims must be made within 180 days of the event that gives rise to a claim for benefits, including, without limitation, the receipt of a benefit statement that is labeled as a final determination (or labeled in terms substantially similar) of your benefits as of a certain date or states a claim for benefits may be filed within 180 days.

(b) **Denial of Applications.** In the event that any application for benefits is denied in whole or in part, the Company shall notify the applicant in writing or electronically of the right to a review of the denial. Such written notice shall set forth, in a manner calculated to be understood by the applicant, specific reasons for the denial, specific references to the Plan provisions on which the denial was based, a description of any information or material necessary to perfect the application, an explanation of why such material is necessary, an explanation of the Plan's review procedure, and a statement of the applicant's right to bring a civil action under Section 502(a) of ERISA following an adverse benefit determination on review. Such notice shall be given to the applicant within 90 days after the Company receives the application, unless special circumstances require an extension of time for processing the application. In no event shall such an extension exceed a period of 90 days from the end of the initial 90 day period. If such an extension is required, written notice thereof shall be furnished to the applicant before the end of the initial 90 day period. Such notice shall indicate the special circumstances requiring an extension of time and the date by which the Company expects to render a decision. If notice is not given to the applicant within the period prescribed by this Section 7.3(b), the application shall be deemed to have been denied for purposes of Section 7.3(d) upon the expiration of such period.

(c) **Requests for Review.** Any person whose application for benefits is denied in whole or in part (or such person's duly authorized representative) may appeal the denial by submitting to the Company a request for a review of such application within 90 days after receiving written notice of the denial. The Company shall give the applicant or such representative an opportunity to review pertinent documents (except legally privileged materials) in preparing such request for review and to submit issues and comments in writing. The request for review shall be in writing and shall be addressed to the Company's principal office. The request for review shall set forth all of the grounds on which it is based, all facts in support of the request, and any other matters which the applicant deems pertinent. The Company may require the applicant to submit such additional facts, documents or other material as it may deem necessary or appropriate in making its review.

(d) **Decisions on Review.** The Company shall act upon each request for review within 60 days after receipt thereof, unless special circumstances require an extension of time for processing, but in no event shall the decision on review be rendered more than 120 days after the Company receives the request for review. If such an extension is required, written notice thereof shall be furnished to the applicant before the end of the initial 90 day period. The Company shall give prompt, written or electronic notice of its decision to the applicant and to the Company. In the event that the Company confirms the denial of the application for benefits in whole or in part, such notice shall set forth, in a manner calculated to be understood by the applicant, the specific reasons for such denial, specific references to the Plan provisions on which the decision is based, and a statement of the applicant's right to bring a civil action under Section 502(a) of ERISA following an adverse benefit determination on review. To the extent that the Company overrules the denial of the application for benefits, such benefits shall be paid to the applicant.

(e) **Rules and Procedures.** The Company shall adopt such rules and procedures, consistent with ERISA and the Plan, as it deems necessary or appropriate in carrying out its responsibilities under this Section 7.3.

(f) **Exhaustion of Administrative Remedies.** No legal or equitable action for benefits under the Plan shall be brought unless and until the claimant (i) has submitted a written application for benefits in accordance with Section 7.3(a); (ii) has been notified that the application is denied; (iii) has filed a written request for a review of the application in accordance with Section 7.3(c); and (iv) has been notified in writing or electronically that the Company has affirmed the denial of the application. If the claimant has entered into an arbitration agreement with the Company, the provisions of that arbitration agreement will govern following the claimant's compliance with the foregoing provisions of this Section 7.3, and shall be the sole and exclusive remedy following compliance with the foregoing provisions. No arbitration or civil action for benefits under the Plan may be brought more than one year following the notification that the appeal was denied in whole or in part, or the event that gave rise to the claim for benefits (including, without limitation, receipt of a benefit statement that is labeled as a final determination (or labeled in terms substantially similar) of your benefits as of a certain date or states you may file a claim for benefits within 180 days), whichever is later. If no arbitration agreement is applicable, any legal or equitable action for benefits under the Plan must be brought in the United States District Court that includes the city or is nearest to the city in which the participant was last employed by the Company.

17. References in the following Sections of the Plan to "the Retirement Plan" shall be changed to "the Retirement Plan (or the AML Plan with respect to Puerto Rico Participants)":

Sections 3.1, 4.3, 4.4, 6.1, 6.2.

18. The list of Participating Subsidiaries and Affiliates of Amgen Inc. in Appendix A is amended to add the following to the end thereof:

"8. Amgen Manufacturing, Limited – January 1, 2012"

To record this Third Amendment to the Plan as set forth herein, the Company has caused its authorized officer to execute this document this 16th day of December 2011.

AMGEN INC.

By: /s/ Brian McNamee

Title: SVP, Human Resources

Exhibit 10.18

SECOND AMENDMENT TO THE
AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN
AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009

The Amgen Nonqualified Deferred Compensation Plan as Amended and Restated Effective January 1, 2009 (the "Plan") is hereby amended, effective October 12, 2011, as follows:

1. Section 3.1 is amended to add a subsection (d) to read as follows:

   (d) If a Participant received a hardship distribution from the 401(k) Plan or the 1165(e) Plan (as defined in Section 3.3) and, as a result of such hardship distribution, the Participant is prohibited from making deferrals to the 401(k) Plan or 1165(e) Plan, as applicable, for all or any portion of any subsequent Plan Year, such Participant shall be prohibited from making any deferrals to the Plan for such Plan Year, notwithstanding anything in Section 3.2 or 8.6 to the contrary. Any deferral for a subsequent Plan Year to which this subsection (d) does not apply must be made in accordance with Section 3.2.

2. The list of Employers in Appendix A is amended and restated to read as follows:

   Amgen Manufacturing, Limited
   Amgen SF, LLC
   Amgen USA Inc.
   Amgen Worldwide Services, Inc.
   BioVex, Inc.
   Immunex Corporation
   Immunex Manufacturing Corporation
   Immunex Rhode Island Corporation

To record this Second Amendment to the Plan as set forth herein, the Company has caused its authorized officer to execute this document this 13th day of October, 2011.

AMGEN INC.

By: /s/ Brian McNamee
Brian McNamee
Senior Vice President, Human Resources

Exhibit 10.21

October 12, 2011

Mr. Anthony C. Hooper
XXXXXXXXXXXX
XXXXXXXXXXXX

Dear Anthony:

On behalf of Amgen Inc. (Amgen or the Company), I am pleased to offer you the position of Executive Vice President, Global Commercial Operations, Level 11, reporting to Robert A. Bradway. This offer and the compensation listed are subject to your appointment by our Board of Directors (the Board) and the Compensation and Management Development Committee (the Compensation Committee) providing final approval of the compensation listed in this letter.

Your salary will be paid bi-weekly in the amount of $36,538.46, with 26 pay periods in one year, subject to federal and state and other applicable tax deductions and withholdings.

You will be entitled to a sign-on bonus of $1,000,000 less federal and state tax deductions and other applicable withholdings. This amount will be paid 30 days after you report to Amgen for full time employment (your Start Date), subject to your execution of the enclosed "Sign-On Bonus Agreement for New Hire Staff Members," and further subject to your being actively employed by Amgen on the payment date. The sign-on bonus must be repaid by you in full if you voluntarily resign your employment for any reason, or if Amgen terminates your employment with Cause (as defined below), at any time prior to the two year anniversary of your Start Date, as provided in the attached Sign-On Bonus Agreement for New Hire Staff Members.

You will be granted as of the Effective Grant Date (as defined below) time-vested restricted stock units (RSUs) valued at $2,475,000 (based on the average daily closing price of Amgen common stock, $.0001 par value per share (the Common Stock) for the 60 trading days immediately preceding the Effective Grant Date. For these purposes, the Effective Grant Date shall be the day that is two business days after the date of the release of Amgen's 2011 third quarter earnings and is expected to fall on October 27, 2011 provided you are actively employed by Amgen on that date; in the event you are not actively employed by Amgen on that date, the Effective Grant Date shall be a date that is as soon as possible after your Start Date, as determined by an award committee, authorized by the Board in accordance with Amgen's equity awards policy. Upon each applicable vesting date (which shall be on each of March 2, 2012; March 2, 2013; March 2, 2014 and March 2, 2015), you will receive a number of shares of Common Stock equal to the number of RSUs that vest, less any shares that are withheld to satisfy applicable taxes. This grant will vest as to whole shares at a rate of 50% on March 2, 2012, and the remaining 50% in equal one-thirds (1/3rd) on March 2, 2013, on March 2, 2014 and on March 2, 2015, contingent upon your acceptance of the grant in accordance with Amgen's grant acceptance policy and your being actively employed by Amgen through each vesting date (except as otherwise specified in the related RSU grant agreement). No fractional shares may be awarded.

You will be granted on the Effective Grant Date three awards denominated in performance units (PUs) with varying performance goals and performance periods. The first PU award shall be valued at $1,925,000 (the First PU Award), the second PU award shall be valued at $1,925,000 (the Second PU Award) and the third PU award shall be valued at $1,925,000 (the Third PU Award). The number of PUs granted shall be based on these values and the average daily closing price of the Common Stock for the 60 trading days immediately preceding the Effective Grant Date. The PUs shall be awarded pursuant to Amgen's 2009 Performance Award Program, with the specific terms and performance goals as approved by the Compensation Committee (Performance Goals), and shall be contingent upon your acceptance of the grant in accordance with Amgen's grant acceptance policy and your being actively employed by Amgen on the Effective Grant Date. The number of PUs earned shall be determined by the extent to which Amgen achieves the Performance Goals. In general, the Performance Goals shall be based on Amgen's total shareholder return (TSR) compared to the

average TSR of the companies in a comparator group as designated by the Compensation Committee for the specified performance period. The PUs earned shall equal the PUs granted multiplied by the payout percentage (the Payout Percentage), derived from the comparison of Amgen's TSR and the average TSR of the companies in the relevant comparator group for the relevant performance period, and shall be between 0% and 150% of the PUs granted. The performance period of the First PU Award shall commence on the Effective Grant Date and end on December 31, 2012; the performance period of the Second PU Award shall commence on the Effective Grant Date and end on December 31, 2013 and the performance period of the Third PU Award shall commence on the Effective Grant Date and end on December 31, 2014. All PUs shall be deemed earned as of the last day of the performance period (Vesting Date) and, when the Compensation Committee has certified the extent to which the Performance Goals have been achieved and the corresponding number of PUs earned, shall be payable on or prior to the March 15th immediately following the end of the performance period, subject to certain exceptions for delayed payment as provided under Section 409A of the Internal Revenue Code of 1986, as amended, and further subject to your being actively employed with Amgen through each Vesting Date (except as otherwise specified in the related PU grant agreement).

The RSUs, PUs and other equity awards will be subject to the terms and conditions set forth in the applicable grant agreements.

Beginning in 2012, you will be eligible to receive stock options, RSUs and/or PUs as part of Amgen's Long-Term Incentive (LTI) program. Grants under the LTI program are discretionary as approved by the Compensation Committee.

For the 2011 cash bonus, you will be eligible to participate in Amgen's Global Management Incentive Plan (the GMIP) pursuant to the terms of the GMIP. Your annual target incentive opportunity will be 80% of your actual base salary earned at Amgen during 2011. Your actual GMIP bonus may be more or less than this target amount, and may vary based on Company performance and the Compensation Committee's assessment of your individual performance and contribution. For the sake of clarity, your target bonus opportunity is based on your actual salary for 2011 and thus it reflects a pro-ration based on the number of days you work for Amgen in 2011. You must be actively employed through the last regularly scheduled business day of a performance year to be eligible for that year's GMIP bonus.

Further, in 2012, at the earlier of ten business days after (i) the filing of your current employer's 2012 proxy statement or (ii) your provision of satisfactory documentation of the 2011 annual cash bonus calculations your current employer used for its Named Executive Officers (NEOs) and the amount your current employer pays you as 2011 base salary, you shall be paid an amount equal to any difference between the bonus you would have earned for 2011 at your current employer using your annualized 2011 base salary paid by your current employer multiplied by the bonus payout percentage based on actual financial and operational performance against objective targets at your current employer as used for its NEOs, multiplied by an individual performance factor of 1.35, less any 2011 bonus amounts you are actually paid by your current employer and less any 2011 bonus amounts paid by Amgen as a result of your participation in the 2011 GMIP. This payment is subject to your being actively employed with Amgen on the date of payment.

In 2012, management will nominate you for inclusion in the Amgen Executive Incentive Plan (the EIP). The EIP is the annual cash incentive plan in which officers of the Company at your level typically participate, and inclusion is determined and approved by the Compensation Committee during the first quarter of each calendar year. Actual awards under our EIP are determined using pre-established Company goals and results measured under our GMIP. Your annual target incentive opportunity (80% of your base salary earnings during the plan year) will not change as the result of your participation in the EIP.

You are also eligible to participate in the Amgen Nonqualified Deferred Compensation Plan (the DCP) to voluntarily defer, on a pre-tax basis, a portion of your annual earnings, including base salary and/or GMIP bonus. Shortly after commencing your employment at Amgen, you will receive an enrollment e-mail regarding the DCP plan for Amgen. A Q&A regarding the DCP is enclosed.

You will be eligible to participate in the Amgen Inc. Change in Control Severance Plan as amended from time-to-time (the COC), as a Group I Participant according to the terms of the COC. If, upon your termination, you are eligible to receive severance benefits under the COC and you are also eligible to receive severance benefits from another plan, agreement or policy, you will be paid the greater of the amount from that plan, agreement or policy or the amount provided in the COC, but not both amounts. A copy of the COC is enclosed as Attachment 2.

If, within the first three years of your employment with Amgen, Amgen terminates your employment without "Cause", as defined below, you will be entitled to the benefits described in this paragraph (the Termination Paragraph), provided that you sign a general release of claims in the form furnished to you by Amgen as a condition to receipt of such payments. The following are such benefits: (1) two (2) times the sum of (i) your annual base salary then in effect and (ii) 80% of your annual base salary then in effect paid in a lump sum as soon as administratively practicable, but in no event later than March 15 of the year following the year in which Amgen terminates your employment and (2) if you elect continuation coverage under the Amgen group medical and dental plans for yourself and your qualified beneficiaries under the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA), Amgen will pay the cost of such coverage until the earlier to occur of the following: (A) eighteen (18) months following your termination of employment or (B) the date on which you are no longer eligible for such COBRA coverage. Notwithstanding the previous sentence, with regard to such COBRA continuation coverage, if the Company determines in its sole discretion that it cannot provide the foregoing benefit without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide to you a taxable monthly payment in an amount equal to the monthly COBRA premium that you would be required to pay to continue your and your covered dependent's group insurance coverages in effect on the date of termination (which amount shall be based on the premiums for the first month of COBRA coverage). Please note that this Termination Paragraph does not alter the at-will nature of your employment at Amgen. For purposes of this paragraph, Amgen shall include Amgen and any Amgen's subsidiary and affiliate companies (for the avoidance of doubt, a transfer of employment to one of Amgen's subsidiary or affiliate companies shall not be deemed a termination of your employment without "Cause").

As an executive at Amgen, you will be eligible for the following: first-class air transportation while traveling on company business; an annual physical examination; and, reimbursement for up to $15,000 (gross) per year for financial counseling, tax preparation and related services.

You will also have the opportunity to participate in our comprehensive benefits program, as in effect from time-to-time in accordance with the terms of Amgen's plans. Amgen's excellent health care plan currently includes medical, dental and vision coverage for you and your eligible dependents. Amgen currently pays the major expense for these programs while staff members share through payroll deductions. Please be advised that in order for you and your dependents to be eligible for Amgen's medical coverage you must:

1. Report to work at Amgen or another location to which you are required to travel and perform the regular duties of your employment.
2. Contact the Amgen Benefits Center at 1-800-97AMGEN, to enroll within 31 days of your Start Date.
3. Meet all other eligibility requirements under the plan.

You will be eligible to participate in the Amgen Retirement and Savings Plan, which is a 401(k) plan that provides an opportunity for you to save a percentage of your pay (based on Internal Revenue Service limits) on a tax-deferred basis. Amgen will also contribute to your 401(k) account to help you save for your future financial goals. These benefits, services and programs are summarized in the enclosed brochure called "A Guide to Total Rewards at Amgen," and may be changed or discontinued by Amgen from time-to-time.

The Company will be performing a background check and will require you to take a drug test. It is a condition of your employment that the Company receives satisfactory results from both the background check and the drug test.

Enclosed and included as part of this offer (Attachment 1) is information regarding Amgen's Proprietary Information and Inventions Agreement, the Immigration Reform & Control Act and a packet of materials entitled "Arbitration of Disputes" which includes a Mutual Agreement to Arbitrate Claims. Provided that the basis is not related to an actual violation of these or any other agreement with Amgen, Amgen agrees to compensate you for Specified Forfeitures and agrees to indemnify and hold you harmless against any Specified Claim, in each case valued as of the Start Date. You agree that you shall submit a claim to Amgen for any Specified Claims and Specified Forfeitures as soon as possible upon notice of the triggering event(s). Such compensation and indemnification is subject to your being actively employed with Amgen on the date of

payment. Also enclosed and included, as part of this offer in Attachment 1, is information regarding Amgen's New Staff Member Letter and Certification. This offer is contingent upon you truthfully and accurately completing the Certification, and returning it to the Company before or on your first day of employment.

This offer of employment is contingent upon your completing the items described in Attachment 1 and upon your ability to perform for Amgen all of the duties of your position without restriction from, or violation of, any enforceable contractual obligations owed to any former employer or entity for whom you worked or provided service(s).

Also enclosed and included, as part of this offer (Offer Letter Benefit Summary), is information about the main points of the relocation assistance that Amgen will provide to you to relocate to the "local area." Please note that relocation assistance is contingent upon your execution of the enclosed "Relocation Agreement for New Hire Staff Members" and that relocation benefits are limited to one benefits package per household. In addition, you are required to reimburse Amgen for the gross amount of the cost of the relocation benefits (according to the attached schedule) if you resign employment for any reason within two years of your Start Date.

You will be contacted by a Relocation Counselor to initiate your relocation benefits within 3 business days after receipt of your signed acceptance of this offer and your signed New Hire Relocation Agreement.

For purposes of the Termination Paragraph, "Cause" means: (i) unfitness for service, inattention to or neglect of duties, or incompetence; (ii) dishonesty; (iii) disregard or violation of the policies or procedures of Amgen; (iv) refusal or failure to follow lawful directions of the Company; (v) illegal, unethical or immoral conduct; (vi) breach of the attached Amgen Proprietary Information and Inventions Agreement; or (vii) any other reason set forth in California Labor Code Section 2924, in all cases, as determined by Amgen, in its sole and absolute discretion. For purposes hereof, "Specified Claim" means any claim resulting from your work for Amgen for recoupment of previously earned or vested compensation or benefits; provided that "earned compensation" does not include any equity awards that were not vested as of the date of the termination of your employment and were not subject to any right to acceleration upon such termination. For purposes hereof, "Specified Forfeitures" means the cancellation or forfeiture of any vested compensation or benefit due to your work for Amgen or the denial of vesting of any compensation or benefit that would have vested upon your termination but for your work for Amgen.

By signing this letter, you understand and agree that your employment with Amgen is at-will. Therefore, your employment can terminate, with or without cause, and with or without notice, at any time, at your option or Amgen's option, and Amgen can terminate or change all other terms and conditions of your employment, with or without cause, and with or without notice, at any time. This at-will relationship will remain in effect throughout your employment with either Amgen Inc. or any of its subsidiaries or affiliates. This letter and its enclosures constitute the entire agreement, arrangement and understanding between you and Amgen on the nature and terms of your employment with Amgen, including, but not limited to, the kind, character and existence of your proposed job duties, the length of time your employment will last and the compensation you will receive. This letter and its enclosures supersede any prior or contemporaneous agreement, arrangement or understanding on this subject matter. By executing this letter as provided below, you expressly acknowledge the termination of any such prior agreement, arrangement or understanding, except as referenced in this letter and/or its enclosures. Also, by your execution of this letter, you affirm that no one has made any written or verbal statement that contradicts the provisions of this letter or its enclosures. The at-will nature of your employment, as set forth in this paragraph, can be modified only by a written agreement signed by both Amgen's Senior Vice President of Human Resources and you which expressly alters it. This at-will relationship may not be modified by any oral or implied agreement or by any Company policies, practices or patterns of conduct.

This offer letter shall be interpreted and administered in a manner such that any amount or benefit payable hereunder shall be paid or provided in a manner that is exempt from Section 409A of the Internal Revenue Code of 1986, as amended (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, Section 409A). None of the amounts or benefits payable hereunder are intended to constitute "nonqualified deferred compensation" within the meaning of Section 409A of the Internal Review Code of 1986, as amended. However, notwithstanding any other provision of this offer letter, if at any time

Amgen determines that any amounts or benefits payable hereunder may be subject to Section 409A, Amgen shall have the right in its sole discretion (without any obligation to do so or to indemnify you or any other person for failure to do so) to adopt such amendments to this offer letter, or take any other actions, as Amgen determines are necessary or appropriate either for such amounts or benefits to be exempt from the application of Section 409A or to comply with the requirements of Section 409A.

The complete terms of the plans, programs and policies referenced to in this letter are set forth in their respective documents, which are maintained by the Company. The Company reserves the right to amend or terminate any of these plans, programs or policies at any time, in its sole discretion. In the event of any difference between this offer letter and the provisions of the respective plan, program or policy document, the respective plan, program, or policy document will govern.

You have made an excellent impression on the staff at Amgen. We are enthusiastic about the contribution you can make, and we believe that Amgen can provide you with attractive opportunities for personal achievement and growth. I look forward to your favorable reply by **October 13, 2011**. If you accept our offer, please sign and date the ***copy*** of the letter and return it in the enclosed envelope to our Staffing Department along with the completed and signed Proprietary Information and Inventions Agreement and the Mutual Agreement to Arbitrate Claims. Please retain the original offer letter for your records. If you have any questions regarding this offer, please contact Greg XXXXXXX at (805) 447-XXXX.

Sincerely,



Robert A. Bradway
President and Chief Operating Officer

RAB:ett
Enclosures

/s/ Anthony C. Hooper 10/14/2011
Signature of Acceptance Date

10/26/2011
Anticipated Start Date

ATTACHMENT 1

In order to accept our offer you will be required to:

A) Complete, date and sign the enclosed Amgen Proprietary Information and Inventions Agreement and return it with your signed offer letter.

B) Sign and date the Amgen New Staff Member Letter and Certification and return it with your signed offer letter.

C) Date and sign the enclosed Mutual Agreement to Arbitrate Claims and return it with your signed offer letter.

D) You will be required to provide Amgen with proof of your identity and eligibility for employment per requirements of the Immigration Reform and Control Act of 1986 within 3 (three) days of hire. Information pertaining to this Act and required proof are enclosed.

E) Sign and date the Consumer Disclosure and Authorization Form (Disclosure Regarding Background Check Investigation

AMGEN NEW STAFF MEMBER LETTER AND CERTIFICATION

Welcome to Amgen (the "Company"). The Company has no need to learn and does not want any proprietary, confidential or trade secret information that belongs to any prior employers. Please review and comply with the following instructions and policies, and execute the Certification below.

- Carefully read the Company's Proprietary Information and Inventions Agreement ("PIIA") that you have executed, and make sure that you understand your obligations under the terms of the PIIA.
- You may not bring any material to the Company from your prior employers in hard copy, in electronic format or in any other form.
- Prior to commencing any work for the Company, conduct a search of your personal computer(s), email accounts, and any other electronic storage devices you possess, as well as any files you maintain in hard copy, for information or materials belonging to your prior employers. You are instructed to destroy, delete or return any such information or materials belonging to your prior employers, consistent with any obligations you have to the prior employers.
- Do not disclose to or provide the Company with any customer lists you obtained from or during your employment with your prior employers. When interacting with doctors or other members of the healthcare industry with whom you may have had contact in connection with any of your prior employment, clearly indicate to such persons that you are an Amgen staff member, and focus on the Company's products rather than using or discussing information related to your prior employment.
- If you have any doubts regarding whether you may take, disclose, upload, access, or use any information in your possession, you must err on the side of not taking, disclosing, uploading, accessing or using the information.
- Do not begin any work for the Company before your employment with your prior employers has officially ended.
- After commencing work for the Company, do not request that any employee of your prior employers provide you with, or take any other steps to obtain, any information of your prior employers.
- Under no circumstances are you permitted to connect to a Company computer any electronic storage device containing information relating to your prior employers. Likewise, in performing work for the Company, you are not permitted to use, disclose, access or upload any such information. If you discover that any confidential, proprietary, or trade secret information of your prior employers has been uploaded to any Company computer or email system(s), immediately inform Human Resources.
- The Company may monitor and/or conduct an audit of your use of Company computer systems, and you should not have any expectation of privacy in data sent, stored or received on any Company systems.

Disclose and identify below all agreements relating to your current or prior employment that may affect your eligibility to become employed by and/or to perform work for the Company, including non-competition agreement(s), agreements relating to the solicitation of employees or customers, or other restrictive agreements (collectively, "Restrictive Agreements"), regardless of whether you believe these agreements are enforceable, or apply to your potential employment with the Company, or have expired, and provide a copy to Human Resources. If "none," please so indicate. Do not leave blank.

Name of Agreement	Employer	Date signed
PSU, Restricted Stock and	BMS	2007 - 2011
Annual Stock Option allocations		

(Attach additional sheets, if necessary)

- If you are subject to an agreement not to solicit employees of your prior employers, you should refrain from doing so. If you are contacted by a former colleague about employment opportunities with the Company, you should refer such inquiries/candidates to Amgen's Staffing Department.
- Do not use any email account (including Company email accounts), text messages, Instant Messaging, or any other method of written communication to store or discuss information relating to your prior employers or to recruit or solicit employees of your former employers.
- Immediately inform your Human Resources Business Partner if you are contacted by any former employer regarding your work for Amgen and/or any non-competition agreements, agreements that relate to the solicitation of employees or customers, or any other restrictive agreements you entered into in connection with any previous employment.

CERTIFICATION

I understand that the above list is only a summary and does not purport to include all of my continuing obligations to the Company. By signing below I certify that I have and will continue to comply with the above instructions and policies.

I hereby agree that the Company may, at its sole option and discretion contact my prior employer(s) to determine whether any Restrictive Agreements exist and, if so, their applicable terms. I acknowledge that the Company may revoke its offer or terminate my employment if it determines in its reasonable business judgment that I have failed to disclose or am otherwise subject to an enforceable Restrictive Agreement.

Nothing in this Letter and Certification is intended to alter, or shall have any impact on, my status as an at-will employee of the Company. In addition to its right to terminate my employment, the Company shall have the right to suspend me from work without pay during its investigation into the existence and/or enforceability of any restrictions on my ability to perform work for the Company.

I agree:

/s/ Anthony C. Hooper
Signature of Staff Member

Anthony C. Hooper
Print Name of Staff Member

10/14/2011
Date

AMGEN SIGN-ON BONUS AGREEMENT
FOR
NEW HIRE STAFF MEMBERS

I, Anthony C. Hooper, agree to accept my sign-on bonus payment ("Bonus") from Amgen on the following terms.

1. The amount of the Bonus is described in the offer letter (as may be amended) provided separately to me.

2. The Bonus will generally be paid to me after thirty (30) days following the date on which I report to Amgen for full time employment with Amgen. If I am not still employed as of the date the Bonus is to be paid, the Bonus will not be paid either in part or in full.

3. The Bonus is intended to facilitate my acceptance of employment with Amgen. While the Bonus is provided by Amgen in its business interests as part of its employee recruitment program, I acknowledge that the Bonus is not reimbursable to me as a matter of law under California Labor Code section 2802 or any similar statute.

4. Amgen is providing me with the Bonus with the expectation that I will not in the short term resign my employment. I understand and acknowledge that the bonus is being given for purposes of retention and conditioned upon my continued service for at least two years of active employment following the start date of my employment with Amgen. While, as an at-will employee, I am free to resign at any time, I agree to reimburse Amgen for the gross amount of my Bonus if I resign my employment for any reason within two years of the start date of my employment. Amgen is also providing the Bonus with the expectation that there will not occur a termination for Cause (as defined below). Thus, I agree to reimburse Amgen for the gross amount of my Bonus if my employment is terminated by Amgen for Cause within two years of the start date of my employment. I also agree that in the event of such a resignation or termination for Cause, the amount to be reimbursed shall be due in full and payable by me immediately in cash (i.e., by check, wire transfer, or similar immediate payment) without further notice or demand by Amgen, and that Amgen shall have the right to offset against compensation then owing to me. Additionally, any Bonus monies that were to be paid at an agreed upon future date but have not yet been paid are not earned and are forfeited upon resignation or termination from the company.

   For these purposes, "Cause" means (i) unfitness for service, inattention to or neglect of duties, or incompetence; (ii) dishonesty; (iii) disregard or violation of the policies or procedures of Amgen; (iv) refusal or failure to follow lawful directions of the Company; (v) illegal, unethical or immoral conduct; (vi) breach of the attached Amgen Proprietary Information and Inventions Agreement; or (vii) any other reason set forth in California Labor Code Section 2924, in all cases, as determined by Amgen, in its sole and absolute discretion.

5. Generally, a new hire sign-on bonus is considered ordinary wage income to the recipient. I understand that Amgen will report to appropriate federal and state taxing authorities all income that Amgen considers to be subject to taxation and will withhold appropriate taxes in accordance with federal and state regulations. I understand that it is my obligation to declare all income and pay all taxes owed on such income, if any.

6. In the event that I fail to reimburse Amgen for my Bonus as required by this agreement and Amgen initiates proceedings to recover such Bonus, the prevailing party in such a suit shall be awarded its reasonable costs and attorney's fees.

7. I understand that this agreement shall be governed by the law of the State of California.

8. Nothing in this agreement will be construed as an employment contract or to guarantee me employment at Amgen for any fixed term. I understand that my employment at Amgen is at will.

9. The provisions of this agreement are severable. If any part is found to be unenforceable, all other provisions shall remain fully valid and enforceable.

I agree:	Amgen Inc:
/s/ Anthony C. Hooper	/s/ Amie Krause
Signature of Staff Member	Signature of Authorized Representative
Anthony C. Hooper	Senior Staffing Manager
Print Name of Staff Member	Title of Representative
10/14/2011	10/18/2011
Date	Date

AMGEN RELOCATION AGREEMENT
FOR
NEW HIRE STAFF MEMBERS

I, Anthony C. Hooper, agree to accept certain relocation benefits from Amgen on the following terms.

1. The relocation benefits to be provided to me are outlined in the Amgen Relocation Policy that applies to staff members at my grade level.

2. I will obtain relocation benefits from Amgen by following the procedures outlined in the Amgen Relocation Policy that applies to staff members at my grade level.

3. I understand that I may obtain an estimate of my relocation costs from Amgen/Amgen's third-party relocation vendor and that the actual cost of my relocation may be more or less than the estimate I am provided. I further understand that I can obtain detailed information about the actual services and costs being incurred during my relocation by contacting Amgen/Amgen's third-party relocation vendor.

4. The relocation benefits are to facilitate my move as a result of my decision to accept an offer of employment with Amgen. I acknowledge that the cost of these benefits is not required to be reimbursed to me as a matter of law under California Labor Code section 2802 or any similar statute.

5. Amgen provides the relocation benefits with the expectation that I will not in the short term resign my employment. I understand and acknowledge that the relocation benefits are being given for purposes of retention and are conditioned upon my continued service through 730 days of active employment from the start date of my employment with Amgen. While, as an at-will employee, I am free to resign at any time, I agree to reimburse Amgen for the gross amount of the cost of the relocation benefits (according to the schedule below) if I resign my employment for any reason within 730 days of the date I report to Amgen for full time employment. Upon my resignation, the amount to be reimbursed shall be immediately due and payable by me without further notice or demand, and that Amgen shall have the right to offset against compensation then owing to me. The schedule for reimbursement is as follows:

Days Since Start Date	% of Gross Cost of Relocation Benefits to be Reimbursed to Amgen
0 to 365 days	100%
366- 450 days	75%
451 - 540 days	50%
541 - 730 days	25%
Over 730 days	0%

6. I understand that Amgen will report to federal and state taxing agencies all income that Amgen considers to be subject to taxation. I understand that it is my obligation to declare all income and pay all taxes owed on such income, if any.

7. In the event that I fail to make a reimbursement required by this agreement and Amgen initiates proceedings to recover such reimbursement, the prevailing party in such a suit shall be awarded its reasonable costs and attorney's fees.

8. I understand that this agreement shall be governed by the law of the State of California.

9. Nothing in this agreement will be construed as an employment contract or to guarantee me employment at Amgen for any fixed term. I understand that my employment at Amgen is at will. Nor does this agreement guarantee me reimbursement of any particular relocation expenses. I understand that reimbursement is governed by the Amgen Relocation Policy and that I must comply with the procedures in that policy.

10. The provisions of this agreement are severable. If any part is found to be unenforceable, all other provisions shall remain fully valid and enforceable.

I agree:

/s/ Anthony C. Hooper
Signature of Staff Member

Anthony C. Hooper
Print Name of Staff Member

10/14/2011
Date

Amgen Inc:

/s/ Amie Krause
Signature of Authorized Representative

Senior Staffing Manager
Title of Representative

10/18/2011
Date

ATTACHMENT 2

AMGEN INC.
CHANGE OF CONTROL SEVERANCE PLAN

AMGEN INC., a Delaware corporation, has established this Change of Control Severance Plan, as amended and restated, effective as of December 9, 2010, as subsequently amended effective March 2, 2011 (the "Plan") for the benefit of certain key employees of Amgen Inc. and Covered Subsidiaries (as defined below).

The purposes of the Plan are as follows:

(1) To reinforce and encourage the continued attention and dedication of members of the Company's management to their assigned duties without the distraction arising from the possibility of a change of control of the Company;

(2) To enable and encourage the Company's management to focus their attention on obtaining the best possible deal for the Company's stockholders and to make an independent evaluation of all possible transactions, without being influenced by their personal concerns regarding the possible impact of various transactions on the security of their jobs and benefits; and

(3) To provide severance benefits to any Participant (as defined below) who incurs a termination of employment under the circumstances described herein within a certain period following a Change of Control (as defined below).

1. **Defined Terms**. For purposes of the Plan, the following terms shall have the meanings indicated below:

(A) *"Accountants"* shall mean the Company's independent registered public accountants serving immediately prior to the Change of Control; *provided, however*, that in the event that the Accountants are also serving as accountant or auditor for the individual, entity or group effecting the Change of Control, the Administration Committee shall appoint another nationally recognized public accounting firm to make the calculations required hereunder (which accounting firm shall then be referred to as the Accountants hereunder).

(B) *"Administration Committee"* shall mean the committee which is responsible for administering the Plan, as described in Section 3(A) hereof.

(C) *"Amgen Retirement Savings Plan"* shall mean the Amgen Retirement and Savings Plan, As Amended and Restated Effective January 1, 2010, or any successor plan.

(D) *"Amgen Supplemental Retirement Plan"* shall mean the Amgen Inc. Supplemental Retirement Plan, Amended and Restated Effective January 1, 2009, or any successor plan.

(E) *"Benefits Continuation Period"* shall mean the earlier to occur of (i) the expiration of a Participant's eligibility for coverage under COBRA, and (ii) the expiration of the eighteen (18) month period immediately following the Participant's Date of Termination.

(F) *"Benefits Multiple"* shall mean (i) with respect to each Group I Participant, two (2), (ii) with respect to each Group II Participant, two (2), and (iii) with respect to each Group III Participant, one (1).

(G) *"Board"* shall mean the Board of Directors of the Company.

(H) *"Cash Severance Payment"* shall mean a lump sum cash payment in an amount equal to the product of (x) the Participant's Benefits Multiple, and (y) the sum of (i) the Participant's annual base salary as in effect immediately prior to the Date of Termination or, if higher, as in effect immediately prior to the Change of Control, plus (ii) the Participant's targeted annual bonus for the year in which such Date of Termination occurs (determined as the product of the Participant's annual base salary and the Participant's target annual bonus percentage, each as in effect immediately prior to the Date of Termination or, if higher, as in effect immediately prior to the Change of Control).

(I) *"Cause,"* with respect to any Participant, shall mean (i) the Participant's conviction of a felony, or (ii) the engaging by the Participant in conduct that constitutes willful gross neglect or willful gross misconduct in carrying out the Participant's duties, resulting, in either case, in material economic harm to the Company, unless the Participant believed in good faith that such conduct was in, or not contrary to, the best interests of the Company. For purposes of clause (ii) above, no act, or failure to act, on the Participant's part shall be deemed "willful" unless done, or omitted to be done, by the Participant not in good faith.

(J) A *"Change of Control"* of the Company shall be deemed to have occurred at any of the following times:

(i) upon the acquisition (other than from the Company) by any person, entity or "group," within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (excluding, for this purpose, the Company or its affiliates, or any employee benefit plan of the Company or its affiliates which acquires beneficial ownership of voting securities of the Company), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of either the then outstanding shares of Common Stock or the combined voting power of the Company's then outstanding voting securities entitled to vote generally in the election of directors; or

(ii) at the time individuals who, as of December 9, 2010, constitute the Board (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board, *provided*, that any person becoming a director subsequent to December 9, 2010, whose election, or nomination for election by the Company's stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board (other than an election or nomination of an individual whose initial assumption of office is in connection with an actual or threatened election contest relating to the election of the directors of the Company) shall be, for purposes of the Plan, considered as though such person were a member of the Incumbent Board; or

(iii) immediately prior to the consummation by the Company of a reorganization, merger, consolidation, (in each case, with respect to which persons who were the stockholders of the Company immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own more than fifty percent (50%) of the combined voting power entitled to vote generally in the election of directors of the reorganized, merged or consolidated company's then outstanding voting securities) or a liquidation or dissolution of the Company or the sale of all or substantially all of the assets of the Company; or

(iv) the occurrence of any other event which the Incumbent Board in its sole discretion determines constitutes a Change of Control.

(K) *"Change of Control Period"* shall mean the period beginning on the date of a Change of Control and ending on the second anniversary of such Change of Control.

(L) *"COBRA"* shall mean the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.

(M) *"Code"* shall mean the Internal Revenue Code of 1986, as amended from time to time.

(N) *"Common Stock"* shall mean the common stock of the Company, par value $0.0001 per share.

(O) *"Company"* shall mean Amgen Inc., a Delaware corporation, and, except in determining under Section 1(J) hereof whether or not any Change of Control of the Company has occurred, shall include any successor to its business and/or assets. "Company" shall exclude any disregarded entity pursuant Treasury Regulations section 301.7701-3, unless the Plan is amended to designate the disregarded entity's employees as Participants.

(P) *"Compensation Committee"* shall mean the Compensation and Management Development Committee of the Board.

(Q) *"Confidential Information"* shall mean information disclosed to the Participant or known by the Participant as a consequence of or through his or her relationship with the Company, about the customers, employees, business methods, public relations methods, organization, procedures or finances, including, without limitation, information of or relating to customer lists, of the Company and its affiliates.

(R) *"Covered Subsidiaries"* shall mean those Subsidiaries of the Company which are incorporated in any of the fifty states of the United States or the District of Columbia, except as otherwise determined in writing by the Administration Committee in its sole discretion and designated on Annex A attached hereto as maintained by the Administration Committee.

(S) *"Date of Termination"* shall mean with respect to any purported termination of a Participant's employment (other than by reason of the Participant's death), (i) if the Participant's employment is terminated for Disability, the date upon which a Notice of Termination is given, and (ii) if the Participant's employment is terminated for any other reason, whether voluntarily or involuntarily, the date that the Participant's employment terminates, as specified in the Notice of Termination (which shall be within sixty (60) days from the date such Notice of Termination is given).

(T) *"Disability"* shall be determined in accordance with the Company's long-term disability plan as in effect immediately prior to a Change of Control.

(U) *"Exchange Act"* shall mean the Securities Exchange Act of 1934, as amended from time to time.

(V) *"Good Reason,"* with respect to any Participant, shall mean the occurrence (without the Participant's express written consent) of any of the following conditions, but only if (1) the Participant provides written notice to the Company of the existence of the condition within thirty (30) days of the initial existence of the condition; (2) the Company fails to remedy the condition within the thirty (30)-day period following the Company's receipt of the notice delivered pursuant to clause (1); and (3) the Participant actually terminates employment within thirty (30) days following the expiration of the thirty (30)-day period described above in clause (2):

(i) any adverse and material diminution in the Participant's authority, duties or responsibilities as they existed immediately prior to the Change of Control or as the same may be increased from time to time thereafter;

(ii) the Company's material reduction of the Participant's annual base salary as in effect immediately prior to the Change of Control;

(iii) relocation of the Company's offices at which the Participant is employed immediately prior to the Change of Control which increases the Participant's daily commute by more than one-hundred (100) miles on a round trip basis; or

(iv) any other action or inaction by the Company that constitutes a material breach of the agreement under which the Participant provides services.

A Participant's right to terminate his or her employment for Good Reason shall not be affected by the Participant's incapacity due to physical or mental illness.

(W) *"Group I Participants"* shall mean those staff members of the Company, who hold the title of senior vice president or equivalent and above, and any other senior executive-level staff members of the Company and the Covered Subsidiaries whom the Administration Committee has designated as Group I Participants, as such group shall be constituted immediately prior to a Change of Control. At or before the occurrence of a Change of Control, the Company shall notify the Group I Participants in writing of their status as Participants in the Plan.

(X) *"Group II Participants"* shall mean those management-level staff members of the Company and the Covered Subsidiaries at Level 8 or equivalent and above and who are not Group I Participants, as such group shall be constituted immediately prior to a Change of Control. At or before the occurrence of a Change of Control, the Company shall notify the Group II Participants in writing of their status as Participants in the Plan.

(Y) *"Group III Participants"* shall mean those management-level staff members of the Company and the Covered Subsidiaries at Level 7 or equivalent, as such group shall be constituted immediately prior to a Change of Control. At or before the occurrence of a Change of Control, the Company shall notify the Group III Participants in writing of their status as Participants in the Plan.

(Z) *"Notice of Termination"* shall mean a notice which shall indicate the specific termination provision in the Plan relied upon and shall set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Participant's employment under the provision so indicated.

(AA) *"Participants"* shall mean, collectively, the Group I Participants, the Group II Participants and the Group III Participants.

(BB) *"Proprietary Information Agreement"* shall mean the Company's form of Proprietary Information and Inventions Agreement in the form in effect immediately prior to a Change of Control.

(CC) "*Subsidiary*" shall mean any entity (other than the Company), in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing more than fifty percent (50%) of the total combined voting power of all classes of securities or interests in one of the other entities in such chain.

2. **Effective Date and Term of Plan**. The Plan, as amended and restated, shall be effective as of December 9, 2010 and shall continue in effect through December 31, 2014; *provided, however*, that commencing on December 31, 2014 and on each December 31 thereafter, the Plan shall automatically be extended for one additional year by adding one year to the last day of the term as then in effect unless, not later than November 30 of such year, the Company shall have given notice to the Participants that the term of the Plan will not be extended; *provided, further*, that if a Change of Control occurs during the original or any extended term of the Plan, the term of the Plan shall continue in effect for a period of not less than twenty-four (24) months beyond the month in which such Change of Control occurred.

3. **Administration**.

(A) The Plan shall be interpreted, administered and operated by the Compensation Committee, except that if the Compensation Committee determines that a Change of Control is likely to occur, the Compensation Committee shall appoint a person or group of persons who shall constitute the Administration Committee after the occurrence of the Change of Control, which Administration Committee shall have the power to interpret, administer and operate the Plan after the occurrence of the Change of Control. The Administration Committee shall have complete authority, in its sole discretion subject to the express provisions of the Plan, to determine who shall be a Participant, to interpret the Plan, to prescribe, amend and rescind rules and regulations relating to it, and to make all other determinations necessary or advisable for the administration of the Plan. The Administration Committee may delegate any of its duties hereunder to such person or persons from time to time as it may designate.

(B) All expenses and liabilities which members of the Administration Committee incur in connection with the administration of the Plan shall be borne by the Company. The Administration Committee may employ attorneys, consultants, accountants, appraisers, brokers, or other persons in connection with such administration, and the Administration Committee, the Company and the Company's officers and directors shall be entitled to rely upon the advice, opinions or valuations of any such persons. No member of the Compensation Committee, the Administration Committee or the Board shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, and all members of the Compensation Committee, the Administration Committee and the Board shall be fully protected by the Company in respect of any such action, determination or interpretation.

4. **Benefits Provided.**

4.1 *Termination After Change of Control*. If a Participant's employment is terminated during a Change of Control Period (a) by the Company other than for Cause or Disability, or (b) by the Participant for Good Reason, the Company shall pay the Participant the amounts, and provide the Participant with the benefits, described in this Section 4.1.

(A) *Cash Severance Payment*. In lieu of any further salary payments to the Participant for periods subsequent to the Date of Termination and in lieu of any severance benefit otherwise payable to the Participant (other than accrued vacation and similar benefits otherwise payable upon termination of employment pursuant to Company policies and programs), the Company shall pay to the Participant the Cash Severance Payment.

(B) *Benefits.* Subject to subsection (B) of Section 11.6 hereof, if, as a result of the Participant's termination of employment, the Participant becomes entitled to, and timely

elects to continue, health care (including any applicable vision benefits) and/or dental coverage under COBRA, the Company shall provide the Participant and his or her dependents with Company-paid group health and dental insurance continuation coverage under COBRA during the Benefits Continuation Period.

(C) The Company shall pay to the Participant any earned but unpaid portion of the Participant's base salary as of the Date of Termination at the rate in effect at the time Notice of Termination is given, plus all other amounts to which the Participant is entitled under any compensation plan or practice of the Company at the time such payments are due.

(D) The Participant shall be fully vested in his or her accrued benefits under the Amgen Retirement Savings Plan and the Amgen Supplemental Retirement Plan, as applicable. The Company shall provide the Participant with either, in the Company's sole discretion, a lump-sum cash payment or a contribution to the Amgen Supplemental Retirement Plan, in an amount equal to the sum of (1) the product of $2,500 and the Benefits Multiple and (2) the product of (x) 0.10, (y) the sum of (i) the Participant's annual base salary as in effect immediately prior to the Date of Termination or, if higher, as in effect immediately prior to the Change of Control, plus (ii) the Participant's targeted annual bonus for the year in which such Date of Termination occurs (determined as the product of the Participant's annual base salary and the Participant's target annual bonus percentage, each as in effect immediately prior to the Date of Termination or, if higher, as in effect immediately prior to the Change of Control) and (z) the Benefits Multiple. Subject to subsection (B) of Section 11.6 hereof, payment under this Section 4.1(D) will be made within 45 days (or as soon thereafter as is administratively practicable) after the Date of Termination, but in no event more than two and one-half months after the end of the calendar year in which the Date of Termination occurs.

(E) In any situation where under applicable law the Company has the power to indemnify (or advance expenses to) the Participant in respect of any judgments, fines, settlements, loss, cost or expense (including attorneys' fees) of any nature related to or arising out of the Participant's activities as an agent, employee, officer or director of the Company or in any other capacity on behalf of or at the request of the Company, the Company shall promptly on written request, indemnify (and advance expenses to) the Participant to the fullest extent permitted by applicable law. Such agreement by the Company shall not be deemed to impair any other obligation of the Company respecting the Participant's indemnification otherwise arising out of this or any other agreement or promise of the Company or under any statute.

(F) For the four (4) year period immediately following the Date of Termination, the Company shall furnish each Participant who was a director and/or officer of the Company at any time prior to the Date of Termination with directors' and/or officers' liability insurance, as applicable, insuring the Participant against insurable events which occur or have occurred while the Participant was a director or officer of the Company, such insurance to have policy limits aggregating not less than the amount in effect immediately prior to the Change of Control, and otherwise to be in substantially the same form and to contain substantially the same terms, conditions and exceptions as the liability insurance policies provided for officers and directors of the Company in force from time to time, *provided, however*, that if the aggregate annual premiums for such insurance at any time during such period exceed one hundred and fifty percent (150%) of the per annum rate of premium currently paid by the Company for such insurance, then the Company shall provide the maximum coverage that will then be available at an annual premium equal to one hundred and fifty percent (150%) of such rate.

4.2

(A) All calculations required to be made under Section 4.1 hereof, including the amount of the Cash Severance Payment and the assumptions to be utilized in arriving at such calculations shall be made by the Accountants. The Accountants shall provide the Participant and the Company with detailed supporting calculations with respect to such calculations at least fifteen (15) business days prior to the date of the Change of Control (or as soon as practicable in the event that the Accountants have less than fifteen (15) business days advance notice of the potential occurrence of the Change of Control) with respect to the impact of any payment which will be made to the Participant before, at or immediately after the Change of Control and from time to time thereafter to the extent that the Participant may become entitled to receive any additional payments or benefits which would affect the amount of any "excess parachute payments" within the meaning of Section 280G(b)(1) of the Code payable to the Participant in order that the Participant may determine whether it is in the best interest of the Participant to waive the receipt of any or all amounts which may constitute "excess parachute payments." Any calculation by the Accountants shall be binding upon the Company and the Participant. All fees and expenses of the Accountants under this Section 4.2 shall be borne solely by the Company.

(B) Notwithstanding any other provision of this Plan, in the event that any payment or benefit received or to be received by the Participant, including any payment or benefit received in connection with a termination of the Participant's employment, whether pursuant to the terms of this Plan or any other plan, arrangement or agreement, (all such payments and benefits, including the payments and benefits under Section 4 hereof, being hereinafter referred to as the "Total Payments") would be subject (in whole or part), to the excise tax imposed under Section 4999 of the Code (the "Excise Tax"), then, after taking into account any reduction in the Total Payments provided by reason of Section 280G of the Code in such other plan, arrangement or agreement, the payments under this Plan shall be reduced in the order specified below, to the extent necessary so that no portion of the Total Payments is subject to the Excise Tax but only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which the Participant would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments). The payments and benefits under this Plan shall be reduced in the following order: (A) reduction of any cash severance payments otherwise payable to the Participant that are exempt from Section 409A of the Code; (B) reduction of any other cash payments or benefits otherwise payable to the Participant that are exempt from Section 409A of the Code, but excluding any payments attributable to any acceleration of vesting or payments with respect to any equity award that are exempt from Section 409A of the Code; (C) reduction of any other payments or benefits otherwise payable to the Participant on a pro-rata basis or such other manner that complies with Section 409A of the Code, but excluding any payments attributable to any acceleration of vesting and payments with respect to any equity award that are exempt from Section 409A of the Code; and (D) reduction of any payments attributable to any acceleration of vesting or payments with respect to any equity award that are exempt from Section 409A of the Code, in each case beginning with payments that would otherwise be made last in time.

(C) For purposes of determining whether and the extent to which the Total Payments will be subject to the Excise Tax, (i) no portion of the Total Payments the receipt or enjoyment of which the Executive shall have waived at such time and in such manner as not to constitute a "payment" within the meaning of Section 280G(b) of the Code shall be taken into account; (ii) no portion of the Total Payments shall be taken into account which, in

the written opinion of the Accountants, does not constitute a "parachute payment" within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, no portion of such Total Payments shall be taken into account which, in the opinion of the Accountants, constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the Base Amount (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation; and (iii) the value of any non-cash benefit or any deferred payment or benefit included in the Total Payments shall be determined by the Accountants in accordance with the principles of Sections 280G(d)(3) and (4) of the Code.

4.3 Subject to subsection (B) of Section 11.6 hereof, the cash payments provided in subsections (A), (C) and (D) of Section 4.1 hereof shall be made by the fifth (5th) day following the receipt by the Participant of the Accountants' calculation, but in no event later than March 15 of the calendar year following the calendar year in which the Participant's employment is terminated. As a result of uncertainty in the application of Section 280G and Section 4999 of the Code at the time of the initial calculation by the Accountants hereunder, it is possible that the Cash Severance Payment made by the Company will have been less than the Company should have paid pursuant to Section 4.1(A) hereof, as the case may be (the amount of any such deficiency, the "Underpayment") or more than the Company should have paid pursuant to Section 4.1(A) hereof, as the case may be (the amount of any such overage, the "Overpayment"). In the event of an Underpayment, the Company shall pay the Participant the amount of such Underpayment (together with interest at 120% of the rate provided in Section 1274(b)(2)(B) of the Code) not later than five (5) business days after the amount of such Underpayment is subsequently determined, *provided*, *however*, such Underpayment shall not be paid later than the end of the calendar year following the calendar year in which the Participant remitted the related taxes. In the event of an Overpayment, the amount of such Overpayment shall constitute a loan by the Company to the Participant, payable not later than five (5) business days after the amount of such Overpayment is subsequently determined (together with interest at 120% of the rate provided in Section 1274(b)(2)(B) of the Code).

4.4 At the time that any payments are made under the Plan, the Company shall provide the Participant with a written statement setting forth the manner in which such payments were calculated and the basis for such calculations including, without limitation, any opinions or other advice the Company has received from its counsel, the Accountants or other advisors or consultants (and any such opinions or advice which are in writing shall be attached to the statement).

5. Termination Procedures.

5.1 *Notice of Termination*. Any purported termination of a Participant's employment following a Change of Control (other than by reason of death) shall be communicated by written Notice of Termination from one party to the other party in accordance with Section 8 hereof. Further, no termination for Cause shall be effective without (a) reasonable notice to the Participant setting forth the reasons for the Company's intention to terminate which specifies the particulars thereof in detail, and (b) in the case of clause (ii) of the definition of Cause above, an opportunity for the Participant to cure such Cause within twenty (20) days after receipt of such notice. With respect to the Group I Participants, the Notice of Termination must include a written statement that a majority of the entire membership of the Board has determined that the Participant was guilty of the conduct constituting Cause. With respect to Group II Participants and Group III Participants, the Notice of Termination must include a written statement by one of the Participant's direct or indirect supervisors that the supervisor has determined that the Participant was guilty of conduct constituting Cause.

6. **No Mitigation**. The Company agrees that, in order for a Participant to be eligible to receive the payments and other benefits described herein, the Participant is not required to seek other employment or to attempt in any way to reduce any amounts payable to the Participant by the Company pursuant to Section 4 hereof. Further, the amount of any payment or benefit provided for in the Plan shall not be reduced by any compensation earned by the Participant as the result of employment by another employer, by retirement benefits, by offset against any amount claimed to be owed by the Participant to the Company, or otherwise.

7. **Successors; Binding Agreement.**

7.1

(A) The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to expressly assume the Plan and all obligations of the Company hereunder in the same manner and to the same extent that the Company would be so obligated if no such succession had taken place.

(B) This Plan shall inure to the benefit of and shall be binding upon the Company, its successors and assigns, but without the prior written consent of the Participants the Plan may not be assigned other than in connection with the merger or sale of any part of the business and/or assets of the Company or similar transaction in which the successor or assignee assumes (whether by operation of law or express assumption) all obligations of the Company hereunder.

7.2 This Plan shall inure to the benefit of and be enforceable by the Participant's personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees, legatees or other beneficiaries. If a Participant shall die while any amount would still be payable to such Participant hereunder (other than amounts which, by their terms, terminate upon the death of the Participant) if such Participant had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of the Plan to the executors, personal representatives or administrators of such Participant's estate.

8. **Notices**. For the purpose of the Plan, notices and all other communications provided for in the Plan shall be in writing and shall be deemed to have been duly given when delivered or mailed by United States registered mail, return receipt requested, postage prepaid, addressed, if to a Participant, to the address on file with the Company and, if to the Company, to the address set forth below, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon actual receipt:

One Amgen Center Drive
Thousand Oaks, California 91320-1789
Attention: Corporate Secretary

9. **Claims Procedures; Expenses.**

9.1 The Participant's assertion of a right to benefits under, in connection with, or in any way related to the Plan constitutes Participant's agreement to resolve covered disputes against any person or entity pursuant to this Section 9.

9.2 *Claim for Benefits*. A Participant may file with the Administration Committee a written claim for benefits under the Plan. The Administration Committee shall, within a reasonable time not to exceed ninety (90) days, unless special circumstances require an extension of time of not more than an additional ninety (90) days (in which event a Participant will be notified of the delay during the first ninety (90) day period), provide adequate notice in writing to any Participant whose claim for benefits shall have been denied, setting forth the following in a manner calculated to be understood by the Participant: (i) the specific reason or reasons for the denial; (ii) specific reference to the provision or provisions of the Plan on which the denial is based; (iii) a description of any additional material or information required to perfect the claim, and an explanation of why such material or information is necessary; and (iv) information as to the steps to be taken in order that the denial of the claim may be reviewed, including a statement of the Participant's right to bring an action under Section 502(a) of the Employee Retirement Income Security Act of 1974, as amended ("ERISA") following an adverse determination of the claim.

9.3 *Review of Claims*. If a Participant's claim has been denied and the Participant wishes to submit a request for a review of such claim, the Participant must follow the claims review procedure below:

(A) Upon the denial of a claim for benefits, a Participant may file a request for review of the claim, in writing, with the Administration Committee or any person or persons to whom the Administration Committee has delegated its duties hereunder, including a claims processor;

(B) The Participant must file the claim for review not later than 60 days after the Participant has received written notification of the denial of the claim;

(C) The Participant has the right to review and obtain copies of all relevant documents relating to the denial of the claim and to submit any issues and comments, in writing, to the Administration Committee;

(D) If the claim is denied, the Administration Committee must provide the Participant with written notice of this denial within 60 days after the Administration Committee's receipt of the Participant's written claim for review. There may be times when this 60-day period may be extended. This extension may only be made, however, when there are special circumstances that are communicated to the Participant in writing within the 60-day period. If there is an extension, a decision will be made as soon as possible, but not later than 120 days after receipt by the Administration Committee of the claim for review; and

(E) The Administration Committee's decision on the claim for review will be communicated to the Participant in writing, and if the claim for review is denied in whole or part, the decision will include: (i) the specific reason or reasons for the denial; (ii) specific reference to the provision or provisions of the Plan on which the denial is based; (iii) a statement that the Participant may receive, upon request and free of charge, reasonable access to and copies of, all documents, records and other information relevant to the claim; and (iv) a statement of the Participant's right to bring an action under Section 502(a) of ERISA.

9.4 *Expenses, Legal Fees*. The Company shall pay to the Participant all reasonable expenses (including reasonable attorneys' fees and legal expenses) incurred by the Participant with respect to any dispute or controversy arising under or in connection with the Plan (including, without limitation, all such fees and expenses, if any, incurred in contesting or disputing any termination of the Participant's employment or in seeking to obtain or enforce any right or benefit provided by the Plan, or in connection with any tax audit or

proceeding to the extent attributable to the application of Section 4999 of the Code to any payment or benefit provided hereunder) if the Participant prevails on any material issue which is in dispute with respect to such dispute or controversy. The Company shall make such payments no later than the last day of the Participant's taxable year immediately following the taxable year in which the expenses are incurred.

10. Confidentiality; Non-Solicitation.

10.1 *Confidentiality*. With respect to each Participant, during the Participant's Benefits Continuation Period, the Participant shall not directly or indirectly disclose or make available to any person, firm, corporation, association or other entity for any reason or purpose whatsoever, any Confidential Information. Upon termination of a Participant's employment with the Company, all Confidential Information in the Participant's possession that is in written or other tangible form (together with all copies or duplicates thereof, including computer files) shall be returned to the Company and shall not be retained by the Participant or furnished to any third party, in any form except as provided herein; *provided, however*, that the Participant shall not be obligated to treat as confidential, or return to the Company copies of any Confidential Information that (i) was publicly known at the time of disclosure to the Participant, (ii) becomes publicly known or available thereafter other than by any means in violation of the Plan or any other duty owed to the Company by any person or entity, or (iii) is lawfully disclosed to the Participant by a third party. In addition, each Participant shall be subject to the Company's policies regarding proprietary information and inventions, as set forth in the Proprietary Information Agreement.

10.2 *Non-Solicitation*. In addition to each Participant's obligations under the Proprietary Information Agreement, during a Participant's Benefits Continuation Period, the Participant shall not, either on the Participant's own account or jointly with or as a manager, agent, officer, employee, consultant, partner, joint venturer, owner or stockholder or otherwise on behalf of any other person, firm or corporation, directly or indirectly solicit or attempt to solicit away from the Company any of its officers or employees or offer employment to any person who is an officer or employee of the Company; *provided*, *however*, that a general advertisement to which an employee of the Company responds shall in no event be deemed to result in a breach of this Section 10.2.

10.3 *Breach; Violation*. In the event that a Participant breaches or violates any provision of Section 10.1 or 10.2 hereof, the Participant shall thereupon forfeit any right and interest of the Participant to receive payments or benefits hereunder, and the Company shall thereupon have no further obligation to provide such payments or benefits to the Participant hereunder.

10.4 *Survival of Provisions*. The provisions of this Section 10 shall survive the termination or expiration of the applicable Participant's employment with the Company and shall be fully enforceable thereafter. If it is determined by a court of competent jurisdiction in any state that any restriction in this Section 10 is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.

11. Miscellaneous.

11.1 *No Waiver*. No waiver by the Company or any Participant, as the case may be, at any time of any breach by the other party of, or of any lack of compliance with, any condition or provision of the Plan to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. All other plans, policies and arrangements of the Company in which the Participant participates during the term of the Plan shall be interpreted so as to avoid the duplication of benefits paid hereunder.

11.2 *No Right to Employment*. Nothing contained in the Plan or any documents relating to the Plan shall (i) confer upon any Participant any right to continue as a Participant or in the employ of the Company or a subsidiary, (ii) constitute any contract or agreement of employment, or (iii) interfere in any way with the at-will nature of the Participant's employment with the Company.

11.3 *Termination and Amendment of Plan*. The Company shall have the right to amend (and to amend or cancel any amendments), or, subject to Section 2 hereof, terminate the Plan at any time by resolution of the Board; *provided*, *however*, that after a Change of Control, the Company may not terminate the Plan and no amendment to the Plan shall be made which removes any Participant from participation in the Plan, which amends subsection (W), (X) or (Y) of Section 1 hereof or which adversely affects a Participant's interests without the express written consent of the Participant(s) so affected. Subject to Section 10.3 hereof, notwithstanding anything contained herein to the contrary, all obligations accrued by Participants prior to any termination of the Plan must be satisfied in full in accordance with the terms hereof.

11.4 *Benefits not Assignable*. Except as otherwise provided herein or by law, no right or interest of any Participant under the Plan shall be assignable or transferable, in whole or in part, either directly or by operation of law or otherwise, including, without limitation, by execution, levy, garnishment, attachment, pledge or in any manner; no attempted assignment or transfer thereof shall be effective; and no right or interest of any Participant under the Plan shall be liable for, or subject to, any obligation or liability of such Participant. When a payment is due under the Plan to a Participant who is unable to care for his or her affairs, payment may be made directly to his or her legal guardian or personal representative.

11.5 *Tax Withholding*. The Company shall withhold from any payments made to a Participant under this Plan all federal, state and local income, employment and other taxes that the Company reasonably determines to be required to be withheld by the Company in connection with such payments, in amounts and in a manner to be determined in the sole discretion of the Company. Except to the extent specifically provided within this Plan or any separate written agreement between a Participant and the Company, a Participant shall be solely responsible for the satisfaction of any taxes with respect to the benefits payable to the Participant under this Plan (including, but not limited to, employment taxes imposed on employees and additional taxes on nonqualified deferred compensation).

11.6 *Code Section 409A*.

(A) *Generally*. Although the Company intends and expects that the Plan and its payments and benefits will not give rise to taxes imposed under Section 409A of the Code, neither the Company, nor its employees, directors, or agents shall have any obligation to mitigate or to hold any Participant harmless from any or all of such taxes.

(B) *Section 409A Six-Month Delayed Payment Rule*. If any payments or benefits that become payable under this Plan on account of the Participant's termination of employment constitute a deferral of compensation under Code Section 409A, such payments or benefits will be provided when the Participant incurs a "separation from service" within the meaning of Treasury Regulation § 1.409A-1(h) or successor provision ("Separation from Service"). If, at the time of the Participant's Separation from Service, the Participant is a "specified employee" (within the meaning of Section 409A of the Code and Treasury Regulation Section 1.409A-1(i) or successor provision), the Company will

not pay or provide any "Specified Benefits" (as defined herein) during the six-month period beginning with the date of the Participant's Separation from Service (the "409A Suspension Period"). In the event of a Participant's death, however, the Specified Benefits shall be paid to the Participant's Beneficiary without regard to the 409A Suspension Period. For purposes of this Plan, "Specified Benefits" are any payments or benefits that would be subject to Section 409A additional taxes if the Company were to pay them, pursuant to this Plan, on account of the Participant's "separation from service." Within 14 calendar days after the end of the 409A Suspension Period, the Participant shall be paid a lump-sum payment in cash equal to any Specified Benefits delayed during the 409A Suspension Period.

11.7 *California Law*. This Plan shall be construed, interpreted and the rights of the parties determined in accordance with the laws of the State of California, to the extent not preempted by federal law, which shall otherwise control.

11.8 *Validity*. The invalidity or unenforceability of any provision of the Plan shall not affect the validity or enforceability of any other provision of the Plan, which shall remain in full force and effect. If the Plan shall for any reason be or become unenforceable by either party, the Plan shall thereupon terminate and become unenforceable by the other party as well.

ANNEX A

AMGEN INC. CHANGE OF CONTROL SEVERANCE PLAN
SUBSIDIARIES EXCLUDED FROM THE DEFINITION "COVERED SUBSIDIARIES"

Effective March 2, 2011, the following designated Subsidiaries shall be excluded from the definition "*Covered Subsidiaries*" in the Amgen Inc. Change of Control Severance Plan (the "Plan") and such designation shall remain in effect until modified by the Administration Committee as defined in the Plan:

NONE

Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission.

SOURCING AND SUPPLY AGREEMENT

This Sourcing and Supply Agreement (this "Agreement") is made by and between Amgen USA Inc. ("Amgen"), a wholly-owned subsidiary of Amgen Inc., and DaVita Inc. ("Dialysis Center") to set forth the terms and conditions upon which Dialysis Center Purchasers shall purchase EPOGEN® (Epoetin alfa) and Amgen shall provide discounts and pay rebates to Dialysis Center on EPOGEN. Each of Amgen and Dialysis Center are referred to herein as a "Party" and together as the "Parties". Amgen Inc. is a party to this Agreement for the purposes set forth in Sections 3.1, 8.2, 9.4, 9.5.1, and 11.14 of this Agreement. Capitalized terms used herein and not otherwise defined herein shall have the meaning set forth in Section 1.

RECITALS

WHEREAS, Amgen is a leading innovator in the field of ESAs with expertise in the field of anemia management and the ability to manufacture and supply safe and efficacious ESAs for the treatment of dialysis patients;

WHEREAS, Dialysis Center is a leading provider of dialysis services in the Territory with expertise in establishing and delivering state-of-the-art, quality-of-care standards, practices and procedures for the care of patients undergoing dialysis;

WHEREAS, Dialysis Center desires to select one ESA supplier to meet its primary ESA needs on a long term basis for patients undergoing dialysis;

WHEREAS, Dialysis Center has evaluated the ESAs available for commercial use and those in clinical development, including potential [*] ESAs, and has determined that EPOGEN® (Epoetin alfa) will be its preferred ESA for managing anemia for patients undergoing dialysis;

WHEREAS, the Parties wish to enter into this Agreement to, among other things, provide for Dialysis Center's selection of Amgen as the Dialysis Center Purchasers' supplier of EPOGEN to meet the Dialysis Center Purchasers' requirements for EPOGEN for the treatment of dialysis patients during the Term, on all of the terms provided herein;

WHEREAS, Dialysis Center seeks stable, predictable and competitive pricing over a seven year period, which it can achieve through the discounts, rebates and other price concessions set forth herein;

WHEREAS, in order to provide Dialysis Center with such pricing over a seven year period, Amgen will make substantial long-term investments and forego other potential opportunities to scale and schedule its manufacturing capacity and supply of EPOGEN for Dialysis Center Purchasers in accordance with Dialysis Center Purchasers' anticipated demand for EPOGEN for use in the Territory as provided under this Agreement;

NOW THEREFORE, in consideration of the foregoing recitals and of the mutual promises and covenants set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, each Party hereby agrees as follows:

1. DEFINITIONS

When used with initial capitals herein, the following terms shall have the meaning ascribed to them below:

1.1. "Actual Supply Shortfall" has the meaning set forth in Section 2.5.

1.2. "Added Dialysis Center Purchaser" has the meaning set forth in Section 2.8.2.

1.3. "Added Dialysis Center Purchaser Effective Date" has the meaning set forth in Section 2.8.2.

1.4. "Added Dialysis Center Purchaser Transaction Date" means with respect to each Added Dialysis Center Purchaser: (a) in the case of a new Dialysis Center Affiliate, the effective date of the acquisition or establishment of the new Dialysis Center Affiliate; or (b) in the case of a new Managed Center, the earlier of (i) the effective date of the contract pursuant to which a dialysis facility becomes a Managed Center or (ii) the date Dialysis Center first provides services to a dialysis facility that results in such facility becoming a Managed Center, in each case after the Term Start Date.

1.5. "Administrator" has the meaning set forth in Section 9.2.1.

1.6. "Affiliate" of a given entity shall mean an entity that controls, is controlled by, or under common control with such given entity. Control shall mean ownership of more than fifty percent (50%) of the voting stock of an entity or, for non-stock entities, the right to more than fifty percent (50%) of the profits of such entity.

1.7. "[*]" has the meaning set forth in Section 2.5.1.

1.8. "Alternative ESA" means an ESA that is available for use in the Territory that is not EPOGEN or Aranesp.

1.9. "Alternative ESA Purchase Amount" has the meaning set forth in Section 2.1.1.

1.10. "Alternative ESA Purchase Event" has the meaning set forth in Section 2.1.1.

1.11. "Alternative ESA Purchase Event Share of Sales" shall be calculated as follows

[*]

A = Committed Unit Purchases of Amgen ESAs during the [*] which an Alternative ESA Purchase Event has occurred

B = Committed Unit Purchases of Amgen ESAs during the [*] which such Alternative ESA Purchase Event has occurred

C = Committed Unit Purchases of Alternative ESAs during the [*] which an Alternative ESA Purchase Event has occurred

D = Committed Unit Purchases of Alternative ESAs during the [*] which such Alternative ESA Purchase Event has occurred

1.12. "Amgen Business Representative" has the meaning set forth in Section 4.1.

1.13. "[*]" means [*] for use with patients receiving Dialysis Services, which [*] is the subject of a written agreement between the Parties or their Affiliates.

1.14. "Amgen ESA Risk Evaluation Program" has the meaning set forth in Section 11.18.

1.15. "Amgen ESAs Share of Sales" shall mean Committed [*] Purchases of Amgen ESAs during the Quarter divided by the sum of Committed [*] Purchases of Amgen ESAs and Committed [*] Purchases of Alternative ESAs during the Quarter.

Amgen ESAs Share of Sales Illustration:

Committed [*] Purchases of Amgen ESAs

÷

Committed [*] Purchases of Amgen ESAs + Committed [*] Purchases of Alternative ESAs

1.16. "Amgen Indemnitees" has the meaning set forth in Section 9.5.2.

1.17. "Appeal Procedures" has the meaning set forth in Section 9.2.3.

1.18. "Aranesp" means Amgen's proprietary darbepoetin alfa product that is marketed by Amgen in the Territory under the trademark Aranesp®.

1.19. "Arbitrator" has the meaning set forth in Section 9.2.1.

1.20. "Authorized Removal Occurrence" has the meaning set forth in Section 2.8.3.

1.21. "Authorized Wholesalers" shall mean those wholesalers listed on Exhibit B, as such list may be modified pursuant to Section 2.7.

1.22. "Authorized Wholesaler List" has the meaning set forth in Section 2.7.

1.23. "Available EPOGEN SKUs" have the meaning set forth in Section 2.4.5.

1.24. "Award" has the meaning set forth in Section 9.2.3.

1.25. "Base Invoice Discount" means the base invoice discount described in Section 2.1 of Exhibit A.

1.26. "Base Rate Rebate" means the base rebate described in Section 3.1 of Exhibit A.

1.27. "Baseline [*]" has the meaning set forth in Section 2.1.2.

1.28. "[*] Rebate" means the [*] rebate described in Section 3.2 of Exhibit A.

1.29. "Best Price" has the meaning set forth in Section 3.6.

1.30. "[*] Rebate" means the [*] rebate described in Section 3.3 of Exhibit A.

1.31. "Business Representatives" has the meaning set forth in Section 4.1.

1.32. "Certification" has the meaning set forth in Section 5.2.

1.33. "Committed [*] Purchases of Amgen ESAs" means, for any period, the aggregate amounts in [*] of EPOGEN and Aranesp purchased by all Dialysis Center Committed Purchasers during such period for use in providing Dialysis Services, net of product returns and adjustments, which aggregate [*] data have been independently confirmed by Amgen through the Relevant Information.

1.34. "Committed [*] Purchases of Alternative ESAs" means, for any period, the aggregate amounts in [*] of all Alternative ESAs purchased by all Dialysis Center Committed Purchasers from any source during such period for use in providing Dialysis Services, (provided that any Alternative ESA provided to a Dialysis Center Committed Purchaser at no or nominal cost from any source shall be considered a purchase), adjusted to be an equivalent [*] of EPOGEN (in [*]) based on the [*] (if the [*] is clearly set forth therein) or otherwise as reasonably determined pursuant to Section 2.1.2, and which aggregate [*] data have been independently confirmed by Amgen through the Relevant Information.

1.35. "Compensation Data" has the meaning set forth in Section 6.1.

1.36. "Confidential Information" has the meaning set forth in Section 11.14.

1.37. "Data" means the data set forth on Schedule 1 provided by Dialysis Center to Amgen pursuant to the terms and conditions of Section 5 and Exhibit A.

1.38. "Debarred Party" has the meaning set forth in Section 10.2.3.

1.39. "Designated Affiliates" shall mean any Affiliate of Dialysis Center listed on Exhibit C, as such list may be modified pursuant to Section 2.8.1.

1.40. "Designated Affiliates List" has the meaning set forth in Section 2.8.1.

1.41. "Dialysis Center Business Representative" has the meaning set forth in Section 4.1.

1.42. "Dialysis Center Committed Purchasers" has the meaning set forth in Section 2.8.5.

1.43. "Dialysis Center Committed Purchasers List" has the meaning set forth in Section 2.8.5.

1.44. "Dialysis Center Indemnitees" has the meaning set forth in Section 9.5.1.

1.45. "Dialysis Center Purchasers" shall mean Dialysis Center, the Designated Affiliates, and the Managed Centers. Dialysis Center Purchasers include Added Dialysis Center Purchasers from and after the Added Dialysis Center Purchaser Effective Date.

1.46. "Dialysis Services" means services related to the treatment of patients receiving renal dialysis, including hemodialysis, peritoneal dialysis, nocturnal dialysis, and home hemodialysis in the Territory during the Term.

1.47. "Disclosing Party" has the meaning set forth in Section 11.14.

1.48. "Discounts" means all rebates and discounts set forth on Exhibit A that may be earned by the Dialysis Center Purchasers pursuant to the terms and conditions set forth in this Agreement, which shall be earned, calculated and vested as provided in Exhibit A.

1.49. "Disputes" has the meaning set forth in Section 9.1.

1.50. "[*]" has the meaning set forth in Section 2.1.2.

1.51. "EPOGEN" means Amgen's proprietary epoetin alfa product that is marketed by Amgen in the Territory under the trademark EPOGEN®.

1.52. "EPOGEN Equivalent Quantity" has the meaning set forth in Section 2.1.1.

1.53. "ESAs" shall mean agents that stimulate erythropoiesis.

1.54. "FDA" has the meaning set forth in Section 8.3.

1.55. "FDA Website" has the meaning set forth in Section 11.18.

1.56. "Firm" has the meaning set forth in Section 3.2.

1.57. "Forecast Shortfall" has the meaning set forth in Section 2.4.2.

1.58. "Forecast Shortfall Amount" has the meaning set forth in Section 2.4.2.

1.59. "Force Majeure Event" has the meaning set forth in Section 11.8.

1.60. "Governmental Authority" shall mean in respect of any individual or entity, any government administrative agency, commission or other governmental authority, body or instrumentality, or any federal, state, or local governmental regulatory body having legal jurisdiction over that individual or entity.

1.61. "Gross Purchases of Amgen ESAs" means, for any period, the aggregate gross amounts paid for purchases of EPOGEN and Aranesp by all Dialysis Center Purchasers during such period for use in providing Dialysis Services, calculated by using [*] in effect on

each date of purchase, net of product returns and adjustments, which aggregate sales data have been independently confirmed by Amgen through the Relevant Information.

1.62. "Hearing" has the meaning set forth in Section 9.2.3.

1.63. "HIPAA" shall mean the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, each as may be amended.

1.64. "IMS" means IMS Health Incorporated, a Delaware corporation and its Affiliates.

1.65. "Indemnified Party" has the meaning set forth in Section 9.6.1.

1.66. "Indemnifying Party" has the meaning set forth in Section 9.6.1.

1.67. "Individually Identifiable Health Information" shall have the meaning specified in HIPAA.

1.68. "Initial [*]" has the meaning set forth in Section 2.1.2.

1.69. "[*]" means an [*] for EPOGEN, Aranesp or an Alternative ESA, as applicable, based on its measured biological activity or effect.

1.70. "Joint Project" has the meaning set forth in Section 7.1.

1.71. "Joint Project Committee" has the meaning set forth in Section 7.1.

1.72. "Law" means, individually and collectively, any and all applicable laws, ordinances, rules, regulations, directives, administrative circulars, guidances and other pronouncements having the effect of law of any Governmental Authority.

1.73. "Liquidated Damages" has the meaning set forth in Section 10.3.

1.74. "Managed Center" shall mean a dialysis facility that is not an Affiliate of Dialysis Center but for which Dialysis Center or an Affiliate of Dialysis Center provides management services or administrative services in which it controls the selection or procurement of ESAs.

1.75. "Managed Centers List" has the meaning set forth in Section 2.8.1.

1.76. "Material Label Change" means a material amendment, change, revision, and/or modification to the Chronic Kidney Disease section of the Boxed Warning of the US prescribing information for EPOGEN as it relates to dialysis use.

1.77. "Minimum Forecast Commitment" has the meaning set forth in Section 2.4.2.

1.78. "[*] Rebate" means the [*] rebate described in Section 3.4 of Exhibit A.

1.79. "Non-Disclosing Party" has the meaning set forth in Section 11.14.

1.80. "Notice of Added Dialysis Center Purchaser" has the meaning set forth in Section 2.8.2.

1.81. "Objection Notice" has the meaning set forth in Section 3.2.

1.82. "Other Agreement(s)" has the meaning set forth in Section 2.2.

1.83. "Other Agreement Early Termination Date" has the meaning set forth in Section 2.2.

1.84. "Party" and "Parties" have the meaning set forth in the preamble hereto.

1.85. "[*]" has the meaning set forth in Section 5.5.

1.86. "Permitted Percentage Variances" has the meaning set forth in Section 2.4.3.

1.87. "Permitted Variance Period" has the meaning set forth in Section 2.4.3.

1.88. "Policies and Procedures" has the meaning set forth in Section 2.8.6.

1.89. "Project Plan" has the meaning set forth in Section 7.1.

1.90. "Project Proposal" has the meaning set forth in Section 7.1.

1.91. "Purchase Commitment" has the meaning set forth in Section 2.1.

1.92. "Qualified Gross Purchases of EPOGEN" shall mean the amount of EPOGEN purchased by Dialysis Center Purchasers during the Term from an Authorized Wholesaler (or from Amgen pursuant to Section 2.7) for use in providing Dialysis Services, and confirmed by Amgen through sales tracking data. Qualified Gross Purchases of EPOGEN shall be calculated using the [*] in effect at the time of the relevant purchase, net of product returns and adjustments.

1.93. "Quarter" shall mean each calendar quarter during the Term (*i.e.*, January 1 through March 31, April 1 through June 30, July 1 through September 30, and/or October 1 through December 31, as applicable).

1.94. "Recall" has the meaning set forth in Section 11.19.

1.95. "Relevant Information" means the Data, all sales tracking data, Self-Reported Purchase Data, Compensation Data and other relevant information, including relevant Third Party reporting agency data.

1.96. "Research Study" has the meaning set forth in Section 5.5.

1.97. "Rolling Forecast" has the meaning set forth in Section 2.4.1.

1.98. "Rolling Forecasts" has the meaning set forth in Section 2.4.1.

1.99. "Rules" has the meaning set forth in Section 9.2.1.

1.100. "Self-Reported Purchase Data" means all [*] purchased of each ESA and the number of patients who received each such ESA from Dialysis Center Purchasers and such other related data as may be specified on Exhibit SR-1.

1.101. "[*]" has the meaning set forth in Section 5.5.

1.102. "Supply Commitment" has the meaning set forth in Section 2.1.

1.103. "Supply Shortfall" has the meaning set forth in Section 2.5.

1.104. "Supply Shortfall Notice" has the meaning set forth in Section 2.5.

1.105. "Supply Shortfall Quarter" has the meaning set forth in Section 2.5.

1.106. "Term" means the period commencing on the Term Start Date and ending on the Term End Date.

1.107. "Term End Date" shall mean December 31, 2018.

1.108. "Term Start Date" shall mean January 1, 2012.

1.109. "Termination Date" means the date upon which this Agreement shall have been terminated in accordance with the terms and conditions of this Agreement pursuant to Section 10.2.

1.110. "Territory" means the United States, and its territories and possessions, including Puerto Rico.

1.111. "Third Party" means any individual or entity other than a Party or an Affiliate of a Party (or, in the case of Dialysis Center, a Managed Center).

1.112. "Third Party Claim(s)" has the meaning set forth in Section 9.5.1.

1.113. "[*]" shall mean the [*] for EPOGEN to [*] as established by [*] in its [*] from time to time, not including prompt pay or other discounts, rebates, or reductions in [*].

2. **PURCHASE AND SUPPLY COMMITMENTS**

2.1. Purchase and Supply Commitments. Subject to the terms and conditions of this Agreement, (i) the Dialysis Center Committed Purchasers shall purchase from Amgen through one or more Authorized Wholesalers those quantities of EPOGEN that are needed to meet an Amgen ESAs Share of Sales of at least ninety percent (90%) during each Quarter of the Term (the "Purchase Commitment"), and (ii) Amgen shall ensure that during each Quarter of the Term [*] percent ([*]%) of the [*] for each such Quarter is available for purchase by the Dialysis Center Purchasers from one or more Authorized Wholesalers (the "Supply Commitment"). Subject to Section 2.3.2 and Section 2.3.3, Amgen acknowledges and agrees that nothing in this Agreement shall prohibit any Dialysis Center Committed Purchaser from purchasing an amount of EPOGEN necessary to satisfy the Purchase Commitment in a particular Quarter regardless of whether such EPOGEN was actually administered by the Dialysis Center Committed Purchasers to their patients for the provision of Dialysis Services during such Quarter.

2.1.1. *Alternative ESA Purchases*. If in any Quarter the Dialysis Center Committed Purchasers do not meet the Purchase Commitment (an "Alternative ESA Purchase Event"), then Dialysis Center shall (i) within thirty (30) days of the end of any such applicable Quarter provide notice to Amgen of such Alternative ESA Purchase Event, including the Committed [*] Purchases of Alternative ESAs in such Quarter and (ii) within thirty (30) days of the end of the Quarter immediately following the Quarter in which the Alternative ESA Purchase Event occurred, the Committed [*] Purchases of Alternative ESAs in such subsequent Quarter. If Dialysis Center provides such notice pursuant to this Section 2.1.1, or if Amgen, in its sole discretion, through the use of Relevant Information determines that there has been an Alternative ESA Purchase Event, then Amgen shall have the right to deliver to Dialysis Center a notice that sets forth the "EPOGEN Equivalent Quantity," which shall be that quantity of EPOGEN (in [*]) [*] but for the Alternative ESA Purchase Event (based on the [*] (if the [*] is clearly set forth therein), or otherwise as reasonably determined by Amgen through the Relevant Information as set forth in Section 2.1.2). In the event the Alternative ESA Purchase Event Share of Sales is equal to or greater than ninety percent (90%), then Dialysis Center shall be deemed to have met the Purchase Commitment for the Quarter in which the Alternative ESA Purchase Event occurred. If the Alternative ESA Purchase Event Share of Sales is less than ninety percent (90%) for any reason, including a Force Majeure Event related to Dialysis Center and/or the Dialysis Center Purchasers, and not the result of a Supply Shortfall, then Amgen shall deliver to Dialysis Center a notice, and Dialysis Center shall pay to Amgen within thirty (30) days of its receipt of such notice, an amount (the "Alternative ESA Purchase Amount") indicated by Amgen (as determined by Amgen based on the Relevant Information) in such notice equal to (a) the EPOGEN Equivalent Quantity multiplied by (b) [*] of EPOGEN earned by the Dialysis Center Committed Purchasers during such Quarter. At Amgen's option, any Alternative ESA Purchase Amount may be offset in whole or in part against any Discounts earned by the Dialysis Center Purchasers on Qualified Gross Purchases of EPOGEN in the applicable Quarter or any subsequent Quarter.

2.1.2. If a Party, in its reasonable discretion, feels that the Dialysis Center Committed Purchasers potentially may not meet the Purchase Commitment due to purchases of Alternative ESAs by the Dialysis Center Committed Purchasers in a Quarter, then Amgen shall in consultation with Dialysis Center determine the appropriate methodology to be used to determine the [*] (in [*]) of an Alternative ESA that was

used by the Dialysis Center Committed Purchasers patients' during the applicable measurement period that is equivalent to a [*] (in [*]) of EPOGEN that was used by the Dialysis Center Committed Purchasers patients' during the applicable measurement period (the "[*]") and Dialysis Center shall reasonably cooperate with Amgen and provide any other reasonable data, including [*] of ESAs utilized during the applicable measurement period, necessary to complete the determination. If Dialysis Center has a reasonable objection to the methodology proposed by Amgen, the Parties shall appoint a mutually agreeable Third Party to determine the methodology to be used with the costs of such Third Party to be borne equally by the Parties. The initial [*] for any particular Alternative ESA as determined by either the Parties or the Third Party appointed by the Parties, as applicable, pursuant to this Section 2.1.2 (the "Initial [*]") shall only apply to the Quarter immediately preceding the Initial [*]. The determination of the [*] for each particular Alternative ESA shall be recalculated for each of the first [*] after the Initial [*] for such Alternative ESA and the calculation of the [*] for such Alternative ESA after each Quarter during such [*] period shall only apply to the immediately preceding Quarter after each such recalculation. The [*] for a particular Alternative ESA for all periods after such [*] period shall be the [*] determined as of the end of the [*] Quarter after the Initial [*] for such Alternative ESA (the "Baseline [*]"); provided, either Party may, no more frequently than once per calendar year, request a recalculation of the Baseline [*], which recalculation shall be applied prospectively, if such Party reasonably believes that the Baseline [*] has materially changed over time, in which event the requesting Party shall bear the costs of any Third Party appointed by the Parties in connection therewith.

2.2. Purchase Commitment Transition Period for Added Dialysis Center Purchasers. If, after the Term Start Date, there is a new Added Dialysis Center Purchaser pursuant to Section 2.8.2, that is a Dialysis Center Committed Purchaser, Dialysis Center shall use its commercially reasonable efforts to cause such Added Dialysis Center Purchaser to meet the Purchase Commitment as soon as practicable, but such Added Dialysis Center Purchaser shall not be obligated to meet the Purchase Commitment until [*] days after the Added Dialysis Center Purchaser Effective Date. If, as of the Added Dialysis Center Purchaser Effective Date regarding an Added Dialysis Center Purchaser, such Added Dialysis Center Purchaser was a party to a written agreement with a Third Party which includes an obligation on the part of such Added Dialysis Center Purchaser to exclusively purchase an Alternative ESA to meet a majority of its ESA requirements for the provision of Dialysis Services in the Territory (an "Other Agreement(s)") and Dialysis Center can demonstrate via reasonable evidence to Amgen that such Other Agreement was entered into by such Added Dialysis Center Purchaser at least [*] days prior to the Added Dialysis Center Purchaser Transaction Date, then such Added Dialysis Center Purchaser shall not be subject to the Purchase Commitment until [*] days after such time that such Other Agreement(s) can be terminated and/or amended to terminate such obligation with respect to the Alternative ESAs without such Added Dialysis Center Purchaser and/or Dialysis Center and/or any of its Affiliates paying any damages and/or other amounts to such Third Party (the "Other Agreement Early Termination Date"); provided that Dialysis Center shall use its best efforts to terminate such Other Agreement as soon Dialysis Center can do so without such Added Dialysis Center Purchaser and/or Dialysis Center and/or any of its Affiliates paying any damages and/or other amounts to such Third Party. Amgen shall not be obligated to meet the Supply Commitment for any Added Dialysis Center Purchaser until the expiration of the [*] day period after the Added Dialysis Center Purchaser Effective Date or, in the case of an

Added Dialysis Center Purchaser that is a party to an Other Agreement, [*] days after the Other Agreement Early Termination Date.

2.3. Eligible Purchases.

2.3.1. *Purchases from Authorized Wholesaler*. Only purchases of EPOGEN made by a Dialysis Center Purchaser from an Authorized Wholesaler shall be eligible to receive the Discounts provided under this Agreement.

2.3.2. *Own Use*. The Dialysis Center Purchasers shall purchase EPOGEN under this Agreement solely for their own use in providing Dialysis Services, and only purchases made by Dialysis Center Purchasers for such use shall be eligible for the Discounts provided under this Agreement and shall be considered Committed [*] Purchases of Amgen ESAs. Dialysis Center on behalf of itself and each other Dialysis Center Purchaser covenants that none of them shall seek to procure any of the Discounts available under this Agreement for any purchases of EPOGEN not for its or their use in providing Dialysis Services, and Dialysis Center shall promptly notify Amgen in the event Amgen shall have provided any Dialysis Center Purchaser with any Discounts hereunder for any EPOGEN that was not used by them for the provision of Dialysis Services.

2.3.3. *Maximum Quarterly Purchase Increases*. Notwithstanding any other provision of this Agreement, no Discounts earned by Dialysis Center shall apply to Qualified Gross Purchases of EPOGEN for any Quarter that exceed [*] percent ([*]%) of the Qualified Gross Purchases of EPOGEN in the immediately preceding Quarter unless Amgen, in its sole discretion, determines that such increase is necessary for Dialysis Center to meet its Purchase Commitment for any such Quarter. Such calculation shall be adjusted to remove from the calculation the effect of any change in [*], or increases/decreases in the number of Dialysis Center Purchasers during the relevant comparison periods.

2.4. Quantity Forecasts and Minimum Forecast Commitment.

2.4.1. *Rolling Forecast*. Each Quarter during the Term, Dialysis Center shall submit in writing to Amgen a rolling [*] month forecast setting forth on a month-by-month basis the aggregate quantities in [*] of EPOGEN by Available EPOGEN SKU that Dialysis Center has determined in good faith are required for all Dialysis Center Purchasers for each month in the forecast period, starting with an initial [*] month forecast beginning as of [*] which shall be delivered to Amgen by [*] (each, a "Rolling Forecast" and collectively the "Rolling Forecasts"). With the exception of the initial Rolling Forecast, Dialysis Center shall submit each Rolling Forecast by no later than the [*] of the [*] of each Quarter during the Term (e.g., by [*] Dialysis Center shall submit a Rolling Forecast for the [*] month period from [*] through [*]). The Rolling Forecasts shall not reflect any EPOGEN requirements for periods after the Term End Date. If Dialysis Center has not timely delivered a Rolling Forecast as provided above, the Rolling Forecast previously in effect shall remain in effect for the periods covered thereby. The purpose of this Section 2.4.1 is to allow Amgen adequate time to adjust its manufacturing planning and operations to properly reflect the anticipated mix of Available EPOGEN SKUs.

2.4.2. *Minimum Forecast Commitment*. Without reducing or limiting the Purchase Commitment set forth in Section 2.1, the forecasted quantities of each Available EPOGEN SKU for months [*] of each Rolling Forecast shall constitute the Dialysis Center Purchasers' aggregate minimum purchase commitment of [*] of EPOGEN by Available EPOGEN SKU (the "Minimum Forecast Commitment"). If

the Dialysis Center Purchasers purchase an aggregate quantity in [*] of EPOGEN by Available EPOGEN SKU during any Quarter that is less than the Minimum Forecast Commitment for any such Quarter (the quantity of any such difference, the "Forecast Shortfall"), then Amgen shall notify Dialysis Center of the Forecast Shortfall in writing. If the Dialysis Center Purchasers purchase a quantity in [*] of EPOGEN by Available EPOGEN SKU during the Quarter in which the Forecast Shortfall occurred and the immediately following Quarter in the aggregate that is less than the aggregate Minimum Forecast Commitments for such two Quarters, Amgen shall notify Dialysis Centers of such failure in writing, and within thirty (30) days of Dialysis Center's receipt of such notice, it shall pay to Amgen an amount equal to [*] percent ([*]%) of (i) the Forecast Shortfall for the applicable Quarter multiplied by (ii) [*] less the Discounts per [*] of EPOGEN for each Available EPOGEN SKU earned by the Dialysis Center Purchasers during such Quarter (the "Forecast Shortfall Amount"). At Amgen's option, any Forecast Shortfall Amount may be offset in whole or in part against any Discounts earned by the Dialysis Center Purchasers on purchases of EPOGEN in the applicable Quarter or any subsequent Quarter.

2.4.3. *Forecast Variance.* Each Rolling Forecast provided by Dialysis Center may [*] quantities of each Available EPOGEN SKU only for new months [*] and may [*] quantities of each Available EPOGEN SKU in the new months [*] from the corresponding months in the immediately prior Rolling Forecast by the "Permitted Percentage Variances" in the table below. The Permitted Percentage Variances for the months of each Rolling Forecast (the "Permitted Variance Period") are as follows:

Months	[*]	[*]	[*]	[*]	[*]
Permitted Percentage Variance	[*]%	[*]%	[*]%	[*]%	[*]%

If Dialysis Center submits a Rolling Forecast that contains a forecast for any month therein that is not in compliance with this Section 2.4.3, Amgen shall have the right, in its sole discretion, to either (a) accept such forecast for any month therein that is not in compliance with this Section; or (b) adjust such non-compliant forecasted quantity for any such month to increase or decrease the amount forecasted for such month by up to the minimum amount necessary to bring such forecasted quantity into compliance with this Section 2.4.3. Dialysis Center may, at any time for any good faith reason, request additional variances to the Permitted Percentage Variances and, in such event, the Parties shall work in good faith to accommodate such request; provided, however, that (i) in no event shall Amgen be liable for any resulting Supply Shortfall or Actual Supply Shortfall and (ii) Dialysis Center shall remain liable for any Forecast Shortfall that may occur. If in any Quarter during the Term, the Dialysis Center Purchasers have a Forecast Shortfall and the Parties have determined, after good faith discussions, that such Forecast Shortfall is the necessary result of a Material Label Change, then the Dialysis Center Purchasers shall not be liable for such Forecast Shortfall.

2.4.4. *Good Faith Estimates*. Each Rolling Forecast submitted by Dialysis Center shall represent good faith estimates of the Dialysis Center Purchasers' actual anticipated purchases of EPOGEN for the treatment of dialysis patients in the

Territory and reasonable inventory requirements for EPOGEN in the Territory during the relevant timeframes.

2.4.5. *Available EPOGEN SKUs*. The Available EPOGEN SKU Schedule attached as Schedule 3 hereto sets forth the "Available EPOGEN SKUs" as of the Term Start Date. Amgen may add Available EPOGEN SKUs to, or remove Available EPOGEN SKUs (with respect to all purchasers of EPOGEN for free-standing dialysis clinics) from, the Available EPOGEN SKUs Schedule upon at least [*] advance written notice to Dialysis Center; provided that Amgen may not remove any Available EPOGEN SKUs from the Available EPOGEN SKUs Schedule that accounted for [*] percent ([*]%) or more of the Qualified Gross Purchases of EPOGEN during the immediately preceding [*] without the prior written consent of Dialysis Center, which consent may be withheld by Dialysis Center in its sole discretion, unless there is an Available EPOGEN SKU that corresponds to the same dosage, size and potency of the deleted Available EPOGEN SKU; and provided further that, notwithstanding the foregoing, Amgen may immediately remove any Available EPOGEN SKU should Amgen determine, in its sole discretion, that the removal of any such Available EPOGEN SKU is for safety or quality or similar reasons. The Parties shall mutually agree upon (a) the first period for which any such new Available EPOGEN SKU may be ordered by the Dialysis Center Purchasers and (b) any permitted adjustments to the EPOGEN SKU mix contained in Dialysis Center's then applicable Rolling Forecast to reflect any changes in the Available EPOGEN SKUs or as otherwise may be required due to any production shortfall applicable to all EPOGEN customers.

2.5. Supply Commitment Shortfalls. Dialysis Center shall promptly notify Amgen in writing (the "Supply Shortfall Notice") if a Dialysis Center Purchaser has not been able to purchase from the Authorized Wholesalers a quantity of EPOGEN in [*] for any Available EPOGEN SKU that meets the Minimum Forecast Commitment for any Quarter for any reason, including as a result of a Force Majeure Event related to Amgen (a "Supply Shortfall Quarter"), setting forth in such notice the quantity of EPOGEN in [*] by Available EPOGEN SKU representing such shortfall, including as a result of a Force Majeure Event related to Amgen (the "Supply Shortfall"). In the event of a Supply Shortfall, Amgen shall not intentionally discriminate against any of the Dialysis Center Purchasers in its allocation of the available quantities of an Available EPOGEN SKU subject to such Supply Shortfall by making its allocation decisions, in whole or in part, on the basis of the prices, Discounts, and/or other financial terms offered to the Dialysis Center Purchasers pursuant to the terms and conditions of this Agreement. In no event shall the inability to obtain a particular Available EPOGEN SKU in a Minimum Forecast Commitment be deemed a Supply Shortfall, if a Dialysis Center Purchaser can purchase (i) the same quantity of EPOGEN in [*] through other Available EPOGEN SKUs or (ii) Aranesp, other than with respect to use by physicians with privileges at a Dialysis Center Purchaser who have obtained approval through Dialysis Center's formulary exception process to use a "short-acting" Alternative ESA instead of Aranesp. If the Authorized Wholesalers are actually unable to supply the Dialysis Center Purchasers with a quantity of (i) EPOGEN or (ii) Aranesp equal to the Supply Shortfall within the time period reasonably required by the Dialysis Center Purchasers as set forth in the Supply Shortfall Notice, which in no event will be less than five (5) business days after Amgen's receipt of the applicable Supply Shortfall Notice, the Purchase Commitment shall be reduced by the quantity of any Supply Shortfall that actually occurs (the "Actual Supply Shortfall").

2.5.1. In the event of an Actual Supply Shortfall, Dialysis Center shall use good faith efforts to procure any Alternative ESAs from a Third Party at the [*]. Dialysis

Center shall deliver to Amgen a statement setting forth the aggregate [*] (*i.e.*, the aggregate [*] less all applicable discounts, rebates, chargebacks and other price adjustments) actually paid by the Dialysis Center Purchasers to any such Third Party for that quantity of Alternative ESAs purchased by such Dialysis Center Purchasers during the Supply Shortfall Quarter solely as a substitute for the Actual Supply Shortfall (the "[*]"); provided that should Dialysis Center be subject to any confidentiality restrictions that Dialysis Center may have with any Third Party from which it procured Alternative ESAs, then the Parties agree to send such [*] to the Firm to be verified. Amgen shall pay to Dialysis Center an amount of cash equal to the difference, if any, between (a) the [*] and (b) the product of (i) (1) [*] in effect for the Supply Shortfall Quarter less (2) the Discounts per [*] of Available EPOGEN SKU earned by the Dialysis Center Purchasers in such Supply Shortfall Quarter multiplied by (ii) the Actual Supply Shortfall. Amgen shall also pay to Dialysis Center any incremental difference in the aggregate [*] of Aranesp purchased by Dialysis Center Purchasers as a result of the Supply Shortfall compared to the aggregate [*] of EPOGEN unless Amgen shall have notified Dialysis Center in advance that Dialysis Center Purchasers may purchase an Alternative ESA as opposed to Aranesp during the Actual Supply Shortfall.

2.5.2. Upon the completion of an Actual Supply Shortfall, the Purchase Commitment, with respect to the quantities of EPOGEN in [*] of the Available EPOGEN SKUs that constitute the Actual Supply Shortfall shall be suspended for a period of [*] days to allow the Dialysis Center Purchasers to transition back from any Alternative ESA's used by the Dialysis Center Purchasers during such Actual Supply Shortfall back to such applicable Available EPOGEN SKU.

2.5.3. Provided that Amgen complies with its obligations under Section 2.5.1, then Amgen will not be in breach of Section 2.1 and the Supply Commitment as a result of the Actual Supply Shortfall.

2.6. [*]. The Dialysis Center Purchasers shall purchase EPOGEN from an Authorized Wholesaler at the then-prevailing [*] (subject to any wholesaler markup, discount, services fees or other charges), and any Discounts shall be applied in accordance with the schedules and terms set forth in Exhibit A and this Agreement. Amgen reserves the right to change [*] at any time, by any amount, without notice. Amgen shall promptly notify Dialysis Center of any change to [*].

2.7. Authorized Wholesalers. Prior to the Term Start Date, Dialysis Center shall select one or more Authorized Wholesalers from the Authorized Wholesaler list prepared by Amgen and set forth on Exhibit B (as such list may be amended from time to time as provided in this Agreement, the "Authorized Wholesaler List"), and only such selected Authorized Wholesalers shall be Authorized Wholesalers for purposes of this Agreement. From and after the Term Start Date, Dialysis Center shall have the right to change its selection of Authorized Wholesalers from the Authorized Wholesaler List with thirty (30) days prior written notice to Amgen. Dialysis Center may request Amgen to add wholesalers to the Authorized Wholesaler List, and Amgen, at its sole discretion, shall have the right to determine whether to approve of such addition to the Authorized Wholesaler List. Amgen shall have the right to add or remove wholesalers from the Authorized Wholesaler List set forth on Exhibit B in the exercise of its commercially reasonable discretion by thirty (30) days prior written notice to Dialysis Center, provided that for any removal (a) Amgen removes such Authorized Wholesaler with respect to providing EPOGEN to all purchasers of EPOGEN for free standing dialysis clinics, or (b) such Authorized Wholesaler requests Amgen to remove it as an Authorized Wholesaler for

Dialysis Center Purchasers. In the event of any removal of an Authorized Wholesaler from the Authorized Wholesaler List by Amgen, Amgen shall work with Dialysis Center to transition the Dialysis Center Purchasers' purchases of EPOGEN to an alternative Authorized Wholesaler, and if no alternative Authorized Wholesaler exists at such time, the Parties shall use reasonable efforts to establish a direct purchasing relationship in any interim period between the removal of the removed Authorized Wholesaler and the initiation of purchases from a new Authorized Wholesaler, if no Authorized Wholesaler exists at such time. Any such direct purchasing relationship shall be subject to credit qualification and the approval by Amgen of an application for direct ship account. If the Dialysis Center Purchasers purchase EPOGEN directly from Amgen as contemplated in this Section 2.7, all purchases of EPOGEN made from Amgen by such Dialysis Center Purchasers shall be deemed Qualified Gross Purchases of EPOGEN and eligible for the Discounts.

2.8. Dialysis Center Purchasers

2.8.1. *Designated Affiliates and Managed Centers*. Only the Designated Affiliates listed on Exhibit C (as such list may be amended from time to time as provided in this Agreement, the "Designated Affiliates List") and the Managed Centers set forth on Exhibit D (as such list may be amended from time to time as provided in this Agreement, the "Managed Centers List") shall be Dialysis Center Purchasers for purposes of this Agreement. Dialysis Center shall promptly update and maintain the accuracy of the Designated Affiliates List and the Managed Centers List throughout the Term, but in no event later than thirty (30) days after the addition or removal of a Dialysis Center Purchaser pursuant to Section 2.8.2 or 2.8.3 below. Dialysis Center shall not acquire, divest, restructure, reorganize or reclassify its Affiliates or Managed Centers, or request any addition or removal of any Dialysis Center Purchaser, with the purpose or intent in whole or in part to avoid or eliminate its obligations or commitments, or the obligations and commitments of each of the Dialysis Center Purchasers set forth in this Agreement.

2.8.2. *Addition of Dialysis Center Purchasers*. After the Term Start Date, subject to Amgen's reasonable consent under this Section 2.8.2, all new Affiliates and Managed Centers in the Territory shall be added to this Agreement and become Dialysis Center Purchasers. Dialysis Center shall provide prior written notice to Amgen of each new Affiliate and Managed Center in the Territory (each a "Notice of Added Dialysis Center Purchaser"), which notice shall include the proposed Added Dialysis Center Purchaser Transaction Date, plus any additional information regarding the proposed Dialysis Center Purchaser that Amgen shall reasonably request. Upon Amgen's reasonable consent and subject to the terms and conditions of Section 2.2 with respect to the Purchase Commitment, the Designated Affiliates List and the Managed Centers List shall be amended to include such Affiliates or Managed Centers effective as of the later of (i) thirty (30) days from the date of Amgen's receipt of a Notice of Added Dialysis Center Purchaser or (ii) the applicable Added Dialysis Center Purchaser Transaction Date (each such effective date, the "Added Dialysis Center Purchaser Effective Date", and each of the Affiliates and Managed Centers added by such amendments, an "Added Dialysis Center Purchaser"). The Designated Affiliates List and the Managed Centers List shall be amended without further action required of the Parties to reflect additions made in accordance with this Section 2.8.2.

2.8.3. *Removal of Dialysis Center Purchasers*. (A) Dialysis Center may remove Designated Affiliates from the Designated Affiliates List and Managed Centers from the Managed Center List only (i) upon the written consent of Amgen, which consent shall not be unreasonably withheld, conditioned, and/or delayed or (ii) upon thirty (30) days prior written notice to Amgen in the event such removal is a result of a (a) sale of all or substantially all of the assets or equity interests of a Designated Affiliate to a Third Party, whether by reorganization, merger, sales of assets, or sale of equity interests, (b) permanent closure of a Designated Affiliate facility or (c) termination of the relevant management agreement for a Managed Center that has ceased its management relationship with Dialysis Center and/or any Affiliate of Dialysis Center (each of the events described in this clause (ii), an "Authorized Removal Occurrence"). Dialysis Center shall provide Amgen written notice describing the nature of any requested removal, including the anticipated effective date of any Authorized Removal Occurrence, and such removal shall be effective thirty (30) days after Amgen has provided Dialysis Center with written consent to such removal or such earlier period as may be agreed to by Amgen or, in the event of an Authorized Removal Occurrence, the effective date of the Authorized Removal Occurrence.

(B) Amgen shall also have the right to remove any Designated Affiliates from the Designated Affiliates List and any Managed Centers from the Managed Centers List upon thirty (30) days (or such shorter /period as may be required by Law or any Governmental Authority) written notice to Dialysis Center (a) that such removal is required by order of a court or Governmental Authority or (b) in instances in which Amgen determines, in its reasonable discretion, that such removal is required (i) to comply with Law or (ii) as a result of any such Designated Affiliate's or Managed Center's negligence or willful misconduct in the use or administration of EPOGEN.

(C) The Designated Affiliates List and the Managed Centers List shall be amended without further action required of the Parties to reflect removals made in accordance with this Section 2.8.3.

2.8.4. *Adjustments to Rolling Forecast*. Following the addition or removal of an Affiliate to or from the Designated Affiliates List or a Managed Center to or from the Managed Centers List, the Parties shall mutually agree in good faith to implement any reasonable and necessary adjustments to the Rolling Forecast to account for such addition or removal of an Affiliate to or from the Designated Affiliates List or a Managed Center to or from the Managed Centers List; provided, that Amgen shall have no obligation under Section 2.5 for an Actual Supply Shortfall in the event that any increase to the quantities of each Available EPOGEN SKU set forth in such adjusted Rolling Forecast is in excess of the applicable Permitted Percentage Variances.

2.8.5. *Dialysis Center Committed Purchasers List*. The Dialysis Center Purchasers as of the Term Start Date shall constitute the initial list of "Dialysis Center Committed Purchasers" as listed on Exhibit E (as such list may be amended from time to time as provided in this Agreement, the "Dialysis Center Committed Purchasers List"). Each Added Dialysis Center Purchaser shall automatically be added to the Dialysis Center Committed Purchasers List as of the Added Dialysis Center Purchaser Effective Date unless Amgen shall have provided notice to the contrary prior to the Added Dialysis Center Purchaser Effective Date. Any Dialysis Center Purchaser removed from the Designated Affiliates List or the Managed Center List in accordance with Section 2.8.3 shall automatically be removed from the Dialysis

Center Committed Purchaser List as of the effective date of such removal from the Designated Affiliates List or the Managed Center List. Amgen shall have the right in its sole discretion to add or remove any Dialysis Center Purchasers from the Dialysis Center Committed Purchasers List upon at least fifteen (15) days' written notice to Dialysis Center, effective as of the first day of the Quarter after the expiration of the fifteen (15) day notice period; provided, that Amgen shall work together with Dialysis Center to agree as to which specific Dialysis Center Purchasers will be added or removed and, in the event, the Parties are unable to agree in a reasonable time, Amgen may in its discretion add or remove specific Dialysis Center Purchasers that are not disproportionate in their use of Alternative ESAs compared to all Dialysis Center Purchasers. For avoidance of doubt, any Dialysis Center Committed Purchaser that is removed from the Dialysis Center Committed Purchasers List but remains on the Designated Affiliates List or the Managed Center List shall still be considered a Dialysis Center Purchaser.

2.8.6. *Access to Dialysis Center Facilities*. Amgen covenants and agrees that neither it nor any of its employees and/or agents shall have the right to access to any Individually Identifiable Health Information while accessing any of the Dialysis Center Purchasers'. The Parties acknowledge and agree that (a) all of Dialysis Center's applicable policies and procedures regarding visitors and any updates thereto (the "Policies and Procedures") that will be in effect during the Term are and will be available for viewing by Amgen and its employees and/or agents during the Term at http://www.davita.com/about/vendor-policies and (b) Amgen and its employees and/or agents shall have [*] during [*] to the Dialysis Center Purchasers' facilities for the purpose of promoting and providing [*] regarding [*] and shall abide by all the Policies and Procedures during the Term to the extent that such Policies and Procedures have not changed since the Term Start Date, other than as required by any applicable Law and/or generally accepted industry guidance covering vendor access to facilities, in a manner that would limit Amgen's rights under this Section 2.8.6; provided, however, that, notwithstanding anything contained in the Policies and Procedures, Amgen's employees and/or agents shall be permitted to utilize, without any pre-approval or review by Dialysis Center, any Amgen internally approved (i) [*] materials that have been submitted to the FDA, (ii) [*] materials, and (iii) [*] materials, provided, such [*] materials have been previously submitted to Dialysis Center's Vice President of Clinical Management and Vendor Relations for approval and not objected to by Dialysis Center's Vice President of Clinical Management and Vendor Relations within [*] business days of such submission; and provided, further, that Amgen shall provide Dialysis Center's Vice President of Clinical Management and Vendor Relations with copies of all materials to be utilized at the Dialysis Center Purchaser's facilities prior to their first use at any facility of the Dialysis Center Purchasers.

3. DISCOUNTS

3.1. Earning, Calculating, Payment and Vesting of Discounts. All Discounts will be earned, calculated and vested as set forth in Exhibit A. For the purposes of calculating the Discounts hereunder, Qualified Gross Purchases of EPOGEN by any Dialysis Center Purchaser shall be deemed to be made on the date of invoice by an Authorized Wholesaler or Amgen pursuant to Section 2.7 to any such Dialysis Center Purchaser. The Discounts (other than invoice discounts) shall be paid in arrears by electronic funds transfer using information provided to Amgen by Dialysis Center as necessary to enable payment. All Discounts, excluding the Base Rate Rebate and the Base Invoice Discount, shall be conditioned upon material compliance with Section 2.8.6. Amgen Inc.

hereby guarantees Amgen's obligations to pay all Discounts earned by Dialysis Center hereunder.

3.2. Verification and Audit. Discounts (including any qualification criteria for any Discounts) specified herein and/or any other amounts paid by one Party to the other Party pursuant to this Agreement are subject to verification and audit of the relevant purchase and other data (including the Data, the Self-Reported Data and the Compensation Data), as reasonably necessary to calculate any amounts payable hereunder. Dialysis Center Purchasers shall maintain their books and records in accordance with U.S. generally accepted accounting principles, consistently applied. To the extent either Amgen or Dialysis Center, in its reasonable discretion, determines that it is necessary to verify and confirm the calculation of: (a) any Discount described in this Agreement in order to audit and assure compliance with the terms of this Agreement and/or (b) any other amount that one Party must pay to the other Party under this Agreement, the requesting Party shall provide written notice of same to the other Party (an "Objection Notice") setting forth in detail any and all items of disagreement related to such computation, statement, and/or amount that must be paid by one Party to the other Party. Amgen and Dialysis Center shall jointly engage (at the requesting Party's sole cost and expense, subject to any reimbursement by the other Party as set forth below) and refer the items in dispute to a nationally recognized firm of independent, certified public accountants as to which Amgen and Dialysis Center mutually agree (the "Firm"), to resolve any disagreements. Amgen and Dialysis Center will direct the Firm to render a written determination within twenty (20) days of its retention, and Amgen and Dialysis Center and their respective employees and/or agents will cooperate with the Firm during its engagement. The Firm shall keep strictly confidential all data reviewed and information learned or obtained in connection with resolving any Objection Notice and shall report to the requesting Party only the conclusion of its review without the disclosure of any Confidential Information. All reports of the Firm shall be made available to both Parties simultaneously, promptly upon completion, and shall be deemed to conclusively and definitively resolve the related Objection Notice, which shall be reimbursed (if applicable) in accordance with this Section 3.2. Any such audit shall be conducted during normal business hours, and so as not to unreasonably interfere with the business of Amgen and/or any of the Dialysis Center Purchasers. In the event any such audit is requested by Amgen and shows that Dialysis Center Purchasers have submitted incorrect information resulting in Dialysis Center receiving in excess of [*] percent ([*]%) of the amount to which it was entitled in any Quarter, Dialysis Center shall reimburse Amgen for the reasonable costs of such audit; otherwise, Amgen shall be responsible for the costs of such audit. In the event any such audit is requested by Dialysis Center and shows that Dialysis Center Purchasers have submitted correct information but have been underpaid by more than [*] percent ([*]%) of the amount to which they were entitled in any Quarter, Amgen shall reimburse Dialysis Center for the reasonable costs of such audit; otherwise, Dialysis Center shall be responsible for the costs of such audit. The determination of the Firm will be conclusive and binding upon Amgen and Dialysis Center. Following any audit that shows any over or underpayment hereunder, the relevant Party shall, within sixty (60) days, make payment to the other Party for the difference between the amount paid hereunder and the amount actually payable hereunder based upon the results of such audit.

3.3. Adjustments for Changes. In accordance with Section 2.8.2 and/or 2.8.3 above, in the event of an Affiliate's addition to or deletion from the Designated Affiliates List or a Managed Center's addition to or deletion from the Managed Centers List during any Quarter of the Term, Amgen shall adjust Qualified Gross Purchases of EPOGEN to account for such Affiliate's addition to or deletion from the Designated Affiliates List or a

Managed Center's addition to or deletion from the Managed Centers List by adding or deleting such Designated Affiliates' or Managed Centers', as applicable, purchases to or from the relevant Quarter or comparison Quarter (or portion thereof).

3.4. Treatment of Discounts and Rebates.

3.4.1. Dialysis Center agrees that Dialysis Center Purchasers shall properly disclose and account for all Discounts earned hereunder, in whatever form, in compliance with all applicable federal, state, and local Laws, including §1128B(b) of the Social Security Act, as amended and its implementing regulations. Dialysis Center agrees that, if required by such statutes or regulations, it (together with its Designated Affiliates) shall and it shall cause its Managed Centers to (i) claim the benefit of such Discount received in the fiscal year in which such Discount was earned or the year after, (ii) fully and accurately report the value of such Discount in any cost reports filed under Title XVIII or Title XIX of the Social Security Act, as amended or a state or local health care program, and (iii) provide, upon request by the U.S. Department of Health and Human Services or a state or local agency or any other federally funded state health care program, the information furnished to Dialysis Center Purchasers by Amgen concerning the amount or value of such Discount.

3.4.2. In order to assist Dialysis Center's compliance with its obligations as set forth in Section 3.4.1 above, Amgen agrees that it will fully and accurately report all Discounts on the invoices or statements submitted to Dialysis Center and use reasonable efforts to inform Dialysis Center of its obligations to report all such Discounts to the extent specified by 42 C.F.R § 1001.952(h)(2)(ii)(A) or where the value of a Discount is not known at the time of sale, Amgen shall fully and accurately report the existence of the Discount program on the invoices or statements submitted to Dialysis Center and use reasonable efforts to inform Dialysis Center of its obligations to report all such Discounts to the extent specified by 42 C.F.R § 1001.952(h)(2)(ii)(B), and when the value of the Discounts become known, provide Dialysis Center with documentation of the calculation of the Discount identifying the specific goods or services purchased to which the Discount will be applied, in accordance with Section 3.5 below.

3.5. Reports. Within ninety (90) days of the end of each Quarter, Amgen shall provide to Dialysis Center a statement of the Discounts earned hereunder with the itemization of EPOGEN purchases made in a particular Quarter, broken down for each Dialysis Center Purchaser and any other information that Dialysis Center may reasonably request that is reasonably available to Amgen and necessary for Dialysis Center to obtain in order to comply with its obligations hereunder. Dialysis Center agrees that it will provide such information to its Dialysis Center Purchasers in a timely manner in order to allow such Dialysis Center Purchasers to meet their reporting and other obligations hereunder and under applicable Law.

3.6. Best Price Limitation. At any time following the repeal, enactment or modification of any Law, policy, program memorandum, or the interpretation thereof, including a decision by the Centers for Medicare & Medicaid Services, that affects the definition of "Best Price" (which, for purposes of this Agreement, shall mean the price reported in Amgen's Best Price Submission under Title XIX of the Social Security Act) or the methodology by which Best Price must be calculated, Amgen shall have the right, in its sole discretion, to determine the extent to which any [*] to any Third Party due to such repeal, enactment, modification or decision may impact Amgen's Best Price calculation under this Agreement alone or in combination with any other [*] in other agreements with Dialysis Center or any Third Party. In the event that Amgen determines reasonably and in good

faith that the then-existing [*] under this Agreement establishes or would establish a new "Best Price," Amgen shall have the right, in its sole discretion, upon the later of (a) the effective date of such repeal, enactment, modification or decision, or (b) notice to Dialysis Center, to [*] the Discounts offered under this Agreement [*], and shall promptly notify Dialysis Center of the [*]; provided that the [*] as adjusted by Amgen shall result in [*] available to Dialysis Center which would [*] the Best Price prior to the effective date of such repeal, enactment, modification or decision, calculated using the modified definition or methodology by which Best Price is to be calculated.

4. GOVERNANCE

4.1. Business Representatives. The "Business Representatives" shall be comprised of: (i) in the case of Amgen, Amgen's General Manager of the Nephrology Business Unit (the "Amgen Business Representative"); and (ii) in the case of Dialysis Center, the Chief Operating Officer of DaVita Inc. (the "Dialysis Center Business Representative"). Each Business Representative shall be entitled to appoint designees who have been identified to the other Business Representative in writing and have equivalent authority to the Party's Business Representative or have been expressly given all requisite authority by the Party's Business Representative.

4.2. Responsibilities of Business Representatives. The Business Representatives shall be responsible for overseeing the Parties' activities and conduct under this Agreement generally, and for ensuring an appropriate level of oversight. The Business Representatives shall meet in person, via teleconference or videoconference at such times as may be deemed necessary by the Parties).

5. PATIENT AND PRODUCT DATA

5.1. Data Submission. Dialysis Center shall deliver all Data to Amgen (or to a data collection vendor specified by Amgen) in the format and manner provided in Exhibit A and subject to the provisions of this Section 5. To the extent Amgen requests that Dialysis Center deliver Data to a data collection vendor, Amgen agrees to cause any such data collection vendor to adhere to and be bound by a substantially similar confidentiality obligation as is applicable to Amgen under this Agreement, and Amgen shall be liable for any failure by any such data collection vendor to act in accordance with such requirements.

5.2. HIPAA Compliance. Neither Party has the intent that Dialysis Center will provide Amgen (or any specified data collection vendor) any Data in violation of HIPAA. Accordingly, the Parties shall engage an appropriately qualified statistician, reasonably acceptable to each Party, who meets the requirements set forth in 45 C.F.R. § 164.514(b)(1) to review the Data and deliver a written certification that shall conclude that, subject to any conditions, requirements or assumptions set forth therein, each delivery of Data pursuant to this Agreement will meet the standards for "de-identification" under HIPAA (the "Certification"). In connection with the Certification, the Parties agree to use their commercially reasonable best efforts to facilitate the completion and delivery of such Certification to each Party in an expedited manner, and Amgen shall bear the pre-approved costs of such Certification. Notwithstanding anything in this Agreement to the contrary, in order to assure compliance, as determined by either Party in its reasonable discretion, with any existing Law relating to patient privacy of medical records, or at any time following the enactment of any Law relating to patient privacy of medical records that in any manner reforms, modifies, alters, restricts, or otherwise affects any of the Data received or to be received in connection with any of the Discounts contemplated under this Agreement, either Party may, upon thirty (30) days' prior written notice, seek to amend this Agreement with respect to the affected Discount. Dialysis Center and

Amgen shall meet and in good faith mutually agree to modify this Agreement to accommodate any such change in the Law, with the intent to, if possible, retain the essential terms of this Section 5 and the affected Discount and pricing structure of this Agreement.

5.3. Case Identifier. Dialysis Center shall consistently use a unique alpha-numeric code (which shall not be derived from Individually Identifiable Health Information) as a "case identifier" to track the care rendered to each individual patient over time, and such case identifier shall be included in the Data provided to Amgen. The key or list matching patient identities to their unique case identifiers shall not be provided to Amgen.

5.4. Data Use. Amgen and its Affiliates shall have the right to use Data (a) to support verification of the services under this Agreement, (b) for its [*] and [*], development of [*], running [*] analyses, overall analyses of how to improve treatment of patients on dialysis and creating tools by its marketing personnel, (c) in the aggregate for publications as part of a larger data set incorporating comparable clinical data received from other dialysis providers in the Territory and provided that no portion of such data shall be attributed to Dialysis Center or its Affiliates, and (d) for purposes of verifying the Dialysis Center Purchasers' performance under this Agreement and the calculation of amounts payable hereunder, including verifying the Dialysis Center Purchasers' Purchase Commitment performance under this Agreement and calculating or determining the Dialysis Center Purchasers' eligibility to receive any Discount. Notwithstanding the foregoing, without Dialysis Center's prior written consent (such consent not to be unreasonably conditioned, withheld or delayed): Amgen and its Affiliates shall not (i) disclose to Third Parties the Data provided by Dialysis Center hereunder except (1) in any publication referenced in clause (c) above, (2) pursuant to public health activities, (3) to agents of Amgen bound by obligations of confidentiality no less restrictive than those contained in Section 11.14 or (4) to other Third Parties as required by Law or regulation as determined in Amgen's discretion; and (ii) sell or resell any such data or derivative works thereof to any Third Party.

5.5. Clinical Research Studies. Dialysis Center and Amgen acknowledge that Dialysis Center, either directly or through DaVita Clinical Research, Inc., an Affiliate of Dialysis Center, may from time to time be engaged in research studies in which patients of the Dialysis Center Purchasers, may serve as clinical trial subjects (a "Research Study"). Notwithstanding any obligation of Dialysis Center in this Agreement to the contrary, including any requirement in Section 3.5 of Exhibit A, Dialysis Center shall not be required to submit Data for any patients of the Dialysis Center Purchasers that are participating in a Research Study (a "[*]"), but shall continue without limitation to be eligible for, and if earned receive, all Discounts granted pursuant to this Agreement, so long as (i) Dialysis Center notifies Amgen of the [*] whose Data will not be delivered by Dialysis Center to Amgen as otherwise required by this Agreement as a result of such patient being a [*], and (ii) the aggregate number of [*] whose Data is excluded by Dialysis Center does not exceed the [*]. For purposes of the foregoing, "[*]" means [*] percent ([*]%) of the aggregate number of persons receiving treatment from the Dialysis Center Purchasers in any calendar month.

6. OTHER DATA

6.1. Compensation Data. Dialysis Center agrees that it shall provide the data, with respect to EPOGEN, set forth on Schedule 2 attached hereto (the "Compensation Data") to Amgen in the electronic format set forth on Schedule 2 on a calendar [*] basis no later than the fourteenth (14th) day of the following calendar [*] following the [*] for which such Compensation Data is being provided. Amgen acknowledges, agrees and covenants

that it shall only use the Compensation Data for sales force targeting and compensation. Dialysis Center and Amgen acknowledge and agree that the Compensation Data does not include and shall never include any Individually Identifiable Health Information of any patient of Dialysis Center Purchasers. Notwithstanding the foregoing, Amgen acknowledges and agrees that Dialysis Center shall only be required to deliver the Compensation Data to Amgen for as long as [*]. Amgen shall indemnify, defend and hold harmless Dialysis Center from and against any and all loss, damage and/or expense (including reasonable attorney's fees) that it may suffer as a result of claims, demands, actions, proceedings, liabilities, costs or judgments, or threats thereof arising out Dialysis Center's supply of the Compensation Data to Amgen.

6.2. Self-Reported Purchase Data. Dialysis Center, on behalf of the Dialysis Center Purchasers, acknowledges, covenants and agrees that it shall submit full and complete Self-Reported Purchase Data for each Quarter to Amgen within forty-five (45) days of the end of each such Quarter through a Purchase Data Submission Form attached here to as Exhibit SR-1. Exhibit SR-1 is subject to modification by mutual written agreement of the Parties. Dialysis Center on behalf of the Dialysis Center Purchasers shall submit Exhibit SR-1 in an Excel file format electronically by e-mail to [*] or in such other manner as may be specified by Amgen through written notification to Dialysis Center.

7. JOINT PROJECTS

7.1. Joint Projects. The Parties shall form a "Joint Project Committee" comprised of three (3) executives from each Party, one (1) of whom shall be a clinical executive, and shall be led by two (2) co-chairs, one (1) appointed by each of the Parties. During the Term, either Party may present to the Joint Project Committee one or more written proposals (a "Project Proposal") for a project or projects to be undertaken jointly by the Parties related to the provision of Dialysis Services (a "Joint Project"), together with a draft project plan for the Joint Project (a "Project Plan") which the Parties shall discuss in good faith. If the Parties agree in writing to undertake a Joint Project, the Parties shall jointly pursue such Joint Project in accordance with the Project Plan without any further approval action required by the Parties.

7.2. Joint Project Committee.

7.2.1. *Joint Project Committee Responsibilities*. The Joint Project Committee shall be responsible for the following:

a) Reviewing and approving each new Project Proposal prior to adoption of any Joint Projects set forth in such new Project Proposal;

b) Reviewing and approving changes to the Project Plans for existing Joint Projects prior to adoption of such changes;

c) Providing for communication and discussion between the Parties to, as appropriate, coordinate and optimize the development activities of the Parties under each Joint Project;

d) Reviewing and monitoring the activities and progress of the Parties against the Joint Projects;

e) Communicating with the Business Representatives regarding all of the foregoing; and

f) Such other matters as are appropriate to make operational the terms of this Agreement in respect of Joint Projects and as the Parties shall agree in writing.

7.2.2. *Meetings*. The Joint Project Committee shall meet in person, via teleconference or videoconference or otherwise, as frequently as deemed necessary by the Joint Project Committee. All Joint Project Committee meetings shall have at least one (1) member appointed by each Party in attendance.

7.2.3. *Decision Making*. The Joint Project Committee shall make decisions by a unanimous vote. The Parties shall use good faith, reasonable efforts to come to a complete agreement. In the event the Joint Project Committee fails to reach unanimity with respect to any matter, such matter shall be escalated to the Business Representatives.

8. WARRANTIES, REPRESENTATIONS AND COVENANTS

8.1. Power and Authority. Each Party represents and warrants to the other that this Agreement: (a) has been duly authorized, executed, and delivered by it, (b) constitutes a valid, legal, and binding agreement enforceable against it in accordance with the terms contained herein, and (c) does not and shall not conflict with or violate any of its other contractual obligations, expressed or implied, to which it is a party or by which it may be bound.

8.2. Compliance with Law and Regulation. Amgen and Amgen Inc. shall, and Dialysis Center shall, comply with all applicable Laws related to the performance of their respective obligations under this Agreement. Each Party represents and warrants that (which representations and warranties shall be ongoing representations and warranties during the Term): (i) it is not currently named on any of the following lists: (A) HHS/OIG List of Excluded Individuals/Entities, (B) GSA List of Parties Excluded from Federal Programs, or (C) OFAC "SDN and Blocked Individuals" and (ii) it shall promptly notify the other Party in the event it becomes named on any of the following lists: (x) HHS/OIG List of Excluded Individuals/Entities, (y) GSA List of Parties Excluded from Federal Programs, or (z) OFAC "SDN and Blocked Individuals".

8.3. Product. Amgen covenants and agrees that EPOGEN is not and will not be adulterated or misbranded within the meaning of the Federal Food, Drug and Cosmetic Act, as amended, or within the meaning of any applicable Law, or is or will be a product which may not be introduced in to interstate commerce. Amgen warrants that EPOGEN purchased pursuant to this Agreement (a) is manufactured, and up to the time of its receipt by Authorized Wholesalers is handled, stored, and transported in accordance with all applicable Laws, and meet all specifications for effectiveness and reliability as required by the United States Food and Drug Administration (the "FDA"), and (b) when used in accordance with the directions in its labeling is fit for the purposes and indications described in its labeling. Amgen warrants that the use of EPOGEN by Dialysis Center Purchasers shall not infringe upon any ownership rights of any other individual or entity or upon any patent, copyright, trademark or other intellectual property or proprietary right or trade secret of any individual or entity. Amgen agrees that as soon as practicable it will notify Dialysis Center of any material defect in EPOGEN delivered to any Dialysis Center Purchasers in accordance with applicable Law.

8.4. Data. Dialysis Center represents and warrants to Amgen that: (a) the Data, the Compensation Data, and the Self-Reported Purchase Data that the Dialysis Center Purchasers deliver to Amgen pursuant to Section 5 and Section 6 shall be: (i) prepared and delivered in accordance with the provisions of Section 5, Section 6 and Exhibit A and (ii) as complete and accurate as is reasonably obtainable in view of the Dialysis Center Purchasers' customary method of compilation and the nature and accuracy of the Dialysis Center Purchasers' resources; (b) the Dialysis Center Purchasers shall not knowingly and intentionally misrepresent any of the Data, the Compensation Data,

and/or the Self-Reported Purchase Data provided by the Dialysis Center Purchasers to Amgen; and (c) Dialysis Center shall promptly notify Amgen in the event it has actual knowledge that any of the Data, the Compensation Data, and/or the Self-Reported Purchase Data is not complete and/or accurate.

8.5. Designated Affiliates List and Managed Centers List. Dialysis Center represents and warrants that the Designated Affiliates List and the Managed Centers List, as each of them is attached to this Agreement as of the Term Start Date (and as of any subsequent date that such lists are updated in accordance with the terms hereof) are complete and accurate lists of all Affiliates of Dialysis Center and Managed Centers of Dialysis Center providing Dialysis Services in the Territory as of the Term Start Date (and as of each such subsequent date).

8.6. Adverse Claims. Each Party represents and warrants to the other Party that, as of the execution of this Agreement, such Party has no actual knowledge of any legal claim or right to be asserted against the other Party or its Affiliates related to the negotiation or execution of this Agreement.

8.7. NO OTHER WARRANTIES. OTHER THAN THE WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES, AND EACH PARTY EXPRESSLY DISCLAIMS, ALL OTHER WARRANTIES, STATUTORY, EXPRESS, AND/OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY AND/OR FITNESS FOR A PARTICULAR PURPOSE. EACH PARTY HEREBY EXPRESSLY WAIVES ANY AND ALL OTHER WARRANTIES, STATUTORY, EXPRESS, AND/OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY AND/OR FITNESS FOR A PARTICULAR PURPOSE.

9. DISPUTE RESOLUTION, INSURANCE and INDEMNITY

9.1. Escalation of Disputes to Business Representatives. The Parties recognize that claims, disputes or controversies arising out of or relating to this Agreement ("Disputes") may occur from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of Disputes arising under this Agreement in an expedient manner by mutual cooperation and, if possible, without resort to litigation.

In the event of any Dispute, and prior to either Party (a) commencing any action in a court of law or under any Governmental Authority, or (b) taking any action to terminate this Agreement as provided in Section 10, the Parties shall first undertake that the employees of each Party with relevant expertise and authority with respect to a Dispute shall meet to discuss such Dispute within five (5) business days of a Party receiving notice of a Dispute (except in the case where delay in resolving any such Dispute would be materially prejudicial to a Party, in which case the Dispute will be referred directly to the Business Representatives). In the event the Parties are unable to resolve any such Dispute within thirty (30) business days of the initial meeting between the Parties, it shall be referred to the Business Representatives, who shall negotiate with one another in good faith to reach a good faith resolution of the Dispute; provided, that the Parties shall use commercially reasonable best efforts to expedite the resolution of any Disputes which by their nature need to be made quickly by the Business Representatives. In the event the Dispute cannot be resolved by the Business Representatives within fifteen (15) business days of the initial meeting between the Business Representatives or such other period of time as is mutually agreed to by the Parties, then, upon the written demand of either Party, the Dispute shall be subject to arbitration, as provided in Section 9.2. Pending resolution of any Dispute, both Parties will continue their performance under this Agreement of all obligations that are not the subject of any such Dispute. If there is a Dispute relating to any amount owed by either Party to the other Party, the undisputed

portion of such amount shall be paid to the other Party in accordance with the terms hereof, and the Parties shall first attempt to resolve the disputed balance in accordance with this Section 9.1.

9.2. Arbitration.

9.2.1. *Claims*. Subject to Section 9.3 below, any Dispute that is not resolved under Section 9.1 within thirty (30) days after a Party's initial written request for resolution, shall be resolved by final and binding arbitration administered by JAMS (the "Administrator") in accordance with its Comprehensive Arbitration Rules and Procedures (the "Rules"), except to the extent any such Rule conflicts with the express provisions of this Section 9.2. (capitalized terms in this Section 9.2 used but not otherwise defined in this Agreement shall have the meanings provided in the Rules.) For Disputes valued at less than Five Million Dollars ($5,000,000), the Arbitration shall be conducted by one (1) neutral arbitrator ("Arbitrator") selected in accordance with the Rules, provided that such Arbitrator shall not be a current or former employee or director, or a current stockholder, of either Party or any of their respective Affiliates. For Disputes valued at or more than Five Million Dollars ($5,000,000), the Arbitration shall be conducted by a panel of three (3) neutral Arbitrators selected in accordance with the Rules, provided that any such Arbitrator shall not be a current or former employee or director, or a current stockholder, of either Party or any of their respective Affiliates. The Arbitration shall be held in Los Angeles, California.

9.2.2. *Discovery*. Within forty-five (45) days after selection of the Arbitrator(s), the Arbitrator(s) shall conduct the Preliminary Conference. In addressing any of the subjects within the scope of the Preliminary Conference, the Arbitrator(s) shall take into account both the needs of the Parties for an understanding of any legitimate issue raised in the Arbitration and the desirability of making discovery efficient and cost-effective. In that regard, the Parties agree to the application of the E-Discovery procedures set forth in Rule 16.2(c) of JAMS' Expedited Procedures; provided that the Parties agree that the time limitations identified in Rule 16.2 of JAMS' Expedited Procedures shall not be binding and the Arbitrator(s) shall set time limitations for discovery and depositions that are reasonable and necessary in light of the issues and matters raised in the Preliminary Conference. In no event shall the time limitations set by the Arbitrator(s) for discovery and depositions be shorter than the time periods for discovery and depositions that are set forth in Rule 16.2 of JAMS' Expedited Procedures.

9.2.3. *Hearing; Decision*. The hearing ("Hearing") shall commence within a reasonable time after the discovery cutoff. The Arbitrator(s) shall require that each Party submit concise written statements of position and shall permit the submission of rebuttal statements, subject to reasonable limitations on the length of such statements to be established by the Arbitrator(s). The Arbitrator(s) shall also permit the submission of expert reports. The Arbitrator(s) shall render the award ("Award") within thirty (30) days after the Arbitrator(s) declares the Hearing closed, and the Award shall include a written statement describing the essential findings and conclusions on which the Award is based, including the calculation of any damages awarded. The Arbitrator(s) will, in rendering his, her or their decision, apply the substantive law of the State of California, without giving effect to its principles of conflicts of law, and without giving effect to any rules or laws relating to arbitration. The Award rendered by the Arbitrator(s) shall be final, binding and non-appealable, and judgment may be entered upon it in any court of competent jurisdiction. However, the Parties agree that the JAMS Optional Arbitration Appeal Procedures

("Appeal Procedures") shall apply to the Arbitration, at the request by either Party in accordance with such Appeal Procedures. If a Party appeals the Award rendered by the Arbitrator(s), the Award issued by the Appeal Panel (as defined in such Appeal Procedures) shall be final, binding and non-appealable, and judgment may be entered upon it in any court of competent jurisdiction.

9.2.4. *Costs*. Each Party shall bear its own attorney's fees, costs, and disbursements arising out of the Arbitration, and shall pay an equal share of the fees and costs of the Arbitrator(s); provided, however, the Arbitrator(s) shall be authorized to determine whether a Party is the prevailing party, and if so, to award to that prevailing party reimbursement for any or all of its reasonable attorneys' fees, costs and disbursements (including, for example, expert witness fees and expenses, photocopy charges, travel expenses, etc.), and/or the fees and costs of the Administrator and the Arbitrator(s).

9.2.5. *Confidentiality*. Each Party acknowledges and agrees that: (a) any discovery pursuant to this Section 9.2, (b) the Hearing, (c) any and all documents exchanged or delivered in connection with the Hearing, settlement negotiations, and/or settlement terms, including the statements of position, rebuttal statements, and expert reports, (d) settlement negotiations and/or settlement terms, and (e) the Award shall be treated as Confidential Information and subject to the terms and conditions of Section 11.14.

9.3. Court Actions. Nothing contained in this Agreement shall deny either Party the right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing discussions between the Parties or any ongoing arbitration proceeding.

9.4. Insurance. Each Party shall secure and maintain in full force and effect throughout the Term (and following termination, to the extent necessary to cover any claims arising from this Agreement) commercial general liability insurance and product liability (in the case of Amgen only) which include contractual liability with limits of no less than [*] dollars ($[*] USD); professional liability insurance (in the case of Dialysis Center only) with limits of no less than [*] dollars ($[*] USD), and workers' compensation with statutory limits. Any limits on each of a Party's insurance coverage shall not be construed to create any limit on such Party's liability with respect to its obligations under this Agreement or otherwise. Each of the Parties shall have the right to satisfy its obligations under this Section 9.4 through self-insurance. Amgen Inc. hereby guarantees the performance of Amgen's obligations as set forth in this Section 9.4.

9.5. Indemnity.

9.5.1. *By Amgen.* Amgen agrees to indemnify, defend, and hold Dialysis Center, its officers, directors, agents and employees (collectively, the "Dialysis Center Indemnitees") harmless from and against any and all loss, damage and/or expense (including reasonable attorney's fees) that they may suffer as a result of Third Party claims, demands, actions, proceedings, liabilities, costs or judgments, or threats thereof ("Third Party Claim(s)") arising out of (i) any defect in the design and/or manufacture of EPOGEN or the storage and/or transportation of EPOGEN in Amgen's possession, including claims for property damage, loss of life, and/or bodily injury; and/or (ii) the breach by Amgen or Amgen Inc. of any of their respective warranties, representations, and/or covenants contained in this Agreement. Notwithstanding anything to the contrary contained herein, Amgen and Amgen Inc. shall not have any obligation to defend, indemnify, and/or hold the

Dialysis Center Indemnitees harmless from any Third Party Claims arising out of the negligent acts and/or omissions and/or willful misconduct of the Dialysis Center Indemnitees. This indemnification shall survive the termination or expiration of this Agreement. Amgen Inc. hereby guarantees the performance of Amgen's obligations as set forth in this Section 9.5.1.

9.5.2. *By Dialysis Center.* Dialysis Center agrees to indemnify, defend, and hold Amgen, its officers, directors, agents and employees (collectively, the "Amgen Indemnitees") harmless from and against any and all Third Party Claims arising out of (i) any Dialysis Center Purchasers' administration, promotion or use of EPOGEN purchased under this Agreement to its patients; (ii) any Dialysis Center Purchasers' failure to store and/or transport any EPOGEN in its possession in accordance with any applicable Law and/or labeling information; and/or (iii) the breach by Dialysis Center of any of its warranties, representations, and/or covenants contained in this Agreement. For purposes of the foregoing, the "administration" of EPOGEN by Dialysis Center shall mean the dispensing and handling by Dialysis Center and its employees of EPOGEN and the actual administration of EPOGEN to patients by Dialysis Center and its employees, but shall exclude physician prescriptions of EPOGEN to patients. Notwithstanding anything to the contrary contained herein, Dialysis Center shall not have any obligation to defend, indemnify, and/or hold the Amgen Indemnitees harmless from any Third Party Claims arising out of the negligent acts and/or omissions and/or willful misconduct of the Amgen Indemnitees. This indemnification shall survive the termination or expiration of this Agreement.

9.6. *Procedure for Third Party Claims*.

9.6.1. *Notice*. The Party receiving indemnification hereunder (the "Indemnified Party") shall give the Party providing indemnification hereunder (the "Indemnifying Party") written notice within fifteen (15) business days after the Indemnified Party receives notice of any Third Party Claim, subject to indemnification hereunder upon which such Indemnified Party intends to base a request for indemnification under Section 9.5.1 or Section 9.5.2. Failure to give any such notice shall not constitute a waiver of any right to indemnification or reduce in any way the indemnification available hereunder, except and only to the extent that as a result of such failure the Indemnifying Party demonstrates that it was directly and materially damaged as a result of such failure to give timely notice.

9.6.2. *Control of Defense.* The Indemnifying Party, at its expense, shall assume control of the defense and resolution of each Third Party Claim using legal counsel reasonably approved by the Indemnified Party and shall keep the Indemnified Party fully and timely informed of the progress of such defense and resolution. With respect to each Third Party Claim, the Indemnified Party shall have the right to retain independent legal counsel at its cost and monitor such Third Party Claim's defense and resolution. In such a case, the Indemnifying Party and its legal counsel shall fully cooperate with the Indemnified Party and its legal counsel in providing such information as the Indemnified Party may reasonably request. Notwithstanding this Section 9.6.2, the Indemnifying Party shall not be entitled to control, but may participate in, and the Indemnified Party shall be entitled to have sole control over and select counsel to conduct, the defense or settlement of each Third Party Claim that: (i) seeks a temporary restraining order, a preliminary or permanent injunction, and/or specific performance against the Indemnified Party, (ii) involves criminal allegations against the Indemnified Party, (iii) if unsuccessful, would set a precedent that would materially interfere with

and/or have a material adverse effect on the business and/or financial condition of the Indemnified Party, and/or (iv) imposes liability on the part of the Indemnified Party for which the Indemnified Party is not entitled to indemnification hereunder. In such an event, the Indemnifying Party will still have all of its obligations hereunder with respect to any such affected Third Party Claims; provided that the Indemnified Party will not settle any such affected Third Party Claims without the prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld, conditioned, and/or delayed by the Indemnifying Party.

9.6.3. *Representation.* If both the Indemnifying Party and the Indemnified Party are named parties in any Third Party Claim and representation of both Parties by the same legal counsel would be inappropriate due to the actual or potential differing interests between them, then the Indemnified Party, at the Indemnifying Party's expense, shall have the right to be represented by separate counsel of the Indemnified Party's choosing.

9.6.4. *Resolution.* The Indemnifying Party shall not settle, compromise or resolve any Third Party Claim without the written consent of the Indemnified Party; provided that, the Indemnifying Party may, without such consent, enter into any such judgment, settlement, compromise or resolution that relates solely to the payment of money damages, involves a full release of the Indemnified Party and does not result in any admission of any fault of the Indemnified Party with respect to such Third Party Claim.

9.6.5. *Payment*. Any final judgment entered or settlement agreed upon in the manner provided in this Section 9.6, as applicable, shall be binding upon the Indemnifying Party and shall conclusively be deemed to be an obligation with respect to which the Indemnified Party is entitled to prompt indemnification hereunder, if applicable. Payment of all amounts owing by the Indemnifying Party under this Section 9.6, as applicable, shall be made promptly upon a final settlement between the Indemnifying Party and the Indemnified Party or upon a final adjudication determined by the Arbitrator(s) that an indemnification obligation is owed by the Indemnifying Party to the Indemnified Party.

10. TERM AND TERMINATION

10.1. Term. This Agreement shall come into effect as of the Term Start Date and shall expire on the earlier of the Term End Date, or the Termination Date.

10.2. Termination for Cause. Amgen or Dialysis Center may terminate this Agreement only in the event of the following:

10.2.1. *Breach of Purchase Commitment*. The Parties acknowledge and agree that the Purchase Commitment is the principal value expected to be received by Amgen under this Agreement and it is the essential inducement for Amgen to enter into this Agreement, pursuant to which it has agreed, among other things, (a) to provide the Dialysis Center Purchasers for the duration of the Term the economic benefits of the Discounts provided for herein, (b) to make the Supply Commitment, which requires that Amgen commit facilities to the manufacture of EPOGEN at the expense of other Amgen uses and allocate significant resources to maintain its manufacturing capabilities and capacity at a commensurate level, (c) to assume the business risks and financial liability in respect of the representations, warranties and covenants made by it hereunder and (d) to forego potential other commercial opportunities in respect of its nephrology business. In the event that the Dialysis

Center Committed Purchasers do not meet an Amgen ESAs Share of Sales of (i) at least [*] percent ([*]%) for [*] or more [*] during the Term with respect to which the Dialysis Center is required to pay the Alternative ESA Purchase Amount with respect to each of such [*] in any [*] period during the Term, or (ii) at least [*] percent ([*]%) in any [*], then Amgen shall be entitled to terminate this Agreement immediately upon written notice to Dialysis Center and, notwithstanding any other provision of this Agreement, thereupon either receive the "Liquidated Damages" defined below or exercise such other rights and remedies as may be allowed at law or in equity under applicable Law.

10.2.2. *Termination for Failure to Supply*. Dialysis Center may terminate this Agreement immediately upon written notice to Amgen in the event that Amgen has not been able to supply to Dialysis Center through one or more Authorized Wholesalers EPOGEN in [*] (or Aranesp subject to the terms of Section 2.5) equal to at least [*] percent ([*]%) of the Minimum Forecast Commitment (other than as a result of one or more Force Majeure Events) for [*].

10.2.3. *Termination for Exclusion from Federal Health Care Program*. Either Amgen or Dialysis Center may immediately terminate this Agreement upon written notice to the other Party in the event there is change in the other Party's status which excludes it from participation in any "Federal health care program" (as defined under 42 U.S.C. § 1320a-7b(f)) (a "Debarred Party"), provided that no Party shall have the right to terminate this Agreement pursuant to this Section 10.2.3 if the Debarred Party can complete its obligations through, or otherwise transfer its obligations to, an Affiliate as permitted by applicable Law.

10.3. Liquidated Damages. The Parties acknowledge that Amgen's actual damages in the event of a termination by Amgen, pursuant to Section 10.2.1 or Section 10.2.3, would be difficult to ascertain, and that the payment of the Liquidated Damages represents the best estimate of the amount of such damages by the Parties at this time. The Parties further expressly acknowledge and agree that the Liquidated Damages are intended not as a penalty, but as full liquidated damages, in the event of Amgen's termination of this Agreement pursuant to Section 10.2.1 or Section 10.2.3 and as compensation for Amgen's losses and other expenses associated with this Agreement.

For purposes of this Agreement, "Liquidated Damages" means, in addition to any amounts owed to Amgen under this Agreement, including for breach of the Purchase Commitment under Section 2.1, an amount in cash equal to [*] percent ([*]%) of the [*] of Amgen's projected [*] for each remaining Quarter (including any fractional Quarters) in the Term, with such [*] equal to A – B, grown Quarterly at a [*] percent ([*]%) annual rate and discounted on a Quarterly basis, at a rate equal to the average annual increase in [*] for EPOGEN on an [*] basis for all calendar years during the Term prior to the related [*] calculation, where:

A = The average [*] for the [*] most recent Quarters prior to the Termination Date in which Dialysis Center satisfied the Purchase Commitment in full (or, if less than [*] such Quarters exist, then "A" shall equal the average of the sum of (i) [*] plus (ii) the [*], for the [*] most recent Quarters prior to the Termination Date); and

B = The average aggregate [*] (other than the [*] Rebate, the [*] Rebate and the [*] Rebate) earned by Dialysis Center Purchasers during the [*] most recent Quarters prior to the Termination Date, regardless of whether Dialysis Center satisfied the Purchase Commitment in such Quarters.

10.4. Effect of Termination. Upon any termination or expiration of this Agreement, (a) any earned and vested Discounts shall be paid in accordance with the terms set forth in Exhibit A, (b) any Alternative ESA Purchase Amounts shall be paid pursuant to Section 2.1.1, (c) any payments by Amgen owing to Dialysis Center under Section 2.5.1 shall be paid, (d) any payment by Dialysis Center owing to Amgen under Section 2.4.2 shall be paid and (e) the Liquidated Damages pursuant to Section 10.3 shall be paid. All Discounts available to Dialysis Center in the particular Quarter in which such termination occurs shall be paid to Dialysis Center based on an achievement of the eligibility and vesting requirements set forth in Exhibit A.

10.5. Survival. Any provision that, either expressly or by its nature is intended to survive this Agreement, shall survive any expiration or termination of this Agreement, including Sections 1, 3, 8, 9, 10, and 11.

11. MISCELLANEOUS

11.1. Amendment. Except as expressly set forth herein, no amendment of this Agreement shall be effective unless expressed in a writing signed by a duly authorized representative of each Party.

11.2. Assignment. Neither Party shall have the right to assign or otherwise transfer this Agreement, or any of its rights and obligations hereunder, in whole or in part, without the other Party's prior written consent, and any attempted assignment or transfer without such consent shall be void; provided, however, that Amgen may assign or otherwise transfer this Agreement and its rights and obligations hereunder to any of its Affiliates that is not in the business of providing Dialysis Services in the Territory. Notwithstanding the foregoing, each Party shall be obligated to assign and transfer this Agreement, without any required consent, to any Person to whom either such Party has transferred all or substantially all of its business relating to this Agreement, and the Parties agree that they shall take all reasonable and necessary actions in respect thereof including the execution and delivery of all appropriate instruments to effectuate such assignment and transfer of this Agreement; provided that any assignment and transfer of this Agreement by Amgen to any Person, a substantial portion of whose business consists of providing Dialysis Services in the Territory, shall require the prior written consent of Dialysis Center, which consent may be withheld by Dialysis Center in its sole and absolute discretion. This Agreement and the provisions hereof shall be binding upon, and inure to the benefit of, the Parties' permitted successors and assigns.

11.3. Modification of Law. If at any time following the Term Start Date, the enactment or modification of any Law occurs and, as a result, either Party's performance of its obligations under this Agreement would not comply with such Law, either Party may, upon notice to the other Party, recommend an amendment to modify this Agreement to address those provisions of the Agreement that may not comply with such Law. The Parties agree to use their commercially reasonable best efforts to modify this Agreement as necessary to bring it into compliance with the Law if that can be done while retaining, in all material respects, the essential rights and benefits of each Party under this Agreement, including the Purchase Commitment, the Supply Commitment, the collection, exchange and use of the Data and the ability for Dialysis Center Purchasers to earn the Discounts that the Dialysis Center Purchasers are eligible to receive hereunder. Promptly following the delivery of such notice describing the Law at issue and the proposed modifications to bring this Agreement into compliance with such Law, Dialysis Center and Amgen shall meet and in good faith seek to mutually agree to amend this Agreement to accommodate any such Law in accordance with this Section 11.3.

11.4. Conflicting Provisions. To the extent that any provisions of Amgen's general or customary policies and procedures or any terms of any purchase order conflict with or are in addition to the terms of this Agreement or any Exhibit or Schedule attached hereto, the terms of this Agreement and its Exhibits and Schedules shall govern.

11.5. Construction. This Agreement shall be deemed to have been jointly drafted by the Parties, and no rule of strict construction shall apply against either Party. As used herein, the word "including" shall mean "including, without limitation."

11.6. Counterparts; Facsimile/PDF Signatures. This Agreement may be executed in one or more counterparts, each of which shall be considered an original. The Parties agree that facsimile or PDF transmission of original signatures shall constitute and be accepted as original signatures.

11.7. Currency. All amounts herein are set forth in United States Dollars.

11.8. Force Majeure. Except as provided in Section 2.1.1 or Section 2.5, neither Party will be liable for delays in performance or nonperformance of this Agreement or any covenant contained herein if such delay or nonperformance is a result of acts of God, acts of civil or military authority, acts of any Governmental Authority, civil disobedience or commotion, epidemics, war, terrorist acts, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, inability to procure necessary raw materials in a commercially reasonable manner or default of suppliers or subcontractors or any events beyond the reasonable control and without the fault or negligence of a Party (all of the foregoing, a "Force Majeure Event"). Force Majeure Events shall not adversely affect Dialysis Center's eligibility for any Discounts.

11.9. Further Assurances. Each Party shall perform all further acts reasonably requested by the other to effectuate the purposes of this Agreement, including obtaining the Certifications under Section 5 or obtaining purchase data necessary from third parties to calculate any amounts payable pursuant to Exhibit A.

11.10. Governing Law. This Agreement shall be governed by the laws of the State of California (without regard to its conflict of law rules) and, except as otherwise set forth in this Agreement, the Parties submit to the jurisdiction of the California courts, both state and federal.

11.11. Merger/No Reliance. This Agreement, together with the Schedules, and the Exhibits constitutes the entire agreement, written or oral, of the Parties as of the Term Start Date concerning the subject matter hereof. The Parties acknowledge that, in making the determination to enter into this Agreement or otherwise, they have not relied, in whole or in part, on any promise, information, understanding, guarantees, discussions, representation, or warranty, expressed or implied, not contained specifically in this Agreement. Without limiting the generality of the foregoing, the Parties agree that neither Party makes or has made any representation or warranty with respect to any potential changes in the dialysis segment or the use or pricing of ESAs in dialysis, including as a result of the introduction of Alternative ESAs (including [*]) including the timing of such introduction(s), the pricing of such Alternative ESAs and their potential physician acceptance and impact on prescribing practices.

11.12. No Partnership. The relationship between Amgen and Dialysis Center is that of independent contractors, and not a partnership or an agency, franchise or other relationship. Neither Party shall have the authority to bind the other.

11.13. Notices. Any notice or other communication required or permitted hereunder (excluding purchase orders) shall be in writing and shall be deemed given or made five (5) days

after deposit in the United States mail with proper postage for first-class registered or certified mail prepaid, return receipt requested, or when delivered personally or by facsimile (as shown by concurrent written transmission confirmation and confirmed by overnight mail), or one (1) day following traceable delivery to a nationally recognized overnight delivery service with instructions for overnight delivery, in each case addressed to the address set forth below, or at such designated address that either Party shall have furnished to the other in accordance with this Section 11.13:

If to Amgen:

Amgen USA Inc.
One Amgen Center Drive, [*]
Thousand Oaks, CA 91320-1789
Attn: Specialist, Contracts & Pricing – Nephrology Business Unit
Fax: [*]

with a copy to :

Amgen USA Inc.
One Amgen Center Drive, [*]
Thousand Oaks, CA 91320-1789
Attn: General Counsel
Fax: [*]

If to Amgen Inc.: Amgen Inc.
One Amgen Center Drive, [*]
Thousand Oaks, CA 91320-1789
Attn: General Counsel
Fax No.: [*]

If to Dialysis Center:

DaVita Inc.
1350 Old Bayshore Highway, Suite 777
Burlingame, California 94010
Attn: Vice-President of Purchasing
Fax No.: [*]

with a copy to:

DaVita Inc.
1551 Wewatta Street
Denver, CO 80202
Attn: Chief Legal Officer
Fax No.: [*]

11.14. Confidentiality. "Confidential Information" means any and all information provided by one Party and/or any of its Affiliates (including Managed Centers in the case of Dialysis Center) (the "Disclosing Party") to the other Party and/or any of its Affiliates (including Managed Centers in the case of Dialysis Center) (the "Non-Disclosing Party") which is identified in writing or orally as confidential by the Disclosing Party to the Non-Disclosing Party or given the nature of the information or circumstances surrounding its disclosure reasonably should be considered as confidential, whether in written, computerized, oral, tangible or intangible, and/or other form. Nothing in this Section 11.14 shall prohibit,

Amgen from using the Data, the Compensation Data, and/or the Self-Reported Purchase Data as provided in Section 5 and Section 6.

11.14.1. *Confidentiality Covenants*. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Non-Disclosing Party agrees that for the Term, and for a period of five (5) years following the Term, the Non-Disclosing Party will keep confidential and not publish or otherwise disclose to any Third Party or use for any purpose, other than in accordance with this Agreement, any Confidential Information, provided, however, that the Non-Disclosing Party may disclose any such Confidential Information to its directors, officers, employees, agents, consultants and advisors as necessary for the Non-Disclosing Party to carry out its rights and obligations under this Agreement on the condition that such directors, officers, employees, agents, consultants and advisors are bound by confidentiality provisions at least as restrictive as those contained in this Agreement. The confidentiality provisions contained in this Section 11.14 shall not apply to the extent that it can be established by the Non-Disclosing Party by competent proof that such Confidential Information:

(a) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Non-Disclosing Party by the Disclosing Party; or

(b) became generally available to the public or otherwise part of the public domain after its disclosure to the Non-Disclosing Party by the Disclosing Party and other than through any act or omission of the Non-Disclosing Party in breach of this Agreement; or

(c) was independently discovered or developed by the Non-Disclosing Party without the use of or reference to the Confidential Information belonging to the Disclosing Party.

11.14.2. *Retention and Destruction of Confidential Information*. At any time upon the written request of the Disclosing Party the Non-Disclosing Party shall promptly return to the Disclosing Party or destroy all Confidential Information. Notwithstanding the return or destruction of the Confidential Information to the Disclosing Party or such other party as designated by the Disclosing Party to the Non-Disclosing Party, the Non-Disclosing Party covenants and agrees that it will continue to abide by its obligations hereunder with respect to any and all Confidential Information.

11.14.3. *Disclosures Required By Law*. In the event that the Non-Disclosing Party and/or any of its directors, officers, employees, agents, consultants and advisors that have received any Confidential Information is required by Law (e.g., by oral questions, interrogatories, request for information or documents, subpoena, civil investigative demand, or similar process) to disclose any Confidential Information, the Non-Disclosing Party agrees to (and shall cause each of its directors, officers, employees, agents, consultants and advisors that have received any Confidential Information to) provide the Disclosing Party with immediate written notice of any such disclosure of Confidential Information that is required by Law in order to provide the Disclosing Party with an opportunity to seek a protective order or other similar order with respect to such Confidential Information. If disclosure of any Confidential Information is required by Law, the Non-Disclosing Party will (and will cause each of its directors, officers, employees, agents, consultants and advisors that have received any Confidential

Information to) furnish only that portion of the Confidential Information which it is legally obligated to disclose by Law and consistent with the terms of any protective order or other similar order obtained by the Disclosing Party with respect to such Confidential Information required to be disclosed by Law.

11.14.4. *Public Announcements; Authorized Disclosure*. Neither Party shall make a public announcement or other public disclosure concerning this Agreement without the consent of the other Party, except that either Party may make such announcement or disclosure if it is required by applicable Law, reasonably necessary for any filings with any Governmental Authority or pursuant to the rules of any securities exchange or interdealer quotation system; provided, that the disclosing Party shall give reasonable prior advance notice of the proposed text of such announcement or disclosure to the other Party for its prior review and approval, which review and approval shall not be unreasonably conditioned, withheld or delayed. The proviso in the immediately preceding sentence shall not apply to Relevant Information included in any cost report filed under Title XVIII or Title XIX of the Social Security Act, or health care program of any Governmental Authority.

11.14.5. *Confidential Terms.* Notwithstanding the foregoing, each Party may disclose the terms of this Agreement in confidence under terms and conditions at least as restrictive as set forth herein on a need-to-know basis to its legal and financial advisors to the extent such disclosure shall be reasonably necessary in connection with such Party's activities as expressly permitted by this Agreement.

11.14.6. *Enforcement.* Each Party agrees that money damages alone would not be an adequate remedy for any breach of the terms and conditions of this Section 11.14. Therefore, in the event of a breach or threatened breach of this Section 11.14, the non-breaching Party may, in addition to other rights and remedies existing in its favor, apply to any court of competent jurisdiction for specific performance and/or injunctive and/or other relief in order to enforce and/or prevent any violation of the provisions of this Section 11.14 by the breaching Party (without proving monetary damages and/or posting a bond and/or other security).

11.15. Severability. Subject to the provisions of Section 11.3, if any one or more of the provisions of this Agreement is held to be invalid or unenforceable, the provisions shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof.

11.16. Waiver. No Party shall be deemed to have waived any right hereunder, unless such waiver is expressed in a writing signed by such Party.

11.17. Open Records. To the extent required by §1861(v)(1)(I) of the Social Security Act, as amended, the Parties will allow the U.S. Department of Health and Human Services, the U.S. Comptroller General and their duly authorized representatives, access to this Agreement and all books, documents and records necessary to certify the nature and extent of costs incurred pursuant to it during the Term and for four (4) years following the last date any EPOGEN or services are furnished under it. If Amgen carries out the duties of this Agreement through a subcontract worth $10,000 or more over a 12-month period with a related organization, the subcontract shall also contain an access clause to permit access by the U.S. Department of Health and Human Services, the U.S. Comptroller General, and their duly authorized representatives to the related organization's books and records.

11.18. Amgen's ESA Risk Evaluation and Mitigation Strategy Program. Dialysis Center and its Designated Affiliates and Managed Centers shall reasonably cooperate and comply with Amgen in Amgen's implementation of its ESA Risk Evaluation and Mitigation Strategy program as found at the FDA website: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM200105.pdf ("the FDA Website") and which may be modified from time to time by the FDA (the "Amgen ESA Risk Evaluation Program"). Dialysis Center shall refer to the FDA Website for updates to the Amgen ESA Risk Evaluation Program.

11.19. Recall. In the event the FDA initiates a mandatory recall or Amgen initiates a recall, field market withdrawal, stock recovery, or other similar action with respect to EPOGEN (a "Recall"), the Dialysis Center Purchasers shall cooperate with Amgen in implementing the Recall consistent with applicable Law, any industry guidance issued by the FDA, and the terms or procedures of the Recall, including reasonable cooperation with any Amgen designated Third Party vendors.

11.20. Assumption of Risk. Each Party expressly accepts and assumes all risks that may arise out of or result from uncertainties or changes to the dialysis market including those resulting from the introduction of Alternative ESAs (including [*]), including the timing of such introduction(s), the pricing of such Alternative ESAs and their potential physician acceptance and impact on prescribing practices.

The Parties have executed this Agreement by their designated representatives set forth below.

AMGEN USA INC.

By: /s/ Anthony C. Hooper
Name (print): Anthony C. Hooper
Title: EVP
Date: 11/15/2011

DIALYSIS CENTER

By: /s/ Dennis Kogod
Name (print): Dennis Kogod
Title: Chief Operating Officer
Date: 11/15/2011

Amgen Inc. with respect to certain provisions of this Agreement as set forth herein.

Amgen Inc.

By: /s/ Anthony C. Hooper
Name (print): Anthony C. Hooper
Title: EVP
Date: 11/15/2011

Exhibit A

Discount Terms and Conditions

1 **DEFINITIONS.** In addition to the defined terms set forth in Section 1 of this Agreement, the following terms, as used in this Exhibit A, shall have the meaning ascribed below.

[*] *Rebate Definitions*

1.1 "Amgen Dialysis Contract" shall mean, as of any determination date, a contract between Amgen or one of its Affiliates and a Qualified Customer in effect as of such date that provides for such Qualified Customer to purchase EPOGEN for its commercial use in providing Dialysis Services in the Territory.

1.2 "Qualified Customer" shall mean a Third Party commercial enterprise collectively with all of its Affiliates and/or any dialysis facility in which a Third Party commercial enterprise and/or any of its Affiliates has an ownership interest of less than fifty percent (50%) but for which the Third Party commercial enterprise and/or any of its Affiliates provides management services or administrative services in which it controls the selection or procurement of ESAs (a) who has entered into an Amgen Dialysis Contract and (b) who is not exempt from consideration in the calculation of Best Price as defined by the Social Security Act at section 1927(c)(1)(C), as amended, and as implemented by regulation (e.g., any hospital participating in 340B Drug Pricing Program, any qualified state pharmaceutical assistance program, or any purchaser under the Federal Supply Schedule would not be a "Qualified Customer" for purposes of this Agreement).

1.3 "[*]" shall mean for each [*] of EPOGEN purchased by a Qualified Customer in any Quarter under an Amgen Dialysis Contract, the [*] in effect on the date of purchase [*] all of the discounts and rebates per [*] of EPOGEN that, for such Quarter were actually earned by such Qualified Customer pursuant to the terms of such Amgen Dialysis Contract (regardless of the actual Quarter in which such discounts or rebates are actually paid to such Qualified Customer); provided, that if any such discounts and rebates once paid are subsequently returned, revised or withdrawn, including pursuant to any retroactive amendment of the Amgen Dialysis Contract or payment settlement (whether in such Quarter or any subsequent Quarter), the applicable "[*]" shall be based on the discounts, rebates and chargebacks taking into full account such returns, revisions or withdrawals.

[*] *Rebate Definitions*

1.4 "[*] Rebate" shall mean the rebate described in Section 3.3 of this Exhibit A.

1.5 "[*] Percentage" shall mean, at any date of determination, an amount equal to

$$\frac{((A - B) \text{ if } > 0)}{C}$$

Where

"A" equals [*]

"B" equals [*]

"C" equals [*] in effect at the time of purchase

For example, a determination of [*] Rebate Percentage would be as follows:

[*] Rebate Percentage Illustration:

(([*] - [*]) if greater than zero)

÷

[*] in effect at the time of purchase

1.6 "[*]" shall mean a trial comparing the [*] of patients receiving EPOGEN and the [*] in connection with the provision of Dialysis Services.

1.7 "[*] Price" shall mean the [*] of the [*] for the applicable Quarter as reported by the Centers for Medicare & Medicaid Services as mandated by the Patient Protection and Affordable Care Act, as amended and reconciled by the Healthcare and Education Reconciliation Act and implementing regulations and as adjusted to take into account the [*] agreed to by the Parties or the results of the [*], as applicable.

1.8 "[*]" shall mean a [*] product that has been approved by the FDA both as a [*] and as [*]. [*] shall have the meanings ascribed to such terms in the Public Health Service Act (Title 42 U.S. Code, Chapter 6A), as such terms may be further defined by the FDA.

1.9 "[*]" shall mean for each [*] of EPOGEN purchased by a Dialysis Center Purchaser under this Agreement in any Quarter, the [*] in effect on the date of purchase less for such Quarter (i) the Discounts that Dialysis Center is eligible to earn under this Agreement during the applicable Quarter, including the [*] Rebate, the [*] Rebate, and the [*] Rebate, as applicable, and (ii) any other discount, rebate or other price adjustment received by a Dialysis Center Purchaser per [*] of EPOGEN which is included in the "Best Price" reported in Amgen's Best Price Submission under Title XIX of the Social Security Act in respect of such EPOGEN purchase.

1.10 "[*]" shall mean, for any Quarter in which the [*] Rebate is applied, an amount equal to

(A * B) + A

Where

"A" equals the [*] Price during such Quarter

"B" equals [*]%

For example, a determination of [*] would be as follows:

[*] Illustration:

([*] Price * [*]%) + [*] Price

Dialysis Share of Sales Definitions

1.11 "Dialysis Market [*] Purchases of [*]" means, for any period, the aggregate [*] paid for purchases of [*] by all purchasers, including those by all Dialysis Center Purchasers, during such period for use in providing Dialysis Services, from any source measured using the prevailing [*] as set by the product manufacturer in effect at the time of purchase to be determined by Amgen based on DDD™ data provided by IMS or if IMS' DDD™ data is unavailable, by reliable alternative means to be determined by Amgen in Amgen's reasonable discretion, subject to verification by Amgen.

1.12 "Dialysis Share of Sales" shall mean Dialysis Center Qualified [*] Purchases [*] during the Quarter divided by Dialysis Market [*] Purchases of [*] during the Quarter.

Dialysis Share of Sales Illustration:

Dialysis Center Qualified [*] Purchases of [*]

÷

Dialysis Market [*] Purchases of [*]

1.13 "Dialysis Share of Sales Requirement" shall mean, for any Quarter, that Dialysis Center had an aggregate Dialysis Share of Sales for any such Quarter and the immediately preceding Quarter that was equal to or greater than [*] percent ([*]%) in the aggregate for such two (2) Quarter period. It is not the intent of the Parties that a [*] of any Alternative ESA (on a [*] equivalent basis) that is significantly higher than the [*] for EPOGEN should negatively affect Dialysis Center's attainment of the Dialysis Share of Sales Requirement. If at any time during a Quarter, an Alternative ESA is introduced with respect to the provision of Dialysis Services which has a [*] for such Alternative ESA to [*] as established by the manufacturer of such Alternative ESA that potentially is significantly greater than (on a [*] equivalent basis) the [*] for EPOGEN (a "[*] Event"), Dialysis Center shall deliver a written notice to Amgen

indicating that there has been a [*] Event (a "[*] Event Notice"). Within thirty (30) days after Amgen's receipt of a [*] Event Notice, the Parties shall meet and discuss in good faith any necessary changes, amendments, and/or adjustments to the calculation of the Dialysis Share of Sales Requirement to account for the impact of such [*] Event on the Parties.

1.14 "Dialysis Center Qualified [*] Purchases of [*]" means, for any period, the aggregate [*] paid for purchases of [*] by all Dialysis Center Purchasers during such period for use in providing Dialysis Services, from any source measured using the prevailing [*] as set by the product manufacturer in effect at the time of purchase to be determined by Amgen based on the DDD™ data provided by IMS or if IMS' DDD™ data is unavailable, by reliable alternative means to be determined by Amgen in Amgen's sole discretion, subject to verification by Amgen.

1.15 "[*] Event" has the meaning set forth in Section 1.13 of this Exhibit A.

1.16 "[*] Event Notice" has the meaning set forth in Section 1.13 of this Exhibit A.

[*] Share of Sales Definitions

1.17 "Dialysis Market [*] Purchases of [*] for [*] Rebate" means, for any period, the aggregate [*] paid for purchases of [*] by all purchasers, but excluding all Dialysis Center Purchasers, during such period for use in providing Dialysis Services, from any source measured using the prevailing [*] as set by the product manufacturer in effect at the time of purchase to be determined by Amgen based on data provided by a third-party reporting agency or if third-party reporting agency data is unavailable, by reliable alternative means to be determined by Amgen in Amgen's sole reasonable discretion, subject to verification by the Parties.

1.18 "[*] Share of Sales" shall mean Qualified [*] Purchases of the [*] during the Quarter divided by Dialysis Market [*] Purchases of [*] for [*] Rebate during the Quarter.

[*] Share of Sales Illustration:

Qualified [*] Purchases of [*]

÷

Dialysis Market [*] Purchases of [*] for [*] Rebate

1.19 "Qualified [*] Purchases of [*]" means, for any period the aggregate [*] paid for purchases of the applicable [*] by all purchasers, but excluding all Dialysis Center Purchasers, during such period for use in providing Dialysis Services, from any source measured using the prevailing [*] as set by the product manufacturer in effect at the time of purchase to be determined by Amgen based on data provided by a third-party reporting agency or if third-party reporting agency data is unavailable, by some alternative means to be determined by Amgen in Amgen's sole discretion, subject to verification by Amgen.

[*] *Rebate Definitions*

1.20 "[*]" shall mean the applicable [*] per [*] of EPOGEN as set forth in the [*] Table below.

[*] Table

Calendar Year	[*]
2012	$[*]
2013	$[*]
2014	$[*]
2015	$[*]
2016	$[*]
2017	$[*]
2018	$[*]

1.21 "[*] Rebate Percentage" shall mean, at any date of determination, an amount equal to

$$\frac{((A - B) \text{ if } > 0)}{C}$$

Where

"A" equals [*]

"B" equals [*]

"C" equals [*] in effect at the time of purchase

For example, a determination of the [*] Rebate Percentage would be as follows:

[*] Rebate Percentage Illustration:

(([*] - [*]) if greater than zero)

÷

[*] in effect at the time of purchase

[*] *Incentive Definitions*

1.22 "[*]" shall mean the [*] incentive described in Section 3.5 of this Exhibit A.

1.23 Other. The Parties acknowledge and agree that (i) the aggregate [*] paid for purchases of [*] by all purchasers for use in providing Dialysis Services in the Territory include purchases by [*] as well as other purchasers of ESAs for use in providing Dialysis Services, (ii) there may not be commercially available data comprising purchases of ESAs by all purchasers for use in providing Dialysis Services in the Territory that Dialysis Center could access in order to understand and track the Dialysis Share of Sales on an ongoing basis, (iii) there is commercially available data comprising purchases of ESAs by [*] in the Territory that Dialysis Center could access, (iv) the [*] purchases of ESAs by [*] in the Territory currently represents approximately [*] percent ([*]%) of [*] purchases of ESAs by all purchases for use in providing Dialysis Services in the Territory, (v) for the sole and limited purpose of determining whether Dialysis Center shall have met the Dialysis Share of Sales requirement under Sections 3.2.1 and 3.4.1 of this Exhibit A, the aggregate [*] paid for purchases of [*] by all purchasers for use in providing Dialysis Services in the Territory shall be calculated as [*] percent ([*]%) of the aggregate [*] purchases of ESAs by [*] in the Territory and (vi) for the sole and limited purpose of determining whether the [*] Share of Sales

requirement under Section 3.3.1 and Section 3.3.2 of this Exhibit A has been met, (a) the aggregate [*] paid for purchases of [*] by all purchasers, but excluding all Dialysis Center Purchasers, for use in providing Dialysis Services in the Territory shall be calculated as [*] percent ([*]%) of the aggregate [*] purchases of ESAs by [*], but excluding all Dialysis Center Purchasers, in the Territory and (b) the aggregate [*] paid for purchases of the applicable [*] by all purchasers, but excluding all Dialysis Center Purchasers, for use in providing Dialysis Services in the Territory shall be calculated as [*] percent ([*]%) of the aggregate [*] purchases of the applicable [*] by [*], but excluding all Dialysis Center Purchasers, in the Territory.

2 PRODUCT INVOICE DISCOUNTS

2.1 Base Invoice Discounts. Subject to the terms and conditions contained in the Agreement, Dialysis Center Purchasers shall be entitled to the Base Invoice Discount set forth in the following Base Invoice Discount Table, applied to [*] in effect at the time of purchase of EPOGEN by Dialysis Center Purchasers under the Agreement, exclusive of any wholesaler markup, discount, service fees or other charges:

Base Invoice Discount Table

PRODUCT	NDC	INVOICE DISCOUNT
EPOGEN	All NDCs	[*]%

3 PRODUCT REBATES

3.1 Base Rate Rebate. Dialysis Center shall earn a non-performance Base Rate Rebate for each Quarter during the Term in the manner described below in this Section 3.1.

3.1.1 Base Rate Rebate Calculation. Amgen shall calculate the amount of Dialysis Center's Base Rate Rebate by multiplying Dialysis Center's Qualified Gross Purchases of EPOGEN during a Quarter by the applicable Base Rate Rebate Percentage for the calendar year in which such Quarter occurs, according to the Base Rate Rebate Percentage Table below.

Base Rate Rebate Percentage Table

Calendar Year	Base Rate Rebate Percentage
2012	[*]%
2013	[*]%
2014	[*]%
2015	[*]%
2016	[*]%
2017	[*]%
2018	[*]%

3.1.2 Payment of Base Rate Rebate. Amgen will pay the Base Rate Rebate within [*] days after the end of the corresponding Quarter, provided Amgen is in receipt of all Relevant Information in a form acceptable to Amgen.

3.1.3 Vesting of Base Rate Rebate. The Base Rate Rebate for a given Quarter shall vest on the last day of such Quarter.

3.2 [*] Rebate. Dialysis Center shall earn the [*] Rebate, if any, for each Quarter during the Term provided it meets the requirements described below in this Section 3.2.

3.2.1 Eligibility for [*] Rebate. Dialysis Center shall be eligible to receive the [*] Rebate for any Quarter during the Term if each of the following shall have occurred in such Quarter: (a) Dialysis Center shall have met the Dialysis Share of Sales Requirement, (b) any Qualified Customer received a [*] under an Amgen Dialysis Contract that is lower than the [*] and (c) either (i) the aggregate net sales for all EPOGEN purchased by any such Qualified Customer who received a [*] under an Amgen Dialysis Contract that is lower than the [*] during such Quarter were greater than [*] percent ([*]%) of the aggregate net sales of EPOGEN to all purchasers in the Territory in such Quarter or (ii) the aggregate net sales for all EPOGEN purchased during such Quarter by all Qualified Customers in the aggregate who received a [*] under an Amgen Dialysis Contract that is lower than the [*] were greater than [*] percent ([*]%) of the aggregate net sales of EPOGEN to all purchasers in the Territory in such Quarter. Amgen's calculation of the [*] Rebate shall not take into account any reallocation of discounts for purposes of any reports filed under Title XVIII or Title XIX of the Social Security Act, under any health care program of a Governmental Authority or pursuant to any other Law.

3.2.2 Calculation of [*] Rebate. Amgen shall calculate the amount of Dialysis Center's [*] Rebate for any Quarter by taking the total of the [*] minus the [*], multiplied by the number of [*] of EPOGEN purchased by all Dialysis Center Purchasers at a [*] during such Quarter.

[*] Rebate Illustration:

([*] – [*])
x
Number of [*] of EPOGEN purchased at [*]

3.2.3 Payment of [*] Rebate Amount. Amgen will pay the [*] Rebate within [*] days after the end of the corresponding Quarter, provided Amgen is in receipt of all Relevant Information in a form acceptable to Amgen.

3.2.4 Vesting of [*] Rebate. The [*] Rebate for a given Quarter shall vest on the last day of such Quarter.

3.3 [*] Rebate. Dialysis Center shall earn a [*] Rebate for each Quarter during the Term in the manner described below in this Section 3.3.

3.3.1 Trigger Event for [*] Rebate. In the event that an [*] had an [*] Share of Sales of greater than [*] percent ([*]%) for [*] consecutive Quarters during the Term, the Parties shall work together in good faith to determine a [*] between the [*] and EPOGEN. In the event the Parties are not able to determine a mutually agreed upon [*] between the [*] and EPOGEN within thirty (30) days of the end of the applicable Quarter at which the [*] Rebate is at issue or such longer period of time as mutually agreed to by the Parties, the Parties shall work together in good faith to undertake a [*], which [*] shall be jointly funded by the Parties. If the Parties fail to agree on a design for the [*], the Parties shall jointly appoint a mutually agreeable Third Party to design and undertake the [*].

3.3.2 Qualification Criteria. If for a Quarter during the Term, an [*] had an [*] Share of Sales of greater than [*] percent ([*]%) for such Quarter and the immediately prior Quarter, then Dialysis Center shall be entitled to the [*] Rebate for such Quarter, as calculated in Section 3.3.3 below.

3.3.3 [*] Rebate Calculation. Amgen shall calculate the amount of Dialysis Center's [*] Rebate by multiplying the Qualified Gross Purchases of EPOGEN during the applicable Quarters by the applicable [*] Rebate Percentage for such applicable Quarters.

3.3.4 Payment of [*] Rebate. Amgen will pay the [*] Rebate within [*] days after the end of the corresponding Quarter, provided Amgen is in receipt of all Relevant Information in a form acceptable to Amgen and provided further, that in the event a final [*] for the applicable [*] has not been determined hereunder within thirty (30) days after the end of the applicable Quarter pursuant to Section 3.3.1 of this Exhibit A, such [*] Rebate will be paid within [*] days after the end of the Quarter in which a final [*] for the applicable [*] has been determined.

3.3.5 Vesting of [*] Rebate. The [*] Rebate for a given Quarter shall vest on the last day of such Quarter.

3.4 [*] Rebate. Dialysis Center shall earn the [*] Rebate for each Quarter during the Term in the manner described below in this Section 3.4

3.4.1 Qualification Criteria. If, for any Quarter during the Term, the [*] exceeds the [*] ("[*] Trigger Event"), then Dialysis Center Purchasers shall be entitled to the [*] Rebate as calculated in Section 3.4.2 below, provided that the Dialysis Share of Sales Requirement is met during such Quarter. Such [*] Rebate shall apply to all purchases of EPOGEN by Dialysis Center Purchasers during such Quarter from the date of the [*] Trigger Event until the date (if any) at which the [*] is equal to or greater than the [*].

3.4.2 Calculation of [*] Rebate. Amgen shall calculate the amount of Dialysis Center's [*] Rebate by multiplying the Qualified Gross Purchases of EPOGEN during the applicable Quarter by the [*] Rebate Percentage for such Quarter; provided, however, that in the event of an increase of [*] other than on the first day of a calendar year, then the [*] Rebate shall be reduced by an amount equal to the Qualified Gross Purchases of EPOGEN during such calendar year prior to the increase in [*] multiplied by the [*] minus the [*].

3.4.3 Payment of [*] Rebate. Amgen will pay such [*] Rebate within [*] days after the end of the corresponding Quarter, provided Amgen is in receipt of all Relevant Information in a form reasonably acceptable to Amgen.

3.4.4 Vesting of [*] Rebate. The [*] Rebate for a given Quarter shall vest on the last day of such Quarter.

3.5 [*] Incentive. Dialysis Center shall earn the [*] for each Quarter during the Term provided all Dialysis Center Purchasers provide to Amgen the Data set forth in Schedule 1 and provided Dialysis Center meets the requirements described below in this Section 3.5.

3.5.1 Submission of Data Requirement. Subject to the validity of a Certification as described in Section 5 of this Agreement, Dialysis Center Purchasers must provide to Amgen the Data in a machine readable format acceptable to Amgen (Excel; or text file that is tab delimited, comma delimited, colon delimited or space delimited including a line of column headers identifying the column contents and [*], if applicable). The Data files shall contain record counts for each file contained in the data submission; provided, however, that Dialysis Center shall be required to submit such test results only for those dialysis patients whose test results are actually determined by laboratories owned and operated by Dialysis Center.

3.5.2 Calculation of [*]. Provided Dialysis Center has fulfilled all requirements described in this Section 3.5 of this Exhibit A, Dialysis Center shall be eligible to receive a [*] percent ([*]%) [*] payment. The [*] will be calculated as a percentage of the Qualified Gross Purchases of EPOGEN during each Quarter.

3.5.3 Payment of [*]. The Data must be submitted, on a calendar monthly basis by the last day of the following calendar month (or the next business day if such last day is not a business day). If the Data is received after such timeframe for any month within a given Quarter, the total Qualified Gross Purchases of EPOGEN during such month will be excluded from the calculation of the [*] for that Quarter. Notwithstanding the foregoing, if Amgen receives all required Data from a minimum of [*] percent ([*]%) of all Dialysis Center Purchasers within the time frame referenced above for any calendar month within a given Quarter, the total Qualified Gross Purchases of EPOGEN during such calendar month, will be included in the calculation of the [*] for that Quarter; provided that for purposes of clarity, the [*] percent ([*]%) will not include Dialysis Center Purchasers that are acute facilities. Failure of Dialysis Center to qualify under this Section 3.5 of this

Exhibit A during a particular Quarter shall not affect Dialysis Center's eligibility to qualify during any other Quarter, nor shall Dialysis Center's qualification during a particular Quarter automatically result in qualification during any other Quarter. If Amgen receives all required Data from less than [*] percent ([*]%) of Dialysis Center Purchasers for any calendar month within a given Quarter, no Qualified Gross Purchases of EPOGEN during such calendar month will be included in the calculation of the [*] for that Quarter; provided, however, that if such [*] percent ([*]%) threshold is not met in any month due to the inclusion of *de novo* facilities that have not yet treated patients and/or inactive facilities, Amgen shall exclude any such facilities identified by Amgen and Dialysis Center from such month when calculating Dialysis Center's eligibility for the [*] at the end of each Quarter. However, if Amgen determines that any Dialysis Center Purchaser is consistently not submitting the required Data, Amgen and Dialysis Center will work collaboratively in resolving such inconsistencies. Amgen will use commercially reasonable efforts to notify Dialysis Center in writing, no later than fifteen (15) business days after the receipt and acceptance by Amgen of the Data of the identity of all Dialysis Center Purchasers, if any, which have failed to meet the Data submission requirements for that month. Amgen reserves the right, in its sole discretion, to exclude any Qualified Gross Purchases of EPOGEN of any Dialysis Center Purchaser that is consistently non-reporting from the calculation of the [*] for any relevant Quarter. Amgen will pay such [*] within [*] days after the end of the corresponding Quarter provided Amgen is in receipt of all Data in the form and in the time period described in Section 3.5.1 and this Section 3.5.3 of this Exhibit A. If the failure of Dialysis Center to deliver any of the Data is a result of a Certification not being valid due to Amgen's failure to satisfy any conditions, requirements or assumptions set forth in such Certification applicable to Amgen, then the [*] shall still be available to Dialysis Center and payable by Amgen, in which case Dialysis Center shall deliver the Data to Amgen as soon as the Certification becomes valid. Upon a valid Certification being issued, Dialysis Center shall submit to Amgen all Data dating back to the date Dialysis Center stopped submitting the Data to Amgen within thirty (30) days.

3.5.4 Vesting of [*]. The [*] for a given Quarter shall vest on the last day of such Quarter.

4 SUMMARY OF DISCOUNTS

Provided Dialysis Center has fulfilled all Discount requirements, the total discount opportunity is as set forth in the Summary of Discounts Table below.

Summary of Discounts Table

	2012	2013	2014	2015	2016	2017	2018
Base Invoice Discount	[*]%	[*]%	[*]%	[*]%	[*]%	[*]%	[*]%
Base Rate Rebate	[*]%	[*]%	[*]%	[*]%	[*]%	[*]%	[*]%
[*] Rebate	[*]%	[*]%	[*]%	[*]%	[*]%	[*]%	[*]%
Total Discount Opportunity	**[*]%**	**[*]%**	**[*]%**	**[*]%**	**[*]%**	**[*]%**	**[*]%**

Exhibit B

Authorized Wholesalers

The below represents a list of wholesalers authorized for participation under the attached Agreement. Any changes must be made in accordance with Section 2.7 of the Agreement. Only purchases from wholesalers set forth on this List (as may be modified pursuant to such Section 2.7) shall be eligible for the discounts and fees set forth in the Agreement. Notice(s) regarding pricing and membership alignment for the Agreement shall be sent to the wholesalers that Dialysis Center has designated for such notification below. In the absence of any such designation, Amgen shall send pricing and membership alignment notices for the Agreement to those Authorized Wholesalers as designated by Dialysis Center in its previously executed Agreement.

_____ American Medical Distributors, Div. of AmerisourceBergen Corporation
_____ American Medical Services, Div. of Henry Schein, Inc.
_____ AmerisourceBergen Corporation
_____ ASD Healthcare, Div. of AmerisourceBergen Specialty Group
_____ Bellco Drug Corporation, Div of AmerisourceBergen Corporation
_____ Besse Medical Supply, Div. of AmerisourceBergen Specialty Group
_____ Borschow Hospital and Medical Supplies, Inc., Div of Cardinal Health, Inc.
_____ Cardinal Health Inc.
_____ Cesar Castillo, Inc.
_____ CuraScript Specialty Distribution (Priority Healthcare Distribution)
_____ Dakota Drug Inc.
_____ Dik Drug Company
_____ DMS Pharmaceutical Group Inc.
_____ Drogueria Central, Inc.
_____ Florida Infusion Services, Inc.
_____ Frank W. Kerr Company
_____ General Injectables & Vaccines, Div. of Henry Schein, Inc.
_____ HD Smith Wholesale Drug Company
_____ Henry Schein, Inc.
_____ J.M. Blanco, Div of AmerisourceBergen Corporation
_____ Kinray, Inc.
_____ McKesson Corporation
_____ McKesson Medical-Surgical Maine Inc., Div. of McKesson Medical-Surgical
_____ McKesson Medical-Surgical Minnesota Supply Inc., Div. of McKesson Medical Surgical
_____ McKesson Medical-Surgical, Div. of McKesson Corporation
_____ McKesson Specialty Care Distribution Corporation, Div. of McKesson Corporation
_____ Metro Medical Supply Inc.
_____ Morris & Dickson Company LLC
_____ N.C. Mutual Wholesale Drug Company
_____ Oncology Supply, Div. of AmerisourceBergen Specialty Group
_____ Rochester Drug Corporation (RDC)
_____ Smith Drug Company
_____ Value Drug Company

Exhibit C

Designated Affiliates List

Designated Affiliates List

Active count	TYPE	CTR #	CENTER NAME	LEGAL NAME	ADDRESS	ADDRESS	CITY	STATE	ZIP
1	Affiliated	398	Los Angeles Dialysis Center	Los Angeles Dialysis Center (LADC)	3901 S WESTERN AVE		LOS ANGELES	CA	90062-1112
2	Affiliated	613	Garfield	Garfield Hemodialysis Center	118 HILLIARD AVE		MONTEREY PARK	CA	91754-1118
3	Affiliated	614	Lynwood	Kidney Dialysis Care Unit (Lynwood)	3600 E MARTIN LUTHER KING JR BLVD		LYNWOOD	CA	90262-2607
4	Affiliated	615	Lakewood Dialysis-CA	Lakewood Dialysis-CA	4611 SILVA ST		LAKEWOOD	CA	90712-2512
5	Affiliated	616	Valley Dialysis	Valley Dialysis	16149 HART ST		VAN NUYS	CA	91406-3906
6	Affiliated	617	Downey Dialysis	Downey Dialysis	8630 FLORENCE AVE	STE 1	DOWNEY	CA	90240-4017
7	Affiliated	618	Covina Dialysis	Covina Dialysis	1547 W GARVEY AVE N		WEST COVINA	CA	91790-2139
8	Affiliated	625	Four Corners Farmington	Four Corners Farmington	801 W BROADWAY		FARMINGTON	NM	87401-5650
9	Affiliated	626	Tuba City Dialysis	Tuba City Dialysis	500 EDGEWATER DR	PO BOX 291	TUBA CITY	AZ	86045-2905
10	Affiliated	627	Camelback Dialysis Center	Camelback Dialysis Center (fka Scottsdale Dialysis Center)	7321 E OSBORN DR		SCOTTSDALE	AZ	85251-6418
11	Affiliated	630	Westbank	Westbank Chronic Renal Center	3631 BEHRMAN PLACE		NEW ORLEANS	LA	70114
12	Affiliated	632	Fleur de Lis	Fleur de Lis Dialysis (fka Tri-Parish)	5555 BULLARD AVE		NEW ORLEANS	LA	70128-3450
13	Affiliated	637	Desert Mountain	Desert Mountain Dialysis	9220 E MOUNTAIN VIEW RD	STE 15	SCOTTSDALE	AZ	85258-5134
14	Affiliated	638	Chinle	Chinle Dialysis	US HWY 191	PO BOX 879	CHINLE	AZ	86503-0879
15	Affiliated	648	Central City	Central City Dialysis Center	1300 MURCHISON DR	STE 32	EL PASO	TX	79902-4840
16	Affiliated	651	Federal Way	Federal Way Community Dialysis Center	1015 S 348TH ST		FEDERAL WAY	WA	98003-7078
17	Affiliated	663	Beverly Hills	Beverly Hills Dialysis Center	50 N LA CIENEGA BLVD	3RD FLOOR, STE 3	BEVERLY HILLS	CA	90211-2205
18	Affiliated	667	Walnut Creek	Walnut Creek Dialysis Center	404 N WIGET LN		WALNUT CREEK	CA	94598-2408
19	Affiliated	672	Norwalk	Norwalk Dialysis Center	12375 E IMPERIAL HWY	STE D3	NORWALK	CA	90650-3129
20	Affiliated	673	El Monte	Greater El Monte Dialysis Center	1938 TYLER AVE	STE J-168	SOUTH EL MONTE	CA	91733-3623
21	Affiliated	676	Bayonet Point	Bayonet Point-Hudson Kidney	14144 NEPHRON LN		HUDSON	FL	34667-6504
22	Affiliated	677	New Port Richey	New Port Richey Kidney Center	7421 RIDGE RD		PORT RICHEY	FL	34668-6933
23	Affiliated	678	Hernando	Hernando Kidney Center, Inc	2985 LANDOVER BLVD		SPRING HILL	FL	34608-7258
24	Affiliated	681	Woodbridge	CDC Of Woodbridge	2751 KILLARNEY DR		WOODBRIDGE	VA	22192-4119
25	Affiliated	682	Manassas	CDC-Manassas Dialysis	10655 LOMOND DR	STE 11	MANASSAS	VA	20109-2877
26	Affiliated	683	Springfield	CDC-Springfield Dialysis	8350 TRAFORD LN	STE A	SPRINGFIELD	VA	22152-1671
27	Affiliated	684	Sterling	CDC-Sterling	46396 BENEDICT DR	STE 1	STERLING	VA	20164-6626
28	Affiliated	687	Alexandria	Springfield-Alexandria	5999 STEVENSON AVE	STE 1	ALEXANDRIA	VA	22304-3302
29	Affiliated	642	Statesboro	Nephrology Center of Statesboro fka Statesboro Dialysis	4B COLLEGE PLZ		STATESBORO	GA	30458-4928
30	Affiliated	643	Vidalia	Nephrology Center of Vidalia	1806 EDWINA DR		VIDALIA	GA	30474-8927
31	Affiliated	657	Papago Dialysis	Papago Dialysis Center (fka PD Central & Squaw Peak)	1401 N 24TH ST	STE 2	PHOENIX	AZ	85008-4638
32	Affiliated	658	Boca Raton	Boca Raton Artificial Kidney Center	998 NW 9TH CT		BOCA RATON	FL	33486-2214
33	Affiliated	644	Piedmont	Buckhead Dialysis	1575 NORTHSIDE DR NW	STE 365	ATLANTA	GA	30318-4210
34	Affiliated	311	Logan Square	Logan Square Dialysis Services	2659 N MILWAUKEE AVE	1ST FL	CHICAGO	IL	60647-1643
35	Affiliated	312	Lake County	Lake County Dialysis Services	918 S MILWAUKEE AVE		LIBERTYVILLE	IL	60048-3229
36	Affiliated	314	Lincoln Park	Lincoln Park Dialysis fka Lincoln Park Nephrology	3157 N LINCOLN AVE		CHICAGO	IL	60657-3111
37	Affiliated	318	Lincoln Pk-PD	Skyline Home Dialysis (fka Lincoln Park PD)	7009 W BELMONT AVE		CHICAGO	IL	60634-4533
38	Affiliated	670	West Palm Beach	Dialysis Associates of the Palm Beaches	2611 POINSETTIA AVE		WEST PALM BEACH	FL	33407-5919
39	Affiliated	693	Sunrise	Sunrise Dialysis Center	13039 HAWTHORNE BLVD		HAWTHORNE	CA	90250-4415
40	Affiliated	655	Kayenta	Kayenta Dialysis	PO BOX 217	US HWY 163 N	KAYENTA	AZ	86033-0217
41	Affiliated	321	Hyde Park	Emerald Dialysis (fka Hyde Park Kidney Center)	710 W 43RD ST		CHICAGO	IL	60609-3435
42	Affiliated	322	Olympia Fields	Olympia Fields Dialysis Center	4557B LINCOLN HWY	STE B	MATTESON	IL	60443-2318
43	Affiliated	351	CKD	Center for Kidney Disease at North Shore	1190 NW 95TH ST	STE 28	MIAMI	FL	33150-2065
44	Affiliated	352	Venture	Center for Kidney Disease at Venture	16855 NE 2ND AVE	STE 25	N MIAMI BEACH	FL	33162-1744
45	Affiliated	360	South Broward	South Broward Artifical Kidney	4401 HOLLYWOOD BLVD		HOLLYWOOD	FL	33021-6609
46	Affiliated	688	East End	East End Dialysis Center	2201 E MAIN ST	STE 1	RICHMOND	VA	23223-7071
47	Affiliated	354	Flamingo Park	Flamingo Park Kidney Cntr, Inc	901 E 10TH AVE	BAY 17	HIALEAH	FL	33010-3762
48	Affiliated	355	Interamerican	InterAmerican Dialysis Center	7815 CORAL WAY	STE 115	MIAMI	FL	33155-6541
49	Affiliated	356	Coral Gables Dialysis Center	Coral Gables Kidney Center (fka LeJeune)	3280 PONCE DE LEON BLVD		CORAL GABLES	FL	33134-7252

50	Affiliated	370	Cielo Vista Dialysis	DaVita East Dialysis dba Cielo Vista Dialysis (fkaTotal Renal Care East Dialysis Center)	7200 GATEWAY BLVD E	STE B	EL PASO	TX	79915-1301
51	Affiliated	371	West Texas Dialysis	DaVita West Dialysis Center dba West Texas (fkaTotal Renal Care West Dialysis Center)	5595 ALAMEDA AVE B	STE B	EL PASO	TX	79905
52	Affiliated	656	Shiprock	Shiprock Dialysis	PO BOX 2156	US HWY 491 N	SHIPROCK	NM	87420-2156
53	Affiliated	202	Arden Hills	Arden Hills Dialysis Unit	3900 NORTHWOODS DR	STE 11	ARDEN HILLS	MN	55112-6911
54	Affiliated	203	Burnsville	Burnsville Dialysis Unit	501 E NICOLLET BLVD	STE 15	BURNSVILLE	MN	55337-6784
55	Affiliated	204	Coon Rapids	Coon Rapids Dialysis Unit	3960 COON RAPIDS BLVD NW	STE 39	COON RAPIDS	MN	55433-2598
56	Affiliated	205	Edina	Edina Dialysis Unit	6550 YORK AVE S	STE 1	EDINA	MN	55435-2332
57	Affiliated	206	Maplewood	Maplewood Dialysis Center	2785 WHITE BEAR AVE N	STE 21	MAPLEWOOD	MN	55109-1320
58	Affiliated	207	Minneapolis	Minneapolis Dialysis Unit	825 S EIGHTH ST	STE SL42	MINNEAPOLIS	MN	55404-1208
59	Affiliated	208	Minnetonka	Minnetonka Dialysis Unit	17809 HUTCHINS DR		MINNETONKA	MN	55345-4100
60	Affiliated	209	St. Paul Dialysis	St. Paul Dialysis Unit	555 PARK ST	STE 18	SAINT PAUL	MN	55103-2192
61	Affiliated	210	Special Needs	University Dialysis Unit Riverside (Minneapolis-Special Needs Dialysis)	1045 WESTGATE DR	STE 9	SAINT PAUL	MN	55114-1079
62	Affiliated	211	West St. Paul	West St. Paul Dialysis	1555 LIVINGSTON AVE		WEST ST PAUL	MN	55118-3411
63	Affiliated	213	Cass Lake	Cass Lake Dialysis Unit	602 GRANT UTLEY ST	PO BOX 757	CASS LAKE	MN	56633-0757
64	Affiliated	215	Faribault	Faribault Dialysis Unit	201 LYNDALE AVE S	STE F	FARIBAULT	MN	55021-5758
65	Affiliated	217	Marshall	Marshall Dialysis Unit	300 S BRUCE ST	AVERA MARSHALL REGIONAL MEDICAL CENTER	MARSHALL	MN	56258-1934
66	Affiliated	218	Montevideo	Montevideo Dialysis Center	824 N 11TH ST	MONTEVIDEO HOSPITAL	MONTEVIDEO	MN	56265-1629
67	Affiliated	220	Pine City	TRC-Pine City (fka-Pine City Dialysis Unit)	129 6TH AVE SE	LAKESIDE MEDICAL CENTER	PINE CITY	MN	55063-1913
68	Affiliated	222	Red Wing	Red Wing Dialysis Unit	3028 N SERVICE DR		RED WING	MN	55066-1921
69	Affiliated	223	Redwood Falls	Redwood Falls Dialysis Center	100 FALLWOOD RD		REDWOOD FALLS	MN	56283-1828
70	Affiliated	240	Mitchell	Mitchell Dialysis	525 N FOSTER	QUEEN OF PEACE HOSPITAL	MITCHELL	SD	57301-2966
71	Affiliated	242	Rosebud	Rosebud Dialysis	1 SOLDIER CREEK RD		ROSEBUD	SD	57570-0610
72	Affiliated	243	Sioux Falls	Sioux Falls Dialysis Community Unit	1325 S CLIFF AVE	STE 46	SIOUX FALLS	SD	57105-1016
73	Affiliated	250	St. Croix Falls	St. Croix Falls Dialysis	744 E LOUISIANA ST		SAINT CROIX FALLS	WI	54024-9501
74	Affiliated	260	Hayward	Hayward Dialysis Center	21615 HESPERIAN BLVD	STE F	HAYWARD	CA	94541-7026
75	Affiliated	262	Pleasanton	Pleasanton Dialysis Center (HEMO) (fka Dublin)	5720 STONERIDGE MALL RD	STE 16	PLEASANTON	CA	94588-2882
76	Affiliated	263	Union City	Union City Dialysis Center (aka TRC-Union City)	32930 ALVARADO NILES RD	STE 3	UNION CITY	CA	94587-8101
77	Affiliated	264	East Bay - PD	East Bay Peritoneal Dialysis Center	13939 E 14TH ST	STE 11	SAN LEANDRO	CA	94578-2613
78	Affiliated	383	Greer	Greer Kidney Center	211 VILLAGE DR		GREER	SC	29651-1238
79	Affiliated	382	Upstate	Upstate Dialysis Center	308 MILLS AVE		GREENVILLE	SC	29605-4022
80	Affiliated	390	Kenner	Kenner Regional Dialysis Center	200 W ESPLANADE AVE	STE 1	KENNER	LA	70065-2473
81	Affiliated	689	Downtown Dialysis	Downtown Dialysis Center	821 N EUTAW ST	STE 41	BALTIMORE	MD	21201-6304
82	Affiliated	331	Eaton Canyon	Eaton Canyon Dialysis	2551 E WASHINGTON BLVD		PASADENA	CA	91107-1446
83	Affiliated	190	Georgetown	Georgetown on the Potomac	3223 K ST NW	STE 11	WASHINGTON	DC	20007-4412
84	Affiliated	395	St. Mary	Newtown Dialysis Center (fka St. Mary Dialysis)	60 BLACKSMITH RD		NEWTOWN	PA	18940-1847
85	Affiliated	393	Bertha Sirk	Bertha Sirk Dialysis Center	5820 YORK RD	STE 1	BALTIMORE	MD	21212-3620
86	Affiliated	394	Greenspring	Greenspring Dialysis Center	4701 MOUNT HOPE DR	STE C	BALTIMORE	MD	21215-3246
87	Affiliated	378	Houston Kidney - NW	Northwest Kidney Center (Houston)	11029 NORTHWEST FWY		HOUSTON	TX	77092-7311
88	Affiliated	379	NorthStar Dialysis	NorthStar Dialysis Center (fka North Houston Kidney Center)	380 W LITTLE YORK RD		HOUSTON	TX	77076-1303
89	Affiliated	363	Port Charlotte	Port Charlotte Artificial Kidney Center	4300 KINGS HWY STE 406		PORT CHARLOTTE	FL	33980
90	Affiliated	364	Gulf Coast PD	Gulf Coast Dialysis	3300 TAMIAMI TRL	STE 11A	PORT CHARLOTTE	FL	33952-8054
91	Affiliated	649	Loma Vista	Loma Vista Dialysis Center Partnership	1382 LOMALAND DR	STE A	EL PASO	TX	79935-5204
92	Affiliated	332	Paramount	Paramount Dialysis Center	8319 ALONDRA BLVD		PARAMOUNT	CA	90723-4403
93	Affiliated	334	East LA	Doctors Dialysis of East LA (aka East Los Angeles Dialysis)	950 S EASTERN AVE		LOS ANGELES	CA	90022-4801
94	Affiliated	335	Montebello	Doctors Dialysis of Montebello	1721 W WHITTIER BLVD		MONTEBELLO	CA	90640-4004
95	Affiliated	361	Pine Island	Pine Island Kidney Center	1871 N PINE ISLAND RD		PLANTATION	FL	33322-5208
96	Affiliated	365	Complete	Complete Dialysis Care	7850 W SAMPLE RD		MARGATE	FL	33065-4710
97	Affiliated	122	Lone Star Dialysis	Lone Star Dialysis (fka Hobby Dialysis)	8560 MONROE RD		HOUSTON	TX	77061-4815
98	Affiliated	255	Forest Lake	Forest Lake Dialysis	1068 S LAKE ST	STE 11	FOREST LAKE	MN	55025-2633
99	Affiliated	690	USC Phase II	TRC/USC Dialysis Center	2310 ALCAZAR ST		LOS ANGELES	CA	90033-5327
100	Affiliated	396	TRC/Union Plaza Ctr	Union Plaza Dialysis Center	810 1ST ST NE	STE 1	WASHINGTON	DC	20002-4227
101	Affiliated	130	Mid-Columbia Kidney	Mid Columbia Kidney Center	6825 BURDEN BLVD	STE A	PASCO	WA	99301-9584
102	Affiliated	131	Mt. Adams Kidney Ctr	Mt. Adams Kidney Center	3220 PICARD PL		SUNNYSIDE	WA	98944-8400
103	Affiliated	650	Lakewood	Lakewood Community Dialysis Center	5919 LAKEWOOD TOWNE CENTER BLVD SW	STE A	LAKEWOOD	WA	98499-6513

104	Affiliated	228	St. Paul Ramsey	St. Paul Capitol Dialysis	555 PARK ST	STE 23	SAINT PAUL	MN	55103-2193
105	Affiliated	229	River City Dialysis	River City Dialysis (fka Lakeview Dialysis)	1970 NORTHWESTERN AVE S		STILLWATER	MN	55082-6567
106	Affiliated	231	Woodbury	Woodbury Dialysis	1850 WEIR DR	STE 3	WOODBURY	MN	55125-2260
107	Affiliated	281	Alhambra	Alhambra Dialysis Center	1315 ALHAMBRA BLVD	STE 1	SACRAMENTO	CA	95816-5245
108	Affiliated	282	Antelope	Antelope Dialysis Center	6406 TUPELO DR	STE A	CITRUS HEIGHTS	CA	95621-1780
109	Affiliated	283	Chico	Chico Dialysis Center (aka Chico Clinic)	530 COHASSET RD		CHICO	CA	95926-2212
110	Affiliated	285	North Clinic	Manzanita Dialysis Center (aka North Clinic)	4005 MANZANITA AVE	STE 17	CARMICHAEL	CA	95608-1779
111	Affiliated	286	Placerville	Cameron Park Dialysis (fka Placerville)	3311 COACH LN	STE C	CAMERON PARK	CA	95682
112	Affiliated	288	South Sacramento	South Sacramento Dialysis Center	7000 FRANKLIN BLVD	STE 88	SACRAMENTO	CA	95823-1838
113	Affiliated	289	Redding	Redding Dialysis Center	1876 PARK MARINA DR		REDDING	CA	96001-0913
114	Affiliated	291	Yuba City	Yuba City Dialysis Center	1525 PLUMAS CT	STE A	YUBA CITY	CA	95991-2971
115	Affiliated	292	University Clinic	University Dialysis Center	777 CAMPUS COMMONS RD	STE 1	SACRAMENTO	CA	95825-8344
116	Affiliated	372	Mesa Vista	Mesa Vista Dialysis Center (El Paso)	2400 N OREGON ST	STE C	EL PASO	TX	79902-3135
117	Affiliated	694	Hollywood	Hollywood Dialysis Center	5108 W SUNSET BLVD		LOS ANGELES	CA	90027-5708
118	Affiliated	697	UCLA Harbor	TRC/Harbor-UCLA MFI Total Renal Dialysis Center	21602 S VERMONT AVE		TORRANCE	CA	90502-1940
119	Affiliated	325	Brighton	Brighton Dialysis (fka Michigan Kidney Center of Brighton)	7960 GRAND RIVER RD	STE 21	BRIGHTON	MI	48114-7336
120	Affiliated	326	Macomb	Macomb Kidney Center (fka Macomb Dialysis)	28295 SCHOENHERR RD	STE A	WARREN	MI	48088-4300
121	Affiliated	327	North Oakland	North Oakland Dialysis	450 N TELEGRAPH RD	STE 6	PONTIAC	MI	48341-1037
122	Affiliated	328	Novi	Novi Dialysis	47250 W 10 MILE RD		NOVI	MI	48374-2932
123	Affiliated	329	Southfield	Cornerstone Dialysis (fka Southfield)	23857 GREENFIELD RD		SOUTHFIELD	MI	48075-3122
124	Affiliated	319	Children’s Mem’l Hosp.	TRC Children’s Dialysis Center aka Children’s Chicago/Children’s Memorial Hospital	2611 N HALSTED ST		CHICAGO	IL	60614-2301
125	Affiliated	151	New Center	New Center Dialysis	3011 W GRAND BLVD	STE 65	DETROIT	MI	48202-3012
126	Affiliated	2003	Whittier	Whittier Dialysis Center (fka Whittier Hills)	10055 WHITTWOOD DR		WHITTIER	CA	90603-2313
127	Affiliated	357	Miami Lakes	Miami Lakes Artificial Kidney Center (ALTHIN)	14600 NW 60TH AVE		MIAMI LAKES	FL	33014-2811
128	Affiliated	571	Anson County	Dialysis Care of Anson County	923 E CASWELL ST		WADESBORO	NC	28170-2305
129	Affiliated	573	Edgecomb County	Dialysis Care of Edgecomb County	3206 WESTERN BLVD		TARBORO	NC	27886-1828
130	Affiliated	574	Franklin County	Dialysis Care of Franklin County	1706 NC HWY 39 N		LOUISBURG	NC	27549-8329
131	Affiliated	575	Hoke County	Dialysis Care of Hoke County	403 S MAIN ST		RAEFORD	NC	28376-3222
132	Affiliated	576	Martin County	Dialysis Care of Martin County	100 MEDICAL DR		WILLIAMSTON	NC	27892-2156
133	Affiliated	578	Montgomery County	Dialysis Care of Montgomery County (aka Montgomery)	323 W MAIN ST		BISCOE	NC	27209-9528
134	Affiliated	579	Moore County	Dialysis Care of Moore County (aka Pinehurst)	16 REGIONAL DR		PINEHURST	NC	28374-8850
135	Affiliated	580	Richmond County	Dialysis Care of Richmond County	771 CHERAW RD		HAMLET	NC	28345-7158
136	Affiliated	581	Rockingham County	Dialysis Care of Rockingham County	251 W KINGS HWY		EDEN	NC	27288-5009
137	Affiliated	582	Rowan County	Dialysis Care of Rowan County	111 DORSETT DR		SALISBURY	NC	28144-2278
138	Affiliated	583	Rutherford County	Dialysis Care of Rutherford County	226 COMMERCIAL ST		FOREST CITY	NC	28043-2851
139	Affiliated	399	Monterey Park	Monterey Park Dialysis Center	2560 CORPORATE PL	STE 1-11 BLDG D	MONTEREY PARK	CA	91754-7612
140	Affiliated	183	Mason Dixon	Mason-Dixon Baltimore County	9635-A LIBERTY RD	STE 1	RANDALLSTOWN	MD	21133-2436
141	Affiliated	184	Carrol County	Carroll County Dialysis Facility	412 MALCOLM DR	STE 31	WESTMINSTER	MD	21157-6167
142	Affiliated	167	South Brooklyn	South Brooklyn Nephrology Center	3915 AVENUE V	STE 14	BROOKLYN	NY	11234-5150
143	Affiliated	843	Phenix City	Phenix City Dialysis Center	1900 OPELIKA RD		PHENIX CITY	AL	36867-3640
144	Affiliated	876	Brea	Brea Dialysis Center	595 TAMARACK AVE	STE A	BREA	CA	92821-3125
145	Affiliated	878	Hemet	Hemet Dialysis Center	3050 W FLORIDA AVE		HEMET	CA	92545-3619
146	Affiliated	883	Temecula	Temecula Dialysis Center	40945 COUNTY CENTER DR	STE G	TEMECULA	CA	92591-6006
147	Affiliated	880	Riverside	Riverside Dialysis Center	4361 LATHAM ST	STE 1	RIVERSIDE	CA	92501-1767
148	Affiliated	870	Napa	Napa Dialysis Center	3900 BEL AIRE PLZ	STE C	NAPA	CA	94558-2823
149	Affiliated	875	Santa Ana	Santa Ana Dialysis Center	1820 E DEERE AVE		SANTA ANA	CA	92705-5721
150	Affiliated	879	Valley View Dialysis Center	Valley View Dialysis Center (aka Morneo Valley)	26900 CACTUS AVE		MORENO VALLEY	CA	92555-3912
151	Affiliated	884	Orange	Mainplace Dialysis Center (fka Orange Dialysis Center)	972 W TOWN AND COUNTRY RD		ORANGE	CA	92868-4714
152	Affiliated	882	San Bernadino	Mountain Vista Dialysis Center (fka San Bernadino Dailysis Center (Mountain Vista))	4041 NORTH UNIVERSITY PKWY		SAN BERNARDINO	CA	92407-1823
153	Affiliated	871	Lakeport	Lakeport Dialysis Center	804 11TH ST	STE 2	LAKEPORT	CA	95453-4102
154	Affiliated	873	Vacaville	Vacaville Dialysis Center	941 MERCHANT ST		VACAVILLE	CA	95688-5315
155	Affiliated	877	Corona	Corona Dialysis Center	1820 FULLERTON AVE	STE 18	CORONA	CA	92881-3147
156	Affiliated	872	Fairfield	Fairfield Dialysis Center	4660 CENTRAL WAY		FAIRFIELD	CA	94534-1803
157	Affiliated	902	Westminster	Westminster Dialysis Center (Federal Heights)	9053 HARLAN ST	STE 9	WESTMINSTER	CO	80031-2908

158	Affiliated	901	Aurora	Aurora Dialysis Center	1411 S POTOMAC ST	AMC II STE 1	AURORA	CO	80012-4536
159	Affiliated	900	Denver	Denver Dialysis Center	2900 DOWNING ST	STE C	DENVER	CO	80205-4699
160	Affiliated	903	Littleton	Littleton Dialysis Center	209 W COUNTY LINE RD		LITTLETON	CO	80129-1901
161	Affiliated	904	South Denver	South Denver Dialysis Center	850 E HARVARD AVE	STE 6	DENVER	CO	80210-5030
162	Affiliated	946	Lee Street Dialysis	Lee Street Dialysis (fka Grant Park Dialysis Center)	5155 LEE ST NE		WASHINGTON	DC	20019-4051
163	Affiliated	868	Leesburg	Leesburg Dialysis Center	801 E DIXIE AVE	STE 18A	LEESBURG	FL	34748-7699
164	Affiliated	866	Panama City	Panama City Dialysis Center	615 HIGHWAY 231		PANAMA CITY	FL	32405-4704
165	Affiliated	867	Marianna	Marianna Dialysis Center	2930 OPTIMIST DR		MARIANNA	FL	32448-7703
166	Affiliated	864	Venice	Venice Dialysis Center	816 PINEBROOK RD		VENICE	FL	34285-7103
167	Affiliated	827	Buena Vista	Buena Vista Dialysis Center	349 GENEVA RD		BUENA VISTA	GA	31803-1701
168	Affiliated	828	Decatur	Decatur Dialysis Center	1987 CANDLER RD		DECATUR	GA	30032-4212
169	Affiliated	825	Moultrie	Moultrie Dialysis Center	2419 S MAIN ST		MOULTRIE	GA	31768-6531
170	Affiliated	820	SW Atlanta	Southwest Atlanta Dialysis Center	3620 MARTIN LUTHER KING DR SW		ATLANTA	GA	30331-3711
171	Affiliated	818	Griffin	Griffin Dialysis Center	731 S 8TH ST		GRIFFIN	GA	30224-4818
172	Affiliated	826	Columbus	Columbus Dialysis Center	6228 BRADLEY PARK DR	STE B	COLUMBUS	GA	31904-3604
173	Affiliated	829	East Macon	East Macon Dialysis Center	165 EMERY HWY	STE 11	MACON	GA	31217-3666
174	Affiliated	817	Jonesboro	Jonesboro Dialysis Center	129 KING ST		JONESBORO	GA	30236-3656
175	Affiliated	824	Milledgeville	Milledgeville Dialysis Center	400 S WAYNE ST		MILLEDGEVILLE	GA	31061-3446
176	Affiliated	823	Fort Valley	Fort Valley Dialysis Center	557 BLUEBIRD BLVD		FORT VALLEY	GA	31030-5083
177	Affiliated	821	Midtown	Linden Dialysis (fka Midtown-Atlanta)	121 LINDEN AVE NE		ATLANTA	GA	30308-2432
178	Affiliated	953	E. St. Louis	Sauget Dialysis (fka East St. Louis Dialysis Center)	2061 GOOSE LAKE RD		SAUGET	IL	62206-2822
179	Affiliated	952	Granite City	Granite City Dialysis Center	9 AMERICAN VLG		GRANITE CITY	IL	62040-3706
180	Affiliated	937	Batesville	Batesville Dialysis Center Aka Renal Treatment Centers-Batesville	232 STATE ROAD 129 S		BATESVILLE	IN	47006-7694
181	Affiliated	938	Lawrenceburg	Lawrenceburg Dialysis Center	721 RUDOLPH WAY		GREENDALE	IN	47025-8378
182	Affiliated	939	Madison	Madison Dialysis Center	220 CLIFTY DR	UNIT K	MADISON	IN	47250-1669
183	Affiliated	836	Newton	Renal Treatment Center-Newton aka-Newton Dialysis Center	1223 WASHINGTON RD		NEWTON	KS	67114-4855
184	Affiliated	837	Derby	Renal Treatment Center-Derby aka Derby Dialysis Center	250 W RED POWELL DR		DERBY	KS	67037-2626
185	Affiliated	834	Winfield	Renal Treatment Center-Winfield aka, Winfield Dialysis Center	1315 E 4TH AVE		WINFIELD	KS	67156-2457
186	Affiliated	830	Wichita	Wichita Dialysis Center	909 N TOPEKA ST		WICHITA	KS	67214-3620
187	Affiliated	833	Garden City	Renal Treatment Center-Garden City Aka-Garden City Dialysis Center	401 N MAIN ST		GARDEN CITY	KS	67846-5429
188	Affiliated	831	E. Wichita	East Wichita Dialysis Center	320 N HILLSIDE ST		WICHITA	KS	67214-4918
189	Affiliated	832	Independance	Independence Dialysis Center	801 W MYRTLE ST		INDEPENDENCE	KS	67301-3239
190	Affiliated	835	Parson, KS	Parsons Dialysis Center	1902 S US HWY 59	BLDG B	PARSONS	KS	67357-4948
191	Affiliated	814	Wheaton	Wheaton Dialysis Center	11941 GEORGIA AVE		WHEATON	MD	20902
192	Affiliated	812	Rockville	Rockville Dialysis Center	14915 BROSCHART RD	STE 1	ROCKVILLE	MD	20850-3367
193	Affiliated	815	Owing Mills	Owings Mills Dialysis Center (fka-Renal Treatment Center-Owings Mills)	10 CROSSROADS DR	STE 11	OWINGS MILLS	MD	21117-5463
194	Affiliated	811	Berlin	Berlin Dialysis Center	314 FRANKLIN AVE	STE 36	BERLIN	MD	21811-1238
195	Affiliated	810	Easton	Easton Dialysis Center	402 MARVEL CT		EASTON	MD	21601-4052
196	Affiliated	813	Chestertown	Chestertown Dialysis Center (fka Renal Treatment Centers-Chestertown)	100 BROWN ST		CHESTERTOWN	MD	21620
197	Affiliated	951	Hope Again	Hope Again Dialysis Center- fka Kennett Dialysis Center	1207 STATE ROUTE VV		KENNETT	MO	63857-3823
198	Affiliated	950	Poplar Bluff	Bluff City Dialysis Center	2400 LUCY LEE PKWY	STE E	POPLAR BLUFF	MO	63901-2429
199	Affiliated	949	Crystal City	Crystal City Dialysis Center	960 SO TRUMAN BLVD		CRYSTAL CITY	MO	63019-1329
200	Affiliated	947	St. Louis	St. Louis Dialysis Center (fka Renal Treatment Center-St. Louis)	2610 CLARK AVE		SAINT LOUIS	MO	63103-2502
201	Affiliated	944	Burlington	Burlington Dialysis	873 HEATHER RD		BURLINGTON	NC	27215-6288
202	Affiliated	838	Scottsbluff	Scottsbluff Dialysis Center	3812 AVENUE B		SCOTTSBLUFF	NE	69361-4780
203	Affiliated	802	Bridgewater	Bridgewater Dialysis Center (fka Renal Treatment Center-Bridgewater)	2121 US HWY 22		BOUND BROOK	NJ	08805-1546
204	Affiliated	845	West Las Vegas	Las Vegas Dialysis Center	150 S VALLEY VIEW BLVD		LAS VEGAS	NV	89107
205	Affiliated	846	North Las Vegas	North Las Vegas Dialysis Center	2300 MCDANIEL ST		NORTH LAS VEGAS	NV	89030-6318
206	Affiliated	940	Cincinnati	Eastgate Dialysis (fka Cincinnati)	4435 AICHOLTZ RD		CINCINNATI	OH	45245-1690
207	Affiliated	885	Tulsa	Tulsa Dialysis	4436 S HARVARD AVE		TULSA	OK	74135-2605
208	Affiliated	897	NW Bethany	Northwest Bethany Dialysis Center	7800 NW 23RD ST	STE A	BETHANY	OK	73008-4948
209	Affiliated	890	Duncan	Duncan Dialysis Center	2645 W ELK AVE		DUNCAN	OK	73533-1572
210	Affiliated	893	Shawnee	Shawnee Dialysis Center	4409 N KICKAPOO AVE	STE 113	SHAWNEE	OK	74804-1224
211	Affiliated	895	Stillwater	Stillwater Dialysis Center	406 E HALL OF FAME AVE	STE 3	STILLWATER	OK	74075-5447

212	Affiliated	955	Midwest City	Midwest City Dialysis Center	7221 E RENO AVE		MIDWEST CITY	OK	73110-4474
213	Affiliated	886	Broken Arrow	Broken Arrow Dialysis Center	1700 N 9TH ST		BROKEN ARROW	OK	74012
214	Affiliated	888	Tahlequah	Tahlequah Dialysis Center	1373 E BOONE ST		TAHLEQUAH	OK	74464-3330
215	Affiliated	899	Edmund	Edmond Dialysis	50 S BAUMANN AVE		EDMOND	OK	73034-5676
216	Affiliated	889	Altus	Altus Dialysis Center	205 S PARK LN	STE 13	ALTUS	OK	73521-5756
217	Affiliated	896	Elk City	Elk City Dialysis Center	1601 W 2ND ST		ELK CITY	OK	73644-4427
218	Affiliated	887	Claremore	Claremore Dialysis Center	202 E BLUE STARR DR		CLAREMORE	OK	74017-4223
219	Affiliated	891	Norman	Norman Dialysis Center	1818 W LINDSEY ST	STE 14 BLDG B	NORMAN	OK	73069-4159
220	Affiliated	862	Pocono	Pocono Dialysis Center	100 PLAZA CT	STE B	EAST STROUDSBURG	PA	18301-8258
221	Affiliated	861	Palmerton	Palmerton Dialysis Center	185 DELAWARE AVE	STE C	PALMERTON	PA	18071-1716
222	Affiliated	860	Jennersville	Jennersville Dialysis Center	1011 W BALTIMORE PIKE		WEST GROVE	PA	19390-9446
223	Affiliated	858	Lewistown	Lewistown Dialysis Center	611 ELECTRIC AVE		LEWISTOWN	PA	17044-1128
224	Affiliated	854	Lemoyne	Camp Hill Dialysis Center (fka Lemoyne Dialysis Center (York Hospital Acutes))	425 N 21ST ST	LOWER LEVEL	CAMP HILL	PA	17011-2223
225	Affiliated	856	Upland	Upland Dialysis Center	1 MEDICAL CENTER BLVD	STE 12	CHESTER	PA	19013-3902
226	Affiliated	848	South Philadelphia	So. Philadelphia Dialysis Center	109 DICKINSON ST		PHILADELPHIA	PA	19147-6107
227	Affiliated	857	Exton	Exton Dialysis Center	710 SPRINGDALE DR		EXTON	PA	19341-2828
228	Affiliated	847	Northeast Philadelphia	NE Philadelphia Dialysis Center	518 KNORR ST		PHILADELPHIA	PA	19111-4604
229	Affiliated	934	Longview	Longview Dialysis Center	425 N FREDONIA ST		LONGVIEW	TX	75601-6464
230	Affiliated	935	Marshall-RTC	Marshall Dialysis Center	1301 S WASHINGTON AVE		MARSHALL	TX	75670-6215
231	Affiliated	933	Conroe	Conroe Dialysis Center	500 MEDICAL CENTER BLVD	STE 175	CONROE	TX	77304-2899
232	Affiliated	928	San Marcos	Hill Country Dialysis Center Of San Marcos	1820 PETER GARZA DR		SAN MARCOS	TX	78666-7407
233	Affiliated	923	Sherman	Sherman Dialysis Center	205 W LAMBERTH RD		SHERMAN	TX	75092-2659
234	Affiliated	932	Tomball	Tomball Dialysis Center	27720A TOMBALL PKWY		TOMBALL	TX	77375-
235	Affiliated	919	Cleveland	Cleveland Dialysis Center	600 E HOUSTON	STE 63	CLEVELAND	TX	77327-4689
236	Affiliated	921	Livingston	Livingston Dialysis Center	209 W PARK		LIVINGSTON	TX	77351-7020
237	Affiliated	920	Kingwood	Kingwood Dialysis Center	2300 GREEN OAK DR	STE 5	KINGWOOD	TX	77339-2053
238	Affiliated	930	North Houston	North Houston Dialysis Center	129 LITTLE YORK RD		HOUSTON	TX	77076-1020
239	Affiliated	926	Omni	Omni Dialysis Center (fka Hamilton Dialysis Center)	9350 KIRBY DR	STE 11	HOUSTON	TX	77054-2528
240	Affiliated	925	Victoria	Victoria Dialysis Center	1405 VICTORIA STATION DR		VICTORIA	TX	77901-3092
241	Affiliated	922	Lufkin	Lufkin Dialysis Center	700 S JOHN REDDITT DR		LUFKIN	TX	75904-3145
242	Affiliated	927	Gonzales	Gonzales Dialysis Center	1406 N SARAH DEWITT DR		GONZALES	TX	78629-2702
243	Affiliated	924	Denison	Denison Dialysis Center	1220 REBA MCENTIRE LANE		DENISON	TX	75020-9057
244	Affiliated	918	South San Antonio	South San Antonio Dialysis Center	1313 SE MILITARY DR	STE 111	SAN ANTONIO	TX	78214-2850
245	Affiliated	913	Austin	Waterloo Dialysis Center (fka Austin Dialysis Center)	5310 BURNET RD	UNIT 122	AUSTIN	TX	78756-2003
246	Affiliated	916	S. Austin	El Milagro Dialysis Unit (fka South Austin Dialysis Center)	2800 S INTERSTATE HWY 35	STE 12	AUSTIN	TX	78704-5700
247	Affiliated	929	SW San Antonio	Southwest San Antonio Dialysis Center	7515 BARLITE BLVD		SAN ANTONIO	TX	78224-1311
248	Affiliated	936	Bedford	HEB Dialysis Center (Bedford)	1401 BROWN TRL	STE A	BEDFORD	TX	76022-6416
249	Affiliated	917	TRC Med Cntr	Med-Center Dialysis, fka Plaza Dialysis Center & Houston Kidney Center #376	5610 ALMEDA RD		HOUSTON	TX	77004-7515
250	Affiliated	908	Chesapeake	Chesapeake Dialysis Center	1400 CROSSWAYS BLVD	CROSSWAYS II STE 16	CHESAPEAKE	VA	23320-2839
251	Affiliated	912	Hopewell	Hopewell Dialysis Center	301 W BROADWAY AVE		HOPEWELL	VA	23860-2645
252	Affiliated	911	Newport News	Newport News Dialysis Center	711 79TH ST		NEWPORT NEWS	VA	23605-2767
253	Affiliated	907	Norfolk	Norfolk Dialysis Center	962 NORFOLK SQ		NORFOLK	VA	23502-3235
254	Affiliated	909	Virginia Beach	Virginia Beach Dialysis Center	740 INDEPENDENCE CIR		VIRGINIA BEACH	VA	23455-6438
255	Affiliated	171	Palmer	Palmer Dialysis Center	30 COMMUNITY DR		EASTON	PA	18045-2658
256	Affiliated	589	Burgaw	SEDC (NC II) Burgaw Dialysis Center	704 S DICKERSON ST	PO BOX 1391	BURGAW	NC	28425-4904
257	Affiliated	590	Elizabethtown	SEDC (NC II) Elizabethtown Dialysis Center	101 DIALYSIS DR		ELIZABETHTOWN	NC	28337-9048
258	Affiliated	591	Jacksonville	SEDC (NC II) Jacksonville Dialysis Center	14 OFFICE PARK DR		JACKSONVILLE	NC	28546-7325
259	Affiliated	592	Kenansville	SEDC (NC II) Kenansville Dialysis Center	305 BEASLEY ST		KENANSVILLE	NC	28349-8798
260	Affiliated	593	Shallotte	SEDC (NC II) Shallotte Dialysis Center	4770 SHALLOTTE AVE		SHALLOTTE	NC	28470-6596
261	Affiliated	594	Whiteville	SEDC (NC II) Whiteville Dialysis Center	608 PECAN LN		WHITEVILLE	NC	28472-2949
262	Affiliated	595	Wilmington	SEDC (NC II) Wilmington Dialysis Center	2215 YAUPON DR		WILMINGTON	NC	28401-7334
263	Affiliated	175	Deerfield	Deerfield Beach Artificial Kidney Center	1983 W HILLSBORO BLVD		DEERFIELD BEACH	FL	33442-1418
264	Affiliated	176	Pampano Beach	Pompano Beach Artificial Kidney Center	600 SW 3RD ST	STE 11	POMPANO BEACH	FL	33060-6936
265	Affiliated	177	Tamarack	Tamarac Artificial Kidney Center	7140 W MCNAB RD		TAMARAC	FL	33321-5306

266	Affiliated	168	Atlantic AKC	Atlantic Artificial Kidney Center	6 INDUSTRIAL WAY W	STE B	EATONTOWN	NJ	07724-2258
267	Affiliated	587	Rowan/Kannapolis	Dialysis Care of Kannapolis	1607 N MAIN ST		KANNAPOLIS	NC	28081-2317
268	Affiliated	654	Cortez	Cortez Dialysis	610 E MAIN ST	STE C	CORTEZ	CO	81321-3308
269	Affiliated	142	West Bountiful 4/6/98	West Bountiful Dialysis	724 W 500 S	STE 3	WEST BOUNTIFUL	UT	84087-1471
270	Affiliated	187	Meherrin	Meherrin Dialysis Center	201A WEAVER AVE		EMPORIA	VA	23847-1248
271	Affiliated	436	Montclair	Montclair Dialysis Center	5050 PALO VERDE ST	STE 1	MONTCLAIR	CA	91763-2329
272	Affiliated	259	Pipestone	Pipestone Dialysis	916 4TH AVE SW		PIPESTONE	MN	56164-1054
273	Affiliated	236	Washington	Washington Dialysis Center	154 WASHINGTON PLZ		WASHINGTON	GA	30673-2074
274	Affiliated	235	Elberton	Elberton Dialysis Center	894 ELBERT ST		ELBERTON	GA	30635-2628
275	Affiliated	174	Gulf Breeze	Gulf Breeze Dialysis Center	1519 MAIN ST		DUNEDIN	FL	34698-4650
276	Affiliated	526	Asheville	Asheville Kidney Center	1600 CENTRE PARK DR		ASHEVILLE	NC	28805-6206
277	Affiliated	528	Sylva	Sylva Dialysis Center	655 ASHEVILLE HWY		SYLVA	NC	28779-2747
278	Affiliated	527	Hendersonville	Hendersonville Dialysis Center	500 BEVERLY HANKS CTR	HWY 25 N	HENDERSONVILLE	NC	28792
279	Affiliated	389	Memorial	Memorial Dialysis	4427 S ROBERTSON ST		NEW ORLEANS	LA	70115-6308
280	Affiliated	127	Warner Robbins	Dialysis Center of Middle Georgia-Warner Robins	509 N HOUSTON RD		WARNER ROBINS	GA	31093-8844
281	Affiliated	126	Macon - Middle Georgia	Dialysis Center of Middle Georgia-Macon	747 2ND ST		MACON	GA	31201-6835
282	Affiliated	344	Oakland PD	Oakland Peritoneal Dialysis Center (Piedmont PD)	5352 CLAREMONT AVE		OAKLAND	CA	94618
283	Affiliated	384	Fairfax	Fairfax Dialysis Center	8501 ARLINGTON BLVD	STE 1	FAIRFAX	VA	22031-4625
284	Affiliated	374	Houston SW	Houston Kidney Center Southwest	11111 BROOKLET DR	STE 1 BLDG 1	HOUSTON	TX	77099-3555
285	Affiliated	545	Pikes Peak	Pikes Peak Dialysis Center	2002 LELARAY ST	STE 13	COLORADO SPRINGS	CO	80909-2804
286	Affiliated	546	Printers Place	Printers Place Dialysis	2802 INTERNATIONAL CIR		COLORADO SPRINGS	CO	80910-3127
287	Affiliated	541	Lakewood Colorado	Lakewood Dialysis Center	1750 PIERCE ST		LAKEWOOD	CO	80214-1434
288	Affiliated	543	Boulder	Boulder Dialysis Center	2880 FOLSOM ST	STE 11	BOULDER	CO	80304-3769
289	Affiliated	542	Thornton	Thornton Dialysis Center	8800 FOX DR		THORNTON	CO	80260-6880
290	Affiliated	544	Arvada	Arvada Dialysis Center	9950 W 80TH AVE	STE 25	ARVADA	CO	80005-3914
291	Affiliated	173	Ft. Lauderdale	CDC South-Ft Lauderdale Renal Associates	6264 N FEDERAL HWY		FORT LAUDERDALE	FL	33308-1904
292	Affiliated	380	Houston Cypress Station	Houston Kidney Center Cypress Station	221 FM 1960 RD W	STE H	HOUSTON	TX	77090-3537
293	Affiliated	169	Erie County	Cleve Hill Dialysis Center (Fka Cleve Hill Limited Partnership-Erie Dialysis &ECMC Dialysis Center At Cleve Hill)	1461 KENSINGTON AVE		BUFFALO	NY	14215-1436
294	Affiliated	430	UCLA Pediatrics	Century City Dialysis (fka UCLA, DaVita Westwood UCLA)	10630 SANTA MONICA BLVD		LOS ANGELES	CA	90025-4837
295	Affiliated	501	Bronx	Bronx Dialysis Center	1615 EASTCHESTER RD		BRONX	NY	10461-2603
296	Affiliated	502	Catskill	Catskill Dialysis Center	139 FORESTBURGH RD		MONTICELLO	NY	12701-2364
297	Affiliated	505	Riverdale	Riverdale Dialysis Center	170 W 233RD ST		BRONX	NY	10463-5639
298	Affiliated	506	South Bronx	South Bronx Dialysis Center	1940 WEBSTER AVE		BRONX	NY	10457-4261
299	Affiliated	507	Stanten Island	Richmond Kidney Center (Staten Island)	1366 VICTORY BLVD		STATEN ISLAND	NY	10301-3907
300	Affiliated	238	McDonough	McDonough Dialysis Center	114 DUNN ST		MCDONOUGH	GA	30253-2347
301	Affiliated	192	Milford	Delaware Valley Dialysis Center (fka Milford)	102 DAVITA DR		MILFORD	PA	18337-9390
302	Affiliated	191	Honesdale	Honesdale Dialysis Center-NE Regional	RR 6 BOX 6636	STOURBRIDGE MALL	HONESDALE	PA	18431-9649
303	Affiliated	247	Memorial	Memorial Dialysis Center	11621 KATY FWY		HOUSTON	TX	77079-1801
304	Affiliated	246	Katy Dialysis Center	Grand Parkway Dialysis Center	403 W GRAND PKWY S	STE T	KATY	TX	77494-8358
305	Affiliated	245	Cyfair Dialysis Center	Cyfair Dialysis Center	9110 JONES RD	STE 11	HOUSTON	TX	77065-4489
306	Affiliated	165	Port Chester	Port Chester Dialysis and Renal Center	38 BULKLEY AVE		PORT CHESTER	NY	10573-3902
307	Affiliated	193	Franklin Dialysis	Franklin Dialysis Center	150 SOUTH INDEPENDENCE WEST	11 PUBLIC LEDGER BLDG	PHILADELPHIA	PA	19106-3413
308	Affiliated	156	Grand Blanc	Grand Blanc Dialysis Center	3625 GENESYS PKWY		GRAND BLANC	MI	48439-8070
309	Affiliated	397	Oxford Court	Oxford Court Dialysis	930 TOWN CENTER DR	STE G1	LANGHORNE	PA	19047-4260
310	Affiliated	348	Antioch	Antioch Dialysis	3100 DELTA FAIR BLVD		ANTIOCH	CA	94509-4001
311	Affiliated	401	North Palm Beach	North Palm Beach Dialysis Center	2841 PGA BLVD		PALM BEACH GARDENS	FL	33410-2910
312	Affiliated	277	Lodi	Lodi Dialysis Center	1610 W KETTLEMAN LN	STE D	LODI	CA	95242-4210
313	Affiliated	438	United	United Dialysis Center	3111 LONG BEACH BLVD		LONG BEACH	CA	90807-5015
314	Affiliated	437	Premier	Premier Dialysis Center	7612 ATLANTIC AVE		CUDAHY	CA	90201-5020
315	Affiliated	349	Salinas	Salinas Dialysis Center	955 BLANCO CIR	STE C	SALINAS	CA	93901-4452
316	Affiliated	428	Lowry I	Lowry Dialysis Center	7465 E 1ST AVE	STE A	DENVER	CO	80230-6877
317	Affiliated	154	Ypsilanti	Ypsilanti Dialysis	2766 WASHTENAW RD		YPSILANTI	MI	48197-1506
318	Affiliated	237	Eastpoint	East Point Dialysis	2669 CHURCH ST		EAST POINT	GA	30344-3115
319	Affiliated	520	Celia Dill	Celia Dill Dialysis Center	667 STONELEIGH AVE	STE 123 BARNS OFFICE CENTER	CARMEL	NY	10512-2454

320	Affiliated	248	Elmbrook	Brookriver Dialysis	8101 BROOKRIVER DR		DALLAS	TX	75247-4003
321	Affiliated	402	Ocala East	OCALA Regional Kidney Center-East	2870 SE 1ST AVE		OCALA	FL	34471-0406
322	Affiliated	403	Ocala West	OCALA Regional Kidney Center-West	9401 SW HWY 200	BLDG 6	OCALA	FL	34481-9612
323	Affiliated	404	Ocala South	OCALA Regional Kidney Center-South	13940 N US HWY 441	BLDG 4	LADY LAKE	FL	32159-8908
324	Affiliated	417	Delta Sierra Dialysis	Delta-Sierra Dialysis Center	555 W BENJAMIN HOLT DR	STE 2	STOCKTON	CA	95207-3839
325	Affiliated	552	Olympic View	Olympic View Dialysis Center	125 16TH AVE E CSB	5TH FL	SEATTLE	WA	98112
326	Affiliated	148	Pratt	Pratt Dialysis Center	203 WATSON ST	STE 11	PRATT	KS	67124-3092
327	Affiliated	196	Buffalo	Renal Care of Buffalo	550 ORCHARD PARK RD		WEST SENECA	NY	14224-2646
328	Affiliated	555	Woodland	Woodland Dialysis Center	912 WOODLAND DR	STE B	ELIZABETHTOWN	KY	42701-2795
329	Affiliated	556	Taylor	Taylor County Dialysis Center	101 KINGSWOOD DR		CAMPBELLSVILLE	KY	42718-9634
330	Affiliated	491	Gary	Comprehensive Renal Care (CRC)-Gary	4802 BROADWAY		GARY	IN	46408-4509
331	Affiliated	492	Hammond	Comprehensive Renal Care (CRC)-Hammond	222 DOUGLAS ST		HAMMOND	IN	46320-1960
332	Affiliated	493	Valparaiso	Comprehensive Renal Care (CRC)-Valparaiso	606 E LINCOLNWAY		VALPARAISO	IN	46383-5728
333	Affiliated	494	Michigan City	Comprehensive Renal Care (CRC)-Michigan City	9836 WEST 400 NORTH		MICHIGAN CITY	IN	46360-2910
334	Affiliated	495	Munster	Comprehensive Renal Care (CRC)-Munster	9100 CALUMET AVE		MUNSTER	IN	46321-1737
335	Affiliated	497	South County-Deaconess	South County Dialysis (Deaconess)	4145 UNION RD		SAINT LOUIS	MO	63129-1064
336	Affiliated	266	South Hayward	South Hayward Dialysis Center	254 JACKSON ST		HAYWARD	CA	94544-1907
337	Affiliated	164	Dyker Heights	Dyker Heights Dialysis Center	1435 86TH ST		BROOKLYN	NY	11228-3435
338	Affiliated	152	Clarkston	Clarkston Dialysis Center	6770 DIXIE HWY	STE 25	CLARKSTON	MI	48346-2089
339	Affiliated	534	Hudson Valley	Hudson Valley Dialysis Center	155 WHITE PLAINS RD		TARRYTOWN	NY	10591-5523
340	Affiliated	971	Central Tulsa	Central Tulsa Dialysis Center	1124 S SAINT LOUIS AVE		TULSA	OK	74120-5413
341	Affiliated	972	Okmulgee	Okmulgee Dialysis Center	201 SO DELAWARE AVE		OKMULGEE	OK	74447-5528
342	Affiliated	974	Muskogee	Muskogee Community Dialysis	2316 W SHAWNEE ST		MUSKOGEE	OK	74401-2228
343	Affiliated	975	Miami-Oklahoma	Tri-State Dialysis Center (fka Miami Dialysis Center (OK))	2510 N MAIN ST		MIAMI	OK	74354-1602
344	Affiliated	977	Stilwell	Stilwell Dialysis Center	80851 HWY 59		STILWELL	OK	74960
345	Affiliated	496	East Chicago	Comprehensive Renal Care (CRC)-East Chicago	4320 FIR ST	UNIT 44	EAST CHICAGO	IN	46312-3078
346	Affiliated	549	Bright Dialysis	Bright Dialysis (fka Fort Pierce Artificial Kidney Center, TRC of Fort Pierce-AKC)	1801 S 23RD ST	STE 1	FORT PIERCE	FL	34950-4830
347	Affiliated	153	Detroit	Detroit Dialysis Center (Eastern Market, Brewery Park Development)	2674 E JEFFERSON AVE		DETROIT	MI	48207-4129
348	Affiliated	166	White Plains	White Plains Dialysis Center	200 HAMILTON AVE	STE 13B	WHITE PLAINS	NY	10601-1859
349	Affiliated	337	Crescent Heights	Crescent Heights Dialysis Center	8151 BEVERLY BLVD		LOS ANGELES	CA	90048-4514
350	Affiliated	547	Pahrump Dialysis	Pahrump Dialysis Center	330 S LOLA LN	STE 1	PAHRUMP	NV	89048-0884
351	Affiliated	598	Cherokee Dialysis Center	Cherokee Dialysis Center	53 ECHOTA CHURCH RD		CHEROKEE	NC	28719-9702
352	Affiliated	444	Utah Valley	Utah Valley Dialysis Center	1055 N 500 W	STE 221	PROVO	UT	84604-3305
353	Affiliated	439	Washington Plaza	Washington Plaza Dialysis Center	516 E WASHINGTON BLVD	# 522	LOS ANGELES	CA	90015-3723
354	Affiliated	539	Commerce City	Commerce City Dialysis Center	6320 HOLLY ST		COMMERCE CITY	CO	80022-3325
355	Affiliated	251	Bloomington Dialysis	Bloomington Dialysis Unit of TRC (fka Richfield)	8591 LYNDALE AVE S		BLOOMINGTON	MN	55420-2237
356	Affiliated	133	Kent Community Dialysis	Kent Dialysis Center	21501 84TH AVE S		KENT	WA	98032-1960
357	Affiliated	278	Florin Dialyis	Florin Dialysis Center	7000 STOCKTON BLVD		SACRAMENTO	CA	95823-2312
358	Affiliated	540	South Las Vegas Dialysis	South Las Vegas Dialysis Center (Palms)	2250 S RANCHO DR	STE 115	LAS VEGAS	NV	89102-4456
359	Affiliated	538	Longmont Dialysis	Longmont Dialysis Center	1715 IRON HORSE DR	STE 17	LONGMONT	CO	80501-9617
360	Affiliated	500	Great Bridge	Great Bridge Dialysis (fka Chesapeake II)	745 BATTLEFIELD BLVD N	STE 1	CHESAPEAKE	VA	23320-0305
361	Affiliated	569	Weaverville Dialysis	Weaverville Dialysis Facility	329 MERRIMON AVE		WEAVERVILLE	NC	28787-9253
362	Affiliated	427	Lakewood Crossing	Lakewood Crossing Dialysis	1057 S WADSWORTH BLVD	STE 1	LAKEWOOD	CO	80226-4361
363	Affiliated	155	Jackson	Jackson Dialysis Center	234 W LOUIS GLICK HWY		JACKSON	MI	49201-1326
364	Affiliated	429	Englewood	Englewood Dialysis Center	3247 S LINCOLN ST		ENGLEWOOD	CO	80113-2505
365	Affiliated	387	Harford Road Dialysis	Harford Road Dialysis Center	5800 HARFORD RD		BALTIMORE	MD	21214-1847
366	Affiliated	179	Arcadia	Arcadia Dialysis Center	1341 E OAK ST		ARCADIA	FL	34266-8902
367	Affiliated	388	Richmond Community	Richmond Community Hospital Dialysis (fkaTRC @ Richmond Community/Richmond II)	1510 N 28TH ST	STE 11	RICHMOND	VA	23223-5311
368	Affiliated	119	Henderson	Henderson Dialysis Center	1002 US HWY 79 N		HENDERSON	TX	75652-6008
369	Affiliated	253	Augusta	Nephrology Center of South Augusta	1631 GORDON HWY STE 1B		AUGUSTA	GA	30906
370	Affiliated	510	Boston Post Road	Boston Post Road Dialysis Center fka Co Op City Dialysis	4026 BOSTON RD		BRONX	NY	10475-1122
371	Affiliated	512	Peekskill	Peekskill Cortlandt Dialysis Center	2050 E MAIN ST	STE 15	CORTLANDT MANOR	NY	10567-2502
372	Affiliated	513	Queens	Queens Dialysis Center	11801 GUY R BREWER BLVD		JAMAICA	NY	11434-2101
373	Affiliated	517	Soundview	Soundview Dialysis Center	1622 BRUCKNER BLVD	STE 24	BRONX	NY	10473-4553

374	Affiliated	516	Port Washington	Port Washington Dialysis Center	50 SEAVIEW BLVD		PORT WASHINGTON	NY	11050-4615
375	Affiliated	515	Lynbrook	Lynbrook Dialysis Center	147 SCRANTON AVE		LYNBROOK	NY	11563-2808
376	Affiliated	518	Yonkers Dialysis Center	Yonkers Dialysis	575 YONKERS AVE		YONKERS	NY	10704-2601
377	Affiliated	537	IHS - Queens Village	Queens Village Dialysis Center	22202 HEMPSTEAD AVE	STE 17	QUEENS VILLAGE	NY	11429-2123
378	Affiliated	536	Coney Island - IHS	Sheepshead Bay Renal Care Center (fka Coney Island)	26 BRIGHTON 11TH ST		BROOKLYN	NY	11235-5304
379	Affiliated	521	Garden City I.H.S	Garden City Dialysis Center	1100 STEWART AVE	STE 2	GARDEN CITY	NY	11530-4839
380	Affiliated	267	Kenneth Hahn- I.R.A	Kenneth Hahn Plaza Dialysis Center (Willowbrook)	11854 S WILMINGTON AVE		LOS ANGELES	CA	90059-3016
381	Affiliated	279	North Highland	North Highlands Dialysis Center	4986 WATT AVE	STE F	NORTH HIGHLANDS	CA	95660-5182
382	Affiliated	294	TRC Orangevale	Orangevale Dialysis Center	9267 GREENBACK LN	STE A2	ORANGEVALE	CA	95662-4864
383	Affiliated	554	Forest Park Dialysis Center	Forest Park Dialysis Center	380 FOREST PKWY	STE C	FOREST PARK	GA	30297-2107
384	Affiliated	446	Grant Park Nursing Home Dialysis	Grant Park Dialysis (fka Grants Park Nursing Home)	5000 NANNIE HELEN BURROUGHS AVE NE		WASHINGTON	DC	20019-5506
385	Affiliated	455	Fourth Street Dialysis	Fourth Street Dialysis	3101 N 4TH ST	STE B	LONGVIEW	TX	75605-5146
386	Affiliated	274	Bay Breeze	Bay Breeze Dialysis	11465 ULMERTON RD		LARGO	FL	33778-1602
387	Affiliated	416	Hopi	Hopi Dialysis Center- fka First Mesa	PO BOX 964	HWY 264	POLACCA	AZ	86042
388	Affiliated	178	Orlando Dialysis	Orlando Dialysis	14050 TOWN LOOP BLVD	STE 14A	ORLANDO	FL	32837-6190
389	Affiliated	170	Celebration Dialysis	Celebration Dialysis	1154 CELEBRATION BLVD		CELEBRATION	FL	34747-4605
390	Affiliated	1500	Mt. Dora Dialysis	Mt. Dora Dialysis	2735 W OLD US HIGHWAY 441		MOUNT DORA	FL	32757-3526
391	Affiliated	1501	Lake Dialysis	Lake Dialysis	221 N 1ST ST		LEESBURG	FL	34748-5150
392	Affiliated	146	Puyallup Community Dialysis	Puyallup Dialysis Center	716 SOUTH HILL PARK DR	STE C	PUYALLUP	WA	98373-1445
393	Affiliated	562	Towson Dialysis	Dulaney Towson Dialysis Center	113 WEST RD	STE 21	TOWSON	MD	21204-2318
394	Affiliated	188	Purcellville	Purcellville Dialysis Center	280 N HATCHER AVE		PURCELLVILLE	VA	20132-3193
395	Affiliated	476	Iris City	Iris City Dialysis (aka Griffin)	521 N EXPRESSWAY	STE 159	GRIFFIN	GA	30223-2073
396	Affiliated	1521	Slidell Kidney Care	Slidell Kidney Care	1150 ROBERT BLVD	STE 24	SLIDELL	LA	70458-2005
397	Affiliated	385	Rivertowne Dialysis	Rivertowne Dialysis (fka Oxon Hill Dialysis)	6192 OXON HILL RD	1ST FL	OXON HILL	MD	20745-3114
398	Affiliated	477	Pearland Dialysis	Pearland Dialysis	6516 BROADWAY ST	STE 122	PEARLAND	TX	77581-7879
399	Affiliated	419	East Aurora Dialysis	East Aurora Dialysis (aka Aurora II)	482 S CHAMBERS RD		AURORA	CO	80017-2092
400	Affiliated	1507	Merrillville Dialysis	CRC-Merrillville Dialysis Center	9223 TAFT ST		MERRILLVILLE	IN	46410-6911
401	Affiliated	563	Bricktown Dialysis	Bricktown Dialysis Center	525 JACK MARTIN BLVD	FL 2	BRICK	NJ	08724-7735
402	Affiliated	423	Sapulpa	Sapulpa Dialysis (fka Jenks-Sapulpa)	9647 RIDGEVIEW ST		TULSA	OK	74131-6205
403	Affiliated	1526	Ellijay Dialysis	Ellijay Dialysis	449 INDUSTRIAL BLVD	STE 24	ELLIJAY	GA	30540-6724
404	Affiliated	1527	Gainesville Dialysis	Gainesville Dialysis	2545 FLINTRIDGE RD	STE 13	GAINESVILLE	GA	30501-7428
405	Affiliated	1528	Newnan Dialysis	Newnan Dialysis	1565 E HWY 34	STE 13	NEWNAN	GA	30265
406	Affiliated	405	Ocala Regional Kidney Center - North	OCALA North Dialysis Center	2620 W HWY 316		CITRA	FL	32113-3555
407	Affiliated	1516	Pin Oak Dialysis	Pin Oak Dialysis Center (aka Katy II)	1302 PIN OAK RD		KATY	TX	77494-6848
408	Affiliated	1523	Imperial Care Dialysis	Imperial Care Dialysis Center	4345 E IMPERIAL HWY		LYNWOOD	CA	90262-2318
409	Affiliated	1533	St. Louis Park Dialysis	St. Louis Park Dialysis Center	3505 LOUISIANA AVE S		ST LOUIS PARK	MN	55426-4121
410	Affiliated	1517	Minneapolis NE Dialysis	Minneapolis NE Dialysis	1049 10TH AVE SE		MINNEAPOLIS	MN	55414-1312
411	Affiliated	298	Flushing Dialysis	Flushing Dialysis Center	3469 PIERSON PL	STE A	FLUSHING	MI	48433-2413
412	Affiliated	1535	Dialysis Systems of Covington	Dialysis Systems of Covington	210 GREENBRIAR BLVD		COVINGTON	LA	70433-7235
413	Affiliated	1536	Dialysis Systems of Hammond	Dialysis Systems of Hammond	15799 PROFESSIONAL PLZ		HAMMOND	LA	70403-1452
414	Affiliated	433	Soledad Dialysis	Soledad Dialysis Center	901 LOS COCHES DR		SOLEDAD	CA	93960-2995
415	Affiliated	443	Lake Elsinore Dialysis	Lake Elsinore Dialysis	32291 MISSION TRL	BLDG S	LAKE ELSINORE	CA	92530
416	Affiliated	1511	Clinton Dialysis Center	Clinton Dialysis Center	150 S 31ST ST		CLINTON	OK	73601-9118
417	Affiliated	456	Bakers Ferry	Bakers Ferry Dialysis	3645 BAKERS FERRY RD SW		ATLANTA	GA	30331-3712
418	Affiliated	1509	Hermiston	Hermiston Community Dialysis Center	1155 W LINDA AVE		HERMISTON	OR	97838-9601
419	Affiliated	1539	Yakima	Yakima Dialysis Center	1221 N 16TH AVE		YAKIMA	WA	98902-1347
420	Affiliated	409	Madison	Madison Dialysis Center	302 HIGHWAY ST		MADISON	NC	27025-1672
421	Affiliated	1508	Swannanoa Dialysis	Swannanoa Dialysis Center (fka Black Mountain, NC)	2305 US HIGHWAY 70		SWANNANOA	NC	28778-8207
422	Affiliated	2009	NE Wichita Dialysis	NE Wichita Dialysis Center	2630 N WEBB RD	STE 1 BLDG 1	WICHITA	KS	67226-8174
423	Affiliated	2005	Chadbourn Dialysis	Chadbourn Dialysis Center (fkaColumbus County)	210 STRAWBERRY BLVD		CHADBOURN	NC	28431-1418
424	Affiliated	1506	Western Home Dialysis	Mile High Home Dialysis PD (fka Western Home)	1750 PIERCE ST	STE A	LAKEWOOD	CO	80214-1434
425	Affiliated	2019	Tustin Dialysis	Tustin Dialysis (aka Santa Ana)	2090 N TUSTIN AVE	STE 1	SANTA ANA	CA	92705-7869
426	Affiliated	182	Appomatox	Appomattox Dialysis (Petersburg)	15 W OLD ST		PETERSBURG	VA	23803-3221
427	Affiliated	2002	Maryville Dialysis	Maryville Dialysis	2130 VADALABENE DR		MARYVILLE	IL	62062-5632

428	Affiliated	2001	Mission Hills	Mission Hills Dialysis (aka Cristo Rey)	2700 N STANTON ST		EL PASO	TX	79902-2500
429	Affiliated	125	Moncrief	Moncrief Dialysis Partners	800 W 34TH ST	STE 11	AUSTIN	TX	78705-1144
430	Affiliated	295	Southfield West Dialysis	Southfield West Dialysis	21900 MELROSE AVE	STE 4	SOUTHFIELD	MI	48075-7967
431	Affiliated	525	Neptune Dialysis	Neptune Dialysis Center	2180 BRADLEY AVE		NEPTUNE	NJ	07753-4427
432	Affiliated	2014	Portsmouth Dialysis	Portsmouth Dialysis Center	2000 HIGH ST		PORTSMOUTH	VA	23704-3012
433	Affiliated	2016	Tokay Dialysis	Tokay Dialysis Center (fka East Lodi, CA)	312 S FAIRMONT AVE	STE A	LODI	CA	95240-3840
434	Affiliated	1504	Mt. Pocono Dialysis	Mt. Pocono Dialysis	100 COMMUNITY DR	STE 16	TOBYHANNA	PA	18466-8986
435	Affiliated	1544	Greater Portsmouth	Greater Portsmouth (aka Bon View Dialysis & Mid Town Hampton Road Dialysis)	3516 QUEEN ST		PORTSMOUTH	VA	23707-3238
436	Affiliated	1545	Peninsula Dialysis	Peninsula Dialysis Center (aka Immaculate Dialysis)	716 DENBIGH BLVD	STE D1 AND D2	NEWPORT NEWS	VA	23608-4414
437	Affiliated	1540	Saginaw Dialysis	Saginaw Dialysis	1527 E GENESEE AVE		SAGINAW	MI	48607-1755
438	Affiliated	1560	Churchview Dialysis	Churchview Dialysis	5970 CHURCHVIEW DR		ROCKFORD	IL	61107-2574
439	Affiliated	1562	Freeport Dialysis	Freeport Dialysis	1028 S KUNKLE BLVD		FREEPORT	IL	61032-6914
440	Affiliated	1563	Rockford Dialysis	Rockford Dialysis	3339 N ROCKTON AVE		ROCKFORD	IL	61103-2839
441	Affiliated	1564	Whiteside Dialysis	Whiteside Dialysis	2600 N LOCUST	STE D	STERLING	IL	61081-4602
442	Affiliated	2021	Pikesville Dialysis	Pikesville Dialysis	1500 REISTERSTOWN RD	STE 22	PIKESVILLE	MD	21208-3836
443	Affiliated	2000	Waynesville Dialysis	Waynesville Dialysis Center (fka Haywood, NC)	11 PARK TERRACE DR		CLYDE	NC	28721-7445
444	Affiliated	296	Davison Dialysis	Davison Dialysis	1011 S STATE RD		DAVISON	MI	48423-1903
445	Affiliated	1557	Flint Dialysis	Flint Dialysis Center	2 HURLEY PLZ	STE 115	FLINT	MI	48503-5904
446	Affiliated	1558	Hallwood Dialysis	Hallwood Dialysis Center	4929 CLIO RD	STE B	FLINT	MI	48504-1886
447	Affiliated	1559	Park Plaza Dialysis	Park Plaza Dialysis	G1075 N BALLENGER HWY		FLINT	MI	48504-4431
448	Affiliated	1518	Rosemead Springs Dialysis	Rosemead Springs Dialysis Center	3212 ROSEMEAD BLVD		EL MONTE	CA	91731-2807
449	Affiliated	2022	Scottsdale Dialysis	Scottsdale Dialysis Center	4725 N SCOTTSDALE RD	STE 1	SCOTTSDALE	AZ	85251-7621
450	Affiliated	1570	Washington Parish Dialysis	Washington Parish Dialysis	724 WASHINGTON ST		FRANKLINTON	LA	70438-1790
451	Affiliated	2027	Brookhollow Dialysis	Brookhollow Dialysis	4918 W 34TH ST		HOUSTON	TX	77092-6606
452	Affiliated	2017	Creekside	Creekside Dialysis Center (fka So. Vacaville, CA)	141 PARKER ST		VACAVILLE	CA	95688-3921
453	Affiliated	529	Middletown	Middletown Dialysis Center (fka-Red Bank)	500 STATE ROUTE 35	UNION SQUARE PLAZA	RED BANK	NJ	07701-5038
454	Affiliated	1541	Southwest Ohio Dialysis	Southwest Ohio Dialysis (Xenia-SWORC)	215 S ALLISON AVE		XENIA	OH	45385-3694
455	Affiliated	369	Oak Park	Oak Park Dialysis Center	13481 W 10 MILE RD		OAK PARK	MI	48237-4633
456	Affiliated	2042	Eden Prairie	Eden Prairie Dialysis	14852 SCENIC HEIGHTS RD	STE 255 BLDG B	EDEN PRAIRIE	MN	55344-2320
457	Affiliated	1530	Owensboro Dialysis	Owensboro Dialysis Center	1930 E PARRISH AVE		OWENSBORO	KY	42303-1443
458	Affiliated	1531	Tell City Dialysis	CRC-Tell City Dialysis Center	1602 MAIN ST		TELL CITY	IN	47586-1310
459	Affiliated	1576	Crestwood Dialysis	Crestwood Dialysis (fka Health Research Group-St. Louis (HRG))	9901 WATSON RD	STE 125	SAINT LOUIS	MO	63126-1855
460	Affiliated	2004	Copperfield Dialysis	Copperfield Dialysis (fka Cabarrus County-NC, and Concord)	1030 VINEHAVEN DR		CONCORD	NC	28025-2438
461	Affiliated	1572	Grand Island Dialysis	Grand Island Dialysis	603 S WEBB RD		GRAND ISLAND	NE	68803-5141
462	Affiliated	1573	Harlan Dialysis	Harlan Dialysis	1213 GARFIELD AVE		HARLAN	IA	51537-2057
463	Affiliated	1574	Shenandoah Dialysis	Shenandoah Dialysis	300 PERSHING AVE		SHENANDOAH	IA	51601-2355
464	Affiliated	2053	Germantown Dialysis	Germantown Dialysis	20111 CENTURY BLVD	STE C	GERMANTOWN	MD	20874-9165
465	Affiliated	2051	Lamplighter Dialysis	Lamplighter Dialysis	12654 LAMPLIGHTER SQUARE		ST LOUIS	MO	63128
466	Affiliated	1578	Kidney Care of Largo	Kidney Care of Largo	1300 MERCANTILE LN	STE 194	UPPER MARLBORO	MD	20774
467	Affiliated	1579	Kidney Care of Laurel	Kidney Care of Laurel	14631 LAUREL BOWIE ROAD	UNITS 1-15	LAUREL	MD	20707
468	Affiliated	2024	Durant Dialysis	Durant Dialysis Center	411 WESTSIDE DR		DURANT	OK	74701-2932
469	Affiliated	2038	Palm Brook Dialysis	Palm Brook Dialysis Center	14664 N DEL WEBB BLVD		SUN CITY	AZ	85351-2137
470	Affiliated	2043	Cambridge Dialysis	Cambridge Dialysis Center	300 BYRN ST		CAMBRIDGE	MD	21613-1908
471	Affiliated	2059	Reston Dialysis Center	Reston Dialysis Center	1875 CAMPUS COMMONS DR	STE 11	RESTON	VA	20191-1564
472	Affiliated	2040	Franconia Dialysis	Franconia Dialysis Centre	5695 KING CENTRE DRIVE		ALEXANDRIA	VA	22315-5744
473	Affiliated	2041	Eagan Dialysis	Eagan Dialysis Unit	2750 BLUE WATER RD	SUITE 3	EAGAN	MN	55121-1400
474	Affiliated	1594	Central Des Moines Dialysis	Central Des Moines Dialysis	1215 PLEASANT ST	STE 16	DES MOINES	IA	50309-1409
475	Affiliated	1595	West Des Moines Dialysis	West Des Moines Dialysis	6800 LAKE DR	STE 185	WEST DES MOINES	IA	50266-2544
476	Affiliated	1596	Creston Dialysis	Creston Dialysis	1700 W TOWNLINE ST		CRESTON	IA	50801-1054
477	Affiliated	1597	Atlantic Dialysis	Atlantic Dialysis	1500 E 10TH ST		ATLANTIC	IA	50022-1935
478	Affiliated	1598	Newton Dialysis	Newton Dialysis	204 N 4TH AVE E	STE 134	NEWTON	IA	50208-3135
479	Affiliated	2046	Dialysis of Des Moines	Riverpoint Dialysis Unit	501 SW 7TH ST	STE B	DES MOINES	IA	50309-4538
480	Affiliated	2060	Bellevue Dialysis	Bellevue Dialysis Center	3535 FACTORIA BLVD SE	STE 15	BELLEVUE	WA	98006-1293
481	Affiliated	414	Somerset Dialysis	Somerset Dialysis Center	240 CHURCHILL AVE		SOMERSET	NJ	08873-3451

482	Affiliated	2031	East Ft. Lauderdale Dialysis	East Ft. Lauderdale Dialysis Center (fka No. Broward)	1301 S ANDREWS AVE	STE 11	FT LAUDERDALE	FL	33316-1823
483	Affiliated	1593	Spring Branch Dialysis	Spring Branch Dialysis	1425 BLALOCK	STE 1	HOUSTON	TX	77055-4446
484	Affiliated	1599	Battle Creek Dialysis	Battle Creek Dialysis	220 E GOODALE AVE		BATTLE CREEK	MI	49037-2728
485	Affiliated	2025	Hampton Avenue Dialysis	Hampton Avenue Dialysis-MO (Forest Park)	1425 HAMPTON AVE		SAINT LOUIS	MO	63139-3115
486	Affiliated	1605	Bogalusa Kidney Care	Bogalusa Kidney Care	2108 SOUTH AVE F		BOGALUSA	LA	70427
487	Affiliated	2055	Bardstown Dialysis	Bardstown Dialysis Center	210 W JOHN FITCH AVE		BARDSTOWN	KY	40004-1115
488	Affiliated	2050	Southern Pines	Southern Pines Dialysis Center	209 WINDSTAR PL		SOUTHERN PINES	NC	28387-7086
489	Affiliated	2030	Montclare Dialysis	Montclare Dialysis Center (aka Belmont Ave)	7009 W BELMONT AVE		CHICAGO	IL	60634-4533
490	Affiliated	2048	Southern Hills	Southern Hills Dialysis Center	9280 W SUNSET RD	STE 11	LAS VEGAS	NV	89148-4861
491	Affiliated	2068	Kilgore Dialysis	Kilgore Dialysis Center	209 HWY 42 NORTH		KILGORE	TX	75662-5019
492	Affiliated	2067	Brighton Dialysis	Brighton Dialysis	4700 E BROMLEY LN	STE 13	BRIGHTON	CO	80601-7821
493	Affiliated	2023	Union Gap	Union Gap Dialysis (aka Yakima)	1236 AHTANUM RIDGE DR	AHTANUM RIDGE BUSINESS PARK	UNION GAP	WA	98903-1813
494	Affiliated	2039	Dallas North Dialysis	Dallas North Dialysis Center (aka Greenville)	11886 GREENVILLE AVE	STE 1B	DALLAS	TX	75243-9743
495	Affiliated	2061	Grovepark Dialysis	Grovepark Dialysis Center (fka Jackson Dialysis)	794 MCDONOUGH RD		JACKSON	GA	30233-1572
496	Affiliated	1583	Eastern Kentucky Dialysis	Eastern Kentucky Dialysis	167 WEDDINGTON BRANCH RD		PIKEVILLE	KY	41501-3204
497	Affiliated	1584	Paintsville Dialysis	Paintsville Dialysis	4750 S KY ROUTE 321		HAGERHILL	KY	41222
498	Affiliated	1582	West Virginia Dialysis	West Virginia Dialysis	300 PROSPERITY LANE	STE 15	LOGAN	WV	25601-3494
499	Affiliated	2049	Reidsville Dialysis	Reidsville Dialysis	1307 FREEWAY DR		REIDSVILLE	NC	27320-7104
500	Affiliated	2034	Elk Grove Dialysis	Elk Grove Dialysis	9281 OFFICE PARK CIR	STE 15	ELK GROVE	CA	95758-8069
501	Affiliated	2035	Weston Dialysis	Weston Dialysis Center (fka Cleveland Clinic)	2685 EXECUTIVE PARK DR	STE 1	WESTON	FL	33331-3651
502	Affiliated	1600	McCook Dialysis	McCook Dialysis Center	801 W C ST		MCCOOK	NE	69001-3591
503	Affiliated	1601	Hastings Dialysis	Hastings Dialysis Center	1900 N SAINT JOSEPH AVE		HASTINGS	NE	68901-2652
504	Affiliated	1602	Capital City Dialysis	Capital City Dialysis	307 N 46TH ST		LINCOLN	NE	68503-3714
505	Affiliated	1616	Renal Care of Bowie	Renal Care of Bowie	4861 TELSA DRIVE	STES G-H	BOWIE	MD	20715-4318
506	Affiliated	1617	Renal Care of Takoma Park	Takoma Park Dialysis (fka Renal Care of Takoma Park)	1502 UNIVERSITY BLVD E		HYATTSVILLE	MD	20783
507	Affiliated	1618	Renal Care of Lanham	Renal Care of Lanham	8855 ANNAPOLIS RD	STE 2	LANHAM	MD	20706-2942
508	Affiliated	1619	Parma Dialysis	Parma Dialysis Center	6735 AMES RD		CLEVELAND	OH	44129-5601
509	Affiliated	1620	Middleburg Heights Dialysis	Middleburg Hts. Dialysis	7360 ENGLE RD		MIDDLEBURG HTS	OH	44130
510	Affiliated	1621	Rocky River Dialysis	Rocky River Dialysis	20220 CENTER RIDGE RD	STE 5	ROCKY RIVER	OH	44116-3567
511	Affiliated	1606	Diamond Valley Dialysis	Diamond Valley Dialysis	1030 E FLORIDA AVE		HEMET	CA	92543-4511
512	Affiliated	1607	Murrieta Dialysis	Murrieta Dialysis	25100 HANCOCK AVE	STE 11	MURRIETA	CA	92562-5973
513	Affiliated	2057	South Chico Dialysis	South Chico Dialysis Center	2345 FOREST AVE		CHICO	CA	95928-7641
514	Affiliated	2099	Dixon Kidney Center	Dixon Kidney Center	1131 N GALENA AVE		DIXON	IL	61021-1015
515	Affiliated	1640	Grand Rapids	PDI-Grand Rapids	801 CHERRY ST SE		GRAND RAPIDS	MI	49506-1440
516	Affiliated	1641	Grand Rapids East	PDI-Grand Rapids East	1230 EKHART ST NE		GRAND RAPIDS	MI	49503-1372
517	Affiliated	1642	Grand Haven	PDI-Grand Haven	16964 ROBBINS RD		GRAND HAVEN	MI	49417-2796
518	Affiliated	1644	Highland Park	PDI-Highland Park	64 VICTOR ST		HIGHLAND PARK	MI	48203-3128
519	Affiliated	1645	Cadieux	PDI-Cadieux	6150 CADIEUX ROAD		DETROIT	MI	48224-2006
520	Affiliated	1646	Montgomery	PDI-Montgomery	1001 FOREST AVE		MONTGOMERY	AL	36106-1181
521	Affiliated	1647	East Montgomery	PDI-East Montgomery	6890 WINTON BLOUNT BLVD		MONTGOMERY	AL	36117-3516
522	Affiliated	1648	Prattville	PDI-Prattville	1815 GLYNWOOD DR		PRATTVILLE	AL	36066-5584
523	Affiliated	1649	Elmore	PDI-Elmore	125 HOSPITAL DR		WETUMPKA	AL	36092-1626
524	Affiliated	1650	Fitchburg	PDI-Fitchburg	551 ELECTRIC AVE		FITCHBURG	MA	01420-5371
525	Affiliated	1652	Rocky Hill	PDI-Rocky Hill	30 WATERCHASE DR		ROCKY HILL	CT	06067-2110
526	Affiliated	1653	Middlesex	PDI-Middlesex Dialysis Center	100 MAIN ST	STE A	MIDDLETOWN	CT	06457-3477
527	Affiliated	1655	Johnstown	PDI-Johnstown	344 BUDFIELD ST		JOHNSTOWN	PA	15904-3214
528	Affiliated	1656	Ebensburg	PDI-Ebensburg	236 JAMESWAY RD		EBENSBURG	PA	15931-4207
529	Affiliated	1657	Walnut Tower	PDI-Walnut Tower	834 WALNUT ST		PHILADELPHIA	PA	19107-5109
530	Affiliated	1659	Lancaster	PDI-Lancaster	1412 E KING ST		LANCASTER	PA	17602-3240
531	Affiliated	1660	Ephrata	PDI-Ephrata	67 W CHURCH ST		STEVENS	PA	17578-9203
532	Affiliated	2083	Pinecrest Dialysis	Pinecrest Dialysis (aka North Marshall-TX)	913 E PINECREST DR		MARSHALL	TX	75670-7309
533	Affiliated	551	Westwood Dialysis	Westwood Dialysis Center (aka West Seattle)	2615 SW TRENTON ST		SEATTLE	WA	98126-3745
534	Affiliated	2107	Louisville Dialysis	Louisville Dialysis	8037 DIXIE HWY		LOUISVILLE	KY	40258-1344
535	Affiliated	2018	Fair Oaks Dialysis	Fair Oaks Dialysis Center (fka Chantilly & Centreville)	3955 PENDER DR	ONE PENDER BUSINESS PARK	FAIRFAX	VA	22030-6091

536	Affiliated	421	Oak Cliff	Oak Cliff Dialysis	2000 S LLEWELLYN AVE		DALLAS	TX	75224-1804
537	Affiliated	2126	Gilmer Dialysis	Gilmer Dialysis Center	519 N WOOD ST		GILMER	TX	75644-1746
538	Affiliated	1608	Chicago Heights Dialysis	Chicago Heights Dialysis	177 W JOE ORR RD	STE B	CHICAGO HEIGHTS	IL	60411-1733
539	Affiliated	1623	East Georgia Dialysis	East Georgia Dialysis	450 GEORGIA AVE	STE A	STATESBORO	GA	30458-5590
540	Affiliated	1639	Northlake Dialysis	Northlake Dialysis	1350 MONTREAL RD	STE 2	TUCKER	GA	30084-8144
541	Affiliated	1680	Down River Dialysis	Downriver Kidney Center	5600 ALLEN RD		ALLEN PARK	MI	48101-2604
542	Affiliated	2063	Belcaro	Belcaro Dialysis Center	755 S COLORADO BLVD		DENVER	CO	80246-8005
543	Affiliated	2076	Sherwood Dialysis Center	Sherwood Dialysis Center	21035 SW PACIFIC HWY		SHERWOOD	OR	97140-8062
544	Affiliated	2054	Lonetree Dialysis	Lonetree Dialysis Center (aka Skyridge)	9777 MOUNT PYRAMID CT	STE 14	ENGLEWOOD	CO	80112-6017
545	Affiliated	2078	River Park Dialysis	River Park Dialysis (aka Conroe)	2010 S LOOP 336 W	STE 2	CONROE	TX	77304-3313
546	Affiliated	2058	Northshore Dialysis	Northshore Kidney Center (fka Slidell II)	106 MEDICAL CENTER DR		SLIDELL	LA	70461-5575
547	Affiliated	2036	Marysville Dialysis	Marysville Dialysis Center	1015 8TH ST		MARYSVILLE	CA	95901-5271
548	Affiliated	2070	West Georgia Dialysis	West Georgia Dialysis	1216 STARK AVE		COLUMBUS	GA	31906-2500
549	Affiliated	2102	East Dearborn Dialysis	Westland Dialysis (aka Canton)	36588 FORD RD		WESTLAND	MI	48185-3769
550	Affiliated	2045	Downtown Houston Dialysis	Downtown Houston Dialysis Center	2207 CRAWFORD ST		HOUSTON	TX	77002-8915
551	Affiliated	2066	Concord Dialysis	Concord Dialysis Center	2300 STANWELL DR	STE C	CONCORD	CA	94520-4841
552	Affiliated	2087	Pendleton Dialysis	Pendleton Dialysis (aka Clemson, Tri-County)	7703 HIGHWAY 76		PENDLETON	SC	29670-1818
553	Affiliated	2106	New Albany Dialysis	New Albany Dialysis	2669 CHARLESTON RD		NEW ALBANY	IN	47150-2573
554	Affiliated	1585	Whitesburg Dialysis	Whitesburg Dialysis	222 HOSPITAL RD	STE D	WHITESBURG	KY	41858-7627
555	Affiliated	2047	Jacinto Dialysis	Jacinto Dialysis Center (aka East Houston)	11515 MARKET STREET RD		HOUSTON	TX	77029-2305
556	Affiliated	2088	Transmountain Dialysis	Transmountain Dialysis (aka Northeast El Paso, Rushfair)	5255 WOODROW BEAN	STE B18	EL PASO	TX	79924-3832
557	Affiliated	2029	Southcrest Dialysis	Southcrest Dialysis (aka South Creek)	9001 S 101ST EAST AVE	STE 11	TULSA	OK	74133-5799
558	Affiliated	2071	Lake Hearn	Lake Hearn Dialysis (aka Dunwoody, Roswell, Northside)	1150 LAKE HEARN DR NE	STE 1	ATLANTA	GA	30342-1566
559	Affiliated	2118	Mt. Greenwood	Mt. Greenwood Dialysis	3401 W 111TH ST		CHICAGO	IL	60655-3329
560	Affiliated	2086	Citrus Valley Dialysis Center	Citrus Valley Dialysis (aka San Bernadino II)	894 HARDT STREET		SAN BERNARDINO	CA	92408-2854
561	Affiliated	2095	McDowell County Dialysis	McDowell County Dialysis Center	100 SPAULDING RD	STE 2	MARION	NC	28752-5116
562	Affiliated	2115	Leigh Dialysis Center	Leigh Dialysis Center (aka Leigh-Kempville-VA)	420 N CENTER DR	STE 128	NORFOLK	VA	23502-4019
563	Affiliated	2120	Dialysis of Lithonia	Dialysis of Lithonia	2485 PARK CENTRAL BLVD		DECATUR	GA	30035-3902
564	Affiliated	2114	Embassy Lake Artificial Kidney Center	Embassy Lake Artificial Kidney Center (fka Davie & South Broward AKC)	11011 SHERIDAN ST	STE 38	HOLLYWOOD	FL	33026-1505
565	Affiliated	2056	Sun City Dialysis	Sun City Dialysis (akaTexas Tech II)	600 NEWMAN ST		EL PASO	TX	79902-5543
566	Affiliated	1651	PDI Worcester	PDI-Worcester Dialysis	19 GLENNIE ST	STE A	WORCESTER	MA	01605-3918
567	Affiliated	2130	Davenport Dialysis Center	Davenport Dialysis Center (aka Haines City II)	45597 HIGHWAY 27	RIDGEVIEW PLAZA	DAVENPORT	FL	33897-4519
568	Affiliated	2081	Cinema Dialysis	Cinema Dialysis (aka OKC South)	3909 S WESTERN AVE		OKLAHOMA CITY	OK	73109-3405
569	Affiliated	2037	Greenwood Dialysis Center	Greenwood Dialysis Center (North Tulsa)	1345 N LANSING AVE		TULSA	OK	74106-5911
570	Affiliated	1712	TRC Alamosa Diakysis	Alamosa Dialysis	612 DEL SOL DR		ALAMOSA	CO	81101-8548
571	Affiliated	1682	South Austin	South Austin Dialysis	6114 S 1ST ST		AUSTIN	TX	78745-4008
572	Affiliated	2109	Durango Dialysis Center	Durango Dialysis Center	72 SUTTLE STREET	STE D	DURANGO	CO	81303-6829
573	Affiliated	1700	Bolivar Dialysis	Bolivar Dialysis	515 PECAN DR		BOLIVAR	TN	38008-1611
574	Affiliated	1701	Brownsville Dialysis	Brownsville Dialysis	380 N DUPREE AVE		BROWNSVILLE	TN	38012-2332
575	Affiliated	1702	Camden Dialysis	Camden Dialysis	168 W MAIN ST	STE A	CAMDEN	TN	38320-1767
576	Affiliated	1703	Collierville Dialysis	Collierville Dialysis	791 W POPLAR AVE		COLLIERVILLE	TN	38017-2543
577	Affiliated	1705	Galleria Dialysis	Galleria Dialysis	9160 HIGHWAY 64		LAKELAND	TN	38002-4766
578	Affiliated	1706	Humboldt Dialysis	Humboldt Dialysis	2214 OSBORNE ST		HUMBOLDT	TN	38343-3044
579	Affiliated	1707	Stonegate Dialysis	North Jackson Dialysis (fka Stonegate)	217 STERLING FARM DR		JACKSON	TN	38305-5727
580	Affiliated	1708	Lexington Dialysis	Lexington Dialysis	317 W CHURCH ST		LEXINGTON	TN	38351-2096
581	Affiliated	1709	Pickwick Dialysis	Pickwick Dialysis	121 PICKWICK ST		SAVANNAH	TN	38372-1953
582	Affiliated	1710	Selmber Dialysis	Selmer Dialysis	251 OAKGROVE RD		SELMER	TN	38375-1881
583	Affiliated	1713	Childs Dialysis	Childs Dialysis	101 MAIN ST		CHILDS	PA	18407-2614
584	Affiliated	1714	Dunmore Dialysis	Dunmore Dialysis	1212 O'NEIL HWY		DUNMORE	PA	18512-1717
585	Affiliated	1716	Old Forge Dialysis	Old Forge Dialysis	325 S MAIN ST		OLD FORGE	PA	18518-1677
586	Affiliated	1717	Scranton Dialysis	Scranton Dialysis	475 MORGAN HWY		SCRANTON	PA	18508-2605
587	Affiliated	1718	Tunkhannock Dialysis	Tunkhannock Dialysis	5950 SR 6		TUNKHANNOCK	PA	18657-7905
588	Affiliated	1725	East Evansville Dialysis	East Evansville Dialysis	1312 PROFESSIONAL BLVD		EVANSVILLE	IN	47714-8007
589	Affiliated	1726	North Evansville Dialysis	North Evansville Dialysis	1151 W BUENA VISTA RD		EVANSVILLE	IN	47710-3334

590	Affiliated	1728	Jasper Dialysis	Jasper Dialysis	721 W 13TH ST	STE 15	JASPER	IN	47546-1856
591	Affiliated	1729	Daviess County Dialysis	Daviess County Dialysis	310 NE 14TH ST		WASHINGTON	IN	47501-2137
592	Affiliated	1730	Gardenside Dialysis	Gardenside Dialysis	70 N GARDENMILE RD		HENDERSON	KY	42420-5529
593	Affiliated	1732	PD Evansville Dialysis	East Evansville Dialysis PD	1312 PROFESSIONAL BLVD		EVANSVILLE	IN	47714-8007
594	Affiliated	2098	Meridian Dialysis Center	Meridian Dialysis Center (aka Bayshore)	201 W FAIRMONT PKWY	STE A	LA PORTE	TX	77571-6303
595	Affiliated	2100	Sycamore Dialysis	Sycamore Dialysis (aka DeKalb)	2200 GATEWAY DR		SYCAMORE	IL	60178-3113
596	Affiliated	2104	Ballenger Pointe Dialysis	Ballenger Pointe Dialysis (aka West Flint)	2262 S BALLENGER HWY		FLINT	MI	48503-3447
597	Affiliated	2139	Leitchfield Dialysis	Leitchfield Dialysis	912 WALLACE AVE	STE 16	LEITCHFIELD	KY	42754-2405
598	Affiliated	2097	Roxbury Dialysis Center	Roxbury Dialysis	622 ROXBURY RD		ROCKFORD	IL	61107-5089
599	Affiliated	2148	LaGrange Dialysis	La Grange Dialysis	240 PARKER DR		LA GRANGE	KY	40031-1200
600	Affiliated	2132	Des Moines East	East Des Moines Dialysis (aka Des Moines II)	1301 PENNSYLVANIA AVE	STE 28	DES MOINES	IA	50316-2365
601	Affiliated	2119	Lake Villa Dialysis	Lake Villa Dialysis	37809 N IL ROUTE 59		LAKE VILLA	IL	60046-7332
602	Affiliated	159	Seneca Dialysis	Seneca County Dialysis	65 SAINT FRANCIS AVE		TIFFIN	OH	44883-3413
603	Affiliated	407	Perry	Perry Dialysis Center	1027 KEITH DR		PERRY	GA	31069-2948
604	Affiliated	661	Wilshire	Wilshire Dialysis	1212 WILSHIRE BLVD		LOS ANGELES	CA	90017-1902
605	Affiliated	692	University Park	University Park Dialysis Center	3986 S FIGUEROA ST		LOS ANGELES	CA	90037-1222
606	Affiliated	1720	Metro East Dialysis	Metro East Dialysis	5105 W MAIN ST		BELLEVILLE	IL	62226-4728
607	Affiliated	2196	Ocala Regional Kidney Centers	Ocala Regional Kidney Centers Home Dialysis Division PD	2860 SE 1ST AVE		OCALA	FL	34471-0406
608	Affiliated	2133	Little Village Dialysis	Little Village Dialysis (Chicago)	2335 W CERMAK RD		CHICAGO	IL	60608-3811
609	Affiliated	2112	Crossroads	Crossroads Dialysis (aka Fullerton Dialysis)	3214 YORBA LINDA BLVD		FULLERTON	CA	92831-1707
610	Affiliated	1727	Vincennes Dialysis	Vincennes Dialysis	700 WILLOW ST		VINCENNES	IN	47591-1028
611	Affiliated	1723	Spring Dialysis	Spring Dialysis	607 TIMBERDALE LN	STE 1	HOUSTON	TX	77090-3043
612	Affiliated	2190	River Center	Rivercenter Dialysis (aka Central San Antonio)	1123 N MAIN AVE	STE 15	SAN ANTONIO	TX	78212-4738
613	Affiliated	2193	Southcross Dialysis Center	Southcross Dialysis (aka SouthEast San Antonio)	4602 E SOUTHCROSS BLVD		SAN ANTONIO	TX	78222-4911
614	Affiliated	2125	Bonham Dialysis	Bonham Dialysis	201 W 5TH ST		BONHAM	TX	75418-4302
615	Affiliated	2192	Northwest Medical Center Dialysis	NW Medical Center Dialysis (aka NorthWest San Antonio)	5284 MEDICAL DR	STE 1	SAN ANTONIO	TX	78229-4849
616	Affiliated	2124	Ontario Dialysis	Ontario Dialysis (aka Dr. Handoko)	1950 S GROVE AVE	STE 11-15	ONTARIO	CA	91761-5693
617	Affiliated	1750	Chipley Community Dialysis	Chipley Dialysis	877 3RD ST	STE 2	CHIPLEY	FL	32428-1855
618	Affiliated	1751	North Ikaloosa	North Okaloosa Dialysis	320 REDSTONE AVE W		CRESTVIEW	FL	32536-6433
619	Affiliated	1752	West Florida Dialysis	West Florida Dialysis	8333 N DAVIS HWY	1ST FLOOR ATTN DIALYSIS ROOM	PENSACOLA	FL	32514-6049
620	Affiliated	1753	Santa Rosa Dialysis	Santa Rosa Dialysis	5819 HIGHWAY 90		MILTON	FL	32583-1763
621	Affiliated	1755	Atmore Dialysis	Atmore Dialysis Center	807 E CRAIG ST		ATMORE	AL	36502-3017
622	Affiliated	1756	South Baldwin Dialysis	South Baldwin Dialysis Center	150 W PEACHTREE AVE		FOLEY	AL	36535-2244
623	Affiliated	1731	Olney Dialysis	Olney Dialysis Center (aka Good Samaritan Hospital)	117 N BOONE ST		OLNEY	IL	62450-2109
624	Affiliated	2156	Lancaster Dialysis	Lancaster Dialysis	2424 W PLEASANT RUN RD		LANCASTER	TX	75146-4005
625	Affiliated	2136	Columbia Dialysis	RTC-Columbia Dialysis (MO)	1701 E BROADWAY	STE G12	COLUMBIA	MO	65201-8029
626	Affiliated	2194	Las Palmas Dialysis Center	Las Palmas Dialysis Center (aka West San Antonio)	803 CASTROVILLE RD	STE 415	SAN ANTONIO	TX	78237-3148
627	Affiliated	2116	South Shore Dialysis Center	South Shore Dialysis (aka Horizon)	212 GULF FWY S	STE G3	LEAGUE CITY	TX	77573-3957
628	Affiliated	2191	Marymount Dilaysis Center	Marymont Dialysis (aka NorthEast San Antonio)	2391 NE LOOP 410	STE 211	SAN ANTONIO	TX	78217-5675
629	Affiliated	1744	Fox River Dialysis	Fox River Dialysis	1910 RIVERSIDE DR		GREEN BAY	WI	54301-2319
630	Affiliated	1745	Titletown Dialysis	Titletown Dialysis	120 SIEGLER ST		GREEN BAY	WI	54303-2636
631	Affiliated	1746	Northwoods Dialysis	Green Bay Northwood Dialysis	W 7305 ELM AVENUE		SHAWANO	WI	54166-1024
632	Affiliated	1758	North Charleston Dialysis	North Charleston Dialysis	5900 RIVERS AVE	STE E	NORTH CHARLESTON	SC	29406
633	Affiliated	1759	Charleston County Dialysis	Faber Place Dialysis	3801 FABER PLACE DR		NORTH CHARLESTON	SC	29405-8533
634	Affiliated	1760	Goose Creek Dialysis	Goose Creek Dialysis	109 GREENLAND DR		GOOSE CREEK	SC	29445-5354
635	Affiliated	2501	Bridgeport Dialysis	Bridgeport Dialysis	900 MADISON AVE	STE 221	BRIDGEPORT	CT	06606-5534
636	Affiliated	2503	Greater Waterbury Dialysis	Greater Waterbury Dialysis	209 HIGHLAND AVE		WATERBURY	CT	06708-3026
637	Affiliated	2506	Shelton Dialysis	Shelton Dialysis	750 BRIDGEPORT AVE		SHELTON	CT	06484-4734
638	Affiliated	2508	Yuma Dialysis	Yuma Dialysis	2130 W 24TH ST		YUMA	AZ	85364-6122
639	Affiliated	2509	Pittsburgh Dialysis	Pittsburgh Dialysis	4312 PENN AVE		PITTSBURGH	PA	15224-1310
640	Affiliated	2510	Elizabeth Dialysis	Elizabeth Dialysis	201 MCKEESPORT RD		ELIZABETH	PA	15037-1623
641	Affiliated	2511	Brandon East Dialysis	Brandon East Dialysis	114 E BRANDON BLVD		BRANDON	FL	33511-5219
642	Affiliated	2513	North Rolling Road Dialysis	North Rolling Road Dialysis	1108 N ROLLING RD		BALTIMORE	MD	21228-3826
643	Affiliated	2521	Memphis South Dialysis	Memphis South Dialysis	1205 MARLIN RD		MEMPHIS	TN	38116-5812

644	Affiliated	2524	Hartford Dialysis	Hartford Dialysis	675 TOWER AVE	RENAL UNIT 2ND FL	HARTFORD	CT	6112
645	Affiliated	2538	New Orleans Uptown Dialysis	New Orleans Uptown Dialysis	1401 FOUCHER ST	4TH FLOOR DIALYSIS	NEW ORLEANS	LA	70115-3515
646	Affiliated	2540	Omaha West Dialysis	Omaha West Dialysis	13014 W DODGE RD		OMAHA	NE	68154-2148
647	Affiliated	2541	White Memorial Dialysis	East Los Angeles Plaza Dialysis (fka White Memorial)	1700 E CESAR E CHAVEZ AVE	STE L 1	LOS ANGELES	CA	90033-2424
648	Affiliated	2542	Imperial Dialysis	Imperial Dialysis	2738 W IMPERIAL HWY		INGLEWOOD	CA	90303-3111
649	Affiliated	2546	North Hollywood Dialysis	North Hollywood Dialysis	12126 VICTORY BLVD		NORTH HOLLYWOOD	CA	91606-3205
650	Affiliated	2555	Mountain View Dialysis	Mountain View Dialysis	2881 BUSINESS PARK CT	STE 13	LAS VEGAS	NV	89128-9019
651	Affiliated	2560	San Juan Capistrano South Dialysis	San Juan Capistrano South Dialysis	31736 RANCHO VIEJO RD	STE B	SAN JUAN CAPISTRANO	CA	92675-2783
652	Affiliated	2564	Mission Viejo Dialysis	Mission Viejo Dialysis	27640 MARGUERITE PKWY		MISSION VIEJO	CA	92692-3604
653	Affiliated	2568	HI-Desert Dialysis	HI-Desert Dialysis	58457 29 PALMS HWY	STE 12	YUCCA VALLEY	CA	92284-5879
654	Affiliated	2571	Banning Dialysis	Banning Dialysis	6090 W RAMSEY ST		BANNING	CA	92220-3052
655	Affiliated	2601	Rainbow City Dialysis	Rainbow City Dialysis	2800 RAINBOW DR		RAINBOW CITY	AL	35906-5811
656	Affiliated	2604	Gadsden Dialysis	Gadsden Dialysis	409 S 1ST ST		GADSDEN	AL	35901-5358
657	Affiliated	2605	Chateau Dialysis	Chateau Dialysis	720 VILLAGE RD		KENNER	LA	70065-2751
658	Affiliated	2606	Donaldsonville Dialysis	Donaldsonville Dialysis	101 PLIMSOL DR		DONALDSONVILLE	LA	70346-4357
659	Affiliated	2609	Dothan Dialysis	Dothan Dialysis	216 GRACELAND DR		DOTHAN	AL	36305-7346
660	Affiliated	2614	Birmingham East Dialysis	Birmingham East Dialysis	1105 E PARK DR		BIRMINGHAM	AL	35235-2560
661	Affiliated	2615	Tuscaloosa Dialysis	Tuscaloosa Dialysis	805 OLD MILL ST		TUSCALOOSA	AL	35401-7132
662	Affiliated	2616	Demopolis Dialysis	Demopolis Dialysis	511 S CEDAR AVE		DEMOPOLIS	AL	36732-2235
663	Affiliated	2623	Singing River Dialysis	Singing River Dialysis	4907 TELEPHONE RD		PASCAGOULA	MS	39567-1823
664	Affiliated	2624	Ocean Springs Dialysis	Ocean Springs Dialysis	13150 PONCE DE LEON DR		OCEAN SPRINGS	MS	39564-2460
665	Affiliated	2625	Lucedale Dialysis	Lucedale Dialysis	652 MANILA ST		LUCEDALE	MS	39452-5962
666	Affiliated	2707	Holmdel Dialysis	Holmdel Dialysis	668 N BEERS ST		HOLMDEL	NJ	07733-1526
667	Affiliated	2855	Alameda County Dialysis	Alameda County Dialysis	10700 MACARTHUR BLVD	STE 14	OAKLAND	CA	94605-5260
668	Affiliated	2908	Elizabeth City Dialysis	Elizabeth City Dialysis	1840 W CITY DR		ELIZABETH CITY	NC	27909-9632
669	Affiliated	2914	Cookeville Dialysis	Cookeville Dialysis	140 W 7TH ST		COOKEVILLE	TN	38501-1726
670	Affiliated	3001	Inglewood Dialysis	Inglewood Dialysis	125 E ARBOR VITAE ST		INGLEWOOD	CA	90301-3839
671	Affiliated	3002	Rome Dialysis	Rome Dialysis	15 JOHN MADDOX DR NW		ROME	GA	30165-1413
672	Affiliated	3004	Pomona Dialysis	Pomona Dialysis	2111 N GAREY AVE		POMONA	CA	91767-2328
673	Affiliated	3005	Oak Street Dialysis	Oak Street Dialysis (fka Valdosta)	2704 N OAK ST	BLDG H	VALDOSTA	GA	31602-1723
674	Affiliated	3006	Channelview Dialysis	Channelview Dialysis	777 SHELDON RD	STE C	CHANNELVIEW	TX	77530-3509
675	Affiliated	3007	Sagemont Dialysis	Sagemont Dialysis	10851 SCARSDALE BLVD	STE 2	HOUSTON	TX	77089-5738
676	Affiliated	3008	San Jacinto Dialysis	San Jacinto Dialysis	11430 EAST FWY	STE 33	HOUSTON	TX	77029-1959
677	Affiliated	3009	Victor Valley Dialysis	Victor Valley Dialysis	16049 KAMANA RD		APPLE VALLEY	CA	92307-1331
678	Affiliated	3010	Delran Dialysis	Delran Dialysis	8008 ROUTE 130		DELRAN	NJ	08075-1869
679	Affiliated	3011	Central Houston Dialysis	Central Houston Dialysis	610 S WAYSIDE DR	UNIT B	HOUSTON	TX	77011-4605
680	Affiliated	3012	Southern Lane Dialysis	Southern Lane Dialysis	1840 SOUTHERN LN		DECATUR	GA	30033-4033
681	Affiliated	3013	Northumberland Dialysis	Northumberland Dialysis	103 W STATE ROUTE 61		MOUNT CARMEL	PA	17851-2539
682	Affiliated	3014	Pryor Dialysis	Pryor Dialysis	309 E GRAHAM AVE		PRYOR	OK	74361-2434
683	Affiliated	3015	Oklahoma City South Dialysis	Oklahoma City South Dialysis	5730 S MAY AVE		OKLAHOMA CITY	OK	73119-5604
684	Affiliated	3016	Abington Dialysis	Abington Dialysis	3940A COMMERCE AVE		WILLOW GROVE	PA	19090-1705
685	Affiliated	3017	Memphis Central Dialysis	Memphis Central Dialysis	889 LINDEN AVE		MEMPHIS	TN	38126-2412
686	Affiliated	3018	Memphis East Dialysis	Memphis East Dialysis	50 HUMPHREYS CTR	STE 42	MEMPHIS	TN	38120-2372
687	Affiliated	3019	Clarksville Dialysis	Clarksville Dialysis	231 HILLCREST DR		CLARKSVILLE	TN	37043-5093
688	Affiliated	3020	Miami Campus Dialysis	Miami Campus Dialysis	1500 NW 12TH AVE	STE 16	MIAMI	FL	33136-1028
689	Affiliated	3021	Orlando Dialysis	Orlando Dialysis	116 STURTEVANT ST		ORLANDO	FL	32806-2021
690	Affiliated	3024	Durham Dialysis	Durham Dialysis	601 FAYETTEVILLE ST		DURHAM	NC	27701-3910
691	Affiliated	3025	Candler County Dialysis	Candler County Dialysis	325 CEDAR ST		METTER	GA	30439-4043
692	Affiliated	3027	Kerrville Dialysis	Kerrville Dialysis	515 GRANADA PL		KERRVILLE	TX	78028-5992
693	Affiliated	3028	Floresville Dialysis	Floresville Dialysis	543 10TH ST		FLORESVILLE	TX	78114-3107
694	Affiliated	3029	Pearsall Dialysis	Pearsall Dialysis	1305 N OAK ST		PEARSALL	TX	78061-3414
695	Affiliated	3030	Nogales Dialysis	Nogales Dialysis	1231 W TARGET RANGE RD		NOGALES	AZ	85621-2417
696	Affiliated	3032	Wilson Dialysis	Wilson Dialysis	1605 MEDICAL PARK DR W		WILSON	NC	27893-2799
697	Affiliated	3033	Goldsboro Dialysis	Goldsboro Dialysis	2609 HOSPITAL RD		GOLDSBORO	NC	27534-9424

698	Affiliated	3034	Roxboro Dialysis	Roxboro Dialysis	718 RIDGE RD		ROXBORO	NC	27573-4508
699	Affiliated	3035	Boston Dialysis	Boston Dialysis	660 HARRISON AVE		BOSTON	MA	02118-2304
700	Affiliated	3037	Jesup Dialysis	Jesup Dialysis	301 PEACHTREE ST		JESUP	GA	31545-0245
701	Affiliated	3038	Sheffield Dialysis	Sheffield Dialysis	1120 S JACKSON HWY	ST 17	SHEFFIELD	AL	35660-5777
702	Affiliated	3039	Berkeley Dialysis	Berkeley Dialysis	2920 TELEGRAPH AVE		BERKELEY	CA	94705-2031
703	Affiliated	3040	Douglas Dialysis	Douglas Dialysis	190 WESTSIDE DR	STE A	DOUGLAS	GA	31533-3534
704	Affiliated	3041	Hopkinsville Dialysis	Hopkinsville Dialysis	1914 S VIRGINIA ST		HOPKINSVILLE	KY	42240-3610
705	Affiliated	3042	Roxborough Dialysis	Roxborough Dialysis	5003 UMBRIA ST		PHILADELPHIA	PA	19128-4301
706	Affiliated	3043	New Haven Dialysis	New Haven Dialysis	100 CHURCH ST S	STE C	NEW HAVEN	CT	06519-1703
707	Affiliated	3044	Ocoee Dialysis	Ocoee Dialysis	11140 W COLONIAL DR	STE 5	OCOEE	FL	34761-3300
708	Affiliated	3045	Waverly Dialysis	Waverly Dialysis	407 E BALTIMORE PIKE		MORTON	PA	19070-1042
709	Affiliated	3046	Sells Dialysis	Sells Dialysis	PO BOX 3030	HWY 86 MILEPOST 113	SELLS	AZ	85634-3030
710	Affiliated	3047	Sierra Vista Dialysis	Sierra Vista Dialysis	629 N HIGHWAY 90	STE 6	SIERRA VISTA	AZ	85635-2257
711	Affiliated	3048	Callaghan Road Dialysis	San Antonio West Dialysis (fka Callaghan Road)	4530 CALLAGHAN RD		SAN ANTONIO	TX	78228
712	Affiliated	3049	Houston Dialysis	Houston Dialysis	7543 SOUTH FWY		HOUSTON	TX	77021-5928
713	Affiliated	3050	South Yuma Dialysis	South Yuma Dialysis	7179 E 31ST PLACE		YUMA	AZ	85365-8392
714	Affiliated	3052	Cherry Hill Dialysis	Cherry Hill Dialysis	1030 KINGS HWY N	STE 1	CHERRY HILL	NJ	08034-1907
715	Affiliated	3055	Escondido Dialysis	Escondido Dialysis	203 E 2ND AVE		ESCONDIDO	CA	92025-4212
716	Affiliated	3056	Brookline Dialysis	Brookline Dialysis	322 WASHINGTON ST		BROOKLINE	MA	02445-6850
717	Affiliated	3057	Reliant Dialysis	Reliant Dialysis	1335 LA CONCHA LN		HOUSTON	TX	77054-1809
718	Affiliated	3058	Fullerton Dialysis	Fullerton Dialysis	238 ORANGEFAIR MALL		FULLERTON	CA	92832-3037
719	Affiliated	3059	Huntington Beach Dialysis	Huntington Beach Dialysis	16892 BOLSA CHICA ST	STE 1	HUNTINGTON BEACH	CA	92649-3571
720	Affiliated	3060	Eastlake Dialysis	Eastlake Dialysis (fka South Dekalb)	1757 CANDLER RD		DECATUR	GA	30032-3276
721	Affiliated	3061	Mt. Olive Dialysis	Mt. Olive Dialysis	105 MICHAEL MARTIN RD		MOUNT OLIVE	NC	28365-1112
722	Affiliated	3062	Southwest San Antonio Dialysis	Southwest San Antonio Dialysis	1620 SOMERSET RD		SAN ANTONIO	TX	78211-3021
723	Affiliated	3064	North Loop East Dialysis	North Loop East Dialysis	7139 NORTH LOOP E		HOUSTON	TX	77028-5903
724	Affiliated	3065	Katy Cinco Ranch Dialysis	Katy Cinco Ranch Dialysis	1265 ROCK CANYON DR		KATY	TX	77450-3831
725	Affiliated	3067	Palm Springs Dialysis	Palm Springs Dialysis	1061 N INDIAN CANYON DR		PALM SPRINGS	CA	92262-4854
726	Affiliated	3069	Muskegon Dialysis	Muskegon Dialysis	1277 MERCY DR		MUSKEGON	MI	49444-4605
727	Affiliated	3070	Loomis Road Dialysis	Loomis Road Dialysis	4120 W LOOMIS RD		GREENFIELD	WI	53221-2052
728	Affiliated	3071	Ludington Dialysis	Ludington Dialysis	5 N ATKINSON DR	STE 11	LUDINGTON	MI	49431-2918
729	Affiliated	3073	Walterboro Dialysis	Walterboro Dialysis	302 RUBY ST		WALTERBORO	SC	29488-2758
730	Affiliated	3074	K Street	K Street Dialysis (fka GWU N Street Dialysis)	2131 K ST NW		WASHINGTON	DC	20037-1898
731	Affiliated	3075	GWU Southeast Dialysis	GWU Southeast Dialysis	3857A PENNSYLVANIA AVE SE		WASHINGTON	DC	20020-1309
732	Affiliated	3076	Lakeside Dialysis	Lakeside Dialysis	10401 HOSPITAL DR	STE G2	CLINTON	MD	20735-3113
733	Affiliated	3077	Summit Dialysis	Summit Dialysis	1139 SPRUCE DR		MOUNTAINSIDE	NJ	07092-2221
734	Affiliated	3078	Aiken Dialysis	Aiken Dialysis	775 MEDICAL PARK DR		AIKEN	SC	29801-6306
735	Affiliated	3092	Ozark Dialysis	Ozark Dialysis	214 HOSPITAL AVE		OZARK	AL	36360-2038
736	Affiliated	3094	Wylds Road Dialysis	Wylds Road Dialysis (fka Augusta South)	1815 WYLDS RD		AUGUSTA	GA	30909-4430
737	Affiliated	3104	Douglasville Dialysis	Douglasville Dialysis	3899 LONGVIEW DR		DOUGLASVILLE	GA	30135-1373
738	Affiliated	3106	Brunswick Dialysis	Brunswick Dialysis	53 SCRANTON CONNECTOR		BRUNSWICK	GA	31525-1862
739	Affiliated	3109	Benicia Dialysis	Benicia Dialysis	560 1ST ST	STE 13 BLDG D	BENICIA	CA	94510-3295
740	Affiliated	3111	Atlanta Dialysis	Atlanta Dialysis	567 NORTH AVE NE	STE 2	ATLANTA	GA	30308-2719
741	Affiliated	3115	Rolla Dialysis	Rolla Dialysis	1503 E 10TH ST		ROLLA	MO	65401-3696
742	Affiliated	3119	East Atlanta Dialysis	East Atlanta Dialysis	1308 MORELAND AVE SE		ATLANTA	GA	30316-3224
743	Affiliated	3120	Brunswick South Dialysis	Brunswick South Dialysis	2930 SPRINGDALE RD		BRUNSWICK	GA	31520
744	Affiliated	3121	Thomaston Dialysis	Thomaston Dialysis	1065 US HIGHWAY 19 NORTH		THOMASTON	GA	30286-2233
745	Affiliated	3128	Piedmont Dialysis	Piedmont Dialysis	105 COLLIER RD NW	STE B	ATLANTA	GA	30309-1730
746	Affiliated	3130	Athens West Dialysis	Athens West Dialysis	2047 PRINCE AVE	STE A	ATHENS	GA	30606-6033
747	Affiliated	3131	Florence Dialysis	Florence Dialysis	422 E DR HICKS BLVD	STE B	FLORENCE	AL	35630-5763
748	Affiliated	3138	Atwater Dialysis	Atwater Dialysis	1201 COMMERCE AVE		ATWATER	CA	95301
749	Affiliated	3143	North Merced Dialysis	Merced Dialysis	3150 G ST	STE A	MERCED	CA	95340-1346
750	Affiliated	3169	Wisconsin Avenue Dialysis	Wisconsin Avenue Dialysis	3801 W WISCONSIN AVE		MILWAUKEE	WI	53208-3155
751	Affiliated	3171	River Center Dialysis	River Center Dialysis	117 N JEFFERSON ST		MILWAUKEE	WI	53202-6160

752	Affiliated	3175	South Fulton Dialysis	South Fulton Dialysis	2685 METROPOLITAN PKWY SW	STE F	ATLANTA	GA	30315-7926
753	Affiliated	3201	Heartland Dialysis	Heartland Dialysis	925 NE 8TH ST		OKLAHOMA CITY	OK	73104-5800
754	Affiliated	3202	Hospital Hill Dialysis	Hospital Hill Dialysis	2250 HOLMES ST		KANSAS CITY	MO	64108-2639
755	Affiliated	3203	Tucson South Dialysis	Tucson South Dialysis	3662 S 16TH AVE		TUCSON	AZ	85713-6001
756	Affiliated	3204	Greene County Dialysis	Greene County Dialysis (AL)	544 US HIGHWAY 43		EUTAW	AL	35462-4017
757	Affiliated	3205	Fayette Dialysis	Fayette Dialysis	2450 TEMPLE AVE N		FAYETTE	AL	35555-1160
758	Affiliated	3206	Tuscaloosa University Dialysis	Tuscaloosa University Dialysis	220 15TH STREET		TUSCALOOSA	AL	35401
759	Affiliated	3207	Goldsboro South Dialysis	Goldsboro South Dialysis	1704 WAYNE MEMORIAL DR		GOLDSBORO	NC	27534-2240
760	Affiliated	3208	Orlando North Dialysis	Orlando North Dialysis	5135 ADANSON ST	STE 7	ORLANDO	FL	32804-1338
761	Affiliated	3209	UT Southwestern-Dallas Dialysis	UT Southwestern-Dallas Dialysis	204 E AIRPORT FREEWAY		IRVING	TX	75062
762	Affiliated	3210	San Diego South Dialysis	San Diego South Dialysis	995 GATEWAY CENTER WAY	STE 11	SAN DIEGO	CA	92102-4550
763	Affiliated	3211	Santa Monica Dialysis	Santa Monica Dialysis	1260 15TH ST	STE 12	SANTA MONICA	CA	90404-1136
764	Affiliated	3212	Airport Dialysis	Airport Dialysis	4632 W CENTURY BLVD		INGLEWOOD	CA	90304-1456
765	Affiliated	3220	Plantation Dialysis	Plantation Dialysis	7061 CYPRESS RD	STE 13	PLANTATION	FL	33317-2243
766	Affiliated	3224	Laurens County Dialysis	Laurens County Dialysis	2400 BELLEVUE RD	STE 8	DUBLIN	GA	31021-2856
767	Affiliated	3225	Ford Factory Square Dialysis	Ford Factory Square Dialysis	567 NORTH AVE NE	STE 1	ATLANTA	GA	30308-2719
768	Affiliated	3226	North Fulton Dialysis	North Fulton Dialysis	1250 NORTHMEADOW PKWY	STE 12	ROSWELL	GA	30076-4914
769	Affiliated	3228	Freehold Dialysis	Freehold Dialysis	300 CRAIG RD		MANALAPAN	NJ	07726-8742
770	Affiliated	3229	Neptune Dialysis	Neptune Route 66 Dialysis	3297 STATE ROUTE 66		NEPTUNE	NJ	07753-2762
771	Affiliated	3231	East Orange Dialysis	East Orange Dialysis	90 WASHINGTON ST	BSMT	EAST ORANGE	NJ	07017-1050
772	Affiliated	3234	UT Southwestern-Oakcliff Dialysis	UT Southwestern-Oakcliff Dialysis	610 WYNNEWOOD DR		DALLAS	TX	75224
773	Affiliated	3236	Atlanta West Dialysis	Atlanta West Dialysis	2538 MARTIN LUTHER KING JR DR SW		ATLANTA	GA	30311-1779
774	Affiliated	3237	Columbia University Dialysis Center	Columbia University Dialysis Center	60 HAVEN AVE		NEW YORK	NY	10032-2604
775	Affiliated	3238	Northeast Cambridge Dialysis	Northeast Cambridge Dialysis	799 CONCORD AVE		CAMBRIDGE	MA	02138-1048
776	Affiliated	3239	New Bedford Dialysis	New Bedford Dialysis	524 UNION ST		NEW BEDFORD	MA	02740-3546
777	Affiliated	3242	Weymouth Dialysis	Weymouth Dialysis	330 LIBBEY INDUSTRIAL PARK	STE 9	WEYMOUTH	MA	02189-3122
778	Affiliated	3243	Woburn Dialysis	Woburn Dialysis	23 WARREN AVE		WOBURN	MA	01801-7906
779	Affiliated	3248	Bryan Dialysis	College Station Dialysis (fka Bryan Dialysis)	701 UNIVERSITY DR E	STE 41	COLLEGE STATION	TX	77840-1866
780	Affiliated	3249	Brenham Dialysis	Brenham Dialysis	2815 HIGHWAY 36 SO		BRENHAM	TX	77833
781	Affiliated	3250	Huntsville Dialysis	Huntsville Dialysis	521 IH 45S	STE 2	HUNTSVILLE	TX	77340-5651
782	Affiliated	3252	Utica Avenue Dialysis Center	Utica Avenue Dialysis Center	1305 UTICA AVE		BROOKLYN	NY	11203-5911
783	Affiliated	3254	New London Dialysis	New London Dialysis	5 SHAWS COVE	STE 1	NEW LONDON	CT	06320-4974
784	Affiliated	3258	Baxley Dialysis	Baxley Dialysis	539 FAIR ST		BAXLEY	GA	31513-0112
785	Affiliated	3261	Pascua Yaqui Tribe Dialysis	Pascua Yaqui Tribe Dialysis	7490 S CAMINO DE OESTE		TUCSON	AZ	85746-9308
786	Affiliated	3262	JHHS North Bond Street Dialysis	JHHS North Bond Street Dialysis	409 N CAROLINE ST		BALTIMORE	MD	21231-1003
787	Affiliated	3263	Syosset Kidney Center	Syosset Kidney Center	1 LOCUST LN		SYOSSET	NY	11791-4834
788	Affiliated	3264	Freeport Kidney Center	Freeport Kidney Center	267 W MERRICK RD		FREEPORT	NY	11520-3346
789	Affiliated	3265	Huntington Station Dialysis Center	HAKC-Huntington	256 BROADWAY		HUNTINGTON STATION	NY	11746-1403
790	Affiliated	3266	Medford Kidney Center	Medford Kidney Center	1725 N OCEAN AVE		MEDFORD	NY	11763-2649
791	Affiliated	3267	Blue Ash Dialysis	Blue Ash Dialysis	10600 MCKINLEY RD		CINCINNATI	OH	45242-3716
792	Affiliated	3269	Mt. Auburn Dialysis	Mt. Auburn Dialysis	2109 READING RD		CINCINNATI	OH	45202-1417
793	Affiliated	3272	Charlottesville Dialysis	Charlottesville Dialysis	1460 PANTOPS MOUNTAIN PLACE		CHARLOTTESVILLE	VA	22911
794	Affiliated	3273	Alexandria Dialysis	Alexandria Dialysis	5150 DUKE ST		ALEXANDRIA	VA	22304-2906
795	Affiliated	3275	Sebastian Dialysis	Sebastian Dialysis	1424 US HWY 1	STE C	SEBASTIAN	FL	32958-1619
796	Affiliated	3276	Crestview Hills Dialysis	Crestview Hills Dialysis	400 CENTERVIEW BLVD		CRESTVIEW HILLS	KY	41017-3478
797	Affiliated	3278	Washington Square Dialysis	Washington Square Dialysis	1112 WASHINGTON SQ		WASHINGTON	MO	63090-5336
798	Affiliated	3279	Florissant Dialysis	Florissant Dialysis	11687 W FLORISSANT AVE		FLORISSANT	MO	63033-6711
799	Affiliated	3282	Ithaca Dialysis Center	Ithaca Dialysis Center	201 DATES DR	STE 26	ITHACA	NY	14850-1345
800	Affiliated	3289	Fairfield Dialysis	Fairfield Dialysis	1210 HICKS BLVD		FAIRFIELD	OH	45014-1921
801	Affiliated	3290	Fairfield Home Training Dialysis	Fairfield Home Training Dialysis	1210 HICKS BLVD		FAIRFIELD	OH	45014-1921
802	Affiliated	3291	South Hill Dialysis	South Hill Dialysis	525 ALEXANDRIA PIKE	STE 12	SOUTHGATE	KY	41071-3243
803	Affiliated	3292	Silver Spring Dialysis	Silver Spring Dialysis	8412 GEORGIA AVE		SILVER SPRING	MD	20910-4406
804	Affiliated	3295	Philadelphia PMC Dialysis	Philadelphia PMC Dialysis	51 N 39TH ST		PHILADELPHIA	PA	19104-2640
805	Affiliated	3298	Tulare Dialysis	Tulare Dialysis	545 E TULARE AVE		TULARE	CA	93274-4220

806	Affiliated	3300	Visalia Dialysis	Visalia Dialysis	5429 W CYPRESS AVE		VISALIA	CA	93277-8341
807	Affiliated	3310	Falls Road Dialysis	Falls Road Dialysis	10753 FALLS RD	STE 115	LUTHERVILLE	MD	21093-4572
808	Affiliated	3312	Malden Dialysis	Wellington Circle Dialysis Center (fka Malden)	10 CABOT RD	STE 13B	MEDFORD	MA	02155-5173
809	Affiliated	3313	Salem Northeast Dialysis	Salem Northeast Dialysis (MA)	10 COLONIAL RD	STE 25	SALEM	MA	01970-2947
810	Affiliated	3314	Lexington	Lexington Prison Unit (OK)	15151 STATE HWY 39 E	PO BOX 26	LEXINGTON	OK	73051-0260
811	Affiliated	3315	Macon County Dialysis	Macon County Dialysis	1090 W MCKINLEY AVE		DECATUR	IL	62526-3208
812	Affiliated	3316	Effingham Dialysis	Effingham Dialysis	904 MEDICAL PARK DR	STE 1	EFFINGHAM	IL	62401-2193
813	Affiliated	3317	Jacksonville Dialysis	Jacksonville Dialysis	1515 W WALNUT ST		JACKSONVILLE	IL	62650-1150
814	Affiliated	3318	Litchfield Dialysis	Litchfield Dialysis	915 ST FRANCES WAY		LITCHFIELD	IL	62056-1775
815	Affiliated	3319	Mattoon Dialysis	Mattoon Dialysis	6051 DEVELOPMENT DR		CHARLESTON	IL	61920-9467
816	Affiliated	3320	Springfield Central Dialysis	Springfield Central Dialysis	932 N RUTLEDGE ST		SPRINGFIELD	IL	62702-3721
817	Affiliated	3321	Taylorville Dialysis	Taylorville Dialysis	901 W SPRESSER ST		TAYLORVILLE	IL	62568-1831
818	Affiliated	3322	Lincoln Dialysis	Lincoln Dialysis	2100 WEST FIFTH		LINCOLN	IL	62656-9115
819	Affiliated	3323	J. B. Zachary Dialysis Center	J. B. Zachary Dialysis Center	333 CASSELL DR	STE 23	BALTIMORE	MD	21224-6815
820	Affiliated	3324	Whitesquare Dialysis	Whitesquare Dialysis	1 NASHUA CT STE E		BALTIMORE	MD	21221
821	Affiliated	3325	25th Street Dialysis	25th Street Dialysis	920 E 25TH ST		BALTIMORE	MD	21218-5503
822	Affiliated	3326	Perth Amboy Dialysis	Perth Amboy Dialysis	530 NEW BRUNSWICK AVE		PERTH AMBOY	NJ	08861-3654
823	Affiliated	3327	Old Bridge Dialysis	Old Bridge Dialysis	3 HOSPITAL PLZ	STE 11	OLD BRIDGE	NJ	08857-3084
824	Affiliated	3328	Pear Tree Dialysis	Pear Tree Dialysis (fka Ukiah)	126 N ORCHARD AVE		UKIAH	CA	95482-4502
825	Affiliated	3334	Hubbard Road Dialysis	Hubbard Road Dialysis	1963 HUBBARD RD		MADISON	OH	44057-2105
826	Affiliated	3335	St. Charles Dialysis	St. Charles Dialysis	2125 BLUESTONE DR		SAINT CHARLES	MO	63303-6704
827	Affiliated	3336	Bel Air Dialysis	Bel Air Dialysis	2225 OLD EMMORTON RD	STE 15	BEL AIR	MD	21015-6122
828	Affiliated	3339	Cedarburg Dialysis	Cedarburg Dialysis	N 54 W 6135 MILL ST		CEDARBURG	WI	53012-2021
829	Affiliated	3340	Western Hills Dialysis	Western Hills Dialysis	3267 WESTBOURNE DR		CINCINNATI	OH	45248-5130
830	Affiliated	3341	Winton Road Dialysis	Winton Road Dialysis	6550 WINTON RD		CINCINNATI	OH	45224-1327
831	Affiliated	3342	Stamford Dialysis	Stamford Dialysis	30 COMMERCE RD		STAMFORD	CT	06902-4550
832	Affiliated	3343	Boaz Dialysis	Boaz Dialysis	16 CENTRAL HENDERSON RD		BOAZ	AL	35957-5922
833	Affiliated	3344	Guernsey County Dialysis	Guernsey County Dialysis	1300 CLARK ST		CAMBRIDGE	OH	43725-8875
834	Affiliated	3345	Marietta Dialysis	Marietta Dialysis	1019 PIKE ST		MARIETTA	OH	45750-3500
835	Affiliated	3346	Zanesville Dialysis	Zanesville Dialysis	3120 NEWARK RD		ZANESVILLE	OH	43701-9659
836	Affiliated	3351	Orlando East Dialysis	Orlando East Dialysis	1160 S SEMORAN BLVD	STE C	ORLANDO	FL	32807-1461
837	Affiliated	3352	Norwich Dialysis	Norwich Dialysis	113 SALEM TPKE		NORWICH	CT	06360-6484
838	Affiliated	3354	Columbus Dialysis	Columbus Dialysis	3830 OLENTANGY RIVER RD		COLUMBUS	OH	43214-5404
839	Affiliated	3362	Pasadena Dialysis	Pasadena Dialysis	8894 FORT SMALLWOOD RD	STE 12	PASADENA	MD	21122-7608
840	Affiliated	3369	Baltimore Geriatric & Rehab Dialysis Center	Baltimore Geriatric & Rehab Dialysis Center	4940 EASTERN AVE	FLOOR 5	BALTIMORE	MD	21224-2735
841	Affiliated	3373	Frederick Dialysis	Frederick Dialysis	140 THOMAS JOHNSON DR	STE 1	FREDERICK	MD	21702-4475
842	Affiliated	3376	Fayetteville Dialysis	Fayetteville Dialysis	1279 HIGHWAY 54 W	STE 11	FAYETTEVILLE	GA	30214-4551
843	Affiliated	3377	Birmingham Central Dialysis	Birmingham Central Dialysis	728 RICHARD ARRINGTON JR BLVD S		BIRMINGHAM	AL	35233-2106
844	Affiliated	3379	Birmingham North Dialysis	Birmingham North Dialysis	1917 32ND AVE N		BIRMINGHAM	AL	35207-3333
845	Affiliated	3380	Bessemer Dialysis	Bessemer Dialysis	901 W LAKE MALL		BESSEMER	AL	35020
846	Affiliated	3382	Ensley Dialysis	Ensley Dialysis	2630 AVENUE E		BIRMINGHAM	AL	35218-2163
847	Affiliated	3383	Sylacauga Dialysis	Sylacauga Dialysis	331 JAMES PAYTON BLVD		SYLACAUGA	AL	35150
848	Affiliated	3385	Branford Dialysis	Branford Dialysis	249 W MAIN ST		BRANFORD	CT	06405-4048
849	Affiliated	3386	Shrewsbury Dialysis	Shrewsbury Dialysis	7435 WATSON RD	STE 119	SAINT LOUIS	MO	63119-4472
850	Affiliated	3389	Milford Dialysis	Milford Dialysis	470 BRIDGEPORT AVE		MILFORD	CT	06460-4167
851	Affiliated	3414	Cedartown Dialysis	Cedartown Dialysis	325 WEST AVE		CEDARTOWN	GA	30125-3439
852	Affiliated	3416	Brookfield Dialysis	Brookfield Dialysis	19395 W CAPITOL DR	BLDG C	BROOKFIELD	WI	53045-2736
853	Affiliated	3417	Henrico County Dialysis	Henrico County Dialysis	5270 CHAMBERLAYNE RD		RICHMOND	VA	23227-2950
854	Affiliated	3418	St. Louis West Dialysis	St. Louis West Dialysis	400 N LINDBERGH BLVD		SAINT LOUIS	MO	63141-7814
855	Affiliated	3420	Springfield Montvale Dialysis	Springfield Montvale Dialysis	2930 MONTVALE DR	STE A	SPRINGFIELD	IL	62704-5376
856	Affiliated	3422	South Norwalk Dialysis	South Norwalk Dialysis	31 STEVENS ST		NORWALK	CT	06850-3805
857	Affiliated	3425	Decatur East Wood Dialysis	Decatur East Wood Dialysis	794 E WOOD ST		DECATUR	IL	62523-1155
858	Affiliated	3426	Schaeffer Drive Dialysis	Schaeffer Drive Dialysis	18100 SCHAEFER HWY		DETROIT	MI	48235-2600
859	Affiliated	3427	Redford Dialysis	Redford Dialysis	22711 GRAND RIVER AVE		DETROIT	MI	48219-3113

860	Affiliated	3428	Kresge Dialysis	Kresge Dialysis	4145 CASS AVE		DETROIT	MI	48201-1707
861	Affiliated	3429	Motor City Dialysis	Motor City Dialysis	4727 SAINT ANTOINE ST	STE 11	DETROIT	MI	48201-1461
862	Affiliated	3431	Whitebridge Dialysis	Whitebridge Dialysis	103 WHITE BRIDGE PIKE	STE 6	NASHVILLE	TN	37209-4539
863	Affiliated	3432	Columbia Dialysis	Columbia Dialysis (TN)	1705 GROVE ST		COLUMBIA	TN	38401-3517
864	Affiliated	3433	Murfreesboro Dialysis	Murfreesboro Dialysis	1346 DOW ST		MURFREESBORO	TN	37130-2470
865	Affiliated	3434	Lawrenceburg Dialysis	Lawrenceburg Dialysis (TN)	2022 N LOCUST AVE		LAWRENCEBURG	TN	38464-2336
866	Affiliated	3436	Sumner Dialysis	Sumner Dialysis	300 STEAM PLANT RD	STE 27	GALLATIN	TN	37066-3019
867	Affiliated	3437	Cumberland Dialysis	Cumberland Dialysis	312 HOSPITAL DR	STE 5	MADISON	TN	37115-5037
868	Affiliated	3438	Williamson County Dialysis	Williamson County Dialysis	3983 CAROTHERS PKWY	STE E-4	FRANKLIN	TN	37067-5936
869	Affiliated	3441	Cumming Dialysis	Cumming Dialysis	911 MARKET PLACE BLVD	STE 3	CUMMING	GA	30041-7938
870	Affiliated	3443	Silverton Dialysis	Silverton Dialysis	6929 SILVERTON AVE		CINCINNATI	OH	45236-3701
871	Affiliated	3445	Atlanta South Dialysis	Atlanta South Dialysis	3158 EAST MAIN ST	STE A	EAST POINT	GA	30344-4800
872	Affiliated	3447	St. Petersburg Dialysis	St. Petersburg Dialysis	1117 ARLINGTON AVE N		ST PETERSBURG	FL	33705-1521
873	Affiliated	3449	Alton Dialysis	Alton Dialysis	3511 COLLEGE AVE		ALTON	IL	62002-5009
874	Affiliated	3451	Edison Dialysis	Edison Dialysis	29 MERIDIAN RD		EDISON	NJ	08820-2823
875	Affiliated	3452	Dundalk Dialysis	Dundalk Dialysis	14 COMMERCE ST		DUNDALK	MD	21222-4307
876	Affiliated	3454	Columbus East Dialysis	Columbus East Dialysis	299 OUTERBELT ST		COLUMBUS	OH	43213-1529
877	Affiliated	3455	Dallas East Dialysis	Dallas East Dialysis	3312 N BUCKNER BLVD	STE 213	DALLAS	TX	75228-5642
878	Affiliated	3456	San Ysidro Dialysis	San Ysidro Dialysis	1445 30TH ST	STE A	SAN DIEGO	CA	92154-3496
879	Affiliated	3457	Olathe Dialysis	Olathe Dialysis	732 W FRONTIER LN		OLATHE	KS	66061-7202
880	Affiliated	3459	Orange City Dialysis	Orange City Dialysis	242 TREEMONT DR	BLDG II	ORANGE CITY	FL	32763-7945
881	Affiliated	3460	Miami East Dialysis	Miami East Dialysis	1250 NW 7TH ST	STE 16	MIAMI	FL	33125-3744
882	Affiliated	3462	Temple Terrace Dialysis	Temple Terrace Dialysis	11306 N 53RD ST		TEMPLE TERRACE	FL	33617-2214
883	Affiliated	3463	Midlothian Dialysis	Midlothian Dialysis	14281 MIDLOTHIAN TPKE	BLDG B	MIDLOTHIAN	VA	23113-6560
884	Affiliated	3464	Christian County Dialysis	Christian County Dialysis	200 BURLEY AVE		HOPKINSVILLE	KY	42240-8725
885	Affiliated	3465	St. Louis West PD Dialysis	St. Louis West PD Dialysis	450 N LINDBERGH BLVD	STE 1C	CREVE COEUR	MO	63141-7858
886	Affiliated	3467	Atlanta Midtown Dialysis	Atlanta Midtown Dialysis PD	418 DECATUR ST SE	STE A	ATLANTA	GA	30312-1801
887	Affiliated	3468	Silverton Home Training Dialysis	Silverton Home Training Dialysis	6929 SILVERTON AVE		CINCINNATI	OH	45236-3701
888	Affiliated	3472	Philadelphia 42nd Street Dialysis	Philadelphia 42nd Street Dialysis	4126 WALNUT ST		PHILADELPHIA	PA	19104-3511
889	Affiliated	3473	Radnor Dialysis	Radnor Dialysis	250 KING OF PRUSSIA RD		RADNOR	PA	19087-5220
890	Affiliated	3475	St. Louis Dialysis	St. Louis Dialysis	324 DE BALIVIERE AVE		SAINT LOUIS	MO	63112-1804
891	Affiliated	3477	Elkins Park Dialysis	Wyncote Dialysis (fka Elkins Park)	1000 EASTON RD	STE 25	WYNCOTE	PA	19095-2934
892	Affiliated	3478	Mainland Dialysis	Mainland Dialysis	2600 GULF FWY		LA MARQUE	TX	77568-4922
893	Affiliated	3479	Island Dialysis	Island Dialysis	5920 BROADWAY ST		GALVESTON	TX	77551-4305
894	Affiliated	3481	Orlando Home Training Dialysis	Orlando Home Training Dialysis	116 STURTEVANT ST	STE 2	ORLANDO	FL	32806-2021
895	Affiliated	3482	Mechanicsville Dialysis	Mechanicsville Dialysis	8191 ATLEE RD		MECHANICSVILLE	VA	23116-1807
896	Affiliated	3484	San Diego East Dialysis	San Diego East Dialysis	292 EUCLID AVE	STE 1	SAN DIEGO	CA	92114-3629
897	Affiliated	3485	Russellville Dialysis	Russellville Dialysis	14897 HIGHWAY 43		RUSSELLVILLE	AL	35653-1954
898	Affiliated	3486	Encinitas Dialysis	Encinitas Dialysis	332 SANTA FE DR	STE 1	ENCINITAS	CA	92024-5143
899	Affiliated	3491	Rushville Dialysis	Rushville Dialysis	112 SULLIVAN DRIVE		RUSHVILLE	IL	62681-1293
900	Affiliated	3493	Plainfield Dialysis	Plainfield Dialysis	1200 RANDOLPH RD	MUHLENBURG CAMPUS	PLAINFIELD	NJ	07060-3361
901	Affiliated	3494	Parkersburg Dialysis	Parkersburg Dialysis	1824 MURDOCH AVE	STE 44	PARKERSBURG	WV	26101-3230
902	Affiliated	3497	Tucson South Central Dialysis	Tucson South Central Dialysis	2024 E IRVINGTON RD	STE 7	TUCSON	AZ	85714-1825
903	Affiliated	3499	Hazelwood Dialysis	Hazelwood Dialysis	637 DUNN RD		HAZELWOOD	MO	63042-1755
904	Affiliated	3503	Durham West Dialysis	Durham West Dialysis	4307 WESTERN PARK PL		DURHAM	NC	27705-1204
905	Affiliated	3504	Liberty Dialysis	Liberty Dialysis	2525 GLEN HENDREN DR		LIBERTY	MO	64068-9625
906	Affiliated	3506	Chino Dialysis	Chino Dialysis	4445 RIVERSIDE DR		CHINO	CA	91710-3961
907	Affiliated	3507	Greenview Dialysis	Greenview Dialysis	18544 W 8 MILE RD		SOUTHFIELD	MI	48075-4194
908	Affiliated	3508	Perry Dialysis	Perry Dialysis	118 W MAIN ST		PERRY	FL	32347-2656
909	Affiliated	3511	Ashtabula Dialysis	Ashtabula Dialysis	1614 W 19TH ST		ASHTABULA	OH	44004-3036
910	Affiliated	3513	Northland Dialysis	Northland Dialysis	2750 CLAY EDWARDS DR	STE 1	N KANSAS CITY	MO	64116-3257
911	Affiliated	3516	Lake St. Louis Dialysis	Lake St. Louis Dialysis	200 BREVCO PLZ	STE 21	LAKE SAINT LOUIS	MO	63367-2950
912	Affiliated	3517	Wyandotte West Dialysis	Wyandotte West Dialysis	8919 PARALLEL PKWY	STE 121	KANSAS CITY	KS	66112-1655
913	Affiliated	3518	Huntingdon Valley Dialysis	Temp CLSD-Huntingdon Valley Dialysis	769 HUNTINGDON PIKE	STE 18	HUNTINGDON VALLEY	PA	19006-8362

914	Affiliated	3519	Glendale Dialysis	Glendale Dialysis	1000 E PALMER AVE		GLENDALE	CA	91205-3532
915	Affiliated	3520	Toledo Dialysis	Toledo Dialysis	1614 S BYRNE RD		TOLEDO	OH	43614-3464
916	Affiliated	3523	Cameron Dialysis	Cameron Dialysis	1003 W 4TH ST		CAMERON	MO	64429-1466
917	Affiliated	3524	Omaha Central Dialysis	Omaha Central Dialysis	144 S 40TH ST		OMAHA	NE	68131-3004
918	Affiliated	3525	Chillicothe Dialysis	Chillicothe Dialysis	588 E BUSINESS 36		CHILLICOTHE	MO	64601-3721
919	Affiliated	4210	Council Bluffs Dialysis	Council Bluffs Dialysis Center	300 W BROADWAY	STE 15	COUNCIL BLUFFS	IA	51503-9077
920	Affiliated	3528	DeRidder Dialysis	DeRidder Dialysis	239 E 1ST ST		DERIDDER	LA	70634-4105
921	Affiliated	3530	Dodge County Dialysis	Dodge County Dialysis	1949 E 23RD AVE S		FREMONT	NE	68025-2452
922	Affiliated	3533	Omaha North Dialysis	Omaha North Dialysis	6572 AMES AVE		OMAHA	NE	68104-1931
923	Affiliated	3534	Omaha South Dialysis	Omaha South Dialysis	3427 L ST	STE 16	OMAHA	NE	68107-2577
924	Affiliated	3535	Lake Charles Southwest Dialysis	Lake Charles Southwest Dialysis	300 W 18th ST		LAKE CHARLES	LA	70601-7342
925	Affiliated	3536	St. Joseph Dialysis	St. Joseph Dialysis	5514 CORPORATE DR	STE 1	SAINT JOSEPH	MO	64507-7752
926	Affiliated	3537	Sulphur Dialysis	Sulphur Dialysis	944 BEGLIS PKWY		SULPHUR	LA	70663-5102
927	Affiliated	3539	Tipton County Dialysis	Tipton County Dialysis	107 TENNESSEE AVE		COVINGTON	TN	38019-3902
928	Affiliated	3540	Dyersburg Dialysis	Dyersburg Dialysis	1575 PARR AVE		DYERSBURG	TN	38024-3151
929	Affiliated	3544	Effingham North Dialysis	Effingham North Dialysis	301 N PINE ST		SPRINGFIELD	GA	31329-3076
930	Affiliated	3545	Westminster South Dialysis	Westminster South Dialysis	14014 MAGNOLIA ST.		WESTMINSTER	CA	92683-4736
931	Affiliated	3546	Williams Street Dialysis	Williams Street Dialysis	2812 WILLIAMS ST		SAVANNAH	GA	31404-4134
932	Affiliated	3547	DeRenne Dialysis	DeRenne Dialysis	5303 MONTGOMERY ST		SAVANNAH	GA	31405-5138
933	Affiliated	3548	Abercorn Dialysis	Abercorn Dialysis	11706 MERCY BLVD	STE 9	SAVANNAH	GA	31419-1751
934	Affiliated	3551	Fort Myers North Dialysis	Fort Myers North Dialysis	16101 N CLEVELAND AVE		N FT MYERS	FL	33903-2148
935	Affiliated	3552	Butler County Dialysis	Butler County Dialysis	3497 S DIXIE HWY		FRANKLIN	OH	45005-5717
936	Affiliated	3556	Willingboro	Willingboro Dialysis	230 VAN SCIVER PKWY		WILLINGBORO	NJ	08046-1131
937	Affiliated	3557	McKeesport West Dialysis	McKeesport West Dialysis	101 9TH ST		MCKEESPORT	PA	15132-3953
938	Affiliated	3559	College Dialysis	College Dialysis	6535 UNIVERSITY AVE		SAN DIEGO	CA	92115-5810
939	Affiliated	3560	Montezuma Dialysis	Montezuma Dialysis	114 DEVAUGHN AVE		MONTEZUMA	GA	31063-1708
940	Affiliated	3561	Romulus Dialysis	Romulus Dialysis	31470 ECORSE RD		ROMULUS	MI	48174-1963
941	Affiliated	3564	Wrightsville Dialysis	Wrightsville Dialysis	2240 W ELM ST		WRIGHTSVILLE	GA	31096-2016
942	Affiliated	3565	Tower Dialysis	Tower Dialysis	8635 W 3RD ST	STE 56W	LOS ANGELES	CA	90048-6110
943	Affiliated	3566	Columbus Downtown Dialysis	Columbus Downtown Dialysis	415 E MOUND ST		COLUMBUS	OH	43215-5512
944	Affiliated	3568	Charlotte East Dialysis	Charlotte East Dialysis	3204 N SHARON AMITY RD		CHARLOTTE	NC	28205-6541
945	Affiliated	3569	Carmel Mountain Dialysis	Carmel Mountain Dialysis	9850 CARMEL MOUNTAIN RD		SAN DIEGO	CA	92129-2892
946	Affiliated	3571	Lenexa Dialysis	Lenexa Dialysis	8630 HALSEY ST		LENEXA	KS	66215-2880
947	Affiliated	3577	Nashua Dialysis	Nashua Dialysis	38 TYLER ST	STE 1	NASHUA	NH	03060-2912
948	Affiliated	3580	Illini Renal Dialysis	Illini Renal Dialysis	507 E UNIVERSITY AVE		CHAMPAIGN	IL	61820-3828
949	Affiliated	3586	Loring Heights Dialysis	Loring Heights Dialysis	1575 NORTHSIDE DR NW	STE 45	ATLANTA	GA	30318-4211
950	Affiliated	3588	Forest Hills Dialysis	Forest Hills Dialysis	2693 FOREST HILLS RD SW		WILSON	NC	27893-8611
951	Affiliated	3589	St. Peters Dialysis	St. Peters Dialysis	300 FIRST EXECUTIVE AVE	STE A	SAINT PETERS	MO	63376-1655
952	Affiliated	3591	Platte Woods Dialysis	Platte Woods Dialysis	7667 NW PRAIRIE VIEW RD		KANSAS CITY	MO	64151-1544
953	Affiliated	3593	Fresno North Dialysis	Fresno Palm Bluffs Dialysis (fka Fresno North)	770 W PINEDALE AVE		FRESNO	CA	93711-5744
954	Affiliated	3594	Middlesex County Dialysis	Burlington Regional Dialysis (fka Middlesex County)	31 MALL RD	STE 1B	BURLINGTON	MA	01803-4138
955	Affiliated	3596	Clearfield Dialysis	Clearfield Dialysis	1033 TURNPIKE AVE	STE 1	CLEARFIELD	PA	16830-3061
956	Affiliated	3597	Papillion Dialysis	Papillion Dialysis	1502 S WASHINGTON ST	STE 1	PAPILLION	NE	68046-3136
957	Affiliated	3598	Birmingham Home Training Dialysis	Birmingham Home Training Dialysis	2101 7TH AVE S		BIRMINGHAM	AL	35233-3105
958	Affiliated	3603	Bayou Dialysis	Magnolia Dialysis	210 E SPILLMAN ST		GONZALES	LA	70737-4604
959	Affiliated	3609	Radford Dialysis	Radford Dialysis	600 E MAIN ST	STE F	RADFORD	VA	24141-1826
960	Affiliated	3610	Eufaula Dialysis	Eufaula Dialysis	220 S ORANGE AVE		EUFAULA	AL	36027-1612
961	Affiliated	3612	Coshocton Dialysis	Coshocton Dialysis	1404 CHESTNUT ST EAST		COSHOCTON	OH	43812-1401
962	Affiliated	3614	Costa Mesa Dialysis	Costa Mesa Dialysis	1590 SCENIC AVE		COSTA MESA	CA	92626-1400
963	Affiliated	3615	Little Rock Dialysis	Central Little Rock Dialysis	5800 W 10TH ST	STE 51	LITTLE ROCK	AR	72204-1760
964	Affiliated	3619	Northport Dialysis	Northport Dialysis	2401 HOSPITAL DR		NORTHPORT	AL	35476-3392
965	Affiliated	3632	Pageland Dialysis	Pageland Dialysis	505A S PEARL ST		PAGELAND	SC	29728-2222
966	Affiliated	3633	Bakersfield South Dialysis	White Lane Dialysis (fka Bakersfield South)	7701 WHITE LN	STE D	BAKERSFIELD	CA	93309-0201
967	Affiliated	3634	Newaygo County Dialysis	Newaygo County Dialysis	1317 W MAIN ST		FREMONT	MI	49412-1478

968	Affiliated	3636	Cedar Lane Dialysis	Cedar Lane Dialysis	6334 CEDAR LN	STE 11	COLUMBIA	MD	21044-3898
969	Affiliated	3639	Torrington Dialysis	Torrington Dialysis	780 LITCHFIELD ST	STE 1	TORRINGTON	CT	06790-6268
970	Affiliated	3642	Janesville Dialysis	Janesville Dialysis	1305 WOODMAN RD		JANESVILLE	WI	53545-1068
971	Affiliated	3643	Bloomfield Dialysis	Bloomfield Dialysis	29 GRIFFIN RD S		BLOOMFIELD	CT	06002-1351
972	Affiliated	3645	Anthem Village Dialysis	Anthem Village Dialysis	2530 ANTHEM VILLAGE DR		HENDERSON	NV	89052-5548
973	Affiliated	3646	Glen Burnie Dialysis	Glen Burnie Dialysis	120 LANGLEY RD N		GLEN BURNIE	MD	21060-6578
974	Affiliated	3655	Melbourne Dialysis	Melbourne Dialysis	2235 S BABCOCK ST		MELBOURNE	FL	32901-5305
975	Affiliated	3656	St. Petersburg South Dialysis	St. Petersburg South Dialysis	2850 34TH ST S		ST PETERSBURG	FL	33711-3817
976	Affiliated	3663	Belpre Dialysis	Belpre Dialysis	2906 WASHINGTON BLVD		BELPRE	OH	45714-1848
977	Affiliated	3666	Stockton Home Training Dialysis	Stockton Home Training Dialysis	545 E CLEVELAND ST	STE A	STOCKTON	CA	95204-5535
978	Affiliated	3670	Rock Prairie Road Dialysis	Rock Prairie Road Dialysis	1605 ROCK PRAIRIE RD	STE 11	COLLEGE STATION	TX	77845-8358
979	Affiliated	3675	Market Street	Market Street Dialysis	3701 MARKET ST	STE 1	PHILADELPHIA	PA	19104-5503
980	Affiliated	3677	Northwood	Northwood Dialysis (aka Toledo East)	611 LEMOYNE RD		NORTHWOOD	OH	43619-1811
981	Affiliated	3701	Tyson’s Corner Dialysis	Tyson’s Corner Dialysis	8391 OLD COURTHOUSE RD	STE 16	VIENNA	VA	22182-3819
982	Affiliated	3704	Southern Maryland Dialysis	Southern Maryland Dialysis	9211 STUART LN	4TH FL	CLINTON	MD	20735-2712
983	Affiliated	3707	Brentwood Dialysis	Brentwood Dialysis	1231 BRENTWOOD RD NE		WASHINGTON	DC	20018-1019
984	Affiliated	3708	Amelia Dialysis	Amelia Dialysis	15151 PATRICK HENRY HWY		AMELIA COURT HOUSE	VA	23002-4700
985	Affiliated	3714	Eighth Street Dialysis	Eighth Street Dialysis	300 8TH ST NE		WASHINGTON	DC	20002-6108
986	Affiliated	3715	Chester Dialysis	Chester Dialysis	10360 IRONBRIDGE RD		CHESTER	VA	23831-1425
987	Affiliated	3716	Howard County Dialysis	Howard County Dialysis	5999 HARPERS FARM RD	STE 11E	COLUMBIA	MD	21044-3023
988	Affiliated	3717	Catonsville Dialysis	Catonsville Dialysis	1581 SULPHUR SPRING RD	STE 112	BALTIMORE	MD	21227
989	Affiliated	3718	Mercy Dialysis	Mercy Dialysis	315 N CALVERT ST	STE 3	BALTIMORE	MD	21202-3611
990	Affiliated	3719	Harbor Park Dialysis	Harbor Park Dialysis	111 CHERRY HILL RD		BALTIMORE	MD	21225-1392
991	Affiliated	3732	Dabney Dialysis	Three Chopt Dialysis (fka Dabney)	8813 THREE CHOPT RD		RICHMOND	VA	23229
992	Affiliated	3733	Hioaks Dialysis	Hioaks Dialysis	671 HIOAKS RD	STE A	RICHMOND	VA	23225-4072
993	Affiliated	3757	Arlington Dialysis	Arlington Dialysis	4805 1st ST N		ARLINGTON	VA	22203
994	Affiliated	3759	Landover Dialysis	Landover Dialysis	1200 MERCANTILE LN	STE 15	UPPER MARLBORO	MD	20774-5389
995	Affiliated	3761	Staunton Dialysis	Staunton Dialysis	29 IDLEWOOD BLVD		STAUNTON	VA	24401-9355
996	Affiliated	3762	Covington Dialysis	Covington Dialysis	2504 VALLEY RIDGE RD		COVINGTON	VA	24426-6339
997	Affiliated	3763	Culpeper Dialysis	Culpeper Dialysis	430 SOUTHRIDGE PARKWAY		CULPEPER	VA	22701-3791
998	Affiliated	3764	Greenbrier Dialysis	Greenbrier Dialysis	129 SENECA TRL		LEWISBURG	WV	24901-1564
999	Affiliated	3765	Harrisonburg Dialysis	Harrisonburg Dialysis	871 CANTRELL AVE	STE 1	HARRISONBURG	VA	22801-4323
1000	Affiliated	3766	Lexington Dialysis	Lexington Dialysis	756 N LEE HWY		LEXINGTON	VA	24450-3724
1001	Affiliated	3802	Manteca Dialysis	Manteca Dialysis	1156 S MAIN ST		MANTECA	CA	95337-9505
1002	Affiliated	3804	Roseburg/Mercy Dialysis	Roseburg/Mercy Dialysis	2599 NW EDENBOWER BLVD		ROSEBURG	OR	97471-6220
1003	Affiliated	3805	Daly City Dialysis	Daly City Dialysis	1498 SOUTHGATE AVE	STE 11	DALY CITY	CA	94015-4015
1004	Affiliated	3806	Vallejo Dialysis	Vallejo Dialysis	121 HOSPITAL DR		VALLEJO	CA	94589-2562
1005	Affiliated	3812	Salem Dialysis	Salem Dialysis (OR)	3550 LIBERTY RD S	STE 1	SALEM	OR	97302-5700
1006	Affiliated	3817	Fresno Dialysis	Fresno Dialysis	1111 E WARNER AVE		FRESNO	CA	93710-4030
1007	Affiliated	3818	Oakland Dialysis	Oakland Dialysis	5354 CLAREMONT AVE		OAKLAND	CA	94618-1035
1008	Affiliated	3820	Bakersfield Dialysis	Bakersfield Brimhall Dialysis (fka California Ave.)	8501 BRIMHALL RD	BLDG 5	BAKERSFIELD	CA	93311-2252
1009	Affiliated	3821	Northeast Bakersfield Dialysis	Northeast Dialysis (fka NE Bakersfield)	3761 MALL VIEW RD		BAKERSFIELD	CA	93306-3048
1010	Affiliated	3830	San Francisco Dialysis	San Francisco Dialysis	1499 WEBSTER ST		SAN FRANCISCO	CA	94115-3705
1011	Affiliated	3831	Hanford Dialysis	Hanford Dialysis	402 W 8TH ST		HANFORD	CA	93230-4536
1012	Affiliated	3840	San Pablo Dialysis	San Pablo Dialysis	14020 SAN PABLO AVE		SAN PABLO	CA	94806-3604
1013	Affiliated	3847	Chinatown Dialysis	Chinatown Dialysis	636 CLAY ST		SAN FRANCISCO	CA	94111-2502
1014	Affiliated	3849	El Cerrito Dialysis	El Cerrito Dialysis	10690 SAN PABLO AVE		EL CERRITO	CA	94530-2620
1015	Affiliated	3857	Tracy Dialysis	Tracy Dialysis	425 W BEVERLY PL	STE A	TRACY	CA	95376-3086
1016	Affiliated	3858	Salem North Dialysis	Salem North Dialysis (OR)	1220 LIBERTY ST NE		SALEM	OR	97301-7330
1017	Affiliated	3860	Auburn Dialysis	Auburn Dialysis	3126 PROFESSIONAL DR	STE 1	AUBURN	CA	95603-2411
1018	Affiliated	3861	Grass Valley Dialysis	Grass Valley Dialysis	360 CROWN POINT CIRCLE	STE 21	GRASS VALLEY	CA	95945-2543
1019	Affiliated	3901	Santee Dialysis	Santee Dialysis	228 BRADFORD BLVD		SANTEE	SC	29142-8677
1020	Affiliated	3903	Upland Dialysis	Upland Dialysis	600 N 13TH AVE		UPLAND	CA	91786-4957
1021	Affiliated	3906	Vance County Dialysis	Vance County Dialysis	854 S BECKFORD DR		HENDERSON	NC	27536-3487

1022	Affiliated	3907	Edenton Dialysis	Edenton Dialysis	703 LUKE ST		EDENTON	NC	27932-9694
1023	Affiliated	3909	Ahoskie Dialysis	Ahoskie Dialysis	129 HERTFORD COUNTY HIGH RD		AHOSKIE	NC	27910-8131
1024	Affiliated	3914	Allendale County Dialysis	Allendale County Dialysis	202 HAMPTON AVE N		FAIRFAX	SC	29827-4510
1025	Affiliated	3916	North Orangeburg Dialysis	North Orangeburg Dialysis	124 FIRE TOWER RD		ORANGEBURG	SC	29118-1443
1026	Affiliated	3917	South Orangeburg Dialysis	South Orangeburg Dialysis	1080 SUMMERS AVE		ORANGEBURG	SC	29115-4920
1027	Affiliated	3931	Greenwood Dialysis	Greenwood Dialysis	109 OVERLAND DR		GREENWOOD	SC	29646-4053
1028	Affiliated	3933	Union County Dialysis	Union County Dialysis	701 E ROOSEVELT BLVD	STE 4	MONROE	NC	28112-4107
1029	Affiliated	3934	South Charlotte Dialysis	South Charlotte Dialysis	6450 BANNINGTON RD		CHARLOTTE	NC	28226-1327
1030	Affiliated	3935	Lancaster SC Dialysis	Lancaster SC Dialysis	980 N WOODLAND DR	STE 1	LANCASTER	SC	29720-1964
1031	Affiliated	3952	Central Bamberg Dialysis	Central Bamberg Dialysis	67 SUNSET DR		BAMBERG	SC	29003-1181
1032	Affiliated	4001	West Tallahassee Dialysis	West Tallahassee Dialysis	2645 W TENNESSEE ST		TALLAHASSEE	FL	32304-2547
1033	Affiliated	4002	Daytona South Dialysis	Daytona South Dialysis	1801 S NOVA RD	STE 36	SOUTH DAYTONA	FL	32119-1775
1034	Affiliated	4003	Daytona Beach Dialysis	Daytona Beach Dialysis	578 HEALTH BLVD		DAYTONA BEACH	FL	32114-1492
1035	Affiliated	4004	West Tampa Dialysis	West Tampa Dialysis	4515 GEORGE RD	STE 3	TAMPA	FL	33634-7300
1036	Affiliated	4005	Fontana Dialysis	Fontana Dialysis	17590 FOOTHILL BLVD		FONTANA	CA	92335-8416
1037	Affiliated	4007	Fort Myers Dialysis	Fort Myers Dialysis	4220 EXECUTIVE CIRCLE	STE 38	FORT MYERS	FL	33916-7993
1038	Affiliated	4009	Lehigh Acres Dialysis	Lehigh Acres Dialysis	2719 4TH ST W		LEHIGH ACRES	FL	33971-1942
1039	Affiliated	4010	Los Banos Dialysis	Los Banos Dialysis	222 I ST		LOS BANOS	CA	93635-4132
1040	Affiliated	4013	Kissimmee Dialysis	Kissimmee Dialysis	802 N JOHN YOUNG PKWY		KISSIMMEE	FL	34741-4912
1041	Affiliated	4014	New Smyrna Beach Dialysis	New Smyrna Beach Dialysis	110 S ORANGE ST		NEW SMYRNA BEACH	FL	32168-7153
1042	Affiliated	4017	Lake Wales Dialysis	Lake Wales Dialysis	1125 BRYN MAWR AVE		LAKE WALES	FL	33853-4333
1043	Affiliated	4018	Dearborn Dialysis	Dearborn Dialysis	1185 MONROE ST		DEARBORN	MI	48124-2814
1044	Affiliated	4020	Greater Miami Dialysis	Greater Miami Dialysis	160 NW 176TH ST	STE 1	MIAMI	FL	33169-5023
1045	Affiliated	4021	Burbank Dialysis	Burbank Dialysis	1211 N SAN FERNANDO BLVD		BURBANK	CA	91504-4234
1046	Affiliated	4024	Lakeland Dialysis	Lakeland Dialysis	515 E BELLA VISTA ST		LAKELAND	FL	33805-3005
1047	Affiliated	4025	Burlington North Dialysis	Burlington North Dialysis	1164 E ROUTE 130		BURLINGTON	NJ	08016-2954
1048	Affiliated	4026	Delano Dialysis	Delano Dialysis	905 MAIN ST		DELANO	CA	93215-1729
1049	Affiliated	4027	Erie Dialysis	Erie Dialysis	350 E BAYFRONT PKWY	STE A	ERIE	PA	16507-2410
1050	Affiliated	4028	Homestead Dialysis	Homestead Dialysis	207 W 7TH AVE		W HOMESTEAD	PA	15120-1002
1051	Affiliated	4029	Plant City Dialysis	Plant City Dialysis	1211 W REYNOLDS ST		PLANT CITY	FL	33563-4321
1052	Affiliated	4030	Winter Haven Dialysis	Winter Haven Dialysis	1625 UNITY WAY NW		WINTER HAVEN	FL	33881
1053	Affiliated	4032	Charlotte Dialysis	Charlotte Dialysis	2321 W MOREHEAD ST	STE 12	CHARLOTTE	NC	28208-5145
1054	Affiliated	4034	McKeesport Dialysis	McKeesport Dialysis	2001 LINCOLN WAY	OAK PARK MALL	MCKEESPORT	PA	15131-2419
1055	Affiliated	4035	Broward Dialysis	Broward Dialysis	1500 N FEDERAL HWY	STE 1	FT LAUDERDALE	FL	33304-5600
1056	Affiliated	4036	Athens Dialysis	Athens Dialysis	15953 ATHENS LIMESTONE DR		ATHENS	AL	35613-2214
1057	Affiliated	4038	Bradenton Dialysis	Bradenton Dialysis	3501 CORTEZ RD W	STE 14	BRADENTON	FL	34210-3104
1058	Affiliated	4039	Deland Dialysis	Deland Dialysis	350 E NEW YORK AVE		DELAND	FL	32724-5510
1059	Affiliated	4040	Boynton/North Delray Dialysis	Boynton/North Delray Dialysis	2655 W ATLANTIC AVE		DELRAY BEACH	FL	33445-4400
1060	Affiliated	4041	Lake Worth Dialysis	Lake Worth Dialysis	2459 S CONGRESS AVE	STE 1	PALM SPRINGS	FL	33406-7616
1061	Affiliated	4042	Palm Coast Dialysis	Palm Coast Dialysis	13 KINGSWOOD DR	STE A	PALM COAST	FL	32137-4614
1062	Affiliated	4043	Fort Myers South Dialysis	Fort Myers South Dialysis	8570 GRANITE CT		FORT MYERS	FL	33908-4102
1063	Affiliated	4044	Woodburn Dialysis	Woodburn Dialysis	1840 NEWBERG HWY	STE 14	WOODBURN	OR	97071-3187
1064	Affiliated	4045	Four Freedoms	Four Freedoms Dialysis (fka Range Street)	289 SW RANGE AVE	STE A	MADISON	FL	32340-2351
1065	Affiliated	4046	West Philadelphia Dialysis	West Philadelphia Dialysis	7609 LINDBERGH BLVD		PHILADELPHIA	PA	19153-2301
1066	Affiliated	4048	Tucson West Dialysis	Tucson West Dialysis	1780 W ANKLAM RD		TUCSON	AZ	85745-2632
1067	Affiliated	4049	Tucson East Dialysis	Tucson East Dialysis	6420 E BROADWAY BLVD	STE C3	TUCSON	AZ	85710-3512
1068	Affiliated	4053	Tallahassee South Dialysis	Tallahassee South Dialysis	2410 S ADAMS ST		TALLAHASSEE	FL	32301-6325
1069	Affiliated	4054	Selma Dialysis	Selma Dialysis	2711 CINEMA WAY	STE 111	SELMA	CA	93662-2662
1070	Affiliated	4055	Hinesville Dialysis	Hinesville Dialysis	522 ELMA G MILES PKWY		HINESVILLE	GA	31313-4021
1071	Affiliated	4056	Los Angeles Downtown Dialysis	Los Angeles Downtown Dialysis	2021 S FLOWER ST		LOS ANGELES	CA	90007-1342
1072	Affiliated	4057	Anaheim Dialysis	Anaheim Dialysis	1107 W LA PALMA AVE		ANAHEIM	CA	92801-2804
1073	Affiliated	4058	Martinsville Dialysis	Martinsville Dialysis	33 BRIDGE ST S		MARTINSVILLE	VA	24112-6214
1074	Affiliated	4060	Jefferson Dialysis	Jefferson Dialysis	14 CLAIRTON BLVD		PITTSBURGH	PA	15236-3911
1075	Affiliated	4061	Saddleback Dialysis	Saddleback Dialysis	23141 PLAZA POINTE DR		LAGUNA HILLS	CA	92653-1425

1076	Affiliated	4064	Sun City Center Dialysis	Sun City Center Dialysis	783 CORTARO DR		RUSKIN	FL	33573-6812
1077	Affiliated	4065	Paris Dialysis	Paris Dialysis	32 STEUBENVILLE PK		PARIS	PA	15021
1078	Affiliated	4066	Central Tampa Dialysis	Central Tampa Dialysis	4204 N MACDILL AVE	SOUTH BLDG	TAMPA	FL	33607-6342
1079	Affiliated	4068	Zephyrhills Dialysis	Zephyrhills Dialysis	6610 STADIUM DR		ZEPHYRHILLS	FL	33542-7510
1080	Affiliated	4069	Bartow Dialysis	Bartow Dialysis	1190 E CHURCH ST		BARTOW	FL	33830-4117
1081	Affiliated	4070	Ormond Beach Dialysis	Ormond Beach Dialysis	495 S NOVA RD	STE 19	ORMOND BEACH	FL	32174-8444
1082	Affiliated	4071	Lakeland South Dialysis	Lakeland South Dialysis	5050 S FLORIDA AVE		LAKELAND	FL	33813-2501
1083	Affiliated	4072	St. Mary’s Dialysis	St. Mary’s Dialysis	2714 OSBORNE RD		ST MARY’S	GA	31558-4049
1084	Affiliated	4073	Miami North Dialysis	Miami North Dialysis	860 NE 125TH ST		NORTH MIAMI	FL	33161-5743
1085	Affiliated	4074	Naples Dialysis	Naples Dialysis	661 9TH ST N		NAPLES	FL	34102-8132
1086	Affiliated	4075	Bonita Springs Dialysis	Bonita Springs Dialysis	9134 BONITA BEACH RD SE		BONITA SPRINGS	FL	34135-4281
1087	Affiliated	4076	Orlando Southwest Dialysis	Orlando Southwest Dialysis	6925 LAKE ELLENOR DR	STE 65	ORLANDO	FL	32809-4670
1088	Affiliated	4088	Quincy Dialysis	Quincy Dialysis	878 STRONG RD		QUINCY	FL	32351-5243
1089	Affiliated	4089	Tallahassee Dialysis	Tallahassee Dialysis	1607 PHYSICIANS DR		TALLAHASSEE	FL	32308-4620
1090	Affiliated	4095	South Beach Dialysis	South Beach Dialysis	4701 N MERIDIAN AVE		MIAMI BEACH	FL	33140-2910
1091	Affiliated	4124	Americus Dialysis	Americus Dialysis	227 N LEE ST		AMERICUS	GA	31709-3525
1092	Affiliated	4204	Corry Dialysis	Corry Dialysis	300 YORK ST		CORRY	PA	16407-1420
1093	Affiliated	4208	Elizabethtown Dialysis	Elizabethtown Dialysis	844 N HANOVER ST		ELIZABETHTOWN	PA	17022-1303
1094	Affiliated	4209	Lumberton Dialysis	Lumberton Dialysis	668 MAIN ST		LUMBERTON	NJ	08048-5016
1095	Affiliated	4211	Cobbs Creek Dialysis	Cobbs Creek Dialysis	1700 S 60TH ST		PHILADELPHIA	PA	19142-1404
1096	Affiliated	4214	Westland Dialysis	Garden West Dialysis (fka Westland)	5715 N VENOY RD		WESTLAND	MI	48185-2830
1097	Affiliated	4215	Meadville Dialysis	Meadville Dialysis	19050 PARK AVENUE PLZ		MEADVILLE	PA	16335-4012
1098	Affiliated	4217	Bradford Dialysis	Bradford Dialysis	665 E MAIN ST		BRADFORD	PA	16701-1869
1099	Affiliated	4219	Southgate Dialysis	Southgate Dialysis	14752 NORTHLINE RD		SOUTHGATE	MI	48195-2467
1100	Affiliated	4223	Waynesburg Dialysis	Waynesburg Dialysis	248 ELM DR		WAYNESBURG	PA	15370-8269
1101	Affiliated	4224	Selinsgrove Dialysis	Selinsgrove Dialysis	1030 N SUSQUEHANNA TRAIL		SELINSGROVE	PA	17870-7767
1102	Affiliated	2153	Arlington Dialysis	Arlington Dialysis	1250 E PIONEER PKWY	STE 7	ARLINGTON	TX	76010-6423
1103	Affiliated	2154	Grapevine Dialysis	Grapevine Dialysis	1600 W NORTHWEST HWY	STE 1	GRAPEVINE	TX	76051-8131
1104	Affiliated	1740	Willow Dialysis	Willow Dialysis	1675 ALEX DR		WILMINGTON	OH	45177-2446
1105	Affiliated	1767	New Braunfels Dialysis	New Braunfels Dialysis	900 LOOP 337		NEW BRAUNFELS	TX	78130-3555
1106	Affiliated	2080	Chickasha Dialysis	Chickasha Dialysis	228 S 29TH ST		CHICKASHA	OK	73018-2502
1107	Affiliated	2184	Sugarloaf	Sugarloaf Dialysis (fka Lawrenceville)	1705 BELLE MEADE CT	STE 11	LAWRENCEVILLE	GA	30043-5895
1108	Affiliated	2166	Buford Dialysis	Buford Dialysis	1550 BUFORD HWY	STE 1E	BUFORD	GA	30518-3666
1109	Affiliated	1749	St. Louis Park PD	St. Louis Park Dialysis Center PD	3505 LOUISIANA AVE S		ST LOUIS PARK	MN	55426-4121
1110	Affiliated	1769	Front Royal Dialysis	Front Royal Dialysis	1077D N SHENANDOAH AVE		FRONT ROYAL	VA	22630-3546
1111	Affiliated	1770	Winchester Dialysis	Winchester Dialysis	2301 VALOR DR		WINCHESTER	VA	22601-6111
1112	Affiliated	2200	New Hope Dialysis	New Hope Dialysis (aka Minneapolis, Golden Valley)	5640 INTERNATIONAL PKWY		NEW HOPE	MN	55428-3047
1113	Affiliated	2175	Richfield Dialysis	Richfield Dialysis	6601 LYNDALE AVE S	STE 15	RICHFIELD	MN	55423-2490
1114	Affiliated	2162	Fairborne Dialysis	Fairborn Dialysis	3070 PRESIDENTIAL DR	STE A	FAIRBORN	OH	45324-6273
1115	Affiliated	1694	Benton Dialysis	Benton Dialysis	1151 ROUTE 14 W		BENTON	IL	62812-1500
1116	Affiliated	1695	Centralia Dialysis	Centralia Dialysis	1231 STATE ROUTE 161		CENTRALIA	IL	62801-6739
1117	Affiliated	1696	Marion Dialysis	Marion Dialysis	324 S 4TH ST		MARION	IL	62959-1241
1118	Affiliated	1697	Mount Vernon Dialysis	Mount Vernon Dialysis	1800 JEFFERSON AVE		MOUNT VERNON	IL	62864-4300
1119	Affiliated	2121	Bayou City Dialysis	Bayou City Dialysis (fka Hanson)	10655 EASTEX FWY		HOUSTON	TX	77093-4323
1120	Affiliated	2117	Metarie Dialysis Center	Metairie Dialysis	7100 AIRLINE DR		METAIRIE	LA	70003-5950
1121	Affiliated	1784	Stony Creek Dialysis	Stony Creek Dialysis	9115 S CICERO AVE		OAK LAWN	IL	60453-1895
1122	Affiliated	1785	Beverly Dialysis	Beverly Dialysis	8109 SOUTH WESTERN AVE		CHICAGO	IL	60620-5939
1123	Affiliated	2089	Summit Dialysis	Summit Dialysis Center	3150 POLK ST		HOUSTON	TX	77003-4631
1124	Affiliated	2212	Upper Valley Dialysis	Upper Valley Dialysis (fka West El Paso)	7933 N MESA ST	STE H	EL PASO	TX	79932-1699
1125	Affiliated	2134	Dallas County	Perry Dialysis (fka Dallas County)	610 10TH ST	STE L1	PERRY	IA	50220-2221
1126	Affiliated	1813	Nampa Dialysis Center	Nampa Dialysis	846 PARKCENTRE WAY		NAMPA	ID	83651-1790
1127	Affiliated	1814	Table Rock Dialysis	Table Rock Dialysis	5610 W GAGE ST	STE B	BOISE	ID	83706
1128	Affiliated	1815	Twin Falls Dialysis	Twin Falls Dialysis	1840 CANYON CREST DR		TWIN FALLS	ID	83301-3007
1129	Affiliated	1816	Burley Dialysis Center	Burley Dialysis	741 N OVERLAND AVE		BURLEY	ID	83318-3440

1130	Affiliated	1817	Gate City Dialysis Center	Gate City Dialysis	2001 BENCH RD		POCATELLO	ID	83201-2033
1131	Affiliated	1818	Four Rivers Dialysis	Four Rivers Dialysis	515 EAST LN		ONTARIO	OR	97914-3953
1132	Affiliated	2231	River Parishes	River Parishes Dialysis (aka La Place)	2880 W AIRLINE HWY		LA PLACE	LA	70068-2922
1133	Affiliated	2177	South Lincoln	South Lincoln Dialysis	3401 PLANTATION DR	STE 14	LINCOLN	NE	68516-4712
1134	Affiliated	2105	Rochester Hills	Rochester Hills Dialysis (aka Sterling Heights)	1886 W AUBURN RD	STE 1	ROCHESTER HILLS	MI	48309-3865
1135	Affiliated	2101	Willowbrook Dialysis	Willowbrook Dialysis	12120 JONES RD	STE G	HOUSTON	TX	77070-5280
1136	Affiliated	2195	Springhurst Dialysis	Springhurst Dialysis (aka Louisville)	10201 CHAMPION FARMS DR		LOUISVILLE	KY	40241-6150
1137	Affiliated	2012	Magnolia West	Magnolia West Dialysis (aka Riverside II)	11161 MAGNOLIA AVE		RIVERSIDE	CA	92505-3605
1138	Affiliated	2206	Garrisonville Dialysis	Garrisonville Dialysis	70 DOC STONE RD	STE 11	STAFFORD	VA	22556-4628
1139	Affiliated	2152	Strongsville Dialysis	Strongsville Dialysis	17792 PEARL RD		STRONGSVILLE	OH	44136-6909
1140	Affiliated	984	Summerlin Dialysis	Summerlin Dialysis Center, LV	653 N TOWN CENTER DR	STE 7 BLDG 2	LAS VEGAS	NV	89144-0503
1141	Affiliated	2127	Red Bluff Dialysis	Red Bluff Dialysis Center	2455 SISTER MARY COLUMBA DR		RED BLUFF	CA	96080-4364
1142	Affiliated	1638	Cobb Dialysis	Cobb Dialysis	3865 MEDICAL PARK DR		AUSTELL	GA	30106-1109
1143	Affiliated	1693	Paulding Dialysis	Paulding Dialysis	4019 JOHNS RD		DALLAS	GA	30132-3420
1144	Affiliated	1839	Sweetwater Dialysis	Sweetwater Dialysis	7117 S SWEETWATER RD		LITHIA SPRINGS	GA	30122-2446
1145	Affiliated	3671	Charlottesville North	Charlottesville North Dialysis	1800 TIMBERWOOD BLVD	STE C	CHARLOTTESVILLE	VA	22911-7544
1146	Affiliated	2186	Southern Crescent	Southern Crescent Dialysis Center (fka Riverdale)	275 UPPER RIVERDALE RD SW	STE B	RIVERDALE	GA	30274-2556
1147	Affiliated	2169	Meridian Park	Meridian Park Dialysis Center (fka Lake Oswego)	19255 SW 65TH AVE	STE 1	TUALATIN	OR	97062-9712
1148	Affiliated	1812	Treasure Valley Dialysis	Treasure Valley Dialysis	3525 E LOUISE ST	STE 155	MERIDIAN	ID	83642-6303
1149	Affiliated	3637	White Oak	White Oak Dialysis (Chronic)	5520 CHEVIOT RD	STE B	CINCINNATI	OH	45247-7069
1150	Affiliated	1786	Ash Tree	Ash Tree Dialysis	2666 N GROVE INDUSTRIAL DR		FRESNO	CA	93727-1552
1151	Affiliated	2242	Madera Dialysis	Almond Wood Dialysis (fka Madera)	501 E ALMOND AVE		MADERA	CA	93637-5661
1152	Affiliated	2209	Carrollton	Carrollton Dialysis	1544 VALWOOD PKWY	STE 114	CARROLLTON	TX	75006-8425
1153	Affiliated	2202	Edna Dialysis	Edna Dialysis	1008 N WELLS ST		EDNA	TX	77957-2153
1154	Affiliated	2208	Bear Creek Dialysis	Bear Creek Dialysis (fka Clay Road)	4978 HIGHWAY 6 N	STE I	HOUSTON	TX	77084-5282
1155	Affiliated	1820	Windham Dialysis	Windham Dialysis	375 TUCKIE RD	STE C	NORTH WINDHAM	CT	06256-1345
1156	Affiliated	1819	Vernon Dialysis	Vernon Dialysis	460 HARTFORD TPKE STE C		VERNON ROCKVILLE	CT	6066
1157	Affiliated	2092	Fountain Dialysis	Fountain Dialysis (aka Security)	6910 BANDLEY DR		FOUNTAIN	CO	80817-2617
1158	Affiliated	1846	Grand Junction	Grand Junction Dialysis Center	710 WELLINGTON AVE	STE 2	GRAND JUNCTION	CO	81501-6100
1159	Affiliated	2183	Fort Mill	Fort Mill Dialysis	1975 CAROLINA PLACE DR		FORT MILL	SC	29708-6922
1160	Affiliated	2215	Mrytle Beach	JV-Myrtle Beach Dialysis	3919 MAYFAIR ST		MYRTLE BEACH	SC	29577-5773
1161	Affiliated	2032	Oakwood	Oakwood Dialysis Center	148 HECTOR AVE		GRETNA	LA	70056-2531
1162	Affiliated	2168	SP Hillsboro	Hillsboro Dialysis	2500 NW 229TH AVE	STE 3 BLDG E	HILLSBORO	OR	97124-7516
1163	Affiliated	2269	Kettering	Kettering Dialysis	5721 BIGGER RD		KETTERING	OH	45440-2752
1164	Affiliated	2246	Mansfield	Mansfield Dialysis Center (aka Dallas)	987 N WALNUT CREEK DR	STE 11	MANSFIELD	TX	76063-8016
1165	Affiliated	2290	Cottage Grove	Cottage Grove Dialysis	8800 E POINT DOUGLAS RD S	STE 1	COTTAGE GROVE	MN	55016-4160
1166	Affiliated	2257	Scott County Dialysis	Scott County Dialysis	7456 S PARK DR		SAVAGE	MN	55378
1167	Affiliated	1773	Virginia Beach	Camelot Dialysis Center	1800 CAMELOT DR	STE 1	VIRGINIA BEACH	VA	23454-2440
1168	Affiliated	1627	Amelia Island	Amelia Island Dialysis	1525 LIME ST	STE 12	FERNANDINA BEACH	FL	32034-3015
1169	Affiliated	2179	Laurel Manor at the Villages	Laurel Manor Dialysis Center at the Villages	1950 LAUREL MANOR DR	STE 19	LADY LAKE	FL	32162-5603
1170	Affiliated	2160	East Deerborn	East Dearborn Dialysis	13200 W WARREN AVE		DEARBORN	MI	48126-2410
1171	Affiliated	1661	North Houston	PDI-North Houston	7115 NORTH LOOP E		HOUSTON	TX	77028-5948
1172	Affiliated	1663	South Houston	PDI-South Houston	5989 SOUTH LOOP E		HOUSTON	TX	77033-1017
1173	Affiliated	1856	Ralph McGill Dialysis Center	Ralph McGill Dialysis	418 DECATUR ST SE		ATLANTA	GA	30312-1801
1174	Affiliated	2144	Chelsea	Chelsea Dialysis	1620 COMMERCE PARK DR	STE 2	CHELSEA	MI	48118-2136
1175	Affiliated	2214	Smokey Mountain	Smoky Mountain Dialysis	1611 ANDREWS RD		MURPHY	NC	28906-5100
1176	Affiliated	3680	Miami Gardens	Miami Gardens Dialysis	3363 NW 167TH ST		MIAMI GARDENS	FL	33056-4254
1177	Affiliated	2222	Deerbrook	Deerbrook Dialysis	9660 FM 1960 BYPASS RD W		HUMBLE	TX	77338-4039
1178	Affiliated	2227	Downtown Dallas	DaVita Downtown Dallas Dialysis Center (fka Grove)	3515 SWISS AVE	STE A	DALLAS	TX	75204-6223
1179	Affiliated	2197	Henderson	Siena Henderson Dialysis Center	2865 SIENNA HEIGHTS DR	STE 141	HENDERSON	NV	89052-4168
1180	Affiliated	2292	Wyandotte	Wyandotte Central Dialysis	3737 STATE AVE		KANSAS CITY	KS	66102-3830
1181	Affiliated	2235	Westview	Westview Dialysis	3749 COMMERCIAL DR	LAFAYETTE PLACE SHOPPING CENTER	INDIANAPOLIS	IN	46222-1676
1182	Affiliated	2286	Garland	Garland Dialysis	776 E CENTERVILLE RD		GARLAND	TX	75041-4640
1183	Affiliated	2333	Aberdeen	Aberdeen Dialysis	780 W BEL AIR AVE		ABERDEEN	MD	21001-2236

1184	Affiliated	2259	Mountain Park	Mountain Park Dialysis	5235 MEMORIAL DR		STONE MOUNTAIN	GA	30083-3112
1185	Affiliated	2229	Downtown San Antonio	Downtown San Antonio Dialysis (Brooklyn St)	615 E QUINCY ST		SAN ANTONIO	TX	78215-1600
1186	Affiliated	2237	Medlock Bridge	Medlock Bridge Dialysis (aka Duluth)	10680 MEDLOCK BRIDGE RD	STE 13	DULUTH	GA	30097-8420
1187	Affiliated	2234	Greene County Dialysis	Greene County Dialysis Center (NC)	1025 KINGOLD BLVD		SNOW HILL	NC	28580-1616
1188	Affiliated	2243	West Broadway Dialysis	West Broadway Dialysis	720 W BROADWAY		LOUISVILLE	KY	40202-2240
1189	Affiliated	2072	St. Pauls Dialysis	St. Pauls Dialysis (aka Robeson County)	564 W MCLEAN ST		SAINT PAULS	NC	28384-1421
1190	Affiliated	2123	Carquinez Dialyis	Carquinez Dialysis (fka SW Vallejo)	125 CORPORATE PL	STE C	VALLEJO	CA	94590-6968
1191	Affiliated	2159	DaVita East	DaVita East Dialysis Clinic (fka La Bamba)	11989 PELLICANO DR		EL PASO	TX	79936-6287
1192	Affiliated	2187	Natomas	Natomas Dialysis	30 GOLDEN LAND CT	BLDG G	SACRAMENTO	CA	95834-2420
1193	Affiliated	2228	Tennesse Valley	Tennessee Valley Dialysis Center (aka Johnson City)	107 WOODLAWN DR	STE 2	JOHNSON CITY	TN	37604-6287
1194	Affiliated	2174	Turfway Dialysis	Turfway Dialysis (fka Florence)	11 SPIRAL DR	STE 15	FLORENCE	KY	41042-1394
1195	Affiliated	2291	Leavenworth	Leavenworth Dialysis	501 OAK ST		LEAVENWORTH	KS	66048-2646
1196	Affiliated	2270	Franklin Dialysis	Franklin Dialysis (IN)	1140 W JEFFERSON ST	STE A	FRANKLIN	IN	46131-2101
1197	Affiliated	2011	Norco	Norco Dialysis (fka Corona II)	1901 TOWN AND COUNTRY DR	STE 1	NORCO	CA	92860-3611
1198	Affiliated	2240	Andover	Andover Dialysis	488 S MAIN ST		ANDOVER	OH	44003-9602
1199	Affiliated	1863	Little Rock	Jacksonville Central Dialysis Center	400 T P WHITE DR		JACKSONVILLE	AR	72076-3287
1200	Affiliated	1864	North Little Rock Dialysis	North Little Rock Center	4505 E MCCAIN BLVD		NORTH LITTLE ROCK	AR	72117-2902
1201	Affiliated	2233	Anadarko	Anadarko Dialysis	412 SE 11TH STREET		ANADARKO	OK	73005-4442
1202	Affiliated	2331	Desert Springs	Desert Springs Dialysis	2110 E FLAMINGO RD	STE 18	LAS VEGAS	NV	89119-5191
1203	Affiliated	2213	Livingston	Vancouver Dialysis Center	9120 NE VANCOUVER MALL DR	STE 16	VANCOUVER	WA	98662-9401
1204	Affiliated	2300	Vancouver	Livingston TN Dialysis	308 OAK ST		LIVINGSTON	TN	38570-1729
1205	Affiliated	2225	Fenton Dialysis	Fenton Dialysis	17420 SILVER PKWY		FENTON	MI	48430-4429
1206	Affiliated	2332	Cold Spring	Cold Springs Dialysis	430 CROSS ROADS BLVD		COLD SPRING	KY	41076-2341
1207	Affiliated	2094	Yucaipa	Yucaipa Dialysis	33487 YUCAIPA BLVD		YUCAIPA	CA	92399-2064
1208	Affiliated	1900	Florida Renal Center	Florida Renal Center	3500 NW 7TH ST		MIAMI	FL	33125-4016
1209	Affiliated	2140	Harbor UCLA	Long Beach Harbor Dialysis (aka UCLA)	1075 E PACIFIC COAST HWY		LONG BEACH	CA	90806-5089
1210	Affiliated	2210	Seaton Drive	Seton Drive Dialysis (fka Greensprings II)	4800 SETON DR		BALTIMORE	MD	21215-3210
1211	Affiliated	1865	South Valley	South Valley Dialysis	17815 VENTURA BLVD	STE 1	ENCINO	CA	91316-3600
1212	Affiliated	2305	West Pensacola	West Pensacola Dialysis	598 N FAIRFIELD DR	STE 1	PENSACOLA	FL	32506-4320
1213	Affiliated	2073	Mar Vista	Mar Vista Dialysis Center (UCLA-Santa Monica)	2020 SANTA MONICA BLVD	STE 1	SANTA MONICA	CA	90404-2139
1214	Affiliated	2082	Riddle Dialysis	Riddle Dialysis	100 GRANITE DR	STE 16	MEDIA	PA	19063-5134
1215	Affiliated	2346	Uptown	Minneapolis Uptown Dialysis	3601 LYNDALE AVE S		MINNEAPOLIS	MN	55409-1103
1216	Affiliated	1907	Lake Griffith East Dialysis	Lake Griffin East Dialysis	401 E NORTH BLVD		LEESBURG	FL	34748-5256
1217	Affiliated	2170	West Linn	West Linn Dialysis	19056 WILLAMETTE DR		WEST LINN	OR	97068-1715
1218	Affiliated	2330	Cape Coral South Dialysis	Cape Coral South Dialysis	3046 DEL PRADO BLVD S	STE 4A	CAPE CORAL	FL	33904-7232
1219	Affiliated	2241	Ceres	Ceres Dialysis Center	1768 MITCHELL RD	STE 38	CERES	CA	95307-2156
1220	Affiliated	1862	Shaker Square	Shaker Square Dialysis	12800 SHAKER BLVD	STE 1	CLEVELAND	OH	44120-2004
1221	Affiliated	1906	St. Cloud Dialysis	St. Cloud Dialysis	4750 OLD CANOE CREEK RD		SAINT CLOUD	FL	34769-1430
1222	Affiliated	1915	Turlock Dialysis Center	Turlock Dialysis Center	50 W SYRACUSE AVE		TURLOCK	CA	95380-3143
1223	Affiliated	2268	Haymarket	Haymarket Dialysis (fka Gainesville)	14664 GAP WAY		GAINESVILLE	VA	20155-1683
1224	Affiliated	2272	Hackettstown	Hackettstown Dialysis	657 WILLOW GROVE ST	WEST WING MEDICAL PLAZA STE 22	HACKETTSTOWN	NJ	07840-1713
1225	Affiliated	2274	Regency	Regency Dialysis Center (fka Jacksonville)	9535 REGENCY SQUARE BLVD N		JACKSONVILLE	FL	32225-8128
1226	Affiliated	2149	Williamsburg	Williamsburg Dialysis (fka Yorktown)	500 SENTARA CIR	STE 13	WILLIAMSBURG	VA	23188-5727
1227	Affiliated	2141	Commerce Township	Commerce Township Dialysis	120 W COMMERCE RD		COMMERCE TOWNSHIP	MI	48382-3915
1228	Affiliated	2147	Kankakee	Kankakee County Dialysis	581 WILLIAM R LATHAM SR DR	STE 14	BOURBONNAIS	IL	60914-2439
1229	Affiliated	2283	Sandusky	Sandusky Dialysis Center	795 BARDSHAR RD		SANDUSKY	OH	44870-1505
1230	Affiliated	2252	Ionia	Ionia Dialysis	2622 HEARTLAND BLVD		IONIA	MI	48846-8757
1231	Affiliated	2289	Indian River	Indian River Dialysis Center	2150 45TH ST	UNIT 12	VERO BEACH	FL	32967-6281
1232	Affiliated	2360	North Henry	North Henry Dialysis (fka Stockbridge)	5627 N HENRY BLVD	STE I1	STOCKBRIDGE	GA	30281-3244
1233	Affiliated	2077	Tacoma Dialysis	Tacoma Dialysis Center	3401 S 19TH ST		TACOMA	WA	98405-1909
1234	Affiliated	1908	Hileah Kidney Center I	Hialeah Artificial Kidney Center	2750 W 68TH ST	STE 27	HIALEAH	FL	33016-5450
1235	Affiliated	2315	St. Francis	Charter Colony Dialysis Center (fka St. Francis Dialysis)	2312 COLONY CROSSING PL		MIDLOTHIAN	VA	23112-4280
1236	Affiliated	2138	Bellflower	Bellflower Dialysis Center (aka Widerhorn)	15736 WOODRUFF AVE		BELLFLOWER	CA	90706-4018
1237	Affiliated	2301	Smyrna	Smyrna Dialysis	537 STONECREST PKWY		SMYRNA	TN	37167-6884

1238	Affiliated	2122	Clearlake	Clearlake Dialysis	14400 OLYMPIC DR		CLEARLAKE	CA	95422-8809
1239	Affiliated	1853	Dialysis Center of Erie	Dialysis Center of Erie	1641 SASSAFRAS ST		ERIE	PA	16502-1858
1240	Affiliated	1854	Warren Dialysis	Warren Dialysis	2 W CRESCENT PARK		WARREN	PA	16365-2111
1241	Affiliated	2322	Maysville	Maysville Dialysis	489 TUCKER DR		MAYSVILLE	KY	41056-9111
1242	Affiliated	2429	Fridley	East River Road Dialysis (fka Fridley Dialysis Unit)	5301 E RIVER RD	STE 117	FRIDLEY	MN	55421-3778
1243	Affiliated	2189	West Sacramento	West Sacramento Dialysis	3450 INDUSTRIAL BLVD	STE 1	WEST SACRAMENTO	CA	95691-5003
1244	Affiliated	2293	Anderson	Anderson Dialysis Center	7502 STATE RD	STE 116	CINCINNATI	OH	45255
1245	Affiliated	2383	North County	North St. Louis County Dialysis	13119 NEW HALLS FERRY RD		FLORISSANT	MO	63033-3228
1246	Affiliated	2439	Fargo	Fargo Dialysis Center	4474 23RD AVE S	STE M	FARGO	ND	58104-8795
1247	Affiliated	2008	Eastchester	Eastchester Road Dialysis Center (Bronx II)	1515 JARRETT PL		BRONX	NY	10461-2606
1248	Affiliated	2224	Fallon	Fallon Dialysis	1103 NEW RIVER PKWY		FALLON	NV	89406-6899
1249	Affiliated	2279	Clarksville North	Clarksville North Dialysis	3071 CLAY LEWIS RD		CLARKSVILLE	TN	37040-5141
1250	Affiliated	2308	Eaton	Eaton Dialysis	105 E WASHINGTON JACKSON RD		EATON	OH	45320-9789
1251	Affiliated	2447	Wallace	Wallace Dialysis	5650 S NC 41 HWY		WALLACE	NC	28466-6094
1252	Affiliated	2288	Central Kalazmazoo	Kalamazoo Central Dialysis	535 S BURDICK ST	STE 11	KALAMAZOO	MI	49007-5261
1253	Affiliated	2287	West Kalamazoo	Kalamazoo West Dialysis	1040 N 10TH ST		KALAMAZOO	MI	49009-6149
1254	Affiliated	1921	Bakersfield	Bakersfield Dialysis Center	5143 OFFICE PARK DR		BAKERSFIELD	CA	93309-0660
1255	Affiliated	1930	Antelope Valley Dialysis	Antelope Valley Dialysis	1759 W AVENUE J	STE 12	LANCASTER	CA	93534-2703
1256	Affiliated	1931	Indian Wells Valley Dialysis	Indian Wells Valley Dialysis	212 S RICHMOND RD		RIDGECREST	CA	93555-4434
1257	Affiliated	1932	Palmdale Regional Dialysis	Palmdale Regional	1643 E PALMDALE BLVD		PALMDALE	CA	93550-4847
1258	Affiliated	2185	South Star / Adamsville	Southstar Adamsville Dialysis (fka Cascade)	3651 BAKERS FERRY RD SW		ATLANTA	GA	30331-3712
1259	Affiliated	2314	Union City	Union City Dialysis	6851 SHANNON PKWY	STE 2	UNION CITY	GA	30291-2049
1260	Affiliated	2345	Waterbury	Waterbury Dialysis Center	150 MATTATUCK HEIGHTS RD		WATERBURY	CT	06705-3893
1261	Affiliated	2421	Butler Farm	Butler Farm Dialysis (Hope II)	501 BUTLER FARM RD		HAMPTON	VA	23666-1777
1262	Affiliated	2337	Blue Mtn Kidney Center	Blue Mountain Kidney Center (aka Wild Horse, Pendleton)	72556 COYOTE RD		PENDLETON	OR	97801-1002
1263	Affiliated	2249	Talladega	Talladega Dialysis	726 BATTLE ST E	STE A	TALLADEGA	AL	35160-2583
1264	Affiliated	2281	Athens East	Athens East Dialysis	2026 S MILLEDGE AVE	STE A2	ATHENS	GA	30605-6480
1265	Affiliated	2412	Mayland	Mayland Dialysis Center (aka Spruce Pine)	575 ALTAPASS HWY		SPRUCE PINE	NC	28777-3012
1266	Affiliated	2236	Salem	Salem Dialysis Center (IN)	1201 N JIM DAY RD	STE 13	SALEM	IN	47167-7219
1267	Affiliated	2239	Lake Cliff	Lake Cliff Dialysis Center	805 N BECKLEY AVE		DALLAS	TX	75203-1612
1268	Affiliated	2363	DVA Mid Cities Dialysis	Mid Cities Dialysis Center	117 E HARWOOD RD		HURST	TX	76054-3043
1269	Affiliated	2362	Boerne	Boerne Dialysis Center	1369 S MAIN ST	STE 11	BOERNE	TX	78006-2860
1270	Affiliated	2318	Columbus West	Columbus West Dialysis	1395 GEORGESVILLE RD		COLUMBUS	OH	43228-3611
1271	Affiliated	2306	Point Place	Point Place Dialysis	4747 SUDER AVE	STE 17	TOLEDO	OH	43611-2869
1272	Affiliated	2350	Delhi Dialysis	Delhi Dialysis	5040 DELHI AVE		CINCINNATI	OH	45238-5388
1273	Affiliated	2253	Pataskala	Pataskala Dialysis Center	642 E BROAD ST		PATASKALA	OH	43062-7627
1274	Affiliated	2384	Eastland	Eastland Dialysis (fka Independence)	19101 E VALLEY VIEW PKWY	STE E	INDEPENDENCE	MO	64055-6907
1275	Affiliated	2254	Wauseon	Wauseon Dialysis Center	721 S SHOOP AVE		WAUSEON	OH	43567-1729
1276	Affiliated	2327	Lebanon Dialysis	Lebanon Dialysis Center (Chronic Only)	918B COLUMBUS AVE		LEBANON	OH	45036-
1277	Affiliated	2460	Horton	Horton Dialysis	1901 EUCLID AVE		HORTON	KS	66439-1238
1278	Affiliated	2280	Lone Peak Dialysis	Lone Peak Dialysis	1175 E 50 S	STE 111	AMERICAN FORK	UT	84003-2845
1279	Affiliated	2347	Mena	Mena Dialysis Center	1200 CRESTWOOD CIR		MENA	AR	71953-5516
1280	Affiliated	1941	FAYETTEVILLE DIALYSIS	Fayetteville Dialysis	509 E MILLSAP RD	STE 111	FAYETTEVILLE	AR	72703-4862
1281	Affiliated	1942	BENTONVILLE DIALYSIS	Bentonville Dialysis	1104 SE 30TH ST		BENTONVILLE	AR	72712-4290
1282	Affiliated	1943	SILOAM SPRINGS DIALYSIS	Siloam Springs Dialysis	500 S MOUNT OLIVE ST	STE 17	SILOAM SPRINGS	AR	72761-3602
1283	Affiliated	1944	SPRINGDALE DIALYSIS	Springdale Dialysis	708 QUANDT AVE		SPRINGDALE	AR	72764-5309
1284	Affiliated	2273	Grosse Pointe	Grosse Pointe Dialysis	18000 E WARREN AVE	STE 1	DETROIT	MI	48224-1336
1285	Affiliated	2448	Indy South Dialysis	Indy South Dialysis	972 EMERSON PKWY	STE E	GREENWOOD	IN	46143-6202
1286	Affiliated	2358	Greensburg Dialysis	Greensburg Dialysis	1531 N COMMERCE EAST DR	STE 6	GREENSBURG	IN	47240-3259
1287	Affiliated	2319	Grove City	Grove City Dialysis	4155 KELNOR DR		GROVE CITY	OH	43123-2960
1288	Affiliated	2338	West Beach	West Beach Dialysis Center	16201 PANAMA CITY BEACH HWY	STE 12	PANAMA CITY BEACH	FL	32413-5301
1289	Affiliated	2371	Birmingham	Center Point Dialysis (aka Birmingham Center)	2337 1ST ST NE		CENTER POINT	AL	35215-3619
1290	Affiliated	2445	Eureka	Eureka Dialysis Center	419 MERAMEC BLVD		EUREKA	MO	63025-3906
1291	Affiliated	2313	Tifton	Tifton Dialysis	624 LOVE AVE		TIFTON	GA	31794-4406

1292	Affiliated	2146	Woodlands	The Woodlands Dialysis	9301 PINECROFT DR	STE 13	SHENANDOAH	TX	77380-3178
1293	Affiliated	2266	Exerter	Exeter Dialysis	1116 W VISALIA RD	STE 16	EXETER	CA	93221-1482
1294	Affiliated	2396	Wayne County	Wayne County Dialysis (fka Fairfield)	303 NW 11TH ST	STE 1	FAIRFIELD	IL	62837-1203
1295	Affiliated	2415	Cordele Dialysis	Cordele Dialysis	1013 E 16TH AVE		CORDELE	GA	31015-1539
1296	Affiliated	2304	Winter Park	Winter Park Dialysis (aka Orlando)	3727 N GOLDENROD RD	STE 11	WINTER PARK	FL	32792-8611
1297	Affiliated	2449	Carmel	Carmel Dialysis	180 E CARMEL DR		CARMEL	IN	46032-2633
1298	Affiliated	2298	Corydon	Corydon Dialysis	1937 OLD HWY 135 NW		CORYDON	IN	47112-2013
1299	Affiliated	2382	Memphis Southeast	Memphis Southeast Dialysis (aka Midtown)	1805 MORIAH WOODS BLVD	STE 11	MEMPHIS	TN	38117-7119
1300	Affiliated	2399	Rim Country	Rim Country Dialysis	809 W LONGHORN RD		PAYSON	AZ	85541-4280
1301	Affiliated	2201	Cedar Park	Cedar Park Dialysis (fka North Austin)	1720 E WHITESTONE BLVD		CEDAR PARK	TX	78613-7640
1302	Affiliated	2368	Ellensburg	Ellensburg Dialysis	2101 W DOLARWAY RD	STE 1	ELLENSBURG	WA	98926-9310
1303	Affiliated	2260	Santa Fe Springs	Santa Fe Springs Dialysis	11147 WASHINGTON BLVD		WHITTIER	CA	90606-3007
1304	Affiliated	1950	Snapfinger Dialysis	Snapfinger Dialysis	5255 SNAPFINGER PARK DR	STE 115	DECATUR	GA	30035-4066
1305	Affiliated	1951	East Dekalb Dialysis	East DeKalb Dialysis	2801 CANDLER RD	STE 23	DECATUR	GA	30034-1429
1306	Affiliated	2258	Meadows East	Meadows East Dialysis	2529 SIX MILE LN		LOUISVILLE	KY	40220-2934
1307	Affiliated	2226	First Colony	First Colony Dialysis (aka Sugarland, Great Woods)	1447 HIGHWAY 6	STE 14	SUGAR LAND	TX	77478-5094
1308	Affiliated	1612	Coastal Kidney Center	Coastal Kidney Center	510 N MACARTHUR AVE		PANAMA CITY	FL	32401-3636
1309	Affiliated	2211	Clinton Township	Clinton Township Dailysis	15918 19 MILE RD	STE 11	CLINTON TOWNSHIP	MI	48038-1101
1310	Affiliated	2207	West Brook	Westbrook Dialysis (fka Palm Brook II)	13907 W CAMINO DEL SOL	STE 13	SUN CITY WEST	AZ	85375-4405
1311	Affiliated	1954	Johnson County	Johnson County Dialysis	10453 W 84TH TER		LENEXA	KS	66214-1641
1312	Affiliated	1956	Wyandotte County	Wyandotte County Dialysis	5001 STATE AVE		KANSAS CITY	KS	66102-3459
1313	Affiliated	2479	Maple Grove	Maple Grove Dialysis Unit	15655 GROVE CIR N		MAPLE GROVE	MN	55369-4489
1314	Affiliated	4336	East End	East End-Pittsburgh Dialysis (fka Wilkinsburg)	7714 PENN AVE PARK PLAZA		PITTSBURGH	PA	15221
1315	Affiliated	2493	Westminster II - North Metro	North Metro Dialysis Center (aka Denver, Westminster II)	12365 HURON ST	STE 5	WESTMINSTER	CO	80234-3498
1316	Affiliated	1960	Vidalia	Vidalia First Street Dialysis	906 E 1ST ST		VIDALIA	GA	30474-4207
1317	Affiliated	2357	Highland Park	Highland Park Dialysis	1559 W 7TH ST		SAINT PAUL	MN	55102-4238
1318	Affiliated	2367	Centennial Parkway	Centennial Dialysis Center	8775 DEER SPRINGS WAY		LAS VEGAS	NV	89149-0416
1319	Affiliated	2250	Lord Baltimore	Northwest Dialysis Center (aka Lord Baltimore, N. Rolling Road II, Owings Mills II)	2245 ROLLING RUN DR	STE 1	WINDSOR MILL	MD	21244-1858
1320	Affiliated	3944	North Charlotte	North Charlotte Dialysis	6620 OLD STATESVILLE RD		CHARLOTTE	NC	28269
1321	Affiliated	2410	Sun Ray Dialysis	Sun Ray Dialysis Unit (fka East St. Paul)	1758 OLD HUDSON RD	STE 1	SAINT PAUL	MN	55106-6161
1322	Affiliated	2425	Vandalia	Vandalia Dialysis	301 MATTES AVE		VANDALIA	IL	62471-2061
1323	Affiliated	2428	Westwood Hills	Westwood Hills Dialysis (fka Minneapolis, Excelsior)	7525 WAYZATA BLVD		SAINT LOUIS PARK	MN	55426-1621
1324	Affiliated	4305	Amery	Amery Dialysis	970 ELDEN AVE		AMERY	WI	54001-1448
1325	Affiliated	2434	Wadsworth	Wadsworth Dialysis	195 WADSWORTH RD	STE 32	WADSWORTH	OH	44281-9504
1326	Affiliated	2419	Dublin	Dublin Dialysis	6770 PERIMETER DR		DUBLIN	OH	43016-8063
1327	Affiliated	4314	Weber Valley	Weber Valley Dialysis (fka Ogden)	1920 W 250TH N		MARRIOTT-SLATERVILLE	UT	84404-9233
1328	Affiliated	2343	West Elk Grove	West Elk Grove Dialysis	2208 KAUSEN DR	STE 1	ELK GROVE	CA	95758-7174
1329	Affiliated	2355	Bedford Park	Bedford Park Dialysis Center	3119 WEBSTER AVE	1ST FLR	BRONX	NY	10467-4905
1330	Affiliated	1747	Cuero Lakeview Dialysis	Cuero Lakeview Dialysis	1105 E BROADWAY ST		CUERO	TX	77954
1331	Affiliated	1961	Madisonville Dialysis	Madisonville Dialysis Center	255 E NORTH ST		MADISONVILLE	KY	42431
1332	Affiliated	2467	Crescent City	Crescent City Dialysis Center	3909 BIENVILLE ST	STE B	NEW ORLEANS	LA	70119-5152
1333	Affiliated	4318	Callowhill	Callowhill Dialysis Center	313 CALLOWHILL ST		PHILADELPHIA	PA	19123-4103
1334	Affiliated	2406	Oak Creek	Oak Creek Dialysis (fka South Milwaukee)	8201 S HOWELL AVE	STE 6	OAK CREEK	WI	53154-8336
1335	Affiliated	4395	Leesburg Virginia	Leesburg Virginia Dialysis	224D CORNWALL ST NW	STE 1	LEESBURG	VA	20176-2700
1336	Affiliated	2386	Joy of Dixon	Joy of Dixon Dialysis Center	1640 N LINCOLN ST		DIXON	CA	95620-9255
1337	Affiliated	2137	Long Beach JV -Bixby Knolls	Bixby Knolls Dialysis (fka Long Beach)	3744 LONG BEACH BLVD		LONG BEACH	CA	90807-3310
1338	Affiliated	1790	Alliance Community Dialysis	Alliance Community Dialysis	270 E STATE ST	STE 11	ALLIANCE	OH	44601-4309
1339	Affiliated	1791	Belden Community Dialysis	Belden Community Dialysis	4685 FULTON DR NW		CANTON	OH	44718-2379
1340	Affiliated	1792	Mercy Canton Dialysis	Mercy Canton Dialysis	1320 MERCY DR NW		CANTON	OH	44708-2614
1341	Affiliated	2294	Marrero	Marrero Dialysis	1908 JUTLAND DR		HARVEY	LA	70058-2359
1342	Affiliated	2351	Miramar	Miramar Kidney Center	2501 DYKES RD	STE 2	MIRAMAR	FL	33027-4217
1343	Affiliated	2418	Chesterton	Chesterton Dialysis	711 PLAZA DR	STE 6	CHESTERTON	IN	46304-5506
1344	Affiliated	4368	St. John	St. John Dialysis	10033 WICKER AVE	STE 6	SAINT JOHN	IN	46373-8777
1345	Affiliated	2256	Princeton	Princeton Dialysis	2227 SHERMAN DR		PRINCETON	IN	47670-1062

1346	Affiliated	4332	Black Rock	Black Rock Dialysis (aka Faifield)	427 STILLSON RD		FAIRFIELD	CT	06824-3153
1347	Affiliated	2422	Williamstown	Williamstown Dialysis (fka Dry Ridge)	103 BARNES RD	STE A	WILLIAMSTOWN	KY	41097-9468
1348	Affiliated	4376	Renaissance	Renaissance Dialysis	1840 DARBY DR		FLORENCE	AL	35630-2623
1349	Affiliated	4360	Portage	Portage Dialysis	5823 US HIGHWAY 6		PORTAGE	IN	46368-4851
1350	Affiliated	2393	Opelika	Opelika Dialysis Center	2340 PEPPERELL PKWY		OPELIKA	AL	36801-6240
1351	Affiliated	2435	Urbana	Urbana Dialysis Center	1880 E US HIGHWAY 36		URBANA	OH	43078-9600
1352	Affiliated	1913	Port Lavaca Dialysis	Port Lavaca Dialysis	1300 N VIRGINIA ST	STE 12	PORT LAVACA	TX	77979-2512
1353	Affiliated	2276	Cornerhouse Dialysis	Cornerhouse Dialysis Center (aka Santa Clara)	2005 NAGLEE AVE		SAN JOSE	CA	95128-4801
1354	Affiliated	2167	Snellville	Snellville Dialysis	2135 MAIN ST E	STE 13	SNELLVILLE	GA	30078-6424
1355	Affiliated	4334	Bloomfield	Bloomfield-Pittsburgh Dialysis	5171 LIBERTY AVE	STE C	PITTSBURGH	PA	15224-2254
1356	Affiliated	2489	Pennsauken	Pennsauken Dialysis	7024 KAIGHNS AVE		PENNSAUKEN	NJ	08109-4417
1357	Affiliated	2433	Logan	Logan Dialysis	12880 GREY ST		LOGAN	OH	43138-9638
1358	Affiliated	2454	Forest Fair	Forest Fair Dialysis (fka Forest Park)	1145 KEMPER MEADOW DR		CINCINNATI	OH	45240-4118
1359	Affiliated	4307	Knoxville	Knoxville Central Dialysis	9141 CROSS PARK DR	STE 12	KNOXVILLE	TN	37923-4557
1360	Affiliated	4338	Kennestone	Kennestone Dialysis (aka Cobb II)	200 COBB PKWY N	STE 318 BLDG 3	MARIETTA	GA	30062-3558
1361	Affiliated	4343	Wiregrass Kidney Center	Wiregrass Kidney Center (fka Ross Circle)	1450 ROSS CLARK CIR		DOTHAN	AL	36301-4765
1362	Affiliated	2432	Memphis Downtown	Memphis Downtown Dialysis	2076 UNION AVE		MEMPHIS	TN	38104-4138
1363	Affiliated	3953	Marshville	Marshville Dialysis Center	7260 E MARSHVILLE BLVD		MARSHVILLE	NC	28103-1191
1364	Affiliated	4356	Shamrock	Shamrock Dialysis	1016 CLAXTON DAIRY RD	STE 1A	DUBLIN	GA	31021-7971
1365	Affiliated	4367	North Colorado Springs	North Colorado Springs Dialysis	6071 E WOODMEN RD	STE 1	COLORADO SPRINGS	CO	80923-2610
1366	Affiliated	2466	Oakes	Oakes Dialysis	413 S 7TH ST		OAKES	ND	58474-1920
1367	Affiliated	1976	Pinnacle Dialysis of Boca Raton	Pinnacle Dialysis of Boca Raton	2900 N MILITARY TRL	STE 195	BOCA RATON	FL	33431-6308
1368	Affiliated	1980	Cedar Valley Dialysis	Cedar Valley Dialysis	1661 W RIDGEWAY AVE		WATERLOO	IA	50701-4541
1369	Affiliated	1981	West Union Dialysis	West Union Dialysis	405 HIGHWAY 150 N		WEST UNION	IA	52175-1003
1370	Affiliated	2161	Rockside	Rockside Dialysis (aka Independence, Parma II)	4801 ACORN DR		INDEPENDENCE	OH	44131-2566
1371	Affiliated	2263	Sunset	Sunset Dialysis Center (fka Sunrise II)	3071 GOLD CANAL DR		RANCHO CORDOVA	CA	95670-6129
1372	Affiliated	2442	Yosemite Street	Yosemite Street Dialysis	1650 W YOSEMITE AVE		MANTECA	CA	95337-5193
1373	Affiliated	2335	Jedburg	Jedburg Dialysis	2897 W 5TH NORTH ST		SUMMERVILLE	SC	29483-9674
1374	Affiliated	2441	Parker Dialysis	Parker Dialysis	10371 S PARK GLENN WAY	STE 18	PARKER	CO	80138-3885
1375	Affiliated	2296	Northgate	Northgate Dialysis Center (aka San Rafael-Terra)	650 LAS GALLINAS AVE		SAN RAFAEL	CA	94903-3620
1376	Affiliated	2271	The Nevada Center	The Nevada Dialysis Center (fka Warm Springs, Green Valley)	1510 W WARM SPRINGS RD	STE 1	HENDERSON	NV	89014-3586
1377	Affiliated	2091	Aventura	Aventura Kidney Center	22 SW 11TH ST	FLOOR 2	HALLANDALE BEACH	FL	33009-7038
1378	Affiliated	2408	US Grant Dialysis	US Grant Dialysis (fka Georgetown, Brown County)	458 HOME ST		GEORGETOWN	OH	45121-1408
1379	Affiliated	4400	Arbor Place	Arbor Place Dialysis	9559 HIGHWAY 5	STE 1	DOUGLASVILLE	GA	30135-1573
1380	Affiliated	4389	South Jacksonville	Jacksonville South Dialysis Center	14965 OLD SAINT AUGUSTINE RD	UNIT 114	JACKSONVILLE	FL	32258-9481
1381	Affiliated	2385	Somerville	Somerville Dialysis	12475 US HIGHWAY 64		SOMERVILLE	TN	38068-6029
1382	Affiliated	4321	District Heights	District Heights Dialysis (aka Pennsylvania Ave)	5701 SILVER HILL RD		DISTRICT HEIGHTS	MD	20747-1102
1383	Affiliated	2414	Edwardsville	Edwardsville Dialysis	235 S BUCHANAN ST		EDWARDSVILLE	IL	62025-2108
1384	Affiliated	2361	Broad St	South Broad Street Dialysis (aka S. Philadelphia II)	1172 S BROAD ST		PHILADELPHIA	PA	19146-3142
1385	Affiliated	2342	Las Vegas Pedidatrics	Las Vegas Pediatrics Dialysis (fka UMC Peds, DaVita Peds)	7271 W SAHARA AVE	STE 12	LAS VEGAS	NV	89117-2862
1386	Affiliated	1990	Apopka Dialysis	Apopka Dialysis	640 EXECUTIVE PARK CT		APOPKA	FL	32703-6075
1387	Affiliated	1991	Cassellberry Dialysis	Casselberry Dialysis	4970 S US HWY 17/92		CASSELBERRY	FL	32707-3888
1388	Affiliated	1992	Central Orlando Dialysis	Central Orlando Dialysis	2548 N ORANGE BLOSSOM TRL	STE 4	ORLANDO	FL	32804-4863
1389	Affiliated	1993	Sanford Dialysis	Sanford Dialysis	1701 W 1ST ST		SANFORD	FL	32771-1605
1390	Affiliated	1994	Winter Park Hemo Dialysis	Winter Park Hemo Dialysis	4100 METRIC DR	STE 3	WINTER PARK	FL	32792-6832
1391	Affiliated	2173	Graham	Graham Dialysis Center	10219 196TH ST CT E	STE C	GRAHAM	WA	98338-7792
1392	Affiliated	2316	Batavia	Batavia Dialysis	4000 GOLDEN AGE DR		BATAVIA	OH	45103-1913
1393	Affiliated	1967	Klamath Falls	Klamath Falls Dialysis	2230 N ELDORADO AVE		KLAMATH FALLS	OR	97601-6418
1394	Affiliated	2336	Longs	Longs Dialysis (fka Conway)	90 CLOVERLEAF DR	STE 36	LONGS	SC	29568-9262
1395	Affiliated	2452	Pooler	Pooler Dialysis	54 TRADERS WAY		POOLER	GA	31322-
1396	Affiliated	4380	Ohio Pike Dialysis	Ohio Pike Dialysis (aka Amelia)	1761 STATE ROUTE 125		AMELIA	OH	45102-2039
1397	Affiliated	2285	Canyon Springs	Canyon Springs Dialysis (aka Moreno Valley)	22555 ALESSANDRO BLVD		MORENO VALLEY	CA	92553-8533
1398	Affiliated	4306	Williamson	South Williamson Dialysis	204 APPALACHIAN PLAZA		SOUTH WILLIAMSON	KY	41503-9404
1399	Affiliated	4402	Gulf Shores	Gulf Shores Dialysis Center	3947 GULF SHORES PKWY	UNIT 15	GULF SHORES	AL	36542-2737

1400	Affiliated	2496	Las Vegas Multi-Care Five Star	Five Star Dialysis Center (fka Las Vegas Multi-Care)	2400 TECH CENTER CT		LAS VEGAS	NV	89128-0804
1401	Affiliated	4358	North Vernon	North Vernon Dialysis	2340 N STATE HWY 7		NORTH VERNON	IN	47265-7183
1402	Affiliated	4316	Olympia	Olympia Dialysis Center	335 COOPER POINT RD NW	STE 15	OLYMPIA	WA	98502-4436
1403	Affiliated	4335	Monroeville	Monroeville Dialysis	2690 MONROEVILLE BLVD		MONROEVILLE	PA	15146-2302
1404	Affiliated	2317	East Galbraith	East Galbraith Dialysis	3877 E GALBRAITH RD	BLDG C	CINCINNATI	OH	45236-1500
1405	Affiliated	2261	San Marcos	San Marcos Dialysis Center	2135 MONTIEL RD	BLDG B	SAN MARCOS	CA	92069-3511
1406	Affiliated	4408	Winter Garden	Winter Garden Dialysis	1222 WINTER GARDEN VINELAND RD	BLDG 3 STE 1	WINTER GARDEN	FL	34787
1407	Affiliated	1926	Bremer County Dialysis	Relo-Bremer County Dialysis (5022-Cedar Valley Waverly Dialysis)	220 10th ST SW		WAVERLY	IA	50677-2930
1408	Affiliated	1927	Black Hawk Dialysis	Black Hawk Dialysis (Waterloo)	3421 W 9TH ST		WATERLOO	IA	50702-5401
1409	Affiliated	2218	Downey Landing	Downey Landing Dialysis Center (aka Downey-Kaiser)	11611 BELLFLOWER BLVD		DOWNEY	CA	90241-5408
1410	Affiliated	2427	Tucson Central	Tucson Central Dialysis	2901 E GRANT RD		TUCSON	AZ	85716-2717
1411	Affiliated	4377	Hamburg	Hamburg Dialysis (fka Lexington)	1745 ALYSHEBA WAY		LEXINGTON	KY	40509-9013
1412	Affiliated	2150	Midtown Norfolk	Midtowne Norfolk Dialysis (aka Ghent II)	2201 COLONIAL AVE		NORFOLK	VA	23517-1928
1413	Affiliated	2394	Yonkers II	Yonkers East Dialysis Center	5 ODELL PLZ	STE 131	YONKERS	NY	10701-1406
1414	Affiliated	2364	Caldwell	Caldwell Dialysis Center	821 S SMEED PKWY		CALDWELL	ID	83605-5130
1415	Affiliated	2278	Hesperia	Hesperia Dialysis Center	14135 MAIN ST	UNIT 51	HESPERIA	CA	92345-8097
1416	Affiliated	2339	Sealy	Sealy Dialysis	2242 CHAMPIONSHIP DR		SEALY	TX	77474-8026
1417	Affiliated	2438	Hearne	Hearne Dialysis Center	106 CEDAR ST		HEARNE	TX	77859-2523
1418	Affiliated	1998	Stockton Kidney Center	Stockton Kidney Center	1523 E MARCH LN	STE 2	STOCKTON	CA	95210-5607
1419	Affiliated	5525	University of South Florida	USF Dialysis	10770 N 46TH ST STE A100		TAMPA	FL	33617-3465
1420	Affiliated	4424	Westborough	Westborough Dialysis Center (fka South San Francisco, Daly City)	925 EL CAMINO REAL		SOUTH SAN FRANCISCO	CA	94080-3203
1421	Affiliated	4359	Rush County	Rush County Dialysis	1400 N CHERRY ST		RUSHVILLE	IN	46173-1097
1422	Affiliated	4339	Defuniak Springs	Defuniak Springs Dialysis	1045 US HWY 331 S	DEFUNIAK SHOPPING PLAZA	DEFUNIAK SPRINGS	FL	32435-3375
1423	Affiliated	2181	Foster city	Foster City Dialysis (fka Belmont)	1261 E HILLSDALE BLVD	STE 2	FOSTER CITY	CA	94404-1236
1424	Affiliated	4427	Red Bank	Redbank Village Dialysis (Cincinnati)	3960 RED BANK RD	STE 16	CINCINNATI	OH	45227-3421
1425	Affiliated	4448	Southport	Southport Dialysis Center	1513 N HOWE ST	STE 15	SOUTHPORT	NC	28461-2770
1426	Affiliated	4446	Orlando Park	Orlando Park Dialysis	5397 W COLONIAL DR	STE 12	ORLANDO	FL	32808-7647
1427	Affiliated	4431	Harrisburg	Harrisburg Dialysis Center (aka Concord)	3310 PERRY ST		CONCORD	NC	28027-3901
1428	Affiliated	2352	Waycross	Satilla River Dialysis	308 CARSWELL AVE		WAYCROSS	GA	31501-4762
1429	Affiliated	4455	Timberlake	Timberlake Dialysis (Kansas City)	12110 HOLMES RD		KANSAS CITY	MO	64145-1707
1430	Affiliated	4447	Dexter	Dexter Dialysis	2010 N OUTER RD		DEXTER	MO	63841
1431	Affiliated	4426	Norwood	Norwood Dialysis (Cincinnati)	2300 WALL ST		CINCINNATI	OH	45212-2781
1432	Affiliated	4420	Peachtree City	Peachtree City Dialysis	2830 W HWY 54	BLDG 1 STE J AND K	PEACHTREE CITY	GA	30269-1026
1433	Affiliated	5516	Rogue Valley	Rogue Valley Dialysis	760 GOLF VIEW DR	UNIT 1	MEDFORD	OR	97504-9685
1434	Affiliated	5517	Redwood Dialysis	Redwood Dialysis	201 SW L ST		GRANTS PASS	OR	97526-2913
1435	Affiliated	4410	Tucker	Tucker Dialysis	4434 HUGH HOWELL RD		TUCKER	GA	30084-4905
1436	Affiliated	4386	Shepherdsville	Shepherdsville Dialysis Center	150 BROOKS WAY	STE 15	BROOKS	KY	40109-6105
1437	Affiliated	4399	Muscle Shoals	Muscle Shoals Dialysis	712 STATE ST		MUSCLE SHOALS	AL	35661-2940
1438	Affiliated	2463	Tel Huron	Tel-Huron Dialysis (fka Waterford)	225 SUMMIT DR		WATERFORD	MI	48328-3364
1439	Affiliated	2481	Cherry Valley	Cherry Valley Dialysis (aka Newark)	1627 W MAIN ST		NEWARK	OH	43055-1345
1440	Affiliated	2437	Taylor	Taylor Dialysis	3100 W 2ND ST		TAYLOR	TX	76574
1441	Affiliated	4430	Forrest City	Forrest City Dialysis	1501 N WASHINGTON ST		FORREST CITY	AR	72335-2152
1442	Affiliated	4309	Kaufman	Kaufman Dialysis	2851 MILLENNIUM DR		KAUFMAN	TX	75142-8865
1443	Affiliated	4348	Artesia	Artesia Dialysis	702 N 13TH ST		ARTESIA	NM	88210-1166
1444	Affiliated	2381	North Hills	North Hills Dialysis	7927 BOULEVARD 26		NORTH RICHLAND HILLS	TX	76180-7103
1445	Affiliated	4428	Millington	Millington Dialysis	8510 WILKINSVILLE RD	STE 121	MILLINGTON	TN	38053-1537
1446	Affiliated	5519	Adams County	Adams County Dialysis	436 N 10TH ST		QUINCY	IL	62301-4152
1447	Affiliated	5518	Hannibal	Hannibal Dialysis	3140 PALMYRA ROAD		HANNIBAL	MO	63401-2204
1448	Affiliated	5520	Pittsfield	Pittsfield Dialysis	640 W WASHINGTON ST		PITTSFIELD	IL	62363-1350
1449	Affiliated	4463	Villa of Waterbury	Villa of Waterbury (fka Kissker Microcenter)	929 WATERBURY FALLS DR		O'FALLON	MO	63368-2202
1450	Affiliated	2465	Washington DC Nursing Facility	Washington DC Nursing Facility	2425 25TH ST SE		WASHINGTON	DC	20020-3408
1451	Affiliated	4325	Moscow	Moscow Dialysis Center	212 RODEO DR	STE 11	MOSCOW	ID	83843-9798
1452	Affiliated	2402	Chinook Kidney Center	Chinook Kidney Center (aka Richland)	1315 AARON DR	BLDG C1	RICHLAND	WA	99352-4678
1453	Affiliated	4416	River's Edge	Rivers Edge Dialysis (aka Athens)	1006 E STATE ST	STE B	ATHENS	OH	45701-2121

1454	Affiliated	5530	North Glendale Dialysis	North Glendale Dialysis	1505 WILSON TER STE 190		GLENDALE	CA	91206-4015
1455	Affiliated	4373	Everett	Everett Dialysis Center (fka Snohomish 2)	8130 EVERGREEN WAY		EVERETT	WA	98203-6419
1456	Affiliated	2069	Harbourview	Harbour View Dialysis (aka Churchland, Suffolk)	1039 CHAMPIONS WAY	BLDG 4	SUFFOLK	VA	23435-3761
1457	Affiliated	4357	Capelville	Capelville Dialysis Center	7008 E SHELBY DR		MEMPHIS	TN	38125-3416
1458	Affiliated	4485	San Leandro	San Leandro Dialysis (Bayfair Mall)	15555 E 14TH	STE 52	SAN LEANDRO	CA	94578-1900
1459	Affiliated	4317	Mill Creek	Mill Creek Dialysis Center (Snohomish/Everett)	18001 BOTHELL EVERETT HWY	STE 112	BOTHELL	WA	98012-1661
1460	Affiliated	2470	Seaview	Seaview Dialysis Center	101 18TH ST SE		LONG BEACH	WA	98631
1461	Affiliated	2461	East Tampa	East Tampa Dialysis (Ybor City)	1701 E 9TH AVE		YBOR CITY	FL	33605-3801
1462	Affiliated	5522	Detroit Road Dialysis	Detroit Road Dialysis	7901 DETROIT AVE		CLEVELAND	OH	44102-2828
1463	Affiliated	5523	St V Quadrangle Dialysis	St V Quadrangle Dialysis	2302 COMMUNITY COLLEGE AVE		CLEVELAND	OH	44115-3117
1464	Affiliated	5524	Westshore Dialysis	Westshore Dialysis	29000 CENTER RIDGE RD		WESTLAKE	OH	44145-5293
1465	Affiliated	2468	Magnolia Dialysis Center Texas	Magnolia Dialysis Center	17649 FM 1488 RD		MAGNOLIA	TX	77354-5235
1466	Affiliated	4471	Highland County	Highland County Dialysis (Hillsboro)	120 ROBERTS LN	STE 4	HILLSBORO	OH	45133-7608
1467	Affiliated	4313	Rockwall	Rockwall Dialysis	2455 RIDGE RD	STE 11	ROCKWALL	TX	75087-5530
1468	Affiliated	4354	Great Northern	Villa of Great Northern (fka North Olmsted)	22710 FAIRVIEW CENTER DR	STE 1	FAIRVIEW PARK	OH	44126-3607
1469	Affiliated	2440	Ridgeland	Ridgeland Dialysis	112 WEATHERSBY ST		RIDGELAND	SC	29936-9514
1470	Affiliated	2334	Livermore	Livermore Dialysis	3201 DOOLAN RD	STE 175	LIVERMORE	CA	94551-9605
1471	Affiliated	2265	Westlake Daly city	Westlake Daly City Dialysis (fka Colma)	2201 JUNIPERO SERRA BLVD	STE 175	DALY CITY	CA	94014-1908
1472	Affiliated	4488	12th Street Covington	12th Street Covington Dialysis	1500 JAMES SIMPSON JR WAY	STE 11	COVINGTON	KY	41011
1473	Affiliated	4384	Bourbon County	Bourbon County Dialysis (fka Paris)	213 LETTON DR	PARIS TOWNE SQUARE	PARIS	KY	40361-2251
1474	Affiliated	2499	Calverton	Calverton Dialysis	4780 CORRIDOR PL	STE C	BELTSVILLE	MD	20705-1165
1475	Affiliated	2199	Aborn	Aborn Dialysis (fka East San Jose)	3162 S WHITE RD	STE 1	SAN JOSE	CA	95148-4019
1476	Affiliated	4438	Clermont	Clermont County Dialysis (Milford,Goshen)	5901 MONTCLAIR BLVD	STE 1	MILFORD	OH	45150-2547
1477	Affiliated	4365	Rita Ranch	Rita Ranch Dialysis (aka Tucson East II)	7355 S HOUGHTON RD	STE 11	TUCSON	AZ	85747-9379
1478	Affiliated	4333	Wake Forest	Wake Forest Dialysis Center	11001 INGLESIDE PL		RALEIGH	NC	27614-8577
1479	Affiliated	4472	Colonial Springs	Colonial Springs Dialysis (fka Powder Springs)	2840 EAST WEST CONNECTOR	STE 35	AUSTELL	GA	30106-6813
1480	Affiliated	2474	Central Dallas	DaVita Central Dallas Dialysis	9500 N CENTRAL EXPY		DALLAS	TX	75231-5002
1481	Affiliated	2188	Sanger	Sanger Sequoia Dialysis	2517 JENSEN AVE	BLDG B	SANGER	CA	93657-2251
1482	Affiliated	4421	Conyers	Conyers Dialysis	1501 MILSTEAD RD NE		CONYERS	GA	30012-3838
1483	Affiliated	4337	Duncanville	Duncanville Dialysis (Cedar Hill)	270 E HIGHWAY 67	STE 1	DUNCANVILLE	TX	75137-4428
1484	Affiliated	4417	Gateway	Gateway Dialysis (Ft.Myers)	5705 LEE BLVD		LEHIGH ACRES	FL	33971-6342
1485	Affiliated	4487	Derry	Derry Dialysis	1 ACTION BLVD	STE 2	LONDONDERRY	NH	03053-3428
1486	Affiliated	4461	Villa of Wentzville Microcenter	Villa of Wentzville (Microcenter)	1126 W PEARCE BLVD	STE 116 & 118	WENTZVILLE	MO	63385-1053
1487	Affiliated	1925	Buchanan County Dialysis	Buchanan County Dialysis (Independence)	1600 1ST ST E		INDEPENDENCE	IA	50644-3155
1488	Affiliated	2450	Hoosier Hills	Hoosier Hills Dialysis	143 S KINGSTON DR		BLOOMINGTON	IN	47408-6342
1489	Affiliated	4492	Palm Breeze	Palm Breeze Dialysis (fka North Port)	14942 TAMIAMI TRL	STE E	NORTH PORT	FL	34287-2705
1490	Affiliated	4362	Big Oaks	Big Oaks Dialysis	5623 W TOUHY AVE		NILES	IL	60714-4019
1491	Affiliated	4407	Pinellas West Shore	Pinellas West Shore Dialysis	3451 66TH ST N	STE A	ST PETERSBURG	FL	33710-1568
1492	Affiliated	2267	Plano	Plano Dialysis	481 SHILOH RD	STE 1	PLANO	TX	75074-7231
1493	Affiliated	4350	Fairview	Villa of Fairview Park (fka Fairview Park Dialysis)	19050 LORAIN RD		FAIRVIEW PARK	OH	44126-1915
1494	Affiliated	2380	Ave Marisa	Ave Maria Dialysis (fka Immokalee)	5340 USEPPA DR		AVE MARIA	FL	34142-5051
1495	Affiliated	5037	Warminster	Franklin Commons Dialysis (fka Warminster)	720 JOHNSVILLE BLVD	STE 8	WARMINSTER	PA	18974-3546
1496	Affiliated	2446	Ripley	Ripley Dialysis Center	854 HWY 51 S		RIPLEY	TN	38063-5536
1497	Affiliated	5538	St Charles / Riverbend	River Bend Dialysis (St. Charles Parish)	1057 PAUL MAILLARD RD	ST B135	LULING	LA	70070-4349
1498	Affiliated	5570	Midwest Springfield	Midwest Springfield Dialysis	2200 N LIMESTONE ST STE 104		SPRINGFIELD	OH	45503-2692
1499	Affiliated	5571	Midwest Fairborn	Midwest Fairborn Dialysis	1266 N BROAD ST		FAIRBORN	OH	45324-5549
1500	Affiliated	5572	Midwest Urbana	Midwest Urbana Dialysis	1430 E US HIGHWAY 36		URBANA	OH	43078-9112
1501	Affiliated	5531	Camarillo	Camarillo Dialysis	2438 N PONDEROSA DR STE C101		CAMARILLO	CA	93010-2465
1502	Affiliated	5532	Thousand Oaks	Thousand Oaks Dialysis	375 ROLLING OAKS DR STE 100		THOUSAND OAKS	CA	91361-1024
1503	Affiliated	5533	Simi Valley	Simi Valley Dialysis	2950 SYCAMORE DR STE 100		SIMI VALLEY	CA	93065-1210
1504	Affiliated	5534	Santa Paula	Santa Paula Dialysis	253 MARCH ST		SANTA PAULA	CA	93060-2511
1505	Affiliated	5548	Ventura	Ventura Dialysis	2705 LOMA VISTA RD STE 101		VENTURA	CA	93003-1596
1506	Affiliated	4468	Villa of St. John	Villa of St John (Crossing Microcenter-MO)	9030 SAINT CHARLES ROCK RD		SAINT LOUIS	MO	63114-4246
1507	Affiliated	4372	Whidbey Island	Whidbey Island Dialysis Center	32650 STATE RD 20	BLDG E STE 18	OAK HARBOR	WA	98277-2641

1508	Affiliated	4437	Baytown	Baytown Dialysis	4665 GARTH RD	STE 9	BAYTOWN	TX	77521-2261
1509	Affiliated	2475	Highland Ranch	Highland Ranch Dialysis Center	7223 CHURCH ST STE A14		HIGHLAND	CA	92346-6837
1510	Affiliated	4474	Tiptonville	Tiptonville Dialysis	795 HAMRA ST		TIPTONVILLE	TN	38079-1663
1511	Affiliated	1902	Carabello	Carabello Dialysis Center	757 E WASHINGTON BLVD		LOS ANGELES	CA	90021-3016
1512	Affiliated	5573	Palmetto	Palmetto Dialysis	317 PROFESSIONAL PARK RD		CLINTON	SC	29325-7625
1513	Affiliated	5574	Greer South	Greer South Dialysis	3254 BRUSHY CREEK RD		GREER	SC	29650-1000
1514	Affiliated	5575	Greenville West End	Greenville West End Dialysis	605 S ACADEMY ST		GREENVILLE	SC	29601-2407
1515	Affiliated	5576	Fountain Inn	Fountain Inn Dialysis	298 CHAPMAN RD		FOUNTAIN INN	SC	29644-6129
1516	Affiliated	5558	Sellersville	Sellersville Dialysis	1112 OLD BETHLEHEM PIKE		SELLERSVILLE	PA	18960-1423
1517	Affiliated	5564	Humbolt Ridge	Humboldt Ridge Dialysis	2211 N HUMBOLDT BLVD		MILWAUKEE	WI	53212-3507
1518	Affiliated	5565	West Appleton	West Appleton Dialysis	10130 W APPLETON AVE	STE 5	MILWAUKEE	WI	53225-2579
1519	Affiliated	5566	Bay Shore	Bay Shore Dialysis	5650 N GREEN BAY AVE	STE 15	GLENDALE	WI	53209-4449
1520	Affiliated	5567	South Ridge	South Ridge Dialysis	4848 S 76TH ST	STE 1	GREENFIELD	WI	53220-4361
1521	Affiliated	5568	Bluemound	Bluemound Dialysis	601 N 99TH ST	STE 1	MILWAUKEE	WI	53226-4362
1522	Affiliated	4385	Versailles	Versailles Dialysis	480 LEXINGTON RD		VERSAILLES	KY	40383-1918
1523	Affiliated	5035	Magnolia Oaks	Magnolia Oaks Dialysis (aka Hinesville)	2377 HWY 196 W		HINESVILLE	GA	31313-8036
1524	Affiliated	4489	Mesa County	Mesa County Dialysis (Grand Junction)	561 25 RD	STE D	GRAND JUNCTION	CO	81505-1303
1525	Affiliated	297	West Bloomfield	West Bloomfield Dialysis	6010 W MAPLE RD	STE 215	WEST BLOOMFIELD	MI	48322-4406
1526	Affiliated	5550	Crystal Springs Dialysis	Crystal Springs Dialysis	720 COG CIRCLE		CRYSTAL LAKE	IL	60014-7301
1527	Affiliated	5551	Cobblestone Dialysis	Cobblestone Dialysis	934 CENTER ST	STE A	ELGIN	IL	60120-2125
1528	Affiliated	5586	Oak Springs Dialysis	Oak Springs Dialysis	764 LOCUST AVE		WASHINGTON	PA	15301-2756
1529	Affiliated	5010	Maple Valley Plaza	Maple Valley Plaza Dialysis (Farmington)	649 MAPLE VALLEY DR		FARMINGTON	MO	63640-1993
1530	Affiliated	4433	Floyd Curl	Floyd Curl Dialysis (San Antonio)	9238 FLOYD CURL DR	STE 12	SAN ANTONIO	TX	78240-1691
1531	Affiliated	2387	Mission Valley	Mission Valley Dialysis (aka McAllen)	1203 ST CLAIRE BLVD 9B		MISSION	TX	78572-6601
1532	Affiliated	2180	Silver Lake	Silver Lake Dialysis	2723 W TEMPLE ST		LOS ANGELES	CA	90026-4723
1533	Affiliated	5578	Lake Park Dialysis	Lake Park Dialysis	1531 E HYDE PARK BLVD		CHICAGO	IL	60615-3039
1534	Affiliated	5579	Stoney Island Dialysis	Stony Island Dialysis	8725 S STONY ISLAND AVE		CHICAGO	IL	60617-2709
1535	Affiliated	5580	Woodlawn Dialysis	Woodlawn Dialysis	1164 E 55TH ST		CHICAGO	IL	60615-5115
1536	Affiliated	4440	Jefferson Ave	Jefferson Avenue Dialysis (aka Village Parkway, Hampton)	11234 JEFFERSON AVE		NEWPORT NEWS	VA	23601-2207
1537	Affiliated	4381	Robinson	Robinson Dialysis	1215 N ALLEN ST	STE B	ROBINSON	IL	62454-1100
1538	Affiliated	4320	Gateway Plaza	Gateway Plaza Dialysis (aka Willowbrook)	1580 W ROSECRANS AVE		COMPTON	CA	90222-3700
1539	Affiliated	4329	Pasadena Foothills	Pasadena Foothills Dialysis (fka Arcadia)	3722 E COLORADO BLVD		PASADENA	CA	91107-3803
1540	Affiliated	914	Live Oak Dialysis	Live Oak Dialysis (fka San Antonio)	6700 RANDOLPH BLVD	STE 11	LIVE OAK	TX	78233-4222
1541	Affiliated	5031	Frackville	Frackville Dialysis (aka JV_Pottsville)	801 SCHUYLKILL MALL		FRACKVILLE	PA	17931-2524
1542	Affiliated	5038	Castor	Cottman Kidney Center (Castor, NE Philadelphia)	7198 CASTOR AVE		PHILADELPHIA	PA	19149-1105
1543	Affiliated	4351	Villa of North Ridgevelle	Villa of North Ridgeville	35143 CENTER RIDGE RD		NORTH RIDGEVILLE	OH	44039-3089
1544	Affiliated	5503	Thorn Run Dialysis	Thorn Run Dialysis	1136 THORN RUN RD	STE J1	MOON TOWNSHIP	PA	15108
1545	Affiliated	5504	Allegheny Valley	Allegheny Valley Dialysis	1620 PACIFIC AVE	HEIGHTS PLAZA SHOPPING CENTER	NATRONA HEIGHTS	PA	15065-2101
1546	Affiliated	5506	Northside	Northside Dialysis (fka Allegheny General)	320 E NORTH AVE	4TH FL, SOUTH TOWER	PITTSBURGH	PA	15212-4756
1547	Affiliated	5507	Somerset	Somerset County Dialysis	229 S KIMBERLY AVE	STE 1	SOMERSET	PA	15501-2022
1548	Affiliated	4493	Carthage	Carthage Dialysis	165 SAVANNAH GARDENS DR		CARTHAGE	NC	28327
1549	Affiliated	2464	Riverwood Dialysis	Riverwood Dialysis (fka Nine Mile, Tree City & Southfield)	24467 W 10 MILE RD		SOUTHFIELD	MI	48033-2931
1550	Affiliated	4415	Burton	Burton Dialysis (fka Flint Northeast)	4015 DAVISON RD		BURTON	MI	48509-1401
1551	Affiliated	4490	Black Canyon	Black Canyon Dialysis (Montrose)	3421 S RIO GRANDE AVE	UNIT D	MONTROSE	CO	81401-4840
1552	Affiliated	4394	Memphis Midtown	Memphis Midtown Dialysis	3430 SUMMER AVE		MEMPHIS	TN	38122-3610
1553	Affiliated	5539	Stonecrest Dialysis	Stonecrest Dialysis	1302 E STATE ST		ROCKFORD	IL	61104-2228
1554	Affiliated	4412	West Plano	West Plano Dialysis	5036 TENNYSON PKWY		PLANO	TX	75024-3002
1555	Affiliated	2217	Redwood City	Redwood City Dialysis (fka Palo Alto)	1000 MARSHALL ST		REDWOOD CITY	CA	94063-2027
1556	Affiliated	1592	State Fair	State Fair Dialysis	19800 WOODWARD AVE		DETROIT	MI	48203-5102
1557	Affiliated	5589	ADC of Ft Lauderdale	Advanced Dialysis Center of Fort Lauderdale	911 E OAKLAND PARK BLVD		OAKLAND PARK	FL	33334-2725
1558	Affiliated	5008	Dover	Dover Community Dialysis (New Philadelphia)	899 E IRON AVE		DOVER	OH	44622-2097
1559	Affiliated	5045	McMinnville	McMinnville Dialysis	200 NE NORTON LN		MCMINNVILLE	OR	97128-8470
1560	Affiliated	5007	Sparta	Sparta Dialysis	150 SAM WALTON DR	STE 8	SPARTA	TN	38583-8818
1561	Affiliated	4409	Kendall	Kendall Kidney Center (fka Dadeland)	8364 MILLS DR	STE 174	MIAMI	FL	33183-4806

1562	Affiliated	4397	Abbeville	Abbeville Dialysis	904 W GREENWOOD ST		ABBEVILLE	SC	29620
1563	Affiliated	2453	Delta View	Delta View Dialysis	1150 E LELAND RD		PITTSBURG	CA	94565-5319
1564	Affiliated	5013	Wolf River	Wolf River Dialysis (Germantown)	7990 TRINITY PL	STE 11	CORDOVA	TN	38018-7731
1565	Affiliated	5601	San Luis Obispo Dialysis	San Luis Obispo Dialysis	1043 MARSH ST		SAN LUIS OBISPO	CA	93401-3629
1566	Affiliated	5602	Templeton Dialysis	Templeton Dialysis	1310 LAS TABLAS RD	STE 11	TEMPLETON	CA	93465-9746
1567	Affiliated	5603	Pismo Beach Dialysis	Pismo Beach Dialysis	320 JAMES WAY	STE 11	PISMO BEACH	CA	93449-2813
1568	Affiliated	5583	Lincoln Way Dialysis	Lincoln Way Dialysis	1303 LINCOLN WAY STE A		WHITE OAK	PA	15131-1603
1569	Affiliated	5023	Grundy Center	Grundy Center Dialysis	101 E J AVENUE		GRUNDY CENTER	IA	50638-2031
1570	Affiliated	3862	Pickens County	Pickens County Dialysis	289 WILLIAM E HILL DR.	STE A	CARROLLTON	AL	35447
1571	Affiliated	5032	Willow Grove	Willow Grove Dialysis (Abington-Maplewood)	1849 DAVISVILLE RD		WILLOW GROVE	PA	19090-4111
1572	Affiliated	2255	Amherst	Amherst Dialysis (Lorain County)	3200 COOPER FOSTER PRK RD W		LORAIN	OH	44053-3654
1573	Affiliated	2220	South Fort Worth	South Fort Worth Dialysis	6260 SOUTHWEST BLVD		BENBROOK	TX	76109-6906
1574	Affiliated	5521	Jerseyville Dialysis	Jerseyville Dialysis	917 S STATE ST		JERSEYVILLE	IL	62052-2344
1575	Affiliated	5605	Independence County Dialysis	Independence County Dialysis	1700 HARRISON ST	STE F	BATESVILLE	AR	72501-7315
1576	Affiliated	5606	Jackson County Dialysis	Jackson County Dialysis	1912 MCLAIN ST	PRATT SQUARE	NEWPORT	AR	72112-3659
1577	Affiliated	5607	Searcy Dialysis	Searcy Dialysis	3208 LANGLEY DR		SEARCY	AR	72143-6020
1578	Affiliated	5608	Springhill Dialysis	Springhill Dialysis	3401 SPRINGHILL DR	STE 19	NORTH LITTLE ROCK	AR	72117-2925
1579	Affiliated	5609	Pulaski County Dialysis	Pulaski County Dialysis	202 JOHN HARDEN DR		JACKSONVILLE	AR	72076-3775
1580	Affiliated	5610	Little Rock Midtown Dialysis	Little Rock Midtown Dialysis	2 LILE CT	STE 12A	LITTLE ROCK	AR	72205-6241
1581	Affiliated	5611	Saline County Dialysis	Saline County Dialysis	1200 N MAIN ST	STE 2	BENTON	AR	72015-3341
1582	Affiliated	5612	Conway Dialysis	Conway Dialysis	2445 CHRISTINA LANE		CONWAY	AR	72034
1583	Affiliated	5614	Valley Baptist Harlingen Dialysis	Valley Baptist-Harlingen Dialysis	2220 HAINE DR STE 40		HARLINGEN	TX	78550-8584
1584	Affiliated	5615	Valley Baptist Raymondville Dialysis	Valley Baptist-Raymondville Dialysis	894 FM 3168		RAYMONDVILLE	TX	78580-4519
1585	Affiliated	2455	Hawaiian Gardens	Hawaiian Gardens Dialysis	12191 226TH ST		HAWAIIAN GARDENS	CA	90716-1510
1586	Affiliated	2310	Huntington park	Huntington Park Dialysis	5942 RUGBY AVE		HUNTINGTON PARK	CA	90255-2803
1587	Affiliated	2462	Poinciana	Poinciana Dialysis	1002 CYPRESS PKWY		KISSIMMEE	FL	34758-3328
1588	Affiliated	5005	Southtowns	Southtowns Dialysis (Hamburg)	4910 CAMP RD	STE 1	HAMBURG	NY	14075-2617
1589	Affiliated	5635	Parma Heights Dialysis	Parma Heights Dialysis	9050 N CHURCH DR		PARMA HEIGHTS	OH	44130-4701
1590	Affiliated	5636	Hillard Dialysis	Hilliard Dialysis	19133 HILLIARD BLVD		ROCKY RIVER	OH	44116-2907
1591	Affiliated	5546	Pacific Dialysis	Pacific Dialysis	2351 CLAY ST	FL 4	SAN FRANCISCO	CA	94115-1931
1592	Affiliated	5547	Davies Dialysis	Davies Dialysis	45 CASTRO ST	SOUTH TOWER 2ND FL	SAN FRANCISCO	CA	94114-1032
1593	Affiliated	4486	Newburgh	Newburgh Dialysis	4311 HIGHWAY 261	STE A	NEWBURGH	IN	47630-2653
1594	Affiliated	5052	Enterprise	Enterprise Dialysis (fka Geneva)	6002 BOLL WEEVIL CIRCLE		ENTERPRISE	AL	36330-9420
1595	Affiliated	4387	State Line	State Line Dialysis	2049 E SHELBY DR		MEMPHIS	TN	38116-7639
1596	Affiliated	5108	Cape Coral North	Cape Coral North Dialysis	1315 SE 8TH TERRACE		CAPE CORAL	FL	33990-3213
1597	Affiliated	5044	Willard Ave	Willard Avenue Dialysis (Newington)	445E WILLARD AVE		NEWINGTON	CT	06111-2318
1598	Affiliated	4363	West Lawn	West Lawn Dialysis (aka Midway)	7000 S PULASKI RD		CHICAGO	IL	60629-5842
1599	Affiliated	4353	Villa of Lakewood	Villa of Lakewood (Northcoast)	14050 MADISON AVE		LAKEWOOD	OH	44107-4530
1600	Affiliated	5054	North Carrolton	North Carrollton Dialysis (Parkview)	195 PARKWOOD CIRCLE		CARROLLTON	GA	30117-8756
1601	Affiliated	5620	Sikeston Jaycee Regional Dialysis	Sikeston Jaycee Regional Dialysis	135 PLAZA DR STE 101		SIKESTON	MO	63801-5148
1602	Affiliated	2244	Radcliff	Radcliff Dialysis	180 E LINCOLN TRAIL BLVD		RADCLIFF	KY	40160-1254
1603	Affiliated	4452	McAfee	McAfee Dialysis (Candler Road Decatur)	1987 CANDLER RD	STE C	DECATUR	GA	30032-4212
1604	Affiliated	5036	Avon	Avon Dialysis (Indy West)	9210 ROCKVILLE RD	STE D	INDIANAPOLIS	IN	46234-2669
1605	Affiliated	2485	Anaheim West	Anaheim West Dialysis	1821 W LINCOLN AVE		ANAHEIM	CA	92801-6731
1606	Affiliated	5043	Port Saint Joe	Port Saint Joe Dialysis	3871 HIGHWAY 98 E	STE 11	PORT ST. JOE	FL	32456-5318
1607	Affiliated	5056	Hayward Mission Hills	Hayward Mission Hills Dialysis	1661 INDUSTRIAL PKWY W		HAYWARD	CA	94544-7046
1608	Affiliated	2472	Cypress Woods Northwest	Cypress Woods Northwest Dialysis (aka NW Houston)	20320 NORTHWEST FWY	STE 1	HOUSTON	TX	77065-
1609	Affiliated	5641	Willow Creek Dialysis	Willow Creek Dialysis	1139 WARWICK WAY		RACINE	WI	53406-5661
1610	Affiliated	5642	Harbor View Dialysis	Harbor View Dialysis	818 6TH ST		RACINE	WI	53403-1176
1611	Affiliated	4451	Red River	Red River Dialysis (fka Shreveport South)	9205 LINWOOD AVE		SHREVEPORT	LA	71106-7006
1612	Affiliated	2392	South Dade Kidney Center	South Dade Kidney Center (Coral Reef)	11040 SW 184TH ST		CUTLER BAY	FL	33157-6602
1613	Affiliated	5604	Niagara Falls Memorial Dialysis	Niagara Falls Memorial Dialysis (was NF Kidney Care Center)	621 10TH ST		NIAGARA FALLS	NY	14301-1813
1614	Affiliated	5617	Silverado Dialysis	Silverado Dialysis	1100 TRANCAS ST	STE 266 AND 267	NAPA	CA	94558-2921
1615	Affiliated	5621	Prairie River Dialysis	Prairie River Dialysis	601 S CENTER AVE		MERRILL	WI	54452-3404

1616	Affiliated	5622	Stevens Point Dialysis	Stevens Point Dialysis	900 ILLINOIS AVE	5th FLR	STEVENS POINT	WI	54481-2885
1617	Affiliated	5623	Grand Seasons Dialysis	Grand Seasons Dialysis	190 GRAND SEASONS DR		WAUPACA	WI	54981-8219
1618	Affiliated	5624	Wausau Dialysis	Wausau Dialysis	2600 STEWART AVE	STE 144	WAUSAU	WI	54401-1403
1619	Affiliated	5625	Pine Crest Dialysis	Pine Crest Dialysis	232 S COURTNEY ST	STE 2	RHINELANDER	WI	54501-3319
1620	Affiliated	5626	Meadow Lane Dialysis	Meadow Lane Dialysis	1120 PINE ST		STANLEY	WI	54768-1297
1621	Affiliated	5627	Wisconsin Rapids Dialysis	Wisconsin Rapids Dialysis	1041B HILL ST		WISCONSIN RAPIDS	WI	54494-5221
1622	Affiliated	5628	Marshfield Dialysis	Marshfield Dialysis	123 NORTHRIDGE ST		MARSHFIELD	WI	54449-8341
1623	Affiliated	5629	Northern Star Dialysis	Northern Star Dialysis	311 ELM ST		WOODRUFF	WI	54568-9190
1624	Affiliated	5632	Ames Mary Greeley Dialysis	Ames Mary Greeley Dialysis	2322 E 13TH ST		AMES	IA	50010-5669
1625	Affiliated	5633	Marshalltown Mary Greeley Dialysis	Marshalltown Mary Greeley Dialysis	3120 S 2ND ST		MARSHALLTOWN	IA	50158-4614
1626	Affiliated	5634	Iowa Falls Mary Greeley Dialysis	Iowa Falls Mary Greeley Dialysis	701 WASHINGTON AVE		IOWA FALLS	IA	50126-2100
1627	Affiliated	5649	Dialysis Center of Hutchinson	Dialysis Center of Hutchinson	1901 N WALDRON ST		HUTCHINSON	KS	67502-1129
1628	Affiliated	5650	Amarillo Dialysis	Amarillo Dialysis	8604 S COULTER ST		AMARILLO	TX	79119-7379
1629	Affiliated	4495	Sagemeadow	Sagemeadow Dialysis (Houston)	10923 SCARSDALE BLVD		HOUSTON	TX	77089-6024
1630	Affiliated	5009	McKinney	McKinney Dialysis	4717 MEDICAL CENTER DR		MCKINNEY	TX	75069-1870
1631	Affiliated	4499	Scottsburg	Scottsburg Dialysis	1619 W MCCLAIN AVE		SCOTTSBURG	IN	47170-1161
1632	Affiliated	2108	Snake River	Snake River Dialysis Center (fka Blackfoot)	1491 PARKWAY DR		BLACKFOOT	ID	83221-1667
1633	Affiliated	5034	Southpoint	Southpoint Dialysis (aka Durham South)	415 W NC HWY 54		DURHAM	NC	27713-7516
1634	Affiliated	5643	Burlingame Dialysis	Burlingame Dialysis	1720 EL CAMINO REAL	STE 12	BURLINGAME	CA	94010-3225
1635	Affiliated	5644	Mills Dialysis	Mills Dialysis	100 S SAN MATEO DR		SAN MATEO	CA	94401-3805
1636	Affiliated	5646	Stuebenville	Steubenville Dialysis	4000 JOHNSON RD		STEUBENVILLE	OH	43952-2300
1637	Affiliated	5656	Premiere Kidney Center of Newark	Premiere Kidney Center of Newark	65 SOUTH TERRACE AVE		NEWARK	OH	43055-1355
1638	Affiliated	5029	Calvine	Calvine Dialysis (Sacramento)	8243 E STOCKTON BLVD	STE 1	SACRAMENTO	CA	95828-8200
1639	Affiliated	4445	Durham Corners dialysis	Durham Corners Dialysis (South Plainfield)	241 DURHAM AVE		SOUTH PLAINFIELD	NJ	07080-2504
1640	Affiliated	4475	Mt Morris	Mt Morris Dialysis (aka North Flint)	6141 N. SAGINAW RD		MOUNT MORRIS	MI	48458-2403
1641	Affiliated	2176	Grandview	Grandview Dialysis	13812 S US HIGHWAY 71		GRANDVIEW	MO	64030-3685
1642	Affiliated	4450	Lemoore	Lemoore Dialysis	1345 W BUSH ST		LEMOORE	CA	93245-3303
1643	Affiliated	5663	Middlebrook Dialysis	Middlebrook Dialysis	12401 MIDDLEBROOK RD	STE 16	GERMANTOWN	MD	20874-1523
1644	Affiliated	5664	Catoctin Dialysis	Catoctin Dialysis	405 W 7TH ST		FREDERICK	MD	21701-4505
1645	Affiliated	5648	Central New York Dialysis Center	Central New York Dialysis Center	910 ERIE BLVD E		SYRACUSE	NY	13210-1060
1646	Affiliated	5014	South Jackson	South Jackson Dialysis	46 HARTS BRIDGE RD		JACKSON	TN	38301-7512
1647	Affiliated	2344	Los Alamitos	Los Alamitos Dialysis	4141 KATELLA AVE		LOS ALAMITOS	CA	90720-3406
1648	Affiliated	5048	Robbinsdale	Robbinsdale Dialysis	3461 W BROADWAY AVE		ROBBINSDALE	MN	55422-2955
1649	Affiliated	5557	Oxnard	Oxnard Dialysis	1900 OUTLET CENTER DR		OXNARD	CA	93036-0677
1650	Affiliated	4429	Marked Tree	DNVO-Marked Tree-AR	216 HESTER PARKER DR		MARKED TREE	AR	72365-2023
1651	Affiliated	5669	Louisa Dialysis	Louisa Dialysis	2145 HWY 2565		LOUISA	KY	41230
1652	Affiliated	5670	Point Pleasant Dialysis	Point Pleasant Dialysis	3683 OHIO RIVER DR		POINT PLEASANT	WV	25550
1653	Affiliated	6802	Marion	Renal Care of Marion (P150)	2921 HWY 77	SUITE #8	MARION	AR	72364-2368
1654	Affiliated	6803	Osceola	Osceola Dialysis (P151)	1420 W KEISER AVE		OSCEOLA	AR	72370-2800
1655	Affiliated	6805	Cottonwood	Cottonwood Dialysis (P153)	203 S CANDY LANE		COTTONWOOD	AZ	86326-8115
1656	Affiliated	6808	Prescott	Prescott Dialysis (P157)	980 WILLOW CREEK RD.	SUITE 11	PRESCOTT	AZ	86301-1619
1657	Affiliated	6811	Naples	Collier County Dialysis (P160)	6625 HILLWAY CIRCLE		NAPLES	FL	34112
1658	Affiliated	6813	Catersville	Cartersville Renal Center (P162)	203 S TENNESSEE ST		CARTERSVILLE	GA	30120
1659	Affiliated	6816	Arlington Heights Renal Center	Arlington Heights Renal Center (P165)	17 W GOLF RD		ARLINGTON HEIGHTS	IL	60006
1660	Affiliated	6817	Hazel Crest Renal Center	Hazel Crest Renal Center (P166)	3470 W 183RD ST		HAZEL CREST	IL	60429
1661	Affiliated	6818	Loop Renal Center	Loop Renal Center (P167)	1101 S CANAL ST	11TH FLR	CHICAGO	IL	60607
1662	Affiliated	6819	Markham Renal Center	Markham Renal Center (P168)	3053 W 159TH ST		MARKHAM	IL	60426
1663	Affiliated	6821	South Holland Renal Center	South Holland Renal Center (P170)	16136 S PARK AVE.		SOUTH HOLLAND	IL	60473
1664	Affiliated	6822	Waukegan Renal Center	Waukegan Renal Center (P171)	1616 GRAND AVE.	STE. C	WAUKEGAN	IL	60085
1665	Affiliated	6936	Waukegan Home Renal Center	Waukegan Home Training (P172)	1616 GRAND AVE	STE F	WAUKEGAN	IL	60085
1666	Affiliated	6825	Baton Rouge	East Baton Rouge Dialysis (P174)	1333 ONEAL LANE		BATON ROUGE	LA	70816
1667	Affiliated	6826	Houma Renal Center	Houma Dialysis (P175)	108 PICONE RD		HOUMA	LA	70363
1668	Affiliated	6827	Amesbury	Amesbury Renal Center (P177)	24 MORRILL PLACE		AMESBURY	MA	1913
1669	Affiliated	6828	North Andover	North Andover Renal Center (P178)	201 SUTTON ST		NORTH ANDOVER	MA	1845

1670	Affiliated	6829	Canton	Canton Renal Center (P179)	620 E PEACE ST		CANTON	MS	39046-4729
1671	Affiliated	6830	Hazelhurst	Hazlehurst Dialysis (P180)	201 N HALEY ST		HAZLEHURST	MS	39083
1672	Affiliated	6831	Jackson North	Jackson North Dialysis (P181)	571 BEASLEY RD	SUITE B	JACKSON	MS	39206-3042
1673	Affiliated	6832	Jackson South	Jackson South Dialysis (P182)	2460 TERRY RD	SUITE 27-J	JACKSON	MS	39204-5767
1674	Affiliated	6833	Jackson Southwest	Jackson Southwest Dialysis (P183)	1828 RAYMOND RD		JACKSON	MS	39204-4126
1675	Affiliated	6834	Lexington	Renal Care of Lexington (P184)	22579 DEPOT STREET		LEXINGTON	MS	39095
1676	Affiliated	6835	Munroe Falls	Munroe Falls Dialysis (P185)	265 N MAIN ST		MUNROE FALLS	OH	44262
1677	Affiliated	6836	Summit	Summit Renal Center (P186)	73 MASSILLON ROAD		AKRON	OH	44312
1678	Affiliated	6837	White Ponds	White Ponds Dialysis (P187)	534 WHITE POND DRIVE	SUITE A	AKRON	OH	44320
1679	Affiliated	6838	Philadelphia	Memphis Street Renal Center (P189)	3310 24 MEMPHIS ST		PHILADELPHIA	PA	19134-4510
1680	Affiliated	6839	Memphis Central Renal Center	Renal Care of Central Memphis (P190)	1331 UNION AVE.	SUITE 11	MEMPHIS	TN	38104-7559
1681	Affiliated	6840	Memphis Graceland Renal Center	Memphis Graceland Renal Center (P191)	4180 AUBURN RD		MEMPHIS	TN	38116-6202
1682	Affiliated	6841	Memphis Midtown Renal Center	Renal Care of Midtown Memphis (P192)	1166 MONROE AVE.		MEMPHIS	TN	38104-6614
1683	Affiliated	6842	Memphis North Renal Center	Renal Care of Memphis North (P193)	4913 RALEIGH COMMON DR.	SUITE 1	MEMPHIS	TN	38128-2485
1684	Affiliated	6844	Whitehaven Renal Center	Whitehaven Renal Center (P195)	3420 ELVIS PRESLEY BLVD.		MEMPHIS	TN	38116-3260
1685	Affiliated	6846	Edinburg	Edinburg Renal Center (P197)	4302 S SUGAR RD	STE 15	EDINBURG	TX	78539-9140
1686	Affiliated	6847	Mcallen	Dialysis Care of McAllen (P198)	411 LINDBERG AVE		MCALLEN	TX	78501-2921
1687	Affiliated	6848	Weslaco	Weslaco Renal Center (P199)	910 SOUTH UTAH		WESLACO	TX	78596-4270
1688	Affiliated	6849	Marlton Dialysis Center	Marlton Dialysis (P200)	769 E ROUTE 70		MARLTON	NJ	08053-2341
1689	Affiliated	6850	Lawrenceville Renal Center	Lawrenceville Renal Center (P201)	1840 PRINCETON AVE		LAWRENCEVILLE	NJ	8648
1690	Affiliated	6851	Austell Renal Center	Austell Renal Center (P202)	3642 MARATHON CIRCLE		AUSTELL	GA	30106- 6821
1691	Affiliated	6852	Bartlett Renal Center	Bartlett Renal Center (P203_P290_P8203)	2920 COVINGTON PIKE		MEMPHIS	TN	38128-6007
1692	Affiliated	6854	Beaverton Dialysis Center	Beaverton Dialysis Center (P206)	15050 SW KOLL PARKWAY	SUITE J	BEAVERTON	OR	97006-6002
1693	Affiliated	6858	Walker County Dialysis	Walker County Dialysis (P212)	589 HIGHWAY 78W		JASPER	AL	35501
1694	Affiliated	6861	Lakewood	Manatee County Dialysis (P215)	8470 COOPER CREEK BVLD		UNIVERSITY PARK	FL	34201
1695	Affiliated	6862	Canton	Northwest Georgia Dialysis (P216)	260 HOSPITAL RD		CANTON	GA	30114
1696	Affiliated	6863	Buffulo Grove Renal Center	Buffalo Grove Dialysis (P218)	1291 W DUNDEE RD		BUFFALO GROVE	IL	60089
1697	Affiliated	6864	Evanston Renal Center	Evanston Renal Center (P219)	1715 CENTRAL ST		EVANSTON	IL	60201
1698	Affiliated	6865	Schaumburg Renal Center	Schaumburg Renal Center (P220)	1156 S. ROSELLE ROAD		SCHAUMBURG	IL	60193
1699	Affiliated	6937	Schaumburg Home Renal Center	Schaumburg Home Training (P270)	17 W GOLF RD		ARLINGTON HEIGHTS	IL	60005
1700	Affiliated	6866	Blue River Valley	Blue River Valley Renal Center (P222)	2309 S MILLER STREET	SUITE 1	SHELBYVILLE	IN	46176-9350
1701	Affiliated	6867	Central Fort Wayne	Central Fort Wayne Dialysis (P223)	1940 BLUFTON RD		FORT WAYNE	IN	46809-1307
1702	Affiliated	6869	Huntington	Renal Care of Huntington (P225)	3040 WEST PARK DRIVE		HUNTINGTON	IN	46750-8956
1703	Affiliated	6870	Lake Avenue Dialysis Renal Center	Lake Avenue Dialysis (P226)	3525 LAKE AVE	STE 4	FORT WAYNE	IN	46805-5545
1704	Affiliated	6871	Marion County	Marion County Dialysis (P229)	3834 S EMERSON AVE	BLDG B	INDIANAPOLIS	IN	46203-5902
1705	Affiliated	6873	Quad Counties Dialysis	Quad Counties Dialysis (P232)	528 NORTH GRANDSTAFF		AUBURN	IN	46706-1660
1706	Affiliated	6875	South Anthony	South Anthony Dialysis (P234)	7017 SOUTH ANTHONY BLVD.		FORT WAYNE	IN	46816-2016
1707	Affiliated	6876	Brandon	Brandon Renal Center (P235)	101 CHRISTIAN DR		BRANDON	MS	39042-2678
1708	Affiliated	6877	Carthage	Renal Care of Carthage (P236)	312 ELLIS STREET		CARTHAGE	MS	39051
1709	Affiliated	6878	Las Cruces Renal Center	Las Cruces Renal Center (P237)	3961 E LOHMAN AVE	STE 29	LAS CRUCES	NM	88011-8272
1710	Affiliated	6879	Northeast Portland	Northeast Portland Renal Center (P240)	703 NE HANCOCK ST		PORTLAND	OR	97212-3955
1711	Affiliated	6880	Oregon Kidney Center	Dialysis Care of Portland (P241)	5318 NE IRVING		PORTLAND	OR	97213
1712	Affiliated	6881	Sunnyside	Sunnyside Renal Center (P242)	6902 SE LAKE ROAD	SUITE 1	MILWAUKIE	OR	97267-2148
1713	Affiliated	6882	Willamette Valley	Williamette Valley Renal Center (P243)	1510 DIVISION STREET	SUITE 9	OREGON CITY	OR	97045-1572
1714	Affiliated	6883	Northern Philadelphia	Northern Philadelphia Dialysis (P244)	5933 N BROAD ST		PHILADELPHIA	PA	19141
1715	Affiliated	6884	North Providence Renal Center	North Providence Renal Center (P246)	1635 MINERAL SPRING AVE		NORTH PROVIDENCE	RI	02904-4025
1716	Affiliated	6889	Alice Renal Center	Alice Renal Center (P252)	2345 ALICE REGIONAL BLVD.		ALICE	TX	78332-7291
1717	Affiliated	6890	Beeville Renal Center	Beeville Renal Center (P253)	1905 NW FRONTAGE		BEEVILLE	TX	78102-2954
1718	Affiliated	6891	Brownsville	Brownsville Renal Center (P254)	2945 CENTRAL BLVD		BROWNSVILLE	TX	78520-8958
1719	Affiliated	6892	Corpus Christi Renal Center	Corpus Christi Dialysis (P255)	2733 SWANTNER DR		CORPUS CHRISTI	TX	78404-2832
1720	Affiliated	6893	Riverside Renal Center	Riverside Renal Center (P256)	13434 LEOPARD RD. SUITE A17		CORPUS CHRISTI	TX	78410-4466
1721	Affiliated	6894	South Texas Renal Center	South Texas Renal Center (P257)	4301 S PADRE ISLAND DR		CORPUS CHRISTI	TX	78411-4433
1722	Affiliated	6896	South Central Renal Center	Morgan Avenue Dialysis (P258)	2222 S MORGAN AVE	SUITE 114	CORPUS CHRISTI	TX	78405-1900
1723	Affiliated	6898	Northeast Texas	Dialylsis Care of Greenville (P260)	4805 WESLEY ST		GREENVILLE	TX	75401-5649

1724	Affiliated	6899	Downtown Spokane	Downtown Spokane Renal Center (P261)	601 W 5TH ST	SUITE F	SPOKANE	WA	99205
1725	Affiliated	6900	North Spokane	North Spokane Renal Center (P262)	12610 E MARIBEAU PRKWY	STE 1	SPOKANE	WA	99216
1726	Affiliated	6901	Spokane Valley	Spokane Valley Renal Center (P263)	12610 EAST MIRABEAU PKY	SUITE 1	SPOKANE	WA	99208-1450
1727	Affiliated	6902	Kansas City	Kansas City Renal Center (P264)	4333 MADISON AVE		KANSAS CITY	MO	64111-3429
1728	Affiliated	6903	Butler Renal Center	Butler Renal Center (P266)	601 W NURSERY		BUTLER	MO	64730
1729	Affiliated	6904	Harrisonville	Harrisonville Renal Center (P267)	308 GALAXIE AVE		HARRISONVILLE	MO	64701-2084
1730	Affiliated	6905	Marshall Renal Center	Marshall Renal Center (P268)	359 W MORGAN		MARSHALL	MO	65340
1731	Affiliated	6907	Akron Renal Center	Akron Renal Center (P272)	525 EAST MARKET STREET		AKRON	OH	44304-1619
1732	Affiliated	6908	Kendallville Renal Center	Kendallville Renal Center (P274)	602 SAWYER RD		KENDALLVILLE	IN	46755- 2566
1733	Affiliated	6909	Greenwood Holly Renal Center	Greenwood Holly Renal Center (P276)	1533 HOLLY RD		CORPUS CHRISTI	TX	78417-2010
1734	Affiliated	6910	Plainfield Renal Center	Plainfield Renal Center (P278)	8110 NETWORK DR		PLAINFIELD	IN	46168-9024
1735	Affiliated	6911	Green Valley Renal Center	Green Valley Dialysis (P279)	1489 W WARM SPRINGS RD	STE 122	HENDERSON	NV	89014-7637
1736	Affiliated	6912	Las Vegas Renal Center	Las Vegas Renal Center (P280)	2333 RENAISSANCE DR		LAS VEGAS	NV	89119-6191
1737	Affiliated	6913	Lees Summit Renal Center	Lees Summit Renal Center (P281)	100 NE MISSOURI RD	STE 1	LEE'S SUMMIT	MO	64086-4702
1738	Affiliated	6914	Westport Renal Center	Westport Renal Center (P282)	3947 BROADWAY STREET		KANSAS CITY	MO	64111-2516
1739	Affiliated	6915	Greensboro Dialysis Center	Greensboro Dialysis Center (P284)	1220 SILOAM RD		GREENSBORO	GA	30642-0390
1740	Affiliated	5057	Forest Landing	DNVO-Forest Landing Dialysis (Harford Cty, Havre de Grace)-MD	2220 COMMERCE AVE	STE 1	FOREST HILL	MD	21050
1741	Affiliated	5033	University City	DNVO-University City Dialysis (Philadelphia)-PA	3020 MARKET ST	STE 13	PHILADELPHIA	PA	19104-2999
1742	Affiliated	2411	Parkland	DNVO-Parkland Dialysis-WA	311 140TH ST SO		TACOMA	WA	98444
1743	Affiliated	5094	Shelbyville Road	DNVO JV-Shelbyville Road Dialysis (DuPont, Louisville)-KY	4600 SHELBYVILLE RD	STE 31	LOUISVILLE	KY	40207
1744	Affiliated	5106	Fort Wayne West Dialysis	DNVO JV-Fort Wayne South-IN	302 E PETTIT AVE		FORT WAYNE	IN	468063007
1745	Affiliated	5671	Suburban Dialysis	ACQ-5671-NY	1542 MAPLE RD		WILLIAMSVILLE	NY	14221
1746	Affiliated	5672	Gates Circle Dialysis	ACQ-5672-NY	3 GATES CIRCLE	1ST FLR	BUFFALO	NY	14209
1747	Affiliated	5673	Orchard Park Dialysis	ACQ-5673-NY	3801 TAYLOR RD		ORCHARD PARK	NY	14127
1748	Affiliated	2420	TC Jester	DNVO-TC Jester-TX	1800 W 26TH ST	STE 11	HOUSTON	TX	77008-1419
1749	Affiliated	4436	Champions	DNVO-Champions Dialysis (Houston)-TX	4427 FM 1960 W	STE D	HOUSTON	TX	77068-3409
1750	Affiliated	5083	Magic City Dialysis MMC	DNVO-Magic City Dialysis (Birmingham)-AL	300 22ND ST SO		BIRMINGHAM	AL	35233-2209
1751	Affiliated	5084	Steel City Dialysis	DNVO-Steel City Dialysis (Birmingham)-AL	1809 AVE H (ENSLEY)		BIRMINGHAM	AL	35218
1752	Affiliated	5081	Jewel Dialysis	DNVO-Jewel Dialysis (Camellia, Birmingham)-AL	514 WEST TOWN PLAZA		BESSEMER	AL	35020
1753	Affiliated	660	Crystal River	Crystal River Dialysis	7435 W GULF TO LAKE HWY		CRYSTAL RIVER	FL	34429-7834
1754	Affiliated	1936	Southwest Kidney	Estrella Dialysis Center	8410 W THOMAS RD	STE 1 BLDG 1	PHOENIX	AZ	85037-3356
1755	Affiliated	1937	Gilbert Dialysis	Gilbert Dialysis Center	5222 E BASELINE RD	STE 14	GILBERT	AZ	85234-2963
1756	Affiliated	1938	Tempe Dialysis	Tempe Dialysis Center	2149 E WARNER RD	STE 11	TEMPE	AZ	85284-3496
1757	Affiliated	1939	Phoenix Dialysis	Phoenix Dialysis Center	337 E CORONADO RD	STE 11	PHOENIX	AZ	85004-1582
1758	Affiliated	1949	Arrowhead Lakes Dialysis	Arrowhead Lakes Dialysis	20325 N 51ST AVE	BLDG 11, STE 186	GLENDALE	AZ	85308-4625
1759	Affiliated	1952	Mountain Vista Dialysis	Mountain Vista Dialysis Center of Arizona	10238 E HAMPTON AVE	STE 18	MESA	AZ	85209-3317
1760	Affiliated	1977	South Meadows Dialysis Center	South Meadows Dialysis Center	10085 DOUBLE R BLVD	STE 16	RENO	NV	89521-4867
1761	Affiliated	1978	Reno Dialysis Center	Reno Dialysis Center	1500 E 2ND ST	STE 11	RENO	NV	89502-1189
1762	Affiliated	1979	Carson City Dialysis Center	Carson City Dialysis Center	3246 N. CARSON ST	STE 11	CARSON CITY	NV	89706-0248
1763	Affiliated	844	Sparks	Sparks Dialysis Center	4860 VISTA BLVD	STE 1	SPARKS	NV	89436-2817
1764	Affiliated	2015	Sierra Rose Dialysis	Sierra Rose Dialysis Center	685 SIERRA ROSE DR		RENO	NV	89511-2060
1765	Affiliated	2325	Northwest Tucson	Northwest Tucson Dialysis	2945 W INA RD	STE 15	TUCSON	AZ	85741-2366
1766	Affiliated	4355	Mesa	Central Mesa Dialysis Center	1134 E UNIVERSITY DR	STE 11	MESA	AZ	85203-8048
1767	Affiliated	4371	Raven	Raven Dialysis Center	3540 E BASELINE RD	STE 11	PHOENIX	AZ	85042-9628
1768	Affiliated	4374	Brookwood	Brookwood Dialysis Center	8910 N 43RD AVE	STE 17	GLENDALE	AZ	85302-5340
1769	Affiliated	4405	Ocotillo	Ocotillo Dialysis	975 W CHANDLER HEIGHTS RD	UNIT 11	CHANDLER	AZ	85248-5724
1770	Affiliated	4364	Maryvale	Maryvale Dialysis Center	4845 W MCDOWELL RD	STE 1A, 2A, 3A	PHOENIX	AZ	85035-4076
	Affiliated	1995	Winter Park Home PD Dialysis	Winter Park Home PD Dialysis	4100 METRIC DR	STE 2	WINTER PARK	FL	32792-6832
	Affiliated	4302	Lockport HHD PD At Home	Lockport Home Dialysis-PD	16626 W 159TH ST	STE 73	LOCKPORT	IL	60441-8019
	Affiliated	1972	HHD 6183 and PD 1972 in Shreveport	Shreveport Home Dialysis PD	1560 IRVING PL		SHREVEPORT	LA	71101-4604
	Affiliated	5618	Home Dialysis of Dayton – South	Home Dialysis of Dayton-South	4700 SPRINGBORO PIKE	STE 3	MORAINE	OH	45439-1964
	Affiliated	5619	Home Dialysis of Dayton	Home Dialysis of Dayton	627 S EDWIN C MOSES BLVD	STE 2B	DAYTON	OH	45417-3474
	Affiliated	144	Timpanogos Dialysis Center	Timpanogos Dialysis	1055 N 500 W	STE 222	PROVO	UT	84604-3329
	Affiliated	216	HOME DIALYSIS UNIT	Home Dialysis /CAPD Unit	825 S 8TH ST STE 1202		MINNEAPOLIS	MN	55404

Affiliated	284	MANZANITA HOME TRAINING CENTER	Manzanita Home Training Center (fka North CAPD)	4005 MANZANITA AVE	STE 18	CARMICHAEL	CA	95608-1779
Affiliated	408	WICHITA DIALYSIS CENTER	Wichita Dialysis Center-PD Program	909 N TOPEKA ST		WICHITA	KS	67214-3620
Affiliated	978	CENTRAL TULSA DIALYSIS CENTER	Central Tulsa PD	1124 S SAINT LOUIS AVE		TULSA	OK	74120-5413
Affiliated	1748	ST PAUL CAPITAL PD	St. Paul Capital Dialysis at Home-PD (fka Capital PD Program)	555 PARK ST	STE 110	SAINT PAUL	MN	55103-2110
Affiliated	1787	ASH TREE PD	Ash Tree PD	2666 N GROVE INDUSTRIAL DR		FRESNO	CA	93727-1552
Affiliated	1821	EMERALD DIALYSIS	Emerald Dialysis PD (fka Hyde Park PD)	710 W 43RD ST		CHICAGO	IL	60609-3435
Affiliated	1822	OLYMPIA FIELDS DIALYSIS	Olympia Fields PD	4557B LINCOLN HWY	STE B	MATTESON	IL	60443-2385
Affiliated	1823	LAKE COUNTY DIALYSIS	Lake County PD	918 S MILWAUKEE AVE		LIBERTYVILLE	IL	60048-3229
Affiliated	1825	COMPREHENSIVE RENAL CARE-GARY	CRC-Gary PD	4802 BROADWAY		GARY	IN	46408-4509
Affiliated	1826	COMPREHENSIVE RENAL CARE-HAMMOND	CRC-Hammond PD	222 DOUGLAS ST		HAMMOND	IN	46320-1960
Affiliated	1827	COMPREHENSIVE RENAL CARE-VALPARAISO	CRC-Valparaiso PD	606 E LINCOLNWAY		VALPARAISO	IN	46383-5728
Affiliated	1828	COMPREHENSIVE RENAL CARE-MICHIGAN CITY	CRC-Michigan City PD	9836 WEST 400 NORTH		MICHIGAN CITY	IN	46360-2910
Affiliated	1829	MERRILLVILLE PD	Merrillville Dialysis PD	9223 TAFT ST		MERRILLVILLE	IN	46410-6911
Affiliated	1833	NAMPA DIALYSIS CENTER	Nampa Dialysis PD	846 PARKCENTRE WAY		NAMPA	ID	83651-1790
Affiliated	1834	TABLE ROCK DIALYSIS CENTER	Table Rock Dialysis PD	5610 W GAGE ST		BOISE	ID	83706
Affiliated	1835	TWIN FALLS DIALYSIS CENTER	Twin Falls Dialysis PD	1840 CANYON CREST DR		TWIN FALLS	ID	83301-3007
Affiliated	1836	TREASURE VALLEY DIALYSIS CENTER	Treasure Valley Dialysis PD & Home	3525 E LOUISE DR	STE 155	MERIDIAN	ID	83642-6303
Affiliated	1837	GATE CITY DIALYSIS CENTER	Gate City Dialysis PD	2001 BENCH RD		POCATELLO	ID	83201-2033
Affiliated	1838	FOUR RIVERS DIALYSIS CENTER	Four Rivers Dialysis PD	515 EAST LN		ONTARIO	OR	97914-3953
Affiliated	1869	LOWRY DIALYSIS CENTER	Lowry Dialysis PD	7465 E 1ST AVE	STE A	DENVER	CO	80230-6877
Affiliated	1905	BURLEY DIALYSIS CENTER	Burley Dialysis PD	741 N OVERLAND AVE		BURLEY	ID	83318-3440
Affiliated	1909	TURFWAY PD DIALYSIS	Turfway PD Training	11 SPIRAL DR	STE 15A	FLORENCE	KY	41042-1394
Affiliated	1910	MARYVILLE DIALYSIS	Maryville Dialysis PD	2136B VADALABENE DR		MARYVILLE	IL	62062-5632
Affiliated	1917	PDL ANNEX-PD	PDL Annex-PD (PDL=Physician Dialysis Lancaster)	2110 HARRISBURG PIKE	STE 310	LANCASTER	PA	17601-2644
Affiliated	1924	KANKAKEE COUNTY DIALYSIS	Kankakee County Dialysis PD	581 WILLIAM R LATHAM SR DR	STE 104	BOURBONNAIS	IL	60914-2439
Affiliated	1946	SNAKE RIVER DIALYSIS PD	DNVO-Snake River Dialysis PD (fka Blackfoot)-ID	1491 PARKWAY DR		BLACKFOOT	ID	83221-1667
Affiliated	1953	NORTH HIGHLANDS DIALYSIS CENTER	North Highlands Dialysis Center PD	4986 WATT AVE	STE C	NORTH HIGHLANDS	CA	95660-5182
Affiliated	1966	AMERY DIALYSIS	Amery Dialysis PD	970 ELDEN AVE		AMERY	WI	54001-1448
Affiliated	1975	KIDNEY HOME CENTER	Kidney HOME (Home Operations & Medical Education) Center PD	2245 ROLLING RUN DR	STE 4	WINDSOR MILL	MD	21244-1858
Affiliated	1988	MEMPHIS DOWNTOWN DIALYSIS	Memphis Downtown Dialysis PD	2076 UNION AVE	FL 2	MEMPHIS	TN	38104-4138
Affiliated	1989	PGH HOME MODALITY COE	Pittsburgh Home Modality Center of Excellence PD	5171 LIBERTY AVE	STE A	PITTSBURGH	PA	15224-2254
Affiliated	2223	LAKE VILLA DIALYSIS	Lake Villa Dialysis PD	37809 N IL RTE 59		LAKE VILLA	IL	60046-7332
Affiliated	2232	RICHFIELD DIALYSIS	Richfield PD Program	6601 LYNDALE AVE S	STE 150	RICHFIELD	MN	55423-2490
Affiliated	2297	TOKAY HOME DIALYSIS CENTER	Tokay Home Dialysis-PD	777 S HAM LN	STE L	LODI	CA	95242-3593
Affiliated	2302	SPIVEY PERITONEAL AND HOME DIALYSIS CENTER	Spivey Peritoneal Dialysis and Home Dialysis Center	1423 STOCKBRIDGE RD	STE B	JONESBORO	GA	30236-3740
Affiliated	2326	WARRENSVILLE HEIGHTS PD DIALYSIS	Warrensville Heights PD Dialysis	4200 WARRENSVILLE CENTER RD	STE 210	WARRENSVILLE HEIGHTS	OH	44122-7000
Affiliated	2340	EASTGATE HOME	Eastgate Home Training	4435 AICHOLTZ RD	STE 800B	CINCINNATI	OH	45245-1692
Affiliated	2366	WESLEY CHAPEL DIALYSIS	Wesley Chapel Dialysis (PD ONLY)	2255 GREEN HEDGES WAY		WESLEY CHAPEL	FL	33544-8183
Affiliated	2400	FRESNO PD	Fresno At Home Center-PD Only	568 E HERNDON AVE	STE 301	FRESNO	CA	93720-2989
Affiliated	2456	GRAND HOME DIALYSIS PD/HHD	Grand Home Dialysis (PD only)	14674 W MOUNTAIN VIEW BLVD	STE 204	SURPRISE	AZ	85374-2708
Affiliated	2458	WASHINGTON COUNTY DIALYSIS	Washington County Dialysis PD Only (fka Hagerstown)	1136 OPAL CT		HAGERSTOWN	MD	21740-5940
Affiliated	2477	SAN JOSE PD	San Jose At Home-PD Only (Freestanding)	4400 STEVENS CREEK BLVD	STE 50	SAN JOSE	CA	95129-1104
Affiliated	2483	FREMONT HOME TRAINING JV	DNVO-Fremont At Home PD/HHD-CA	39355 CALIFORNIA AVE		FREMONT	CA	94538
Affiliated	2490	HOME DIALYSIS OPTIONS OF BALDWIN COUNTY	Home Dialysis Options of Baldwin County-PD Only	27880 N MAIN ST	STE A	DAPHNE	AL	36526-7080
Affiliated	3299	TRI COUNTIES HOME TRAINING	Tri Counties Home Dialysis	433 S BRIDGE ST		VISALIA	CA	93277-2801
Affiliated	3640	WHITE OAK HOME TRAINING DIALYSIS	White Oak Home Training	5520 CHEVIOT RD	STE B	CINCINNATI	OH	45247-7069
Affiliated	3683	BUTLER COUNTY HOME TRAINING DIALYSIS	Butler County Home Training	3497 S DIXIE HWY		FRANKLIN	OH	45005-5717
Affiliated	3727	HANFORD AT HOME DIALYSIS	Hanford Home Dialysis PD	900 N DOUTY ST		HANFORD	CA	93230-3918
Affiliated	3735	HIOAKS DIALYSIS PD	Hioaks Dialysis PD	681 HIOAKS RD	STE B	RICHMOND	VA	23225-4043
Affiliated	3891	MEMPHIS EAST DIALYSIS PD	Memphis East Dialysis PD	50 HUMPHREYS CTR	STE 28B	MEMPHIS	TN	38120-2369
Affiliated	3892	NASHVILLE HOME TRAINING DIALYSIS PD	Nashville Home Training Dialysis PD	1919 CHARLOTTE AVE	STE 200	NASHVILLE	TN	37203-2245
Affiliated	3989	DEARBORN HOME DIALYSIS	Dearborn Home Dialysis-PD	22030 PARK ST		DEARBORN	MI	48124-2854
Affiliated	4308	GALLERIA HOME TRAINING DIALYSIS	Galleria Home Training Dialysis PD (aka SW Tennessee)	9045 HIGHWAY 64	STE 102	LAKELAND	TN	38002-8394
Affiliated	4310	GREATER TAMPA AT HOME	Greater Tampa At Home PD	4204 N MACDILL AVE	STE 1B NORTH BLDG	TAMPA	FL	33607-6364

Affiliated	4315	LORAIN COUNTY HOME DIALYSIS	DNVO-Lorain County Home Dialysis HHD/PD-OH	824 E BROAD ST		ELYRIA	OH	44035-6557
Affiliated	4375	GARFIELD HOME PROGRAM	Garfield Home Program (PD Only)	228 N GARFIELD AVE	STE 301	MONTEREY PARK	CA	91754-1709
Affiliated	4453	BINZ HOME TRAINING	Binz Home Training - PD only	1213 HERMANN DR	STE 180	HOUSTON	TX	77004-7018
Affiliated	5021	FRANKLIN AT HOME PD	Franklin At Home PD	301 CALLOWHILL ST		PHILADELPHIA	PA	19123-4117
Affiliated	5028	CALDWELL DIALYSIS CENTER PD	Caldwell Dialysis Center	821 S SMEED PKWY		CALDWELL	ID	83605-5130
Affiliated	5170	FORT WAYNE HOME DIALYSIS	DNVO-Fort Wayne Home Dialysis (PD-HHD)-IN	3124 E STATE BLVD	STE 5B	FORT WAYNE	IN	46805-4763
Affiliated	5556	VISALIA AT HOME	Visalia At Home PD	1120 N CHINOWTH ST		VISALIA	CA	93291-7896
Affiliated	5569	BLUEMOUND PD	Bluemound PD	601 N 99TH ST STE 300		WAUWATOSA	WI	53226-4362
Affiliated	5581	WOODLAWN HOME PROGRAM PD	Woodlawn Home Program PD Only	5841 S MARYLAND AVE	RM L-026	CHICAGO	IL	60637-1447
Affiliated	5599	BEVERLY DIALYSIS PD	Beverly PD	8109 S WESTERN AVE		CHICAGO	IL	60620-5939
Affiliated	5600	WOODLAWN PEDIATRIC HOME PROGRAM	Woodlawn Pediatrics Home Program PD Only	5841 S MARYLAND AVE L026		CHICAGO	IL	60615
Affiliated	5616	SPRINGHILL HOME TRAINING DIALYSIS	Springhill Home Training (PD Only)	3401 SPRINGHILL DR	STE 330	NORTH LITTLE ROCK	AR	72117-2945
Affiliated	5647	FIRST COLONIAL DAVITA PD	First Colonial DaVita PD	1157 FIRST COLONIAL RD	STE 200	VIRGINIA BEACH	VA	23454-2432
Affiliated	5898	AMHERST AT HOME	Amherst At Home	3200 COOPER FOSTER PRK RD W		LORAIN	OH	44053-3654
Affiliated	5900	CATHERDRAL CITY AT HOME	DNVO JV-Cathedral City At Home-CA	30-885 DATE PALM DR		CATHEDRAL CITY	CA	92234-2958
Affiliated	5904	ROBBINSDALE AT HOME	Robbinsdale At Home	3461 WEST BROADWAY AVE		ROBBINSDALE	MN	55422-2955
Affiliated	5905	NORTH PALM BEACH AT HOME	North Palm Beach At Home	2841 PGA BLVD		PALM BEACH GARDENS	FL	33410-2910
Affiliated	5907	SOUTHTOWNS AT HOME	Southtowns At Home (Hamburg)	4910 CAMP RD	STE 100	HAMBURG	NY	14075-2617
Affiliated	5909	FORT WAYNE HOME AT HOME	DNVO-Fort Wayne Home At Home	3124 E STATE BLVD	STE 5B	FORT WAYNE	IN	46805-4763
Affiliated	5910	FORT WAYNE WEST AT HOME	DNVO JV-Fort Wayne West At Home	4916 ILLINOIS RD	STE 118	FORT WAYNE	IN	46804-5116
Affiliated	5913	WINCHESTER AT HOME	Winchester At Home	2301 VALOR DR		WINCHESTER	VA	22601-6111
Affiliated	5914	MARSHFIELD AT HOME	Marshfield At Home	123 NORTHRIDGE ST		MARSHFIELD	WI	54449-8341
Affiliated	5915	MOSCOW AT HOME	Moscow At Home	212 RODEO DR	STE 110	MOSCOW	ID	83843-9791
Affiliated	5919	AVON AT HOME	Avon At Home	9210 ROCKVILLE RD	STE D	INDIANAPOLIS	IN	46234-2670
Affiliated	5923	NORTHSIDE AT HOME	Northside At Home	320 E NORTH AVE	4TH FLOOR SOUTH TOWER	PITTSBURGH	PA	15212-4756
Affiliated	5926	PANAMA CITY AT HOME	Panama City At Home	615 HIGHWAY 231		PANAMA CITY	FL	32405-4704
Affiliated	5927	MAGNOLIA OAKS AT HOME	Magnolia Oaks At Home (aka Hinesville, Satilla River)	2377 HIGHWAY 196 W	BLDG A MAGNOLIA OAKS	HINESVILLE	GA	31313-8036
Affiliated	5928	WESTBANK AT HOME	Westbank At Home	3631 BEHRMAN PL		NEW ORLEANS	LA	70114-0906
Affiliated	5931	ROCKSIDE AT HOME	Rockside At Home	4801 ACORN DR		INDEPENDENCE	OH	44131-2566
Affiliated	5932	WADSWORTH AT HOME	Wadsworth At Home	195 WADSWORTH RD STE 302	FOUNDERS HALL 3RD FLOOR	WADSWORTH	OH	44281-9504
Affiliated	5933	WOODLAWN AT HOME HHD	Woodlawn Home Program At Home	5841 S MARYLAND AVE	RM L-026	CHICAGO	IL	60637-1447
Affiliated	5934	WESLEY CHAPEL AT HOME	Wesley Chapel At Home	2255 GREEN HEDGES WAY		WESLEY CHAPEL	FL	33544-8183
Affiliated	5935	THOUSAND OAKS AT HOME	Thousand Oaks At Home	375 ROLLING OAKS DR	STE 100	THOUSAND OAKS	CA	91361-1024
Affiliated	5936	SIMI VALLEY AT HOME	Simi Valley At Home	2950 SYCAMORE DR	STE 100	SIMI VALLEY	CA	93065-1210
Affiliated	5937	MIDWEST FAIRBORN AT HOME	Midwest Fairborn At Home	1266 N BROAD ST		FAIRBORN	OH	45324
Affiliated	5938	NORTH ST LOUIS COUNTY AT HOME	North St. Louis County At Home	13119 NEW HALLS FERRY RD		FLORISSANT	MO	63033-3228
Affiliated	5939	BLUEMOUND AT HOME	Bluemound At Home	601 N 99TH ST	STE 110	WAUWATOSA	WI	53226
Affiliated	5940	MESA COUNTY AT HOME	Mesa County At Home (Grand Junction)	561 25 RD	STE D	GRAND JUNCTION	CO	81505-1303
Affiliated	5942	PLANO AT HOME	Plano At Home	481 SHILOH RD	STE 100	PLANO	TX	75074-7231
Affiliated	5943	WEST BLOOMFIELD AT HOME	West Bloomfield At Home	6010 W MAPLE RD STE 215		WEST BLOOMFIELD	MI	48322-4406
Affiliated	5945	BINZ HOME TRAINING AT HOME	Binz Home Training At Home	1213 HERMANN DR STE 180		HOUSTON	TX	77004-7070
Affiliated	5947	HANNIBAL AT HOME	Hannibal At Home	3140 PALMYRA RD		HANNIBAL	MO	63401-2204
Affiliated	5949	BEVERLY AT HOME	Beverly At Home	8109 SOUTH WESTERN AVE		CHICAGO	IL	60620-5939
Affiliated	5950	NORTH JACKSON AT HOME	North Jackson At Home (fka Stonegate)	217 STERLING FARM DR		JACKSON	TN	38305-5727
Affiliated	5951	PORTAGE AT HOME	Portage At Home	5823 US HIGHWAY 6		PORTAGE	IN	46368-4851
Affiliated	5952	ROGUE VALLEY AT HOME	Rogue Valley At Home	760 GOLF VIEW DR UNIT 100		MEDFORD	OR	97504-9685
Affiliated	5953	EVERETT AT HOME	Everett At Home	8130 EVERGREEN WAY STE C		EVERETT	WA	98203-6419
Affiliated	5954	OLYMPIA AT HOME	Olympia At Home	335 COOPER POINT ROAD NW	SUITE 105	OLYMPIA	WA	98502-4436
Affiliated	5955	LORAIN COUNTY HOME AT HOME	DNVO-Lorain County Home At Home	824 EAST BROAD ST		ELYRIA	OH	44035-6559
Affiliated	5956	RENAISSANCE AT HOME	Renaissance At Home	1840 DARBY DR		FLORENCE	AL	35630-2623
Affiliated	5957	POOLER AT HOME	Pooler At Home	54 TRADERS WAY	LIVE OAK PLAZA	POOLER	GA	31322-4158
Affiliated	5958	GULF SHORES AT HOME	Gulf Shores At Home	3947 GULF SHORES PKWY	UNIT 150	GULF SHORES	AL	36542-2735
Affiliated	5959	FRANKLIN AT HOME	Franklin At Home	301 CALLOWHILL ST		PHILADELPHIA	PA	19123-4117
Affiliated	5961	RENO AT HOME	Reno At Home	1500 EAST 2ND STREET	STE 101, 106	RENO	NV	89502-1189

Affiliated	5963	JACKSONVILLE SOUTH AT HOME	Jacksonville South At Home	14965 OLD SAINT AUGUSTINE RD	UNIT 114	JACKSONVILLE	FL	32258-9481
Affiliated	5964	LAKE ST LOUIS AT HOME	Lake St. Louis At Home	200 BREVCO PLZ	STE 202	LAKE ST LOUIS	MO	63367-2950
Affiliated	5965	UNION CITY AT HOME (GA)	Union City At Home (GA)	6851 SHANNON PARKWAY	STE 200	UNION CITY	GA	30291-2049
Affiliated	5966	WEBER VALLEY AT HOME	Weber Valley At Home	1920 W 250TH N		MARRIOTT-SLATERVILLE	UT	84404-9233
Affiliated	5968	PARKER DIALYSIS CENTER	Parker At Home	10371 S PARK GLENN WAY	STE 180	PARKER	CO	80138-3871
Affiliated	5971	KENNESTONE AT HOME	Kennestone At Home	200 COBB PKWY N	STE 318	MARIETTA	GA	30062-3558
Affiliated	5973	NORTH COLORADO SPRINGS AT HOME	North Colorado Springs At Home	6071 E WOODMEN RD	STE 100	COLORADO SPRINGS	CO	80923-2610
Affiliated	5974	PGH HOME MODALITY COD/HHD	Pittsburgh Home Modality Center of Excellence At Home	5171 LIBERTY AVE	STE A	PITTSBURGH	PA	15224-2254
Affiliated	5977	FRESNO AT HOME CENTER	Fresno At Home Center-HHD Only	568 E HERNDON AVE	STE 301	FRESNO	CA	93720-2989
Affiliated	5978	BLUFF CITY AT HOME	Bluff City At Home	2400 LUCY LEE PKWY	STE E	POPLAR BLUFF	MO	63901-2427
Affiliated	5979	NORTH METRO AT HOME	North Metro At Home	12365 HURON ST	STE 500	WESTMINSTER	CO	80234-3498
Affiliated	5980	FIVE STAR AT HOME	Five Star At Home (fka Las Vegas Multi-Care)	2400 TECH CENTER CT		LAS VEGAS	NV	89128-0804
Affiliated	5981	KIDNEY HOME AT HOME	Kidney HOME (Home Operations & Medical Education) At Home	2245 ROLLING RUN DR	STE 3	WINDSOR MILL	MD	21244-1858
Affiliated	5982	FARGO AT HOME	Fargo At Home	4474 23RD AVE S	STE M	FARGO	ND	58104-8795
Affiliated	5983	GALLERIA HOME TRAINING AT HOME	Galleria Home Training At Home	9045 HIGHWAY 64	STE 102	LAKELAND	TN	38002-8394
Affiliated	5986	BELDEN COMMUNITY AT HOME	Belden Community At Home	4685 FULTON DR NW		CANTON	OH	44718-2379
Affiliated	5987	MAINPLACE AT HOME	Mainplace At Home	972 W TOWN AND COUNTRY RD		ORANGE	CA	92868-4714
Affiliated	5988	PENNSAUKEN AT HOME	Pennsauken At Home	7024 KAIGHNS AVE		PENNSAUKEN	NJ	08109-4417
Affiliated	5989	JEDBURG AT HOME	Jedburg At Home	2897 W 5TH NORTH ST		SUMMERVILLE	SC	29483-9674
Affiliated	5993	CAPE CORAL SOUTH AT HOME	Cape Coral South At Home	3046 DEL PRADO BLVD S	STE 4A	CAPE CORAL	FL	33904-7232
Affiliated	5994	GREATER TAMPA HOME AT HOME	Greater Tampa At Home	4204 N MACDILL AVE	STE 1B NORTH BLDG	TAMPA	FL	33607-6364
Affiliated	5995	ATHENS EAST AT HOME	Athens East At Home	2026 S MILLEDGE AVE	STE A2	ATHENS	GA	30605-6480
Affiliated	5996	UNIVERSITY UNIT RIVERSIDE AT HOME	University Unit Riverside At Home	1045 WESTGATE DR	STE 90	SAINT PAUL	MN	55114-1079
Affiliated	5997	WOODRIDGE AT HOME	Woodridge Home At Home	7425 JANES AVE	STE 103	WOODRIDGE	IL	60517-2356
Affiliated	5998	INDY SOUTH AT HOME	Indy South At Home	972 EMERSON PKWY	STE E	GREENWOOD	IN	46143-6202
Affiliated	5999	LOCKPORT HOME AT HOME	Lockport Home Dialysis At Home	16626 W 159TH ST	STE 703	LOCKPORT	IL	60441-8019
Affiliated	6000	CAMELBACK AT HOME HEMO	Camelback Dialysis At Home	7321 E OSBORN DR		SCOTTSDALE	AZ	85251-6418
Affiliated	6002	WEST BOUNTIFUL DIALYSIS AT HOME	West Bountiful Dialysis At Home	724 W 500 S	STE 300	WEST BOUNTIFUL	UT	84087-1471
Affiliated	6002	WEST BOUNTIFUL DIALYSIS AT HOME	West Bountiful Dialysis At Home	724 W 500 S	STE 300	WEST BOUNTIFUL	UT	84087-1471
Affiliated	6004	CORNERSTONE DIALYSIS AT HOME	Cornerstone Dialysis At Home	23857 GREENFIELD RD		SOUTHFIELD	MI	48075-3122
Affiliated	6006	DIALYSIS CARE OF MOORE COUNTY AT HOME	Dialysis Care of Moore County At Home (aka Pinehurst)	16 REGIONAL DR		PINEHURST	NC	28374-8850
Affiliated	6007	HOME DIALYSIS AT HOME	Home Dialysis At Home (Minneapolis)	825 S 8TH ST	STE 1224	MINNEAPOLIS	MN	55404-1223
Affiliated	6009	ST PAUL CAPITOL DIALYSIS AT HOME	St Paul Capital Dialysis At Home	555 PARK ST	STE 210	SAINT PAUL	MN	55103-2193
Affiliated	6011	BALLENGER PT AT HOME	Ballenger Pt. At Home	2262 S BALLENGER HWY		FLINT	MI	48503-3447
Affiliated	6012	LAKEWOOD AT HOME	Lakewood At Home	1750 PIERCE ST		LAKEWOOD	CO	80214-1434
Affiliated	6013	MED-CENTER AT HOME	Med-Center at Home	7580 FANNIN ST	STE 230	HOUSTON	TX	77054-1939
Affiliated	6014	UTAH VALLEY DIALYSIS AT HOME	Utah Valley Dialysis At Home	1055 N 500 W	STE 221	PROVO	UT	84604-3305
Affiliated	6015	LOWRY AT HOME	Lowry At Home	7465 E 1ST AVE	STE A	DENVER	CO	80230-6877
Affiliated	6016	MANZANITA AT HOME	Manzanita At Home	4005 MANZANITA AVE	STE 17	CARMICHAEL	CA	95608-1779
Affiliated	6017	FIRST COLONIAL DAVITA AT HOME	First Colonial DaVita At Home	1157 FIRST COLONIAL RD	STE 200	VIRGINIA BEACH	VA	23454-2432
Affiliated	6019	LAKEWOOD WASHINGTON AT HOME	Lakewood Washington At Home	5919 LAKEWOOD TOWNE CENTER BLVD SW	STE A	LAKEWOOD	WA	98499-6513
Affiliated	6020	GRAPEVINE AT HOME	Grapevine At Home	1600 W NORTHWEST HWY	STE 100	GRAPEVINE	TX	76051-8131
Affiliated	6021	GRAND RAPIDS AT HOME (CHERRY STREET)	Grand Rapids At Home (Cherry Street)	801 CHERRY ST SE		GRAND RAPIDS	MI	49506-1440
Affiliated	6022	FEDERAL WAY AT HOME	Federal Way At Home	1015 S 348TH ST		FEDERAL WAY	WA	98003-7078
Affiliated	6023	CENTURY CITY AT HOME	Century City At Home	10630 SANTA MONICA BLVD		LOS ANGELES	CA	90025
Affiliated	6024	REDDING AT HOME	Redding At Home	1876 PARK MARINA DR		REDDING	CA	96001-0913
Affiliated	6025	OLYMPIA FIELDS AT HOME	Olympia Fields At Home	4557B LINCOLN HWY	STE B	MATTESON	IL	60443-2318
Affiliated	6026	MT VERNON AT HOME	Mount Vernon At Home	1800 JEFFERSON AVE		MOUNT VERNON	IL	62864-4300
Affiliated	6028	YAKIMA AT HOME	Yakima At Home	1221 N 16TH AVE		YAKIMA	WA	98902-1347
Affiliated	6029	MID-COLUMBIA AT HOME	Mid Columbia At Home	6825 BURDEN BLVD	STE A	PASCO	WA	99301-9584
Affiliated	6030	GEORGETOWN ON THE POTOMAC AT HOME	Georgetown on the Potomac At Home	3323 K STREET NW	SUITE 110	WASHINGTON	DC	20007
Affiliated	6031	SIOUX FALLS AT HOME	Sioux Falls At Home	800 E 21ST ST		SIOUX FALLS	SD	57105-1016
Affiliated	6032	HILLSBORO AT HOME	Hillsboro At Home	2500 NW 229TH AVE	STE 300 BLDG E	HILLSBORO	OR	97124-7516
Affiliated	6033	PIKES PEAK AT HOME	Pikes Peak At Home	2002 LELARAY ST	STE 130	COLORADO SPRINGS	CO	80909-2804

Affiliated	6034	WALNUT CREEK AT HOME	Walnut Creek At Home	400 N WIGET LN		WALNUT CREEK	CA	94598-2408
Affiliated	6035	SAN ANTONIO AT HOME	San Antonio At Home	5284 MEDICAL DR	STE 100	SAN ANTONIO	TX	78229-4849
Affiliated	6036	SANTA ROSA AT HOME	Santa Rosa At Home	5819 HIGHWAY 90		MILTON	FL	32583-1763
Affiliated	6037	DUNMORE AT HOME	Dunmore At Home	1212 ONEILL HWY		DUNMORE	PA	18512-1717
Affiliated	6038	PALMERTON AT HOME	Palmerton At Home	185 DELAWARE AVE	STE C	PALMERTON	PA	18071-1716
Affiliated	6039	LONGVIEW AT HOME	Longview At Home	425 N FREDONIA ST		LONGVIEW	TX	75601-6464
Affiliated	6040	JB ZACHARY AT HOME	JB Zachary At Home	333 CASSELL DR	STE 2300	BALTIMORE	MD	21224-6815
Affiliated	6041	MEMPHIS EAST AT HOME	Memphis East At Home	50 HUMPHREYS CTR	STE 28B	MEMPHIS	TN	38120-2369
Affiliated	6042	PLAINFIELD AT HOME	Plainfield At Home	1200 RANDOLPH RD	KENYAN HOUSE	PLAINFIELD	NJ	07060-3361
Affiliated	6045	CHARLOTTE AT HOME	Charlotte (NC) At Home	2321 W MOREHEAD ST	STE 102	CHARLOTTE	NC	28208-5145
Affiliated	6046	DALY CITY AT HOME	Daly City At Home	1498 SOUTHGATE AVE	STE 101	DALY CITY	CA	94015-4015
Affiliated	6047	SALEM AT HOME	Salem At Home (OR)	3550 LIBERTY RD S	STE 100	SALEM	OR	97302-5700
Affiliated	6048	OMAHA WEST AT HOME	Omaha West At Home	13014 W DODGE RD		OMAHA	NE	68154-2148
Affiliated	6049	TUCSON EAST AT HOME	Tucson East At Home	6420 E BROADWAY BLVD	STE C300	TUCSON	AZ	85710-3512
Affiliated	6050	WHITE OAK AT HOME	White Oak At Home	5520 CHEVIOT RD	STE B	CINCINNATI	OH	45247-7069
Affiliated	6051	BELPRE AT HOME	Belpre At Home	2906 WASHINGTON BLVD		BELPRE	OH	45714-1848
Affiliated	6052	BIRMINGHAM AT HOME	Birmingham At Home	2101 7TH AVE S		BIRMINGHAM	AL	35233-3105
Affiliated	6053	STAMFORD AT HOME	Stamford At Home	30 COMMERCE RD		STAMFORD	CT	06902-4506
Affiliated	6054	WHITEBRIDGE AT HOME	Whitebridge At Home	103 WHITE BRIDGE PIKE	STE 6	NASHVILLE	TN	37209-4539
Affiliated	6055	ZANESVILLE AT HOME	Zanesville At Home	3120 NEWARK RD		ZANESVILLE	OH	43701-9659
Affiliated	6056	TYSON'S CORNER AT HOME	Tyson's Corner At Home	8391 OLD COURTHOUSE RD	STE 160	VIENNA	VA	22182-3819
Affiliated	6057	BRADFORD AT HOME	Bradford At Home	665 E MAIN ST		BRADFORD	PA	16701-1869
Affiliated	6059	NORTHLAND AT HOME	Northland At Home	2750 CLAY EDWARDS DR	STE 515	N KANSAS CITY	MO	64116-3258
Affiliated	6060	LAKE WORTH AT HOME	Lake Worth At Home	2459 S CONGRESS AVE	STE 100	PALM SPRINGS	FL	33406-7616
Affiliated	6061	MEADVILLE AT HOME	Meadville At Home	19050 PARK AVENUE PLZ		MEADVILLE	PA	16335-4012
Affiliated	6063	WILLINGBORO AT HOME	Willingboro At Home	230 VAN SCIVER PKWY		WILLINGBORO	NJ	08046-1131
Affiliated	6064	DERENNE AT HOME	DeRenne At Home	5303 MONTGOMERY ST		SAVANNAH	GA	31405-5138
Affiliated	6065	BRUNSWICK AT HOME	Brunswick At Home	53 SCRANTON CONNECTOR		BRUNSWICK	GA	31525-1862
Affiliated	6067	AIKEN AT HOME	Aiken At Home	775 MEDICAL PARK DR		AIKEN	SC	29801-6306
Affiliated	6068	BRIDGEPORT AT HOME	Bridgeport At Home	900 MADISON AVE		BRIDGEPORT	CT	06606-5534
Affiliated	6069	ST PETERSBURG AT HOME	St Petersburg At Home	2850 34TH ST S		ST PETERSBURG	FL	33711-3817
Affiliated	6070	DENISON AT HOME	Denison At Home	1220 REBA MACENTIRE LN		DENISON	TX	75020-9057
Affiliated	6072	ATLANTIC AT HOME	Atlantic At Home	6 INDUSTRIAL WAY W	STE B	EATONTOWN	NJ	07724-2258
Affiliated	6073	NEWTOWN AT HOME	Newtown At Home (fka St. Mary)	60 BLACKSMITH RD		NEWTOWN	PA	18940-1847
Affiliated	6075	FOX RIVER AT HOME	Fox River At Home	1910 RIVERSIDE DR		GREEN BAY	WI	54301-2319
Affiliated	6076	TOKAY AT HOME	Tokay At Home	777 S HAM LN	STE L	LODI	CA	95242-3593
Affiliated	6077	CAPITAL CITY AT HOME	Capital City At Home	307 N 46TH ST		LINCOLN	NE	68503-3714
Affiliated	6081	GREATER MIAMI AT HOME	Greater Miami At Home	160 NW 176TH ST	STE 100	MIAMI	FL	33169-5023
Affiliated	6083	EFFINGHAM AT HOME	Effingham At Home	904 MEDICAL PARK DR	STE 1	EFFINGHAM	IL	62401-2193
Affiliated	6084	SPRINGFIELD CENTRAL AT HOME	Springfield Central At Home	932 N RUTLEDGE ST		SPRINGFIELD	IL	62702-3721
Affiliated	6085	DECATUR EAST WOOD AT HOME	Decatur East Wood At Home	794 E WOOD ST		DECATUR	IL	62523-1155
Affiliated	6086	ILLINI AT HOME	Illini At Home	507 E UNIVERSITY AVE		CHAMPAIGN	IL	61820-3828
Affiliated	6087	JANESVILLE AT HOME	Janesville At Home	1305 WOODMAN RD		JANESVILLE	WI	53545-1068
Affiliated	6088	NEW HAVEN AT HOME	New Haven At Home	100 CHURCH ST S	STE C	NEW HAVEN	CT	06519-1703
Affiliated	6089	NASHUA AT HOME	Nashua At Home	38 TYLER ST	STE 100	NASHUA	NH	03060-2912
Affiliated	6090	EAST EVANSVILLE AT HOME	East Evansville At Home	1312 PROFESSIONAL BLVD		EVANSVILLE	IN	47714-8007
Affiliated	6095	BROOKRIVER AT HOME	Brookriver At Home	8101 BROOKRIVER DR		DALLAS	TX	75247-4003
Affiliated	6098	METRO EAST AT HOME	Metro East At Home	5105 W MAIN ST		BELLEVILLE	IL	62226-4728
Affiliated	6099	MARION AT HOME	Marion At Home	324 S 4TH ST		MARION	IL	62959-1241
Affiliated	6100	ROXBURY AT HOME	Roxbury At Home	622 ROXBURY RD		ROCKFORD	IL	61107-5089
Affiliated	6101	SYCAMORE AT HOME	Sycamore At Home	2200 GATEWAY DR		SYCAMORE	IL	60178-3113
Affiliated	6103	WESTVIEW AT HOME	Westview At Home	3749 COMMERCIAL DR	STE B	INDIANAPOLIS	IN	46222-1676
Affiliated	6105	OCALA AT HOME	Ocala At Home	2860 SE 1ST AVE		OCALA	FL	34471-0406
Affiliated	6106	COMPLETE CARE AT HOME	Complete Care At Home	7850 W SAMPLE RD		MARGATE	FL	33065-4710

Affiliated	6107	INTERAMERICAN AT HOME	InterAmerican At Home	7815 CORAL WAY	STE 115	MIAMI	FL	33155-6541
Affiliated	6109	PURCELLVILLE AT HOME	Purcellville At Home	280 N HATCHER AVE		PURCELLVILLE	VA	20132-3193
Affiliated	6110	TABLE ROCK AT HOME	Table Rock At Home	5610 GAGE ST	STE B	BOISE	ID	83706
Affiliated	6111	TWIN FALLS AT HOME	Twin Falls At Home	1840 CANYON CREST DR		TWIN FALLS	ID	83301-3007
Affiliated	6113	FOUR RIVERS AT HOME	Four Rivers At Home	515 EAST LN		ONTARIO	OR	97914-3953
Affiliated	6114	OLYMPIC VIEW AT HOME	Olympic View At Home	125 16TH AVE E	FL 5	SEATTLE	WA	98112-5211
Affiliated	6115	SPIVEY AT HOME	Spivey At Home	1423 STOCKBRIDGE RD	STE B	JONESBORO	GA	30236-3740
Affiliated	6116	EAST DES MOINES AT HOME	East Des Moines At Home	1301 PENNSYLVANIA AVE	STE 208	DES MOINES	IA	50316-2365
Affiliated	6118	KETTERING AT HOME	Kettering At Home	5721 BIGGER RD		KETTERING	OH	45440-2752
Affiliated	6119	CITRUS VALLEY AT HOME	Citrus Valley At Home	894 HARDT ST		SAN BERNARDINO	CA	92408-2854
Affiliated	6124	MERIDIAN PARK AT HOME	Meridian Park At Home	19255 SW 65TH AVE	STE 100	TUALATIN	OR	97062-9712
Affiliated	6125	MARYVILLE AT HOME	Maryville At Home	2136B VADALABENE DR		MARYVILLE	IL	62062-5632
Affiliated	6128	PDI-WORCESTER AT HOME	PDI-Worcester At Home	19 GLENNIE ST	STE A	WORCESTER	MA	01605-3918
Affiliated	6129	PDI-ROCKY HILL AT HOME	PDI-Rocky Hill At Home	30 WATERCHASE DR		ROCKY HILL	CT	06067-2110
Affiliated	6133	WICHITA AT HOME	Wichita At Home	909 N TOPEKA ST		WICHITA	KS	67214-3620
Affiliated	6134	ASHEVILLE KIDNEY AT HOME	Asheville Kidney At Home	1600 CENTERPARK DR		ASHEVILLE	NC	28805-6206
Affiliated	6136	STRONGSVILLE AT HOME	Strongsville At Home	17792 PEARL RD		STRONGSVILLE	OH	44136-6909
Affiliated	6137	BATON ROUGE AT HOME	DSI Divest-Baton Rouge At Home	3888 NORTH BLVD	STE 101	BATON ROUGE	LA	70806-3824
Affiliated	6138	WEST BROADWAY DIALYSIS AT HOME	West Broadway At Home	720 W BROADWAY	STE 200	LOUISVILLE	KY	40202-3245
Affiliated	6140	BRONX AT HOME	Bronx At Home	1615 EASTCHESTER RD		BRONX	NY	10461-2603
Affiliated	6142	CLEVE HILL AT HOME	Cleve Hill At Home	1461 KENSINGTON AVE		BUFFALO	NY	14215-1436
Affiliated	6144	WHITE PLAINS AT HOME	White Plains At Home	200 HAMILTON AVE	STE 13B	WHITE PLAINS	NY	10601-1859
Affiliated	6146	LAKE VILLA AT HOME	Lake Villa At Home	37809 N IL ROUTE 59		LAKE VILLA	IL	60046-7332
Affiliated	6148	TULSA AT HOME	Tulsa At Home	4436 S HARVARD AVE		TULSA	OK	74135-2605
Affiliated	6151	LITHONIA AT HOME	Lithonia At Home	2485 PARK CENTRAL BLVD		DECATUR	GA	30035-3902
Affiliated	6152	LANHAM AT HOME	Lanham At Home	8855 ANNAPOLIS RD	STE 200	LANHAM	MD	20706-2919
Affiliated	6153	HAMMOND AT HOME	Hammond At Home	222 DOUGLAS ST		HAMMOND	IN	46320-1960
Affiliated	6156	UNION CITY CENTER AT HOME (CA)	Union City Center At Home (CA)	32930 ALVARADO NILES RD	STE 300	UNION CITY	CA	94587-8101
Affiliated	6157	CHICO AT HOME	Chico At Home	530 COHASSET RD		CHICO	CA	95926-2212
Affiliated	6158	MONTCLAIR AT HOME	Montclair At Home	5050 PALO VERDE ST	STE 100	MONTCLAIR	CA	91763-2333
Affiliated	6161	PDI - LANCASTER AT HOME	PDI-Lancaster At Home	1412 E KING ST		LANCASTER	PA	17602-3240
Affiliated	6162	PDI JOHNSTOWN AT HOME	PDI-Johnstown At Home	344 BUDFIELD ST		JOHNSTOWN	PA	15904-3214
Affiliated	6163	CAMP HILL AT HOME	Camp Hill At Home	425 N 21ST ST	PLAZA 21 BLDG 1ST FL	CAMP HILL	PA	17011-2202
Affiliated	6164	PDI MONTGOMERY AT HOME	PDI-Montgomery At Home	1001 FOREST AVE		MONTGOMERY	AL	36106-1181
Affiliated	6165	FAIRFAX AT HOME	Fairfax At Home	8501 ARLINGTON BLVD	STE 100	FAIRFAX	VA	22031-4625
Affiliated	6170	WEST SACRAMENTO AT HOME	West Sacramento At Home	3450 INDUSTRIAL BLVD	STE 100	WEST SACRAMENTO	CA	95691-5003
Affiliated	6171	EAST MACON AT HOME	East Macon At Home	165 EMERY HWY	STE 101	MACON	GA	31217-3666
Affiliated	6178	GERMANTOWN AT HOME	Germantown At Home	20111 CENTURY BLVD	STE C	GERMANTOWN	MD	20874-9165
Affiliated	6180	SEDC-WILMINGTON AT HOME	SEDC-Wilmington (NC) At Home	2215 YAUPON DR		WILMINGTON	NC	28401-7334
Affiliated	6182	HERMISTON COMMUNITY AT HOME	Hermiston Community At Home	1155 W LINDA AVE		HERMISTON	OR	97838-9601
Affiliated	6183	SHREVEPORT HHD LA	Shreveport Home Dialysis At Home	1560 IRVING PL		SHREVEPORT	LA	71101-4604
Affiliated	6184	DOWNTOWN SAN ANTONIO AT HOME	Downtown San Antonio At Home	615 E QUINCY ST		SAN ANTONIO	TX	78212
Affiliated	6186	COLUMBIA MO AT HOME	RTC-Columbia (MO) At Home	1701 E BROADWAY	STE G102	COLUMBIA	MO	65201-8029
Affiliated	6188	REGENCY AT HOME	Regency At Home (fka Jacksonville)	9535 REGENCY SQUARE BLVD N		JACKSONVILLE	FL	32225-8128
Affiliated	6193	WEST GEORGIA AT HOME	West Georgia At Home (fka Columbus (GA))	1216 STARK AVE		COLUMBUS	GA	31906-2500
Affiliated	6194	BUFORD AT HOME	Buford At Home	1550 BUFORD HWY	STE 1E	BUFORD	GA	30518-3666
Affiliated	6195	KALAMAZOO WEST AT HOME	Kalamazoo West At Home	1040 N 10TH ST		KALAMAZOO	MI	49009-6149
Affiliated	6196	SOUTH VALLEY AT HOME	South Valley At Home	17815 VENTURA BLVD	STE 100	ENCINO	CA	91316-3600
Affiliated	6204	QUEENS VILLAGE AT HOME	Queens Village At Home	22202 HEMPSTEAD AVE	STE 170	QUEENS VILLAGE	NY	11429-2123
Affiliated	6207	LANSING AT HOME-MI	Lansing Home Hemodialysis At Home	1675 WATERTOWER PL	STE 700	EAST LANSING	MI	48823-6397
Affiliated	6208	SOUTH COUNTY AT HOME	South County At Home (Deaconess)	4145 UNION RD		SAINT LOUIS	MO	63129-1064
Affiliated	6211	TACOMA AT HOME	Tacoma At Home	3401 S 19TH ST		TACOMA	WA	98405-1909
Affiliated	6213	CEDAR PARK AT HOME	Cedar Park At Home (fka North Austin)	1720 E WHITESTONE BLVD		CEDAR PARK	TX	78613-7640
Affiliated	6214	SOUTH FORT WORTH DIALYSIS AT HOME	South Fort Worth At Home	6260 SOUTHWEST BLVD		BENBROOK	TX	76109-6906

Affiliated	6215	THE WOODLANDS AT HOME	DNVO-The Woodlands At Home	9301 PINECROFT DR		SHENANDOAH	TX	77380-3179
Affiliated	6218	ARROWHEAD LAKES AT HOME	Arrowhead Lakes At Home	20325 N 51ST AVE	STE 184 BLDG 11	GLENDALE	AZ	85308-4625
Affiliated	6220	COLUMBUS WEST HOME TRAINING	Columbus West Home Training At Home	1391 GEORGESVILLE RD		COLUMBUS	OH	43228-3611
Affiliated	6221	RICHMOND KIDNEY CENTER AT HOME	Richmond Kidney Center At Home (Staten Island)	1366 VICTORY BLVD		STATEN ISLAND	NY	10301-3907
Affiliated	6225	DIALYSIS CARE OF KANNAPOLIS AT HOME	Dialysis Care of Kannapolis At Home	1607 N MAIN ST		KANNAPOLIS	NC	28081-2317
Affiliated	6226	BUTLER-FARM AT HOME	Butler Farm At Home	501 BUTLER FARM RD	STE A	HAMPTON	VA	23666-1777
Affiliated	6228	NEW PORT RICHEY AT HOME	New Port Richey Kidney At Home	7421 RIDGE RD		PORT RICHEY	FL	34668-6933
Affiliated	6229	GRAND HOME AT HOME	Grand Home At Home	14674 W MOUNTAIN VIEW BLVD	STE 204	SURPRISE	AZ	85374-2708
Affiliated	6230	WILLIAMSBURG AT HOME	Williamsburg At Home (fka Yorktown)	500 SENTARA CIR	STE 103	WILLIAMSBURG	VA	23188-5727
Affiliated	6231	BALDWIN COUNTY AT HOME	Home Dialysis Options of Baldwin County At Home	27880 N MAIN ST	STE A	DAPHNE	AL	36526-7080
Affiliated	6232	CLINTON TOWNSHIP AT HOME	Clinton Township at Home	15918 19 MILE RD	STE 110	CLINTON TOWNSHIP	MI	48038-1101
Affiliated	6233	GROSSE POINTE AT HOME	Grosse Pointe At Home	18000 E WARREN AVE	STE 100	DETROIT	MI	48224-1336
Affiliated	6234	GREENSBURG AT HOME	Greensburg At Home	1531 N COMMERCE EAST DR	STE 6	GREENSBURG	IN	47240-3259
Affiliated	6236	GULF BREEZE AT HOME	Gulf Breeze At Home	1519 MAIN ST		DUNEDIN	FL	34698-4650
Affiliated	6237	JACKSONVILLE CENTRAL AT HOME	Jacksonville Central At Home	400 T P WHITE DR		JACKSONVILLE	AR	72076-3287
Affiliated	6238	SAN JOSE AT HOME	San Jose At Home (Freestanding)	4400 STEVENS CREEK BLVD	STE 50	SAN JOSE	CA	95129-1104
Affiliated	6243	ORLANDO AT HOME	Orlando At Home (0178)	14050 TOWN LOOP BLVD	STE 104B	ORLANDO	FL	32837-6190
Affiliated	6244	KENNEDY HOME DIALYSIS-AT HOME	Kennedy Home Dialysis-At Home	5509 N CUMBERLAND AVE	STE 515	CHICAGO	IL	60656-4702
Affiliated	6245	YPSILANTI AT HOME	Ypsilanti At Home	2762 WASHTENAW RD		YPSILANTI	MI	48197-1506
Affiliated	6246	JACKSONVILLE AT HOME	SEDC (NC II) Jacksonville At Home	14 OFFICE PARK DR		JACKSONVILLE	NC	28546-7325
Affiliated	6247	LEBANON AT HOME	Lebanon At Home	918 COLUMBUS AVE	STE 2 UNIT B	LEBANON	OH	45036-1402
Affiliated	6248	SLIDELL KIDNEY CARE AT HOME	Slidell Kidney Care At Home	1150 ROBERT BLVD	STE 240	SLIDELL	LA	70458-2005
Affiliated	6249	WATERBURY AT HOME	Waterbury At Home	150 MATTATUCK HEIGHTS RD		WATERBURY	CT	06705-3893
Affiliated	6251	WHITE LANE AT HOME	White Lane At Home	7701 WHITE LN	STE D	BAKERSFIELD	CA	93309-0201
Affiliated	6253	HANFORD AT HOME	Hanford At Home	900 N DOUTY ST		HANFORD	CA	93230-3918
Affiliated	6254	ANAHEIM AT HOME	Anaheim At Home	1107 W LA PALMA AVE		ANAHEIM	CA	92801-2804
Affiliated	6255	MERCED AT HOME	Merced At Home	3150 NORTH G ST	STE B	MERCED	CA	95340-1346
Affiliated	6257	ST JOSEPH AT HOME	St. Joseph At Home	5514 CORPORATE DR	STE 100	SAINT JOSEPH	MO	64507-7752
Affiliated	6258	CENTRAL LITTLE ROCK AT HOME	Central Little Rock At Home	5800 W 10TH ST	STE 510	LITTLE ROCK	AR	72204-1760
Affiliated	6260	DURHAM WEST AT HOME	Durham West At Home	4307 WESTERN PARK PL	STE 101	DURHAM	NC	27705-1204
Affiliated	6262	TOLEDO AT HOME	Toledo At Home	1614 S BYRNE RD		TOLEDO	OH	43614-3464
Affiliated	6263	HIOAKS AT HOME	Hioaks At Home	681 HIOAKS RD	STE D	RICHMOND	VA	23225-4043
Affiliated	6264	ELIZABETH AT HOME	Elizabeth At Home	201 MCKEESPORT RD		ELIZABETH	PA	15037-1623
Affiliated	6265	ABINGTON AT HOME	Abington At Home	3940A COMMERCE AVE		WILLOW GROVE	PA	19090-1705
Affiliated	6267	NORTH ORANGEBURG AT HOME	North Orangeburg At Home	124 FIRE TOWER RD		ORANGEBURG	SC	29118-1401
Affiliated	6268	DEARBORN HOME DIALYSIS - AT HOME	Dearborn Home Dialysis-At Home	22030 PARK ST		DEARBORN	MI	48124-2854
Affiliated	6269	OCEAN SPRINGS AT HOME	Ocean Springs At Home	13150 PONCE DEL LEON		OCEAN SPRINGS	MS	39564-2460
Affiliated	6270	HAKC - HUNTINGTON AT HOME	HAKC-Huntington At Home	256 BROADWAY		HUNTINGTON STATION	NY	11746-1403
Affiliated	6271	42ND ST AT HOME	Philadelphia 42nd Street At Home	4126 WALNUT ST		PHILADELPHIA	PA	19104-3511
Affiliated	6275	CHARLOTTESVILLE NORTH AT HOME	Charlottesville North At Home	1800 TIMBERWOOD BLVD	STE C	CHARLOTTESVILLE	VA	22911-7544
Affiliated	6276	HEARTLAND AT HOME	Heartland At Home	925 NE 8TH ST		OKLAHOMA CITY	OK	73104-5800
Affiliated	6278	LAKELAND SOUTH AT HOME	Lakeland South At Home	5050 S FLORIDA AVE	STE 1	LAKELAND	FL	33813-2501
Affiliated	6282	RAINBOW CITY AT HOME	Rainbow City At Home	2800 RAINBOW DR		RAINBOW CITY	AL	35906-5811
Affiliated	6283	ATHENS AT HOME	Athens At Home	15953 ATHENS LIMESTONE DR	STE 15	ATHENS	AL	35613-2214
Affiliated	6284	SYLACAUGA AT HOME	Sylacauga At Home	331 JAMES PAYTON BLVD		SYLACAUGA	AL	35150
Affiliated	6287	PITTSBURGH AT HOME	Pittsburgh At Home	4312 PENN AVE		PITTSBURGH	PA	15224-1310
Affiliated	6289	RADNOR AT HOME	Radnor At Home	250 KING OF PRUSSIA RD		RADNOR	PA	19087-5220
Affiliated	6291	RADFORD AT HOME	Radford At Home	600 E MAIN ST	STE B	RADFORD	VA	24141-1826
Affiliated	6292	HARRISONBURG AT HOME	Harrisonburg At Home	871 CANTRELL AVE	STE 100	HARRISONBURG	VA	22801-4323
Affiliated	6293	KERRVILLE AT HOME	Kerrville At Home	515 GRANADA PL		KERRVILLE	TX	78028-5992
Affiliated	6294	WEST TALLAHASSEE AT HOME	West Tallahassee At Home	2645 W TENNESSEE ST	STE 8	TALLAHASSEE	FL	32304-2521
Affiliated	6295	ROME AT HOME	Rome At Home	15 JOHN MADDOX DR NW		ROME	GA	30165-1413
Affiliated	6297	ST LOUIS WEST AT HOME	St. Louis West At Home	450 N LINDBERGH BLVD	STE 100C	CREVE COEUR	MO	63141-7858
Affiliated	6298	COOKEVILLE AT HOME	Cookeville At Home	140 W 7TH ST		COOKEVILLE	TN	38501-1726

Affiliated	6300	DOTHAN AT HOME	Dothan At Home	216 GRACELAND DR		DOTHAN	AL	36305-7346
Affiliated	6302	HENRICO COUNTY AT HOME	Henrico County At Home	5270 CHAMBERLAYNE RD		RICHMOND	VA	23227-2950
Affiliated	6303	WEYMOUTH CLINIC AT HOME	Weymouth At Home	330 LIBBEY INDUSTRIAL PKWY	STE 900	WEYMOUTH	MA	02189-3122
Affiliated	6304	ERIE AT HOME	Erie At Home	350 E BAYFRONT PKWY	STE A	ERIE	PA	16507-2410
Affiliated	6305	WILSON AT HOME	Wilson At Home	1605 MEDICAL PARK DR W		WILSON	NC	27893-2799
Affiliated	6306	NORTH FULTON AT HOME	North Fulton At Home	1250 NORTHMEADOW PKWY	STE 120	ROSWELL	GA	30076-4914
Affiliated	6311	BRADENTON AT HOME	Bradenton At Home	3501 CORTEZ RD W	STE 104	BRADENTON	FL	34210-3104
Affiliated	6312	COLUMBIA UNIVERSITY AT HOME	Columbia University At Home	60 HAVEN AVENUE		NEW YORK	NY	10032-2604
Affiliated	6313	NEW BEDFORD AT HOME	New Bedford At Home	524 UNION ST		NEW BEDFORD	MA	02740-3546
Affiliated	6314	MUSKEGON AT HOME	Muskegon At Home	1277 MERCY DR		MUSKEGON	MI	49444-4605
Affiliated	6315	WELLINGTON CIRCLE AT HOME	Wellington Circle At Home	10 CABOT RD	STE 103B	MEDFORD	MA	02155-5173
Affiliated	6316	FREDERICK AT HOME	Frederick At Home	140 THOMAS JOHNSON DR	STE 100	FREDERICK	MD	21702-4475
Affiliated	6317	SELINSGROVE AT HOME	Selinsgrove At Home	1030 N SUSQUEHANNA TRL		SELINSGROVE	PA	17870-7767
Affiliated	6318	LAKE CHARLES SOUTHWEST AT HOME	Lake Charles Southwest At Home	300 18th ST		LAKE CHARLES	LA	70601-7342
Affiliated	6319	LENEXA AT HOME	Lenexa At Home	8630 HALSEY ST		LENEXA	KS	66215-2880
Affiliated	6321	NASHVILLE HOME TRAINING AT HOME	Nashville Home Training At Home	1919 CHARLOTTE AVE	STE 200	NASHVILLE	TN	37203-2245
Affiliated	6322	GOLDSBORO AT HOME	Goldsboro At Home	2609 HOSPITAL RD		GOLDSBORO	NC	27534-9424
Affiliated	6323	MIAMI CAMPUS AT HOME	Miami Campus At Home	1500 NW 12TH AVE	STE 106	MIAMI	FL	33136-1028
Affiliated	6324	DAYTONA BEACH AT HOME	Daytona Beach At Home	578 HEALTH BLVD		DAYTONA BEACH	FL	32114-1492
Affiliated	6325	GRASS VALLEY AT HOME	Grass Valley At Home	360 CROWN POINT CIR	STE 210	GRASS VALLEY	CA	95945-2543
Affiliated	6326	POMONA AT HOME	Pomona At Home	2111 NORTH GAREY AVENUE		POMONA	CA	91767
Affiliated	6327	MID ATLANTA HOME AT HOME	MidAtlanta Home At Home	418 DECATUR ST SE	SUITE B	ATLANTA	GA	30312-1801
Affiliated	6328	MARTINSVILLE AT HOME	Martinsville Dialysis	33 BRIDGE ST S		MARTINSVILLE	VA	24112-6214
Affiliated	6329	HUBBARD ROAD AT HOME	Hubbard Road At Home	1963 HUBBARD RD		MADISON	OH	44057
Affiliated	6350	PLAINFIELD RENAL CENTER AT HOME	Plainfield Renal At Home (P278)	8110 NETWORK DR		PLAINFIELD	IN	46168-9024
Affiliated	6351	NORTH ANDOVER RENAL CENTER AT HOME	North Andover Renal At Home (P178)	201 SUTTON ST		NORTH ANDOVER	MA	1845
Affiliated	6352	JACKSON NORTH DIALYSIS AT HOME	Jackson North At Home (P181)	571 BEASLEY RD	STE B	JACKSON	MS	39206-3042
Affiliated	6353	SUMMIT RENAL AT HOME	Summit Renal At Home (P186)	73 MASSILLON RD		AKRON	OH	44312-1028
Affiliated	6354	MARLTON DIALYSIS AT HOME	Marlton At Home (P200)	769 E RTE 70		MARLTON	NJ	08053-2341
Affiliated	6355	CENTRAL FORT WAYNE DIALYSIS AT HOME	Central Fort Wayne At Home (P223)	1940 BLUFTON RD		FORT WAYNE	IN	46809-1307
Affiliated	6356	LAS CRUCES RENAL CENTER AT HOME	Las Cruces Renal At Home (P237)	3961 E LOHMAN AVE	STE 29	LAS CRUCES	NM	88011-8272
Affiliated	6357	NORTHEAST PORTLAND RENAL CENTER AT HOME	Northeast Portland Renal At Home (P240)	703 NE HANCOCK ST		PORTLAND	OR	97212-3955
Affiliated	6358	KANSAS CITY RENAL CENTER AT HOME	Kansas City Renal At Home (P264)	4333 MADISON AVE		KANSAS CITY	MO	64111-3429
Affiliated	6359	COASTAL DIALYSIS AT HOME	South Texas Renal At Home (P257)	4300 S PADRE ISLAND DR		CORPUS CHRISTI	TX	78411-4433
Affiliated	6360	NORTH SPOKANE RENAL CENTER AT HOME	North Spokane Renal At Home (P262)	12610 E MARIBEAU PRKWY	STE 100	SPOKANE	WA	99216
Affiliated	5659	TEMPE DIALYSIS PD	Tempe Dialysis Center PD	2149 EAST WARNER RD	STE 109	TEMPE	AZ	85284-3496
Affiliated	5660	ARROWHEAD LAKES DIALYSIS PD	Arrowhead Lakes Dialysis PD	20325 N 51ST AVE	BLDG 11, STE 184	GLENDALE	AZ	85308-4625
Affiliated	5916	SHAKER SQUARE AT HOME	Shaker Square At Home	12800 SHAKER BLVD	STE 1	CLEVELAND	OH	44120-2004
Affiliated	6130	SIERRA ROSE AT HOME	Sierra Rose At Home	685 SIERRA ROSE DR		RENO	NV	89511-2060
Affiliated	6217	TEMPE AT HOME	Tempe At Home	2149 E WARNER RD	STE 109	TEMPE	AZ	85284-3496
Affiliated	6281	TUSCALOOSA AT HOME	Tuscaloosa At Home	805 OLD MILL ST		TUSCALOOSA	AL	35401-7132

TEMPORARY CLOSURES

(Included above are several centers that have temporarily suspended operations for a variety of reasons, but are scheduled to resume operations within the coming few months)

614	Lynwood
643	Vidalia
3518	Huntingdon Valley Dialysis
626	Tuba City
903	Littleton

Exhibit D

Managed Centers List

Exhibit D

Managed Centers List

Active count	TYPE	CTR #	CENTER NAME	LEGAL NAME	ADDRESS	ADDRESS	CITY	STATE	ZIP
1771	Administrative Services	181	Childrens Hospital	MGD-Children’s National Medical Center	111 MICHIGAN AVE NW		WASHINGTON	DC	20010-2916
1772	Administrative Services	1624	Renal Care Seat Pleasant	MGD-Renal Care of Seat Pleasant	6274 CENTRAL AVE		SEAT PLEASANT	MD	20743
1773	Administrative Services	1715	Moses Taylor Hospital Renal Unit	Moses Taylor Hospital Renal Unit	700 QUINCY AVE		SCRANTON	PA	18510-1724
1774	Administrative Services	3330	Aurora Medical Group - Fond du Lac	Aurora Medical Group-Fond du Lac	210 WISCONSIN AMERICAN DR	ATTN DAVITA DIALYSIS (WEST END OF BLDG)	FOND DU LAC	WI	54937-2999
1775	Administrative Services	3331	Aurora Medical Group - Sheboygan	Aurora Medical Group-Sheboygan	2414 KOHLER MEMORIAL DR		SHEBOYGAN	WI	53081-3129
1776	Administrative Services	3338	Aurora Medical Group - Lake Geneva	Aurora Medical Group-Lake Geneva	146 E GENEVA SQ		LAKE GENEVA	WI	53147-9694
1777	Administrative Services	3555	Aurora Medical Group - Marinette Dialysis	Aurora Medical Group-Marinette Dialysis	4061 OLD PESHTIGO RD		MARINETTE	WI	54143
1778	Administrative Services	3607	Aurora Medical Group - Brown County Dialysis	Aurora Medical Group-Brown County Dialysis	1751 DECKNER AVE		GREEN BAY	WI	54302-2630
1779	Administrative Services	3641	Aurora Medical Group - Sturgeon Bay Dialysis	Aurora Medical Group-Sturgeon Bay Dialysis	108 S 10TH AVE		STURGEON BAY	WI	54235-1802
1780	Administrative Services	3653	Aurora Medical Group - Oshkosh West Dialysis	Aurora Medical Group-Oshkosh West Dialysis	855 N WESTHAVEN DR		OSHKOSH	WI	54904-7668
1781	Administrative Services	3665	Aurora Medical Group - Manitowoc Dialysis	Aurora Medical Group-Manitowoc Dialysis	601 REED AVE		MANITOWOC	WI	54220-2026
1782	Administrative Services	3672	Aurora Medical Group - Wautoma Dialysis	Aurora Medical Group-Wautoma Dialysis	900 EAST DIVISION ST		WAUTOMA	WI	54982-6944
1783	Administrative Services	1868	Maize Dialysis	Maize Dialysis Center	10001 GRADY AVE		MAIZE	KS	67101
1784	Administrative Services	1912	Kidney Dialysis Center	MGD-Kidney Dialysis Center, LLC (MMG Macon)	640 MARTIN LUTHER KING JR BLVD		MACON	GA	31201-3206
	Administrative Services	6079	MAGNOLIA WEST AT HOME	Magnolia West At Home	11161 MAGNOLIA AVE	STE B	RIVERSIDE	CA	92505-3605
	Administrative Services	1903	Riverside PD Central NAMG	Riverside PD Central	3660 PARK SIERRA DR	STE 18	RIVERSIDE	CA	92505-3071

Exhibit E

Dialysis Center Committed Purchasers List

Dialysis Center Committed Purchasers List

Active count	TYPE	CTR #	CENTER NAME	LEGAL NAME	ADDRESS	ADDRESS	CITY	STATE	ZIP
1	Affiliated	398	Los Angeles Dialysis Center	Los Angeles Dialysis Center (LADC)	3901 S WESTERN AVE		LOS ANGELES	CA	90062-1112
2	Affiliated	613	Garfield	Garfield Hemodialysis Center	118 HILLIARD AVE		MONTEREY PARK	CA	91754-1118
3	Affiliated	614	Lynwood	Kidney Dialysis Care Unit (Lynwood)	3600 E MARTIN LUTHER KING JR BLVD		LYNWOOD	CA	90262-2607
4	Affiliated	615	Lakewood Dialysis-CA	Lakewood Dialysis-CA	4611 SILVA ST		LAKEWOOD	CA	90712-2512
5	Affiliated	616	Valley Dialysis	Valley Dialysis	16149 HART ST		VAN NUYS	CA	91406-3906
6	Affiliated	617	Downey Dialysis	Downey Dialysis	8630 FLORENCE AVE	STE 1	DOWNEY	CA	90240-4017
7	Affiliated	618	Covina Dialysis	Covina Dialysis	1547 W GARVEY AVE N		WEST COVINA	CA	91790-2139
8	Affiliated	625	Four Corners Farmington	Four Corners Farmington	801 W BROADWAY		FARMINGTON	NM	87401-5650
9	Affiliated	626	Tuba City Dialysis	Tuba City Dialysis	500 EDGEWATER DR	PO BOX 291	TUBA CITY	AZ	86045-2905
10	Affiliated	627	Camelback Dialysis Center	Camelback Dialysis Center (fka Scottsdale Dialysis Center)	7321 E OSBORN DR		SCOTTSDALE	AZ	85251-6418
11	Affiliated	630	Westbank	Westbank Chronic Renal Center	3631 BEHRMAN PLACE		NEW ORLEANS	LA	70114
12	Affiliated	632	Fleur de Lis	Fleur de Lis Dialysis (fka Tri-Parish)	5555 BULLARD AVE		NEW ORLEANS	LA	70128-3450
13	Affiliated	637	Desert Mountain	Desert Mountain Dialysis	9220 E MOUNTAIN VIEW RD	STE 15	SCOTTSDALE	AZ	85258-5134
14	Affiliated	638	Chinle	Chinle Dialysis	US HWY 191	PO BOX 879	CHINLE	AZ	86503-0879
15	Affiliated	648	Central City	Central City Dialysis Center	1300 MURCHISON DR	STE 32	EL PASO	TX	79902-4840
16	Affiliated	651	Federal Way	Federal Way Community Dialysis Center	1015 S 348TH ST		FEDERAL WAY	WA	98003-7078
17	Affiliated	663	Beverly Hills	Beverly Hills Dialysis Center	50 N LA CIENEGA BLVD	3RD FLOOR, STE 3	BEVERLY HILLS	CA	90211-2205
18	Affiliated	667	Walnut Creek	Walnut Creek Dialysis Center	404 N WIGET LN		WALNUT CREEK	CA	94598-2408
19	Affiliated	672	Norwalk	Norwalk Dialysis Center	12375 E IMPERIAL HWY	STE D3	NORWALK	CA	90650-3129
20	Affiliated	673	El Monte	Greater El Monte Dialysis Center	1938 TYLER AVE	STE J-168	SOUTH EL MONTE	CA	91733-3623
21	Affiliated	676	Bayonet Point	Bayonet Point-Hudson Kidney	14144 NEPHRON LN		HUDSON	FL	34667-6504
22	Affiliated	677	New Port Richey	New Port Richey Kidney Center	7421 RIDGE RD		PORT RICHEY	FL	34668-6933
23	Affiliated	678	Hernando	Hernando Kidney Center, Inc	2985 LANDOVER BLVD		SPRING HILL	FL	34608-7258
24	Affiliated	681	Woodbridge	CDC Of Woodbridge	2751 KILLARNEY DR		WOODBRIDGE	VA	22192-4119
25	Affiliated	682	Manassas	CDC-Manassas Dialysis	10655 LOMOND DR	STE 11	MANASSAS	VA	20109-2877
26	Affiliated	683	Springfield	CDC-Springfield Dialysis	8350 TRAFORD LN	STE A	SPRINGFIELD	VA	22152-1671
27	Affiliated	684	Sterling	CDC-Sterling	46396 BENEDICT DR	STE 1	STERLING	VA	20164-6626
28	Affiliated	687	Alexandria	Springfield-Alexandria	5999 STEVENSON AVE	STE 1	ALEXANDRIA	VA	22304-3302
29	Affiliated	642	Statesboro	Nephrology Center of Statesboro fka Statesboro Dialysis	4B COLLEGE PLZ		STATESBORO	GA	30458-4928
30	Affiliated	643	Vidalia	Nephrology Center of Vidalia	1806 EDWINA DR		VIDALIA	GA	30474-8927
31	Affiliated	657	Papago Dialysis	Papago Dialysis Center (fka PD Central & Squaw Peak)	1401 N 24TH ST	STE 2	PHOENIX	AZ	85008-4638
32	Affiliated	658	Boca Raton	Boca Raton Artificial Kidney Center	998 NW 9TH CT		BOCA RATON	FL	33486-2214
33	Affiliated	644	Piedmont	Buckhead Dialysis	1575 NORTHSIDE DR NW	STE 365	ATLANTA	GA	30318-4210
34	Affiliated	311	Logan Square	Logan Square Dialysis Services	2659 N MILWAUKEE AVE	1ST FL	CHICAGO	IL	60647-1643
35	Affiliated	312	Lake County	Lake County Dialysis Services	918 S MILWAUKEE AVE		LIBERTYVILLE	IL	60048-3229
36	Affiliated	314	Lincoln Park	Lincoln Park Dialysis fka Lincoln Park Nephrology	3157 N LINCOLN AVE		CHICAGO	IL	60657-3111
37	Affiliated	318	Lincoln Pk-PD	Skyline Home Dialysis (fka Lincoln Park PD)	7009 W BELMONT AVE		CHICAGO	IL	60634-4533
38	Affiliated	670	West Palm Beach	Dialysis Associates of the Palm Beaches	2611 POINSETTIA AVE		WEST PALM BEACH	FL	33407-5919
39	Affiliated	693	Sunrise	Sunrise Dialysis Center	13039 HAWTHORNE BLVD		HAWTHORNE	CA	90250-4415
40	Affiliated	655	Kayenta	Kayenta Dialysis	PO BOX 217	US HWY 163 N	KAYENTA	AZ	86033-0217
41	Affiliated	321	Hyde Park	Emerald Dialysis (fka Hyde Park Kidney Center)	710 W 43RD ST		CHICAGO	IL	60609-3435
42	Affiliated	322	Olympia Fields	Olympia Fields Dialysis Center	4557B LINCOLN HWY	STE B	MATTESON	IL	60443-2318
43	Affiliated	351	CKD	Center for Kidney Disease at North Shore	1190 NW 95TH ST	STE 28	MIAMI	FL	33150-2065
44	Affiliated	352	Venture	Center for Kidney Disease at Venture	16855 NE 2ND AVE	STE 25	N MIAMI BEACH	FL	33162-1744
45	Affiliated	360	South Broward	South Broward Artifical Kidney	4401 HOLLYWOOD BLVD		HOLLYWOOD	FL	33021-6609
46	Affiliated	688	East End	East End Dialysis Center	2201 E MAIN ST	STE 1	RICHMOND	VA	23223-7071
47	Affiliated	354	Flamingo Park	Flamingo Park Kidney Cntr, Inc	901 E 10TH AVE	BAY 17	HIALEAH	FL	33010-3762
48	Affiliated	355	Interamerican	InterAmerican Dialysis Center	7815 CORAL WAY	STE 115	MIAMI	FL	33155-6541
49	Affiliated	356	Coral Gables Dialysis Center	Coral Gables Kidney Center (fka LeJeune)	3280 PONCE DE LEON BLVD		CORAL GABLES	FL	33134-7252

50	Affiliated	370	Cielo Vista Dialysis	DaVita East Dialysis dba Cielo Vista Dialysis (fkaTotal Renal Care East Dialysis Center)	7200 GATEWAY BLVD E	STE B	EL PASO	TX	79915-1301
51	Affiliated	371	West Texas Dialysis	DaVita West Dialysis Center dba West Texas (fkaTotal Renal Care West Dialysis Center)	5595 ALAMEDA AVE B	STE B	EL PASO	TX	79905
52	Affiliated	656	Shiprock	Shiprock Dialysis	PO BOX 2156	US HWY 491 N	SHIPROCK	NM	87420-2156
53	Affiliated	202	Arden Hills	Arden Hills Dialysis Unit	3900 NORTHWOODS DR	STE 11	ARDEN HILLS	MN	55112-6911
54	Affiliated	203	Burnsville	Burnsville Dialysis Unit	501 E NICOLLET BLVD	STE 15	BURNSVILLE	MN	55337-6784
55	Affiliated	204	Coon Rapids	Coon Rapids Dialysis Unit	3960 COON RAPIDS BLVD NW	STE 39	COON RAPIDS	MN	55433-2598
56	Affiliated	205	Edina	Edina Dialysis Unit	6550 YORK AVE S	STE 1	EDINA	MN	55435-2332
57	Affiliated	206	Maplewood	Maplewood Dialysis Center	2785 WHITE BEAR AVE N	STE 21	MAPLEWOOD	MN	55109-1320
58	Affiliated	207	Minneapolis	Minneapolis Dialysis Unit	825 S EIGHTH ST	STE SL42	MINNEAPOLIS	MN	55404-1208
59	Affiliated	208	Minnetonka	Minnetonka Dialysis Unit	17809 HUTCHINS DR		MINNETONKA	MN	55345-4100
60	Affiliated	209	St. Paul Dialysis	St. Paul Dialysis Unit	555 PARK ST	STE 18	SAINT PAUL	MN	55103-2192
61	Affiliated	210	Special Needs	University Dialysis Unit Riverside (Minneapolis-Special Needs Dialysis)	1045 WESTGATE DR	STE 9	SAINT PAUL	MN	55114-1079
62	Affiliated	211	West St. Paul	West St. Paul Dialysis	1555 LIVINGSTON AVE		WEST ST PAUL	MN	55118-3411
63	Affiliated	213	Cass Lake	Cass Lake Dialysis Unit	602 GRANT UTLEY ST	PO BOX 757	CASS LAKE	MN	56633-0757
64	Affiliated	215	Faribault	Faribault Dialysis Unit	201 LYNDALE AVE S	STE F	FARIBAULT	MN	55021-5758
65	Affiliated	217	Marshall	Marshall Dialysis Unit	300 S BRUCE ST	AVERA MARSHALL REGIONAL MEDICAL CENTER	MARSHALL	MN	56258-1934
66	Affiliated	218	Montevideo	Montevideo Dialysis Center	824 N 11TH ST	MONTEVIDEO HOSPITAL	MONTEVIDEO	MN	56265-1629
67	Affiliated	220	Pine City	TRC-Pine City (fka-Pine City Dialysis Unit)	129 6TH AVE SE	LAKESIDE MEDICAL CENTER	PINE CITY	MN	55063-1913
68	Affiliated	222	Red Wing	Red Wing Dialysis Unit	3028 N SERVICE DR		RED WING	MN	55066-1921
69	Affiliated	223	Redwood Falls	Redwood Falls Dialysis Center	100 FALLWOOD RD		REDWOOD FALLS	MN	56283-1828
70	Affiliated	240	Mitchell	Mitchell Dialysis	525 N FOSTER	QUEEN OF PEACE HOSPITAL	MITCHELL	SD	57301-2966
71	Affiliated	242	Rosebud	Rosebud Dialysis	1 SOLDIER CREEK RD		ROSEBUD	SD	57570-0610
72	Affiliated	243	Sioux Falls	Sioux Falls Dialysis Community Unit	1325 S CLIFF AVE	STE 46	SIOUX FALLS	SD	57105-1016
73	Affiliated	250	St. Croix Falls	St. Croix Falls Dialysis	744 E LOUISIANA ST		SAINT CROIX FALLS	WI	54024-9501
74	Affiliated	260	Hayward	Hayward Dialysis Center	21615 HESPERIAN BLVD	STE F	HAYWARD	CA	94541-7026
75	Affiliated	262	Pleasanton	Pleasanton Dialysis Center (HEMO) (fka Dublin)	5720 STONERIDGE MALL RD	STE 16	PLEASANTON	CA	94588-2882
76	Affiliated	263	Union City	Union City Dialysis Center (aka TRC-Union City)	32930 ALVARADO NILES RD	STE 3	UNION CITY	CA	94587-8101
77	Affiliated	264	East Bay - PD	East Bay Peritoneal Dialysis Center	13939 E 14TH ST	STE 11	SAN LEANDRO	CA	94578-2613
78	Affiliated	383	Greer	Greer Kidney Center	211 VILLAGE DR		GREER	SC	29651-1238
79	Affiliated	382	Upstate	Upstate Dialysis Center	308 MILLS AVE		GREENVILLE	SC	29605-4022
80	Affiliated	390	Kenner	Kenner Regional Dialysis Center	200 W ESPLANADE AVE	STE 1	KENNER	LA	70065-2473
81	Affiliated	689	Downtown Dialysis	Downtown Dialysis Center	821 N EUTAW ST	STE 41	BALTIMORE	MD	21201-6304
82	Affiliated	331	Eaton Canyon	Eaton Canyon Dialysis	2551 E WASHINGTON BLVD		PASADENA	CA	91107-1446
83	Affiliated	190	Georgetown	Georgetown on the Potomac	3223 K ST NW	STE 11	WASHINGTON	DC	20007-4412
84	Affiliated	395	St. Mary	Newtown Dialysis Center (fka St. Mary Dialysis)	60 BLACKSMITH RD		NEWTOWN	PA	18940-1847
85	Affiliated	393	Bertha Sirk	Bertha Sirk Dialysis Center	5820 YORK RD	STE 1	BALTIMORE	MD	21212-3620
86	Affiliated	394	Greenspring	Greenspring Dialysis Center	4701 MOUNT HOPE DR	STE C	BALTIMORE	MD	21215-3246
87	Affiliated	378	Houston Kidney - NW	Northwest Kidney Center (Houston)	11029 NORTHWEST FWY		HOUSTON	TX	77092-7311
88	Affiliated	379	NorthStar Dialysis	NorthStar Dialysis Center (fka North Houston Kidney Center)	380 W LITTLE YORK RD		HOUSTON	TX	77076-1303
89	Affiliated	363	Port Charlotte	Port Charlotte Artificial Kidney Center	4300 KINGS HWY STE 406		PORT CHARLOTTE	FL	33980
90	Affiliated	364	Gulf Coast PD	Gulf Coast Dialysis	3300 TAMIAMI TRL	STE 11A	PORT CHARLOTTE	FL	33952-8054
91	Affiliated	649	Loma Vista	Loma Vista Dialysis Center Partnership	1382 LOMALAND DR	STE A	EL PASO	TX	79935-5204
92	Affiliated	332	Paramount	Paramount Dialysis Center	8319 ALONDRA BLVD		PARAMOUNT	CA	90723-4403
93	Affiliated	334	East LA	Doctors Dialysis of East LA (aka East Los Angeles Dialysis)	950 S EASTERN AVE		LOS ANGELES	CA	90022-4801
94	Affiliated	335	Montebello	Doctors Dialysis of Montebello	1721 W WHITTIER BLVD		MONTEBELLO	CA	90640-4004
95	Affiliated	361	Pine Island	Pine Island Kidney Center	1871 N PINE ISLAND RD		PLANTATION	FL	33322-5208
96	Affiliated	365	Complete	Complete Dialysis Care	7850 W SAMPLE RD		MARGATE	FL	33065-4710
97	Affiliated	122	Lone Star Dialysis	Lone Star Dialysis (fka Hobby Dialysis)	8560 MONROE RD		HOUSTON	TX	77061-4815
98	Affiliated	255	Forest Lake	Forest Lake Dialysis	1068 S LAKE ST	STE 11	FOREST LAKE	MN	55025-2633
99	Affiliated	690	USC Phase II	TRC/USC Dialysis Center	2310 ALCAZAR ST		LOS ANGELES	CA	90033-5327
100	Affiliated	396	TRC/Union Plaza Ctr	Union Plaza Dialysis Center	810 1ST ST NE	STE 1	WASHINGTON	DC	20002-4227
101	Affiliated	130	Mid-Columbia Kidney	Mid Columbia Kidney Center	6825 BURDEN BLVD	STE A	PASCO	WA	99301-9584
102	Affiliated	131	Mt. Adams Kidney Ctr	Mt. Adams Kidney Center	3220 PICARD PL		SUNNYSIDE	WA	98944-8400
103	Affiliated	650	Lakewood	Lakewood Community Dialysis Center	5919 LAKEWOOD TOWNE CENTER BLVD SW	STE A	LAKEWOOD	WA	98499-6513

104	Affiliated	228	St. Paul Ramsey	St. Paul Capitol Dialysis	555 PARK ST	STE 23	SAINT PAUL	MN	55103-2193
105	Affiliated	229	River City Dialysis	River City Dialysis (fka Lakeview Dialysis)	1970 NORTHWESTERN AVE S		STILLWATER	MN	55082-6567
106	Affiliated	231	Woodbury	Woodbury Dialysis	1850 WEIR DR	STE 3	WOODBURY	MN	55125-2260
107	Affiliated	281	Alhambra	Alhambra Dialysis Center	1315 ALHAMBRA BLVD	STE 1	SACRAMENTO	CA	95816-5245
108	Affiliated	282	Antelope	Antelope Dialysis Center	6406 TUPELO DR	STE A	CITRUS HEIGHTS	CA	95621-1780
109	Affiliated	283	Chico	Chico Dialysis Center (aka Chico Clinic)	530 COHASSET RD		CHICO	CA	95926-2212
110	Affiliated	285	North Clinic	Manzanita Dialysis Center (aka North Clinic)	4005 MANZANITA AVE	STE 17	CARMICHAEL	CA	95608-1779
111	Affiliated	286	Placerville	Cameron Park Dialysis (fka Placerville)	3311 COACH LN	STE C	CAMERON PARK	CA	95682
112	Affiliated	288	South Sacramento	South Sacramento Dialysis Center	7000 FRANKLIN BLVD	STE 88	SACRAMENTO	CA	95823-1838
113	Affiliated	289	Redding	Redding Dialysis Center	1876 PARK MARINA DR		REDDING	CA	96001-0913
114	Affiliated	291	Yuba City	Yuba City Dialysis Center	1525 PLUMAS CT	STE A	YUBA CITY	CA	95991-2971
115	Affiliated	292	University Clinic	University Dialysis Center	777 CAMPUS COMMONS RD	STE 1	SACRAMENTO	CA	95825-8344
116	Affiliated	372	Mesa Vista	Mesa Vista Dialysis Center (El Paso)	2400 N OREGON ST	STE C	EL PASO	TX	79902-3135
117	Affiliated	694	Hollywood	Hollywood Dialysis Center	5108 W SUNSET BLVD		LOS ANGELES	CA	90027-5708
118	Affiliated	697	UCLA Harbor	TRC/Harbor-UCLA MFI Total Renal Dialysis Center	21602 S VERMONT AVE		TORRANCE	CA	90502-1940
119	Affiliated	325	Brighton	Brighton Dialysis (fka Michigan Kidney Center of Brighton)	7960 GRAND RIVER RD	STE 21	BRIGHTON	MI	48114-7336
120	Affiliated	326	Macomb	Macomb Kidney Center (fka Macomb Dialysis)	28295 SCHOENHERR RD	STE A	WARREN	MI	48088-4300
121	Affiliated	327	North Oakland	North Oakland Dialysis	450 N TELEGRAPH RD	STE 6	PONTIAC	MI	48341-1037
122	Affiliated	328	Novi	Novi Dialysis	47250 W 10 MILE RD		NOVI	MI	48374-2932
123	Affiliated	329	Southfield	Cornerstone Dialysis (fka Southfield)	23857 GREENFIELD RD		SOUTHFIELD	MI	48075-3122
124	Affiliated	319	Children’s Mem’l Hosp.	TRC Children’s Dialysis Center aka Children’s Chicago/Children’s Memorial Hospital	2611 N HALSTED ST		CHICAGO	IL	60614-2301
125	Affiliated	151	New Center	New Center Dialysis	3011 W GRAND BLVD	STE 65	DETROIT	MI	48202-3012
126	Affiliated	2003	Whittier	Whittier Dialysis Center (fka Whittier Hills)	10055 WHITTWOOD DR		WHITTIER	CA	90603-2313
127	Affiliated	357	Miami Lakes	Miami Lakes Artificial Kidney Center (ALTHIN)	14600 NW 60TH AVE		MIAMI LAKES	FL	33014-2811
128	Affiliated	571	Anson County	Dialysis Care of Anson County	923 E CASWELL ST		WADESBORO	NC	28170-2305
129	Affiliated	573	Edgecomb County	Dialysis Care of Edgecomb County	3206 WESTERN BLVD		TARBORO	NC	27886-1828
130	Affiliated	574	Franklin County	Dialysis Care of Franklin County	1706 NC HWY 39 N		LOUISBURG	NC	27549-8329
131	Affiliated	575	Hoke County	Dialysis Care of Hoke County	403 S MAIN ST		RAEFORD	NC	28376-3222
132	Affiliated	576	Martin County	Dialysis Care of Martin County	100 MEDICAL DR		WILLIAMSTON	NC	27892-2156
133	Affiliated	578	Montgomery County	Dialysis Care of Montgomery County (aka Montgomery)	323 W MAIN ST		BISCOE	NC	27209-9528
134	Affiliated	579	Moore County	Dialysis Care of Moore County (aka Pinehurst)	16 REGIONAL DR		PINEHURST	NC	28374-8850
135	Affiliated	580	Richmond County	Dialysis Care of Richmond County	771 CHERAW RD		HAMLET	NC	28345-7158
136	Affiliated	581	Rockingham County	Dialysis Care of Rockingham County	251 W KINGS HWY		EDEN	NC	27288-5009
137	Affiliated	582	Rowan County	Dialysis Care of Rowan County	111 DORSETT DR		SALISBURY	NC	28144-2278
138	Affiliated	583	Rutherford County	Dialysis Care of Rutherford County	226 COMMERCIAL ST		FOREST CITY	NC	28043-2851
139	Affiliated	399	Monterey Park	Monterey Park Dialysis Center	2560 CORPORATE PL	STE 1-11 BLDG D	MONTEREY PARK	CA	91754-7612
140	Affiliated	183	Mason Dixon	Mason-Dixon Baltimore County	9635-A LIBERTY RD	STE 1	RANDALLSTOWN	MD	21133-2436
141	Affiliated	184	Carrol County	Carroll County Dialysis Facility	412 MALCOLM DR	STE 31	WESTMINSTER	MD	21157-6167
142	Affiliated	167	South Brooklyn	South Brooklyn Nephrology Center	3915 AVENUE V	STE 14	BROOKLYN	NY	11234-5150
143	Affiliated	843	Phenix City	Phenix City Dialysis Center	1900 OPELIKA RD		PHENIX CITY	AL	36867-3640
144	Affiliated	876	Brea	Brea Dialysis Center	595 TAMARACK AVE	STE A	BREA	CA	92821-3125
145	Affiliated	878	Hemet	Hemet Dialysis Center	3050 W FLORIDA AVE		HEMET	CA	92545-3619
146	Affiliated	883	Temecula	Temecula Dialysis Center	40945 COUNTY CENTER DR	STE G	TEMECULA	CA	92591-6006
147	Affiliated	880	Riverside	Riverside Dialysis Center	4361 LATHAM ST	STE 1	RIVERSIDE	CA	92501-1767
148	Affiliated	870	Napa	Napa Dialysis Center	3900 BEL AIRE PLZ	STE C	NAPA	CA	94558-2823
149	Affiliated	875	Santa Ana	Santa Ana Dialysis Center	1820 E DEERE AVE		SANTA ANA	CA	92705-5721
150	Affiliated	879	Valley View Dialysis Center	Valley View Dialysis Center (aka Morneo Valley)	26900 CACTUS AVE		MORENO VALLEY	CA	92555-3912
151	Affiliated	884	Orange	Mainplace Dialysis Center (fka Orange Dialysis Center)	972 W TOWN AND COUNTRY RD		ORANGE	CA	92868-4714
152	Affiliated	882	San Bernadino	Mountain Vista Dialysis Center (fka San Bernadino Dailysis Center (Mountain Vista))	4041 NORTH UNIVERSITY PKWY		SAN BERNARDINO	CA	92407-1823
153	Affiliated	871	Lakeport	Lakeport Dialysis Center	804 11TH ST	STE 2	LAKEPORT	CA	95453-4102
154	Affiliated	873	Vacaville	Vacaville Dialysis Center	941 MERCHANT ST		VACAVILLE	CA	95688-5315
155	Affiliated	877	Corona	Corona Dialysis Center	1820 FULLERTON AVE	STE 18	CORONA	CA	92881-3147
156	Affiliated	872	Fairfield	Fairfield Dialysis Center	4660 CENTRAL WAY		FAIRFIELD	CA	94534-1803
157	Affiliated	902	Westminster	Westminster Dialysis Center (Federal Heights)	9053 HARLAN ST	STE 9	WESTMINSTER	CO	80031-2908

158	Affiliated	901	Aurora	Aurora Dialysis Center	1411 S POTOMAC ST	AMC II STE 1	AURORA	CO	80012-4536
159	Affiliated	900	Denver	Denver Dialysis Center	2900 DOWNING ST	STE C	DENVER	CO	80205-4699
160	Affiliated	903	Littleton	Littleton Dialysis Center	209 W COUNTY LINE RD		LITTLETON	CO	80129-1901
161	Affiliated	904	South Denver	South Denver Dialysis Center	850 E HARVARD AVE	STE 6	DENVER	CO	80210-5030
162	Affiliated	946	Lee Street Dialysis	Lee Street Dialysis (fka Grant Park Dialysis Center)	5155 LEE ST NE		WASHINGTON	DC	20019-4051
163	Affiliated	868	Leesburg	Leesburg Dialysis Center	801 E DIXIE AVE	STE 18A	LEESBURG	FL	34748-7699
164	Affiliated	866	Panama City	Panama City Dialysis Center	615 HIGHWAY 231		PANAMA CITY	FL	32405-4704
165	Affiliated	867	Marianna	Marianna Dialysis Center	2930 OPTIMIST DR		MARIANNA	FL	32448-7703
166	Affiliated	864	Venice	Venice Dialysis Center	816 PINEBROOK RD		VENICE	FL	34285-7103
167	Affiliated	827	Buena Vista	Buena Vista Dialysis Center	349 GENEVA RD		BUENA VISTA	GA	31803-1701
168	Affiliated	828	Decatur	Decatur Dialysis Center	1987 CANDLER RD		DECATUR	GA	30032-4212
169	Affiliated	825	Moultrie	Moultrie Dialysis Center	2419 S MAIN ST		MOULTRIE	GA	31768-6531
170	Affiliated	820	SW Atlanta	Southwest Atlanta Dialysis Center	3620 MARTIN LUTHER KING DR SW		ATLANTA	GA	30331-3711
171	Affiliated	818	Griffin	Griffin Dialysis Center	731 S 8TH ST		GRIFFIN	GA	30224-4818
172	Affiliated	826	Columbus	Columbus Dialysis Center	6228 BRADLEY PARK DR	STE B	COLUMBUS	GA	31904-3604
173	Affiliated	829	East Macon	East Macon Dialysis Center	165 EMERY HWY	STE 11	MACON	GA	31217-3666
174	Affiliated	817	Jonesboro	Jonesboro Dialysis Center	129 KING ST		JONESBORO	GA	30236-3656
175	Affiliated	824	Milledgeville	Milledgeville Dialysis Center	400 S WAYNE ST		MILLEDGEVILLE	GA	31061-3446
176	Affiliated	823	Fort Valley	Fort Valley Dialysis Center	557 BLUEBIRD BLVD		FORT VALLEY	GA	31030-5083
177	Affiliated	821	Midtown	Linden Dialysis (fka Midtown-Atlanta)	121 LINDEN AVE NE		ATLANTA	GA	30308-2432
178	Affiliated	953	E. St. Louis	Sauget Dialysis (fka East St. Louis Dialysis Center)	2061 GOOSE LAKE RD		SAUGET	IL	62206-2822
179	Affiliated	952	Granite City	Granite City Dialysis Center	9 AMERICAN VLG		GRANITE CITY	IL	62040-3706
180	Affiliated	937	Batesville	Batesville Dialysis Center Aka Renal Treatment Centers-Batesville	232 STATE ROAD 129 S		BATESVILLE	IN	47006-7694
181	Affiliated	938	Lawrenceburg	Lawrenceburg Dialysis Center	721 RUDOLPH WAY		GREENDALE	IN	47025-8378
182	Affiliated	939	Madison	Madison Dialysis Center	220 CLIFTY DR	UNIT K	MADISON	IN	47250-1669
183	Affiliated	836	Newton	Renal Treatment Center-Newton aka-Newton Dialysis Center	1223 WASHINGTON RD		NEWTON	KS	67114-4855
184	Affiliated	837	Derby	Renal Treatment Center-Derby aka Derby Dialysis Center	250 W RED POWELL DR		DERBY	KS	67037-2626
185	Affiliated	834	Winfield	Renal Treatment Center-Winfield aka, Winfield Dialysis Center	1315 E 4TH AVE		WINFIELD	KS	67156-2457
186	Affiliated	830	Wichita	Wichita Dialysis Center	909 N TOPEKA ST		WICHITA	KS	67214-3620
187	Affiliated	833	Garden City	Renal Treatment Center-Garden City Aka-Garden City Dialysis Center	401 N MAIN ST		GARDEN CITY	KS	67846-5429
188	Affiliated	831	E. Wichita	East Wichita Dialysis Center	320 N HILLSIDE ST		WICHITA	KS	67214-4918
189	Affiliated	832	Independance	Independence Dialysis Center	801 W MYRTLE ST		INDEPENDENCE	KS	67301-3239
190	Affiliated	835	Parson, KS	Parsons Dialysis Center	1902 S US HWY 59	BLDG B	PARSONS	KS	67357-4948
191	Affiliated	814	Wheaton	Wheaton Dialysis Center	11941 GEORGIA AVE		WHEATON	MD	20902
192	Affiliated	812	Rockville	Rockville Dialysis Center	14915 BROSCHART RD	STE 1	ROCKVILLE	MD	20850-3367
193	Affiliated	815	Owing Mills	Owings Mills Dialysis Center (fka-Renal Treatment Center-Owings Mills)	10 CROSSROADS DR	STE 11	OWINGS MILLS	MD	21117-5463
194	Affiliated	811	Berlin	Berlin Dialysis Center	314 FRANKLIN AVE	STE 36	BERLIN	MD	21811-1238
195	Affiliated	810	Easton	Easton Dialysis Center	402 MARVEL CT		EASTON	MD	21601-4052
196	Affiliated	813	Chestertown	Chestertown Dialysis Center (fka Renal Treatment Centers-Chestertown)	100 BROWN ST		CHESTERTOWN	MD	21620
197	Affiliated	951	Hope Again	Hope Again Dialysis Center- fka Kennett Dialysis Center	1207 STATE ROUTE VV		KENNETT	MO	63857-3823
198	Affiliated	950	Poplar Bluff	Bluff City Dialysis Center	2400 LUCY LEE PKWY	STE E	POPLAR BLUFF	MO	63901-2429
199	Affiliated	949	Crystal City	Crystal City Dialysis Center	960 SO TRUMAN BLVD		CRYSTAL CITY	MO	63019-1329
200	Affiliated	947	St. Louis	St. Louis Dialysis Center (fka Renal Treatment Center-St. Louis)	2610 CLARK AVE		SAINT LOUIS	MO	63103-2502
201	Affiliated	944	Burlington	Burlington Dialysis	873 HEATHER RD		BURLINGTON	NC	27215-6288
202	Affiliated	838	Scottsbluff	Scottsbluff Dialysis Center	3812 AVENUE B		SCOTTSBLUFF	NE	69361-4780
203	Affiliated	802	Bridgewater	Bridgewater Dialysis Center (fka Renal Treatment Center-Bridgewater)	2121 US HWY 22		BOUND BROOK	NJ	08805-1546
204	Affiliated	845	West Las Vegas	Las Vegas Dialysis Center	150 S VALLEY VIEW BLVD		LAS VEGAS	NV	89107
205	Affiliated	846	North Las Vegas	North Las Vegas Dialysis Center	2300 MCDANIEL ST		NORTH LAS VEGAS	NV	89030-6318
206	Affiliated	940	Cincinnati	Eastgate Dialysis (fka Cincinnati)	4435 AICHOLTZ RD		CINCINNATI	OH	45245-1690
207	Affiliated	885	Tulsa	Tulsa Dialysis	4436 S HARVARD AVE		TULSA	OK	74135-2605
208	Affiliated	897	NW Bethany	Northwest Bethany Dialysis Center	7800 NW 23RD ST	STE A	BETHANY	OK	73008-4948
209	Affiliated	890	Duncan	Duncan Dialysis Center	2645 W ELK AVE		DUNCAN	OK	73533-1572
210	Affiliated	893	Shawnee	Shawnee Dialysis Center	4409 N KICKAPOO AVE	STE 113	SHAWNEE	OK	74804-1224
211	Affiliated	895	Stillwater	Stillwater Dialysis Center	406 E HALL OF FAME AVE	STE 3	STILLWATER	OK	74075-5447

212	Affiliated	955	Midwest City	Midwest City Dialysis Center	7221 E RENO AVE		MIDWEST CITY	OK	73110-4474
213	Affiliated	886	Broken Arrow	Broken Arrow Dialysis Center	1700 N 9TH ST		BROKEN ARROW	OK	74012
214	Affiliated	888	Tahlequah	Tahlequah Dialysis Center	1373 E BOONE ST		TAHLEQUAH	OK	74464-3330
215	Affiliated	899	Edmund	Edmond Dialysis	50 S BAUMANN AVE		EDMOND	OK	73034-5676
216	Affiliated	889	Altus	Altus Dialysis Center	205 S PARK LN	STE 13	ALTUS	OK	73521-5756
217	Affiliated	896	Elk City	Elk City Dialysis Center	1601 W 2ND ST		ELK CITY	OK	73644-4427
218	Affiliated	887	Claremore	Claremore Dialysis Center	202 E BLUE STARR DR		CLAREMORE	OK	74017-4223
219	Affiliated	891	Norman	Norman Dialysis Center	1818 W LINDSEY ST	STE 14 BLDG B	NORMAN	OK	73069-4159
220	Affiliated	862	Pocono	Pocono Dialysis Center	100 PLAZA CT	STE B	EAST STROUDSBURG	PA	18301-8258
221	Affiliated	861	Palmerton	Palmerton Dialysis Center	185 DELAWARE AVE	STE C	PALMERTON	PA	18071-1716
222	Affiliated	860	Jennersville	Jennersville Dialysis Center	1011 W BALTIMORE PIKE		WEST GROVE	PA	19390-9446
223	Affiliated	858	Lewistown	Lewistown Dialysis Center	611 ELECTRIC AVE		LEWISTOWN	PA	17044-1128
224	Affiliated	854	Lemoyne	Camp Hill Dialysis Center (fka Lemoyne Dialysis Center (York Hospital Acutes))	425 N 21ST ST	LOWER LEVEL	CAMP HILL	PA	17011-2223
225	Affiliated	856	Upland	Upland Dialysis Center	1 MEDICAL CENTER BLVD	STE 12	CHESTER	PA	19013-3902
226	Affiliated	848	South Philadelphia	So. Philadelphia Dialysis Center	109 DICKINSON ST		PHILADELPHIA	PA	19147-6107
227	Affiliated	857	Exton	Exton Dialysis Center	710 SPRINGDALE DR		EXTON	PA	19341-2828
228	Affiliated	847	Northeast Philadelphia	NE Philadelphia Dialysis Center	518 KNORR ST		PHILADELPHIA	PA	19111-4604
229	Affiliated	934	Longview	Longview Dialysis Center	425 N FREDONIA ST		LONGVIEW	TX	75601-6464
230	Affiliated	935	Marshall-RTC	Marshall Dialysis Center	1301 S WASHINGTON AVE		MARSHALL	TX	75670-6215
231	Affiliated	933	Conroe	Conroe Dialysis Center	500 MEDICAL CENTER BLVD	STE 175	CONROE	TX	77304-2899
232	Affiliated	928	San Marcos	Hill Country Dialysis Center Of San Marcos	1820 PETER GARZA DR		SAN MARCOS	TX	78666-7407
233	Affiliated	923	Sherman	Sherman Dialysis Center	205 W LAMBERTH RD		SHERMAN	TX	75092-2659
234	Affiliated	932	Tomball	Tomball Dialysis Center	27720A TOMBALL PKWY		TOMBALL	TX	77375-
235	Affiliated	919	Cleveland	Cleveland Dialysis Center	600 E HOUSTON	STE 63	CLEVELAND	TX	77327-4689
236	Affiliated	921	Livingston	Livingston Dialysis Center	209 W PARK		LIVINGSTON	TX	77351-7020
237	Affiliated	920	Kingwood	Kingwood Dialysis Center	2300 GREEN OAK DR	STE 5	KINGWOOD	TX	77339-2053
238	Affiliated	930	North Houston	North Houston Dialysis Center	129 LITTLE YORK RD		HOUSTON	TX	77076-1020
239	Affiliated	926	Omni	Omni Dialysis Center (fka Hamilton Dialysis Center)	9350 KIRBY DR	STE 11	HOUSTON	TX	77054-2528
240	Affiliated	925	Victoria	Victoria Dialysis Center	1405 VICTORIA STATION DR		VICTORIA	TX	77901-3092
241	Affiliated	922	Lufkin	Lufkin Dialysis Center	700 S JOHN REDDITT DR		LUFKIN	TX	75904-3145
242	Affiliated	927	Gonzales	Gonzales Dialysis Center	1406 N SARAH DEWITT DR		GONZALES	TX	78629-2702
243	Affiliated	924	Denison	Denison Dialysis Center	1220 REBA MCENTIRE LANE		DENISON	TX	75020-9057
244	Affiliated	918	South San Antonio	South San Antonio Dialysis Center	1313 SE MILITARY DR	STE 111	SAN ANTONIO	TX	78214-2850
245	Affiliated	913	Austin	Waterloo Dialysis Center (fka Austin Dialysis Center)	5310 BURNET RD	UNIT 122	AUSTIN	TX	78756-2003
246	Affiliated	916	S. Austin	El Milagro Dialysis Unit (fka South Austin Dialysis Center)	2800 S INTERSTATE HWY 35	STE 12	AUSTIN	TX	78704-5700
247	Affiliated	929	SW San Antonio	Southwest San Antonio Dialysis Center	7515 BARLITE BLVD		SAN ANTONIO	TX	78224-1311
248	Affiliated	936	Bedford	HEB Dialysis Center (Bedford)	1401 BROWN TRL	STE A	BEDFORD	TX	76022-6416
249	Affiliated	917	TRC Med Cntr	Med-Center Dialysis, fka Plaza Dialysis Center & Houston Kidney Center #376	5610 ALMEDA RD		HOUSTON	TX	77004-7515
250	Affiliated	908	Chesapeake	Chesapeake Dialysis Center	1400 CROSSWAYS BLVD	CROSSWAYS II STE 16	CHESAPEAKE	VA	23320-2839
251	Affiliated	912	Hopewell	Hopewell Dialysis Center	301 W BROADWAY AVE		HOPEWELL	VA	23860-2645
252	Affiliated	911	Newport News	Newport News Dialysis Center	711 79TH ST		NEWPORT NEWS	VA	23605-2767
253	Affiliated	907	Norfolk	Norfolk Dialysis Center	962 NORFOLK SQ		NORFOLK	VA	23502-3235
254	Affiliated	909	Virginia Beach	Virginia Beach Dialysis Center	740 INDEPENDENCE CIR		VIRGINIA BEACH	VA	23455-6438
255	Affiliated	171	Palmer	Palmer Dialysis Center	30 COMMUNITY DR		EASTON	PA	18045-2658
256	Affiliated	589	Burgaw	SEDC (NC II) Burgaw Dialysis Center	704 S DICKERSON ST	PO BOX 1391	BURGAW	NC	28425-4904
257	Affiliated	590	Elizabethtown	SEDC (NC II) Elizabethtown Dialysis Center	101 DIALYSIS DR		ELIZABETHTOWN	NC	28337-9048
258	Affiliated	591	Jacksonville	SEDC (NC II) Jacksonville Dialysis Center	14 OFFICE PARK DR		JACKSONVILLE	NC	28546-7325
259	Affiliated	592	Kenansville	SEDC (NC II) Kenansville Dialysis Center	305 BEASLEY ST		KENANSVILLE	NC	28349-8798
260	Affiliated	593	Shallotte	SEDC (NC II) Shallotte Dialysis Center	4770 SHALLOTTE AVE		SHALLOTTE	NC	28470-6596
261	Affiliated	594	Whiteville	SEDC (NC II) Whiteville Dialysis Center	608 PECAN LN		WHITEVILLE	NC	28472-2949
262	Affiliated	595	Wilmington	SEDC (NC II) Wilmington Dialysis Center	2215 YAUPON DR		WILMINGTON	NC	28401-7334
263	Affiliated	175	Deerfield	Deerfield Beach Artificial Kidney Center	1983 W HILLSBORO BLVD		DEERFIELD BEACH	FL	33442-1418
264	Affiliated	176	Pampano Beach	Pompano Beach Artificial Kidney Center	600 SW 3RD ST	STE 11	POMPANO BEACH	FL	33060-6936
265	Affiliated	177	Tamarack	Tamarac Artificial Kidney Center	7140 W MCNAB RD		TAMARAC	FL	33321-5306

266	Affiliated	168	Atlantic AKC	Atlantic Artificial Kidney Center	6 INDUSTRIAL WAY W	STE B	EATONTOWN	NJ	07724-2258
267	Affiliated	587	Rowan/Kannapolis	Dialysis Care of Kannapolis	1607 N MAIN ST		KANNAPOLIS	NC	28081-2317
268	Affiliated	654	Cortez	Cortez Dialysis	610 E MAIN ST	STE C	CORTEZ	CO	81321-3308
269	Affiliated	142	West Bountiful 4/6/98	West Bountiful Dialysis	724 W 500 S	STE 3	WEST BOUNTIFUL	UT	84087-1471
270	Affiliated	187	Meherrin	Meherrin Dialysis Center	201A WEAVER AVE		EMPORIA	VA	23847-1248
271	Affiliated	436	Montclair	Montclair Dialysis Center	5050 PALO VERDE ST	STE 1	MONTCLAIR	CA	91763-2329
272	Affiliated	259	Pipestone	Pipestone Dialysis	916 4TH AVE SW		PIPESTONE	MN	56164-1054
273	Affiliated	236	Washington	Washington Dialysis Center	154 WASHINGTON PLZ		WASHINGTON	GA	30673-2074
274	Affiliated	235	Elberton	Elberton Dialysis Center	894 ELBERT ST		ELBERTON	GA	30635-2628
275	Affiliated	174	Gulf Breeze	Gulf Breeze Dialysis Center	1519 MAIN ST		DUNEDIN	FL	34698-4650
276	Affiliated	526	Asheville	Asheville Kidney Center	1600 CENTRE PARK DR		ASHEVILLE	NC	28805-6206
277	Affiliated	528	Sylva	Sylva Dialysis Center	655 ASHEVILLE HWY		SYLVA	NC	28779-2747
278	Affiliated	527	Hendersonville	Hendersonville Dialysis Center	500 BEVERLY HANKS CTR	HWY 25 N	HENDERSONVILLE	NC	28792
279	Affiliated	389	Memorial	Memorial Dialysis	4427 S ROBERTSON ST		NEW ORLEANS	LA	70115-6308
280	Affiliated	127	Warner Robbins	Dialysis Center of Middle Georgia-Warner Robins	509 N HOUSTON RD		WARNER ROBINS	GA	31093-8844
281	Affiliated	126	Macon - Middle Georgia	Dialysis Center of Middle Georgia-Macon	747 2ND ST		MACON	GA	31201-6835
282	Affiliated	344	Oakland PD	Oakland Peritoneal Dialysis Center (Piedmont PD)	5352 CLAREMONT AVE		OAKLAND	CA	94618
283	Affiliated	384	Fairfax	Fairfax Dialysis Center	8501 ARLINGTON BLVD	STE 1	FAIRFAX	VA	22031-4625
284	Affiliated	374	Houston SW	Houston Kidney Center Southwest	11111 BROOKLET DR	STE 1 BLDG 1	HOUSTON	TX	77099-3555
285	Affiliated	545	Pikes Peak	Pikes Peak Dialysis Center	2002 LELARAY ST	STE 13	COLORADO SPRINGS	CO	80909-2804
286	Affiliated	546	Printers Place	Printers Place Dialysis	2802 INTERNATIONAL CIR		COLORADO SPRINGS	CO	80910-3127
287	Affiliated	541	Lakewood Colorado	Lakewood Dialysis Center	1750 PIERCE ST		LAKEWOOD	CO	80214-1434
288	Affiliated	543	Boulder	Boulder Dialysis Center	2880 FOLSOM ST	STE 11	BOULDER	CO	80304-3769
289	Affiliated	542	Thornton	Thornton Dialysis Center	8800 FOX DR		THORNTON	CO	80260-6880
290	Affiliated	544	Arvada	Arvada Dialysis Center	9950 W 80TH AVE	STE 25	ARVADA	CO	80005-3914
291	Affiliated	173	Ft. Lauderdale	CDC South-Ft Lauderdale Renal Associates	6264 N FEDERAL HWY		FORT LAUDERDALE	FL	33308-1904
292	Affiliated	380	Houston Cypress Station	Houston Kidney Center Cypress Station	221 FM 1960 RD W	STE H	HOUSTON	TX	77090-3537
293	Affiliated	169	Erie County	Cleve Hill Dialysis Center (Fka Cleve Hill Limited Partnership-Erie Dialysis &ECMC Dialysis Center At Cleve Hill)	1461 KENSINGTON AVE		BUFFALO	NY	14215-1436
294	Affiliated	430	UCLA Pediatrics	Century City Dialysis (fka UCLA, DaVita Westwood UCLA)	10630 SANTA MONICA BLVD		LOS ANGELES	CA	90025-4837
295	Affiliated	501	Bronx	Bronx Dialysis Center	1615 EASTCHESTER RD		BRONX	NY	10461-2603
296	Affiliated	502	Catskill	Catskill Dialysis Center	139 FORESTBURGH RD		MONTICELLO	NY	12701-2364
297	Affiliated	505	Riverdale	Riverdale Dialysis Center	170 W 233RD ST		BRONX	NY	10463-5639
298	Affiliated	506	South Bronx	South Bronx Dialysis Center	1940 WEBSTER AVE		BRONX	NY	10457-4261
299	Affiliated	507	Stanten Island	Richmond Kidney Center (Staten Island)	1366 VICTORY BLVD		STATEN ISLAND	NY	10301-3907
300	Affiliated	238	McDonough	McDonough Dialysis Center	114 DUNN ST		MCDONOUGH	GA	30253-2347
301	Affiliated	192	Milford	Delaware Valley Dialysis Center (fka Milford)	102 DAVITA DR		MILFORD	PA	18337-9390
302	Affiliated	191	Honesdale	Honesdale Dialysis Center-NE Regional	RR 6 BOX 6636	STOURBRIDGE MALL	HONESDALE	PA	18431-9649
303	Affiliated	247	Memorial	Memorial Dialysis Center	11621 KATY FWY		HOUSTON	TX	77079-1801
304	Affiliated	246	Katy Dialysis Center	Grand Parkway Dialysis Center	403 W GRAND PKWY S	STE T	KATY	TX	77494-8358
305	Affiliated	245	Cyfair Dialysis Center	Cyfair Dialysis Center	9110 JONES RD	STE 11	HOUSTON	TX	77065-4489
306	Affiliated	165	Port Chester	Port Chester Dialysis and Renal Center	38 BULKLEY AVE		PORT CHESTER	NY	10573-3902
307	Affiliated	193	Franklin Dialysis	Franklin Dialysis Center	150 SOUTH INDEPENDENCE WEST	11 PUBLIC LEDGER BLDG	PHILADELPHIA	PA	19106-3413
308	Affiliated	156	Grand Blanc	Grand Blanc Dialysis Center	3625 GENESYS PKWY		GRAND BLANC	MI	48439-8070
309	Affiliated	397	Oxford Court	Oxford Court Dialysis	930 TOWN CENTER DR	STE G1	LANGHORNE	PA	19047-4260
310	Affiliated	348	Antioch	Antioch Dialysis	3100 DELTA FAIR BLVD		ANTIOCH	CA	94509-4001
311	Affiliated	401	North Palm Beach	North Palm Beach Dialysis Center	2841 PGA BLVD		PALM BEACH GARDENS	FL	33410-2910
312	Affiliated	277	Lodi	Lodi Dialysis Center	1610 W KETTLEMAN LN	STE D	LODI	CA	95242-4210
313	Affiliated	438	United	United Dialysis Center	3111 LONG BEACH BLVD		LONG BEACH	CA	90807-5015
314	Affiliated	437	Premier	Premier Dialysis Center	7612 ATLANTIC AVE		CUDAHY	CA	90201-5020
315	Affiliated	349	Salinas	Salinas Dialysis Center	955 BLANCO CIR	STE C	SALINAS	CA	93901-4452
316	Affiliated	428	Lowry I	Lowry Dialysis Center	7465 E 1ST AVE	STE A	DENVER	CO	80230-6877
317	Affiliated	154	Ypsilanti	Ypsilanti Dialysis	2766 WASHTENAW RD		YPSILANTI	MI	48197-1506
318	Affiliated	237	Eastpoint	East Point Dialysis	2669 CHURCH ST		EAST POINT	GA	30344-3115
319	Affiliated	520	Celia Dill	Celia Dill Dialysis Center	667 STONELEIGH AVE	STE 123 BARNS OFFICE CENTER	CARMEL	NY	10512-2454

320	Affiliated	248	Elmbrook	Brookriver Dialysis	8101 BROOKRIVER DR		DALLAS	TX	75247-4003
321	Affiliated	402	Ocala East	OCALA Regional Kidney Center-East	2870 SE 1ST AVE		OCALA	FL	34471-0406
322	Affiliated	403	Ocala West	OCALA Regional Kidney Center-West	9401 SW HWY 200	BLDG 6	OCALA	FL	34481-9612
323	Affiliated	404	Ocala South	OCALA Regional Kidney Center-South	13940 N US HWY 441	BLDG 4	LADY LAKE	FL	32159-8908
324	Affiliated	417	Delta Sierra Dialysis	Delta-Sierra Dialysis Center	555 W BENJAMIN HOLT DR	STE 2	STOCKTON	CA	95207-3839
325	Affiliated	552	Olympic View	Olympic View Dialysis Center	125 16TH AVE E CSB	5TH FL	SEATTLE	WA	98112
326	Affiliated	148	Pratt	Pratt Dialysis Center	203 WATSON ST	STE 11	PRATT	KS	67124-3092
327	Affiliated	196	Buffalo	Renal Care of Buffalo	550 ORCHARD PARK RD		WEST SENECA	NY	14224-2646
328	Affiliated	555	Woodland	Woodland Dialysis Center	912 WOODLAND DR	STE B	ELIZABETHTOWN	KY	42701-2795
329	Affiliated	556	Taylor	Taylor County Dialysis Center	101 KINGSWOOD DR		CAMPBELLSVILLE	KY	42718-9634
330	Affiliated	491	Gary	Comprehensive Renal Care (CRC)-Gary	4802 BROADWAY		GARY	IN	46408-4509
331	Affiliated	492	Hammond	Comprehensive Renal Care (CRC)-Hammond	222 DOUGLAS ST		HAMMOND	IN	46320-1960
332	Affiliated	493	Valparaiso	Comprehensive Renal Care (CRC)-Valparaiso	606 E LINCOLNWAY		VALPARAISO	IN	46383-5728
333	Affiliated	494	Michigan City	Comprehensive Renal Care (CRC)-Michigan City	9836 WEST 400 NORTH		MICHIGAN CITY	IN	46360-2910
334	Affiliated	495	Munster	Comprehensive Renal Care (CRC)-Munster	9100 CALUMET AVE		MUNSTER	IN	46321-1737
335	Affiliated	497	South County-Deaconess	South County Dialysis (Deaconess)	4145 UNION RD		SAINT LOUIS	MO	63129-1064
336	Affiliated	266	South Hayward	South Hayward Dialysis Center	254 JACKSON ST		HAYWARD	CA	94544-1907
337	Affiliated	164	Dyker Heights	Dyker Heights Dialysis Center	1435 86TH ST		BROOKLYN	NY	11228-3435
338	Affiliated	152	Clarkston	Clarkston Dialysis Center	6770 DIXIE HWY	STE 25	CLARKSTON	MI	48346-2089
339	Affiliated	534	Hudson Valley	Hudson Valley Dialysis Center	155 WHITE PLAINS RD		TARRYTOWN	NY	10591-5523
340	Affiliated	971	Central Tulsa	Central Tulsa Dialysis Center	1124 S SAINT LOUIS AVE		TULSA	OK	74120-5413
341	Affiliated	972	Okmulgee	Okmulgee Dialysis Center	201 SO DELAWARE AVE		OKMULGEE	OK	74447-5528
342	Affiliated	974	Muskogee	Muskogee Community Dialysis	2316 W SHAWNEE ST		MUSKOGEE	OK	74401-2228
343	Affiliated	975	Miami-Oklahoma	Tri-State Dialysis Center (fka Miami Dialysis Center (OK))	2510 N MAIN ST		MIAMI	OK	74354-1602
344	Affiliated	977	Stilwell	Stilwell Dialysis Center	80851 HWY 59		STILWELL	OK	74960
345	Affiliated	496	East Chicago	Comprehensive Renal Care (CRC)-East Chicago	4320 FIR ST	UNIT 44	EAST CHICAGO	IN	46312-3078
346	Affiliated	549	Bright Dialysis	Bright Dialysis (fka Fort Pierce Artificial Kidney Center, TRC of Fort Pierce-AKC)	1801 S 23RD ST	STE 1	FORT PIERCE	FL	34950-4830
347	Affiliated	153	Detroit	Detroit Dialysis Center (Eastern Market, Brewery Park Development)	2674 E JEFFERSON AVE		DETROIT	MI	48207-4129
348	Affiliated	166	White Plains	White Plains Dialysis Center	200 HAMILTON AVE	STE 13B	WHITE PLAINS	NY	10601-1859
349	Affiliated	337	Crescent Heights	Crescent Heights Dialysis Center	8151 BEVERLY BLVD		LOS ANGELES	CA	90048-4514
350	Affiliated	547	Pahrump Dialysis	Pahrump Dialysis Center	330 S LOLA LN	STE 1	PAHRUMP	NV	89048-0884
351	Affiliated	598	Cherokee Dialysis Center	Cherokee Dialysis Center	53 ECHOTA CHURCH RD		CHEROKEE	NC	28719-9702
352	Affiliated	444	Utah Valley	Utah Valley Dialysis Center	1055 N 500 W	STE 221	PROVO	UT	84604-3305
353	Affiliated	439	Washington Plaza	Washington Plaza Dialysis Center	516 E WASHINGTON BLVD	# 522	LOS ANGELES	CA	90015-3723
354	Affiliated	539	Commerce City	Commerce City Dialysis Center	6320 HOLLY ST		COMMERCE CITY	CO	80022-3325
355	Affiliated	251	Bloomington Dialysis	Bloomington Dialysis Unit of TRC (fka Richfield)	8591 LYNDALE AVE S		BLOOMINGTON	MN	55420-2237
356	Affiliated	133	Kent Community Dialysis	Kent Dialysis Center	21501 84TH AVE S		KENT	WA	98032-1960
357	Affiliated	278	Florin Dialyis	Florin Dialysis Center	7000 STOCKTON BLVD		SACRAMENTO	CA	95823-2312
358	Affiliated	540	South Las Vegas Dialysis	South Las Vegas Dialysis Center (Palms)	2250 S RANCHO DR	STE 115	LAS VEGAS	NV	89102-4456
359	Affiliated	538	Longmont Dialysis	Longmont Dialysis Center	1715 IRON HORSE DR	STE 17	LONGMONT	CO	80501-9617
360	Affiliated	500	Great Bridge	Great Bridge Dialysis (fka Chesapeake II)	745 BATTLEFIELD BLVD N	STE 1	CHESAPEAKE	VA	23320-0305
361	Affiliated	569	Weaverville Dialysis	Weaverville Dialysis Facility	329 MERRIMON AVE		WEAVERVILLE	NC	28787-9253
362	Affiliated	427	Lakewood Crossing	Lakewood Crossing Dialysis	1057 S WADSWORTH BLVD	STE 1	LAKEWOOD	CO	80226-4361
363	Affiliated	155	Jackson	Jackson Dialysis Center	234 W LOUIS GLICK HWY		JACKSON	MI	49201-1326
364	Affiliated	429	Englewood	Englewood Dialysis Center	3247 S LINCOLN ST		ENGLEWOOD	CO	80113-2505
365	Affiliated	387	Harford Road Dialysis	Harford Road Dialysis Center	5800 HARFORD RD		BALTIMORE	MD	21214-1847
366	Affiliated	179	Arcadia	Arcadia Dialysis Center	1341 E OAK ST		ARCADIA	FL	34266-8902
367	Affiliated	388	Richmond Community	Richmond Community Hospital Dialysis (fkaTRC @ Richmond Community/Richmond II)	1510 N 28TH ST	STE 11	RICHMOND	VA	23223-5311
368	Affiliated	119	Henderson	Henderson Dialysis Center	1002 US HWY 79 N		HENDERSON	TX	75652-6008
369	Affiliated	253	Augusta	Nephrology Center of South Augusta	1631 GORDON HWY STE 1B		AUGUSTA	GA	30906
370	Affiliated	510	Boston Post Road	Boston Post Road Dialysis Center fka Co Op City Dialysis	4026 BOSTON RD		BRONX	NY	10475-1122
371	Affiliated	512	Peekskill	Peekskill Cortlandt Dialysis Center	2050 E MAIN ST	STE 15	CORTLANDT MANOR	NY	10567-2502
372	Affiliated	513	Queens	Queens Dialysis Center	11801 GUY R BREWER BLVD		JAMAICA	NY	11434-2101
373	Affiliated	517	Soundview	Soundview Dialysis Center	1622 BRUCKNER BLVD	STE 24	BRONX	NY	10473-4553

374	Affiliated	516	Port Washington	Port Washington Dialysis Center	50 SEAVIEW BLVD		PORT WASHINGTON	NY	11050-4615
375	Affiliated	515	Lynbrook	Lynbrook Dialysis Center	147 SCRANTON AVE		LYNBROOK	NY	11563-2808
376	Affiliated	518	Yonkers Dialysis Center	Yonkers Dialysis	575 YONKERS AVE		YONKERS	NY	10704-2601
377	Affiliated	537	IHS - Queens Village	Queens Village Dialysis Center	22202 HEMPSTEAD AVE	STE 17	QUEENS VILLAGE	NY	11429-2123
378	Affiliated	536	Coney Island - IHS	Sheepshead Bay Renal Care Center (fka Coney Island)	26 BRIGHTON 11TH ST		BROOKLYN	NY	11235-5304
379	Affiliated	521	Garden City I.H.S	Garden City Dialysis Center	1100 STEWART AVE	STE 2	GARDEN CITY	NY	11530-4839
380	Affiliated	267	Kenneth Hahn- I.R.A	Kenneth Hahn Plaza Dialysis Center (Willowbrook)	11854 S WILMINGTON AVE		LOS ANGELES	CA	90059-3016
381	Affiliated	279	North Highland	North Highlands Dialysis Center	4986 WATT AVE	STE F	NORTH HIGHLANDS	CA	95660-5182
382	Affiliated	294	TRC Orangevale	Orangevale Dialysis Center	9267 GREENBACK LN	STE A2	ORANGEVALE	CA	95662-4864
383	Affiliated	554	Forest Park Dialysis Center	Forest Park Dialysis Center	380 FOREST PKWY	STE C	FOREST PARK	GA	30297-2107
384	Affiliated	446	Grant Park Nursing Home Dialysis	Grant Park Dialysis (fka Grants Park Nursing Home)	5000 NANNIE HELEN BURROUGHS AVE NE		WASHINGTON	DC	20019-5506
385	Affiliated	455	Fourth Street Dialysis	Fourth Street Dialysis	3101 N 4TH ST	STE B	LONGVIEW	TX	75605-5146
386	Affiliated	274	Bay Breeze	Bay Breeze Dialysis	11465 ULMERTON RD		LARGO	FL	33778-1602
387	Affiliated	416	Hopi	Hopi Dialysis Center- fka First Mesa	PO BOX 964	HWY 264	POLACCA	AZ	86042
388	Affiliated	178	Orlando Dialysis	Orlando Dialysis	14050 TOWN LOOP BLVD	STE 14A	ORLANDO	FL	32837-6190
389	Affiliated	170	Celebration Dialysis	Celebration Dialysis	1154 CELEBRATION BLVD		CELEBRATION	FL	34747-4605
390	Affiliated	1500	Mt. Dora Dialysis	Mt. Dora Dialysis	2735 W OLD US HIGHWAY 441		MOUNT DORA	FL	32757-3526
391	Affiliated	1501	Lake Dialysis	Lake Dialysis	221 N 1ST ST		LEESBURG	FL	34748-5150
392	Affiliated	146	Puyallup Community Dialysis	Puyallup Dialysis Center	716 SOUTH HILL PARK DR	STE C	PUYALLUP	WA	98373-1445
393	Affiliated	562	Towson Dialysis	Dulaney Towson Dialysis Center	113 WEST RD	STE 21	TOWSON	MD	21204-2318
394	Affiliated	188	Purcellville	Purcellville Dialysis Center	280 N HATCHER AVE		PURCELLVILLE	VA	20132-3193
395	Affiliated	476	Iris City	Iris City Dialysis (aka Griffin)	521 N EXPRESSWAY	STE 159	GRIFFIN	GA	30223-2073
396	Affiliated	1521	Slidell Kidney Care	Slidell Kidney Care	1150 ROBERT BLVD	STE 24	SLIDELL	LA	70458-2005
397	Affiliated	385	Rivertowne Dialysis	Rivertowne Dialysis (fka Oxon Hill Dialysis)	6192 OXON HILL RD	1ST FL	OXON HILL	MD	20745-3114
398	Affiliated	477	Pearland Dialysis	Pearland Dialysis	6516 BROADWAY ST	STE 122	PEARLAND	TX	77581-7879
399	Affiliated	419	East Aurora Dialysis	East Aurora Dialysis (aka Aurora II)	482 S CHAMBERS RD		AURORA	CO	80017-2092
400	Affiliated	1507	Merrillville Dialysis	CRC-Merrillville Dialysis Center	9223 TAFT ST		MERRILLVILLE	IN	46410-6911
401	Affiliated	563	Bricktown Dialysis	Bricktown Dialysis Center	525 JACK MARTIN BLVD	FL 2	BRICK	NJ	08724-7735
402	Affiliated	423	Sapulpa	Sapulpa Dialysis (fka Jenks-Sapulpa)	9647 RIDGEVIEW ST		TULSA	OK	74131-6205
403	Affiliated	1526	Ellijay Dialysis	Ellijay Dialysis	449 INDUSTRIAL BLVD	STE 24	ELLIJAY	GA	30540-6724
404	Affiliated	1527	Gainesville Dialysis	Gainesville Dialysis	2545 FLINTRIDGE RD	STE 13	GAINESVILLE	GA	30501-7428
405	Affiliated	1528	Newnan Dialysis	Newnan Dialysis	1565 E HWY 34	STE 13	NEWNAN	GA	30265
406	Affiliated	405	Ocala Regional Kidney Center - North	OCALA North Dialysis Center	2620 W HWY 316		CITRA	FL	32113-3555
407	Affiliated	1516	Pin Oak Dialysis	Pin Oak Dialysis Center (aka Katy II)	1302 PIN OAK RD		KATY	TX	77494-6848
408	Affiliated	1523	Imperial Care Dialysis	Imperial Care Dialysis Center	4345 E IMPERIAL HWY		LYNWOOD	CA	90262-2318
409	Affiliated	1533	St. Louis Park Dialysis	St. Louis Park Dialysis Center	3505 LOUISIANA AVE S		ST LOUIS PARK	MN	55426-4121
410	Affiliated	1517	Minneapolis NE Dialysis	Minneapolis NE Dialysis	1049 10TH AVE SE		MINNEAPOLIS	MN	55414-1312
411	Affiliated	298	Flushing Dialysis	Flushing Dialysis Center	3469 PIERSON PL	STE A	FLUSHING	MI	48433-2413
412	Affiliated	1535	Dialysis Systems of Covington	Dialysis Systems of Covington	210 GREENBRIAR BLVD		COVINGTON	LA	70433-7235
413	Affiliated	1536	Dialysis Systems of Hammond	Dialysis Systems of Hammond	15799 PROFESSIONAL PLZ		HAMMOND	LA	70403-1452
414	Affiliated	433	Soledad Dialysis	Soledad Dialysis Center	901 LOS COCHES DR		SOLEDAD	CA	93960-2995
415	Affiliated	443	Lake Elsinore Dialysis	Lake Elsinore Dialysis	32291 MISSION TRL	BLDG S	LAKE ELSINORE	CA	92530
416	Affiliated	1511	Clinton Dialysis Center	Clinton Dialysis Center	150 S 31ST ST		CLINTON	OK	73601-9118
417	Affiliated	456	Bakers Ferry	Bakers Ferry Dialysis	3645 BAKERS FERRY RD SW		ATLANTA	GA	30331-3712
418	Affiliated	1509	Hermiston	Hermiston Community Dialysis Center	1155 W LINDA AVE		HERMISTON	OR	97838-9601
419	Affiliated	1539	Yakima	Yakima Dialysis Center	1221 N 16TH AVE		YAKIMA	WA	98902-1347
420	Affiliated	409	Madison	Madison Dialysis Center	302 HIGHWAY ST		MADISON	NC	27025-1672
421	Affiliated	1508	Swannanoa Dialysis	Swannanoa Dialysis Center (fka Black Mountain, NC)	2305 US HIGHWAY 70		SWANNANOA	NC	28778-8207
422	Affiliated	2009	NE Wichita Dialysis	NE Wichita Dialysis Center	2630 N WEBB RD	STE 1 BLDG 1	WICHITA	KS	67226-8174
423	Affiliated	2005	Chadbourn Dialysis	Chadbourn Dialysis Center (fkaColumbus County)	210 STRAWBERRY BLVD		CHADBOURN	NC	28431-1418
424	Affiliated	1506	Western Home Dialysis	Mile High Home Dialysis PD (fka Western Home)	1750 PIERCE ST	STE A	LAKEWOOD	CO	80214-1434
425	Affiliated	2019	Tustin Dialysis	Tustin Dialysis (aka Santa Ana)	2090 N TUSTIN AVE	STE 1	SANTA ANA	CA	92705-7869
426	Affiliated	182	Appomatox	Appomattox Dialysis (Petersburg)	15 W OLD ST		PETERSBURG	VA	23803-3221
427	Affiliated	2002	Maryville Dialysis	Maryville Dialysis	2130 VADALABENE DR		MARYVILLE	IL	62062-5632

428	Affiliated	2001	Mission Hills	Mission Hills Dialysis (aka Cristo Rey)	2700 N STANTON ST		EL PASO	TX	79902-2500
429	Affiliated	125	Moncrief	Moncrief Dialysis Partners	800 W 34TH ST	STE 11	AUSTIN	TX	78705-1144
430	Affiliated	295	Southfield West Dialysis	Southfield West Dialysis	21900 MELROSE AVE	STE 4	SOUTHFIELD	MI	48075-7967
431	Affiliated	525	Neptune Dialysis	Neptune Dialysis Center	2180 BRADLEY AVE		NEPTUNE	NJ	07753-4427
432	Affiliated	2014	Portsmouth Dialysis	Portsmouth Dialysis Center	2000 HIGH ST		PORTSMOUTH	VA	23704-3012
433	Affiliated	2016	Tokay Dialysis	Tokay Dialysis Center (fka East Lodi, CA)	312 S FAIRMONT AVE	STE A	LODI	CA	95240-3840
434	Affiliated	1504	Mt. Pocono Dialysis	Mt. Pocono Dialysis	100 COMMUNITY DR	STE 16	TOBYHANNA	PA	18466-8986
435	Affiliated	1544	Greater Portsmouth	Greater Portsmouth (aka Bon View Dialysis & Mid Town Hampton Road Dialysis)	3516 QUEEN ST		PORTSMOUTH	VA	23707-3238
436	Affiliated	1545	Peninsula Dialysis	Peninsula Dialysis Center (aka Immaculate Dialysis)	716 DENBIGH BLVD	STE D1 AND D2	NEWPORT NEWS	VA	23608-4414
437	Affiliated	1540	Saginaw Dialysis	Saginaw Dialysis	1527 E GENESEE AVE		SAGINAW	MI	48607-1755
438	Affiliated	1560	Churchview Dialysis	Churchview Dialysis	5970 CHURCHVIEW DR		ROCKFORD	IL	61107-2574
439	Affiliated	1562	Freeport Dialysis	Freeport Dialysis	1028 S KUNKLE BLVD		FREEPORT	IL	61032-6914
440	Affiliated	1563	Rockford Dialysis	Rockford Dialysis	3339 N ROCKTON AVE		ROCKFORD	IL	61103-2839
441	Affiliated	1564	Whiteside Dialysis	Whiteside Dialysis	2600 N LOCUST	STE D	STERLING	IL	61081-4602
442	Affiliated	2021	Pikesville Dialysis	Pikesville Dialysis	1500 REISTERSTOWN RD	STE 22	PIKESVILLE	MD	21208-3836
443	Affiliated	2000	Waynesville Dialysis	Waynesville Dialysis Center (fka Haywood, NC)	11 PARK TERRACE DR		CLYDE	NC	28721-7445
444	Affiliated	296	Davison Dialysis	Davison Dialysis	1011 S STATE RD		DAVISON	MI	48423-1903
445	Affiliated	1557	Flint Dialysis	Flint Dialysis Center	2 HURLEY PLZ	STE 115	FLINT	MI	48503-5904
446	Affiliated	1558	Hallwood Dialysis	Hallwood Dialysis Center	4929 CLIO RD	STE B	FLINT	MI	48504-1886
447	Affiliated	1559	Park Plaza Dialysis	Park Plaza Dialysis	G1075 N BALLENGER HWY		FLINT	MI	48504-4431
448	Affiliated	1518	Rosemead Springs Dialysis	Rosemead Springs Dialysis Center	3212 ROSEMEAD BLVD		EL MONTE	CA	91731-2807
449	Affiliated	2022	Scottsdale Dialysis	Scottsdale Dialysis Center	4725 N SCOTTSDALE RD	STE 1	SCOTTSDALE	AZ	85251-7621
450	Affiliated	1570	Washington Parish Dialysis	Washington Parish Dialysis	724 WASHINGTON ST		FRANKLINTON	LA	70438-1790
451	Affiliated	2027	Brookhollow Dialysis	Brookhollow Dialysis	4918 W 34TH ST		HOUSTON	TX	77092-6606
452	Affiliated	2017	Creekside	Creekside Dialysis Center (fka So. Vacaville, CA)	141 PARKER ST		VACAVILLE	CA	95688-3921
453	Affiliated	529	Middletown	Middletown Dialysis Center (fka-Red Bank)	500 STATE ROUTE 35	UNION SQUARE PLAZA	RED BANK	NJ	07701-5038
454	Affiliated	1541	Southwest Ohio Dialysis	Southwest Ohio Dialysis (Xenia-SWORC)	215 S ALLISON AVE		XENIA	OH	45385-3694
455	Affiliated	369	Oak Park	Oak Park Dialysis Center	13481 W 10 MILE RD		OAK PARK	MI	48237-4633
456	Affiliated	2042	Eden Prairie	Eden Prairie Dialysis	14852 SCENIC HEIGHTS RD	STE 255 BLDG B	EDEN PRAIRIE	MN	55344-2320
457	Affiliated	1530	Owensboro Dialysis	Owensboro Dialysis Center	1930 E PARRISH AVE		OWENSBORO	KY	42303-1443
458	Affiliated	1531	Tell City Dialysis	CRC-Tell City Dialysis Center	1602 MAIN ST		TELL CITY	IN	47586-1310
459	Affiliated	1576	Crestwood Dialysis	Crestwood Dialysis (fka Health Research Group-St. Louis (HRG))	9901 WATSON RD	STE 125	SAINT LOUIS	MO	63126-1855
460	Affiliated	2004	Copperfield Dialysis	Copperfield Dialysis (fka Cabarrus County-NC, and Concord)	1030 VINEHAVEN DR		CONCORD	NC	28025-2438
461	Affiliated	1572	Grand Island Dialysis	Grand Island Dialysis	603 S WEBB RD		GRAND ISLAND	NE	68803-5141
462	Affiliated	1573	Harlan Dialysis	Harlan Dialysis	1213 GARFIELD AVE		HARLAN	IA	51537-2057
463	Affiliated	1574	Shenandoah Dialysis	Shenandoah Dialysis	300 PERSHING AVE		SHENANDOAH	IA	51601-2355
464	Affiliated	2053	Germantown Dialysis	Germantown Dialysis	20111 CENTURY BLVD	STE C	GERMANTOWN	MD	20874-9165
465	Affiliated	2051	Lamplighter Dialysis	Lamplighter Dialysis	12654 LAMPLIGHTER SQUARE		ST LOUIS	MO	63128
466	Affiliated	1578	Kidney Care of Largo	Kidney Care of Largo	1300 MERCANTILE LN	STE 194	UPPER MARLBORO	MD	20774
467	Affiliated	1579	Kidney Care of Laurel	Kidney Care of Laurel	14631 LAUREL BOWIE ROAD	UNITS 1-15	LAUREL	MD	20707
468	Affiliated	2024	Durant Dialysis	Durant Dialysis Center	411 WESTSIDE DR		DURANT	OK	74701-2932
469	Affiliated	2038	Palm Brook Dialysis	Palm Brook Dialysis Center	14664 N DEL WEBB BLVD		SUN CITY	AZ	85351-2137
470	Affiliated	2043	Cambridge Dialysis	Cambridge Dialysis Center	300 BYRN ST		CAMBRIDGE	MD	21613-1908
471	Affiliated	2059	Reston Dialysis Center	Reston Dialysis Center	1875 CAMPUS COMMONS DR	STE 11	RESTON	VA	20191-1564
472	Affiliated	2040	Franconia Dialysis	Franconia Dialysis Centre	5695 KING CENTRE DRIVE		ALEXANDRIA	VA	22315-5744
473	Affiliated	2041	Eagan Dialysis	Eagan Dialysis Unit	2750 BLUE WATER RD	SUITE 3	EAGAN	MN	55121-1400
474	Affiliated	1594	Central Des Moines Dialysis	Central Des Moines Dialysis	1215 PLEASANT ST	STE 16	DES MOINES	IA	50309-1409
475	Affiliated	1595	West Des Moines Dialysis	West Des Moines Dialysis	6800 LAKE DR	STE 185	WEST DES MOINES	IA	50266-2544
476	Affiliated	1596	Creston Dialysis	Creston Dialysis	1700 W TOWNLINE ST		CRESTON	IA	50801-1054
477	Affiliated	1597	Atlantic Dialysis	Atlantic Dialysis	1500 E 10TH ST		ATLANTIC	IA	50022-1935
478	Affiliated	1598	Newton Dialysis	Newton Dialysis	204 N 4TH AVE E	STE 134	NEWTON	IA	50208-3135
479	Affiliated	2046	Dialysis of Des Moines	Riverpoint Dialysis Unit	501 SW 7TH ST	STE B	DES MOINES	IA	50309-4538
480	Affiliated	2060	Bellevue Dialysis	Bellevue Dialysis Center	3535 FACTORIA BLVD SE	STE 15	BELLEVUE	WA	98006-1293
481	Affiliated	414	Somerset Dialysis	Somerset Dialysis Center	240 CHURCHILL AVE		SOMERSET	NJ	08873-3451

482	Affiliated	2031	East Ft. Lauderdale Dialysis	East Ft. Lauderdale Dialysis Center (fka No. Broward)	1301 S ANDREWS AVE	STE 11	FT LAUDERDALE	FL	33316-1823
483	Affiliated	1593	Spring Branch Dialysis	Spring Branch Dialysis	1425 BLALOCK	STE 1	HOUSTON	TX	77055-4446
484	Affiliated	1599	Battle Creek Dialysis	Battle Creek Dialysis	220 E GOODALE AVE		BATTLE CREEK	MI	49037-2728
485	Affiliated	2025	Hampton Avenue Dialysis	Hampton Avenue Dialysis-MO (Forest Park)	1425 HAMPTON AVE		SAINT LOUIS	MO	63139-3115
486	Affiliated	1605	Bogalusa Kidney Care	Bogalusa Kidney Care	2108 SOUTH AVE F		BOGALUSA	LA	70427
487	Affiliated	2055	Bardstown Dialysis	Bardstown Dialysis Center	210 W JOHN FITCH AVE		BARDSTOWN	KY	40004-1115
488	Affiliated	2050	Southern Pines	Southern Pines Dialysis Center	209 WINDSTAR PL		SOUTHERN PINES	NC	28387-7086
489	Affiliated	2030	Montclare Dialysis	Montclare Dialysis Center (aka Belmont Ave)	7009 W BELMONT AVE		CHICAGO	IL	60634-4533
490	Affiliated	2048	Southern Hills	Southern Hills Dialysis Center	9280 W SUNSET RD	STE 11	LAS VEGAS	NV	89148-4861
491	Affiliated	2068	Kilgore Dialysis	Kilgore Dialysis Center	209 HWY 42 NORTH		KILGORE	TX	75662-5019
492	Affiliated	2067	Brighton Dialysis	Brighton Dialysis	4700 E BROMLEY LN	STE 13	BRIGHTON	CO	80601-7821
493	Affiliated	2023	Union Gap	Union Gap Dialysis (aka Yakima)	1236 AHTANUM RIDGE DR	AHTANUM RIDGE BUSINESS PARK	UNION GAP	WA	98903-1813
494	Affiliated	2039	Dallas North Dialysis	Dallas North Dialysis Center (aka Greenville)	11886 GREENVILLE AVE	STE 1B	DALLAS	TX	75243-9743
495	Affiliated	2061	Grovepark Dialysis	Grovepark Dialysis Center (fka Jackson Dialysis)	794 MCDONOUGH RD		JACKSON	GA	30233-1572
496	Affiliated	1583	Eastern Kentucky Dialysis	Eastern Kentucky Dialysis	167 WEDDINGTON BRANCH RD		PIKEVILLE	KY	41501-3204
497	Affiliated	1584	Paintsville Dialysis	Paintsville Dialysis	4750 S KY ROUTE 321		HAGERHILL	KY	41222
498	Affiliated	1582	West Virginia Dialysis	West Virginia Dialysis	300 PROSPERITY LANE	STE 15	LOGAN	WV	25601-3494
499	Affiliated	2049	Reidsville Dialysis	Reidsville Dialysis	1307 FREEWAY DR		REIDSVILLE	NC	27320-7104
500	Affiliated	2034	Elk Grove Dialysis	Elk Grove Dialysis	9281 OFFICE PARK CIR	STE 15	ELK GROVE	CA	95758-8069
501	Affiliated	2035	Weston Dialysis	Weston Dialysis Center (fka Cleveland Clinic)	2685 EXECUTIVE PARK DR	STE 1	WESTON	FL	33331-3651
502	Affiliated	1600	McCook Dialysis	McCook Dialysis Center	801 W C ST		MCCOOK	NE	69001-3591
503	Affiliated	1601	Hastings Dialysis	Hastings Dialysis Center	1900 N SAINT JOSEPH AVE		HASTINGS	NE	68901-2652
504	Affiliated	1602	Capital City Dialysis	Capital City Dialysis	307 N 46TH ST		LINCOLN	NE	68503-3714
505	Affiliated	1616	Renal Care of Bowie	Renal Care of Bowie	4861 TELSA DRIVE	STES G-H	BOWIE	MD	20715-4318
506	Affiliated	1617	Renal Care of Takoma Park	Takoma Park Dialysis (fka Renal Care of Takoma Park)	1502 UNIVERSITY BLVD E		HYATTSVILLE	MD	20783
507	Affiliated	1618	Renal Care of Lanham	Renal Care of Lanham	8855 ANNAPOLIS RD	STE 2	LANHAM	MD	20706-2942
508	Affiliated	1619	Parma Dialysis	Parma Dialysis Center	6735 AMES RD		CLEVELAND	OH	44129-5601
509	Affiliated	1620	Middleburg Heights Dialysis	Middleburg Hts. Dialysis	7360 ENGLE RD		MIDDLEBURG HTS	OH	44130
510	Affiliated	1621	Rocky River Dialysis	Rocky River Dialysis	20220 CENTER RIDGE RD	STE 5	ROCKY RIVER	OH	44116-3567
511	Affiliated	1606	Diamond Valley Dialysis	Diamond Valley Dialysis	1030 E FLORIDA AVE		HEMET	CA	92543-4511
512	Affiliated	1607	Murrieta Dialysis	Murrieta Dialysis	25100 HANCOCK AVE	STE 11	MURRIETA	CA	92562-5973
513	Affiliated	2057	South Chico Dialysis	South Chico Dialysis Center	2345 FOREST AVE		CHICO	CA	95928-7641
514	Affiliated	2099	Dixon Kidney Center	Dixon Kidney Center	1131 N GALENA AVE		DIXON	IL	61021-1015
515	Affiliated	1640	Grand Rapids	PDI-Grand Rapids	801 CHERRY ST SE		GRAND RAPIDS	MI	49506-1440
516	Affiliated	1641	Grand Rapids East	PDI-Grand Rapids East	1230 EKHART ST NE		GRAND RAPIDS	MI	49503-1372
517	Affiliated	1642	Grand Haven	PDI-Grand Haven	16964 ROBBINS RD		GRAND HAVEN	MI	49417-2796
518	Affiliated	1644	Highland Park	PDI-Highland Park	64 VICTOR ST		HIGHLAND PARK	MI	48203-3128
519	Affiliated	1645	Cadieux	PDI-Cadieux	6150 CADIEUX ROAD		DETROIT	MI	48224-2006
520	Affiliated	1646	Montgomery	PDI-Montgomery	1001 FOREST AVE		MONTGOMERY	AL	36106-1181
521	Affiliated	1647	East Montgomery	PDI-East Montgomery	6890 WINTON BLOUNT BLVD		MONTGOMERY	AL	36117-3516
522	Affiliated	1648	Prattville	PDI-Prattville	1815 GLYNWOOD DR		PRATTVILLE	AL	36066-5584
523	Affiliated	1649	Elmore	PDI-Elmore	125 HOSPITAL DR		WETUMPKA	AL	36092-1626
524	Affiliated	1650	Fitchburg	PDI-Fitchburg	551 ELECTRIC AVE		FITCHBURG	MA	01420-5371
525	Affiliated	1652	Rocky Hill	PDI-Rocky Hill	30 WATERCHASE DR		ROCKY HILL	CT	06067-2110
526	Affiliated	1653	Middlesex	PDI-Middlesex Dialysis Center	100 MAIN ST	STE A	MIDDLETOWN	CT	06457-3477
527	Affiliated	1655	Johnstown	PDI-Johnstown	344 BUDFIELD ST		JOHNSTOWN	PA	15904-3214
528	Affiliated	1656	Ebensburg	PDI-Ebensburg	236 JAMESWAY RD		EBENSBURG	PA	15931-4207
529	Affiliated	1657	Walnut Tower	PDI-Walnut Tower	834 WALNUT ST		PHILADELPHIA	PA	19107-5109
530	Affiliated	1659	Lancaster	PDI-Lancaster	1412 E KING ST		LANCASTER	PA	17602-3240
531	Affiliated	1660	Ephrata	PDI-Ephrata	67 W CHURCH ST		STEVENS	PA	17578-9203
532	Affiliated	2083	Pinecrest Dialysis	Pinecrest Dialysis (aka North Marshall-TX)	913 E PINECREST DR		MARSHALL	TX	75670-7309
533	Affiliated	551	Westwood Dialysis	Westwood Dialysis Center (aka West Seattle)	2615 SW TRENTON ST		SEATTLE	WA	98126-3745
534	Affiliated	2107	Louisville Dialysis	Louisville Dialysis	8037 DIXIE HWY		LOUISVILLE	KY	40258-1344
535	Affiliated	2018	Fair Oaks Dialysis	Fair Oaks Dialysis Center (fka Chantilly & Centreville)	3955 PENDER DR	ONE PENDER BUSINESS PARK	FAIRFAX	VA	22030-6091

536	Affiliated	421	Oak Cliff	Oak Cliff Dialysis	2000 S LLEWELLYN AVE		DALLAS	TX	75224-1804
537	Affiliated	2126	Gilmer Dialysis	Gilmer Dialysis Center	519 N WOOD ST		GILMER	TX	75644-1746
538	Affiliated	1608	Chicago Heights Dialysis	Chicago Heights Dialysis	177 W JOE ORR RD	STE B	CHICAGO HEIGHTS	IL	60411-1733
539	Affiliated	1623	East Georgia Dialysis	East Georgia Dialysis	450 GEORGIA AVE	STE A	STATESBORO	GA	30458-5590
540	Affiliated	1639	Northlake Dialysis	Northlake Dialysis	1350 MONTREAL RD	STE 2	TUCKER	GA	30084-8144
541	Affiliated	1680	Down River Dialysis	Downriver Kidney Center	5600 ALLEN RD		ALLEN PARK	MI	48101-2604
542	Affiliated	2063	Belcaro	Belcaro Dialysis Center	755 S COLORADO BLVD		DENVER	CO	80246-8005
543	Affiliated	2076	Sherwood Dialysis Center	Sherwood Dialysis Center	21035 SW PACIFIC HWY		SHERWOOD	OR	97140-8062
544	Affiliated	2054	Lonetree Dialysis	Lonetree Dialysis Center (aka Skyridge)	9777 MOUNT PYRAMID CT	STE 14	ENGLEWOOD	CO	80112-6017
545	Affiliated	2078	River Park Dialysis	River Park Dialysis (aka Conroe)	2010 S LOOP 336 W	STE 2	CONROE	TX	77304-3313
546	Affiliated	2058	Northshore Dialysis	Northshore Kidney Center (fka Slidell II)	106 MEDICAL CENTER DR		SLIDELL	LA	70461-5575
547	Affiliated	2036	Marysville Dialysis	Marysville Dialysis Center	1015 8TH ST		MARYSVILLE	CA	95901-5271
548	Affiliated	2070	West Georgia Dialysis	West Georgia Dialysis	1216 STARK AVE		COLUMBUS	GA	31906-2500
549	Affiliated	2102	East Dearborn Dialysis	Westland Dialysis (aka Canton)	36588 FORD RD		WESTLAND	MI	48185-3769
550	Affiliated	2045	Downtown Houston Dialysis	Downtown Houston Dialysis Center	2207 CRAWFORD ST		HOUSTON	TX	77002-8915
551	Affiliated	2066	Concord Dialysis	Concord Dialysis Center	2300 STANWELL DR	STE C	CONCORD	CA	94520-4841
552	Affiliated	2087	Pendleton Dialysis	Pendleton Dialysis (aka Clemson, Tri-County)	7703 HIGHWAY 76		PENDLETON	SC	29670-1818
553	Affiliated	2106	New Albany Dialysis	New Albany Dialysis	2669 CHARLESTON RD		NEW ALBANY	IN	47150-2573
554	Affiliated	1585	Whitesburg Dialysis	Whitesburg Dialysis	222 HOSPITAL RD	STE D	WHITESBURG	KY	41858-7627
555	Affiliated	2047	Jacinto Dialysis	Jacinto Dialysis Center (aka East Houston)	11515 MARKET STREET RD		HOUSTON	TX	77029-2305
556	Affiliated	2088	Transmountain Dialysis	Transmountain Dialysis (aka Northeast El Paso, Rushfair)	5255 WOODROW BEAN	STE B18	EL PASO	TX	79924-3832
557	Affiliated	2029	Southcrest Dialysis	Southcrest Dialysis (aka South Creek)	9001 S 101ST EAST AVE	STE 11	TULSA	OK	74133-5799
558	Affiliated	2071	Lake Hearn	Lake Hearn Dialysis (aka Dunwoody, Roswell, Northside)	1150 LAKE HEARN DR NE	STE 1	ATLANTA	GA	30342-1566
559	Affiliated	2118	Mt. Greenwood	Mt. Greenwood Dialysis	3401 W 111TH ST		CHICAGO	IL	60655-3329
560	Affiliated	2086	Citrus Valley Dialysis Center	Citrus Valley Dialysis (aka San Bernadino II)	894 HARDT STREET		SAN BERNARDINO	CA	92408-2854
561	Affiliated	2095	McDowell County Dialysis	McDowell County Dialysis Center	100 SPAULDING RD	STE 2	MARION	NC	28752-5116
562	Affiliated	2115	Leigh Dialysis Center	Leigh Dialysis Center (aka Leigh-Kempville-VA)	420 N CENTER DR	STE 128	NORFOLK	VA	23502-4019
563	Affiliated	2120	Dialysis of Lithonia	Dialysis of Lithonia	2485 PARK CENTRAL BLVD		DECATUR	GA	30035-3902
564	Affiliated	2114	Embassy Lake Artificial Kidney Center	Embassy Lake Artificial Kidney Center (fka Davie & South Broward AKC)	11011 SHERIDAN ST	STE 38	HOLLYWOOD	FL	33026-1505
565	Affiliated	2056	Sun City Dialysis	Sun City Dialysis (akaTexas Tech II)	600 NEWMAN ST		EL PASO	TX	79902-5543
566	Affiliated	1651	PDI Worcester	PDI-Worcester Dialysis	19 GLENNIE ST	STE A	WORCESTER	MA	01605-3918
567	Affiliated	2130	Davenport Dialysis Center	Davenport Dialysis Center (aka Haines City II)	45597 HIGHWAY 27	RIDGEVIEW PLAZA	DAVENPORT	FL	33897-4519
568	Affiliated	2081	Cinema Dialysis	Cinema Dialysis (aka OKC South)	3909 S WESTERN AVE		OKLAHOMA CITY	OK	73109-3405
569	Affiliated	2037	Greenwood Dialysis Center	Greenwood Dialysis Center (North Tulsa)	1345 N LANSING AVE		TULSA	OK	74106-5911
570	Affiliated	1712	TRC Alamosa Diakysis	Alamosa Dialysis	612 DEL SOL DR		ALAMOSA	CO	81101-8548
571	Affiliated	1682	South Austin	South Austin Dialysis	6114 S 1ST ST		AUSTIN	TX	78745-4008
572	Affiliated	2109	Durango Dialysis Center	Durango Dialysis Center	72 SUTTLE STREET	STE D	DURANGO	CO	81303-6829
573	Affiliated	1700	Bolivar Dialysis	Bolivar Dialysis	515 PECAN DR		BOLIVAR	TN	38008-1611
574	Affiliated	1701	Brownsville Dialysis	Brownsville Dialysis	380 N DUPREE AVE		BROWNSVILLE	TN	38012-2332
575	Affiliated	1702	Camden Dialysis	Camden Dialysis	168 W MAIN ST	STE A	CAMDEN	TN	38320-1767
576	Affiliated	1703	Collierville Dialysis	Collierville Dialysis	791 W POPLAR AVE		COLLIERVILLE	TN	38017-2543
577	Affiliated	1705	Galleria Dialysis	Galleria Dialysis	9160 HIGHWAY 64		LAKELAND	TN	38002-4766
578	Affiliated	1706	Humboldt Dialysis	Humboldt Dialysis	2214 OSBORNE ST		HUMBOLDT	TN	38343-3044
579	Affiliated	1707	Stonegate Dialysis	North Jackson Dialysis (fka Stonegate)	217 STERLING FARM DR		JACKSON	TN	38305-5727
580	Affiliated	1708	Lexington Dialysis	Lexington Dialysis	317 W CHURCH ST		LEXINGTON	TN	38351-2096
581	Affiliated	1709	Pickwick Dialysis	Pickwick Dialysis	121 PICKWICK ST		SAVANNAH	TN	38372-1953
582	Affiliated	1710	Selmber Dialysis	Selmer Dialysis	251 OAKGROVE RD		SELMER	TN	38375-1881
583	Affiliated	1713	Childs Dialysis	Childs Dialysis	101 MAIN ST		CHILDS	PA	18407-2614
584	Affiliated	1714	Dunmore Dialysis	Dunmore Dialysis	1212 O'NEIL HWY		DUNMORE	PA	18512-1717
585	Affiliated	1716	Old Forge Dialysis	Old Forge Dialysis	325 S MAIN ST		OLD FORGE	PA	18518-1677
586	Affiliated	1717	Scranton Dialysis	Scranton Dialysis	475 MORGAN HWY		SCRANTON	PA	18508-2605
587	Affiliated	1718	Tunkhannock Dialysis	Tunkhannock Dialysis	5950 SR 6		TUNKHANNOCK	PA	18657-7905
588	Affiliated	1725	East Evansville Dialysis	East Evansville Dialysis	1312 PROFESSIONAL BLVD		EVANSVILLE	IN	47714-8007
589	Affiliated	1726	North Evansville Dialysis	North Evansville Dialysis	1151 W BUENA VISTA RD		EVANSVILLE	IN	47710-3334

590	Affiliated	1728	Jasper Dialysis	Jasper Dialysis	721 W 13TH ST	STE 15	JASPER	IN	47546-1856
591	Affiliated	1729	Daviess County Dialysis	Daviess County Dialysis	310 NE 14TH ST		WASHINGTON	IN	47501-2137
592	Affiliated	1730	Gardenside Dialysis	Gardenside Dialysis	70 N GARDENMILE RD		HENDERSON	KY	42420-5529
593	Affiliated	1732	PD Evansville Dialysis	East Evansville Dialysis PD	1312 PROFESSIONAL BLVD		EVANSVILLE	IN	47714-8007
594	Affiliated	2098	Meridian Dialysis Center	Meridian Dialysis Center (aka Bayshore)	201 W FAIRMONT PKWY	STE A	LA PORTE	TX	77571-6303
595	Affiliated	2100	Sycamore Dialysis	Sycamore Dialysis (aka DeKalb)	2200 GATEWAY DR		SYCAMORE	IL	60178-3113
596	Affiliated	2104	Ballenger Pointe Dialysis	Ballenger Pointe Dialysis (aka West Flint)	2262 S BALLENGER HWY		FLINT	MI	48503-3447
597	Affiliated	2139	Leitchfield Dialysis	Leitchfield Dialysis	912 WALLACE AVE	STE 16	LEITCHFIELD	KY	42754-2405
598	Affiliated	2097	Roxbury Dialysis Center	Roxbury Dialysis	622 ROXBURY RD		ROCKFORD	IL	61107-5089
599	Affiliated	2148	LaGrange Dialysis	La Grange Dialysis	240 PARKER DR		LA GRANGE	KY	40031-1200
600	Affiliated	2132	Des Moines East	East Des Moines Dialysis (aka Des Moines II)	1301 PENNSYLVANIA AVE	STE 28	DES MOINES	IA	50316-2365
601	Affiliated	2119	Lake Villa Dialysis	Lake Villa Dialysis	37809 N IL ROUTE 59		LAKE VILLA	IL	60046-7332
602	Affiliated	159	Seneca Dialysis	Seneca County Dialysis	65 SAINT FRANCIS AVE		TIFFIN	OH	44883-3413
603	Affiliated	407	Perry	Perry Dialysis Center	1027 KEITH DR		PERRY	GA	31069-2948
604	Affiliated	661	Wilshire	Wilshire Dialysis	1212 WILSHIRE BLVD		LOS ANGELES	CA	90017-1902
605	Affiliated	692	University Park	University Park Dialysis Center	3986 S FIGUEROA ST		LOS ANGELES	CA	90037-1222
606	Affiliated	1720	Metro East Dialysis	Metro East Dialysis	5105 W MAIN ST		BELLEVILLE	IL	62226-4728
607	Affiliated	2196	Ocala Regional Kidney Centers	Ocala Regional Kidney Centers Home Dialysis Division PD	2860 SE 1ST AVE		OCALA	FL	34471-0406
608	Affiliated	2133	Little Village Dialysis	Little Village Dialysis (Chicago)	2335 W CERMAK RD		CHICAGO	IL	60608-3811
609	Affiliated	2112	Crossroads	Crossroads Dialysis (aka Fullerton Dialysis)	3214 YORBA LINDA BLVD		FULLERTON	CA	92831-1707
610	Affiliated	1727	Vincennes Dialysis	Vincennes Dialysis	700 WILLOW ST		VINCENNES	IN	47591-1028
611	Affiliated	1723	Spring Dialysis	Spring Dialysis	607 TIMBERDALE LN	STE 1	HOUSTON	TX	77090-3043
612	Affiliated	2190	River Center	Rivercenter Dialysis (aka Central San Antonio)	1123 N MAIN AVE	STE 15	SAN ANTONIO	TX	78212-4738
613	Affiliated	2193	Southcross Dialysis Center	Southcross Dialysis (aka SouthEast San Antonio)	4602 E SOUTHCROSS BLVD		SAN ANTONIO	TX	78222-4911
614	Affiliated	2125	Bonham Dialysis	Bonham Dialysis	201 W 5TH ST		BONHAM	TX	75418-4302
615	Affiliated	2192	Northwest Medical Center Dialysis	NW Medical Center Dialysis (aka NorthWest San Antonio)	5284 MEDICAL DR	STE 1	SAN ANTONIO	TX	78229-4849
616	Affiliated	2124	Ontario Dialysis	Ontario Dialysis (aka Dr. Handoko)	1950 S GROVE AVE	STE 11-15	ONTARIO	CA	91761-5693
617	Affiliated	1750	Chipley Community Dialysis	Chipley Dialysis	877 3RD ST	STE 2	CHIPLEY	FL	32428-1855
618	Affiliated	1751	North Ikaloosa	North Okaloosa Dialysis	320 REDSTONE AVE W		CRESTVIEW	FL	32536-6433
619	Affiliated	1752	West Florida Dialysis	West Florida Dialysis	8333 N DAVIS HWY	1ST FLOOR ATTN DIALYSIS ROOM	PENSACOLA	FL	32514-6049
620	Affiliated	1753	Santa Rosa Dialysis	Santa Rosa Dialysis	5819 HIGHWAY 90		MILTON	FL	32583-1763
621	Affiliated	1755	Atmore Dialysis	Atmore Dialysis Center	807 E CRAIG ST		ATMORE	AL	36502-3017
622	Affiliated	1756	South Baldwin Dialysis	South Baldwin Dialysis Center	150 W PEACHTREE AVE		FOLEY	AL	36535-2244
623	Affiliated	1731	Olney Dialysis	Olney Dialysis Center (aka Good Samaritan Hospital)	117 N BOONE ST		OLNEY	IL	62450-2109
624	Affiliated	2156	Lancaster Dialysis	Lancaster Dialysis	2424 W PLEASANT RUN RD		LANCASTER	TX	75146-4005
625	Affiliated	2136	Columbia Dialysis	RTC-Columbia Dialysis (MO)	1701 E BROADWAY	STE G12	COLUMBIA	MO	65201-8029
626	Affiliated	2194	Las Palmas Dialysis Center	Las Palmas Dialysis Center (aka West San Antonio)	803 CASTROVILLE RD	STE 415	SAN ANTONIO	TX	78237-3148
627	Affiliated	2116	South Shore Dialysis Center	South Shore Dialysis (aka Horizon)	212 GULF FWY S	STE G3	LEAGUE CITY	TX	77573-3957
628	Affiliated	2191	Marymount Dilaysis Center	Marymont Dialysis (aka NorthEast San Antonio)	2391 NE LOOP 410	STE 211	SAN ANTONIO	TX	78217-5675
629	Affiliated	1744	Fox River Dialysis	Fox River Dialysis	1910 RIVERSIDE DR		GREEN BAY	WI	54301-2319
630	Affiliated	1745	Titletown Dialysis	Titletown Dialysis	120 SIEGLER ST		GREEN BAY	WI	54303-2636
631	Affiliated	1746	Northwoods Dialysis	Green Bay Northwood Dialysis	W 7305 ELM AVENUE		SHAWANO	WI	54166-1024
632	Affiliated	1758	North Charleston Dialysis	North Charleston Dialysis	5900 RIVERS AVE	STE E	NORTH CHARLESTON	SC	29406
633	Affiliated	1759	Charleston County Dialysis	Faber Place Dialysis	3801 FABER PLACE DR		NORTH CHARLESTON	SC	29405-8533
634	Affiliated	1760	Goose Creek Dialysis	Goose Creek Dialysis	109 GREENLAND DR		GOOSE CREEK	SC	29445-5354
635	Affiliated	2501	Bridgeport Dialysis	Bridgeport Dialysis	900 MADISON AVE	STE 221	BRIDGEPORT	CT	06606-5534
636	Affiliated	2503	Greater Waterbury Dialysis	Greater Waterbury Dialysis	209 HIGHLAND AVE		WATERBURY	CT	06708-3026
637	Affiliated	2506	Shelton Dialysis	Shelton Dialysis	750 BRIDGEPORT AVE		SHELTON	CT	06484-4734
638	Affiliated	2508	Yuma Dialysis	Yuma Dialysis	2130 W 24TH ST		YUMA	AZ	85364-6122
639	Affiliated	2509	Pittsburgh Dialysis	Pittsburgh Dialysis	4312 PENN AVE		PITTSBURGH	PA	15224-1310
640	Affiliated	2510	Elizabeth Dialysis	Elizabeth Dialysis	201 MCKEESPORT RD		ELIZABETH	PA	15037-1623
641	Affiliated	2511	Brandon East Dialysis	Brandon East Dialysis	114 E BRANDON BLVD		BRANDON	FL	33511-5219
642	Affiliated	2513	North Rolling Road Dialysis	North Rolling Road Dialysis	1108 N ROLLING RD		BALTIMORE	MD	21228-3826
643	Affiliated	2521	Memphis South Dialysis	Memphis South Dialysis	1205 MARLIN RD		MEMPHIS	TN	38116-5812

644	Affiliated	2524	Hartford Dialysis	Hartford Dialysis	675 TOWER AVE	RENAL UNIT 2ND FL	HARTFORD	CT	6112
645	Affiliated	2538	New Orleans Uptown Dialysis	New Orleans Uptown Dialysis	1401 FOUCHER ST	4TH FLOOR DIALYSIS	NEW ORLEANS	LA	70115-3515
646	Affiliated	2540	Omaha West Dialysis	Omaha West Dialysis	13014 W DODGE RD		OMAHA	NE	68154-2148
647	Affiliated	2541	White Memorial Dialysis	East Los Angeles Plaza Dialysis (fka White Memorial)	1700 E CESAR E CHAVEZ AVE	STE L 1	LOS ANGELES	CA	90033-2424
648	Affiliated	2542	Imperial Dialysis	Imperial Dialysis	2738 W IMPERIAL HWY		INGLEWOOD	CA	90303-3111
649	Affiliated	2546	North Hollywood Dialysis	North Hollywood Dialysis	12126 VICTORY BLVD		NORTH HOLLYWOOD	CA	91606-3205
650	Affiliated	2555	Mountain View Dialysis	Mountain View Dialysis	2881 BUSINESS PARK CT	STE 13	LAS VEGAS	NV	89128-9019
651	Affiliated	2560	San Juan Capistrano South Dialysis	San Juan Capistrano South Dialysis	31736 RANCHO VIEJO RD	STE B	SAN JUAN CAPISTRANO	CA	92675-2783
652	Affiliated	2564	Mission Viejo Dialysis	Mission Viejo Dialysis	27640 MARGUERITE PKWY		MISSION VIEJO	CA	92692-3604
653	Affiliated	2568	HI-Desert Dialysis	HI-Desert Dialysis	58457 29 PALMS HWY	STE 12	YUCCA VALLEY	CA	92284-5879
654	Affiliated	2571	Banning Dialysis	Banning Dialysis	6090 W RAMSEY ST		BANNING	CA	92220-3052
655	Affiliated	2601	Rainbow City Dialysis	Rainbow City Dialysis	2800 RAINBOW DR		RAINBOW CITY	AL	35906-5811
656	Affiliated	2604	Gadsden Dialysis	Gadsden Dialysis	409 S 1ST ST		GADSDEN	AL	35901-5358
657	Affiliated	2605	Chateau Dialysis	Chateau Dialysis	720 VILLAGE RD		KENNER	LA	70065-2751
658	Affiliated	2606	Donaldsonville Dialysis	Donaldsonville Dialysis	101 PLIMSOL DR		DONALDSONVILLE	LA	70346-4357
659	Affiliated	2609	Dothan Dialysis	Dothan Dialysis	216 GRACELAND DR		DOTHAN	AL	36305-7346
660	Affiliated	2614	Birmingham East Dialysis	Birmingham East Dialysis	1105 E PARK DR		BIRMINGHAM	AL	35235-2560
661	Affiliated	2615	Tuscaloosa Dialysis	Tuscaloosa Dialysis	805 OLD MILL ST		TUSCALOOSA	AL	35401-7132
662	Affiliated	2616	Demopolis Dialysis	Demopolis Dialysis	511 S CEDAR AVE		DEMOPOLIS	AL	36732-2235
663	Affiliated	2623	Singing River Dialysis	Singing River Dialysis	4907 TELEPHONE RD		PASCAGOULA	MS	39567-1823
664	Affiliated	2624	Ocean Springs Dialysis	Ocean Springs Dialysis	13150 PONCE DE LEON DR		OCEAN SPRINGS	MS	39564-2460
665	Affiliated	2625	Lucedale Dialysis	Lucedale Dialysis	652 MANILA ST		LUCEDALE	MS	39452-5962
666	Affiliated	2707	Holmdel Dialysis	Holmdel Dialysis	668 N BEERS ST		HOLMDEL	NJ	07733-1526
667	Affiliated	2855	Alameda County Dialysis	Alameda County Dialysis	10700 MACARTHUR BLVD	STE 14	OAKLAND	CA	94605-5260
668	Affiliated	2908	Elizabeth City Dialysis	Elizabeth City Dialysis	1840 W CITY DR		ELIZABETH CITY	NC	27909-9632
669	Affiliated	2914	Cookeville Dialysis	Cookeville Dialysis	140 W 7TH ST		COOKEVILLE	TN	38501-1726
670	Affiliated	3001	Inglewood Dialysis	Inglewood Dialysis	125 E ARBOR VITAE ST		INGLEWOOD	CA	90301-3839
671	Affiliated	3002	Rome Dialysis	Rome Dialysis	15 JOHN MADDOX DR NW		ROME	GA	30165-1413
672	Affiliated	3004	Pomona Dialysis	Pomona Dialysis	2111 N GAREY AVE		POMONA	CA	91767-2328
673	Affiliated	3005	Oak Street Dialysis	Oak Street Dialysis (fka Valdosta)	2704 N OAK ST	BLDG H	VALDOSTA	GA	31602-1723
674	Affiliated	3006	Channelview Dialysis	Channelview Dialysis	777 SHELDON RD	STE C	CHANNELVIEW	TX	77530-3509
675	Affiliated	3007	Sagemont Dialysis	Sagemont Dialysis	10851 SCARSDALE BLVD	STE 2	HOUSTON	TX	77089-5738
676	Affiliated	3008	San Jacinto Dialysis	San Jacinto Dialysis	11430 EAST FWY	STE 33	HOUSTON	TX	77029-1959
677	Affiliated	3009	Victor Valley Dialysis	Victor Valley Dialysis	16049 KAMANA RD		APPLE VALLEY	CA	92307-1331
678	Affiliated	3010	Delran Dialysis	Delran Dialysis	8008 ROUTE 130		DELRAN	NJ	08075-1869
679	Affiliated	3011	Central Houston Dialysis	Central Houston Dialysis	610 S WAYSIDE DR	UNIT B	HOUSTON	TX	77011-4605
680	Affiliated	3012	Southern Lane Dialysis	Southern Lane Dialysis	1840 SOUTHERN LN		DECATUR	GA	30033-4033
681	Affiliated	3013	Northumberland Dialysis	Northumberland Dialysis	103 W STATE ROUTE 61		MOUNT CARMEL	PA	17851-2539
682	Affiliated	3014	Pryor Dialysis	Pryor Dialysis	309 E GRAHAM AVE		PRYOR	OK	74361-2434
683	Affiliated	3015	Oklahoma City South Dialysis	Oklahoma City South Dialysis	5730 S MAY AVE		OKLAHOMA CITY	OK	73119-5604
684	Affiliated	3016	Abington Dialysis	Abington Dialysis	3940A COMMERCE AVE		WILLOW GROVE	PA	19090-1705
685	Affiliated	3017	Memphis Central Dialysis	Memphis Central Dialysis	889 LINDEN AVE		MEMPHIS	TN	38126-2412
686	Affiliated	3018	Memphis East Dialysis	Memphis East Dialysis	50 HUMPHREYS CTR	STE 42	MEMPHIS	TN	38120-2372
687	Affiliated	3019	Clarksville Dialysis	Clarksville Dialysis	231 HILLCREST DR		CLARKSVILLE	TN	37043-5093
688	Affiliated	3020	Miami Campus Dialysis	Miami Campus Dialysis	1500 NW 12TH AVE	STE 16	MIAMI	FL	33136-1028
689	Affiliated	3021	Orlando Dialysis	Orlando Dialysis	116 STURTEVANT ST		ORLANDO	FL	32806-2021
690	Affiliated	3024	Durham Dialysis	Durham Dialysis	601 FAYETTEVILLE ST		DURHAM	NC	27701-3910
691	Affiliated	3025	Candler County Dialysis	Candler County Dialysis	325 CEDAR ST		METTER	GA	30439-4043
692	Affiliated	3027	Kerrville Dialysis	Kerrville Dialysis	515 GRANADA PL		KERRVILLE	TX	78028-5992
693	Affiliated	3028	Floresville Dialysis	Floresville Dialysis	543 10TH ST		FLORESVILLE	TX	78114-3107
694	Affiliated	3029	Pearsall Dialysis	Pearsall Dialysis	1305 N OAK ST		PEARSALL	TX	78061-3414
695	Affiliated	3030	Nogales Dialysis	Nogales Dialysis	1231 W TARGET RANGE RD		NOGALES	AZ	85621-2417
696	Affiliated	3032	Wilson Dialysis	Wilson Dialysis	1605 MEDICAL PARK DR W		WILSON	NC	27893-2799
697	Affiliated	3033	Goldsboro Dialysis	Goldsboro Dialysis	2609 HOSPITAL RD		GOLDSBORO	NC	27534-9424

698	Affiliated	3034	Roxboro Dialysis	Roxboro Dialysis	718 RIDGE RD		ROXBORO	NC	27573-4508
699	Affiliated	3035	Boston Dialysis	Boston Dialysis	660 HARRISON AVE		BOSTON	MA	02118-2304
700	Affiliated	3037	Jesup Dialysis	Jesup Dialysis	301 PEACHTREE ST		JESUP	GA	31545-0245
701	Affiliated	3038	Sheffield Dialysis	Sheffield Dialysis	1120 S JACKSON HWY	ST 17	SHEFFIELD	AL	35660-5777
702	Affiliated	3039	Berkeley Dialysis	Berkeley Dialysis	2920 TELEGRAPH AVE		BERKELEY	CA	94705-2031
703	Affiliated	3040	Douglas Dialysis	Douglas Dialysis	190 WESTSIDE DR	STE A	DOUGLAS	GA	31533-3534
704	Affiliated	3041	Hopkinsville Dialysis	Hopkinsville Dialysis	1914 S VIRGINIA ST		HOPKINSVILLE	KY	42240-3610
705	Affiliated	3042	Roxborough Dialysis	Roxborough Dialysis	5003 UMBRIA ST		PHILADELPHIA	PA	19128-4301
706	Affiliated	3043	New Haven Dialysis	New Haven Dialysis	100 CHURCH ST S	STE C	NEW HAVEN	CT	06519-1703
707	Affiliated	3044	Ocoee Dialysis	Ocoee Dialysis	11140 W COLONIAL DR	STE 5	OCOEE	FL	34761-3300
708	Affiliated	3045	Waverly Dialysis	Waverly Dialysis	407 E BALTIMORE PIKE		MORTON	PA	19070-1042
709	Affiliated	3046	Sells Dialysis	Sells Dialysis	PO BOX 3030	HWY 86 MILEPOST 113	SELLS	AZ	85634-3030
710	Affiliated	3047	Sierra Vista Dialysis	Sierra Vista Dialysis	629 N HIGHWAY 90	STE 6	SIERRA VISTA	AZ	85635-2257
711	Affiliated	3048	Callaghan Road Dialysis	San Antonio West Dialysis (fka Callaghan Road)	4530 CALLAGHAN RD		SAN ANTONIO	TX	78228
712	Affiliated	3049	Houston Dialysis	Houston Dialysis	7543 SOUTH FWY		HOUSTON	TX	77021-5928
713	Affiliated	3050	South Yuma Dialysis	South Yuma Dialysis	7179 E 31ST PLACE		YUMA	AZ	85365-8392
714	Affiliated	3052	Cherry Hill Dialysis	Cherry Hill Dialysis	1030 KINGS HWY N	STE 1	CHERRY HILL	NJ	08034-1907
715	Affiliated	3055	Escondido Dialysis	Escondido Dialysis	203 E 2ND AVE		ESCONDIDO	CA	92025-4212
716	Affiliated	3056	Brookline Dialysis	Brookline Dialysis	322 WASHINGTON ST		BROOKLINE	MA	02445-6850
717	Affiliated	3057	Reliant Dialysis	Reliant Dialysis	1335 LA CONCHA LN		HOUSTON	TX	77054-1809
718	Affiliated	3058	Fullerton Dialysis	Fullerton Dialysis	238 ORANGEFAIR MALL		FULLERTON	CA	92832-3037
719	Affiliated	3059	Huntington Beach Dialysis	Huntington Beach Dialysis	16892 BOLSA CHICA ST	STE 1	HUNTINGTON BEACH	CA	92649-3571
720	Affiliated	3060	Eastlake Dialysis	Eastlake Dialysis (fka South Dekalb)	1757 CANDLER RD		DECATUR	GA	30032-3276
721	Affiliated	3061	Mt. Olive Dialysis	Mt. Olive Dialysis	105 MICHAEL MARTIN RD		MOUNT OLIVE	NC	28365-1112
722	Affiliated	3062	Southwest San Antonio Dialysis	Southwest San Antonio Dialysis	1620 SOMERSET RD		SAN ANTONIO	TX	78211-3021
723	Affiliated	3064	North Loop East Dialysis	North Loop East Dialysis	7139 NORTH LOOP E		HOUSTON	TX	77028-5903
724	Affiliated	3065	Katy Cinco Ranch Dialysis	Katy Cinco Ranch Dialysis	1265 ROCK CANYON DR		KATY	TX	77450-3831
725	Affiliated	3067	Palm Springs Dialysis	Palm Springs Dialysis	1061 N INDIAN CANYON DR		PALM SPRINGS	CA	92262-4854
726	Affiliated	3069	Muskegon Dialysis	Muskegon Dialysis	1277 MERCY DR		MUSKEGON	MI	49444-4605
727	Affiliated	3070	Loomis Road Dialysis	Loomis Road Dialysis	4120 W LOOMIS RD		GREENFIELD	WI	53221-2052
728	Affiliated	3071	Ludington Dialysis	Ludington Dialysis	5 N ATKINSON DR	STE 11	LUDINGTON	MI	49431-2918
729	Affiliated	3073	Walterboro Dialysis	Walterboro Dialysis	302 RUBY ST		WALTERBORO	SC	29488-2758
730	Affiliated	3074	K Street	K Street Dialysis (fka GWU N Street Dialysis)	2131 K ST NW		WASHINGTON	DC	20037-1898
731	Affiliated	3075	GWU Southeast Dialysis	GWU Southeast Dialysis	3857A PENNSYLVANIA AVE SE		WASHINGTON	DC	20020-1309
732	Affiliated	3076	Lakeside Dialysis	Lakeside Dialysis	10401 HOSPITAL DR	STE G2	CLINTON	MD	20735-3113
733	Affiliated	3077	Summit Dialysis	Summit Dialysis	1139 SPRUCE DR		MOUNTAINSIDE	NJ	07092-2221
734	Affiliated	3078	Aiken Dialysis	Aiken Dialysis	775 MEDICAL PARK DR		AIKEN	SC	29801-6306
735	Affiliated	3092	Ozark Dialysis	Ozark Dialysis	214 HOSPITAL AVE		OZARK	AL	36360-2038
736	Affiliated	3094	Wylds Road Dialysis	Wylds Road Dialysis (fka Augusta South)	1815 WYLDS RD		AUGUSTA	GA	30909-4430
737	Affiliated	3104	Douglasville Dialysis	Douglasville Dialysis	3899 LONGVIEW DR		DOUGLASVILLE	GA	30135-1373
738	Affiliated	3106	Brunswick Dialysis	Brunswick Dialysis	53 SCRANTON CONNECTOR		BRUNSWICK	GA	31525-1862
739	Affiliated	3109	Benicia Dialysis	Benicia Dialysis	560 1ST ST	STE 13 BLDG D	BENICIA	CA	94510-3295
740	Affiliated	3111	Atlanta Dialysis	Atlanta Dialysis	567 NORTH AVE NE	STE 2	ATLANTA	GA	30308-2719
741	Affiliated	3115	Rolla Dialysis	Rolla Dialysis	1503 E 10TH ST		ROLLA	MO	65401-3696
742	Affiliated	3119	East Atlanta Dialysis	East Atlanta Dialysis	1308 MORELAND AVE SE		ATLANTA	GA	30316-3224
743	Affiliated	3120	Brunswick South Dialysis	Brunswick South Dialysis	2930 SPRINGDALE RD		BRUNSWICK	GA	31520
744	Affiliated	3121	Thomaston Dialysis	Thomaston Dialysis	1065 US HIGHWAY 19 NORTH		THOMASTON	GA	30286-2233
745	Affiliated	3128	Piedmont Dialysis	Piedmont Dialysis	105 COLLIER RD NW	STE B	ATLANTA	GA	30309-1730
746	Affiliated	3130	Athens West Dialysis	Athens West Dialysis	2047 PRINCE AVE	STE A	ATHENS	GA	30606-6033
747	Affiliated	3131	Florence Dialysis	Florence Dialysis	422 E DR HICKS BLVD	STE B	FLORENCE	AL	35630-5763
748	Affiliated	3138	Atwater Dialysis	Atwater Dialysis	1201 COMMERCE AVE		ATWATER	CA	95301
749	Affiliated	3143	North Merced Dialysis	Merced Dialysis	3150 G ST	STE A	MERCED	CA	95340-1346
750	Affiliated	3169	Wisconsin Avenue Dialysis	Wisconsin Avenue Dialysis	3801 W WISCONSIN AVE		MILWAUKEE	WI	53208-3155
751	Affiliated	3171	River Center Dialysis	River Center Dialysis	117 N JEFFERSON ST		MILWAUKEE	WI	53202-6160

752	Affiliated	3175	South Fulton Dialysis	South Fulton Dialysis	2685 METROPOLITAN PKWY SW	STE F	ATLANTA	GA	30315-7926
753	Affiliated	3201	Heartland Dialysis	Heartland Dialysis	925 NE 8TH ST		OKLAHOMA CITY	OK	73104-5800
754	Affiliated	3202	Hospital Hill Dialysis	Hospital Hill Dialysis	2250 HOLMES ST		KANSAS CITY	MO	64108-2639
755	Affiliated	3203	Tucson South Dialysis	Tucson South Dialysis	3662 S 16TH AVE		TUCSON	AZ	85713-6001
756	Affiliated	3204	Greene County Dialysis	Greene County Dialysis (AL)	544 US HIGHWAY 43		EUTAW	AL	35462-4017
757	Affiliated	3205	Fayette Dialysis	Fayette Dialysis	2450 TEMPLE AVE N		FAYETTE	AL	35555-1160
758	Affiliated	3206	Tuscaloosa University Dialysis	Tuscaloosa University Dialysis	220 15TH STREET		TUSCALOOSA	AL	35401
759	Affiliated	3207	Goldsboro South Dialysis	Goldsboro South Dialysis	1704 WAYNE MEMORIAL DR		GOLDSBORO	NC	27534-2240
760	Affiliated	3208	Orlando North Dialysis	Orlando North Dialysis	5135 ADANSON ST	STE 7	ORLANDO	FL	32804-1338
761	Affiliated	3209	UT Southwestern-Dallas Dialysis	UT Southwestern-Dallas Dialysis	204 E AIRPORT FREEWAY		IRVING	TX	75062
762	Affiliated	3210	San Diego South Dialysis	San Diego South Dialysis	995 GATEWAY CENTER WAY	STE 11	SAN DIEGO	CA	92102-4550
763	Affiliated	3211	Santa Monica Dialysis	Santa Monica Dialysis	1260 15TH ST	STE 12	SANTA MONICA	CA	90404-1136
764	Affiliated	3212	Airport Dialysis	Airport Dialysis	4632 W CENTURY BLVD		INGLEWOOD	CA	90304-1456
765	Affiliated	3220	Plantation Dialysis	Plantation Dialysis	7061 CYPRESS RD	STE 13	PLANTATION	FL	33317-2243
766	Affiliated	3224	Laurens County Dialysis	Laurens County Dialysis	2400 BELLEVUE RD	STE 8	DUBLIN	GA	31021-2856
767	Affiliated	3225	Ford Factory Square Dialysis	Ford Factory Square Dialysis	567 NORTH AVE NE	STE 1	ATLANTA	GA	30308-2719
768	Affiliated	3226	North Fulton Dialysis	North Fulton Dialysis	1250 NORTHMEADOW PKWY	STE 12	ROSWELL	GA	30076-4914
769	Affiliated	3228	Freehold Dialysis	Freehold Dialysis	300 CRAIG RD		MANALAPAN	NJ	07726-8742
770	Affiliated	3229	Neptune Dialysis	Neptune Route 66 Dialysis	3297 STATE ROUTE 66		NEPTUNE	NJ	07753-2762
771	Affiliated	3231	East Orange Dialysis	East Orange Dialysis	90 WASHINGTON ST	BSMT	EAST ORANGE	NJ	07017-1050
772	Affiliated	3234	UT Southwestern-Oakcliff Dialysis	UT Southwestern-Oakcliff Dialysis	610 WYNNEWOOD DR		DALLAS	TX	75224
773	Affiliated	3236	Atlanta West Dialysis	Atlanta West Dialysis	2538 MARTIN LUTHER KING JR DR SW		ATLANTA	GA	30311-1779
774	Affiliated	3237	Columbia University Dialysis Center	Columbia University Dialysis Center	60 HAVEN AVE		NEW YORK	NY	10032-2604
775	Affiliated	3238	Northeast Cambridge Dialysis	Northeast Cambridge Dialysis	799 CONCORD AVE		CAMBRIDGE	MA	02138-1048
776	Affiliated	3239	New Bedford Dialysis	New Bedford Dialysis	524 UNION ST		NEW BEDFORD	MA	02740-3546
777	Affiliated	3242	Weymouth Dialysis	Weymouth Dialysis	330 LIBBEY INDUSTRIAL PARK	STE 9	WEYMOUTH	MA	02189-3122
778	Affiliated	3243	Woburn Dialysis	Woburn Dialysis	23 WARREN AVE		WOBURN	MA	01801-7906
779	Affiliated	3248	Bryan Dialysis	College Station Dialysis (fka Bryan Dialysis)	701 UNIVERSITY DR E	STE 41	COLLEGE STATION	TX	77840-1866
780	Affiliated	3249	Brenham Dialysis	Brenham Dialysis	2815 HIGHWAY 36 SO		BRENHAM	TX	77833
781	Affiliated	3250	Huntsville Dialysis	Huntsville Dialysis	521 IH 45S	STE 2	HUNTSVILLE	TX	77340-5651
782	Affiliated	3252	Utica Avenue Dialysis Center	Utica Avenue Dialysis Center	1305 UTICA AVE		BROOKLYN	NY	11203-5911
783	Affiliated	3254	New London Dialysis	New London Dialysis	5 SHAWS COVE	STE 1	NEW LONDON	CT	06320-4974
784	Affiliated	3258	Baxley Dialysis	Baxley Dialysis	539 FAIR ST		BAXLEY	GA	31513-0112
785	Affiliated	3261	Pascua Yaqui Tribe Dialysis	Pascua Yaqui Tribe Dialysis	7490 S CAMINO DE OESTE		TUCSON	AZ	85746-9308
786	Affiliated	3262	JHHS North Bond Street Dialysis	JHHS North Bond Street Dialysis	409 N CAROLINE ST		BALTIMORE	MD	21231-1003
787	Affiliated	3263	Syosset Kidney Center	Syosset Kidney Center	1 LOCUST LN		SYOSSET	NY	11791-4834
788	Affiliated	3264	Freeport Kidney Center	Freeport Kidney Center	267 W MERRICK RD		FREEPORT	NY	11520-3346
789	Affiliated	3265	Huntington Station Dialysis Center	HAKC-Huntington	256 BROADWAY		HUNTINGTON STATION	NY	11746-1403
790	Affiliated	3266	Medford Kidney Center	Medford Kidney Center	1725 N OCEAN AVE		MEDFORD	NY	11763-2649
791	Affiliated	3267	Blue Ash Dialysis	Blue Ash Dialysis	10600 MCKINLEY RD		CINCINNATI	OH	45242-3716
792	Affiliated	3269	Mt. Auburn Dialysis	Mt. Auburn Dialysis	2109 READING RD		CINCINNATI	OH	45202-1417
793	Affiliated	3272	Charlottesville Dialysis	Charlottesville Dialysis	1460 PANTOPS MOUNTAIN PLACE		CHARLOTTESVILLE	VA	22911
794	Affiliated	3273	Alexandria Dialysis	Alexandria Dialysis	5150 DUKE ST		ALEXANDRIA	VA	22304-2906
795	Affiliated	3275	Sebastian Dialysis	Sebastian Dialysis	1424 US HWY 1	STE C	SEBASTIAN	FL	32958-1619
796	Affiliated	3276	Crestview Hills Dialysis	Crestview Hills Dialysis	400 CENTERVIEW BLVD		CRESTVIEW HILLS	KY	41017-3478
797	Affiliated	3278	Washington Square Dialysis	Washington Square Dialysis	1112 WASHINGTON SQ		WASHINGTON	MO	63090-5336
798	Affiliated	3279	Florissant Dialysis	Florissant Dialysis	11687 W FLORISSANT AVE		FLORISSANT	MO	63033-6711
799	Affiliated	3282	Ithaca Dialysis Center	Ithaca Dialysis Center	201 DATES DR	STE 26	ITHACA	NY	14850-1345
800	Affiliated	3289	Fairfield Dialysis	Fairfield Dialysis	1210 HICKS BLVD		FAIRFIELD	OH	45014-1921
801	Affiliated	3290	Fairfield Home Training Dialysis	Fairfield Home Training Dialysis	1210 HICKS BLVD		FAIRFIELD	OH	45014-1921
802	Affiliated	3291	South Hill Dialysis	South Hill Dialysis	525 ALEXANDRIA PIKE	STE 12	SOUTHGATE	KY	41071-3243
803	Affiliated	3292	Silver Spring Dialysis	Silver Spring Dialysis	8412 GEORGIA AVE		SILVER SPRING	MD	20910-4406
804	Affiliated	3295	Philadelphia PMC Dialysis	Philadelphia PMC Dialysis	51 N 39TH ST		PHILADELPHIA	PA	19104-2640
805	Affiliated	3298	Tulare Dialysis	Tulare Dialysis	545 E TULARE AVE		TULARE	CA	93274-4220

806	Affiliated	3300	Visalia Dialysis	Visalia Dialysis	5429 W CYPRESS AVE		VISALIA	CA	93277-8341
807	Affiliated	3310	Falls Road Dialysis	Falls Road Dialysis	10753 FALLS RD	STE 115	LUTHERVILLE	MD	21093-4572
808	Affiliated	3312	Malden Dialysis	Wellington Circle Dialysis Center (fka Malden)	10 CABOT RD	STE 13B	MEDFORD	MA	02155-5173
809	Affiliated	3313	Salem Northeast Dialysis	Salem Northeast Dialysis (MA)	10 COLONIAL RD	STE 25	SALEM	MA	01970-2947
810	Affiliated	3314	Lexington	Lexington Prison Unit (OK)	15151 STATE HWY 39 E	PO BOX 26	LEXINGTON	OK	73051-0260
811	Affiliated	3315	Macon County Dialysis	Macon County Dialysis	1090 W MCKINLEY AVE		DECATUR	IL	62526-3208
812	Affiliated	3316	Effingham Dialysis	Effingham Dialysis	904 MEDICAL PARK DR	STE 1	EFFINGHAM	IL	62401-2193
813	Affiliated	3317	Jacksonville Dialysis	Jacksonville Dialysis	1515 W WALNUT ST		JACKSONVILLE	IL	62650-1150
814	Affiliated	3318	Litchfield Dialysis	Litchfield Dialysis	915 ST FRANCES WAY		LITCHFIELD	IL	62056-1775
815	Affiliated	3319	Mattoon Dialysis	Mattoon Dialysis	6051 DEVELOPMENT DR		CHARLESTON	IL	61920-9467
816	Affiliated	3320	Springfield Central Dialysis	Springfield Central Dialysis	932 N RUTLEDGE ST		SPRINGFIELD	IL	62702-3721
817	Affiliated	3321	Taylorville Dialysis	Taylorville Dialysis	901 W SPRESSER ST		TAYLORVILLE	IL	62568-1831
818	Affiliated	3322	Lincoln Dialysis	Lincoln Dialysis	2100 WEST FIFTH		LINCOLN	IL	62656-9115
819	Affiliated	3323	J. B. Zachary Dialysis Center	J. B. Zachary Dialysis Center	333 CASSELL DR	STE 23	BALTIMORE	MD	21224-6815
820	Affiliated	3324	Whitesquare Dialysis	Whitesquare Dialysis	1 NASHUA CT STE E		BALTIMORE	MD	21221
821	Affiliated	3325	25th Street Dialysis	25th Street Dialysis	920 E 25TH ST		BALTIMORE	MD	21218-5503
822	Affiliated	3326	Perth Amboy Dialysis	Perth Amboy Dialysis	530 NEW BRUNSWICK AVE		PERTH AMBOY	NJ	08861-3654
823	Affiliated	3327	Old Bridge Dialysis	Old Bridge Dialysis	3 HOSPITAL PLZ	STE 11	OLD BRIDGE	NJ	08857-3084
824	Affiliated	3328	Pear Tree Dialysis	Pear Tree Dialysis (fka Ukiah)	126 N ORCHARD AVE		UKIAH	CA	95482-4502
825	Affiliated	3334	Hubbard Road Dialysis	Hubbard Road Dialysis	1963 HUBBARD RD		MADISON	OH	44057-2105
826	Affiliated	3335	St. Charles Dialysis	St. Charles Dialysis	2125 BLUESTONE DR		SAINT CHARLES	MO	63303-6704
827	Affiliated	3336	Bel Air Dialysis	Bel Air Dialysis	2225 OLD EMMORTON RD	STE 15	BEL AIR	MD	21015-6122
828	Affiliated	3339	Cedarburg Dialysis	Cedarburg Dialysis	N 54 W 6135 MILL ST		CEDARBURG	WI	53012-2021
829	Affiliated	3340	Western Hills Dialysis	Western Hills Dialysis	3267 WESTBOURNE DR		CINCINNATI	OH	45248-5130
830	Affiliated	3341	Winton Road Dialysis	Winton Road Dialysis	6550 WINTON RD		CINCINNATI	OH	45224-1327
831	Affiliated	3342	Stamford Dialysis	Stamford Dialysis	30 COMMERCE RD		STAMFORD	CT	06902-4550
832	Affiliated	3343	Boaz Dialysis	Boaz Dialysis	16 CENTRAL HENDERSON RD		BOAZ	AL	35957-5922
833	Affiliated	3344	Guernsey County Dialysis	Guernsey County Dialysis	1300 CLARK ST		CAMBRIDGE	OH	43725-8875
834	Affiliated	3345	Marietta Dialysis	Marietta Dialysis	1019 PIKE ST		MARIETTA	OH	45750-3500
835	Affiliated	3346	Zanesville Dialysis	Zanesville Dialysis	3120 NEWARK RD		ZANESVILLE	OH	43701-9659
836	Affiliated	3351	Orlando East Dialysis	Orlando East Dialysis	1160 S SEMORAN BLVD	STE C	ORLANDO	FL	32807-1461
837	Affiliated	3352	Norwich Dialysis	Norwich Dialysis	113 SALEM TPKE		NORWICH	CT	06360-6484
838	Affiliated	3354	Columbus Dialysis	Columbus Dialysis	3830 OLENTANGY RIVER RD		COLUMBUS	OH	43214-5404
839	Affiliated	3362	Pasadena Dialysis	Pasadena Dialysis	8894 FORT SMALLWOOD RD	STE 12	PASADENA	MD	21122-7608
840	Affiliated	3369	Baltimore Geriatric & Rehab Dialysis Center	Baltimore Geriatric & Rehab Dialysis Center	4940 EASTERN AVE	FLOOR 5	BALTIMORE	MD	21224-2735
841	Affiliated	3373	Frederick Dialysis	Frederick Dialysis	140 THOMAS JOHNSON DR	STE 1	FREDERICK	MD	21702-4475
842	Affiliated	3376	Fayetteville Dialysis	Fayetteville Dialysis	1279 HIGHWAY 54 W	STE 11	FAYETTEVILLE	GA	30214-4551
843	Affiliated	3377	Birmingham Central Dialysis	Birmingham Central Dialysis	728 RICHARD ARRINGTON JR BLVD S		BIRMINGHAM	AL	35233-2106
844	Affiliated	3379	Birmingham North Dialysis	Birmingham North Dialysis	1917 32ND AVE N		BIRMINGHAM	AL	35207-3333
845	Affiliated	3380	Bessemer Dialysis	Bessemer Dialysis	901 W LAKE MALL		BESSEMER	AL	35020
846	Affiliated	3382	Ensley Dialysis	Ensley Dialysis	2630 AVENUE E		BIRMINGHAM	AL	35218-2163
847	Affiliated	3383	Sylacauga Dialysis	Sylacauga Dialysis	331 JAMES PAYTON BLVD		SYLACAUGA	AL	35150
848	Affiliated	3385	Branford Dialysis	Branford Dialysis	249 W MAIN ST		BRANFORD	CT	06405-4048
849	Affiliated	3386	Shrewsbury Dialysis	Shrewsbury Dialysis	7435 WATSON RD	STE 119	SAINT LOUIS	MO	63119-4472
850	Affiliated	3389	Milford Dialysis	Milford Dialysis	470 BRIDGEPORT AVE		MILFORD	CT	06460-4167
851	Affiliated	3414	Cedartown Dialysis	Cedartown Dialysis	325 WEST AVE		CEDARTOWN	GA	30125-3439
852	Affiliated	3416	Brookfield Dialysis	Brookfield Dialysis	19395 W CAPITOL DR	BLDG C	BROOKFIELD	WI	53045-2736
853	Affiliated	3417	Henrico County Dialysis	Henrico County Dialysis	5270 CHAMBERLAYNE RD		RICHMOND	VA	23227-2950
854	Affiliated	3418	St. Louis West Dialysis	St. Louis West Dialysis	400 N LINDBERGH BLVD		SAINT LOUIS	MO	63141-7814
855	Affiliated	3420	Springfield Montvale Dialysis	Springfield Montvale Dialysis	2930 MONTVALE DR	STE A	SPRINGFIELD	IL	62704-5376
856	Affiliated	3422	South Norwalk Dialysis	South Norwalk Dialysis	31 STEVENS ST		NORWALK	CT	06850-3805
857	Affiliated	3425	Decatur East Wood Dialysis	Decatur East Wood Dialysis	794 E WOOD ST		DECATUR	IL	62523-1155
858	Affiliated	3426	Schaeffer Drive Dialysis	Schaeffer Drive Dialysis	18100 SCHAEFER HWY		DETROIT	MI	48235-2600
859	Affiliated	3427	Redford Dialysis	Redford Dialysis	22711 GRAND RIVER AVE		DETROIT	MI	48219-3113

860	Affiliated	3428	Kresge Dialysis	Kresge Dialysis	4145 CASS AVE		DETROIT	MI	48201-1707
861	Affiliated	3429	Motor City Dialysis	Motor City Dialysis	4727 SAINT ANTOINE ST	STE 11	DETROIT	MI	48201-1461
862	Affiliated	3431	Whitebridge Dialysis	Whitebridge Dialysis	103 WHITE BRIDGE PIKE	STE 6	NASHVILLE	TN	37209-4539
863	Affiliated	3432	Columbia Dialysis	Columbia Dialysis (TN)	1705 GROVE ST		COLUMBIA	TN	38401-3517
864	Affiliated	3433	Murfreesboro Dialysis	Murfreesboro Dialysis	1346 DOW ST		MURFREESBORO	TN	37130-2470
865	Affiliated	3434	Lawrenceburg Dialysis	Lawrenceburg Dialysis (TN)	2022 N LOCUST AVE		LAWRENCEBURG	TN	38464-2336
866	Affiliated	3436	Sumner Dialysis	Sumner Dialysis	300 STEAM PLANT RD	STE 27	GALLATIN	TN	37066-3019
867	Affiliated	3437	Cumberland Dialysis	Cumberland Dialysis	312 HOSPITAL DR	STE 5	MADISON	TN	37115-5037
868	Affiliated	3438	Williamson County Dialysis	Williamson County Dialysis	3983 CAROTHERS PKWY	STE E-4	FRANKLIN	TN	37067-5936
869	Affiliated	3441	Cumming Dialysis	Cumming Dialysis	911 MARKET PLACE BLVD	STE 3	CUMMING	GA	30041-7938
870	Affiliated	3443	Silverton Dialysis	Silverton Dialysis	6929 SILVERTON AVE		CINCINNATI	OH	45236-3701
871	Affiliated	3445	Atlanta South Dialysis	Atlanta South Dialysis	3158 EAST MAIN ST	STE A	EAST POINT	GA	30344-4800
872	Affiliated	3447	St. Petersburg Dialysis	St. Petersburg Dialysis	1117 ARLINGTON AVE N		ST PETERSBURG	FL	33705-1521
873	Affiliated	3449	Alton Dialysis	Alton Dialysis	3511 COLLEGE AVE		ALTON	IL	62002-5009
874	Affiliated	3451	Edison Dialysis	Edison Dialysis	29 MERIDIAN RD		EDISON	NJ	08820-2823
875	Affiliated	3452	Dundalk Dialysis	Dundalk Dialysis	14 COMMERCE ST		DUNDALK	MD	21222-4307
876	Affiliated	3454	Columbus East Dialysis	Columbus East Dialysis	299 OUTERBELT ST		COLUMBUS	OH	43213-1529
877	Affiliated	3455	Dallas East Dialysis	Dallas East Dialysis	3312 N BUCKNER BLVD	STE 213	DALLAS	TX	75228-5642
878	Affiliated	3456	San Ysidro Dialysis	San Ysidro Dialysis	1445 30TH ST	STE A	SAN DIEGO	CA	92154-3496
879	Affiliated	3457	Olathe Dialysis	Olathe Dialysis	732 W FRONTIER LN		OLATHE	KS	66061-7202
880	Affiliated	3459	Orange City Dialysis	Orange City Dialysis	242 TREEMONT DR	BLDG II	ORANGE CITY	FL	32763-7945
881	Affiliated	3460	Miami East Dialysis	Miami East Dialysis	1250 NW 7TH ST	STE 16	MIAMI	FL	33125-3744
882	Affiliated	3462	Temple Terrace Dialysis	Temple Terrace Dialysis	11306 N 53RD ST		TEMPLE TERRACE	FL	33617-2214
883	Affiliated	3463	Midlothian Dialysis	Midlothian Dialysis	14281 MIDLOTHIAN TPKE	BLDG B	MIDLOTHIAN	VA	23113-6560
884	Affiliated	3464	Christian County Dialysis	Christian County Dialysis	200 BURLEY AVE		HOPKINSVILLE	KY	42240-8725
885	Affiliated	3465	St. Louis West PD Dialysis	St. Louis West PD Dialysis	450 N LINDBERGH BLVD	STE 1C	CREVE COEUR	MO	63141-7858
886	Affiliated	3467	Atlanta Midtown Dialysis	Atlanta Midtown Dialysis PD	418 DECATUR ST SE	STE A	ATLANTA	GA	30312-1801
887	Affiliated	3468	Silverton Home Training Dialysis	Silverton Home Training Dialysis	6929 SILVERTON AVE		CINCINNATI	OH	45236-3701
888	Affiliated	3472	Philadelphia 42nd Street Dialysis	Philadelphia 42nd Street Dialysis	4126 WALNUT ST		PHILADELPHIA	PA	19104-3511
889	Affiliated	3473	Radnor Dialysis	Radnor Dialysis	250 KING OF PRUSSIA RD		RADNOR	PA	19087-5220
890	Affiliated	3475	St. Louis Dialysis	St. Louis Dialysis	324 DE BALIVIERE AVE		SAINT LOUIS	MO	63112-1804
891	Affiliated	3477	Elkins Park Dialysis	Wyncote Dialysis (fka Elkins Park)	1000 EASTON RD	STE 25	WYNCOTE	PA	19095-2934
892	Affiliated	3478	Mainland Dialysis	Mainland Dialysis	2600 GULF FWY		LA MARQUE	TX	77568-4922
893	Affiliated	3479	Island Dialysis	Island Dialysis	5920 BROADWAY ST		GALVESTON	TX	77551-4305
894	Affiliated	3481	Orlando Home Training Dialysis	Orlando Home Training Dialysis	116 STURTEVANT ST	STE 2	ORLANDO	FL	32806-2021
895	Affiliated	3482	Mechanicsville Dialysis	Mechanicsville Dialysis	8191 ATLEE RD		MECHANICSVILLE	VA	23116-1807
896	Affiliated	3484	San Diego East Dialysis	San Diego East Dialysis	292 EUCLID AVE	STE 1	SAN DIEGO	CA	92114-3629
897	Affiliated	3485	Russellville Dialysis	Russellville Dialysis	14897 HIGHWAY 43		RUSSELLVILLE	AL	35653-1954
898	Affiliated	3486	Encinitas Dialysis	Encinitas Dialysis	332 SANTA FE DR	STE 1	ENCINITAS	CA	92024-5143
899	Affiliated	3491	Rushville Dialysis	Rushville Dialysis	112 SULLIVAN DRIVE		RUSHVILLE	IL	62681-1293
900	Affiliated	3493	Plainfield Dialysis	Plainfield Dialysis	1200 RANDOLPH RD	MUHLENBURG CAMPUS	PLAINFIELD	NJ	07060-3361
901	Affiliated	3494	Parkersburg Dialysis	Parkersburg Dialysis	1824 MURDOCH AVE	STE 44	PARKERSBURG	WV	26101-3230
902	Affiliated	3497	Tucson South Central Dialysis	Tucson South Central Dialysis	2024 E IRVINGTON RD	STE 7	TUCSON	AZ	85714-1825
903	Affiliated	3499	Hazelwood Dialysis	Hazelwood Dialysis	637 DUNN RD		HAZELWOOD	MO	63042-1755
904	Affiliated	3503	Durham West Dialysis	Durham West Dialysis	4307 WESTERN PARK PL		DURHAM	NC	27705-1204
905	Affiliated	3504	Liberty Dialysis	Liberty Dialysis	2525 GLEN HENDREN DR		LIBERTY	MO	64068-9625
906	Affiliated	3506	Chino Dialysis	Chino Dialysis	4445 RIVERSIDE DR		CHINO	CA	91710-3961
907	Affiliated	3507	Greenview Dialysis	Greenview Dialysis	18544 W 8 MILE RD		SOUTHFIELD	MI	48075-4194
908	Affiliated	3508	Perry Dialysis	Perry Dialysis	118 W MAIN ST		PERRY	FL	32347-2656
909	Affiliated	3511	Ashtabula Dialysis	Ashtabula Dialysis	1614 W 19TH ST		ASHTABULA	OH	44004-3036
910	Affiliated	3513	Northland Dialysis	Northland Dialysis	2750 CLAY EDWARDS DR	STE 1	N KANSAS CITY	MO	64116-3257
911	Affiliated	3516	Lake St. Louis Dialysis	Lake St. Louis Dialysis	200 BREVCO PLZ	STE 21	LAKE SAINT LOUIS	MO	63367-2950
912	Affiliated	3517	Wyandotte West Dialysis	Wyandotte West Dialysis	8919 PARALLEL PKWY	STE 121	KANSAS CITY	KS	66112-1655
913	Affiliated	3518	Huntingdon Valley Dialysis	Temp CLSD-Huntingdon Valley Dialysis	769 HUNTINGDON PIKE	STE 18	HUNTINGDON VALLEY	PA	19006-8362

914	Affiliated	3519	Glendale Dialysis	Glendale Dialysis	1000 E PALMER AVE		GLENDALE	CA	91205-3532
915	Affiliated	3520	Toledo Dialysis	Toledo Dialysis	1614 S BYRNE RD		TOLEDO	OH	43614-3464
916	Affiliated	3523	Cameron Dialysis	Cameron Dialysis	1003 W 4TH ST		CAMERON	MO	64429-1466
917	Affiliated	3524	Omaha Central Dialysis	Omaha Central Dialysis	144 S 40TH ST		OMAHA	NE	68131-3004
918	Affiliated	3525	Chillicothe Dialysis	Chillicothe Dialysis	588 E BUSINESS 36		CHILLICOTHE	MO	64601-3721
919	Affiliated	4210	Council Bluffs Dialysis	Council Bluffs Dialysis Center	300 W BROADWAY	STE 15	COUNCIL BLUFFS	IA	51503-9077
920	Affiliated	3528	DeRidder Dialysis	DeRidder Dialysis	239 E 1ST ST		DERIDDER	LA	70634-4105
921	Affiliated	3530	Dodge County Dialysis	Dodge County Dialysis	1949 E 23RD AVE S		FREMONT	NE	68025-2452
922	Affiliated	3533	Omaha North Dialysis	Omaha North Dialysis	6572 AMES AVE		OMAHA	NE	68104-1931
923	Affiliated	3534	Omaha South Dialysis	Omaha South Dialysis	3427 L ST	STE 16	OMAHA	NE	68107-2577
924	Affiliated	3535	Lake Charles Southwest Dialysis	Lake Charles Southwest Dialysis	300 W 18th ST		LAKE CHARLES	LA	70601-7342
925	Affiliated	3536	St. Joseph Dialysis	St. Joseph Dialysis	5514 CORPORATE DR	STE 1	SAINT JOSEPH	MO	64507-7752
926	Affiliated	3537	Sulphur Dialysis	Sulphur Dialysis	944 BEGLIS PKWY		SULPHUR	LA	70663-5102
927	Affiliated	3539	Tipton County Dialysis	Tipton County Dialysis	107 TENNESSEE AVE		COVINGTON	TN	38019-3902
928	Affiliated	3540	Dyersburg Dialysis	Dyersburg Dialysis	1575 PARR AVE		DYERSBURG	TN	38024-3151
929	Affiliated	3544	Effingham North Dialysis	Effingham North Dialysis	301 N PINE ST		SPRINGFIELD	GA	31329-3076
930	Affiliated	3545	Westminster South Dialysis	Westminster South Dialysis	14014 MAGNOLIA ST.		WESTMINSTER	CA	92683-4736
931	Affiliated	3546	Williams Street Dialysis	Williams Street Dialysis	2812 WILLIAMS ST		SAVANNAH	GA	31404-4134
932	Affiliated	3547	DeRenne Dialysis	DeRenne Dialysis	5303 MONTGOMERY ST		SAVANNAH	GA	31405-5138
933	Affiliated	3548	Abercorn Dialysis	Abercorn Dialysis	11706 MERCY BLVD	STE 9	SAVANNAH	GA	31419-1751
934	Affiliated	3551	Fort Myers North Dialysis	Fort Myers North Dialysis	16101 N CLEVELAND AVE		N FT MYERS	FL	33903-2148
935	Affiliated	3552	Butler County Dialysis	Butler County Dialysis	3497 S DIXIE HWY		FRANKLIN	OH	45005-5717
936	Affiliated	3556	Willingboro	Willingboro Dialysis	230 VAN SCIVER PKWY		WILLINGBORO	NJ	08046-1131
937	Affiliated	3557	McKeesport West Dialysis	McKeesport West Dialysis	101 9TH ST		MCKEESPORT	PA	15132-3953
938	Affiliated	3559	College Dialysis	College Dialysis	6535 UNIVERSITY AVE		SAN DIEGO	CA	92115-5810
939	Affiliated	3560	Montezuma Dialysis	Montezuma Dialysis	114 DEVAUGHN AVE		MONTEZUMA	GA	31063-1708
940	Affiliated	3561	Romulus Dialysis	Romulus Dialysis	31470 ECORSE RD		ROMULUS	MI	48174-1963
941	Affiliated	3564	Wrightsville Dialysis	Wrightsville Dialysis	2240 W ELM ST		WRIGHTSVILLE	GA	31096-2016
942	Affiliated	3565	Tower Dialysis	Tower Dialysis	8635 W 3RD ST	STE 56W	LOS ANGELES	CA	90048-6110
943	Affiliated	3566	Columbus Downtown Dialysis	Columbus Downtown Dialysis	415 E MOUND ST		COLUMBUS	OH	43215-5512
944	Affiliated	3568	Charlotte East Dialysis	Charlotte East Dialysis	3204 N SHARON AMITY RD		CHARLOTTE	NC	28205-6541
945	Affiliated	3569	Carmel Mountain Dialysis	Carmel Mountain Dialysis	9850 CARMEL MOUNTAIN RD		SAN DIEGO	CA	92129-2892
946	Affiliated	3571	Lenexa Dialysis	Lenexa Dialysis	8630 HALSEY ST		LENEXA	KS	66215-2880
947	Affiliated	3577	Nashua Dialysis	Nashua Dialysis	38 TYLER ST	STE 1	NASHUA	NH	03060-2912
948	Affiliated	3580	Illini Renal Dialysis	Illini Renal Dialysis	507 E UNIVERSITY AVE		CHAMPAIGN	IL	61820-3828
949	Affiliated	3586	Loring Heights Dialysis	Loring Heights Dialysis	1575 NORTHSIDE DR NW	STE 45	ATLANTA	GA	30318-4211
950	Affiliated	3588	Forest Hills Dialysis	Forest Hills Dialysis	2693 FOREST HILLS RD SW		WILSON	NC	27893-8611
951	Affiliated	3589	St. Peters Dialysis	St. Peters Dialysis	300 FIRST EXECUTIVE AVE	STE A	SAINT PETERS	MO	63376-1655
952	Affiliated	3591	Platte Woods Dialysis	Platte Woods Dialysis	7667 NW PRAIRIE VIEW RD		KANSAS CITY	MO	64151-1544
953	Affiliated	3593	Fresno North Dialysis	Fresno Palm Bluffs Dialysis (fka Fresno North)	770 W PINEDALE AVE		FRESNO	CA	93711-5744
954	Affiliated	3594	Middlesex County Dialysis	Burlington Regional Dialysis (fka Middlesex County)	31 MALL RD	STE 1B	BURLINGTON	MA	01803-4138
955	Affiliated	3596	Clearfield Dialysis	Clearfield Dialysis	1033 TURNPIKE AVE	STE 1	CLEARFIELD	PA	16830-3061
956	Affiliated	3597	Papillion Dialysis	Papillion Dialysis	1502 S WASHINGTON ST	STE 1	PAPILLION	NE	68046-3136
957	Affiliated	3598	Birmingham Home Training Dialysis	Birmingham Home Training Dialysis	2101 7TH AVE S		BIRMINGHAM	AL	35233-3105
958	Affiliated	3603	Bayou Dialysis	Magnolia Dialysis	210 E SPILLMAN ST		GONZALES	LA	70737-4604
959	Affiliated	3609	Radford Dialysis	Radford Dialysis	600 E MAIN ST	STE F	RADFORD	VA	24141-1826
960	Affiliated	3610	Eufaula Dialysis	Eufaula Dialysis	220 S ORANGE AVE		EUFAULA	AL	36027-1612
961	Affiliated	3612	Coshocton Dialysis	Coshocton Dialysis	1404 CHESTNUT ST EAST		COSHOCTON	OH	43812-1401
962	Affiliated	3614	Costa Mesa Dialysis	Costa Mesa Dialysis	1590 SCENIC AVE		COSTA MESA	CA	92626-1400
963	Affiliated	3615	Little Rock Dialysis	Central Little Rock Dialysis	5800 W 10TH ST	STE 51	LITTLE ROCK	AR	72204-1760
964	Affiliated	3619	Northport Dialysis	Northport Dialysis	2401 HOSPITAL DR		NORTHPORT	AL	35476-3392
965	Affiliated	3632	Pageland Dialysis	Pageland Dialysis	505A S PEARL ST		PAGELAND	SC	29728-2222
966	Affiliated	3633	Bakersfield South Dialysis	White Lane Dialysis (fka Bakersfield South)	7701 WHITE LN	STE D	BAKERSFIELD	CA	93309-0201
967	Affiliated	3634	Newaygo County Dialysis	Newaygo County Dialysis	1317 W MAIN ST		FREMONT	MI	49412-1478

968	Affiliated	3636	Cedar Lane Dialysis	Cedar Lane Dialysis	6334 CEDAR LN	STE 11	COLUMBIA	MD	21044-3898
969	Affiliated	3639	Torrington Dialysis	Torrington Dialysis	780 LITCHFIELD ST	STE 1	TORRINGTON	CT	06790-6268
970	Affiliated	3642	Janesville Dialysis	Janesville Dialysis	1305 WOODMAN RD		JANESVILLE	WI	53545-1068
971	Affiliated	3643	Bloomfield Dialysis	Bloomfield Dialysis	29 GRIFFIN RD S		BLOOMFIELD	CT	06002-1351
972	Affiliated	3645	Anthem Village Dialysis	Anthem Village Dialysis	2530 ANTHEM VILLAGE DR		HENDERSON	NV	89052-5548
973	Affiliated	3646	Glen Burnie Dialysis	Glen Burnie Dialysis	120 LANGLEY RD N		GLEN BURNIE	MD	21060-6578
974	Affiliated	3655	Melbourne Dialysis	Melbourne Dialysis	2235 S BABCOCK ST		MELBOURNE	FL	32901-5305
975	Affiliated	3656	St. Petersburg South Dialysis	St. Petersburg South Dialysis	2850 34TH ST S		ST PETERSBURG	FL	33711-3817
976	Affiliated	3663	Belpre Dialysis	Belpre Dialysis	2906 WASHINGTON BLVD		BELPRE	OH	45714-1848
977	Affiliated	3666	Stockton Home Training Dialysis	Stockton Home Training Dialysis	545 E CLEVELAND ST	STE A	STOCKTON	CA	95204-5535
978	Affiliated	3670	Rock Prairie Road Dialysis	Rock Prairie Road Dialysis	1605 ROCK PRAIRIE RD	STE 11	COLLEGE STATION	TX	77845-8358
979	Affiliated	3675	Market Street	Market Street Dialysis	3701 MARKET ST	STE 1	PHILADELPHIA	PA	19104-5503
980	Affiliated	3677	Northwood	Northwood Dialysis (aka Toledo East)	611 LEMOYNE RD		NORTHWOOD	OH	43619-1811
981	Affiliated	3701	Tyson's Corner Dialysis	Tyson's Corner Dialysis	8391 OLD COURTHOUSE RD	STE 16	VIENNA	VA	22182-3819
982	Affiliated	3704	Southern Maryland Dialysis	Southern Maryland Dialysis	9211 STUART LN	4TH FL	CLINTON	MD	20735-2712
983	Affiliated	3707	Brentwood Dialysis	Brentwood Dialysis	1231 BRENTWOOD RD NE		WASHINGTON	DC	20018-1019
984	Affiliated	3708	Amelia Dialysis	Amelia Dialysis	15151 PATRICK HENRY HWY		AMELIA COURT HOUSE	VA	23002-4700
985	Affiliated	3714	Eighth Street Dialysis	Eighth Street Dialysis	300 8TH ST NE		WASHINGTON	DC	20002-6108
986	Affiliated	3715	Chester Dialysis	Chester Dialysis	10360 IRONBRIDGE RD		CHESTER	VA	23831-1425
987	Affiliated	3716	Howard County Dialysis	Howard County Dialysis	5999 HARPERS FARM RD	STE 11E	COLUMBIA	MD	21044-3023
988	Affiliated	3717	Catonsville Dialysis	Catonsville Dialysis	1581 SULPHUR SPRING RD	STE 112	BALTIMORE	MD	21227
989	Affiliated	3718	Mercy Dialysis	Mercy Dialysis	315 N CALVERT ST	STE 3	BALTIMORE	MD	21202-3611
990	Affiliated	3719	Harbor Park Dialysis	Harbor Park Dialysis	111 CHERRY HILL RD		BALTIMORE	MD	21225-1392
991	Affiliated	3732	Dabney Dialysis	Three Chopt Dialysis (fka Dabney)	8813 THREE CHOPT RD		RICHMOND	VA	23229
992	Affiliated	3733	Hioaks Dialysis	Hioaks Dialysis	671 HIOAKS RD	STE A	RICHMOND	VA	23225-4072
993	Affiliated	3757	Arlington Dialysis	Arlington Dialysis	4805 1st ST N		ARLINGTON	VA	22203
994	Affiliated	3759	Landover Dialysis	Landover Dialysis	1200 MERCANTILE LN	STE 15	UPPER MARLBORO	MD	20774-5389
995	Affiliated	3761	Staunton Dialysis	Staunton Dialysis	29 IDLEWOOD BLVD		STAUNTON	VA	24401-9355
996	Affiliated	3762	Covington Dialysis	Covington Dialysis	2504 VALLEY RIDGE RD		COVINGTON	VA	24426-6339
997	Affiliated	3763	Culpeper Dialysis	Culpeper Dialysis	430 SOUTHRIDGE PARKWAY		CULPEPER	VA	22701-3791
998	Affiliated	3764	Greenbrier Dialysis	Greenbrier Dialysis	129 SENECA TRL		LEWISBURG	WV	24901-1564
999	Affiliated	3765	Harrisonburg Dialysis	Harrisonburg Dialysis	871 CANTRELL AVE	STE 1	HARRISONBURG	VA	22801-4323
1000	Affiliated	3766	Lexington Dialysis	Lexington Dialysis	756 N LEE HWY		LEXINGTON	VA	24450-3724
1001	Affiliated	3802	Manteca Dialysis	Manteca Dialysis	1156 S MAIN ST		MANTECA	CA	95337-9505
1002	Affiliated	3804	Roseburg/Mercy Dialysis	Roseburg/Mercy Dialysis	2599 NW EDENBOWER BLVD		ROSEBURG	OR	97471-6220
1003	Affiliated	3805	Daly City Dialysis	Daly City Dialysis	1498 SOUTHGATE AVE	STE 11	DALY CITY	CA	94015-4015
1004	Affiliated	3806	Vallejo Dialysis	Vallejo Dialysis	121 HOSPITAL DR		VALLEJO	CA	94589-2562
1005	Affiliated	3812	Salem Dialysis	Salem Dialysis (OR)	3550 LIBERTY RD S	STE 1	SALEM	OR	97302-5700
1006	Affiliated	3817	Fresno Dialysis	Fresno Dialysis	1111 E WARNER AVE		FRESNO	CA	93710-4030
1007	Affiliated	3818	Oakland Dialysis	Oakland Dialysis	5354 CLAREMONT AVE		OAKLAND	CA	94618-1035
1008	Affiliated	3820	Bakersfield Dialysis	Bakersfield Brimhall Dialysis (fka California Ave.)	8501 BRIMHALL RD	BLDG 5	BAKERSFIELD	CA	93311-2252
1009	Affiliated	3821	Northeast Bakersfield Dialysis	Northeast Dialysis (fka NE Bakersfield)	3761 MALL VIEW RD		BAKERSFIELD	CA	93306-3048
1010	Affiliated	3830	San Francisco Dialysis	San Francisco Dialysis	1499 WEBSTER ST		SAN FRANCISCO	CA	94115-3705
1011	Affiliated	3831	Hanford Dialysis	Hanford Dialysis	402 W 8TH ST		HANFORD	CA	93230-4536
1012	Affiliated	3840	San Pablo Dialysis	San Pablo Dialysis	14020 SAN PABLO AVE		SAN PABLO	CA	94806-3604
1013	Affiliated	3847	Chinatown Dialysis	Chinatown Dialysis	636 CLAY ST		SAN FRANCISCO	CA	94111-2502
1014	Affiliated	3849	El Cerrito Dialysis	El Cerrito Dialysis	10690 SAN PABLO AVE		EL CERRITO	CA	94530-2620
1015	Affiliated	3857	Tracy Dialysis	Tracy Dialysis	425 W BEVERLY PL	STE A	TRACY	CA	95376-3086
1016	Affiliated	3858	Salem North Dialysis	Salem North Dialysis (OR)	1220 LIBERTY ST NE		SALEM	OR	97301-7330
1017	Affiliated	3860	Auburn Dialysis	Auburn Dialysis	3126 PROFESSIONAL DR	STE 1	AUBURN	CA	95603-2411
1018	Affiliated	3861	Grass Valley Dialysis	Grass Valley Dialysis	360 CROWN POINT CIRCLE	STE 21	GRASS VALLEY	CA	95945-2543
1019	Affiliated	3901	Santee Dialysis	Santee Dialysis	228 BRADFORD BLVD		SANTEE	SC	29142-8677
1020	Affiliated	3903	Upland Dialysis	Upland Dialysis	600 N 13TH AVE		UPLAND	CA	91786-4957
1021	Affiliated	3906	Vance County Dialysis	Vance County Dialysis	854 S BECKFORD DR		HENDERSON	NC	27536-3487

1022	Affiliated	3907	Edenton Dialysis	Edenton Dialysis	703 LUKE ST		EDENTON	NC	27932-9694
1023	Affiliated	3909	Ahoskie Dialysis	Ahoskie Dialysis	129 HERTFORD COUNTY HIGH RD		AHOSKIE	NC	27910-8131
1024	Affiliated	3914	Allendale County Dialysis	Allendale County Dialysis	202 HAMPTON AVE N		FAIRFAX	SC	29827-4510
1025	Affiliated	3916	North Orangeburg Dialysis	North Orangeburg Dialysis	124 FIRE TOWER RD		ORANGEBURG	SC	29118-1443
1026	Affiliated	3917	South Orangeburg Dialysis	South Orangeburg Dialysis	1080 SUMMERS AVE		ORANGEBURG	SC	29115-4920
1027	Affiliated	3931	Greenwood Dialysis	Greenwood Dialysis	109 OVERLAND DR		GREENWOOD	SC	29646-4053
1028	Affiliated	3933	Union County Dialysis	Union County Dialysis	701 E ROOSEVELT BLVD	STE 4	MONROE	NC	28112-4107
1029	Affiliated	3934	South Charlotte Dialysis	South Charlotte Dialysis	6450 BANNINGTON RD		CHARLOTTE	NC	28226-1327
1030	Affiliated	3935	Lancaster SC Dialysis	Lancaster SC Dialysis	980 N WOODLAND DR	STE 1	LANCASTER	SC	29720-1964
1031	Affiliated	3952	Central Bamberg Dialysis	Central Bamberg Dialysis	67 SUNSET DR		BAMBERG	SC	29003-1181
1032	Affiliated	4001	West Tallahassee Dialysis	West Tallahassee Dialysis	2645 W TENNESSEE ST		TALLAHASSEE	FL	32304-2547
1033	Affiliated	4002	Daytona South Dialysis	Daytona South Dialysis	1801 S NOVA RD	STE 36	SOUTH DAYTONA	FL	32119-1775
1034	Affiliated	4003	Daytona Beach Dialysis	Daytona Beach Dialysis	578 HEALTH BLVD		DAYTONA BEACH	FL	32114-1492
1035	Affiliated	4004	West Tampa Dialysis	West Tampa Dialysis	4515 GEORGE RD	STE 3	TAMPA	FL	33634-7300
1036	Affiliated	4005	Fontana Dialysis	Fontana Dialysis	17590 FOOTHILL BLVD		FONTANA	CA	92335-8416
1037	Affiliated	4007	Fort Myers Dialysis	Fort Myers Dialysis	4220 EXECUTIVE CIRCLE	STE 38	FORT MYERS	FL	33916-7993
1038	Affiliated	4009	Lehigh Acres Dialysis	Lehigh Acres Dialysis	2719 4TH ST W		LEHIGH ACRES	FL	33971-1942
1039	Affiliated	4010	Los Banos Dialysis	Los Banos Dialysis	222 I ST		LOS BANOS	CA	93635-4132
1040	Affiliated	4013	Kissimmee Dialysis	Kissimmee Dialysis	802 N JOHN YOUNG PKWY		KISSIMMEE	FL	34741-4912
1041	Affiliated	4014	New Smyrna Beach Dialysis	New Smyrna Beach Dialysis	110 S ORANGE ST		NEW SMYRNA BEACH	FL	32168-7153
1042	Affiliated	4017	Lake Wales Dialysis	Lake Wales Dialysis	1125 BRYN MAWR AVE		LAKE WALES	FL	33853-4333
1043	Affiliated	4018	Dearborn Dialysis	Dearborn Dialysis	1185 MONROE ST		DEARBORN	MI	48124-2814
1044	Affiliated	4020	Greater Miami Dialysis	Greater Miami Dialysis	160 NW 176TH ST	STE 1	MIAMI	FL	33169-5023
1045	Affiliated	4021	Burbank Dialysis	Burbank Dialysis	1211 N SAN FERNANDO BLVD		BURBANK	CA	91504-4234
1046	Affiliated	4024	Lakeland Dialysis	Lakeland Dialysis	515 E BELLA VISTA ST		LAKELAND	FL	33805-3005
1047	Affiliated	4025	Burlington North Dialysis	Burlington North Dialysis	1164 E ROUTE 130		BURLINGTON	NJ	08016-2954
1048	Affiliated	4026	Delano Dialysis	Delano Dialysis	905 MAIN ST		DELANO	CA	93215-1729
1049	Affiliated	4027	Erie Dialysis	Erie Dialysis	350 E BAYFRONT PKWY	STE A	ERIE	PA	16507-2410
1050	Affiliated	4028	Homestead Dialysis	Homestead Dialysis	207 W 7TH AVE		W HOMESTEAD	PA	15120-1002
1051	Affiliated	4029	Plant City Dialysis	Plant City Dialysis	1211 W REYNOLDS ST		PLANT CITY	FL	33563-4321
1052	Affiliated	4030	Winter Haven Dialysis	Winter Haven Dialysis	1625 UNITY WAY NW		WINTER HAVEN	FL	33881
1053	Affiliated	4032	Charlotte Dialysis	Charlotte Dialysis	2321 W MOREHEAD ST	STE 12	CHARLOTTE	NC	28208-5145
1054	Affiliated	4034	McKeesport Dialysis	McKeesport Dialysis	2001 LINCOLN WAY	OAK PARK MALL	MCKEESPORT	PA	15131-2419
1055	Affiliated	4035	Broward Dialysis	Broward Dialysis	1500 N FEDERAL HWY	STE 1	FT LAUDERDALE	FL	33304-5600
1056	Affiliated	4036	Athens Dialysis	Athens Dialysis	15953 ATHENS LIMESTONE DR		ATHENS	AL	35613-2214
1057	Affiliated	4038	Bradenton Dialysis	Bradenton Dialysis	3501 CORTEZ RD W	STE 14	BRADENTON	FL	34210-3104
1058	Affiliated	4039	Deland Dialysis	Deland Dialysis	350 E NEW YORK AVE		DELAND	FL	32724-5510
1059	Affiliated	4040	Boynton/North Delray Dialysis	Boynton/North Delray Dialysis	2655 W ATLANTIC AVE		DELRAY BEACH	FL	33445-4400
1060	Affiliated	4041	Lake Worth Dialysis	Lake Worth Dialysis	2459 S CONGRESS AVE	STE 1	PALM SPRINGS	FL	33406-7616
1061	Affiliated	4042	Palm Coast Dialysis	Palm Coast Dialysis	13 KINGSWOOD DR	STE A	PALM COAST	FL	32137-4614
1062	Affiliated	4043	Fort Myers South Dialysis	Fort Myers South Dialysis	8570 GRANITE CT		FORT MYERS	FL	33908-4102
1063	Affiliated	4044	Woodburn Dialysis	Woodburn Dialysis	1840 NEWBERG HWY	STE 14	WOODBURN	OR	97071-3187
1064	Affiliated	4045	Four Freedoms	Four Freedoms Dialysis (fka Range Street)	289 SW RANGE AVE	STE A	MADISON	FL	32340-2351
1065	Affiliated	4046	West Philadelphia Dialysis	West Philadelphia Dialysis	7609 LINDBERGH BLVD		PHILADELPHIA	PA	19153-2301
1066	Affiliated	4048	Tucson West Dialysis	Tucson West Dialysis	1780 W ANKLAM RD		TUCSON	AZ	85745-2632
1067	Affiliated	4049	Tucson East Dialysis	Tucson East Dialysis	6420 E BROADWAY BLVD	STE C3	TUCSON	AZ	85710-3512
1068	Affiliated	4053	Tallahassee South Dialysis	Tallahassee South Dialysis	2410 S ADAMS ST		TALLAHASSEE	FL	32301-6325
1069	Affiliated	4054	Selma Dialysis	Selma Dialysis	2711 CINEMA WAY	STE 111	SELMA	CA	93662-2662
1070	Affiliated	4055	Hinesville Dialysis	Hinesville Dialysis	522 ELMA G MILES PKWY		HINESVILLE	GA	31313-4021
1071	Affiliated	4056	Los Angeles Downtown Dialysis	Los Angeles Downtown Dialysis	2021 S FLOWER ST		LOS ANGELES	CA	90007-1342
1072	Affiliated	4057	Anaheim Dialysis	Anaheim Dialysis	1107 W LA PALMA AVE		ANAHEIM	CA	92801-2804
1073	Affiliated	4058	Martinsville Dialysis	Martinsville Dialysis	33 BRIDGE ST S		MARTINSVILLE	VA	24112-6214
1074	Affiliated	4060	Jefferson Dialysis	Jefferson Dialysis	14 CLAIRTON BLVD		PITTSBURGH	PA	15236-3911
1075	Affiliated	4061	Saddleback Dialysis	Saddleback Dialysis	23141 PLAZA POINTE DR		LAGUNA HILLS	CA	92653-1425

1076	Affiliated	4064	Sun City Center Dialysis	Sun City Center Dialysis	783 CORTARO DR		RUSKIN	FL	33573-6812
1077	Affiliated	4065	Paris Dialysis	Paris Dialysis	32 STEUBENVILLE PK		PARIS	PA	15021
1078	Affiliated	4066	Central Tampa Dialysis	Central Tampa Dialysis	4204 N MACDILL AVE	SOUTH BLDG	TAMPA	FL	33607-6342
1079	Affiliated	4068	Zephyrhills Dialysis	Zephyrhills Dialysis	6610 STADIUM DR		ZEPHYRHILLS	FL	33542-7510
1080	Affiliated	4069	Bartow Dialysis	Bartow Dialysis	1190 E CHURCH ST		BARTOW	FL	33830-4117
1081	Affiliated	4070	Ormond Beach Dialysis	Ormond Beach Dialysis	495 S NOVA RD	STE 19	ORMOND BEACH	FL	32174-8444
1082	Affiliated	4071	Lakeland South Dialysis	Lakeland South Dialysis	5050 S FLORIDA AVE		LAKELAND	FL	33813-2501
1083	Affiliated	4072	St. Mary’s Dialysis	St. Mary’s Dialysis	2714 OSBORNE RD		ST MARY’S	GA	31558-4049
1084	Affiliated	4073	Miami North Dialysis	Miami North Dialysis	860 NE 125TH ST		NORTH MIAMI	FL	33161-5743
1085	Affiliated	4074	Naples Dialysis	Naples Dialysis	661 9TH ST N		NAPLES	FL	34102-8132
1086	Affiliated	4075	Bonita Springs Dialysis	Bonita Springs Dialysis	9134 BONITA BEACH RD SE		BONITA SPRINGS	FL	34135-4281
1087	Affiliated	4076	Orlando Southwest Dialysis	Orlando Southwest Dialysis	6925 LAKE ELLENOR DR	STE 65	ORLANDO	FL	32809-4670
1088	Affiliated	4088	Quincy Dialysis	Quincy Dialysis	878 STRONG RD		QUINCY	FL	32351-5243
1089	Affiliated	4089	Tallahassee Dialysis	Tallahassee Dialysis	1607 PHYSICIANS DR		TALLAHASSEE	FL	32308-4620
1090	Affiliated	4095	South Beach Dialysis	South Beach Dialysis	4701 N MERIDIAN AVE		MIAMI BEACH	FL	33140-2910
1091	Affiliated	4124	Americus Dialysis	Americus Dialysis	227 N LEE ST		AMERICUS	GA	31709-3525
1092	Affiliated	4204	Corry Dialysis	Corry Dialysis	300 YORK ST		CORRY	PA	16407-1420
1093	Affiliated	4208	Elizabethtown Dialysis	Elizabethtown Dialysis	844 N HANOVER ST		ELIZABETHTOWN	PA	17022-1303
1094	Affiliated	4209	Lumberton Dialysis	Lumberton Dialysis	668 MAIN ST		LUMBERTON	NJ	08048-5016
1095	Affiliated	4211	Cobbs Creek Dialysis	Cobbs Creek Dialysis	1700 S 60TH ST		PHILADELPHIA	PA	19142-1404
1096	Affiliated	4214	Westland Dialysis	Garden West Dialysis (fka Westland)	5715 N VENOY RD		WESTLAND	MI	48185-2830
1097	Affiliated	4215	Meadville Dialysis	Meadville Dialysis	19050 PARK AVENUE PLZ		MEADVILLE	PA	16335-4012
1098	Affiliated	4217	Bradford Dialysis	Bradford Dialysis	665 E MAIN ST		BRADFORD	PA	16701-1869
1099	Affiliated	4219	Southgate Dialysis	Southgate Dialysis	14752 NORTHLINE RD		SOUTHGATE	MI	48195-2467
1100	Affiliated	4223	Waynesburg Dialysis	Waynesburg Dialysis	248 ELM DR		WAYNESBURG	PA	15370-8269
1101	Affiliated	4224	Selinsgrove Dialysis	Selinsgrove Dialysis	1030 N SUSQUEHANNA TRAIL		SELINSGROVE	PA	17870-7767
1102	Affiliated	2153	Arlington Dialysis	Arlington Dialysis	1250 E PIONEER PKWY	STE 7	ARLINGTON	TX	76010-6423
1103	Affiliated	2154	Grapevine Dialysis	Grapevine Dialysis	1600 W NORTHWEST HWY	STE 1	GRAPEVINE	TX	76051-8131
1104	Affiliated	1740	Willow Dialysis	Willow Dialysis	1675 ALEX DR		WILMINGTON	OH	45177-2446
1105	Affiliated	1767	New Braunfels Dialysis	New Braunfels Dialysis	900 LOOP 337		NEW BRAUNFELS	TX	78130-3555
1106	Affiliated	2080	Chickasha Dialysis	Chickasha Dialysis	228 S 29TH ST		CHICKASHA	OK	73018-2502
1107	Affiliated	2184	Sugarloaf	Sugarloaf Dialysis (fka Lawrenceville)	1705 BELLE MEADE CT	STE 11	LAWRENCEVILLE	GA	30043-5895
1108	Affiliated	2166	Buford Dialysis	Buford Dialysis	1550 BUFORD HWY	STE 1E	BUFORD	GA	30518-3666
1109	Affiliated	1749	St. Louis Park PD	St. Louis Park Dialysis Center PD	3505 LOUISIANA AVE S		ST LOUIS PARK	MN	55426-4121
1110	Affiliated	1769	Front Royal Dialysis	Front Royal Dialysis	1077D N SHENANDOAH AVE		FRONT ROYAL	VA	22630-3546
1111	Affiliated	1770	Winchester Dialysis	Winchester Dialysis	2301 VALOR DR		WINCHESTER	VA	22601-6111
1112	Affiliated	2200	New Hope Dialysis	New Hope Dialysis (aka Minneapolis, Golden Valley)	5640 INTERNATIONAL PKWY		NEW HOPE	MN	55428-3047
1113	Affiliated	2175	Richfield Dialysis	Richfield Dialysis	6601 LYNDALE AVE S	STE 15	RICHFIELD	MN	55423-2490
1114	Affiliated	2162	Fairborne Dialysis	Fairborn Dialysis	3070 PRESIDENTIAL DR	STE A	FAIRBORN	OH	45324-6273
1115	Affiliated	1694	Benton Dialysis	Benton Dialysis	1151 ROUTE 14 W		BENTON	IL	62812-1500
1116	Affiliated	1695	Centralia Dialysis	Centralia Dialysis	1231 STATE ROUTE 161		CENTRALIA	IL	62801-6739
1117	Affiliated	1696	Marion Dialysis	Marion Dialysis	324 S 4TH ST		MARION	IL	62959-1241
1118	Affiliated	1697	Mount Vernon Dialysis	Mount Vernon Dialysis	1800 JEFFERSON AVE		MOUNT VERNON	IL	62864-4300
1119	Affiliated	2121	Bayou City Dialysis	Bayou City Dialysis (fka Hanson)	10655 EASTEX FWY		HOUSTON	TX	77093-4323
1120	Affiliated	2117	Metarie Dialysis Center	Metairie Dialysis	7100 AIRLINE DR		METAIRIE	LA	70003-5950
1121	Affiliated	1784	Stony Creek Dialysis	Stony Creek Dialysis	9115 S CICERO AVE		OAK LAWN	IL	60453-1895
1122	Affiliated	1785	Beverly Dialysis	Beverly Dialysis	8109 SOUTH WESTERN AVE		CHICAGO	IL	60620-5939
1123	Affiliated	2089	Summit Dialysis	Summit Dialysis Center	3150 POLK ST		HOUSTON	TX	77003-4631
1124	Affiliated	2212	Upper Valley Dialysis	Upper Valley Dialysis (fka West El Paso)	7933 N MESA ST	STE H	EL PASO	TX	79932-1699
1125	Affiliated	2134	Dallas County	Perry Dialysis (fka Dallas County)	610 10TH ST	STE L1	PERRY	IA	50220-2221
1126	Affiliated	1813	Nampa Dialysis Center	Nampa Dialysis	846 PARKCENTRE WAY		NAMPA	ID	83651-1790
1127	Affiliated	1814	Table Rock Dialysis	Table Rock Dialysis	5610 W GAGE ST	STE B	BOISE	ID	83706
1128	Affiliated	1815	Twin Falls Dialysis	Twin Falls Dialysis	1840 CANYON CREST DR		TWIN FALLS	ID	83301-3007
1129	Affiliated	1816	Burley Dialysis Center	Burley Dialysis	741 N OVERLAND AVE		BURLEY	ID	83318-3440

1130	Affiliated	1817	Gate City Dialysis Center	Gate City Dialysis	2001 BENCH RD		POCATELLO	ID	83201-2033
1131	Affiliated	1818	Four Rivers Dialysis	Four Rivers Dialysis	515 EAST LN		ONTARIO	OR	97914-3953
1132	Affiliated	2231	River Parishes	River Parishes Dialysis (aka La Place)	2880 W AIRLINE HWY		LA PLACE	LA	70068-2922
1133	Affiliated	2177	South Lincoln	South Lincoln Dialysis	3401 PLANTATION DR	STE 14	LINCOLN	NE	68516-4712
1134	Affiliated	2105	Rochester Hills	Rochester Hills Dialysis (aka Sterling Heights)	1886 W AUBURN RD	STE 1	ROCHESTER HILLS	MI	48309-3865
1135	Affiliated	2101	Willowbrook Dialysis	Willowbrook Dialysis	12120 JONES RD	STE G	HOUSTON	TX	77070-5280
1136	Affiliated	2195	Springhurst Dialysis	Springhurst Dialysis (aka Louisville)	10201 CHAMPION FARMS DR		LOUISVILLE	KY	40241-6150
1137	Affiliated	2012	Magnolia West	Magnolia West Dialysis (aka Riverside II)	11161 MAGNOLIA AVE		RIVERSIDE	CA	92505-3605
1138	Affiliated	2206	Garrisonville Dialysis	Garrisonville Dialysis	70 DOC STONE RD	STE 11	STAFFORD	VA	22556-4628
1139	Affiliated	2152	Strongsville Dialysis	Strongsville Dialysis	17792 PEARL RD		STRONGSVILLE	OH	44136-6909
1140	Affiliated	984	Summerlin Dialysis	Summerlin Dialysis Center, LV	653 N TOWN CENTER DR	STE 7 BLDG 2	LAS VEGAS	NV	89144-0503
1141	Affiliated	2127	Red Bluff Dialysis	Red Bluff Dialysis Center	2455 SISTER MARY COLUMBA DR		RED BLUFF	CA	96080-4364
1142	Affiliated	1638	Cobb Dialysis	Cobb Dialysis	3865 MEDICAL PARK DR		AUSTELL	GA	30106-1109
1143	Affiliated	1693	Paulding Dialysis	Paulding Dialysis	4019 JOHNS RD		DALLAS	GA	30132-3420
1144	Affiliated	1839	Sweetwater Dialysis	Sweetwater Dialysis	7117 S SWEETWATER RD		LITHIA SPRINGS	GA	30122-2446
1145	Affiliated	3671	Charlottesville North	Charlottesville North Dialysis	1800 TIMBERWOOD BLVD	STE C	CHARLOTTESVILLE	VA	22911-7544
1146	Affiliated	2186	Southern Crescent	Southern Crescent Dialysis Center (fka Riverdale)	275 UPPER RIVERDALE RD SW	STE B	RIVERDALE	GA	30274-2556
1147	Affiliated	2169	Meridian Park	Meridian Park Dialysis Center (fka Lake Oswego)	19255 SW 65TH AVE	STE 1	TUALATIN	OR	97062-9712
1148	Affiliated	1812	Treasure Valley Dialysis	Treasure Valley Dialysis	3525 E LOUISE ST	STE 155	MERIDIAN	ID	83642-6303
1149	Affiliated	3637	White Oak	White Oak Dialysis (Chronic)	5520 CHEVIOT RD	STE B	CINCINNATI	OH	45247-7069
1150	Affiliated	1786	Ash Tree	Ash Tree Dialysis	2666 N GROVE INDUSTRIAL DR		FRESNO	CA	93727-1552
1151	Affiliated	2242	Madera Dialysis	Almond Wood Dialysis (fka Madera)	501 E ALMOND AVE		MADERA	CA	93637-5661
1152	Affiliated	2209	Carrollton	Carrollton Dialysis	1544 VALWOOD PKWY	STE 114	CARROLLTON	TX	75006-8425
1153	Affiliated	2202	Edna Dialysis	Edna Dialysis	1008 N WELLS ST		EDNA	TX	77957-2153
1154	Affiliated	2208	Bear Creek Dialysis	Bear Creek Dialysis (fka Clay Road)	4978 HIGHWAY 6 N	STE I	HOUSTON	TX	77084-5282
1155	Affiliated	1820	Windham Dialysis	Windham Dialysis	375 TUCKIE RD	STE C	NORTH WINDHAM	CT	06256-1345
1156	Affiliated	1819	Vernon Dialysis	Vernon Dialysis	460 HARTFORD TPKE STE C		VERNON ROCKVILLE	CT	6066
1157	Affiliated	2092	Fountain Dialysis	Fountain Dialysis (aka Security)	6910 BANDLEY DR		FOUNTAIN	CO	80817-2617
1158	Affiliated	1846	Grand Junction	Grand Junction Dialysis Center	710 WELLINGTON AVE	STE 2	GRAND JUNCTION	CO	81501-6100
1159	Affiliated	2183	Fort Mill	Fort Mill Dialysis	1975 CAROLINA PLACE DR		FORT MILL	SC	29708-6922
1160	Affiliated	2215	Mrytle Beach	JV-Myrtle Beach Dialysis	3919 MAYFAIR ST		MYRTLE BEACH	SC	29577-5773
1161	Affiliated	2032	Oakwood	Oakwood Dialysis Center	148 HECTOR AVE		GRETNA	LA	70056-2531
1162	Affiliated	2168	SP Hillsboro	Hillsboro Dialysis	2500 NW 229TH AVE	STE 3 BLDG E	HILLSBORO	OR	97124-7516
1163	Affiliated	2269	Kettering	Kettering Dialysis	5721 BIGGER RD		KETTERING	OH	45440-2752
1164	Affiliated	2246	Mansfield	Mansfield Dialysis Center (aka Dallas)	987 N WALNUT CREEK DR	STE 11	MANSFIELD	TX	76063-8016
1165	Affiliated	2290	Cottage Grove	Cottage Grove Dialysis	8800 E POINT DOUGLAS RD S	STE 1	COTTAGE GROVE	MN	55016-4160
1166	Affiliated	2257	Scott County Dialysis	Scott County Dialysis	7456 S PARK DR		SAVAGE	MN	55378
1167	Affiliated	1773	Virginia Beach	Camelot Dialysis Center	1800 CAMELOT DR	STE 1	VIRGINIA BEACH	VA	23454-2440
1168	Affiliated	1627	Amelia Island	Amelia Island Dialysis	1525 LIME ST	STE 12	FERNANDINA BEACH	FL	32034-3015
1169	Affiliated	2179	Laurel Manor at the Villages	Laurel Manor Dialysis Center at the Villages	1950 LAUREL MANOR DR	STE 19	LADY LAKE	FL	32162-5603
1170	Affiliated	2160	East Deerborn	East Dearborn Dialysis	13200 W WARREN AVE		DEARBORN	MI	48126-2410
1171	Affiliated	1661	North Houston	PDI-North Houston	7115 NORTH LOOP E		HOUSTON	TX	77028-5948
1172	Affiliated	1663	South Houston	PDI-South Houston	5989 SOUTH LOOP E		HOUSTON	TX	77033-1017
1173	Affiliated	1856	Ralph McGill Dialysis Center	Ralph McGill Dialysis	418 DECATUR ST SE		ATLANTA	GA	30312-1801
1174	Affiliated	2144	Chelsea	Chelsea Dialysis	1620 COMMERCE PARK DR	STE 2	CHELSEA	MI	48118-2136
1175	Affiliated	2214	Smokey Mountain	Smoky Mountain Dialysis	1611 ANDREWS RD		MURPHY	NC	28906-5100
1176	Affiliated	3680	Miami Gardens	Miami Gardens Dialysis	3363 NW 167TH ST		MIAMI GARDENS	FL	33056-4254
1177	Affiliated	2222	Deerbrook	Deerbrook Dialysis	9660 FM 1960 BYPASS RD W		HUMBLE	TX	77338-4039
1178	Affiliated	2227	Downtown Dallas	DaVita Downtown Dallas Dialysis Center (fka Grove)	3515 SWISS AVE	STE A	DALLAS	TX	75204-6223
1179	Affiliated	2197	Henderson	Siena Henderson Dialysis Center	2865 SIENNA HEIGHTS DR	STE 141	HENDERSON	NV	89052-4168
1180	Affiliated	2292	Wyandotte	Wyandotte Central Dialysis	3737 STATE AVE		KANSAS CITY	KS	66102-3830
1181	Affiliated	2235	Westview	Westview Dialysis	3749 COMMERCIAL DR	LAFAYETTE PLACE SHOPPING CENTER	INDIANAPOLIS	IN	46222-1676
1182	Affiliated	2286	Garland	Garland Dialysis	776 E CENTERVILLE RD		GARLAND	TX	75041-4640
1183	Affiliated	2333	Aberdeen	Aberdeen Dialysis	780 W BEL AIR AVE		ABERDEEN	MD	21001-2236

1184	Affiliated	2259	Mountain Park	Mountain Park Dialysis	5235 MEMORIAL DR		STONE MOUNTAIN	GA	30083-3112
1185	Affiliated	2229	Downtown San Antonio	Downtown San Antonio Dialysis (Brooklyn St)	615 E QUINCY ST		SAN ANTONIO	TX	78215-1600
1186	Affiliated	2237	Medlock Bridge	Medlock Bridge Dialysis (aka Duluth)	10680 MEDLOCK BRIDGE RD	STE 13	DULUTH	GA	30097-8420
1187	Affiliated	2234	Greene County Dialysis	Greene County Dialysis Center (NC)	1025 KINGOLD BLVD		SNOW HILL	NC	28580-1616
1188	Affiliated	2243	West Broadway Dialysis	West Broadway Dialysis	720 W BROADWAY		LOUISVILLE	KY	40202-2240
1189	Affiliated	2072	St. Pauls Dialysis	St. Pauls Dialysis (aka Robeson County)	564 W MCLEAN ST		SAINT PAULS	NC	28384-1421
1190	Affiliated	2123	Carquinez Dialyis	Carquinez Dialysis (fka SW Vallejo)	125 CORPORATE PL	STE C	VALLEJO	CA	94590-6968
1191	Affiliated	2159	DaVita East	DaVita East Dialysis Clinic (fka La Bamba)	11989 PELLICANO DR		EL PASO	TX	79936-6287
1192	Affiliated	2187	Natomas	Natomas Dialysis	30 GOLDEN LAND CT	BLDG G	SACRAMENTO	CA	95834-2420
1193	Affiliated	2228	Tennesse Valley	Tennessee Valley Dialysis Center (aka Johnson City)	107 WOODLAWN DR	STE 2	JOHNSON CITY	TN	37604-6287
1194	Affiliated	2174	Turfway Dialysis	Turfway Dialysis (fka Florence)	11 SPIRAL DR	STE 15	FLORENCE	KY	41042-1394
1195	Affiliated	2291	Leavenworth	Leavenworth Dialysis	501 OAK ST		LEAVENWORTH	KS	66048-2646
1196	Affiliated	2270	Franklin Dialysis	Franklin Dialysis (IN)	1140 W JEFFERSON ST	STE A	FRANKLIN	IN	46131-2101
1197	Affiliated	2011	Norco	Norco Dialysis (fka Corona II)	1901 TOWN AND COUNTRY DR	STE 1	NORCO	CA	92860-3611
1198	Affiliated	2240	Andover	Andover Dialysis	488 S MAIN ST		ANDOVER	OH	44003-9602
1199	Affiliated	1863	Little Rock	Jacksonville Central Dialysis Center	400 T P WHITE DR		JACKSONVILLE	AR	72076-3287
1200	Affiliated	1864	North Little Rock Dialysis	North Little Rock Center	4505 E MCCAIN BLVD		NORTH LITTLE ROCK	AR	72117-2902
1201	Affiliated	2233	Anadarko	Anadarko Dialysis	412 SE 11TH STREET		ANADARKO	OK	73005-4442
1202	Affiliated	2331	Desert Springs	Desert Springs Dialysis	2110 E FLAMINGO RD	STE 18	LAS VEGAS	NV	89119-5191
1203	Affiliated	2213	Livingston	Vancouver Dialysis Center	9120 NE VANCOUVER MALL DR	STE 16	VANCOUVER	WA	98662-9401
1204	Affiliated	2300	Vancouver	Livingston TN Dialysis	308 OAK ST		LIVINGSTON	TN	38570-1729
1205	Affiliated	2225	Fenton Dialysis	Fenton Dialysis	17420 SILVER PKWY		FENTON	MI	48430-4429
1206	Affiliated	2332	Cold Spring	Cold Springs Dialysis	430 CROSS ROADS BLVD		COLD SPRING	KY	41076-2341
1207	Affiliated	2094	Yucaipa	Yucaipa Dialysis	33487 YUCAIPA BLVD		YUCAIPA	CA	92399-2064
1208	Affiliated	1900	Florida Renal Center	Florida Renal Center	3500 NW 7TH ST		MIAMI	FL	33125-4016
1209	Affiliated	2140	Harbor UCLA	Long Beach Harbor Dialysis (aka UCLA)	1075 E PACIFIC COAST HWY		LONG BEACH	CA	90806-5089
1210	Affiliated	2210	Seaton Drive	Seton Drive Dialysis (fka Greensprings II)	4800 SETON DR		BALTIMORE	MD	21215-3210
1211	Affiliated	1865	South Valley	South Valley Dialysis	17815 VENTURA BLVD	STE 1	ENCINO	CA	91316-3600
1212	Affiliated	2305	West Pensacola	West Pensacola Dialysis	598 N FAIRFIELD DR	STE 1	PENSACOLA	FL	32506-4320
1213	Affiliated	2073	Mar Vista	Mar Vista Dialysis Center (UCLA-Santa Monica)	2020 SANTA MONICA BLVD	STE 1	SANTA MONICA	CA	90404-2139
1214	Affiliated	2082	Riddle Dialysis	Riddle Dialysis	100 GRANITE DR	STE 16	MEDIA	PA	19063-5134
1215	Affiliated	2346	Uptown	Minneapolis Uptown Dialysis	3601 LYNDALE AVE S		MINNEAPOLIS	MN	55409-1103
1216	Affiliated	1907	Lake Griffith East Dialysis	Lake Griffin East Dialysis	401 E NORTH BLVD		LEESBURG	FL	34748-5256
1217	Affiliated	2170	West Linn	West Linn Dialysis	19056 WILLAMETTE DR		WEST LINN	OR	97068-1715
1218	Affiliated	2330	Cape Coral South Dialysis	Cape Coral South Dialysis	3046 DEL PRADO BLVD S	STE 4A	CAPE CORAL	FL	33904-7232
1219	Affiliated	2241	Ceres	Ceres Dialysis Center	1768 MITCHELL RD	STE 38	CERES	CA	95307-2156
1220	Affiliated	1862	Shaker Square	Shaker Square Dialysis	12800 SHAKER BLVD	STE 1	CLEVELAND	OH	44120-2004
1221	Affiliated	1906	St. Cloud Dialysis	St. Cloud Dialysis	4750 OLD CANOE CREEK RD		SAINT CLOUD	FL	34769-1430
1222	Affiliated	1915	Turlock Dialysis Center	Turlock Dialysis Center	50 W SYRACUSE AVE		TURLOCK	CA	95380-3143
1223	Affiliated	2268	Haymarket	Haymarket Dialysis (fka Gainesville)	14664 GAP WAY		GAINESVILLE	VA	20155-1683
1224	Affiliated	2272	Hackettstown	Hackettstown Dialysis	657 WILLOW GROVE ST	WEST WING MEDICAL PLAZA STE 22	HACKETTSTOWN	NJ	07840-1713
1225	Affiliated	2274	Regency	Regency Dialysis Center (fka Jacksonville)	9535 REGENCY SQUARE BLVD N		JACKSONVILLE	FL	32225-8128
1226	Affiliated	2149	Williamsburg	Williamsburg Dialysis (fka Yorktown)	500 SENTARA CIR	STE 13	WILLIAMSBURG	VA	23188-5727
1227	Affiliated	2141	Commerce Township	Commerce Township Dialysis	120 W COMMERCE RD		COMMERCE TOWNSHIP	MI	48382-3915
1228	Affiliated	2147	Kankakee	Kankakee County Dialysis	581 WILLIAM R LATHAM SR DR	STE 14	BOURBONNAIS	IL	60914-2439
1229	Affiliated	2283	Sandusky	Sandusky Dialysis Center	795 BARDSHAR RD		SANDUSKY	OH	44870-1505
1230	Affiliated	2252	Ionia	Ionia Dialysis	2622 HEARTLAND BLVD		IONIA	MI	48846-8757
1231	Affiliated	2289	Indian River	Indian River Dialysis Center	2150 45TH ST	UNIT 12	VERO BEACH	FL	32967-6281
1232	Affiliated	2360	North Henry	North Henry Dialysis (fka Stockbridge)	5627 N HENRY BLVD	STE I1	STOCKBRIDGE	GA	30281-3244
1233	Affiliated	2077	Tacoma Dialysis	Tacoma Dialysis Center	3401 S 19TH ST		TACOMA	WA	98405-1909
1234	Affiliated	1908	Hileah Kidney Center I	Hialeah Artificial Kidney Center	2750 W 68TH ST	STE 27	HIALEAH	FL	33016-5450
1235	Affiliated	2315	St. Francis	Charter Colony Dialysis Center (fka St. Francis Dialysis)	2312 COLONY CROSSING PL		MIDLOTHIAN	VA	23112-4280
1236	Affiliated	2138	Bellflower	Bellflower Dialysis Center (aka Widerhorn)	15736 WOODRUFF AVE		BELLFLOWER	CA	90706-4018
1237	Affiliated	2301	Smyrna	Smyrna Dialysis	537 STONECREST PKWY		SMYRNA	TN	37167-6884

1238	Affiliated	2122	Clearlake	Clearlake Dialysis	14400 OLYMPIC DR		CLEARLAKE	CA	95422-8809
1239	Affiliated	1853	Dialysis Center of Erie	Dialysis Center of Erie	1641 SASSAFRAS ST		ERIE	PA	16502-1858
1240	Affiliated	1854	Warren Dialysis	Warren Dialysis	2 W CRESCENT PARK		WARREN	PA	16365-2111
1241	Affiliated	2322	Maysville	Maysville Dialysis	489 TUCKER DR		MAYSVILLE	KY	41056-9111
1242	Affiliated	2429	Fridley	East River Road Dialysis (fka Fridley Dialysis Unit)	5301 E RIVER RD	STE 117	FRIDLEY	MN	55421-3778
1243	Affiliated	2189	West Sacramento	West Sacramento Dialysis	3450 INDUSTRIAL BLVD	STE 1	WEST SACRAMENTO	CA	95691-5003
1244	Affiliated	2293	Anderson	Anderson Dialysis Center	7502 STATE RD	STE 116	CINCINNATI	OH	45255
1245	Affiliated	2383	North County	North St. Louis County Dialysis	13119 NEW HALLS FERRY RD		FLORISSANT	MO	63033-3228
1246	Affiliated	2439	Fargo	Fargo Dialysis Center	4474 23RD AVE S	STE M	FARGO	ND	58104-8795
1247	Affiliated	2008	Eastchester	Eastchester Road Dialysis Center (Bronx II)	1515 JARRETT PL		BRONX	NY	10461-2606
1248	Affiliated	2224	Fallon	Fallon Dialysis	1103 NEW RIVER PKWY		FALLON	NV	89406-6899
1249	Affiliated	2279	Clarksville North	Clarksville North Dialysis	3071 CLAY LEWIS RD		CLARKSVILLE	TN	37040-5141
1250	Affiliated	2308	Eaton	Eaton Dialysis	105 E WASHINGTON JACKSON RD		EATON	OH	45320-9789
1251	Affiliated	2447	Wallace	Wallace Dialysis	5650 S NC 41 HWY		WALLACE	NC	28466-6094
1252	Affiliated	2288	Central Kalazmazoo	Kalamazoo Central Dialysis	535 S BURDICK ST	STE 11	KALAMAZOO	MI	49007-5261
1253	Affiliated	2287	West Kalamazoo	Kalamazoo West Dialysis	1040 N 10TH ST		KALAMAZOO	MI	49009-6149
1254	Affiliated	1921	Bakersfield	Bakersfield Dialysis Center	5143 OFFICE PARK DR		BAKERSFIELD	CA	93309-0660
1255	Affiliated	1930	Antelope Valley Dialysis	Antelope Valley Dialysis	1759 W AVENUE J	STE 12	LANCASTER	CA	93534-2703
1256	Affiliated	1931	Indian Wells Valley Dialysis	Indian Wells Valley Dialysis	212 S RICHMOND RD		RIDGECREST	CA	93555-4434
1257	Affiliated	1932	Palmdale Regional Dialysis	Palmdale Regional	1643 E PALMDALE BLVD		PALMDALE	CA	93550-4847
1258	Affiliated	2185	South Star / Adamsville	Southstar Adamsville Dialysis (fka Cascade)	3651 BAKERS FERRY RD SW		ATLANTA	GA	30331-3712
1259	Affiliated	2314	Union City	Union City Dialysis	6851 SHANNON PKWY	STE 2	UNION CITY	GA	30291-2049
1260	Affiliated	2345	Waterbury	Waterbury Dialysis Center	150 MATTATUCK HEIGHTS RD		WATERBURY	CT	06705-3893
1261	Affiliated	2421	Butler Farm	Butler Farm Dialysis (Hope II)	501 BUTLER FARM RD		HAMPTON	VA	23666-1777
1262	Affiliated	2337	Blue Mtn Kidney Center	Blue Mountain Kidney Center (aka Wild Horse, Pendleton)	72556 COYOTE RD		PENDLETON	OR	97801-1002
1263	Affiliated	2249	Talladega	Talladega Dialysis	726 BATTLE ST E	STE A	TALLADEGA	AL	35160-2583
1264	Affiliated	2281	Athens East	Athens East Dialysis	2026 S MILLEDGE AVE	STE A2	ATHENS	GA	30605-6480
1265	Affiliated	2412	Mayland	Mayland Dialysis Center (aka Spruce Pine)	575 ALTAPASS HWY		SPRUCE PINE	NC	28777-3012
1266	Affiliated	2236	Salem	Salem Dialysis Center (IN)	1201 N JIM DAY RD	STE 13	SALEM	IN	47167-7219
1267	Affiliated	2239	Lake Cliff	Lake Cliff Dialysis Center	805 N BECKLEY AVE		DALLAS	TX	75203-1612
1268	Affiliated	2363	DVA Mid Cities Dialysis	Mid Cities Dialysis Center	117 E HARWOOD RD		HURST	TX	76054-3043
1269	Affiliated	2362	Boerne	Boerne Dialysis Center	1369 S MAIN ST	STE 11	BOERNE	TX	78006-2860
1270	Affiliated	2318	Columbus West	Columbus West Dialysis	1395 GEORGESVILLE RD		COLUMBUS	OH	43228-3611
1271	Affiliated	2306	Point Place	Point Place Dialysis	4747 SUDER AVE	STE 17	TOLEDO	OH	43611-2869
1272	Affiliated	2350	Delhi Dialysis	Delhi Dialysis	5040 DELHI AVE		CINCINNATI	OH	45238-5388
1273	Affiliated	2253	Pataskala	Pataskala Dialysis Center	642 E BROAD ST		PATASKALA	OH	43062-7627
1274	Affiliated	2384	Eastland	Eastland Dialysis (fka Independence)	19101 E VALLEY VIEW PKWY	STE E	INDEPENDENCE	MO	64055-6907
1275	Affiliated	2254	Wauseon	Wauseon Dialysis Center	721 S SHOOP AVE		WAUSEON	OH	43567-1729
1276	Affiliated	2327	Lebanon Dialysis	Lebanon Dialysis Center (Chronic Only)	918B COLUMBUS AVE		LEBANON	OH	45036-
1277	Affiliated	2460	Horton	Horton Dialysis	1901 EUCLID AVE		HORTON	KS	66439-1238
1278	Affiliated	2280	Lone Peak Dialysis	Lone Peak Dialysis	1175 E 50 S	STE 111	AMERICAN FORK	UT	84003-2845
1279	Affiliated	2347	Mena	Mena Dialysis Center	1200 CRESTWOOD CIR		MENA	AR	71953-5516
1280	Affiliated	1941	FAYETTEVILLE DIALYSIS	Fayetteville Dialysis	509 E MILLSAP RD	STE 111	FAYETTEVILLE	AR	72703-4862
1281	Affiliated	1942	BENTONVILLE DIALYSIS	Bentonville Dialysis	1104 SE 30TH ST		BENTONVILLE	AR	72712-4290
1282	Affiliated	1943	SILOAM SPRINGS DIALYSIS	Siloam Springs Dialysis	500 S MOUNT OLIVE ST	STE 17	SILOAM SPRINGS	AR	72761-3602
1283	Affiliated	1944	SPRINGDALE DIALYSIS	Springdale Dialysis	708 QUANDT AVE		SPRINGDALE	AR	72764-5309
1284	Affiliated	2273	Grosse Pointe	Grosse Pointe Dialysis	18000 E WARREN AVE	STE 1	DETROIT	MI	48224-1336
1285	Affiliated	2448	Indy South Dialysis	Indy South Dialysis	972 EMERSON PKWY	STE E	GREENWOOD	IN	46143-6202
1286	Affiliated	2358	Greensburg Dialysis	Greensburg Dialysis	1531 N COMMERCE EAST DR	STE 6	GREENSBURG	IN	47240-3259
1287	Affiliated	2319	Grove City	Grove City Dialysis	4155 KELNOR DR		GROVE CITY	OH	43123-2960
1288	Affiliated	2338	West Beach	West Beach Dialysis Center	16201 PANAMA CITY BEACH HWY	STE 12	PANAMA CITY BEACH	FL	32413-5301
1289	Affiliated	2371	Birmingham	Center Point Dialysis (aka Birmingham Center)	2337 1ST ST NE		CENTER POINT	AL	35215-3619
1290	Affiliated	2445	Eureka	Eureka Dialysis Center	419 MERAMEC BLVD		EUREKA	MO	63025-3906
1291	Affiliated	2313	Tifton	Tifton Dialysis	624 LOVE AVE		TIFTON	GA	31794-4406

1292	Affiliated	2146	Woodlands	The Woodlands Dialysis	9301 PINECROFT DR	STE 13	SHENANDOAH	TX	77380-3178
1293	Affiliated	2266	Exerter	Exeter Dialysis	1116 W VISALIA RD	STE 16	EXETER	CA	93221-1482
1294	Affiliated	2396	Wayne County	Wayne County Dialysis (fka Fairfield)	303 NW 11TH ST	STE 1	FAIRFIELD	IL	62837-1203
1295	Affiliated	2415	Cordele Dialysis	Cordele Dialysis	1013 E 16TH AVE		CORDELE	GA	31015-1539
1296	Affiliated	2304	Winter Park	Winter Park Dialysis (aka Orlando)	3727 N GOLDENROD RD	STE 11	WINTER PARK	FL	32792-8611
1297	Affiliated	2449	Carmel	Carmel Dialysis	180 E CARMEL DR		CARMEL	IN	46032-2633
1298	Affiliated	2298	Corydon	Corydon Dialysis	1937 OLD HWY 135 NW		CORYDON	IN	47112-2013
1299	Affiliated	2382	Memphis Southeast	Memphis Southeast Dialysis (aka Midtown)	1805 MORIAH WOODS BLVD	STE 11	MEMPHIS	TN	38117-7119
1300	Affiliated	2399	Rim Country	Rim Country Dialysis	809 W LONGHORN RD		PAYSON	AZ	85541-4280
1301	Affiliated	2201	Cedar Park	Cedar Park Dialysis (fka North Austin)	1720 E WHITESTONE BLVD		CEDAR PARK	TX	78613-7640
1302	Affiliated	2368	Ellensburg	Ellensburg Dialysis	2101 W DOLARWAY RD	STE 1	ELLENSBURG	WA	98926-9310
1303	Affiliated	2260	Santa Fe Springs	Santa Fe Springs Dialysis	11147 WASHINGTON BLVD		WHITTIER	CA	90606-3007
1304	Affiliated	1950	Snapfinger Dialysis	Snapfinger Dialysis	5255 SNAPFINGER PARK DR	STE 115	DECATUR	GA	30035-4066
1305	Affiliated	1951	East Dekalb Dialysis	East DeKalb Dialysis	2801 CANDLER RD	STE 23	DECATUR	GA	30034-1429
1306	Affiliated	2258	Meadows East	Meadows East Dialysis	2529 SIX MILE LN		LOUISVILLE	KY	40220-2934
1307	Affiliated	2226	First Colony	First Colony Dialysis (aka Sugarland, Great Woods)	1447 HIGHWAY 6	STE 14	SUGAR LAND	TX	77478-5094
1308	Affiliated	1612	Coastal Kidney Center	Coastal Kidney Center	510 N MACARTHUR AVE		PANAMA CITY	FL	32401-3636
1309	Affiliated	2211	Clinton Township	Clinton Township Dailysis	15918 19 MILE RD	STE 11	CLINTON TOWNSHIP	MI	48038-1101
1310	Affiliated	2207	West Brook	Westbrook Dialysis (fka Palm Brook II)	13907 W CAMINO DEL SOL	STE 13	SUN CITY WEST	AZ	85375-4405
1311	Affiliated	1954	Johnson County	Johnson County Dialysis	10453 W 84TH TER		LENEXA	KS	66214-1641
1312	Affiliated	1956	Wyandotte County	Wyandotte County Dialysis	5001 STATE AVE		KANSAS CITY	KS	66102-3459
1313	Affiliated	2479	Maple Grove	Maple Grove Dialysis Unit	15655 GROVE CIR N		MAPLE GROVE	MN	55369-4489
1314	Affiliated	4336	East End	East End-Pittsburgh Dialysis (fka Wilkinsburg)	7714 PENN AVE PARK PLAZA		PITTSBURGH	PA	15221
1315	Affiliated	2493	Westminster II - North Metro	North Metro Dialysis Center (aka Denver, Westminster II)	12365 HURON ST	STE 5	WESTMINSTER	CO	80234-3498
1316	Affiliated	1960	Vidalia	Vidalia First Street Dialysis	906 E 1ST ST		VIDALIA	GA	30474-4207
1317	Affiliated	2357	Highland Park	Highland Park Dialysis	1559 W 7TH ST		SAINT PAUL	MN	55102-4238
1318	Affiliated	2367	Centennial Parkway	Centennial Dialysis Center	8775 DEER SPRINGS WAY		LAS VEGAS	NV	89149-0416
1319	Affiliated	2250	Lord Baltimore	Northwest Dialysis Center (aka Lord Baltimore, N. Rolling Road II, Owings Mills II)	2245 ROLLING RUN DR	STE 1	WINDSOR MILL	MD	21244-1858
1320	Affiliated	3944	North Charlotte	North Charlotte Dialysis	6620 OLD STATESVILLE RD		CHARLOTTE	NC	28269
1321	Affiliated	2410	Sun Ray Dialysis	Sun Ray Dialysis Unit (fka East St. Paul)	1758 OLD HUDSON RD	STE 1	SAINT PAUL	MN	55106-6161
1322	Affiliated	2425	Vandalia	Vandalia Dialysis	301 MATTES AVE		VANDALIA	IL	62471-2061
1323	Affiliated	2428	Westwood Hills	Westwood Hills Dialysis (fka Minneapolis, Excelsior)	7525 WAYZATA BLVD		SAINT LOUIS PARK	MN	55426-1621
1324	Affiliated	4305	Amery	Amery Dialysis	970 ELDEN AVE		AMERY	WI	54001-1448
1325	Affiliated	2434	Wadsworth	Wadsworth Dialysis	195 WADSWORTH RD	STE 32	WADSWORTH	OH	44281-9504
1326	Affiliated	2419	Dublin	Dublin Dialysis	6770 PERIMETER DR		DUBLIN	OH	43016-8063
1327	Affiliated	4314	Weber Valley	Weber Valley Dialysis (fka Ogden)	1920 W 250TH N		MARRIOTT-SLATERVILLE	UT	84404-9233
1328	Affiliated	2343	West Elk Grove	West Elk Grove Dialysis	2208 KAUSEN DR	STE 1	ELK GROVE	CA	95758-7174
1329	Affiliated	2355	Bedford Park	Bedford Park Dialysis Center	3119 WEBSTER AVE	1ST FLR	BRONX	NY	10467-4905
1330	Affiliated	1747	Cuero Lakeview Dialysis	Cuero Lakeview Dialysis	1105 E BROADWAY ST		CUERO	TX	77954
1331	Affiliated	1961	Madisonville Dialysis	Madisonville Dialysis Center	255 E NORTH ST		MADISONVILLE	KY	42431
1332	Affiliated	2467	Crescent City	Crescent City Dialysis Center	3909 BIENVILLE ST	STE B	NEW ORLEANS	LA	70119-5152
1333	Affiliated	4318	Callowhill	Callowhill Dialysis Center	313 CALLOWHILL ST		PHILADELPHIA	PA	19123-4103
1334	Affiliated	2406	Oak Creek	Oak Creek Dialysis (fka South Milwaukee)	8201 S HOWELL AVE	STE 6	OAK CREEK	WI	53154-8336
1335	Affiliated	4395	Leesburg Virginia	Leesburg Virginia Dialysis	224D CORNWALL ST NW	STE 1	LEESBURG	VA	20176-2700
1336	Affiliated	2386	Joy of Dixon	Joy of Dixon Dialysis Center	1640 N LINCOLN ST		DIXON	CA	95620-9255
1337	Affiliated	2137	Long Beach JV -Bixby Knolls	Bixby Knolls Dialysis (fka Long Beach)	3744 LONG BEACH BLVD		LONG BEACH	CA	90807-3310
1338	Affiliated	1790	Alliance Community Dialysis	Alliance Community Dialysis	270 E STATE ST	STE 11	ALLIANCE	OH	44601-4309
1339	Affiliated	1791	Belden Community Dialysis	Belden Community Dialysis	4685 FULTON DR NW		CANTON	OH	44718-2379
1340	Affiliated	1792	Mercy Canton Dialysis	Mercy Canton Dialysis	1320 MERCY DR NW		CANTON	OH	44708-2614
1341	Affiliated	2294	Marrero	Marrero Dialysis	1908 JUTLAND DR		HARVEY	LA	70058-2359
1342	Affiliated	2351	Miramar	Miramar Kidney Center	2501 DYKES RD	STE 2	MIRAMAR	FL	33027-4217
1343	Affiliated	2418	Chesterton	Chesterton Dialysis	711 PLAZA DR	STE 6	CHESTERTON	IN	46304-5506
1344	Affiliated	4368	St. John	St. John Dialysis	10033 WICKER AVE	STE 6	SAINT JOHN	IN	46373-8777
1345	Affiliated	2256	Princeton	Princeton Dialysis	2227 SHERMAN DR		PRINCETON	IN	47670-1062

1346	Affiliated	4332	Black Rock	Black Rock Dialysis (aka Faifield)	427 STILLSON RD		FAIRFIELD	CT	06824-3153
1347	Affiliated	2422	Williamstown	Williamstown Dialysis (fka Dry Ridge)	103 BARNES RD	STE A	WILLIAMSTOWN	KY	41097-9468
1348	Affiliated	4376	Renaissance	Renaissance Dialysis	1840 DARBY DR		FLORENCE	AL	35630-2623
1349	Affiliated	4360	Portage	Portage Dialysis	5823 US HIGHWAY 6		PORTAGE	IN	46368-4851
1350	Affiliated	2393	Opelika	Opelika Dialysis Center	2340 PEPPERELL PKWY		OPELIKA	AL	36801-6240
1351	Affiliated	2435	Urbana	Urbana Dialysis Center	1880 E US HIGHWAY 36		URBANA	OH	43078-9600
1352	Affiliated	1913	Port Lavaca Dialysis	Port Lavaca Dialysis	1300 N VIRGINIA ST	STE 12	PORT LAVACA	TX	77979-2512
1353	Affiliated	2276	Cornerhouse Dialysis	Cornerhouse Dialysis Center (aka Santa Clara)	2005 NAGLEE AVE		SAN JOSE	CA	95128-4801
1354	Affiliated	2167	Snellville	Snellville Dialysis	2135 MAIN ST E	STE 13	SNELLVILLE	GA	30078-6424
1355	Affiliated	4334	Bloomfield	Bloomfield-Pittsburgh Dialysis	5171 LIBERTY AVE	STE C	PITTSBURGH	PA	15224-2254
1356	Affiliated	2489	Pennsauken	Pennsauken Dialysis	7024 KAIGHNS AVE		PENNSAUKEN	NJ	08109-4417
1357	Affiliated	2433	Logan	Logan Dialysis	12880 GREY ST		LOGAN	OH	43138-9638
1358	Affiliated	2454	Forest Fair	Forest Fair Dialysis (fka Forest Park)	1145 KEMPER MEADOW DR		CINCINNATI	OH	45240-4118
1359	Affiliated	4307	Knoxville	Knoxville Central Dialysis	9141 CROSS PARK DR	STE 12	KNOXVILLE	TN	37923-4557
1360	Affiliated	4338	Kennestone	Kennestone Dialysis (aka Cobb II)	200 COBB PKWY N	STE 318 BLDG 3	MARIETTA	GA	30062-3558
1361	Affiliated	4343	Wiregrass Kidney Center	Wiregrass Kidney Center (fka Ross Circle)	1450 ROSS CLARK CIR		DOTHAN	AL	36301-4765
1362	Affiliated	2432	Memphis Downtown	Memphis Downtown Dialysis	2076 UNION AVE		MEMPHIS	TN	38104-4138
1363	Affiliated	3953	Marshville	Marshville Dialysis Center	7260 E MARSHVILLE BLVD		MARSHVILLE	NC	28103-1191
1364	Affiliated	4356	Shamrock	Shamrock Dialysis	1016 CLAXTON DAIRY RD	STE 1A	DUBLIN	GA	31021-7971
1365	Affiliated	4367	North Colorado Springs	North Colorado Springs Dialysis	6071 E WOODMEN RD	STE 1	COLORADO SPRINGS	CO	80923-2610
1366	Affiliated	2466	Oakes	Oakes Dialysis	413 S 7TH ST		OAKES	ND	58474-1920
1367	Affiliated	1976	Pinnacle Dialysis of Boca Raton	Pinnacle Dialysis of Boca Raton	2900 N MILITARY TRL	STE 195	BOCA RATON	FL	33431-6308
1368	Affiliated	1980	Cedar Valley Dialysis	Cedar Valley Dialysis	1661 W RIDGEWAY AVE		WATERLOO	IA	50701-4541
1369	Affiliated	1981	West Union Dialysis	West Union Dialysis	405 HIGHWAY 150 N		WEST UNION	IA	52175-1003
1370	Affiliated	2161	Rockside	Rockside Dialysis (aka Independence, Parma II)	4801 ACORN DR		INDEPENDENCE	OH	44131-2566
1371	Affiliated	2263	Sunset	Sunset Dialysis Center (fka Sunrise II)	3071 GOLD CANAL DR		RANCHO CORDOVA	CA	95670-6129
1372	Affiliated	2442	Yosemite Street	Yosemite Street Dialysis	1650 W YOSEMITE AVE		MANTECA	CA	95337-5193
1373	Affiliated	2335	Jedburg	Jedburg Dialysis	2897 W 5TH NORTH ST		SUMMERVILLE	SC	29483-9674
1374	Affiliated	2441	Parker Dialysis	Parker Dialysis	10371 S PARK GLENN WAY	STE 18	PARKER	CO	80138-3885
1375	Affiliated	2296	Northgate	Northgate Dialysis Center (aka San Rafael-Terra)	650 LAS GALLINAS AVE		SAN RAFAEL	CA	94903-3620
1376	Affiliated	2271	The Nevada Center	The Nevada Dialysis Center (fka Warm Springs, Green Valley)	1510 W WARM SPRINGS RD	STE 1	HENDERSON	NV	89014-3586
1377	Affiliated	2091	Aventura	Aventura Kidney Center	22 SW 11TH ST	FLOOR 2	HALLANDALE BEACH	FL	33009-7038
1378	Affiliated	2408	US Grant Dialysis	US Grant Dialysis (fka Georgetown, Brown County)	458 HOME ST		GEORGETOWN	OH	45121-1408
1379	Affiliated	4400	Arbor Place	Arbor Place Dialysis	9559 HIGHWAY 5	STE 1	DOUGLASVILLE	GA	30135-1573
1380	Affiliated	4389	South Jacksonville	Jacksonville South Dialysis Center	14965 OLD SAINT AUGUSTINE RD	UNIT 114	JACKSONVILLE	FL	32258-9481
1381	Affiliated	2385	Somerville	Somerville Dialysis	12475 US HIGHWAY 64		SOMERVILLE	TN	38068-6029
1382	Affiliated	4321	District Heights	District Heights Dialysis (aka Pennsylvania Ave)	5701 SILVER HILL RD		DISTRICT HEIGHTS	MD	20747-1102
1383	Affiliated	2414	Edwardsville	Edwardsville Dialysis	235 S BUCHANAN ST		EDWARDSVILLE	IL	62025-2108
1384	Affiliated	2361	Broad St	South Broad Street Dialysis (aka S. Philadelphia II)	1172 S BROAD ST		PHILADELPHIA	PA	19146-3142
1385	Affiliated	2342	Las Vegas Pedidatrics	Las Vegas Pediatrics Dialysis (fka UMC Peds, DaVita Peds)	7271 W SAHARA AVE	STE 12	LAS VEGAS	NV	89117-2862
1386	Affiliated	1990	Apopka Dialysis	Apopka Dialysis	640 EXECUTIVE PARK CT		APOPKA	FL	32703-6075
1387	Affiliated	1991	Cassellberry Dialysis	Casselberry Dialysis	4970 S US HWY 17/92		CASSELBERRY	FL	32707-3888
1388	Affiliated	1992	Central Orlando Dialysis	Central Orlando Dialysis	2548 N ORANGE BLOSSOM TRL	STE 4	ORLANDO	FL	32804-4863
1389	Affiliated	1993	Sanford Dialysis	Sanford Dialysis	1701 W 1ST ST		SANFORD	FL	32771-1605
1390	Affiliated	1994	Winter Park Hemo Dialysis	Winter Park Hemo Dialysis	4100 METRIC DR	STE 3	WINTER PARK	FL	32792-6832
1391	Affiliated	2173	Graham	Graham Dialysis Center	10219 196TH ST CT E	STE C	GRAHAM	WA	98338-7792
1392	Affiliated	2316	Batavia	Batavia Dialysis	4000 GOLDEN AGE DR		BATAVIA	OH	45103-1913
1393	Affiliated	1967	Klamath Falls	Klamath Falls Dialysis	2230 N ELDORADO AVE		KLAMATH FALLS	OR	97601-6418
1394	Affiliated	2336	Longs	Longs Dialysis (fka Conway)	90 CLOVERLEAF DR	STE 36	LONGS	SC	29568-9262
1395	Affiliated	2452	Pooler	Pooler Dialysis	54 TRADERS WAY		POOLER	GA	31322-
1396	Affiliated	4380	Ohio Pike Dialysis	Ohio Pike Dialysis (aka Amelia)	1761 STATE ROUTE 125		AMELIA	OH	45102-2039
1397	Affiliated	2285	Canyon Springs	Canyon Springs Dialysis (aka Moreno Valley)	22555 ALESSANDRO BLVD		MORENO VALLEY	CA	92553-8533
1398	Affiliated	4306	Williamson	South Williamson Dialysis	204 APPALACHIAN PLAZA		SOUTH WILLIAMSON	KY	41503-9404
1399	Affiliated	4402	Gulf Shores	Gulf Shores Dialysis Center	3947 GULF SHORES PKWY	UNIT 15	GULF SHORES	AL	36542-2737

1400	Affiliated	2496	Las Vegas Multi-Care Five Star	Five Star Dialysis Center (fka Las Vegas Multi-Care)	2400 TECH CENTER CT		LAS VEGAS	NV	89128-0804
1401	Affiliated	4358	North Vernon	North Vernon Dialysis	2340 N STATE HWY 7		NORTH VERNON	IN	47265-7183
1402	Affiliated	4316	Olympia	Olympia Dialysis Center	335 COOPER POINT RD NW	STE 15	OLYMPIA	WA	98502-4436
1403	Affiliated	4335	Monroeville	Monroeville Dialysis	2690 MONROEVILLE BLVD		MONROEVILLE	PA	15146-2302
1404	Affiliated	2317	East Galbraith	East Galbraith Dialysis	3877 E GALBRAITH RD	BLDG C	CINCINNATI	OH	45236-1500
1405	Affiliated	2261	San Marcos	San Marcos Dialysis Center	2135 MONTIEL RD	BLDG B	SAN MARCOS	CA	92069-3511
1406	Affiliated	4408	Winter Garden	Winter Garden Dialysis	1222 WINTER GARDEN VINELAND RD	BLDG 3 STE 1	WINTER GARDEN	FL	34787
1407	Affiliated	1926	Bremer County Dialysis	Relo-Bremer County Dialysis (5022-Cedar Valley Waverly Dialysis)	220 10th ST SW		WAVERLY	IA	50677-2930
1408	Affiliated	1927	Black Hawk Dialysis	Black Hawk Dialysis (Waterloo)	3421 W 9TH ST		WATERLOO	IA	50702-5401
1409	Affiliated	2218	Downey Landing	Downey Landing Dialysis Center (aka Downey-Kaiser)	11611 BELLFLOWER BLVD		DOWNEY	CA	90241-5408
1410	Affiliated	2427	Tucson Central	Tucson Central Dialysis	2901 E GRANT RD		TUCSON	AZ	85716-2717
1411	Affiliated	4377	Hamburg	Hamburg Dialysis (fka Lexington)	1745 ALYSHEBA WAY		LEXINGTON	KY	40509-9013
1412	Affiliated	2150	Midtown Norfolk	Midtowne Norfolk Dialysis (aka Ghent II)	2201 COLONIAL AVE		NORFOLK	VA	23517-1928
1413	Affiliated	2394	Yonkers II	Yonkers East Dialysis Center	5 ODELL PLZ	STE 131	YONKERS	NY	10701-1406
1414	Affiliated	2364	Caldwell	Caldwell Dialysis Center	821 S SMEED PKWY		CALDWELL	ID	83605-5130
1415	Affiliated	2278	Hesperia	Hesperia Dialysis Center	14135 MAIN ST	UNIT 51	HESPERIA	CA	92345-8097
1416	Affiliated	2339	Sealy	Sealy Dialysis	2242 CHAMPIONSHIP DR		SEALY	TX	77474-8026
1417	Affiliated	2438	Hearne	Hearne Dialysis Center	106 CEDAR ST		HEARNE	TX	77859-2523
1418	Affiliated	1998	Stockton Kidney Center	Stockton Kidney Center	1523 E MARCH LN	STE 2	STOCKTON	CA	95210-5607
1419	Affiliated	5525	University of South Florida	USF Dialysis	10770 N 46TH ST STE A100		TAMPA	FL	33617-3465
1420	Affiliated	4424	Westborough	Westborough Dialysis Center (fka South San Francisco, Daly City)	925 EL CAMINO REAL		SOUTH SAN FRANCISCO	CA	94080-3203
1421	Affiliated	4359	Rush County	Rush County Dialysis	1400 N CHERRY ST		RUSHVILLE	IN	46173-1097
1422	Affiliated	4339	Defuniak Springs	Defuniak Springs Dialysis	1045 US HWY 331 S	DEFUNIAK SHOPPING PLAZA	DEFUNIAK SPRINGS	FL	32435-3375
1423	Affiliated	2181	Foster city	Foster City Dialysis (fka Belmont)	1261 E HILLSDALE BLVD	STE 2	FOSTER CITY	CA	94404-1236
1424	Affiliated	4427	Red Bank	Redbank Village Dialysis (Cincinnati)	3960 RED BANK RD	STE 16	CINCINNATI	OH	45227-3421
1425	Affiliated	4448	Southport	Southport Dialysis Center	1513 N HOWE ST	STE 15	SOUTHPORT	NC	28461-2770
1426	Affiliated	4446	Orlando Park	Orlando Park Dialysis	5397 W COLONIAL DR	STE 12	ORLANDO	FL	32808-7647
1427	Affiliated	4431	Harrisburg	Harrisburg Dialysis Center (aka Concord)	3310 PERRY ST		CONCORD	NC	28027-3901
1428	Affiliated	2352	Waycross	Satilla River Dialysis	308 CARSWELL AVE		WAYCROSS	GA	31501-4762
1429	Affiliated	4455	Timberlake	Timberlake Dialysis (Kansas City)	12110 HOLMES RD		KANSAS CITY	MO	64145-1707
1430	Affiliated	4447	Dexter	Dexter Dialysis	2010 N OUTER RD		DEXTER	MO	63841
1431	Affiliated	4426	Norwood	Norwood Dialysis (Cincinnati)	2300 WALL ST		CINCINNATI	OH	45212-2781
1432	Affiliated	4420	Peachtree City	Peachtree City Dialysis	2830 W HWY 54	BLDG 1 STE J AND K	PEACHTREE CITY	GA	30269-1026
1433	Affiliated	5516	Rogue Valley	Rogue Valley Dialysis	760 GOLF VIEW DR	UNIT 1	MEDFORD	OR	97504-9685
1434	Affiliated	5517	Redwood Dialysis	Redwood Dialysis	201 SW L ST		GRANTS PASS	OR	97526-2913
1435	Affiliated	4410	Tucker	Tucker Dialysis	4434 HUGH HOWELL RD		TUCKER	GA	30084-4905
1436	Affiliated	4386	Shepherdsville	Shepherdsville Dialysis Center	150 BROOKS WAY	STE 15	BROOKS	KY	40109-6105
1437	Affiliated	4399	Muscle Shoals	Muscle Shoals Dialysis	712 STATE ST		MUSCLE SHOALS	AL	35661-2940
1438	Affiliated	2463	Tel Huron	Tel-Huron Dialysis (fka Waterford)	225 SUMMIT DR		WATERFORD	MI	48328-3364
1439	Affiliated	2481	Cherry Valley	Cherry Valley Dialysis (aka Newark)	1627 W MAIN ST		NEWARK	OH	43055-1345
1440	Affiliated	2437	Taylor	Taylor Dialysis	3100 W 2ND ST		TAYLOR	TX	76574
1441	Affiliated	4430	Forrest City	Forrest City Dialysis	1501 N WASHINGTON ST		FORREST CITY	AR	72335-2152
1442	Affiliated	4309	Kaufman	Kaufman Dialysis	2851 MILLENNIUM DR		KAUFMAN	TX	75142-8865
1443	Affiliated	4348	Artesia	Artesia Dialysis	702 N 13TH ST		ARTESIA	NM	88210-1166
1444	Affiliated	2381	North Hills	North Hills Dialysis	7927 BOULEVARD 26		NORTH RICHLAND HILLS	TX	76180-7103
1445	Affiliated	4428	Millington	Millington Dialysis	8510 WILKINSVILLE RD	STE 121	MILLINGTON	TN	38053-1537
1446	Affiliated	5519	Adams County	Adams County Dialysis	436 N 10TH ST		QUINCY	IL	62301-4152
1447	Affiliated	5518	Hannibal	Hannibal Dialysis	3140 PALMYRA ROAD		HANNIBAL	MO	63401-2204
1448	Affiliated	5520	Pittsfield	Pittsfield Dialysis	640 W WASHINGTON ST		PITTSFIELD	IL	62363-1350
1449	Affiliated	4463	Villa of Waterbury	Villa of Waterbury (fka Kissker Microcenter)	929 WATERBURY FALLS DR		O'FALLON	MO	63368-2202
1450	Affiliated	2465	Washington DC Nursing Facility	Washington DC Nursing Facility	2425 25TH ST SE		WASHINGTON	DC	20020-3408
1451	Affiliated	4325	Moscow	Moscow Dialysis Center	212 RODEO DR	STE 11	MOSCOW	ID	83843-9798
1452	Affiliated	2402	Chinook Kidney Center	Chinook Kidney Center (aka Richland)	1315 AARON DR	BLDG C1	RICHLAND	WA	99352-4678
1453	Affiliated	4416	River's Edge	Rivers Edge Dialysis (aka Athens)	1006 E STATE ST	STE B	ATHENS	OH	45701-2121

1454	Affiliated	5530	North Glendale Dialysis	North Glendale Dialysis	1505 WILSON TER STE 190		GLENDALE	CA	91206-4015
1455	Affiliated	4373	Everett	Everett Dialysis Center (fka Snohomish 2)	8130 EVERGREEN WAY		EVERETT	WA	98203-6419
1456	Affiliated	2069	Harbourview	Harbour View Dialysis (aka Churchland, Suffolk)	1039 CHAMPIONS WAY	BLDG 4	SUFFOLK	VA	23435-3761
1457	Affiliated	4357	Capelville	Capelville Dialysis Center	7008 E SHELBY DR		MEMPHIS	TN	38125-3416
1458	Affiliated	4485	San Leandro	San Leandro Dialysis (Bayfair Mall)	15555 E 14TH	STE 52	SAN LEANDRO	CA	94578-1900
1459	Affiliated	4317	Mill Creek	Mill Creek Dialysis Center (Snohomish/Everett)	18001 BOTHELL EVERETT HWY	STE 112	BOTHELL	WA	98012-1661
1460	Affiliated	2470	Seaview	Seaview Dialysis Center	101 18TH ST SE		LONG BEACH	WA	98631
1461	Affiliated	2461	East Tampa	East Tampa Dialysis (Ybor City)	1701 E 9TH AVE		YBOR CITY	FL	33605-3801
1462	Affiliated	5522	Detroit Road Dialysis	Detroit Road Dialysis	7901 DETROIT AVE		CLEVELAND	OH	44102-2828
1463	Affiliated	5523	St V Quadrangle Dialysis	St V Quadrangle Dialysis	2302 COMMUNITY COLLEGE AVE		CLEVELAND	OH	44115-3117
1464	Affiliated	5524	Westshore Dialysis	Westshore Dialysis	29000 CENTER RIDGE RD		WESTLAKE	OH	44145-5293
1465	Affiliated	2468	Magnolia Dialysis Center Texas	Magnolia Dialysis Center	17649 FM 1488 RD		MAGNOLIA	TX	77354-5235
1466	Affiliated	4471	Highland County	Highland County Dialysis (Hillsboro)	120 ROBERTS LN	STE 4	HILLSBORO	OH	45133-7608
1467	Affiliated	4313	Rockwall	Rockwall Dialysis	2455 RIDGE RD	STE 11	ROCKWALL	TX	75087-5530
1468	Affiliated	4354	Great Northern	Villa of Great Northern (fka North Olmsted)	22710 FAIRVIEW CENTER DR	STE 1	FAIRVIEW PARK	OH	44126-3607
1469	Affiliated	2440	Ridgeland	Ridgeland Dialysis	112 WEATHERSBY ST		RIDGELAND	SC	29936-9514
1470	Affiliated	2334	Livermore	Livermore Dialysis	3201 DOOLAN RD	STE 175	LIVERMORE	CA	94551-9605
1471	Affiliated	2265	Westlake Daly city	Westlake Daly City Dialysis (fka Colma)	2201 JUNIPERO SERRA BLVD	STE 175	DALY CITY	CA	94014-1908
1472	Affiliated	4488	12th Street Covington	12th Street Covington Dialysis	1500 JAMES SIMPSON JR WAY	STE 11	COVINGTON	KY	41011
1473	Affiliated	4384	Bourbon County	Bourbon County Dialysis (fka Paris)	213 LETTON DR	PARIS TOWNE SQUARE	PARIS	KY	40361-2251
1474	Affiliated	2499	Calverton	Calverton Dialysis	4780 CORRIDOR PL	STE C	BELTSVILLE	MD	20705-1165
1475	Affiliated	2199	Aborn	Aborn Dialysis (fka East San Jose)	3162 S WHITE RD	STE 1	SAN JOSE	CA	95148-4019
1476	Affiliated	4438	Clermont	Clermont County Dialysis (Milford,Goshen)	5901 MONTCLAIR BLVD	STE 1	MILFORD	OH	45150-2547
1477	Affiliated	4365	Rita Ranch	Rita Ranch Dialysis (aka Tucson East II)	7355 S HOUGHTON RD	STE 11	TUCSON	AZ	85747-9379
1478	Affiliated	4333	Wake Forest	Wake Forest Dialysis Center	11001 INGLESIDE PL		RALEIGH	NC	27614-8577
1479	Affiliated	4472	Colonial Springs	Colonial Springs Dialysis (fka Powder Springs)	2840 EAST WEST CONNECTOR	STE 35	AUSTELL	GA	30106-6813
1480	Affiliated	2474	Central Dallas	DaVita Central Dallas Dialysis	9500 N CENTRAL EXPY		DALLAS	TX	75231-5002
1481	Affiliated	2188	Sanger	Sanger Sequoia Dialysis	2517 JENSEN AVE	BLDG B	SANGER	CA	93657-2251
1482	Affiliated	4421	Conyers	Conyers Dialysis	1501 MILSTEAD RD NE		CONYERS	GA	30012-3838
1483	Affiliated	4337	Duncanville	Duncanville Dialysis (Cedar Hill)	270 E HIGHWAY 67	STE 1	DUNCANVILLE	TX	75137-4428
1484	Affiliated	4417	Gateway	Gateway Dialysis (Ft.Myers)	5705 LEE BLVD		LEHIGH ACRES	FL	33971-6342
1485	Affiliated	4487	Derry	Derry Dialysis	1 ACTION BLVD	STE 2	LONDONDERRY	NH	03053-3428
1486	Affiliated	4461	Villa of Wentzville Microcenter	Villa of Wentzville (Microcenter)	1126 W PEARCE BLVD	STE 116 & 118	WENTZVILLE	MO	63385-1053
1487	Affiliated	1925	Buchanan County Dialysis	Buchanan County Dialysis (Independence)	1600 1ST ST E		INDEPENDENCE	IA	50644-3155
1488	Affiliated	2450	Hoosier Hills	Hoosier Hills Dialysis	143 S KINGSTON DR		BLOOMINGTON	IN	47408-6342
1489	Affiliated	4492	Palm Breeze	Palm Breeze Dialysis (fka North Port)	14942 TAMIAMI TRL	STE E	NORTH PORT	FL	34287-2705
1490	Affiliated	4362	Big Oaks	Big Oaks Dialysis	5623 W TOUHY AVE		NILES	IL	60714-4019
1491	Affiliated	4407	Pinellas West Shore	Pinellas West Shore Dialysis	3451 66TH ST N	STE A	ST PETERSBURG	FL	33710-1568
1492	Affiliated	2267	Plano	Plano Dialysis	481 SHILOH RD	STE 1	PLANO	TX	75074-7231
1493	Affiliated	4350	Fairview	Villa of Fairview Park (fka Fairview Park Dialysis)	19050 LORAIN RD		FAIRVIEW PARK	OH	44126-1915
1494	Affiliated	2380	Ave Marisa	Ave Maria Dialysis (fka Immokalee)	5340 USEPPA DR		AVE MARIA	FL	34142-5051
1495	Affiliated	5037	Warminster	Franklin Commons Dialysis (fka Warminster)	720 JOHNSVILLE BLVD	STE 8	WARMINSTER	PA	18974-3546
1496	Affiliated	2446	Ripley	Ripley Dialysis Center	854 HWY 51 S		RIPLEY	TN	38063-5536
1497	Affiliated	5538	St Charles / Riverbend	River Bend Dialysis (St. Charles Parish)	1057 PAUL MAILLARD RD	ST B135	LULING	LA	70070-4349
1498	Affiliated	5570	Midwest Springfield	Midwest Springfield Dialysis	2200 N LIMESTONE ST STE 104		SPRINGFIELD	OH	45503-2692
1499	Affiliated	5571	Midwest Fairborn	Midwest Fairborn Dialysis	1266 N BROAD ST		FAIRBORN	OH	45324-5549
1500	Affiliated	5572	Midwest Urbana	Midwest Urbana Dialysis	1430 E US HIGHWAY 36		URBANA	OH	43078-9112
1501	Affiliated	5531	Camarillo	Camarillo Dialysis	2438 N PONDEROSA DR STE C101		CAMARILLO	CA	93010-2465
1502	Affiliated	5532	Thousand Oaks	Thousand Oaks Dialysis	375 ROLLING OAKS DR STE 100		THOUSAND OAKS	CA	91361-1024
1503	Affiliated	5533	Simi Valley	Simi Valley Dialysis	2950 SYCAMORE DR STE 100		SIMI VALLEY	CA	93065-1210
1504	Affiliated	5534	Santa Paula	Santa Paula Dialysis	253 MARCH ST		SANTA PAULA	CA	93060-2511
1505	Affiliated	5548	Ventura	Ventura Dialysis	2705 LOMA VISTA RD STE 101		VENTURA	CA	93003-1596
1506	Affiliated	4468	Villa of St. John	Villa of St John (Crossing Microcenter-MO)	9030 SAINT CHARLES ROCK RD		SAINT LOUIS	MO	63114-4246
1507	Affiliated	4372	Whidbey Island	Whidbey Island Dialysis Center	32650 STATE RD 20	BLDG E STE 18	OAK HARBOR	WA	98277-2641

1508	Affiliated	4437	Baytown	Baytown Dialysis	4665 GARTH RD	STE 9	BAYTOWN	TX	77521-2261
1509	Affiliated	2475	Highland Ranch	Highland Ranch Dialysis Center	7223 CHURCH ST STE A14		HIGHLAND	CA	92346-6837
1510	Affiliated	4474	Tiptonville	Tiptonville Dialysis	795 HAMRA ST		TIPTONVILLE	TN	38079-1663
1511	Affiliated	1902	Carabello	Carabello Dialysis Center	757 E WASHINGTON BLVD		LOS ANGELES	CA	90021-3016
1512	Affiliated	5573	Palmetto	Palmetto Dialysis	317 PROFESSIONAL PARK RD		CLINTON	SC	29325-7625
1513	Affiliated	5574	Greer South	Greer South Dialysis	3254 BRUSHY CREEK RD		GREER	SC	29650-1000
1514	Affiliated	5575	Greenville West End	Greenville West End Dialysis	605 S ACADEMY ST		GREENVILLE	SC	29601-2407
1515	Affiliated	5576	Fountain Inn	Fountain Inn Dialysis	298 CHAPMAN RD		FOUNTAIN INN	SC	29644-6129
1516	Affiliated	5558	Sellersville	Sellersville Dialysis	1112 OLD BETHLEHEM PIKE		SELLERSVILLE	PA	18960-1423
1517	Affiliated	5564	Humbolt Ridge	Humboldt Ridge Dialysis	2211 N HUMBOLDT BLVD		MILWAUKEE	WI	53212-3507
1518	Affiliated	5565	West Appleton	West Appleton Dialysis	10130 W APPLETON AVE	STE 5	MILWAUKEE	WI	53225-2579
1519	Affiliated	5566	Bay Shore	Bay Shore Dialysis	5650 N GREEN BAY AVE	STE 15	GLENDALE	WI	53209-4449
1520	Affiliated	5567	South Ridge	South Ridge Dialysis	4848 S 76TH ST	STE 1	GREENFIELD	WI	53220-4361
1521	Affiliated	5568	Bluemound	Bluemound Dialysis	601 N 99TH ST	STE 1	MILWAUKEE	WI	53226-4362
1522	Affiliated	4385	Versailles	Versailles Dialysis	480 LEXINGTON RD		VERSAILLES	KY	40383-1918
1523	Affiliated	5035	Magnolia Oaks	Magnolia Oaks Dialysis (aka Hinesville)	2377 HWY 196 W		HINESVILLE	GA	31313-8036
1524	Affiliated	4489	Mesa County	Mesa County Dialysis (Grand Junction)	561 25 RD	STE D	GRAND JUNCTION	CO	81505-1303
1525	Affiliated	297	West Bloomfield	West Bloomfield Dialysis	6010 W MAPLE RD	STE 215	WEST BLOOMFIELD	MI	48322-4406
1526	Affiliated	5550	Crystal Springs Dialysis	Crystal Springs Dialysis	720 COG CIRCLE		CRYSTAL LAKE	IL	60014-7301
1527	Affiliated	5551	Cobblestone Dialysis	Cobblestone Dialysis	934 CENTER ST	STE A	ELGIN	IL	60120-2125
1528	Affiliated	5586	Oak Springs Dialysis	Oak Springs Dialysis	764 LOCUST AVE		WASHINGTON	PA	15301-2756
1529	Affiliated	5010	Maple Valley Plaza	Maple Valley Plaza Dialysis (Farmington)	649 MAPLE VALLEY DR		FARMINGTON	MO	63640-1993
1530	Affiliated	4433	Floyd Curl	Floyd Curl Dialysis (San Antonio)	9238 FLOYD CURL DR	STE 12	SAN ANTONIO	TX	78240-1691
1531	Affiliated	2387	Mission Valley	Mission Valley Dialysis (aka McAllen)	1203 ST CLAIRE BLVD 9B		MISSION	TX	78572-6601
1532	Affiliated	2180	Silver Lake	Silver Lake Dialysis	2723 W TEMPLE ST		LOS ANGELES	CA	90026-4723
1533	Affiliated	5578	Lake Park Dialysis	Lake Park Dialysis	1531 E HYDE PARK BLVD		CHICAGO	IL	60615-3039
1534	Affiliated	5579	Stoney Island Dialysis	Stony Island Dialysis	8725 S STONY ISLAND AVE		CHICAGO	IL	60617-2709
1535	Affiliated	5580	Woodlawn Dialysis	Woodlawn Dialysis	1164 E 55TH ST		CHICAGO	IL	60615-5115
1536	Affiliated	4440	Jefferson Ave	Jefferson Avenue Dialysis (aka Village Parkway, Hampton)	11234 JEFFERSON AVE		NEWPORT NEWS	VA	23601-2207
1537	Affiliated	4381	Robinson	Robinson Dialysis	1215 N ALLEN ST	STE B	ROBINSON	IL	62454-1100
1538	Affiliated	4320	Gateway Plaza	Gateway Plaza Dialysis (aka Willowbrook)	1580 W ROSECRANS AVE		COMPTON	CA	90222-3700
1539	Affiliated	4329	Pasadena Foothills	Pasadena Foothills Dialysis (fka Arcadia)	3722 E COLORADO BLVD		PASADENA	CA	91107-3803
1540	Affiliated	914	Live Oak Dialysis	Live Oak Dialysis (fka San Antonio)	6700 RANDOLPH BLVD	STE 11	LIVE OAK	TX	78233-4222
1541	Affiliated	5031	Frackville	Frackville Dialysis (aka JV_Pottsville)	801 SCHUYLKILL MALL		FRACKVILLE	PA	17931-2524
1542	Affiliated	5038	Castor	Cottman Kidney Center (Castor, NE Philadelphia)	7198 CASTOR AVE		PHILADELPHIA	PA	19149-1105
1543	Affiliated	4351	Villa of North Ridgevelle	Villa of North Ridgeville	35143 CENTER RIDGE RD		NORTH RIDGEVILLE	OH	44039-3089
1544	Affiliated	5503	Thorn Run Dialysis	Thorn Run Dialysis	1136 THORN RUN RD	STE J1	MOON TOWNSHIP	PA	15108
1545	Affiliated	5504	Allegheny Valley	Allegheny Valley Dialysis	1620 PACIFIC AVE	HEIGHTS PLAZA SHOPPING CENTER	NATRONA HEIGHTS	PA	15065-2101
1546	Affiliated	5506	Northside	Northside Dialysis (fka Allegheny General)	320 E NORTH AVE	4TH FL, SOUTH TOWER	PITTSBURGH	PA	15212-4756
1547	Affiliated	5507	Somerset	Somerset County Dialysis	229 S KIMBERLY AVE	STE 1	SOMERSET	PA	15501-2022
1548	Affiliated	4493	Carthage	Carthage Dialysis	165 SAVANNAH GARDENS DR		CARTHAGE	NC	28327
1549	Affiliated	2464	Riverwood Dialysis	Riverwood Dialysis (fka Nine Mile, Tree City & Southfield)	24467 W 10 MILE RD		SOUTHFIELD	MI	48033-2931
1550	Affiliated	4415	Burton	Burton Dialysis (fka Flint Northeast)	4015 DAVISON RD		BURTON	MI	48509-1401
1551	Affiliated	4490	Black Canyon	Black Canyon Dialysis (Montrose)	3421 S RIO GRANDE AVE	UNIT D	MONTROSE	CO	81401-4840
1552	Affiliated	4394	Memphis Midtown	Memphis Midtown Dialysis	3430 SUMMER AVE		MEMPHIS	TN	38122-3610
1553	Affiliated	5539	Stonecrest Dialysis	Stonecrest Dialysis	1302 E STATE ST		ROCKFORD	IL	61104-2228
1554	Affiliated	4412	West Plano	West Plano Dialysis	5036 TENNYSON PKWY		PLANO	TX	75024-3002
1555	Affiliated	2217	Redwood City	Redwood City Dialysis (fka Palo Alto)	1000 MARSHALL ST		REDWOOD CITY	CA	94063-2027
1556	Affiliated	1592	State Fair	State Fair Dialysis	19800 WOODWARD AVE		DETROIT	MI	48203-5102
1557	Affiliated	5589	ADC of Ft Lauderdale	Advanced Dialysis Center of Fort Lauderdale	911 E OAKLAND PARK BLVD		OAKLAND PARK	FL	33334-2725
1558	Affiliated	5008	Dover	Dover Community Dialysis (New Philadelphia)	899 E IRON AVE		DOVER	OH	44622-2097
1559	Affiliated	5045	McMinnville	McMinnville Dialysis	200 NE NORTON LN		MCMINNVILLE	OR	97128-8470
1560	Affiliated	5007	Sparta	Sparta Dialysis	150 SAM WALTON DR	STE 8	SPARTA	TN	38583-8818
1561	Affiliated	4409	Kendall	Kendall Kidney Center (fka Dadeland)	8364 MILLS DR	STE 174	MIAMI	FL	33183-4806

1562	Affiliated	4397	Abbeville	Abbeville Dialysis	904 W GREENWOOD ST		ABBEVILLE	SC	29620
1563	Affiliated	2453	Delta View	Delta View Dialysis	1150 E LELAND RD		PITTSBURG	CA	94565-5319
1564	Affiliated	5013	Wolf River	Wolf River Dialysis (Germantown)	7990 TRINITY PL	STE 11	CORDOVA	TN	38018-7731
1565	Affiliated	5601	San Luis Obispo Dialysis	San Luis Obispo Dialysis	1043 MARSH ST		SAN LUIS OBISPO	CA	93401-3629
1566	Affiliated	5602	Templeton Dialysis	Templeton Dialysis	1310 LAS TABLAS RD	STE 11	TEMPLETON	CA	93465-9746
1567	Affiliated	5603	Pismo Beach Dialysis	Pismo Beach Dialysis	320 JAMES WAY	STE 11	PISMO BEACH	CA	93449-2813
1568	Affiliated	5583	Lincoln Way Dialysis	Lincoln Way Dialysis	1303 LINCOLN WAY STE A		WHITE OAK	PA	15131-1603
1569	Affiliated	5023	Grundy Center	Grundy Center Dialysis	101 E J AVENUE		GRUNDY CENTER	IA	50638-2031
1570	Affiliated	3862	Pickens County	Pickens County Dialysis	289 WILLIAM E HILL DR.	STE A	CARROLLTON	AL	35447
1571	Affiliated	5032	Willow Grove	Willow Grove Dialysis (Abington-Maplewood)	1849 DAVISVILLE RD		WILLOW GROVE	PA	19090-4111
1572	Affiliated	2255	Amherst	Amherst Dialysis (Lorain County)	3200 COOPER FOSTER PRK RD W		LORAIN	OH	44053-3654
1573	Affiliated	2220	South Fort Worth	South Fort Worth Dialysis	6260 SOUTHWEST BLVD		BENBROOK	TX	76109-6906
1574	Affiliated	5521	Jerseyville Dialysis	Jerseyville Dialysis	917 S STATE ST		JERSEYVILLE	IL	62052-2344
1575	Affiliated	5605	Independence County Dialysis	Independence County Dialysis	1700 HARRISON ST	STE F	BATESVILLE	AR	72501-7315
1576	Affiliated	5606	Jackson County Dialysis	Jackson County Dialysis	1912 MCLAIN ST	PRATT SQUARE	NEWPORT	AR	72112-3659
1577	Affiliated	5607	Searcy Dialysis	Searcy Dialysis	3208 LANGLEY DR		SEARCY	AR	72143-6020
1578	Affiliated	5608	Springhill Dialysis	Springhill Dialysis	3401 SPRINGHILL DR	STE 19	NORTH LITTLE ROCK	AR	72117-2925
1579	Affiliated	5609	Pulaski County Dialysis	Pulaski County Dialysis	202 JOHN HARDEN DR		JACKSONVILLE	AR	72076-3775
1580	Affiliated	5610	Little Rock Midtown Dialysis	Little Rock Midtown Dialysis	2 LILE CT	STE 12A	LITTLE ROCK	AR	72205-6241
1581	Affiliated	5611	Saline County Dialysis	Saline County Dialysis	1200 N MAIN ST	STE 2	BENTON	AR	72015-3341
1582	Affiliated	5612	Conway Dialysis	Conway Dialysis	2445 CHRISTINA LANE		CONWAY	AR	72034
1583	Affiliated	5614	Valley Baptist Harlingen Dialysis	Valley Baptist-Harlingen Dialysis	2220 HAINE DR STE 40		HARLINGEN	TX	78550-8584
1584	Affiliated	5615	Valley Baptist Raymondville Dialysis	Valley Baptist-Raymondville Dialysis	894 FM 3168		RAYMONDVILLE	TX	78580-4519
1585	Affiliated	2455	Hawaiian Gardens	Hawaiian Gardens Dialysis	12191 226TH ST		HAWAIIAN GARDENS	CA	90716-1510
1586	Affiliated	2310	Huntington park	Huntington Park Dialysis	5942 RUGBY AVE		HUNTINGTON PARK	CA	90255-2803
1587	Affiliated	2462	Poinciana	Poinciana Dialysis	1002 CYPRESS PKWY		KISSIMMEE	FL	34758-3328
1588	Affiliated	5005	Southtowns	Southtowns Dialysis (Hamburg)	4910 CAMP RD	STE 1	HAMBURG	NY	14075-2617
1589	Affiliated	5635	Parma Heights Dialysis	Parma Heights Dialysis	9050 N CHURCH DR		PARMA HEIGHTS	OH	44130-4701
1590	Affiliated	5636	Hillard Dialysis	Hilliard Dialysis	19133 HILLIARD BLVD		ROCKY RIVER	OH	44116-2907
1591	Affiliated	5546	Pacific Dialysis	Pacific Dialysis	2351 CLAY ST	FL 4	SAN FRANCISCO	CA	94115-1931
1592	Affiliated	5547	Davies Dialysis	Davies Dialysis	45 CASTRO ST	SOUTH TOWER 2ND FL	SAN FRANCISCO	CA	94114-1032
1593	Affiliated	4486	Newburgh	Newburgh Dialysis	4311 HIGHWAY 261	STE A	NEWBURGH	IN	47630-2653
1594	Affiliated	5052	Enterprise	Enterprise Dialysis (fka Geneva)	6002 BOLL WEEVIL CIRCLE		ENTERPRISE	AL	36330-9420
1595	Affiliated	4387	State Line	State Line Dialysis	2049 E SHELBY DR		MEMPHIS	TN	38116-7639
1596	Affiliated	5108	Cape Coral North	Cape Coral North Dialysis	1315 SE 8TH TERRACE		CAPE CORAL	FL	33990-3213
1597	Affiliated	5044	Willard Ave	Willard Avenue Dialysis (Newington)	445E WILLARD AVE		NEWINGTON	CT	06111-2318
1598	Affiliated	4363	West Lawn	West Lawn Dialysis (aka Midway)	7000 S PULASKI RD		CHICAGO	IL	60629-5842
1599	Affiliated	4353	Villa of Lakewood	Villa of Lakewood (Northcoast)	14050 MADISON AVE		LAKEWOOD	OH	44107-4530
1600	Affiliated	5054	North Carrolton	North Carrollton Dialysis (Parkview)	195 PARKWOOD CIRCLE		CARROLLTON	GA	30117-8756
1601	Affiliated	5620	Sikeston Jaycee Regional Dialysis	Sikeston Jaycee Regional Dialysis	135 PLAZA DR STE 101		SIKESTON	MO	63801-5148
1602	Affiliated	2244	Radcliff	Radcliff Dialysis	180 E LINCOLN TRAIL BLVD		RADCLIFF	KY	40160-1254
1603	Affiliated	4452	McAfee	McAfee Dialysis (Candler Road Decatur)	1987 CANDLER RD	STE C	DECATUR	GA	30032-4212
1604	Affiliated	5036	Avon	Avon Dialysis (Indy West)	9210 ROCKVILLE RD	STE D	INDIANAPOLIS	IN	46234-2669
1605	Affiliated	2485	Anaheim West	Anaheim West Dialysis	1821 W LINCOLN AVE		ANAHEIM	CA	92801-6731
1606	Affiliated	5043	Port Saint Joe	Port Saint Joe Dialysis	3871 HIGHWAY 98 E	STE 11	PORT ST. JOE	FL	32456-5318
1607	Affiliated	5056	Hayward Mission Hills	Hayward Mission Hills Dialysis	1661 INDUSTRIAL PKWY W		HAYWARD	CA	94544-7046
1608	Affiliated	2472	Cypress Woods Northwest	Cypress Woods Northwest Dialysis (aka NW Houston)	20320 NORTHWEST FWY	STE 1	HOUSTON	TX	77065-
1609	Affiliated	5641	Willow Creek Dialysis	Willow Creek Dialysis	1139 WARWICK WAY		RACINE	WI	53406-5661
1610	Affiliated	5642	Harbor View Dialysis	Harbor View Dialysis	818 6TH ST		RACINE	WI	53403-1176
1611	Affiliated	4451	Red River	Red River Dialysis (fka Shreveport South)	9205 LINWOOD AVE		SHREVEPORT	LA	71106-7006
1612	Affiliated	2392	South Dade Kidney Center	South Dade Kidney Center (Coral Reef)	11040 SW 184TH ST		CUTLER BAY	FL	33157-6602
1613	Affiliated	5604	Niagara Falls Memorial Dialysis	Niagara Falls Memorial Dialysis (was NF Kidney Care Center)	621 10TH ST		NIAGARA FALLS	NY	14301-1813
1614	Affiliated	5617	Silverado Dialysis	Silverado Dialysis	1100 TRANCAS ST	STE 266 AND 267	NAPA	CA	94558-2921
1615	Affiliated	5621	Prairie River Dialysis	Prairie River Dialysis	601 S CENTER AVE		MERRILL	WI	54452-3404

1616	Affiliated	5622	Stevens Point Dialysis	Stevens Point Dialysis	900 ILLINOIS AVE	5th FLR	STEVENS POINT	WI	54481-2885
1617	Affiliated	5623	Grand Seasons Dialysis	Grand Seasons Dialysis	190 GRAND SEASONS DR		WAUPACA	WI	54981-8219
1618	Affiliated	5624	Wausau Dialysis	Wausau Dialysis	2600 STEWART AVE	STE 144	WAUSAU	WI	54401-1403
1619	Affiliated	5625	Pine Crest Dialysis	Pine Crest Dialysis	232 S COURTNEY ST	STE 2	RHINELANDER	WI	54501-3319
1620	Affiliated	5626	Meadow Lane Dialysis	Meadow Lane Dialysis	1120 PINE ST		STANLEY	WI	54768-1297
1621	Affiliated	5627	Wisconsin Rapids Dialysis	Wisconsin Rapids Dialysis	1041B HILL ST		WISCONSIN RAPIDS	WI	54494-5221
1622	Affiliated	5628	Marshfield Dialysis	Marshfield Dialysis	123 NORTHRIDGE ST		MARSHFIELD	WI	54449-8341
1623	Affiliated	5629	Northern Star Dialysis	Northern Star Dialysis	311 ELM ST		WOODRUFF	WI	54568-9190
1624	Affiliated	5632	Ames Mary Greeley Dialysis	Ames Mary Greeley Dialysis	2322 E 13TH ST		AMES	IA	50010-5669
1625	Affiliated	5633	Marshalltown Mary Greeley Dialysis	Marshalltown Mary Greeley Dialysis	3120 S 2ND ST		MARSHALLTOWN	IA	50158-4614
1626	Affiliated	5634	Iowa Falls Mary Greeley Dialysis	Iowa Falls Mary Greeley Dialysis	701 WASHINGTON AVE		IOWA FALLS	IA	50126-2100
1627	Affiliated	5649	Dialysis Center of Hutchinson	Dialysis Center of Hutchinson	1901 N WALDRON ST		HUTCHINSON	KS	67502-1129
1628	Affiliated	5650	Amarillo Dialysis	Amarillo Dialysis	8604 S COULTER ST		AMARILLO	TX	79119-7379
1629	Affiliated	4495	Sagemeadow	Sagemeadow Dialysis (Houston)	10923 SCARSDALE BLVD		HOUSTON	TX	77089-6024
1630	Affiliated	5009	McKinney	McKinney Dialysis	4717 MEDICAL CENTER DR		MCKINNEY	TX	75069-1870
1631	Affiliated	4499	Scottsburg	Scottsburg Dialysis	1619 W MCCLAIN AVE		SCOTTSBURG	IN	47170-1161
1632	Affiliated	2108	Snake River	Snake River Dialysis Center (fka Blackfoot)	1491 PARKWAY DR		BLACKFOOT	ID	83221-1667
1633	Affiliated	5034	Southpoint	Southpoint Dialysis (aka Durham South)	415 W NC HWY 54		DURHAM	NC	27713-7516
1634	Affiliated	5643	Burlingame Dialysis	Burlingame Dialysis	1720 EL CAMINO REAL	STE 12	BURLINGAME	CA	94010-3225
1635	Affiliated	5644	Mills Dialysis	Mills Dialysis	100 S SAN MATEO DR		SAN MATEO	CA	94401-3805
1636	Affiliated	5646	Stuebenville	Steubenville Dialysis	4000 JOHNSON RD		STEUBENVILLE	OH	43952-2300
1637	Affiliated	5656	Premiere Kidney Center of Newark	Premiere Kidney Center of Newark	65 SOUTH TERRACE AVE		NEWARK	OH	43055-1355
1638	Affiliated	5029	Calvine	Calvine Dialysis (Sacramento)	8243 E STOCKTON BLVD	STE 1	SACRAMENTO	CA	95828-8200
1639	Affiliated	4445	Durham Corners dialysis	Durham Corners Dialysis (South Plainfield)	241 DURHAM AVE		SOUTH PLAINFIELD	NJ	07080-2504
1640	Affiliated	4475	Mt Morris	Mt Morris Dialysis (aka North Flint)	6141 N. SAGINAW RD		MOUNT MORRIS	MI	48458-2403
1641	Affiliated	2176	Grandview	Grandview Dialysis	13812 S US HIGHWAY 71		GRANDVIEW	MO	64030-3685
1642	Affiliated	4450	Lemoore	Lemoore Dialysis	1345 W BUSH ST		LEMOORE	CA	93245-3303
1643	Affiliated	5663	Middlebrook Dialysis	Middlebrook Dialysis	12401 MIDDLEBROOK RD	STE 16	GERMANTOWN	MD	20874-1523
1644	Affiliated	5664	Catoctin Dialysis	Catoctin Dialysis	405 W 7TH ST		FREDERICK	MD	21701-4505
1645	Affiliated	5648	Central New York Dialysis Center	Central New York Dialysis Center	910 ERIE BLVD E		SYRACUSE	NY	13210-1060
1646	Affiliated	5014	South Jackson	South Jackson Dialysis	46 HARTS BRIDGE RD		JACKSON	TN	38301-7512
1647	Affiliated	2344	Los Alamitos	Los Alamitos Dialysis	4141 KATELLA AVE		LOS ALAMITOS	CA	90720-3406
1648	Affiliated	5048	Robbinsdale	Robbinsdale Dialysis	3461 W BROADWAY AVE		ROBBINSDALE	MN	55422-2955
1649	Affiliated	5557	Oxnard	Oxnard Dialysis	1900 OUTLET CENTER DR		OXNARD	CA	93036-0677
1650	Affiliated	4429	Marked Tree	DNVO-Marked Tree-AR	216 HESTER PARKER DR		MARKED TREE	AR	72365-2023
1651	Affiliated	5669	Louisa Dialysis	Louisa Dialysis	2145 HWY 2565		LOUISA	KY	41230
1652	Affiliated	5670	Point Pleasant Dialysis	Point Pleasant Dialysis	3683 OHIO RIVER DR		POINT PLEASANT	WV	25550
1653	Affiliated	6802	Marion	Renal Care of Marion (P150)	2921 HWY 77	SUITE #8	MARION	AR	72364-2368
1654	Affiliated	6803	Osceola	Osceola Dialysis (P151)	1420 W KEISER AVE		OSCEOLA	AR	72370-2800
1655	Affiliated	6805	Cottonwood	Cottonwood Dialysis (P153)	203 S CANDY LANE		COTTONWOOD	AZ	86326-8115
1656	Affiliated	6808	Prescott	Prescott Dialysis (P157)	980 WILLOW CREEK RD.	SUITE 11	PRESCOTT	AZ	86301-1619
1657	Affiliated	6811	Naples	Collier County Dialysis (P160)	6625 HILLWAY CIRCLE		NAPLES	FL	34112
1658	Affiliated	6813	Catersville	Cartersville Renal Center (P162)	203 S TENNESSEE ST		CARTERSVILLE	GA	30120
1659	Affiliated	6816	Arlington Heights Renal Center	Arlington Heights Renal Center (P165)	17 W GOLF RD		ARLINGTON HEIGHTS	IL	60006
1660	Affiliated	6817	Hazel Crest Renal Center	Hazel Crest Renal Center (P166)	3470 W 183RD ST		HAZEL CREST	IL	60429
1661	Affiliated	6818	Loop Renal Center	Loop Renal Center (P167)	1101 S CANAL ST	11TH FLR	CHICAGO	IL	60607
1662	Affiliated	6819	Markham Renal Center	Markham Renal Center (P168)	3053 W 159TH ST		MARKHAM	IL	60426
1663	Affiliated	6821	South Holland Renal Center	South Holland Renal Center (P170)	16136 S PARK AVE.		SOUTH HOLLAND	IL	60473
1664	Affiliated	6822	Waukegan Renal Center	Waukegan Renal Center (P171)	1616 GRAND AVE.	STE. C	WAUKEGAN	IL	60085
1665	Affiliated	6936	Waukegan Home Renal Center	Waukegan Home Training (P172)	1616 GRAND AVE	STE F	WAUKEGAN	IL	60085
1666	Affiliated	6825	Baton Rouge	East Baton Rouge Dialysis (P174)	1333 ONEAL LANE		BATON ROUGE	LA	70816
1667	Affiliated	6826	Houma Renal Center	Houma Dialysis (P175)	108 PICONE RD		HOUMA	LA	70363
1668	Affiliated	6827	Amesbury	Amesbury Renal Center (P177)	24 MORRILL PLACE		AMESBURY	MA	1913
1669	Affiliated	6828	North Andover	North Andover Renal Center (P178)	201 SUTTON ST		NORTH ANDOVER	MA	1845

1670	Affiliated	6829	Canton	Canton Renal Center (P179)	620 E PEACE ST		CANTON	MS	39046-4729
1671	Affiliated	6830	Hazelhurst	Hazlehurst Dialysis (P180)	201 N HALEY ST		HAZLEHURST	MS	39083
1672	Affiliated	6831	Jackson North	Jackson North Dialysis (P181)	571 BEASLEY RD	SUITE B	JACKSON	MS	39206-3042
1673	Affiliated	6832	Jackson South	Jackson South Dialysis (P182)	2460 TERRY RD	SUITE 27-J	JACKSON	MS	39204-5767
1674	Affiliated	6833	Jackson Southwest	Jackson Southwest Dialysis (P183)	1828 RAYMOND RD		JACKSON	MS	39204-4126
1675	Affiliated	6834	Lexington	Renal Care of Lexington (P184)	22579 DEPOT STREET		LEXINGTON	MS	39095
1676	Affiliated	6835	Munroe Falls	Munroe Falls Dialysis (P185)	265 N MAIN ST		MUNROE FALLS	OH	44262
1677	Affiliated	6836	Summit	Summit Renal Center (P186)	73 MASSILLON ROAD		AKRON	OH	44312
1678	Affiliated	6837	White Ponds	White Ponds Dialysis (P187)	534 WHITE POND DRIVE	SUITE A	AKRON	OH	44320
1679	Affiliated	6838	Philadelphia	Memphis Street Renal Center (P189)	3310 24 MEMPHIS ST		PHILADELPHIA	PA	19134-4510
1680	Affiliated	6839	Memphis Central Renal Center	Renal Care of Central Memphis (P190)	1331 UNION AVE.	SUITE 11	MEMPHIS	TN	38104-7559
1681	Affiliated	6840	Memphis Graceland Renal Center	Memphis Graceland Renal Center (P191)	4180 AUBURN RD		MEMPHIS	TN	38116-6202
1682	Affiliated	6841	Memphis Midtown Renal Center	Renal Care of Midtown Memphis (P192)	1166 MONROE AVE.		MEMPHIS	TN	38104-6614
1683	Affiliated	6842	Memphis North Renal Center	Renal Care of Memphis North (P193)	4913 RALEIGH COMMON DR.	SUITE 1	MEMPHIS	TN	38128-2485
1684	Affiliated	6844	Whitehaven Renal Center	Whitehaven Renal Center (P195)	3420 ELVIS PRESLEY BLVD.		MEMPHIS	TN	38116-3260
1685	Affiliated	6846	Edinburg	Edinburg Renal Center (P197)	4302 S SUGAR RD	STE 15	EDINBURG	TX	78539-9140
1686	Affiliated	6847	Mcallen	Dialysis Care of McAllen (P198)	411 LINDBERG AVE		MCALLEN	TX	78501-2921
1687	Affiliated	6848	Weslaco	Weslaco Renal Center (P199)	910 SOUTH UTAH		WESLACO	TX	78596-4270
1688	Affiliated	6849	Marlton Dialysis Center	Marlton Dialysis (P200)	769 E ROUTE 70		MARLTON	NJ	08053-2341
1689	Affiliated	6850	Lawrenceville Renal Center	Lawrenceville Renal Center (P201)	1840 PRINCETON AVE		LAWRENCEVILLE	NJ	8648
1690	Affiliated	6851	Austell Renal Center	Austell Renal Center (P202)	3642 MARATHON CIRCLE		AUSTELL	GA	30106-6821
1691	Affiliated	6852	Bartlett Renal Center	Bartlett Renal Center (P203_P290_P8203)	2920 COVINGTON PIKE		MEMPHIS	TN	38128-6007
1692	Affiliated	6854	Beaverton Dialysis Center	Beaverton Dialysis Center (P206)	15050 SW KOLL PARKWAY	SUITE J	BEAVERTON	OR	97006-6002
1693	Affiliated	6858	Walker County Dialysis	Walker County Dialysis (P212)	589 HIGHWAY 78W		JASPER	AL	35501
1694	Affiliated	6861	Lakewood	Manatee County Dialysis (P215)	8470 COOPER CREEK BVLD		UNIVERSITY PARK	FL	34201
1695	Affiliated	6862	Canton	Northwest Georgia Dialysis (P216)	260 HOSPITAL RD		CANTON	GA	30114
1696	Affiliated	6863	Buffulo Grove Renal Center	Buffalo Grove Dialysis (P218)	1291 W DUNDEE RD		BUFFALO GROVE	IL	60089
1697	Affiliated	6864	Evanston Renal Center	Evanston Renal Center (P219)	1715 CENTRAL ST		EVANSTON	IL	60201
1698	Affiliated	6865	Schaumburg Renal Center	Schaumburg Renal Center (P220)	1156 S. ROSELLE ROAD		SCHAUMBURG	IL	60193
1699	Affiliated	6937	Schaumburg Home Renal Center	Schaumburg Home Training (P270)	17 W GOLF RD		ARLINGTON HEIGHTS	IL	60005
1700	Affiliated	6866	Blue River Valley	Blue River Valley Renal Center (P222)	2309 S MILLER STREET	SUITE 1	SHELBYVILLE	IN	46176-9350
1701	Affiliated	6867	Central Fort Wayne	Central Fort Wayne Dialysis (P223)	1940 BLUFTON RD		FORT WAYNE	IN	46809-1307
1702	Affiliated	6869	Huntington	Renal Care of Huntington (P225)	3040 WEST PARK DRIVE		HUNTINGTON	IN	46750-8956
1703	Affiliated	6870	Lake Avenue Dialysis Renal Center	Lake Avenue Dialysis (P226)	3525 LAKE AVE	STE 4	FORT WAYNE	IN	46805-5545
1704	Affiliated	6871	Marion County	Marion County Dialysis (P229)	3834 S EMERSON AVE	BLDG B	INDIANAPOLIS	IN	46203-5902
1705	Affiliated	6873	Quad Counties Dialysis	Quad Counties Dialysis (P232)	528 NORTH GRANDSTAFF		AUBURN	IN	46706-1660
1706	Affiliated	6875	South Anthony	South Anthony Dialysis (P234)	7017 SOUTH ANTHONY BLVD.		FORT WAYNE	IN	46816-2016
1707	Affiliated	6876	Brandon	Brandon Renal Center (P235)	101 CHRISTIAN DR		BRANDON	MS	39042-2678
1708	Affiliated	6877	Carthage	Renal Care of Carthage (P236)	312 ELLIS STREET		CARTHAGE	MS	39051
1709	Affiliated	6878	Las Cruces Renal Center	Las Cruces Renal Center (P237)	3961 E LOHMAN AVE	STE 29	LAS CRUCES	NM	88011-8272
1710	Affiliated	6879	Northeast Portland	Northeast Portland Renal Center (P240)	703 NE HANCOCK ST		PORTLAND	OR	97212-3955
1711	Affiliated	6880	Oregon Kidney Center	Dialysis Care of Portland (P241)	5318 NE IRVING		PORTLAND	OR	97213
1712	Affiliated	6881	Sunnyside	Sunnyside Renal Center (P242)	6902 SE LAKE ROAD	SUITE 1	MILWAUKIE	OR	97267-2148
1713	Affiliated	6882	Willamette Valley	Williamette Valley Renal Center (P243)	1510 DIVISION STREET	SUITE 9	OREGON CITY	OR	97045-1572
1714	Affiliated	6883	Northern Philadelphia	Northern Philadelphia Dialysis (P244)	5933 N BROAD ST		PHILADELPHIA	PA	19141
1715	Affiliated	6884	North Providence Renal Center	North Providence Renal Center (P246)	1635 MINERAL SPRING AVE		NORTH PROVIDENCE	RI	02904-4025
1716	Affiliated	6889	Alice Renal Center	Alice Renal Center (P252)	2345 ALICE REGIONAL BLVD.		ALICE	TX	78332-7291
1717	Affiliated	6890	Beeville Renal Center	Beeville Renal Center (P253)	1905 NW FRONTAGE		BEEVILLE	TX	78102-2954
1718	Affiliated	6891	Brownsville	Brownsville Renal Center (P254)	2945 CENTRAL BLVD		BROWNSVILLE	TX	78520-8958
1719	Affiliated	6892	Corpus Christi Renal Center	Corpus Christi Dialysis (P255)	2733 SWANTNER DR		CORPUS CHRISTI	TX	78404-2832
1720	Affiliated	6893	Riverside Renal Center	Riverside Renal Center (P256)	13434 LEOPARD RD. SUITE A17		CORPUS CHRISTI	TX	78410-4466
1721	Affiliated	6894	South Texas Renal Center	South Texas Renal Center (P257)	4301 S PADRE ISLAND DR		CORPUS CHRISTI	TX	78411-4433
1722	Affiliated	6896	South Central Renal Center	Morgan Avenue Dialysis (P258)	2222 S MORGAN AVE	SUITE 114	CORPUS CHRISTI	TX	78405-1900
1723	Affiliated	6898	Northeast Texas	Dialylsis Care of Greenville (P260)	4805 WESLEY ST		GREENVILLE	TX	75401-5649

1724	Affiliated	6899	Downtown Spokane	Downtown Spokane Renal Center (P261)	601 W 5TH ST	SUITE F	SPOKANE	WA	99205
1725	Affiliated	6900	North Spokane	North Spokane Renal Center (P262)	12610 E MARIBEAU PRKWY	STE 1	SPOKANE	WA	99216
1726	Affiliated	6901	Spokane Valley	Spokane Valley Renal Center (P263)	12610 EAST MIRABEAU PKY	SUITE 1	SPOKANE	WA	99208-1450
1727	Affiliated	6902	Kansas City	Kansas City Renal Center (P264)	4333 MADISON AVE		KANSAS CITY	MO	64111-3429
1728	Affiliated	6903	Butler Renal Center	Butler Renal Center (P266)	601 W NURSERY		BUTLER	MO	64730
1729	Affiliated	6904	Harrisonville	Harrisonville Renal Center (P267)	308 GALAXIE AVE		HARRISONVILLE	MO	64701-2084
1730	Affiliated	6905	Marshall Renal Center	Marshall Renal Center (P268)	359 W MORGAN		MARSHALL	MO	65340
1731	Affiliated	6907	Akron Renal Center	Akron Renal Center (P272)	525 EAST MARKET STREET		AKRON	OH	44304-1619
1732	Affiliated	6908	Kendallville Renal Center	Kendallville Renal Center (P274)	602 SAWYER RD		KENDALLVILLE	IN	46755-2566
1733	Affiliated	6909	Greenwood Holly Renal Center	Greenwood Holly Renal Center (P276)	1533 HOLLY RD		CORPUS CHRISTI	TX	78417-2010
1734	Affiliated	6910	Plainfield Renal Center	Plainfield Renal Center (P278)	8110 NETWORK DR		PLAINFIELD	IN	46168-9024
1735	Affiliated	6911	Green Valley Renal Center	Green Valley Dialysis (P279)	1489 W WARM SPRINGS RD	STE 122	HENDERSON	NV	89014-7637
1736	Affiliated	6912	Las Vegas Renal Center	Las Vegas Renal Center (P280)	2333 RENAISSANCE DR		LAS VEGAS	NV	89119-6191
1737	Affiliated	6913	Lees Summit Renal Center	Lees Summit Renal Center (P281)	100 NE MISSOURI RD	STE 1	LEE'S SUMMIT	MO	64086-4702
1738	Affiliated	6914	Westport Renal Center	Westport Renal Center (P282)	3947 BROADWAY STREET		KANSAS CITY	MO	64111-2516
1739	Affiliated	6915	Greensboro Dialysis Center	Greensboro Dialysis Center (P284)	1220 SILOAM RD		GREENSBORO	GA	30642-0390
1740	Affiliated	5057	Forest Landing	DNVO-Forest Landing Dialysis (Harford Cty, Havre de Grace)-MD	2220 COMMERCE AVE	STE 1	FOREST HILL	MD	21050
1741	Affiliated	5033	University City	DNVO-University City Dialysis (Philadelphia)-PA	3020 MARKET ST	STE 13	PHILADELPHIA	PA	19104-2999
1742	Affiliated	2411	Parkland	DNVO-Parkland Dialysis-WA	311 140TH ST SO		TACOMA	WA	98444
1743	Affiliated	5094	Shelbyville Road	DNVO JV-Shelbyville Road Dialysis (DuPont, Louisville)-KY	4600 SHELBYVILLE RD	STE 31	LOUISVILLE	KY	40207
1744	Affiliated	5106	Fort Wayne West Dialysis	DNVO JV-Fort Wayne South-IN	302 E PETTIT AVE		FORT WAYNE	IN	468063007
1745	Affiliated	5671	Suburban Dialysis	ACQ-5671-NY	1542 MAPLE RD		WILLIAMSVILLE	NY	14221
1746	Affiliated	5672	Gates Circle Dialysis	ACQ-5672-NY	3 GATES CIRCLE	1ST FLR	BUFFALO	NY	14209
1747	Affiliated	5673	Orchard Park Dialysis	ACQ-5673-NY	3801 TAYLOR RD		ORCHARD PARK	NY	14127
1748	Affiliated	2420	TC Jester	DNVO-TC Jester-TX	1800 W 26TH ST	STE 11	HOUSTON	TX	77008-1419
1749	Affiliated	4436	Champions	DNVO-Champions Dialysis (Houston)-TX	4427 FM 1960 W	STE D	HOUSTON	TX	77068-3409
1750	Affiliated	5083	Magic City Dialysis MMC	DNVO-Magic City Dialysis (Birmingham)-AL	300 22ND ST SO		BIRMINGHAM	AL	35233-2209
1751	Affiliated	5084	Steel City Dialysis	DNVO-Steel City Dialysis (Birmingham)-AL	1809 AVE H (ENSLEY)		BIRMINGHAM	AL	35218
1752	Affiliated	5081	Jewel Dialysis	DNVO-Jewel Dialysis (Camellia, Birmingham)-AL	514 WEST TOWN PLAZA		BESSEMER	AL	35020
1753	Affiliated	660	Crystal River	Crystal River Dialysis	7435 W GULF TO LAKE HWY		CRYSTAL RIVER	FL	34429-7834
1754	Affiliated	1936	Southwest Kidney	Estrella Dialysis Center	8410 W THOMAS RD	STE 1 BLDG 1	PHOENIX	AZ	85037-3356
1755	Affiliated	1937	Gilbert Dialysis	Gilbert Dialysis Center	5222 E BASELINE RD	STE 14	GILBERT	AZ	85234-2963
1756	Affiliated	1938	Tempe Dialysis	Tempe Dialysis Center	2149 E WARNER RD	STE 11	TEMPE	AZ	85284-3496
1757	Affiliated	1939	Phoenix Dialysis	Phoenix Dialysis Center	337 E CORONADO RD	STE 11	PHOENIX	AZ	85004-1582
1758	Affiliated	1949	Arrowhead Lakes Dialysis	Arrowhead Lakes Dialysis	20325 N 51ST AVE	BLDG 11, STE 186	GLENDALE	AZ	85308-4625
1759	Affiliated	1952	Mountain Vista Dialysis	Mountain Vista Dialysis Center of Arizona	10238 E HAMPTON AVE	STE 18	MESA	AZ	85209-3317
1760	Affiliated	1977	South Meadows Dialysis Center	South Meadows Dialysis Center	10085 DOUBLE R BLVD	STE 16	RENO	NV	89521-4867
1761	Affiliated	1978	Reno Dialysis Center	Reno Dialysis Center	1500 E 2ND ST	STE 11	RENO	NV	89502-1189
1762	Affiliated	1979	Carson City Dialysis Center	Carson City Dialysis Center	3246 N. CARSON ST	STE 11	CARSON CITY	NV	89706-0248
1763	Affiliated	844	Sparks	Sparks Dialysis Center	4860 VISTA BLVD	STE 1	SPARKS	NV	89436-2817
1764	Affiliated	2015	Sierra Rose Dialysis	Sierra Rose Dialysis Center	685 SIERRA ROSE DR		RENO	NV	89511-2060
1765	Affiliated	2325	Northwest Tucson	Northwest Tucson Dialysis	2945 W INA RD	STE 15	TUCSON	AZ	85741-2366
1766	Affiliated	4355	Mesa	Central Mesa Dialysis Center	1134 E UNIVERSITY DR	STE 11	MESA	AZ	85203-8048
1767	Affiliated	4371	Raven	Raven Dialysis Center	3540 E BASELINE RD	STE 11	PHOENIX	AZ	85042-9628
1768	Affiliated	4374	Brookwood	Brookwood Dialysis Center	8910 N 43RD AVE	STE 17	GLENDALE	AZ	85302-5340
1769	Affiliated	4405	Ocotillo	Ocotillo Dialysis	975 W CHANDLER HEIGHTS RD	UNIT 11	CHANDLER	AZ	85248-5724
1770	Affiliated	4364	Maryvale	Maryvale Dialysis Center	4845 W MCDOWELL RD	STE 1A, 2A, 3A	PHOENIX	AZ	85035-4076
1771	Administrative Services	181	Childrens Hospital	MGD-Children's National Medical Center	111 MICHIGAN AVE NW		WASHINGTON	DC	20010-2916
1772	Administrative Services	1624	Renal Care Seat Pleasant	MGD-Renal Care of Seat Pleasant	6274 CENTRAL AVE		SEAT PLEASANT	MD	20743
1773	Administrative Services	1715	Moses Taylor Hospital Renal Unit	Moses Taylor Hospital Renal Unit	700 QUINCY AVE		SCRANTON	PA	18510-1724
1774	Administrative Services	3330	Aurora Medical Group - Fond du Lac	Aurora Medical Group-Fond du Lac	210 WISCONSIN AMERICAN DR	ATTN DAVITA DIALYSIS (WEST END OF BLDG)	FOND DU LAC	WI	54937-2999
1775	Administrative Services	3331	Aurora Medical Group - Sheboygan	Aurora Medical Group-Sheboygan	2414 KOHLER MEMORIAL DR		SHEBOYGAN	WI	53081-3129
1776	Administrative Services	3338	Aurora Medical Group - Lake Geneva	Aurora Medical Group-Lake Geneva	146 E GENEVA SQ		LAKE GENEVA	WI	53147-9694
1777	Administrative Services	3555	Aurora Medical Group - Marinette Dialysis	Aurora Medical Group-Marinette Dialysis	4061 OLD PESHTIGO RD		MARINETTE	WI	54143

1778	Administrative Services	3607	Aurora Medical Group - Brown County Dialysis	Aurora Medical Group-Brown County Dialysis	1751 DECKNER AVE		GREEN BAY	WI	54302-2630
1779	Administrative Services	3641	Aurora Medical Group - Sturgeon Bay Dialysis	Aurora Medical Group-Sturgeon Bay Dialysis	108 S 10TH AVE		STURGEON BAY	WI	54235-1802
1780	Administrative Services	3653	Aurora Medical Group - Oshkosh West Dialysis	Aurora Medical Group-Oshkosh West Dialysis	855 N WESTHAVEN DR		OSHKOSH	WI	54904-7668
1781	Administrative Services	3665	Aurora Medical Group - Manitowoc Dialysis	Aurora Medical Group-Manitowoc Dialysis	601 REED AVE		MANITOWOC	WI	54220-2026
1782	Administrative Services	3672	Aurora Medical Group - Wautoma Dialysis	Aurora Medical Group-Wautoma Dialysis	900 EAST DIVISION ST		WAUTOMA	WI	54982-6944
1783	Administrative Services	1868	Maize Dialysis	Maize Dialysis Center	10001 GRADY AVE		MAIZE	KS	67101
1784	Administrative Services	1912	Kidney Dialysis Center	MGD-Kidney Dialysis Center, LLC (MMG Macon)	640 MARTIN LUTHER KING JR BLVD		MACON	GA	31201-3206
	Administrative Services	6079	MAGNOLIA WEST AT HOME	Magnolia West At Home	11161 MAGNOLIA AVE	STE B	RIVERSIDE	CA	92505-3605
	Administrative Services	1903	Riverside PD Central NAMG	Riverside PD Central	3660 PARK SIERRA DR	STE 18	RIVERSIDE	CA	92505-3071
	Affiliated	1995	Winter Park Home PD Dialysis	Winter Park Home PD Dialysis	4100 METRIC DR	STE 2	WINTER PARK	FL	32792-6832
	Affiliated	4302	Lockport HHD PD At Home	Lockport Home Dialysis-PD	16626 W 159TH ST	STE 73	LOCKPORT	IL	60441-8019
	Affiliated	1972	HHD 6183 and PD 1972 in Shreveport	Shreveport Home Dialysis PD	1560 IRVING PL		SHREVEPORT	LA	71101-4604
	Affiliated	5618	Home Dialysis of Dayton – South	Home Dialysis of Dayton-South	4700 SPRINGBORO PIKE	STE 3	MORAINE	OH	45439-1964
	Affiliated	5619	Home Dialysis of Dayton	Home Dialysis of Dayton	627 S EDWIN C MOSES BLVD	STE 2B	DAYTON	OH	45417-3474
	Affiliated	144	Timpanogos Dialysis Center	Timpanogos Dialysis	1055 N 500 W	STE 222	PROVO	UT	84604-3329
	Affiliated	216	HOME DIALYSIS UNIT	Home Dialysis /CAPD Unit	825 S 8TH ST STE 1202		MINNEAPOLIS	MN	55404
	Affiliated	284	MANZANITA HOME TRAINING CENTER	Manzanita Home Training Center (fka North CAPD)	4005 MANZANITA AVE	STE 18	CARMICHAEL	CA	95608-1779
	Affiliated	408	WICHITA DIALYSIS CENTER	Wichita Dialysis Center-PD Program	909 N TOPEKA ST		WICHITA	KS	67214-3620
	Affiliated	978	CENTRAL TULSA DIALYSIS CENTER	Central Tulsa PD	1124 S SAINT LOUIS AVE		TULSA	OK	74120-5413
	Affiliated	1748	ST PAUL CAPITAL PD	St. Paul Capital Dialysis at Home-PD (fka Capital PD Program)	555 PARK ST	STE 110	SAINT PAUL	MN	55103-2110
	Affiliated	1787	ASH TREE PD	Ash Tree PD	2666 N GROVE INDUSTRIAL DR		FRESNO	CA	93727-1552
	Affiliated	1821	EMERALD DIALYSIS	Emerald Dialysis PD (fka Hyde Park PD)	710 W 43RD ST		CHICAGO	IL	60609-3435
	Affiliated	1822	OLYMPIA FIELDS DIALYSIS	Olympia Fields PD	4557B LINCOLN HWY	STE B	MATTESON	IL	60443-2385
	Affiliated	1823	LAKE COUNTY DIALYSIS	Lake County PD	918 S MILWAUKEE AVE		LIBERTYVILLE	IL	60048-3229
	Affiliated	1825	COMPREHENSIVE RENAL CARE-GARY	CRC-Gary PD	4802 BROADWAY		GARY	IN	46408-4509
	Affiliated	1826	COMPREHENSIVE RENAL CARE-HAMMOND	CRC-Hammond PD	222 DOUGLAS ST		HAMMOND	IN	46320-1960
	Affiliated	1827	COMPREHENSIVE RENAL CARE-VALPARAISO	CRC-Valparaiso PD	606 E LINCOLNWAY		VALPARAISO	IN	46383-5728
	Affiliated	1828	COMPREHENSIVE RENAL CARE-MICHIGAN CITY	CRC-Michigan City PD	9836 WEST 400 NORTH		MICHIGAN CITY	IN	46360-2910
	Affiliated	1829	MERRILLVILLE PD	Merrillville Dialysis PD	9223 TAFT ST		MERRILLVILLE	IN	46410-6911
	Affiliated	1833	NAMPA DIALYSIS CENTER	Nampa Dialysis PD	846 PARKCENTRE WAY		NAMPA	ID	83651-1790
	Affiliated	1834	TABLE ROCK DIALYSIS CENTER	Table Rock Dialysis PD	5610 W GAGE ST		BOISE	ID	83706
	Affiliated	1835	TWIN FALLS DIALYSIS CENTER	Twin Falls Dialysis PD	1840 CANYON CREST DR		TWIN FALLS	ID	83301-3007
	Affiliated	1836	TREASURE VALLEY DIALYSIS CENTER	Treasure Valley Dialysis PD & Home	3525 E LOUISE DR	STE 155	MERIDIAN	ID	83642-6303
	Affiliated	1837	GATE CITY DIALYSIS CENTER	Gate City Dialysis PD	2001 BENCH RD		POCATELLO	ID	83201-2033
	Affiliated	1838	FOUR RIVERS DIALYSIS CENTER	Four Rivers Dialysis PD	515 EAST LN		ONTARIO	OR	97914-3953
	Affiliated	1869	LOWRY DIALYSIS CENTER	Lowry Dialysis PD	7465 E 1ST AVE	STE A	DENVER	CO	80230-6877
	Affiliated	1905	BURLEY DIALYSIS CENTER	Burley Dialysis PD	741 N OVERLAND AVE		BURLEY	ID	83318-3440
	Affiliated	1909	TURFWAY PD DIALYSIS	Turfway PD Training	11 SPIRAL DR	STE 15A	FLORENCE	KY	41042-1394
	Affiliated	1910	MARYVILLE DIALYSIS	Maryville Dialysis PD	2136B VADALABENE DR		MARYVILLE	IL	62062-5632
	Affiliated	1917	PDL ANNEX-PD	PDL Annex-PD (PDL=Physician Dialysis Lancaster)	2110 HARRISBURG PIKE	STE 310	LANCASTER	PA	17601-2644
	Affiliated	1924	KANKAKEE COUNTY DIALYSIS	Kankakee County Dialysis PD	581 WILLIAM R LATHAM SR DR	STE 104	BOURBONNAIS	IL	60914-2439
	Affiliated	1946	SNAKE RIVER DIALYSIS PD	DNVO-Snake River Dialysis PD (fka Blackfoot)-ID	1491 PARKWAY DR		BLACKFOOT	ID	83221-1667
	Affiliated	1953	NORTH HIGHLANDS DIALYSIS CENTER	North Highlands Dialysis Center PD	4986 WATT AVE	STE C	NORTH HIGHLANDS	CA	95660-5182
	Affiliated	1966	AMERY DIALYSIS	Amery Dialysis PD	970 ELDEN AVE		AMERY	WI	54001-1448
	Affiliated	1975	KIDNEY HOME CENTER	Kidney HOME (Home Operations & Medical Education) Center PD	2245 ROLLING RUN DR	STE 4	WINDSOR MILL	MD	21244-1858
	Affiliated	1988	MEMPHIS DOWNTOWN DIALYSIS	Memphis Downtown Dialysis PD	2076 UNION AVE	FL 2	MEMPHIS	TN	38104-4138
	Affiliated	1989	PGH HOME MODALITY COE	Pittsburgh Home Modality Center of Excellence PD	5171 LIBERTY AVE	STE A	PITTSBURGH	PA	15224-2254
	Affiliated	2223	LAKE VILLA DIALYSIS	Lake Villa Dialysis PD	37809 N IL RTE 59		LAKE VILLA	IL	60046-7332
	Affiliated	2232	RICHFIELD DIALYSIS	Richfield PD Program	6601 LYNDALE AVE S	STE 150	RICHFIELD	MN	55423-2490
	Affiliated	2297	TOKAY HOME DIALYSIS CENTER	Tokay Home Dialysis-PD	777 S HAM LN	STE L	LODI	CA	95242-3593
	Affiliated	2302	SPIVEY PERITONEAL AND HOME DIALYSIS CENTER	Spivey Peritoneal Dialysis and Home Dialysis Center	1423 STOCKBRIDGE RD	STE B	JONESBORO	GA	30236-3740
	Affiliated	2326	WARRENSVILLE HEIGHTS PD DIALYSIS	Warrensville Heights PD Dialysis	4200 WARRENSVILLE CENTER RD	STE 210	WARRENSVILLE HEIGHTS	OH	44122-7000
	Affiliated	2340	EASTGATE HOME	Eastgate Home Training	4435 AICHOLTZ RD	STE 800B	CINCINNATI	OH	45245-1692
	Affiliated	2366	WESLEY CHAPEL DIALYSIS	Wesley Chapel Dialysis (PD ONLY)	2255 GREEN HEDGES WAY		WESLEY CHAPEL	FL	33544-8183

Affiliated	2400	FRESNO PD	Fresno At Home Center-PD Only	568 E HERNDON AVE	STE 301	FRESNO	CA	93720-2989
Affiliated	2456	GRAND HOME DIALYSIS PD/HHD	Grand Home Dialysis (PD only)	14674 W MOUNTAIN VIEW BLVD	STE 204	SURPRISE	AZ	85374-2708
Affiliated	2458	WASHINGTON COUNTY DIALYSIS	Washington County Dialysis PD Only (fka Hagerstown)	1136 OPAL CT		HAGERSTOWN	MD	21740-5940
Affiliated	2477	SAN JOSE PD	San Jose At Home-PD Only (Freestanding)	4400 STEVENS CREEK BLVD	STE 50	SAN JOSE	CA	95129-1104
Affiliated	2483	FREMONT HOME TRAINING JV	DNVO-Fremont At Home PD/HHD-CA	39355 CALIFORNIA AVE		FREMONT	CA	94538
Affiliated	2490	HOME DIALYSIS OPTIONS OF BALDWIN COUNTY	Home Dialysis Options of Baldwin County-PD Only	27880 N MAIN ST	STE A	DAPHNE	AL	36526-7080
Affiliated	3299	TRI COUNTIES HOME TRAINING	Tri Counties Home Dialysis	433 S BRIDGE ST		VISALIA	CA	93277-2801
Affiliated	3640	WHITE OAK HOME TRAINING DIALYSIS	White Oak Home Training	5520 CHEVIOT RD	STE B	CINCINNATI	OH	45247-7069
Affiliated	3683	BUTLER COUNTY HOME TRAINING DIALYSIS	Butler County Home Training	3497 S DIXIE HWY		FRANKLIN	OH	45005-5717
Affiliated	3727	HANFORD AT HOME DIALYSIS	Hanford Home Dialysis PD	900 N DOUTY ST		HANFORD	CA	93230-3918
Affiliated	3735	HIOAKS DIALYSIS PD	Hioaks Dialysis PD	681 HIOAKS RD	STE B	RICHMOND	VA	23225-4043
Affiliated	3891	MEMPHIS EAST DIALYSIS PD	Memphis East Dialysis PD	50 HUMPHREYS CTR	STE 28B	MEMPHIS	TN	38120-2369
Affiliated	3892	NASHVILLE HOME TRAINING DIALYSIS PD	Nashville Home Training Dialysis PD	1919 CHARLOTTE AVE	STE 200	NASHVILLE	TN	37203-2245
Affiliated	3989	DEARBORN HOME DIALYSIS	Dearborn Home Dialysis-PD	22030 PARK ST		DEARBORN	MI	48124-2854
Affiliated	4308	GALLERIA HOME TRAINING DIALYSIS	Galleria Home Training Dialysis PD (aka SW Tennessee)	9045 HIGHWAY 64	STE 102	LAKELAND	TN	38002-8394
Affiliated	4310	GREATER TAMPA AT HOME	Greater Tampa At Home PD	4204 N MACDILL AVE	STE 1B NORTH BLDG	TAMPA	FL	33607-6364
Affiliated	4315	LORAIN COUNTY HOME DIALYSIS	DNVO-Lorain County Home Dialysis HHD/PD-OH	824 E BROAD ST		ELYRIA	OH	44035-6557
Affiliated	4375	GARFIELD HOME PROGRAM	Garfield Home Program (PD Only)	228 N GARFIELD AVE	STE 301	MONTEREY PARK	CA	91754-1709
Affiliated	4453	BINZ HOME TRAINING	Binz Home Training - PD only	1213 HERMANN DR	STE 180	HOUSTON	TX	77004-7018
Affiliated	5021	FRANKLIN AT HOME PD	Franklin At Home PD	301 CALLOWHILL ST		PHILADELPHIA	PA	19123-4117
Affiliated	5028	CALDWELL DIALYSIS CENTER PD	Caldwell Dialysis Center	821 S SMEED PKWY		CALDWELL	ID	83605-5130
Affiliated	5170	FORT WAYNE HOME DIALYSIS	DNVO-Fort Wayne Home Dialysis (PD-HHD)-IN	3124 E STATE BLVD	STE 5B	FORT WAYNE	IN	46805-4763
Affiliated	5556	VISALIA AT HOME	Visalia At Home PD	1120 N CHINOWTH ST		VISALIA	CA	93291-7896
Affiliated	5569	BLUEMOUND PD	Bluemound PD	601 N 99TH ST STE 300		WAUWATOSA	WI	53226-4362
Affiliated	5581	WOODLAWN HOME PROGRAM PD	Woodlawn Home Program PD Only	5841 S MARYLAND AVE	RM L-026	CHICAGO	IL	60637-1447
Affiliated	5599	BEVERLY DIALYSIS PD	Beverly PD	8109 S WESTERN AVE		CHICAGO	IL	60620-5939
Affiliated	5600	WOODLAWN PEDIATRIC HOME PROGRAM	Woodlawn Pediatrics Home Program PD Only	5841 S MARYLAND AVE L026		CHICAGO	IL	60615
Affiliated	5616	SPRINGHILL HOME TRAINING DIALYSIS	Springhill Home Training (PD Only)	3401 SPRINGHILL DR	STE 330	NORTH LITTLE ROCK	AR	72117-2945
Affiliated	5647	FIRST COLONIAL DAVITA PD	First Colonial DaVita PD	1157 FIRST COLONIAL RD	STE 200	VIRGINIA BEACH	VA	23454-2432
Affiliated	5898	AMHERST AT HOME	Amherst At Home	3200 COOPER FOSTER PRK RD W		LORAIN	OH	44053-3654
Affiliated	5900	CATHERDRAL CITY AT HOME	DNVO JV-Cathedral City At Home-CA	30-885 DATE PALM DR		CATHEDRAL CITY	CA	92234-2958
Affiliated	5904	ROBBINSDALE AT HOME	Robbinsdale At Home	3461 WEST BROADWAY AVE		ROBBINSDALE	MN	55422-2955
Affiliated	5905	NORTH PALM BEACH AT HOME	North Palm Beach At Home	2841 PGA BLVD		PALM BEACH GARDENS	FL	33410-2910
Affiliated	5907	SOUTHTOWNS AT HOME	Southtowns At Home (Hamburg)	4910 CAMP RD	STE 100	HAMBURG	NY	14075-2617
Affiliated	5909	FORT WAYNE HOME AT HOME	DNVO-Fort Wayne Home At Home	3124 E STATE BLVD	STE 5B	FORT WAYNE	IN	46805-4763
Affiliated	5910	FORT WAYNE WEST AT HOME	DNVO JV-Fort Wayne West At Home	4916 ILLINOIS RD	STE 118	FORT WAYNE	IN	46804-5116
Affiliated	5913	WINCHESTER AT HOME	Winchester At Home	2301 VALOR DR		WINCHESTER	VA	22601-6111
Affiliated	5914	MARSHFIELD AT HOME	Marshfield At Home	123 NORTHRIDGE ST		MARSHFIELD	WI	54449-8341
Affiliated	5915	MOSCOW AT HOME	Moscow At Home	212 RODEO DR	STE 110	MOSCOW	ID	83843-9791
Affiliated	5919	AVON AT HOME	Avon At Home	9210 ROCKVILLE RD	STE D	INDIANAPOLIS	IN	46234-2670
Affiliated	5923	NORTHSIDE AT HOME	Northside At Home	320 E NORTH AVE	4TH FLOOR SOUTH TOWER	PITTSBURGH	PA	15212-4756
Affiliated	5926	PANAMA CITY AT HOME	Panama City At Home	615 HIGHWAY 231		PANAMA CITY	FL	32405-4704
Affiliated	5927	MAGNOLIA OAKS AT HOME	Magnolia Oaks At Home (aka Hinesville, Satilla River)	2377 HIGHWAY 196 W	BLDG A MAGNOLIA OAKS	HINESVILLE	GA	31313-8036
Affiliated	5928	WESTBANK AT HOME	Westbank At Home	3631 BEHRMAN PL		NEW ORLEANS	LA	70114-0906
Affiliated	5931	ROCKSIDE AT HOME	Rockside At Home	4801 ACORN DR		INDEPENDENCE	OH	44131-2566
Affiliated	5932	WADSWORTH AT HOME	Wadsworth At Home	195 WADSWORTH RD STE 302	FOUNDERS HALL 3RD FLOOR	WADSWORTH	OH	44281-9504
Affiliated	5933	WOODLAWN AT HOME HHD	Woodlawn Home Program At Home	5841 S MARYLAND AVE	RM L-026	CHICAGO	IL	60637-1447
Affiliated	5934	WESLEY CHAPEL AT HOME	Wesley Chapel At Home	2255 GREEN HEDGES WAY		WESLEY CHAPEL	FL	33544-8183
Affiliated	5935	THOUSAND OAKS AT HOME	Thousand Oaks At Home	375 ROLLING OAKS DR	STE 100	THOUSAND OAKS	CA	91361-1024
Affiliated	5936	SIMI VALLEY AT HOME	Simi Valley At Home	2950 SYCAMORE DR	STE 100	SIMI VALLEY	CA	93065-1210
Affiliated	5937	MIDWEST FAIRBORN AT HOME	Midwest Fairborn At Home	1266 N BROAD ST		FAIRBORN	OH	45324
Affiliated	5938	NORTH ST LOUIS COUNTY AT HOME	North St. Louis County At Home	13119 NEW HALLS FERRY RD		FLORISSANT	MO	63033-3228
Affiliated	5939	BLUEMOUND AT HOME	Bluemound At Home	601 N 99TH ST	STE 110	WAUWATOSA	WI	53226
Affiliated	5940	MESA COUNTY AT HOME	Mesa County At Home (Grand Junction)	561 25 RD	STE D	GRAND JUNCTION	CO	81505-1303

Affiliated	5942	PLANO AT HOME	Plano At Home	481 SHILOH RD	STE 100	PLANO	TX	75074-7231
Affiliated	5943	WEST BLOOMFIELD AT HOME	West Bloomfield At Home	6010 W MAPLE RD STE 215		WEST BLOOMFIELD	MI	48322-4406
Affiliated	5945	BINZ HOME TRAINING AT HOME	Binz Home Training At Home	1213 HERMANN DR STE 180		HOUSTON	TX	77004-7070
Affiliated	5947	HANNIBAL AT HOME	Hannibal At Home	3140 PALMYRA RD		HANNIBAL	MO	63401-2204
Affiliated	5949	BEVERLY AT HOME	Beverly At Home	8109 SOUTH WESTERN AVE		CHICAGO	IL	60620-5939
Affiliated	5950	NORTH JACKSON AT HOME	North Jackson At Home (fka Stonegate)	217 STERLING FARM DR		JACKSON	TN	38305-5727
Affiliated	5951	PORTAGE AT HOME	Portage At Home	5823 US HIGHWAY 6		PORTAGE	IN	46368-4851
Affiliated	5952	ROGUE VALLEY AT HOME	Rogue Valley At Home	760 GOLF VIEW DR UNIT 100		MEDFORD	OR	97504-9685
Affiliated	5953	EVERETT AT HOME	Everett At Home	8130 EVERGREEN WAY STE C		EVERETT	WA	98203-6419
Affiliated	5954	OLYMPIA AT HOME	Olympia At Home	335 COOPER POINT ROAD NW	SUITE 105	OLYMPIA	WA	98502-4436
Affiliated	5955	LORAIN COUNTY HOME AT HOME	DNVO-Lorain County Home At Home	824 EAST BROAD ST		ELYRIA	OH	44035-6559
Affiliated	5956	RENAISSANCE AT HOME	Renaissance At Home	1840 DARBY DR		FLORENCE	AL	35630-2623
Affiliated	5957	POOLER AT HOME	Pooler At Home	54 TRADERS WAY	LIVE OAK PLAZA	POOLER	GA	31322-4158
Affiliated	5958	GULF SHORES AT HOME	Gulf Shores At Home	3947 GULF SHORES PKWY	UNIT 150	GULF SHORES	AL	36542-2735
Affiliated	5959	FRANKLIN AT HOME	Franklin At Home	301 CALLOWHILL ST		PHILADELPHIA	PA	19123-4117
Affiliated	5961	RENO AT HOME	Reno At Home	1500 EAST 2ND STREET	STE 101, 106	RENO	NV	89502-1189
Affiliated	5963	JACKSONVILLE SOUTH AT HOME	Jacksonville South At Home	14965 OLD SAINT AUGUSTINE RD	UNIT 114	JACKSONVILLE	FL	32258-9481
Affiliated	5964	LAKE ST LOUIS AT HOME	Lake St. Louis At Home	200 BREVCO PLZ	STE 202	LAKE ST LOUIS	MO	63367-2950
Affiliated	5965	UNION CITY AT HOME (GA)	Union City At Home (GA)	6851 SHANNON PARKWAY	STE 200	UNION CITY	GA	30291-2049
Affiliated	5966	WEBER VALLEY AT HOME	Weber Valley At Home	1920 W 250TH N		MARRIOTT-SLATERVILLE	UT	84404-9233
Affiliated	5968	PARKER DIALYSIS CENTER	Parker At Home	10371 S PARK GLENN WAY	STE 180	PARKER	CO	80138-3871
Affiliated	5971	KENNESTONE AT HOME	Kennestone At Home	200 COBB PKWY N	STE 318	MARIETTA	GA	30062-3558
Affiliated	5973	NORTH COLORADO SPRINGS AT HOME	North Colorado Springs At Home	6071 E WOODMEN RD	STE 100	COLORADO SPRINGS	CO	80923-2610
Affiliated	5974	PGH HOME MODALITY COD/HHD	Pittsburgh Home Modality Center of Excellence At Home	5171 LIBERTY AVE	STE A	PITTSBURGH	PA	15224-2254
Affiliated	5977	FRESNO AT HOME CENTER	Fresno At Home Center-HHD Only	568 E HERNDON AVE	STE 301	FRESNO	CA	93720-2989
Affiliated	5978	BLUFF CITY AT HOME	Bluff City At Home	2400 LUCY LEE PKWY	STE E	POPLAR BLUFF	MO	63901-2427
Affiliated	5979	NORTH METRO AT HOME	North Metro At Home	12365 HURON ST	STE 500	WESTMINSTER	CO	80234-3498
Affiliated	5980	FIVE STAR AT HOME	Five Star At Home (fka Las Vegas Multi-Care)	2400 TECH CENTER CT		LAS VEGAS	NV	89128-0804
Affiliated	5981	KIDNEY HOME AT HOME	Kidney HOME (Home Operations & Medical Education) At Home	2245 ROLLING RUN DR	STE 3	WINDSOR MILL	MD	21244-1858
Affiliated	5982	FARGO AT HOME	Fargo At Home	4474 23RD AVE S	STE M	FARGO	ND	58104-8795
Affiliated	5983	GALLERIA HOME TRAINING AT HOME	Galleria Home Training At Home	9045 HIGHWAY 64	STE 102	LAKELAND	TN	38002-8394
Affiliated	5986	BELDEN COMMUNITY AT HOME	Belden Community At Home	4685 FULTON DR NW		CANTON	OH	44718-2379
Affiliated	5987	MAINPLACE AT HOME	Mainplace At Home	972 W TOWN AND COUNTRY RD		ORANGE	CA	92868-4714
Affiliated	5988	PENNSAUKEN AT HOME	Pennsauken At Home	7024 KAIGHNS AVE		PENNSAUKEN	NJ	08109-4417
Affiliated	5989	JEDBURG AT HOME	Jedburg At Home	2897 W 5TH NORTH ST		SUMMERVILLE	SC	29483-9674
Affiliated	5993	CAPE CORAL SOUTH AT HOME	Cape Coral South At Home	3046 DEL PRADO BLVD S	STE 4A	CAPE CORAL	FL	33904-7232
Affiliated	5994	GREATER TAMPA HOME AT HOME	Greater Tampa At Home	4204 N MACDILL AVE	STE 1B NORTH BLDG	TAMPA	FL	33607-6364
Affiliated	5995	ATHENS EAST AT HOME	Athens East At Home	2026 S MILLEDGE AVE	STE A2	ATHENS	GA	30605-6480
Affiliated	5996	UNIVERSITY UNIT RIVERSIDE AT HOME	University Unit Riverside At Home	1045 WESTGATE DR	STE 90	SAINT PAUL	MN	55114-1079
Affiliated	5997	WOODRIDGE AT HOME	Woodridge Home At Home	7425 JANES AVE	STE 103	WOODRIDGE	IL	60517-2356
Affiliated	5998	INDY SOUTH AT HOME	Indy South At Home	972 EMERSON PKWY	STE E	GREENWOOD	IN	46143-6202
Affiliated	5999	LOCKPORT HOME AT HOME	Lockport Home Dialysis At Home	16626 W 159TH ST	STE 703	LOCKPORT	IL	60441-8019
Affiliated	6000	CAMELBACK AT HOME HEMO	Camelback Dialysis At Home	7321 E OSBORN DR		SCOTTSDALE	AZ	85251-6418
Affiliated	6002	WEST BOUNTIFUL DIALYSIS AT HOME	West Bountiful Dialysis At Home	724 W 500 S	STE 300	WEST BOUNTIFUL	UT	84087-1471
Affiliated	6002	WEST BOUNTIFUL DIALYSIS AT HOME	West Bountiful Dialysis At Home	724 W 500 S	STE 300	WEST BOUNTIFUL	UT	84087-1471
Affiliated	6004	CORNERSTONE DIALYSIS AT HOME	Cornerstone Dialysis At Home	23857 GREENFIELD RD		SOUTHFIELD	MI	48075-3122
Affiliated	6006	DIALYSIS CARE OF MOORE COUNTY AT HOME	Dialysis Care of Moore County At Home (aka Pinehurst)	16 REGIONAL DR		PINEHURST	NC	28374-8850
Affiliated	6007	HOME DIALYSIS AT HOME	Home Dialysis At Home (Minneapolis)	825 S 8TH ST	STE 1224	MINNEAPOLIS	MN	55404-1223
Affiliated	6009	ST PAUL CAPITOL DIALYSIS AT HOME	St Paul Capital Dialysis At Home	555 PARK ST	STE 210	SAINT PAUL	MN	55103-2193
Affiliated	6011	BALLENGER PT AT HOME	Ballenger Pt. At Home	2262 S BALLENGER HWY		FLINT	MI	48503-3447
Affiliated	6012	LAKEWOOD AT HOME	Lakewood At Home	1750 PIERCE ST		LAKEWOOD	CO	80214-1434
Affiliated	6013	MED-CENTER AT HOME	Med-Center at Home	7580 FANNIN ST	STE 230	HOUSTON	TX	77054-1939
Affiliated	6014	UTAH VALLEY DIALYSIS AT HOME	Utah Valley Dialysis At Home	1055 N 500 W	STE 221	PROVO	UT	84604-3305
Affiliated	6015	LOWRY AT HOME	Lowry At Home	7465 E 1ST AVE	STE A	DENVER	CO	80230-6877

Affiliated	6016	MANZANITA AT HOME	Manzanita At Home	4005 MANZANITA AVE	STE 17	CARMICHAEL	CA	95608-1779
Affiliated	6017	FIRST COLONIAL DAVITA AT HOME	First Colonial DaVita At Home	1157 FIRST COLONIAL RD	STE 200	VIRGINIA BEACH	VA	23454-2432
Affiliated	6019	LAKEWOOD WASHINGTON AT HOME	Lakewood Washington At Home	5919 LAKEWOOD TOWNE CENTER BLVD SW	STE A	LAKEWOOD	WA	98499-6513
Affiliated	6020	GRAPEVINE AT HOME	Grapevine At Home	1600 W NORTHWEST HWY	STE 100	GRAPEVINE	TX	76051-8131
Affiliated	6021	GRAND RAPIDS AT HOME (CHERRY STREET)	Grand Rapids At Home (Cherry Street)	801 CHERRY ST SE		GRAND RAPIDS	MI	49506-1440
Affiliated	6022	FEDERAL WAY AT HOME	Federal Way At Home	1015 S 348TH ST		FEDERAL WAY	WA	98003-7078
Affiliated	6023	CENTURY CITY AT HOME	Century City At Home	10630 SANTA MONICA BLVD		LOS ANGELES	CA	90025
Affiliated	6024	REDDING AT HOME	Redding At Home	1876 PARK MARINA DR		REDDING	CA	96001-0913
Affiliated	6025	OLYMPIA FIELDS AT HOME	Olympia Fields At Home	4557B LINCOLN HWY	STE B	MATTESON	IL	60443-2318
Affiliated	6026	MT VERNON AT HOME	Mount Vernon At Home	1800 JEFFERSON AVE		MOUNT VERNON	IL	62864-4300
Affiliated	6028	YAKIMA AT HOME	Yakima At Home	1221 N 16TH AVE		YAKIMA	WA	98902-1347
Affiliated	6029	MID-COLUMBIA AT HOME	Mid Columbia At Home	6825 BURDEN BLVD	STE A	PASCO	WA	99301-9584
Affiliated	6030	GEORGETOWN ON THE POTOMAC AT HOME	Georgetown on the Potomac At Home	3323 K STREET NW	SUITE 110	WASHINGTON	DC	20007
Affiliated	6031	SIOUX FALLS AT HOME	Sioux Falls At Home	800 E 21ST ST		SIOUX FALLS	SD	57105-1016
Affiliated	6032	HILLSBORO AT HOME	Hillsboro At Home	2500 NW 229TH AVE	STE 300 BLDG E	HILLSBORO	OR	97124-7516
Affiliated	6033	PIKES PEAK AT HOME	Pikes Peak At Home	2002 LELARAY ST	STE 130	COLORADO SPRINGS	CO	80909-2804
Affiliated	6034	WALNUT CREEK AT HOME	Walnut Creek At Home	400 N WIGET LN		WALNUT CREEK	CA	94598-2408
Affiliated	6035	SAN ANTONIO AT HOME	San Antonio At Home	5284 MEDICAL DR	STE 100	SAN ANTONIO	TX	78229-4849
Affiliated	6036	SANTA ROSA AT HOME	Santa Rosa At Home	5819 HIGHWAY 90		MILTON	FL	32583-1763
Affiliated	6037	DUNMORE AT HOME	Dunmore At Home	1212 ONEILL HWY		DUNMORE	PA	18512-1717
Affiliated	6038	PALMERTON AT HOME	Palmerton At Home	185 DELAWARE AVE	STE C	PALMERTON	PA	18071-1716
Affiliated	6039	LONGVIEW AT HOME	Longview At Home	425 N FREDONIA ST		LONGVIEW	TX	75601-6464
Affiliated	6040	JB ZACHARY AT HOME	JB Zachary At Home	333 CASSELL DR	STE 2300	BALTIMORE	MD	21224-6815
Affiliated	6041	MEMPHIS EAST AT HOME	Memphis East At Home	50 HUMPHREYS CTR	STE 28B	MEMPHIS	TN	38120-2369
Affiliated	6042	PLAINFIELD AT HOME	Plainfield At Home	1200 RANDOLPH RD	KENYAN HOUSE	PLAINFIELD	NJ	07060-3361
Affiliated	6045	CHARLOTTE AT HOME	Charlotte (NC) At Home	2321 W MOREHEAD ST	STE 102	CHARLOTTE	NC	28208-5145
Affiliated	6046	DALY CITY AT HOME	Daly City At Home	1498 SOUTHGATE AVE	STE 101	DALY CITY	CA	94015-4015
Affiliated	6047	SALEM AT HOME	Salem At Home (OR)	3550 LIBERTY RD S	STE 100	SALEM	OR	97302-5700
Affiliated	6048	OMAHA WEST AT HOME	Omaha West At Home	13014 W DODGE RD		OMAHA	NE	68154-2148
Affiliated	6049	TUCSON EAST AT HOME	Tucson East At Home	6420 E BROADWAY BLVD	STE C300	TUCSON	AZ	85710-3512
Affiliated	6050	WHITE OAK AT HOME	White Oak At Home	5520 CHEVIOT RD	STE B	CINCINNATI	OH	45247-7069
Affiliated	6051	BELPRE AT HOME	Belpre At Home	2906 WASHINGTON BLVD		BELPRE	OH	45714-1848
Affiliated	6052	BIRMINGHAM AT HOME	Birmingham At Home	2101 7TH AVE S		BIRMINGHAM	AL	35233-3105
Affiliated	6053	STAMFORD AT HOME	Stamford At Home	30 COMMERCE RD		STAMFORD	CT	06902-4506
Affiliated	6054	WHITEBRIDGE AT HOME	Whitebridge At Home	103 WHITE BRIDGE PIKE	STE 6	NASHVILLE	TN	37209-4539
Affiliated	6055	ZANESVILLE AT HOME	Zanesville At Home	3120 NEWARK RD		ZANESVILLE	OH	43701-9659
Affiliated	6056	TYSON'S CORNER AT HOME	Tyson's Corner At Home	8391 OLD COURTHOUSE RD	STE 160	VIENNA	VA	22182-3819
Affiliated	6057	BRADFORD AT HOME	Bradford At Home	665 E MAIN ST		BRADFORD	PA	16701-1869
Affiliated	6059	NORTHLAND AT HOME	Northland At Home	2750 CLAY EDWARDS DR	STE 515	N KANSAS CITY	MO	64116-3258
Affiliated	6060	LAKE WORTH AT HOME	Lake Worth At Home	2459 S CONGRESS AVE	STE 100	PALM SPRINGS	FL	33406-7616
Affiliated	6061	MEADVILLE AT HOME	Meadville At Home	19050 PARK AVENUE PLZ		MEADVILLE	PA	16335-4012
Affiliated	6063	WILLINGBORO AT HOME	Willingboro At Home	230 VAN SCIVER PKWY		WILLINGBORO	NJ	08046-1131
Affiliated	6064	DERENNE AT HOME	DeRenne At Home	5303 MONTGOMERY ST		SAVANNAH	GA	31405-5138
Affiliated	6065	BRUNSWICK AT HOME	Brunswick At Home	53 SCRANTON CONNECTOR		BRUNSWICK	GA	31525-1862
Affiliated	6067	AIKEN AT HOME	Aiken At Home	775 MEDICAL PARK DR		AIKEN	SC	29801-6306
Affiliated	6068	BRIDGEPORT AT HOME	Bridgeport At Home	900 MADISON AVE		BRIDGEPORT	CT	06606-5534
Affiliated	6069	ST PETERSBURG AT HOME	St Petersburg At Home	2850 34TH ST S		ST PETERSBURG	FL	33711-3817
Affiliated	6070	DENISON AT HOME	Denison At Home	1220 REBA MACENTIRE LN		DENISON	TX	75020-9057
Affiliated	6072	ATLANTIC AT HOME	Atlantic At Home	6 INDUSTRIAL WAY W	STE B	EATONTOWN	NJ	07724-2258
Affiliated	6073	NEWTOWN AT HOME	Newtown At Home (fka St. Mary)	60 BLACKSMITH RD		NEWTOWN	PA	18940-1847
Affiliated	6075	FOX RIVER AT HOME	Fox River At Home	1910 RIVERSIDE DR		GREEN BAY	WI	54301-2319
Affiliated	6076	TOKAY AT HOME	Tokay At Home	777 S HAM LN	STE L	LODI	CA	95242-3593
Affiliated	6077	CAPITAL CITY AT HOME	Capital City At Home	307 N 46TH ST		LINCOLN	NE	68503-3714
Affiliated	6081	GREATER MIAMI AT HOME	Greater Miami At Home	160 NW 176TH ST	STE 100	MIAMI	FL	33169-5023

Affiliated	6083	EFFINGHAM AT HOME	Effingham At Home	904 MEDICAL PARK DR	STE 1	EFFINGHAM	IL	62401-2193
Affiliated	6084	SPRINGFIELD CENTRAL AT HOME	Springfield Central At Home	932 N RUTLEDGE ST		SPRINGFIELD	IL	62702-3721
Affiliated	6085	DECATUR EAST WOOD AT HOME	Decatur East Wood At Home	794 E WOOD ST		DECATUR	IL	62523-1155
Affiliated	6086	ILLINI AT HOME	Illini At Home	507 E UNIVERSITY AVE		CHAMPAIGN	IL	61820-3828
Affiliated	6087	JANESVILLE AT HOME	Janesville At Home	1305 WOODMAN RD		JANESVILLE	WI	53545-1068
Affiliated	6088	NEW HAVEN AT HOME	New Haven At Home	100 CHURCH ST S	STE C	NEW HAVEN	CT	06519-1703
Affiliated	6089	NASHUA AT HOME	Nashua At Home	38 TYLER ST	STE 100	NASHUA	NH	03060-2912
Affiliated	6090	EAST EVANSVILLE AT HOME	East Evansville At Home	1312 PROFESSIONAL BLVD		EVANSVILLE	IN	47714-8007
Affiliated	6095	BROOKRIVER AT HOME	Brookriver At Home	8101 BROOKRIVER DR		DALLAS	TX	75247-4003
Affiliated	6098	METRO EAST AT HOME	Metro East At Home	5105 W MAIN ST		BELLEVILLE	IL	62226-4728
Affiliated	6099	MARION AT HOME	Marion At Home	324 S 4TH ST		MARION	IL	62959-1241
Affiliated	6100	ROXBURY AT HOME	Roxbury At Home	622 ROXBURY RD		ROCKFORD	IL	61107-5089
Affiliated	6101	SYCAMORE AT HOME	Sycamore At Home	2200 GATEWAY DR		SYCAMORE	IL	60178-3113
Affiliated	6103	WESTVIEW AT HOME	Westview At Home	3749 COMMERCIAL DR	STE B	INDIANAPOLIS	IN	46222-1676
Affiliated	6105	OCALA AT HOME	Ocala At Home	2860 SE 1ST AVE		OCALA	FL	34471-0406
Affiliated	6106	COMPLETE CARE AT HOME	Complete Care At Home	7850 W SAMPLE RD		MARGATE	FL	33065-4710
Affiliated	6107	INTERAMERICAN AT HOME	InterAmerican At Home	7815 CORAL WAY	STE 115	MIAMI	FL	33155-6541
Affiliated	6109	PURCELLVILLE AT HOME	Purcellville At Home	280 N HATCHER AVE		PURCELLVILLE	VA	20132-3193
Affiliated	6110	TABLE ROCK AT HOME	Table Rock At Home	5610 GAGE ST	STE B	BOISE	ID	83706
Affiliated	6111	TWIN FALLS AT HOME	Twin Falls At Home	1840 CANYON CREST DR		TWIN FALLS	ID	83301-3007
Affiliated	6113	FOUR RIVERS AT HOME	Four Rivers At Home	515 EAST LN		ONTARIO	OR	97914-3953
Affiliated	6114	OLYMPIC VIEW AT HOME	Olympic View At Home	125 16TH AVE E	FL 5	SEATTLE	WA	98112-5211
Affiliated	6115	SPIVEY AT HOME	Spivey At Home	1423 STOCKBRIDGE RD	STE B	JONESBORO	GA	30236-3740
Affiliated	6116	EAST DES MOINES AT HOME	East Des Moines At Home	1301 PENNSYLVANIA AVE	STE 208	DES MOINES	IA	50316-2365
Affiliated	6118	KETTERING AT HOME	Kettering At Home	5721 BIGGER RD		KETTERING	OH	45440-2752
Affiliated	6119	CITRUS VALLEY AT HOME	Citrus Valley At Home	894 HARDT ST		SAN BERNARDINO	CA	92408-2854
Affiliated	6124	MERIDIAN PARK AT HOME	Meridian Park At Home	19255 SW 65TH AVE	STE 100	TUALATIN	OR	97062-9712
Affiliated	6125	MARYVILLE AT HOME	Maryville At Home	2136B VADALABENE DR		MARYVILLE	IL	62062-5632
Affiliated	6128	PDI-WORCESTER AT HOME	PDI-Worcester At Home	19 GLENNIE ST	STE A	WORCESTER	MA	01605-3918
Affiliated	6129	PDI-ROCKY HILL AT HOME	PDI-Rocky Hill At Home	30 WATERCHASE DR		ROCKY HILL	CT	06067-2110
Affiliated	6133	WICHITA AT HOME	Wichita At Home	909 N TOPEKA ST		WICHITA	KS	67214-3620
Affiliated	6134	ASHEVILLE KIDNEY AT HOME	Asheville Kidney At Home	1600 CENTERPARK DR		ASHEVILLE	NC	28805-6206
Affiliated	6136	STRONGSVILLE AT HOME	Strongsville At Home	17792 PEARL RD		STRONGSVILLE	OH	44136-6909
Affiliated	6137	BATON ROUGE AT HOME	DSI Divest-Baton Rouge At Home	3888 NORTH BLVD	STE 101	BATON ROUGE	LA	70806-3824
Affiliated	6138	WEST BROADWAY DIALYSIS AT HOME	West Broadway At Home	720 W BROADWAY	STE 200	LOUISVILLE	KY	40202-3245
Affiliated	6140	BRONX AT HOME	Bronx At Home	1615 EASTCHESTER RD		BRONX	NY	10461-2603
Affiliated	6142	CLEVE HILL AT HOME	Cleve Hill At Home	1461 KENSINGTON AVE		BUFFALO	NY	14215-1436
Affiliated	6144	WHITE PLAINS AT HOME	White Plains At Home	200 HAMILTON AVE	STE 13B	WHITE PLAINS	NY	10601-1859
Affiliated	6146	LAKE VILLA AT HOME	Lake Villa At Home	37809 N IL ROUTE 59		LAKE VILLA	IL	60046-7332
Affiliated	6148	TULSA AT HOME	Tulsa At Home	4436 S HARVARD AVE		TULSA	OK	74135-2605
Affiliated	6151	LITHONIA AT HOME	Lithonia At Home	2485 PARK CENTRAL BLVD		DECATUR	GA	30035-3902
Affiliated	6152	LANHAM AT HOME	Lanham At Home	8855 ANNAPOLIS RD	STE 200	LANHAM	MD	20706-2919
Affiliated	6153	HAMMOND AT HOME	Hammond At Home	222 DOUGLAS ST		HAMMOND	IN	46320-1960
Affiliated	6156	UNION CITY CENTER AT HOME (CA)	Union City Center At Home (CA)	32930 ALVARADO NILES RD	STE 300	UNION CITY	CA	94587-8101
Affiliated	6157	CHICO AT HOME	Chico At Home	530 COHASSET RD		CHICO	CA	95926-2212
Affiliated	6158	MONTCLAIR AT HOME	Montclair At Home	5050 PALO VERDE ST	STE 100	MONTCLAIR	CA	91763-2333
Affiliated	6161	PDI - LANCASTER AT HOME	PDI-Lancaster At Home	1412 E KING ST		LANCASTER	PA	17602-3240
Affiliated	6162	PDI JOHNSTOWN AT HOME	PDI-Johnstown At Home	344 BUDFIELD ST		JOHNSTOWN	PA	15904-3214
Affiliated	6163	CAMP HILL AT HOME	Camp Hill At Home	425 N 21ST ST	PLAZA 21 BLDG 1ST FL	CAMP HILL	PA	17011-2202
Affiliated	6164	PDI MONTGOMERY AT HOME	PDI-Montgomery At Home	1001 FOREST AVE		MONTGOMERY	AL	36106-1181
Affiliated	6165	FAIRFAX AT HOME	Fairfax At Home	8501 ARLINGTON BLVD	STE 100	FAIRFAX	VA	22031-4625
Affiliated	6170	WEST SACRAMENTO AT HOME	West Sacramento At Home	3450 INDUSTRIAL BLVD	STE 100	WEST SACRAMENTO	CA	95691-5003
Affiliated	6171	EAST MACON AT HOME	East Macon At Home	165 EMERY HWY	STE 101	MACON	GA	31217-3666
Affiliated	6178	GERMANTOWN AT HOME	Germantown At Home	20111 CENTURY BLVD	STE C	GERMANTOWN	MD	20874-9165

Affiliated	6180	SEDC-WILMINGTON AT HOME	SEDC-Wilmington (NC) At Home	2215 YAUPON DR		WILMINGTON	NC	28401-7334
Affiliated	6182	HERMISTON COMMUNITY AT HOME	Hermiston Community At Home	1155 W LINDA AVE		HERMISTON	OR	97838-9601
Affiliated	6183	SHREVEPORT HHD LA	Shreveport Home Dialysis At Home	1560 IRVING PL		SHREVEPORT	LA	71101-4604
Affiliated	6184	DOWNTOWN SAN ANTONIO AT HOME	Downtown San Antonio At Home	615 E QUINCY ST		SAN ANTONIO	TX	78212
Affiliated	6186	COLUMBIA MO AT HOME	RTC-Columbia (MO) At Home	1701 E BROADWAY	STE G102	COLUMBIA	MO	65201-8029
Affiliated	6188	REGENCY AT HOME	Regency At Home (fka Jacksonville)	9535 REGENCY SQUARE BLVD N		JACKSONVILLE	FL	32225-8128
Affiliated	6193	WEST GEORGIA AT HOME	West Georgia At Home (fka Columbus (GA))	1216 STARK AVE		COLUMBUS	GA	31906-2500
Affiliated	6194	BUFORD AT HOME	Buford At Home	1550 BUFORD HWY	STE 1E	BUFORD	GA	30518-3666
Affiliated	6195	KALAMAZOO WEST AT HOME	Kalamazoo West At Home	1040 N 10TH ST		KALAMAZOO	MI	49009-6149
Affiliated	6196	SOUTH VALLEY AT HOME	South Valley At Home	17815 VENTURA BLVD	STE 100	ENCINO	CA	91316-3600
Affiliated	6204	QUEENS VILLAGE AT HOME	Queens Village At Home	22202 HEMPSTEAD AVE	STE 170	QUEENS VILLAGE	NY	11429-2123
Affiliated	6207	LANSING AT HOME-MI	Lansing Home Hemodialysis At Home	1675 WATERTOWER PL	STE 700	EAST LANSING	MI	48823-6397
Affiliated	6208	SOUTH COUNTY AT HOME	South County At Home (Deaconess)	4145 UNION RD		SAINT LOUIS	MO	63129-1064
Affiliated	6211	TACOMA AT HOME	Tacoma At Home	3401 S 19TH ST		TACOMA	WA	98405-1909
Affiliated	6213	CEDAR PARK AT HOME	Cedar Park At Home (fka North Austin)	1720 E WHITESTONE BLVD		CEDAR PARK	TX	78613-7640
Affiliated	6214	SOUTH FORT WORTH DIALYSIS AT HOME	South Fort Worth At Home	6260 SOUTHWEST BLVD		BENBROOK	TX	76109-6906
Affiliated	6215	THE WOODLANDS AT HOME	DNVO-The Woodlands At Home	9301 PINECROFT DR		SHENANDOAH	TX	77380-3179
Affiliated	6218	ARROWHEAD LAKES AT HOME	Arrowhead Lakes At Home	20325 N 51ST AVE	STE 184 BLDG 11	GLENDALE	AZ	85308-4625
Affiliated	6220	COLUMBUS WEST HOME TRAINING	Columbus West Home Training At Home	1391 GEORGESVILLE RD		COLUMBUS	OH	43228-3611
Affiliated	6221	RICHMOND KIDNEY CENTER AT HOME	Richmond Kidney Center At Home (Staten Island)	1366 VICTORY BLVD		STATEN ISLAND	NY	10301-3907
Affiliated	6225	DIALYSIS CARE OF KANNAPOLIS AT HOME	Dialysis Care of Kannapolis At Home	1607 N MAIN ST		KANNAPOLIS	NC	28081-2317
Affiliated	6226	BUTLER-FARM AT HOME	Butler Farm At Home	501 BUTLER FARM RD	STE A	HAMPTON	VA	23666-1777
Affiliated	6228	NEW PORT RICHEY AT HOME	New Port Richey Kidney At Home	7421 RIDGE RD		PORT RICHEY	FL	34668-6933
Affiliated	6229	GRAND HOME AT HOME	Grand Home At Home	14674 W MOUNTAIN VIEW BLVD	STE 204	SURPRISE	AZ	85374-2708
Affiliated	6230	WILLIAMSBURG AT HOME	Williamsburg At Home (fka Yorktown)	500 SENTARA CIR	STE 103	WILLIAMSBURG	VA	23188-5727
Affiliated	6231	BALDWIN COUNTY AT HOME	Home Dialysis Options of Baldwin County At Home	27880 N MAIN ST	STE A	DAPHNE	AL	36526-7080
Affiliated	6232	CLINTON TOWNSHIP AT HOME	Clinton Township at Home	15918 19 MILE RD	STE 110	CLINTON TOWNSHIP	MI	48038-1101
Affiliated	6233	GROSSE POINTE AT HOME	Grosse Pointe At Home	18000 E WARREN AVE	STE 100	DETROIT	MI	48224-1336
Affiliated	6234	GREENSBURG AT HOME	Greensburg At Home	1531 N COMMERCE EAST DR	STE 6	GREENSBURG	IN	47240-3259
Affiliated	6236	GULF BREEZE AT HOME	Gulf Breeze At Home	1519 MAIN ST		DUNEDIN	FL	34698-4650
Affiliated	6237	JACKSONVILLE CENTRAL AT HOME	Jacksonville Central At Home	400 T P WHITE DR		JACKSONVILLE	AR	72076-3287
Affiliated	6238	SAN JOSE AT HOME	San Jose At Home (Freestanding)	4400 STEVENS CREEK BLVD	STE 50	SAN JOSE	CA	95129-1104
Affiliated	6243	ORLANDO AT HOME	Orlando At Home (0178)	14050 TOWN LOOP BLVD	STE 104B	ORLANDO	FL	32837-6190
Affiliated	6244	KENNEDY HOME DIALYSIS-AT HOME	Kennedy Home Dialysis-At Home	5509 N CUMBERLAND AVE	STE 515	CHICAGO	IL	60656-4702
Affiliated	6245	YPSILANTI AT HOME	Ypsilanti At Home	2762 WASHTENAW RD		YPSILANTI	MI	48197-1506
Affiliated	6246	JACKSONVILLE AT HOME	SEDC (NC II) Jacksonville At Home	14 OFFICE PARK DR		JACKSONVILLE	NC	28546-7325
Affiliated	6247	LEBANON AT HOME	Lebanon At Home	918 COLUMBUS AVE	STE 2 UNIT B	LEBANON	OH	45036-1402
Affiliated	6248	SLIDELL KIDNEY CARE AT HOME	Slidell Kidney Care At Home	1150 ROBERT BLVD	STE 240	SLIDELL	LA	70458-2005
Affiliated	6249	WATERBURY AT HOME	Waterbury At Home	150 MATTATUCK HEIGHTS RD		WATERBURY	CT	06705-3893
Affiliated	6251	WHITE LANE AT HOME	White Lane At Home	7701 WHITE LN	STE D	BAKERSFIELD	CA	93309-0201
Affiliated	6253	HANFORD AT HOME	Hanford At Home	900 N DOUTY ST		HANFORD	CA	93230-3918
Affiliated	6254	ANAHEIM AT HOME	Anaheim At Home	1107 W LA PALMA AVE		ANAHEIM	CA	92801-2804
Affiliated	6255	MERCED AT HOME	Merced At Home	3150 NORTH G ST	STE B	MERCED	CA	95340-1346
Affiliated	6257	ST JOSEPH AT HOME	St. Joseph At Home	5514 CORPORATE DR	STE 100	SAINT JOSEPH	MO	64507-7752
Affiliated	6258	CENTRAL LITTLE ROCK AT HOME	Central Little Rock At Home	5800 W 10TH ST	STE 510	LITTLE ROCK	AR	72204-1760
Affiliated	6260	DURHAM WEST AT HOME	Durham West At Home	4307 WESTERN PARK PL	STE 101	DURHAM	NC	27705-1204
Affiliated	6262	TOLEDO AT HOME	Toledo At Home	1614 S BYRNE RD		TOLEDO	OH	43614-3464
Affiliated	6263	HIOAKS AT HOME	Hioaks At Home	681 HIOAKS RD	STE D	RICHMOND	VA	23225-4043
Affiliated	6264	ELIZABETH AT HOME	Elizabeth At Home	201 MCKEESPORT RD		ELIZABETH	PA	15037-1623
Affiliated	6265	ABINGTON AT HOME	Abington At Home	3940A COMMERCE AVE		WILLOW GROVE	PA	19090-1705
Affiliated	6267	NORTH ORANGEBURG AT HOME	North Orangeburg At Home	124 FIRE TOWER RD		ORANGEBURG	SC	29118-1401
Affiliated	6268	DEARBORN HOME DIALYSIS - AT HOME	Dearborn Home Dialysis-At Home	22030 PARK ST		DEARBORN	MI	48124-2854
Affiliated	6269	OCEAN SPRINGS AT HOME	Ocean Springs At Home	13150 PONCE DEL LEON		OCEAN SPRINGS	MS	39564-2460
Affiliated	6270	HAKC - HUNTINGTON AT HOME	HAKC-Huntington At Home	256 BROADWAY		HUNTINGTON STATION	NY	11746-1403

Affiliated	6271	42ND ST AT HOME	Philadelphia 42nd Street At Home	4126 WALNUT ST		PHILADELPHIA	PA	19104-3511
Affiliated	6275	CHARLOTTESVILLE NORTH AT HOME	Charlottesville North At Home	1800 TIMBERWOOD BLVD	STE C	CHARLOTTESVILLE	VA	22911-7544
Affiliated	6276	HEARTLAND AT HOME	Heartland At Home	925 NE 8TH ST		OKLAHOMA CITY	OK	73104-5800
Affiliated	6278	LAKELAND SOUTH AT HOME	Lakeland South At Home	5050 S FLORIDA AVE	STE 1	LAKELAND	FL	33813-2501
Affiliated	6282	RAINBOW CITY AT HOME	Rainbow City At Home	2800 RAINBOW DR		RAINBOW CITY	AL	35906-5811
Affiliated	6283	ATHENS AT HOME	Athens At Home	15953 ATHENS LIMESTONE DR	STE 15	ATHENS	AL	35613-2214
Affiliated	6284	SYLACAUGA AT HOME	Sylacauga At Home	331 JAMES PAYTON BLVD		SYLACAUGA	AL	35150
Affiliated	6287	PITTSBURGH AT HOME	Pittsburgh At Home	4312 PENN AVE		PITTSBURGH	PA	15224-1310
Affiliated	6289	RADNOR AT HOME	Radnor At Home	250 KING OF PRUSSIA RD		RADNOR	PA	19087-5220
Affiliated	6291	RADFORD AT HOME	Radford At Home	600 E MAIN ST	STE B	RADFORD	VA	24141-1826
Affiliated	6292	HARRISONBURG AT HOME	Harrisonburg At Home	871 CANTRELL AVE	STE 100	HARRISONBURG	VA	22801-4323
Affiliated	6293	KERRVILLE AT HOME	Kerrville At Home	515 GRANADA PL		KERRVILLE	TX	78028-5992
Affiliated	6294	WEST TALLAHASSEE AT HOME	West Tallahassee At Home	2645 W TENNESSEE ST	STE 8	TALLAHASSEE	FL	32304-2521
Affiliated	6295	ROME AT HOME	Rome At Home	15 JOHN MADDOX DR NW		ROME	GA	30165-1413
Affiliated	6297	ST LOUIS WEST AT HOME	St. Louis West At Home	450 N LINDBERGH BLVD	STE 100C	CREVE COEUR	MO	63141-7858
Affiliated	6298	COOKEVILLE AT HOME	Cookeville At Home	140 W 7TH ST		COOKEVILLE	TN	38501-1726
Affiliated	6300	DOTHAN AT HOME	Dothan At Home	216 GRACELAND DR		DOTHAN	AL	36305-7346
Affiliated	6302	HENRICO COUNTY AT HOME	Henrico County At Home	5270 CHAMBERLAYNE RD		RICHMOND	VA	23227-2950
Affiliated	6303	WEYMOUTH CLINIC AT HOME	Weymouth At Home	330 LIBBEY INDUSTRIAL PKWY	STE 900	WEYMOUTH	MA	02189-3122
Affiliated	6304	ERIE AT HOME	Erie At Home	350 E BAYFRONT PKWY	STE A	ERIE	PA	16507-2410
Affiliated	6305	WILSON AT HOME	Wilson At Home	1605 MEDICAL PARK DR W		WILSON	NC	27893-2799
Affiliated	6306	NORTH FULTON AT HOME	North Fulton At Home	1250 NORTHMEADOW PKWY	STE 120	ROSWELL	GA	30076-4914
Affiliated	6311	BRADENTON AT HOME	Bradenton At Home	3501 CORTEZ RD W	STE 104	BRADENTON	FL	34210-3104
Affiliated	6312	COLUMBIA UNIVERSITY AT HOME	Columbia University At Home	60 HAVEN AVENUE		NEW YORK	NY	10032-2604
Affiliated	6313	NEW BEDFORD AT HOME	New Bedford At Home	524 UNION ST		NEW BEDFORD	MA	02740-3546
Affiliated	6314	MUSKEGON AT HOME	Muskegon At Home	1277 MERCY DR		MUSKEGON	MI	49444-4605
Affiliated	6315	WELLINGTON CIRCLE AT HOME	Wellington Circle At Home	10 CABOT RD	STE 103B	MEDFORD	MA	02155-5173
Affiliated	6316	FREDERICK AT HOME	Frederick At Home	140 THOMAS JOHNSON DR	STE 100	FREDERICK	MD	21702-4475
Affiliated	6317	SELINSGROVE AT HOME	Selinsgrove At Home	1030 N SUSQUEHANNA TRL		SELINSGROVE	PA	17870-7767
Affiliated	6318	LAKE CHARLES SOUTHWEST AT HOME	Lake Charles Southwest At Home	300 18th ST		LAKE CHARLES	LA	70601-7342
Affiliated	6319	LENEXA AT HOME	Lenexa At Home	8630 HALSEY ST		LENEXA	KS	66215-2880
Affiliated	6321	NASHVILLE HOME TRAINING AT HOME	Nashville Home Training At Home	1919 CHARLOTTE AVE	STE 200	NASHVILLE	TN	37203-2245
Affiliated	6322	GOLDSBORO AT HOME	Goldsboro At Home	2609 HOSPITAL RD		GOLDSBORO	NC	27534-9424
Affiliated	6323	MIAMI CAMPUS AT HOME	Miami Campus At Home	1500 NW 12TH AVE	STE 106	MIAMI	FL	33136-1028
Affiliated	6324	DAYTONA BEACH AT HOME	Daytona Beach At Home	578 HEALTH BLVD		DAYTONA BEACH	FL	32114-1492
Affiliated	6325	GRASS VALLEY AT HOME	Grass Valley At Home	360 CROWN POINT CIR	STE 210	GRASS VALLEY	CA	95945-2543
Affiliated	6326	POMONA AT HOME	Pomona At Home	2111 NORTH GAREY AVENUE		POMONA	CA	91767
Affiliated	6327	MID ATLANTA HOME AT HOME	MidAtlanta Home At Home	418 DECATUR ST SE	SUITE B	ATLANTA	GA	30312-1801
Affiliated	6328	MARTINSVILLE AT HOME	Martinsville Dialysis	33 BRIDGE ST S		MARTINSVILLE	VA	24112-6214
Affiliated	6329	HUBBARD ROAD AT HOME	Hubbard Road At Home	1963 HUBBARD RD		MADISON	OH	44057
Affiliated	6350	PLAINFIELD RENAL CENTER AT HOME	Plainfield Renal At Home (P278)	8110 NETWORK DR		PLAINFIELD	IN	46168-9024
Affiliated	6351	NORTH ANDOVER RENAL CENTER AT HOME	North Andover Renal At Home (P178)	201 SUTTON ST		NORTH ANDOVER	MA	1845
Affiliated	6352	JACKSON NORTH DIALYSIS AT HOME	Jackson North At Home (P181)	571 BEASLEY RD	STE B	JACKSON	MS	39206-3042
Affiliated	6353	SUMMIT RENAL AT HOME	Summit Renal At Home (P186)	73 MASSILLON RD		AKRON	OH	44312-1028
Affiliated	6354	MARLTON DIALYSIS AT HOME	Marlton At Home (P200)	769 E RTE 70		MARLTON	NJ	08053-2341
Affiliated	6355	CENTRAL FORT WAYNE DIALYSIS AT HOME	Central Fort Wayne At Home (P223)	1940 BLUFTON RD		FORT WAYNE	IN	46809-1307
Affiliated	6356	LAS CRUCES RENAL CENTER AT HOME	Las Cruces Renal At Home (P237)	3961 E LOHMAN AVE	STE 29	LAS CRUCES	NM	88011-8272
Affiliated	6357	NORTHEAST PORTLAND RENAL CENTER AT HOME	Northeast Portland Renal At Home (P240)	703 NE HANCOCK ST		PORTLAND	OR	97212-3955
Affiliated	6358	KANSAS CITY RENAL CENTER AT HOME	Kansas City Renal At Home (P264)	4333 MADISON AVE		KANSAS CITY	MO	64111-3429
Affiliated	6359	COASTAL DIALYSIS AT HOME	South Texas Renal At Home (P257)	4300 S PADRE ISLAND DR		CORPUS CHRISTI	TX	78411-4433
Affiliated	6360	NORTH SPOKANE RENAL CENTER AT HOME	North Spokane Renal At Home (P262)	12610 E MARIBEAU PRKWY	STE 100	SPOKANE	WA	99216
Affiliated	5659	TEMPE DIALYSIS PD	Tempe Dialysis Center PD	2149 EAST WARNER RD	STE 109	TEMPE	AZ	85284-3496
Affiliated	5660	ARROWHEAD LAKES DIALYSIS PD	Arrowhead Lakes Dialysis PD	20325 N 51ST AVE	BLDG 11, STE 184	GLENDALE	AZ	85308-4625
Affiliated	5916	SHAKER SQUARE AT HOME	Shaker Square At Home	12800 SHAKER BLVD	STE 1	CLEVELAND	OH	44120-2004

Affiliated	6130	SIERRA ROSE AT HOME	Sierra Rose At Home	685 SIERRA ROSE DR		RENO	NV	89511-2060
Affiliated	6217	TEMPE AT HOME	Tempe At Home	2149 E WARNER RD	STE 109	TEMPE	AZ	85284-3496
Affiliated	6281	TUSCALOOSA AT HOME	Tuscaloosa At Home	805 OLD MILL ST		TUSCALOOSA	AL	35401-7132

TEMPORARY CLOSURES
(Included above are several centers that have temporarily suspended operations for a variety of reasons, but are scheduled to resume operations within the coming few months)

614	Lynwood
643	Vidalia
3518	Huntingdon Valley Dialysis
626	Tuba City
903	Littleton

Exhibit SR-1

Purchase Data Submission Form

Contract #: **«Contract»** Dialysis Center: **DaVita Inc.**

1. Purchase Data For Measurement Period: *[Enter Measurement Period (for example, Q4 2013)]*

ESA 1: *[Product NameX]*

ESA 2: *[Product NameY]*

ESA 3: *[Product NameZ]*

[Example 1 for illustration purposes only]

	Dialysis Center Committed Purchasers
ESA	**Total Number of [*] Purchased**
ESA 1	*1,000* [*]
ESA 2	*XX mcg*
ESA 3	*2,000* [*]

[Example 2 for illustration purposes only]

	Dialysis Center Purchasers
ESA	**Total Number of [*] Purchased**
ESA 1	*1,000* [*]
ESA 2	*XX mcg*
ESA 3	*2,000* [*]

2. Number of patients who received any and each ESA or combination from Dialysis Center Purchasers during the entire Measurement Period.

[Example 1 for illustration purposes only]

ESA	Total Number of Patients
ESA 1	*50*
ESA 2	*10*
ESA 3	*5*

[Example 2 for illustration purposes only]

ESA	Total Number of Patients
ESA 1	*60*
ESA 2	

[Example 3 for illustration purposes only]

ESA	Total Number of Patients
ESA 1	*100*
ESA 3	

[Example 4 for illustration purposes only]

ESA	Total Number of Patients
ESA 2	*100*
ESA 3	

Completed Purchase Data Submission Forms should be submitted electronically as an Excel file to Amgen by e-mail at [*], *or as otherwise specified in writing by Amgen.*

Schedule 1

Data

Category	Data Element	Facility	Patient
Facility Reference	Facility Name	ü	
	Address	ü	
	City, State, Zip	ü	
	Phone	ü	
	Facility ID (unique within account)	ü	
	Regional ID (unique within account)	ü	
	State in which facility is located	ü	
Patient Demographics	De-identified Patient ID		ü
	Date of Service (Treatment Date)		ü
	Treatment Date/Date of Encounter (evaluated as treatment date)		ü
	[*] (in [*])		ü
	[*] Date		ü
	Date of [*] (month, day & year)		ü
	Date of [*]		ü
	[*] Date		ü
	[*] Date		ü
	[*]		By the end of Q4 2012
	[*] Type ([*],[*],[*])*		ü
	[*] Date*		ü
	Primary Payor (Govnt - Medicare, Medicaid, VA or Commercial - Medicare Advantage, MCO, HMO, PPO)		By the end of Q1 2012
	Secondary Payor (Govnt - Medicare, Medicaid, VA or Commercial - Medicare Advantage, MCO, HMO, PPO)		By the end of Q1 2012
Medications	ESA Name		ü
	ESA Dose (EPOGEN / Aranesp)		ü
	EPOGEN Administration Frequency (On DVA offered Protocol)		By the end of Q1 2012
	Aranesp Administration Frequency*		By the end of Q1 2012
	ESA Route of Administration		By the end of Q1 2012
	ESA Start Date		By the end of Q1 2012
	ESA Stop Date (Missed dose due to held)*		By the end of Q1 2012
	[*] Name		ü
	[*]		ü

	[*] Administration Frequency (Maintenance / Loading)*	By the end of Q1 2012
	[*] Order (Not administered, stop)*	By the end of Q1 2012
	Vitamin D Name	ü
	Vitamin D Dose	ü
	Vitamin D Order (Stop date)*	By the end of Q1 2012
Lab Measurements	Hemoglobin	ü
	[*]	ü
	[*]	ü
	[*] / [*]	ü
	[*]	ü
	[*] ([*] or [*])	ü
	[*]	ü
	Corrected [*]	ü
	Corrected [*] Product	ü
	Albumin	ü
Other Measurements	[*]	ü
	[*]	ü
	[*]	ü
	Kt/v	ü
	URR (until CMS no longer requires)	ü
	Modality	ü
	PD treatments (# pts per month)	ü
	Home HD treatments (# pts per month)*	ü
	Home HD treatments (# txs per month)	By the end of Q1 2012

* For designated fields, Dialysis Center will provide Amgen business rules to calculate value of the field based on the submitted Data.

Timing on providing Data with specific target date in the data column means Data or business rules will be delivered to Amgen by the end of the specified Quarter. For example: by end of Q1 2012 means deadline for delivery is March 31, 2012.

Schedule 2

Compensation Data

Product Data Submission Requirements. Compensation Data shall be sent in either Excel or a tab-delimited text file to the following email address: [*]. The file naming convention shall include the Dialysis Center name, EPOGEN, and data month and year (i.e. DaVita_Epogen_January_2011). Dialysis Center must supply all of the information set forth in the table below.

ID	Data Field Name	Data Field Description
1	Unique Account Identifier	DaVita's numeric identifier for each account (PFac & OFac)
2	Account Name	Account requesting EPOGEN
3	Account Street Address	Account requesting EPOGEN
4	Account City	Account requesting EPOGEN
5	Account State	Account requesting EPOGEN
6	Account zip	Account requesting EPOGEN
7	Dispensing Pharmacy for EPOGEN	DaVita's numeric identifier for location that has dispensed EPOGEN
8	EPOGEN NDC Number	
9	EPOGEN Description	Name of EPOGEN including strength (Label Name)
10	Quantity Shipped	
11	Unit Of Measure	Tabs, bottles, vials, etc.
12	EPOGEN shipped/dispensed date	

Schedule 3

Available EPOGEN SKU Schedule

EPOGEN® (Epoetin alfa):

VII. NDC	Description
55513-126-10	2,000 Unit, 1 mL (2,000 Units/mL) single-use vial 10 vials/pack, 10 packs/case
55513-267-10	3,000 Unit, 1 mL (3,000 Units/mL) single-use vial 10 vials/pack, 10 packs/case
55513-148-10	4,000 Unit, 1 mL (4,000 Units/mL) single-use vial 10 vials/pack, 10 packs/case
55513-144-10	10,000 Unit, 1 mL (10,000 Units/mL) single-use vial 10 vials/pack, 10 packs/case
55513-283-10	20,000 Unit, 2 mL (10,000 Units/mL) multi-use vial 10 vials/pack, 4 packs/case
55513-478-10	20,000 Unit, 1 mL (20,000 Units/mL) multi-use vial 10 vials/pack, 4 packs/case

AMGEN INC.

SUBSIDIARY (Name under which subsidiary does business)	STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION
Immunex Corporation	Washington
Amgen Manufacturing, Limited	Bermuda
Amgen USA Inc.	Delaware

CERTIFICATIONS

I, Kevin W. Sharer, Chairman of the Board and Chief Executive Officer of Amgen Inc., certify that:

1. I have reviewed this Annual Report on Form 10-K of Amgen Inc.;
2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
   (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and
   (d) Disclosed in this annual report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
   (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
   (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 29, 2012

/s/ KEVIN W. SHARER

Kevin W. Sharer
Chairman of the Board and Chief Executive Officer

CERTIFICATIONS

I, Jonathan M. Peacock, Executive Vice President and Chief Financial Officer of Amgen Inc., certify that:

1. I have reviewed this Annual Report on Form 10-K of Amgen Inc.;

2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

   (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

   (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and

   (d) Disclosed in this annual report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

   (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

   (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 29, 2012

/s/ JONATHAN M. PEACOCK

Jonathan M. Peacock
Executive Vice President and Chief Financial Officer

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the "Company") hereby certifies that:

(i) the accompanying Annual Report on Form 10-K of the Company for the period ended December 31, 2011 (the "Report") fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 29, 2012

/s/ KEVIN W. SHARER

Kevin W. Sharer
Chairman of the Board and Chief Executive Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 ("Section 906"), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Certification of Chief Financial Officer

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the "Company") hereby certifies that:

(i) the accompanying Annual Report on Form 10-K of the Company for the period ended December 31, 2011 (the "Report") fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 29, 2012

/s/ JONATHAN M. PEACOCK

Jonathan M. Peacock
Executive Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 ("Section 906"), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.